Patient O O
: O O
Name O O
, O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
10 O O
: O O
14 O O
P O O
  
3 O O
: O O
09 O O
P O O
CLINIC O O
NOTE O O
The O O
patient O O
was O O
seen O O
and O O
examined O O
in O O
clinic O O
with O O
Dr O O
. O O
  
Name O O
. O O
  
DIAGNOSIS O O
: O O
Mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
INTERVAL O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
returns O O
today O O
for O O
followup O O
and O O
assessment O O
prior O O
to O O
the O O
fifth O O
cycle O O
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
/ I-Drug I-Drug
Rituxan I-Drug I-Drug
protocol O O
. O O
  
He O O
continues O O
to O O
do O O
well O O
. O O
  
He O O
has O O
recovered O O
his O O
cell O O
counts O O
quite O O
quickly O O
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
is O O
eating O O
well O O
, O O
has O O
a O O
good O O
appetite O O
and O O
has O O
maintained O O
a O O
stable O O
weight O O
. O O
  
He O O
denies O O
any O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
or O O
dyspnea B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
headache B-SSLIF B-SSLIF
or O O
dizziness B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
change O O
to O O
his O O
bowel O O
habits O O
. O O
  
He O O
has O O
some B-Severity B-Severity
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
, O O
however O O
, O O
it O O
does O O
not O O
bother O O
him O O
too O O
much O O
. O O
  
PAST O O
MEDICAL O O
, O O
FAMILY O O
AND O O
SOCIAL O O
HISTORY O O
: O O
Reviewed O O
and O O
unchanged O O
. O O
  
MEDICATIONS O O
: O O
These O O
are O O
reviewed O O
and O O
reconciled O O
in O O
Company O O
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
comprehensive O O
review O O
of O O
systems O O
is O O
otherwise O O
negative O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
Today O O
, O O
his O O
temperature O O
36.4 O O
, O O
his O O
blood O O
pressure O O
131 O O
/ O O
78 O O
, O O
respirations O O
16 O O
and O O
pulse O O
is O O
112 O O
. O O
  
His O O
weight O O
is O O
73.4 O O
kg O O
that O O
is O O
stable O O
. O O
  
HEENT O O
: O O
Within O O
normal O O
limits O O
. O O
  
No O O
pallor B-SSLIF B-SSLIF
, O O
no O O
icterus B-SSLIF B-SSLIF
. O O
  
Oral O O
mucosa O O
is O O
normal O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
No O O
cervical B-SSLIF B-SSLIF
lymph I-SSLIF I-SSLIF
node I-SSLIF I-SSLIF
enlargement I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
HEART O O
: O O
S1 O O
and O O
S2 O O
heard O O
normal O O
. O O
  
No O O
murmurs B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
work O O
from O O
today O O
were O O
reviewed O O
. O O
  
His O O
CBC O O
, O O
hemoglobin O O
is O O
  
9.9 O O
, O O
hematocrit O O
29.2 O O
, O O
white O O
count O O
is O O
11.9 O O
and O O
platelets O O
are O O
117 O O
, O O
000 O O
. O O
  
Blood O O
chemistry O O
shows O O
normal O O
electrolytes O O
. O O
  
Normal O O
BUN O O
at O O
6 O O
and O O
creatinine O O
1.06 O O
. O O
  
Recent O O
imaging O O
was O O
reviewed O O
. O O
  
CT O O
scan O O
of O O
the O O
chest O O
with O O
contrast O O
on O O
Date O O
, O O
shows O O
bilateral B-SSLIF B-SSLIF
axillary I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
subpectoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
, O O
borderline B-Severity B-Severity
size I-Severity I-Severity
mediastinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
There O O
is O O
a O O
large B-Severity B-Severity
left B-SSLIF B-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
, O O
which O O
is O O
free O O
flowing O O
. O O
  
He O O
has O O
severe B-Severity B-Severity
compression B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
body I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
T12 I-SSLIF I-SSLIF
. O O
  
A O O
CT O O
abdomen O O
has O O
not O O
been O O
reported O O
at O O
the O O
time O O
of O O
this O O
dictation O O
. O O
  
Review O O
of O O
his O O
pathology O O
, O O
his O O
latest O O
bone O O
marrow O O
from O O
Date O O
, O O
showed O O
less O O
than O O
5% O O
marrow O O
involvement O O
by O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
however O O
, O O
it O O
is O O
persistent O O
. O O
  
PAX O O
- O O
5 O O
positive O O
and O O
cyclin O O
D1 O O
is O O
positive O O
. O O
  
Cellularity O O
is O O
70% O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
  
1 O O
. O O
  
This O O
is O O
a O O
68 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
ECOG O O
performance O O
status O O
1 O O
, O O
who O O
is O O
doing O O
well O O
after O O
4 O O
cycles O O
of O O
chemotherapy B-Drug B-Drug
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
He O O
is O O
doing O O
well O O
with O O
this O O
. O O
  
We O O
will O O
continue O O
the O O
same O O
treatment O O
. O O
  
2 O O
. O O
  
He O O
will O O
receive O O
1 B-Frequency B-Frequency
dose I-Frequency I-Frequency
of O O
Rituxan B-Drug B-Drug
at O O
500 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
today O O
. O O
  
3 O O
. O O
  
He O O
will O O
be O O
admitted O O
early O O
next O O
week O O
for O O
cycle O O
#5 O O
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
. O O
  
4. O O
Infectious O O
disease O O
. O O
  
Prophylactic B-Indication B-Indication
Noxafil B-Drug B-Drug
will O O
be O O
held O O
today O O
as O O
well O O
as O O
the O O
acyclovir B-Drug B-Drug
. O O
  
He O O
will O O
continue O O
on O O
the O O
Valtrex B-Drug B-Drug
as O O
he O O
has O O
had O O
shingles B-Indication B-Indication
. O O
  
5. O O
Nutritional O O
status O O
. O O
  
He O O
is O O
maintaining O O
his O O
nutrition O O
status O O
. O O
  
We O O
will O O
perform O O
a O O
bone O O
marrow O O
examination O O
today O O
for O O
assessment O O
of O O
persistent O O
disease O O
. O O
  
At O O
the O O
time O O
that O O
his O O
disease O O
becomes O O
negative O O
, O O
then O O
he O O
will O O
be O O
a O O
candidate O O
for O O
collection O O
of O O
cells O O
and O O
an O O
autologous O O
transplant O O
afterward O O
. O O
  
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
. O O
  
I O O
discussed O O
the O O
case O O
with O O
the O O
fellow O O
and O O
agree O O
with O O
the O O
findings O O
and O O
plan O O
as O O
documented O O
in O O
the O O
fellow's O O
note O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
20 O O
: O O
30 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Date O O
of O O
service O O
: O O
Date O O
DIAGNOSES O O
: O O
  
1. O O
Mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
status O O
post O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
based O O
therapy O O
, O O
the O O
last O O
2 O O
with O O
bortezomib B-Drug B-Drug
followed O O
by O O
2 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
bendamustine B-Drug B-Drug
, O O
bortezomib B-Drug B-Drug
, O O
rituximab B-Drug B-Drug
based O O
therapy O O
. O O
  
2. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
vincristine B-Drug B-Drug
and O O
bortezomib B-Drug B-Drug
. O O
  
3. O O
Hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
core I-SSLIF I-SSLIF
antibody I-SSLIF I-SSLIF
positivity I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
Name O O
Name O O
comes O O
for O O
a O O
followup O O
prior O O
to O O
his O O
admission O O
for O O
an O O
allogeneic O O
stem O O
cell O O
transplantation O O
. O O
  
He O O
is O O
a O O
gentleman O O
with O O
diagnosis O O
of O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
He O O
has O O
completed O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
based O O
therapy O O
with O O
still O O
persistent O O
disease O O
at O O
least O O
at O O
the O O
molecular O O
level O O
in O O
the O O
bone O O
marrow O O
. O O
  
He O O
subsequently O O
has O O
received O O
2 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
chemotherapy B-Drug B-Drug
with O O
bortezomib B-Drug B-Drug
and O O
bendamustine B-Drug B-Drug
based O O
therapy O O
. O O
  
His O O
last O O
marrow O O
had O O
shown O O
him O O
to O O
be O O
in O O
complete O O
remission O O
, O O
but O O
there O O
were O O
increased B-SSLIF B-SSLIF
mast I-SSLIF I-SSLIF
cells I-SSLIF I-SSLIF
, O O
raising O O
a O O
suspicion O O
of O O
mastocytosis B-SSLIF B-SSLIF
. O O
  
Cytogenetics O O
were O O
negative O O
for O O
abnormalities B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
chromosome I-SSLIF I-SSLIF
4q I-SSLIF I-SSLIF
region I-SSLIF I-SSLIF
. O O
  
C O O
- O O
kit O O
mutation O O
is O O
still O O
pending O O
. O O
  
In O O
the O O
meantime O O
, O O
his O O
symptomatology O O
has O O
been O O
that O O
of O O
pricking B-ADE B-ADE
pain I-ADE I-ADE
sensations I-ADE I-ADE
in I-ADE I-ADE
the I-ADE I-ADE
face I-ADE I-ADE
, O O
mostly O O
after O O
this O O
last O O
cycle O O
of O O
chemotherapy B-Drug B-Drug
, O O
but O O
today O O
he O O
states O O
he O O
feels O O
great O O
. O O
  
No O O
complains O O
, O O
he O O
specifically O O
denies O O
any O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
or O O
diarrhea B-SSLIF B-SSLIF
. O O
  
Denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
has O O
been O O
eating O O
and O O
drinking O O
fairly O O
well O O
. O O
  
He O O
has O O
been O O
maintaining O O
his O O
weight O O
. O O
  
FAMILY O O
HISTORY O O
, O O
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
since O O
Date O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
As O O
per O O
HPI O O
and O O
major O O
issue O O
is O O
resolving O O
numbness B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
hands I-SSLIF I-SSLIF
and O O
paresthesias B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
, O O
which O O
have O O
occasionally O O
been O O
painful B-SSLIF B-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
On O O
examination O O
, O O
the O O
patient O O
is O O
a O O
well O O
- O O
built O O
male O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Noted O O
. O O
  
Blood O O
pressure O O
is O O
114 O O
/ O O
75 O O
, O O
pulse O O
94 O O
, O O
respirations O O
20 O O
. O O
  
He O O
is O O
afebrile O O
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
no O O
wheezes B-SSLIF B-SSLIF
, O O
no O O
rhnchi B-SSLIF B-SSLIF
or O O
rales B-SSLIF B-SSLIF
. O O
  
HEART O O
: O O
Sounds O O
are O O
normal O O
. O O
  
S1 O O
and O O
S2 O O
present O O
, O O
no O O
murmurs B-SSLIF B-SSLIF
, O O
rubs B-SSLIF B-SSLIF
or O O
gallops B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
. O O
  
no O O
organomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
, O O
white O O
count O O
of O O
3.8 O O
, O O
hemoglobin O O
12.1 O O
and O O
a O O
platelet O O
count O O
of O O
183 O O
, O O
000 O O
. O O
  
creatinine O O
0.87 O O
. O O
  
Rest O O
of O O
his O O
labs O O
are O O
within O O
normal O O
limits O O
. O O
  
A O O
serum O O
tryptase O O
level O O
was O O
5.7 O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Mantel B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
had O O
deletion O O
of O O
P53 O O
and O O
took O O
really O O
long O O
time O O
to O O
go O O
into O O
complete O O
remission O O
. O O
  
Because O O
of O O
his O O
marrow O O
reserve O O
at O O
that O O
time O O
, O O
a O O
decision O O
was O O
made O O
to O O
proceed O O
with O O
an O O
allogenic O O
stem O O
cell O O
transplant O O
. O O
  
In O O
that O O
regard O O
, O O
he O O
is O O
being O O
prepared O O
with O O
Zevalin B-Drug B-Drug
followed O O
by O O
melphalan B-Drug B-Drug
pre O O
and O O
Cytoxan B-Drug B-Drug
post O O
- O O
transplant O O
. O O
  
He O O
did O O
sign O O
appropriate O O
consents O O
. O O
  
Today O O
he O O
feels O O
well O O
, O O
he O O
is O O
proceeding O O
with O O
treatment O O
as O O
planned O O
and O O
will O O
be O O
admitted O O
next O O
week O O
. O O
  
2. O O
Hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
is O O
ineligible O O
because O O
of O O
the O O
presence O O
of O O
hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
IgM I-SSLIF I-SSLIF
antibody I-SSLIF I-SSLIF
, O O
though O O
he O O
does O O
not O O
have O O
any O O
viral O O
DNA O O
by O O
either O O
antigenemia O O
or O O
a O O
PCR O O
assay O O
. O O
  
That O O
makes O O
him O O
ineligible O O
, O O
but O O
the O O
risk O O
/ O O
benefit O O
ratio O O
favors O O
proceeding O O
towards O O
the O O
transplant O O
. O O
  
This O O
was O O
discussed O O
with O O
the O O
patient O O
. O O
  
The O O
potential O O
risk O O
of O O
the O O
transplant O O
including O O
hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
reactivation I-SSLIF I-SSLIF
and O O
possible O O
death B-SSLIF B-SSLIF
were O O
also O O
discussed O O
with O O
the O O
patient O O
. O O
  
The O O
patient's O O
donor O O
is O O
also O O
ineligible O O
because O O
of O O
his O O
residence O O
in O O
Europe O O
and O O
this O O
was O O
discussed O O
with O O
the O O
patient O O
the O O
reason O O
for O O
donor's O O
ineligibility O O
for O O
a O O
residence O O
in O O
area O O
, O O
which O O
in O O
the O O
past O O
has O O
been O O
at O O
risk O O
for O O
mad B-SSLIF B-SSLIF
cow I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
2. O O
Hepatitis B-Indication B-Indication
B I-Indication I-Indication
core I-Indication I-Indication
antibody I-Indication I-Indication
positivity I-Indication I-Indication
. O O
  
He O O
is O O
seen O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
Since O O
we O O
are O O
going O O
to O O
proceed O O
with O O
a O O
transplant O O
, O O
we O O
are O O
going O O
to O O
put O O
him O O
on O O
prophylaxis B-Indication B-Indication
therapy O O
. O O
  
Initially O O
, O O
Baraclude B-Drug B-Drug
was O O
ordered O O
for O O
him O O
, O O
but O O
there O O
is O O
a O O
copay O O
of O O
500 O O
dollars O O
, O O
which O O
the O O
patient O O
could O O
not O O
afford O O
. O O
  
His O O
other O O
option O O
is O O
tenofovir B-Drug B-Drug
, O O
but O O
that O O
has O O
a O O
significant O O
copay O O
as O O
well O O
. O O
  
The O O
patient O O
will O O
be O O
in O O
contact O O
with O O
the O O
proper O O
members O O
of O O
our O O
team O O
to O O
discuss O O
his O O
copay O O
for O O
his O O
medication O O
. O O
  
3. O O
Peripheral B-Indication B-Indication
neuropathy I-Indication I-Indication
. O O
  
This O O
is O O
probably O O
drug O O
induced O O
. O O
  
He O O
is O O
improving O O
on O O
Neurontin B-Drug B-Drug
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
10 O O
: O O
41AM O O
EST O O
Attending O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
Date O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
M.D. O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
13 O O
: O O
53 O O
PM O O
Special O O
Procedure O O
NAME O O
OF O O
THE O O
PROCEDURE O O
: O O
Bone O O
marrow O O
aspiration O O
and O O
biopsy O O
. O O
  
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
After O O
an O O
informed O O
consent O O
and O O
timeout O O
, O O
bone O O
marrow O O
aspiration O O
and O O
biopsy O O
were O O
performed O O
under O O
local O O
anesthesia O O
in O O
sterile O O
condition O O
with O O
the O O
patient O O
in O O
left O O
lateral O O
position O O
. O O
  
This O O
procedure O O
was O O
performed O O
by O O
Name O O
Name O O
under O O
my O O
direct O O
observation O O
and O O
supervision O O
. O O
  
Approximately O O
7 O O
- O O
8 O O
mL O O
of O O
bone O O
marrow O O
was O O
aspirated O O
from O O
the O O
right O O
posterior O O
superior O O
iliac O O
crest O O
without O O
problems O O
. O O
  
Subsequent O O
to O O
that O O
, O O
a O O
bone O O
marrow O O
biopsy O O
was O O
performed O O
using O O
the O O
Jamshidi O O
needle O O
from O O
the O O
same O O
incision O O
site O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
. O O
  
He O O
was O O
asked O O
to O O
lie O O
down O O
flat O O
for O O
half O O
an O O
hour O O
after O O
the O O
procedure O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
, O O
M.D. O O
  
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
10 O O
: O O
22PM O O
EST O O
Author O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
DOV O O
: O O
Date O O
Clinic O O
Note O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
69 O O
year O O
old O O
male O O
with O O
h O O
/ O O
o O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
s O O
/ O O
p O O
allogenic O O
stem O O
cell O O
transplant O O
D73 O O
who O O
presents O O
for O O
f O O
/ O O
u O O
visit O O
. O O
  
He O O
is O O
feeling O O
well O O
today O O
. O O
  
He O O
does O O
continue O O
to O O
get O O
occassional O O
chills B-SSLIF B-SSLIF
still O O
but O O
his O O
infectious O O
w O O
/ O O
u O O
has O O
been O O
negative O O
to O O
date O O
except O O
for O O
low B-Severity B-Severity
level I-Severity I-Severity
CMV B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
cold O O
symptoms O O
. O O
  
He O O
is O O
eating O O
and O O
drinking O O
well O O
. O O
  
He O O
denies O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
, O O
rash B-SSLIF B-SSLIF
, O O
LE B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
ROS O O
: O O
Remaining O O
10 O O
pt O O
review O O
of O O
systems O O
negative O O
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
a O O
leanly O O
built O O
male O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Wt O O
70.4kg O O
, O O
temperature O O
36.39 O O
, O O
BP O O
144 O O
/ O O
79 O O
, O O
pulse O O
65 O O
, O O
RR O O
20 O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
Sounds O O
are O O
normal O O
. O O
  
ABDOMEN O O
: O O
Soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
reveal O O
a O O
white O O
count O O
of O O
1700 O O
, O O
hemoglobin O O
of O O
10.2 O O
and O O
a O O
platelet O O
count O O
of O O
58 O O
, O O
000 O O
. O O
  
Absolute O O
neutrophil O O
count O O
is O O
380< O O
Na O O
140 O O
, O O
K O O
3.9 O O
, O O
creatinine O O
1.19 O O
, O O
Mg O O
1.7 O O
PROBLEMS O O
: O O
  
1. O O
Graft O O
: O O
Cytogenetics O O
from O O
bmbx O O
done O O
this O O
week O O
shows O O
1 O O
/ O O
500 O O
clones O O
of O O
CCDN1 O O
- O O
IGH O O
rearrangement O O
, O O
after O O
discussion O O
with O O
Dr O O
. O O
  
Name O O
we O O
are O O
going O O
to O O
watch O O
this O O
. O O
  
His O O
chimerism O O
CD34 O O
from O O
marrow O O
96% O O
donor O O
and O O
CD3 O O
whole O O
blood O O
is O O
97% O O
donor O O
. O O
  
He O O
will O O
receive O O
neupogen B-Drug B-Drug
today O O
. O O
  
2. O O
Infectious O O
disease O O
: O O
HHV B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
6 I-SSLIF I-SSLIF
is O O
negative O O
, O O
CMV B-SSLIF B-SSLIF
is O O
low B-Severity B-Severity
level I-Severity I-Severity
and O O
blood O O
cultures O O
were O O
negative O O
from O O
this O O
week O O
. O O
  
3. O O
GVHD B-Indication B-Indication
: O O
He O O
does O O
not O O
have O O
any O O
active O O
GVHD B-SSLIF B-SSLIF
, O O
is O O
on O O
sirolimus B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
Monday B-Frequency B-Frequency
, I-Frequency I-Frequency
Wednesday I-Frequency I-Frequency
and I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, O O
which O O
is O O
being O O
tapered O O
off O O
and O O
also O O
prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
4. O O
FEN O O
: O O
patient O O
is O O
eating O O
and O O
drinking O O
well O O
, O O
he O O
does O O
not O O
need O O
electrolyte O O
replacement O O
cc O O
: O O
  
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
PA O O
Date O O
9 O O
: O O
04AM O O
EST O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
8 O O
: O O
22AM O O
EST O O
Attending O O
Patient O O
: O O
Name O O
, O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
7 O O
: O O
54 O O
P O O
  
12 O O
: O O
40 O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
status O O
post O O
7th O O
cycle O O
of O O
chemotherapy B-Drug B-Drug
on O O
the O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
protocol O O
, O O
the O O
last O O
2 O O
cycles O O
along O O
with O O
bortezomib B-Drug B-Drug
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
comes O O
back O O
for O O
followup O O
examination O O
today O O
. O O
  
He O O
is O O
approximately O O
2 O O
weeks O O
status O O
post O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
protocol O O
, O O
7th O O
cycle O O
on O O
the O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
protocol O O
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
With O O
the O O
last O O
cycle O O
, O O
he O O
got O O
4 B-Dose B-Dose
doses O O
of O O
Velcade B-Drug B-Drug
also O O
, O O
2 O O
before O O
and O O
2 O O
after O O
the O O
regimen O O
. O O
  
He O O
comes O O
back O O
for O O
followup O O
examination O O
today O O
. O O
  
He O O
tells O O
me O O
that O O
since O O
Saturday O O
, O O
which O O
would O O
have O O
been O O
day O O
13 O O
of O O
his O O
therapy O O
, O O
he O O
had O O
had O O
significant B-Severity B-Severity
abdominal B-SSLIF B-SSLIF
cramps I-SSLIF I-SSLIF
and O O
diarrhea B-SSLIF B-SSLIF
. O O
  
The O O
diarrhea B-SSLIF B-SSLIF
is O O
better O O
and O O
so O O
are O O
the O O
cramps B-SSLIF B-SSLIF
, O O
but O O
they O O
continue O O
to O O
persist O O
. O O
  
He O O
denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
some O O
postnasal B-SSLIF B-SSLIF
drip I-SSLIF I-SSLIF
and O O
slight B-Severity B-Severity
soreness B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
throat I-SSLIF I-SSLIF
and O O
pain B-SSLIF B-SSLIF
behind I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
ears I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Rest O O
of O O
the O O
review O O
of O O
systems O O
is O O
negative O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
leanly O O
built O O
male O O
, O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Noted O O
. O O
  
He O O
is O O
afebrile B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
are I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
slightly B-Severity B-Severity
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
The O O
throat O O
is O O
not O O
injected O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
Thyroid B-SSLIF B-SSLIF
gland I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
HEART O O
: O O
Heart O O
sounds O O
are O O
normal O O
. O O
  
ABDOMEN O O
: O O
Soft O O
and O O
nontender O O
. O O
  
I O O
do O O
not O O
appreciate O O
any O O
tenderness B-SSLIF B-SSLIF
and O O
the O O
bowel O O
sounds O O
are O O
present O O
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
, O O
grossly O O
exam O O
is O O
normal O O
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
reveals O O
a O O
white O O
count O O
of O O
0.9 O O
, O O
hemoglobin O O
of O O
8.7 O O
and O O
a O O
platelet O O
count O O
of O O
8000 O O
. O O
  
Segs O O
72 O O
, O O
lymphocytes O O
5% O O
. O O
  
Also O O
K O O
was O O
  
3.1 O O
, O O
albumin O O
was O O
2.9 O O
, O O
magnesium O O
1.8 O O
and O O
creatinine O O
1.07 O O
. O O
  
Review O O
of O O
the O O
IgH O O
/ O O
bcl1 O O
gene O O
rearrangement O O
in O O
this O O
bone O O
marrow O O
was O O
negative O O
indicating O O
that O O
cannot O O
be O O
used O O
to O O
follow O O
his O O
MRD O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Mantel B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
status O O
post O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
chemotherapy B-Drug B-Drug
with O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
. O O
  
The O O
patient O O
is O O
slowly O O
recovering O O
his O O
counts O O
. O O
  
He O O
received O O
Neulasta B-Drug B-Drug
. O O
  
I O O
am O O
going O O
to O O
wait O O
until O O
Wednesday O O
to O O
see O O
his O O
CD34 O O
count O O
in O O
the O O
blood O O
to O O
see O O
still O O
whether O O
potentially O O
we O O
can O O
obtain O O
stem O O
cells O O
or O O
not O O
. O O
  
2. O O
Infectious O O
disease O O
: O O
The O O
patient O O
has O O
some B-Severity B-Severity
aches B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
ear I-SSLIF I-SSLIF
and O O
also O O
is O O
having O O
some B-Severity B-Severity
diarrhea B-SSLIF B-SSLIF
. O O
  
He O O
has O O
not O O
yet O O
passed O O
any O O
stools O O
here O O
today O O
, O O
but O O
if O O
he O O
does O O
, O O
we O O
are O O
going O O
to O O
send O O
stool O O
for O O
fecal B-SSLIF B-SSLIF
leukocytes I-SSLIF I-SSLIF
and O O
C. B-SSLIF B-SSLIF
diff I-SSLIF I-SSLIF
. O O
  
I O O
am O O
not O O
inclined O O
to O O
treat O O
him O O
without O O
the O O
positive O O
C. B-SSLIF B-SSLIF
diff I-SSLIF I-SSLIF
analysis O O
because O O
this O O
could O O
also O O
be O O
Velcade B-Drug B-Drug
. O O
  
3. O O
Disease O O
status O O
: O O
We O O
will O O
obtain O O
IgH O O
gene O O
arrangement O O
PCR O O
in O O
a O O
couple O O
of O O
days O O
when O O
his O O
counts O O
are O O
a O O
little O O
bit O O
elevated O O
. O O
  
If O O
in O O
case O O
that O O
turns O O
out O O
to O O
be O O
negative O O
, O O
we O O
will O O
go O O
ahead O O
and O O
look O O
at O O
the O O
bone O O
marrow O O
aspirate O O
again O O
. O O
  
In O O
the O O
meantime O O
, O O
we O O
will O O
also O O
get O O
a O O
sense O O
whether O O
or O O
not O O
we O O
have O O
adequate O O
stem O O
cells O O
in O O
the O O
peripheral O O
blood O O
for O O
mobilization O O
. O O
  
At O O
this O O
time O O
, O O
I O O
am O O
not O O
inclined O O
to O O
treat O O
him O O
with O O
anymore O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
based O O
regimen O O
. O O
  
If O O
there O O
is O O
persistent B-Indication B-Indication
disease I-Indication I-Indication
, O O
we O O
will O O
switch O O
him O O
to O O
Rituxan B-Drug B-Drug
, O O
bendamustine B-Drug B-Drug
, O O
Velcade B-Drug B-Drug
based O O
regimen O O
and O O
I O O
will O O
continue O O
it O O
until O O
we O O
are O O
able O O
to O O
bridge O O
him O O
to O O
an O O
allogenic O O
stem O O
cell O O
transplant O O
. O O
  
There O O
are O O
plenty O O
of O O
donors O O
for O O
the O O
same O O
. O O
  
If O O
he O O
has O O
cleared O O
his O O
marrow O O
vis O O
- O O
? O O
- O O
vis O O
IgH O O
gene O O
arrangement O O
and O O
he O O
has O O
enough O O
stem O O
cell O O
result O O
, O O
we O O
will O O
collect O O
and O O
do O O
an O O
autologous O O
stem O O
cell O O
transplant O O
on O O
the O O
patient O O
. O O
  
I O O
will O O
also O O
evaluate O O
his O O
ear O O
again O O
after O O
the O O
recovery O O
of O O
his O O
count O O
to O O
consider O O
sending O O
him O O
for O O
ENT O O
evaluation O O
. O O
  
I O O
spent O O
40 O O
minutes O O
with O O
the O O
patient O O
with O O
about O O
30 O O
minutes O O
direct O O
face O O
- O O
to O O
- O O
face O O
discussing O O
evaluating O O
the O O
patient O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
18 O O
: O O
38 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Location O O
  
Street_Address O O
City O O
State O O
/ O O
Zipcode O O
Name O O
Name O O
Name O O
, O O
MD O O
Location O O
  
Street_Address O O
City O O
State O O
/ O O
Zipcode O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
M.D. O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
07 O O
: O O
58 O O
AM O O
Clinic O O
Note O O
DIAGNOSIS O O
: O O
Mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
status O O
post O O
matched O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
123 O O
days O O
ago O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
comes O O
back O O
for O O
followup O O
examination O O
today O O
. O O
  
He O O
is O O
123 O O
days O O
status O O
post O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
for O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
in O O
first O O
complete O O
remission O O
. O O
  
Overall O O
, O O
he O O
has O O
been O O
doing O O
fairly O O
well O O
. O O
  
He O O
denies O O
any O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
or O O
diarrhea B-SSLIF B-SSLIF
. O O
  
Denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
has O O
been O O
eating O O
and O O
drinking O O
fairly O O
well O O
. O O
  
He O O
recently O O
had O O
an O O
upper B-SSLIF B-SSLIF
respiratory I-SSLIF I-SSLIF
infection I-SSLIF I-SSLIF
from O O
which O O
he O O
has O O
been O O
improving O O
. O O
  
He O O
denies O O
any O O
other O O
symptomatology O O
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
, O O
specifically O O
he O O
has O O
been O O
taking O O
Rapamune B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
on I-Frequency I-Frequency
every I-Frequency I-Frequency
Monday I-Frequency I-Frequency
, O O
prednisone B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
is O O
also O O
on O O
dapsone B-Drug B-Drug
, O O
acyclovir B-Drug B-Drug
and O O
Noxafil B-Drug B-Drug
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
well O O
- O O
built O O
male O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Noted O O
. O O
  
His O O
weight O O
was O O
not O O
performed O O
today O O
, O O
blood O O
pressure O O
was O O
133 O O
/ O O
73 O O
, O O
pulse O O
is O O
88 O O
. O O
  
He O O
is O O
afebrile B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
Thyroid B-SSLIF B-SSLIF
gland I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
HEART O O
: O O
Sounds O O
are O O
normal O O
. O O
  
There O O
is O O
no O O
murmur B-SSLIF B-SSLIF
, O O
rub B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
LABORATORY O O
TEST O O
: O O
Done O O
today O O
reveals O O
a O O
white O O
count O O
of O O
4900 O O
, O O
hemoglobin O O
of O O
10.5 O O
and O O
a O O
platelet O O
count O O
of O O
95 O O
, O O
000 O O
. O O
  
Absolute O O
neutrophil O O
count O O
is O O
_____ O O
, O O
BUN O O
is O O
21 O O
, O O
creatinine O O
is O O
1.03 O O
, O O
albumin O O
is O O
3.8 O O
. O O
  
Sirolimus O O
level O O
was O O
2.1 O O
and O O
CMV O O
quant O O
PCR O O
showed O O
105 O O
copies O O
. O O
  
Bone O O
marrow O O
revealed O O
a O O
cellular O O
marrow O O
with O O
maturing O O
trilineage O O
hematopoiesis O O
. O O
  
There O O
was O O
no O O
evidence O O
of O O
lymphoma B-SSLIF B-SSLIF
seen O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Graft O O
: O O
The O O
patient O O
is O O
well O O
engrafted O O
of O O
growth B-Drug B-Drug
factors I-Drug I-Drug
and O O
transfusion O O
independent O O
. O O
  
2. O O
Graft B-Indication B-Indication
versus I-Indication I-Indication
host I-Indication I-Indication
disease I-Indication I-Indication
: O O
There O O
is O O
no O O
active O O
graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
I O O
am O O
further O O
tapering O O
his O O
immunosuppression O O
to O O
prednisone B-Drug B-Drug
of O O
10 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
will O O
continue O O
his O O
Sirolimus B-Drug B-Drug
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Infectious O O
disease O O
: O O
The O O
patient O O
has O O
had O O
an O O
upper B-SSLIF B-SSLIF
respiratory I-SSLIF I-SSLIF
viral I-SSLIF I-SSLIF
symptomatology I-SSLIF I-SSLIF
which O O
he O O
tells O O
me O O
is O O
getting O O
better O O
. O O
  
I O O
obtained O O
a O O
respiratory O O
viral O O
panel O O
today O O
. O O
  
He O O
also O O
has O O
had O O
mild B-Severity B-Severity
reactivation B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
CMV I-SSLIF I-SSLIF
and O O
has O O
105 O O
copies O O
currently O O
. O O
  
We O O
will O O
also O O
continue O O
to O O
follow O O
that O O
. O O
  
Nutritionally O O
, O O
he O O
is O O
doing O O
well O O
. O O
  
He O O
continues O O
on O O
Synthroid B-Drug B-Drug
replacement O O
for O O
his O O
hypothyroidism B-Indication B-Indication
. O O
  
Peripheral B-Indication B-Indication
neuropathy I-Indication I-Indication
, O O
this O O
seems O O
to O O
be O O
stable O O
on O O
gabapentin B-Drug B-Drug
. O O
  
He O O
is O O
going O O
to O O
be O O
followed O O
back O O
in O O
about O O
2 O O
weeks O O
with O O
repeat O O
blood O O
counts O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
6 O O
: O O
23PM O O
EST O O
Attending O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Admit O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
Date O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
19 O O
: O O
08 O O
PM O O
INFECTIOUS O O
DISEASE O O
CONSULT O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
ATTENDING O O
OF O O
RECORD O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
REASON O O
FOR O O
CONSULT O O
: O O
Fever B-SSLIF B-SSLIF
, O O
rash B-SSLIF B-SSLIF
? O O
pneumonia B-SSLIF B-SSLIF
. O O
  
Information O O
taken O O
from O O
the O O
patient O O
and O O
medical O O
records O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
69 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
history O O
of O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
, O O
who O O
was O O
admitted O O
on O O
Date O O
for O O
matched O O
- O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
. O O
  
Cells O O
were O O
infused O O
on O O
Date O O
. O O
  
He O O
has O O
been O O
on O O
acyclovir B-Drug B-Drug
and O O
posaconazole B-Drug B-Drug
, O O
and O O
when O O
his O O
cell B-SSLIF B-SSLIF
counts I-SSLIF I-SSLIF
start I-SSLIF I-SSLIF
decreasing I-SSLIF I-SSLIF
, O O
he O O
started O O
on O O
levofloxacin B-Drug B-Drug
on O O
Date O O
. O O
  
On O O
Date O O
, O O
the O O
patient O O
had O O
one O O
episode O O
of O O
fever B-SSLIF B-SSLIF
with O O
temperature O O
38 O O
. O O
  
CXR O O
was O O
suspicious O O
for O O
bilateral B-Indication B-Indication
consolidations I-Indication I-Indication
. O O
  
Vancomycin B-Drug B-Drug
and O O
piperacillin B-Drug B-Drug
/ I-Drug I-Drug
tazobactam I-Drug I-Drug
were O O
started O O
. O O
  
He O O
developed O O
a O O
maculopapular B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
starting O O
on O O
Date O O
involving O O
the O O
upper O O
trunk O O
and O O
arms O O
that O O
has O O
gotten O O
worse O O
over O O
the O O
last O O
48 O O
hrs O O
. O O
  
The O O
rash B-SSLIF B-SSLIF
does O O
not O O
itch B-SSLIF B-SSLIF
or O O
hurt B-SSLIF B-SSLIF
. O O
  
He O O
is O O
still O O
having O O
intermittent O O
fever B-SSLIF B-SSLIF
mainly O O
after O O
Date O O
with O O
Tmax O O
38.5 O O
on O O
Date O O
. O O
  
The O O
patient O O
reports O O
feeling O O
well O O
, O O
and O O
denies O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
SOB B-SSLIF B-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
, O O
dysuria B-SSLIF B-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
As O O
above O O
, O O
and O O
otherwise O O
negative O O
. O O
  
No O O
insect B-SSLIF B-SSLIF
bites I-SSLIF I-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
As O O
above O O
, O O
and O O
hypothyroidism B-SSLIF B-SSLIF
status O O
post O O
thyroidectomy O O
, O O
neuropathy B-SSLIF B-SSLIF
thought O O
to O O
be O O
secondary O O
to O O
chemotherapy B-Drug B-Drug
, O O
inguinal O O
hernia O O
surgery O O
in O O
Date O O
, O O
lymph O O
node O O
biopsy O O
in O O
Date O O
. O O
  
Based O O
on O O
hepatitis O O
B O O
serology O O
( O O
see O O
below O O
) O O
, O O
the O O
patient O O
was O O
started O O
on O O
entecavir B-Drug B-Drug
prophylaxis B-Indication B-Indication
on O O
Date O O
. O O
  
HOME O O
MEDICATIONS O O
: O O
Levothyroxine B-Drug B-Drug
, O O
omeprazole B-Drug B-Drug
, O O
acyclovir B-Drug B-Drug
and O O
Compazine B-Drug B-Drug
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Brother O O
died B-SSLIF B-SSLIF
of O O
MI B-SSLIF B-SSLIF
at O O
age O O
58 O O
with O O
a O O
history O O
of O O
stroke B-SSLIF B-SSLIF
and O O
leukemia B-SSLIF B-SSLIF
. O O
  
Another O O
brother O O
had O O
CAD B-SSLIF B-SSLIF
and O O
diabetes B-SSLIF B-SSLIF
. O O
  
His O O
son O O
died B-SSLIF B-SSLIF
of O O
colorectal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
currently O O
lives O O
alone O O
. O O
  
No O O
pets O O
. O O
  
Denies O O
any O O
alcohol O O
or O O
tobacco O O
use O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Pale B-SSLIF B-SSLIF
but O O
not O O
in O O
distress B-SSLIF B-SSLIF
. O O
  
Seems O O
comfortable O O
and O O
in O O
good O O
spirits O O
. O O
  
Temperature O O
curve O O
with O O
T O O
- O O
max O O
38.5 O O
on O O
Date O O
, O O
blood O O
pressure O O
122 O O
/ O O
66 O O
, O O
heart O O
rate O O
80 O O
, O O
respiratory O O
rate O O
8 O O
, O O
94 O O
percent O O
O2 O O
on O O
room O O
air O O
. O O
  
HEENT O O
: O O
Oropharynx O O
clear O O
. O O
  
LYMPH O O
: O O
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
HEART O O
: O O
Regular O O
, O O
S1 O O
, O O
no O O
murmur B-SSLIF B-SSLIF
was O O
heard O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
Good O O
bilateral O O
air O O
entry O O
. O O
  
No O O
crackles B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Positive O O
bowel O O
sounds O O
, O O
soft O O
, O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
VASCULAR O O
: O O
Right O O
PICC O O
line O O
site O O
clear O O
and O O
non O O
- O O
tender O O
. O O
  
Extremities O O
war O O
, O O
symmetric O O
pulses O O
, O O
no O O
edema B-SSLIF B-SSLIF
. O O
  
MUSCULOSKELETAL O O
: O O
Normal O O
joints O O
. O O
  
SKIN O O
: O O
Maculopapular B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
scalp I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
trunk I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
arms I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
mid I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
mid I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
abdomen I-SSLIF I-SSLIF
. O O
  
No O O
purpura B-SSLIF B-SSLIF
, O O
no O O
vesicles B-SSLIF B-SSLIF
. O O
  
No O O
rash B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
palms I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
soles I-SSLIF I-SSLIF
. O O
  
NEURO O O
: O O
Strength O O
and O O
sensation O O
grossly O O
intact O O
. O O
  
LABORATORY O O
STUDIES O O
: O O
Recent O O
data O O
was O O
reviewed O O
. O O
  
Of O O
note O O
, O O
WBC O O
<0.2 O O
, O O
creatinine O O
1.6 O O
, O O
normal O O
liver O O
enzymes O O
. O O
  
Blood O O
cultures O O
Date O O
, O O
Date O O
, O O
and O O
Date O O
no O O
growth O O
. O O
  
UA O O
negative O O
. O O
  
Urine O O
culture O O
Date O O
and O O
Date O O
negative O O
. O O
  
On O O
Date O O
, O O
HBV O O
core O O
IgM O O
positive O O
and O O
surface O O
antigen O O
negative O O
and O O
surface O O
antibody O O
not O O
done O O
. O O
  
On O O
Date O O
, O O
HBV O O
core O O
total O O
antibody O O
and O O
surface O O
antibody O O
both O O
positive O O
and O O
PCR O O
negative O O
. O O
  
IMAGING O O
STUDIES O O
: O O
CT O O
reviewed O O
, O O
mild B-Severity B-Severity
left B-SSLIF B-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
with O O
no O O
clear O O
consolidation O O
. O O
  
IMPRESSION O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
69 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
history O O
of O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
who O O
was O O
admitted O O
for O O
an O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
infused O O
on O O
Date O O
( O O
sirolimus B-Drug B-Drug
started O O
on O O
Date O O
) O O
, O O
and O O
subsequently O O
developed O O
fever B-SSLIF B-SSLIF
intermittent O O
since O O
Date O O
and O O
rash B-SSLIF B-SSLIF
starting O O
on O O
Date O O
. O O
  
There O O
has O O
been O O
a O O
concern O O
for O O
pneumonia B-SSLIF B-SSLIF
on O O
CT O O
scan O O
, O O
but O O
no O O
clinical O O
symptoms O O
. O O
  
1. O O
Fever B-SSLIF B-SSLIF
and O O
rash B-SSLIF B-SSLIF
, O O
which O O
are O O
not O O
clearly O O
related O O
. O O
  
An O O
infectious B-SSLIF B-SSLIF
process I-SSLIF I-SSLIF
including O O
viral B-SSLIF B-SSLIF
etiologies O O
are O O
possible O O
, O O
but O O
the O O
clinical O O
syndrome O O
is O O
more O O
consistent O O
with O O
GVHD B-SSLIF B-SSLIF
or O O
drug B-ADE B-ADE
reaction I-ADE I-ADE
. O O
  
Of O O
the O O
medications O O
being O O
given O O
, O O
the O O
rate O O
of O O
rash B-ADE B-ADE
for O O
piperacillin B-Drug B-Drug
is O O
about O O
5% O O
, O O
entecavir B-Drug B-Drug
less O O
than O O
1% O O
, O O
and O O
sirolimus B-Drug B-Drug
10 O O
- O O
20% O O
based O O
on O O
pharmacy O O
references O O
. O O
  
There O O
are O O
no O O
signs O O
or O O
symptoms O O
of O O
GI B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
GU I-SSLIF I-SSLIF
infections I-SSLIF I-SSLIF
. O O
  
Chest O O
CT O O
showed O O
left B-SSLIF B-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
, O O
however O O
no O O
obvious O O
consolidation B-SSLIF B-SSLIF
, O O
and O O
the O O
patient O O
has O O
no O O
cough B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
oxygen O O
requirment O O
. O O
  
Sirolimus B-Drug B-Drug
is O O
also O O
known O O
to O O
cause O O
pleural B-ADE B-ADE
effusions I-ADE I-ADE
. O O
  
2. O O
Possible O O
history O O
of O O
hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
infection I-SSLIF I-SSLIF
. O O
  
However O O
, O O
HBV O O
core O O
total O O
and O O
core O O
IgM O O
are O O
both O O
positive O O
, O O
which O O
may O O
indicate O O
false O O
positive O O
core O O
IgM O O
as O O
the O O
cause O O
of O O
core O O
total O O
antibody O O
positive O O
( O O
rather O O
than O O
positive O O
core O O
IgG O O
as O O
the O O
cause O O
, O O
which O O
would O O
indicate O O
past O O
infection O O
) O O
. O O
  
The O O
patient O O
is O O
HBV O O
immune O O
with O O
surface O O
antibody O O
positive O O
. O O
  
He O O
has O O
been O O
on O O
entecavir B-Drug B-Drug
since O O
Date O O
. O O
  
3. O O
Mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
4. O O
Acute O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
5 O O
. O O
  
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
RECOMMENDATION O O
: O O
  
1. O O
Send O O
MRSA O O
swab O O
. O O
  
2. O O
Given O O
worsening B-SSLIF B-SSLIF
kidney I-SSLIF I-SSLIF
function I-SSLIF I-SSLIF
and O O
in O O
the O O
setting O O
of O O
unexplained O O
rash B-SSLIF B-SSLIF
with O O
no O O
clear O O
signs O O
or O O
symptoms O O
of O O
pneumonia B-SSLIF B-SSLIF
, O O
consider O O
stopping O O
vancomycin B-Drug B-Drug
and O O
piperacillin B-Drug B-Drug
/ I-Drug I-Drug
tazobactam I-Drug I-Drug
. O O
  
Consider O O
ceftazidime B-Drug B-Drug
( O O
renaly B-Route B-Route
dosed O O
) O O
if O O
ongoing O O
fever B-Indication B-Indication
. O O
  
Antibiotics B-Drug B-Drug
can O O
be O O
further O O
adjusted O O
based O O
on O O
clinical O O
status O O
and O O
further O O
microbiology O O
data O O
. O O
  
3. O O
Consider O O
dermatology O O
consult O O
for O O
further O O
evaluation O O
of O O
rash B-SSLIF B-SSLIF
. O O
  
4. O O
Check O O
CORE O O
total O O
, O O
IgG O O
, O O
and O O
IgM O O
antibodies O O
. O O
  
Core O O
IgM O O
positive O O
is O O
likely O O
false O O
( O O
assuming O O
no O O
clinical O O
primary O O
HBV O O
infection O O
) O O
, O O
while O O
core O O
IgG O O
positive O O
indicates O O
past O O
infection B-SSLIF B-SSLIF
. O O
  
Thank O O
you O O
for O O
this O O
interesting O O
consult O O
. O O
  
Please O O
feel O O
free O O
to O O
call O O
us O O
for O O
any O O
other O O
questions O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
, O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
Last O O
Edited O O
By O O
Name O O
Name O O
, O O
MD O O
# O O
Identifiers O O
on O O
Date O O
20 O O
: O O
39 O O
Revision O O
Number O O
- O O
2 O O
Last O O
Edited O O
By O O
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
. O O
  
I O O
discussed O O
the O O
Name O O
Name O O
Name O O
, O O
MD O O
# O O
Medical_Record_Number O O
case O O
with O O
the O O
fellow O O
and O O
agree O O
with O O
the O O
findings O O
on O O
Date O O
13 O O
: O O
45 O O
and O O
plan O O
as O O
documented O O
in O O
the O O
fellows O O
note O O
. O O
  
Revision O O
Number O O
- O O
3 O O
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
# O O
Medical_Record_Number O O
on O O
Date O O
13 O O
: O O
45 O O
Name O O
Name O O
, O O
MD O O
# O O
Medical_Record_Number O O
on O O
Date O O
20 O O
: O O
39 O O
Date O O
of O O
service O O
: O O
Date O O
CHIEF O O
COMPLAIN O O
: O O
Evaluation O O
for O O
possible O O
blood O O
transfusions O O
after O O
HyperCVAD B-Drug B-Drug
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
INTERVAL O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
returns O O
today O O
for O O
followup O O
and O O
assessment O O
after O O
his O O
recent O O
fifth O O
cycle O O
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
/ I-Drug I-Drug
Rituxan I-Drug I-Drug
protocol O O
. O O
  
He O O
continues O O
to O O
do O O
well O O
. O O
  
He O O
has O O
been O O
noted O O
to O O
have O O
fall O O
in O O
his O O
counts O O
and O O
for O O
concern O O
of O O
need O O
for O O
transfusions O O
he O O
came O O
to O O
have O O
his O O
blood O O
checked O O
and O O
possibly O O
be O O
transfused O O
today O O
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
is O O
eating O O
well O O
, O O
has O O
a O O
good O O
appetite O O
and O O
has O O
maintained O O
a O O
stable O O
weight O O
. O O
  
He O O
denies O O
any O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
or O O
dyspnea B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
headache B-SSLIF B-SSLIF
or O O
dizziness B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
change O O
to O O
his O O
bowel O O
habits O O
. O O
  
He O O
has O O
some B-Severity B-Severity
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
, O O
however O O
, O O
it O O
does O O
not O O
bother O O
him O O
too O O
much O O
. O O
  
PAST O O
MEDICAL O O
, O O
FAMILY O O
AND O O
SOCIAL O O
HISTORY O O
: O O
Reviewed O O
and O O
unchanged O O
. O O
  
MEDICATIONS O O
: O O
These O O
are O O
reviewed O O
and O O
reconciled O O
in O O
Company O O
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
comprehensive O O
review O O
of O O
systems O O
is O O
otherwise O O
negative O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
temperature O O
is O O
36.2 O O
, O O
blood O O
pressure O O
110 O O
/ O O
77 O O
, O O
heart O O
rate O O
71 O O
, O O
respirations O O
18 O O
. O O
  
GENERAL O O
: O O
He O O
is O O
alert O O
, O O
awake O O
and O O
oriented O O
x3 O O
, O O
in O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Reveals O O
normocephalic O O
, O O
atraumatic B-SSLIF B-SSLIF
head O O
. O O
  
Extraocular O O
movements O O
intact O O
. O O
  
Pupils O O
equal O O
, O O
round O O
and O O
reactive O O
to O O
light O O
and O O
accommodation O O
. O O
  
Mouth O O
mucosa O O
moist O O
and O O
pink O O
. O O
  
Oropharynx O O
clear O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
lymphadenopathy B-SSLIF B-SSLIF
appreciated I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
cervical I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
regions I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
No O O
rales B-SSLIF B-SSLIF
, O O
no O O
rhonchi B-SSLIF B-SSLIF
, O O
n O O
murmurs B-SSLIF B-SSLIF
, O O
rubs B-SSLIF B-SSLIF
or O O
gallops B-SSLIF B-SSLIF
. O O
  
HEART O O
: O O
Shows O O
regular O O
rate O O
and O O
rhythm O O
, O O
normal O O
sounds O O
S1 O O
and O O
S2 O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
and O O
nondistended B-SSLIF B-SSLIF
, O O
bowel O O
sounds O O
present O O
by O O
auscultation O O
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
edema B-SSLIF B-SSLIF
, O O
cyanosis B-SSLIF B-SSLIF
or O O
clubbing B-SSLIF B-SSLIF
bilaterally O O
. O O
  
Only O O
mild B-Severity B-Severity
redness B-SSLIF B-SSLIF
not O O
tenderness B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
toe I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
is O O
grossly O O
stable O O
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
work O O
from O O
today O O
were O O
reviewed O O
. O O
  
His O O
WBC O O
is O O
0.7 O O
, O O
hemoglobin O O
is O O
8.4 O O
, O O
hematocrit O O
24.4 O O
, O O
and O O
platelets O O
are O O
34 O O
, O O
000 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
  
68 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
ECOG O O
performance O O
status O O
1 O O
, O O
who O O
is O O
doing O O
well O O
after O O
5 O O
cycles O O
of O O
chemotherapy B-Drug B-Drug
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
comes O O
to O O
be O O
evaluated O O
for O O
possible O O
blood O O
transfusions O O
. O O
  
1. O O
Pancytopenia B-SSLIF B-SSLIF
. O O
  
No O O
need O O
for O O
transfusions O O
today O O
, O O
it O O
appears O O
as O O
if O O
his O O
counts O O
are O O
recovering O O
. O O
  
He O O
has O O
an O O
appointment O O
early O O
next O O
week O O
. O O
  
He O O
is O O
denying O O
any O O
symptoms O O
. O O
  
2. O O
Infectious O O
disease O O
. O O
  
Prophylactic B-Indication B-Indication
Noxafil B-Drug B-Drug
, O O
levaquin B-Drug B-Drug
and O O
acyclovir B-Drug B-Drug
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
12 O O
: O O
23PM O O
EST O O
Attending O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
M.D. O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
16 O O
: O O
38 O O
PM O O
Clinic O O
Note O O
DIAGNOSES O O
: O O
  
1. O O
Mantel B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
status O O
post O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
approximately O O
10 O O
months O O
ago O O
. O O
  
2. O O
Hypogammaglobulinemia B-SSLIF B-SSLIF
post O O
- O O
stem O O
cell O O
transplant O O
. O O
  
3. O O
History O O
of O O
exposure B-Indication B-Indication
to I-Indication I-Indication
hepatitis I-Indication I-Indication
B I-Indication I-Indication
infection I-Indication I-Indication
in O O
the O O
past O O
. O O
  
Currently O O
, O O
on O O
Baraclude B-Drug B-Drug
therapy O O
. O O
  
4. O O
Hypothyroidism B-SSLIF B-SSLIF
. O O
  
5. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
chemotherapy B-Drug B-Drug
, O O
currently O O
improved O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
comes O O
back O O
for O O
followup O O
examination O O
today O O
. O O
  
He O O
is O O
approximately O O
1 O O
year O O
status O O
post O O
unrelated O O
donor O O
cord O O
blood O O
stem O O
cell O O
transplant O O
for O O
his O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
His O O
preparative O O
regimen O O
included O O
post O O
- O O
transplant O O
cyclophosphamide B-Drug B-Drug
. O O
  
Overall O O
, O O
he O O
has O O
been O O
doing O O
well O O
since O O
his O O
last O O
visit O O
. O O
  
He O O
denies O O
any O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
or O O
diarrhea B-SSLIF B-SSLIF
. O O
  
Denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
has O O
been O O
eating O O
and O O
drinking O O
fairly O O
well O O
. O O
  
He O O
has O O
been O O
maintaining O O
his O O
weight O O
. O O
  
His O O
neuropathic B-Indication B-Indication
symptoms I-Indication I-Indication
have O O
completely O O
resolved O O
at O O
this O O
time O O
and O O
he O O
wants O O
to O O
taper O O
off O O
his O O
gabapentin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
, O O
specifically O O
he O O
is O O
taking O O
acyclovir B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
, O O
Baraclude B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
and O O
gabapentin B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
along O O
with O O
levothyroxine B-Drug B-Drug
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
a O O
well O O
- O O
built O O
male O O
, O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Noted O O
. O O
  
His O O
blood O O
pressure O O
is O O
153 O O
/ O O
83 O O
, O O
pulse O O
70 O O
, O O
respirations O O
20 O O
. O O
  
He O O
is O O
afebrile O O
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
are I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
There O O
are O O
no O O
changes O O
consistent O O
with O O
graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
trachea O O
is O O
central O O
. O O
  
Thyroid B-SSLIF B-SSLIF
gland I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
HEART O O
: O O
Heart O O
sounds O O
are O O
normal O O
. O O
  
There O O
is O O
no O O
murmur B-SSLIF B-SSLIF
, O O
rub B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
reveal O O
a O O
white O O
count O O
of O O
4800 O O
, O O
hemoglobin O O
of O O
12.8 O O
and O O
a O O
platelet O O
count O O
of O O
167 O O
, O O
000 O O
. O O
  
Segs O O
. O O
  
52% O O
, O O
lymphocytes O O
31% O O
. O O
  
BUN O O
is O O
29 O O
, O O
creatinine O O
is O O
1.27 O O
. O O
  
Albumin O O
is O O
4.2 O O
, O O
cholesterol O O
is O O
252 O O
, O O
triglycerides O O
185 O O
, O O
magnesium O O
2.1 O O
. O O
  
Free O O
T O O
and O O
free O O
T4 O O
level O O
are O O
within O O
normal O O
limits O O
, O O
though O O
his O O
thyroid B-SSLIF B-SSLIF
stimulating I-SSLIF I-SSLIF
hormone I-SSLIF I-SSLIF
level I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
mildly I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
, O O
is O O
4.61 O O
micro O O
international O O
units O O
per O O
mL O O
. O O
  
Results O O
of O O
his O O
lymphocytes O O
subset O O
panel O O
and O O
immunoglobulin O O
levels O O
are O O
still O O
pending O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Graft O O
: O O
The O O
patient O O
is O O
well O O
engrafted O O
of O O
growth B-Drug B-Drug
factors I-Drug I-Drug
and O O
transfusion O O
independent O O
1 O O
year O O
status O O
post O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
. O O
  
2. O O
Graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
does O O
not O O
have O O
any O O
active O O
graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
He O O
is O O
off O O
all O O
immunosuppressive B-Drug B-Drug
therapy I-Drug I-Drug
. O O
  
3. O O
Infectious B-Indication B-Indication
disease I-Indication I-Indication
. O O
  
The O O
patient O O
does O O
not O O
have O O
any O O
active O O
infection B-SSLIF B-SSLIF
. O O
  
He O O
continues O O
on O O
prophylactic B-Indication B-Indication
acyclovir B-Drug B-Drug
. O O
  
He O O
is O O
also O O
on O O
Baraclude B-Drug B-Drug
therapy O O
because O O
of O O
his O O
previous O O
exposure B-Indication B-Indication
to I-Indication I-Indication
hepatitis I-Indication I-Indication
B I-Indication I-Indication
. O O
  
I O O
am O O
going O O
to O O
be O O
continuing O O
that O O
for O O
an O O
extended O O
period.immunoglobulin O O
levels O O
have O O
recovered O O
. O O
  
4. O O
History O O
of O O
prior O O
neuropathy B-ADE B-ADE
, O O
this O O
was O O
secondary O O
to O O
his O O
prior O O
therapy O O
. O O
  
However O O
, O O
since O O
his O O
neuropathy B-Indication B-Indication
has O O
resolved O O
, O O
I O O
am O O
going O O
to O O
be O O
tapering O O
him O O
off O O
gabapentin B-Drug B-Drug
. O O
  
He O O
is O O
only O O
on O O
low O O
- O O
dose O O
, O O
which O O
is O O
100 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
and O O
I O O
have O O
asked O O
him O O
to O O
start O O
100 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
I O O
am O O
going O O
to O O
take O O
him O O
off O O
gabapentin B-Drug B-Drug
in O O
a O O
month O O
. O O
  
5. O O
History O O
of O O
hypothyroidism B-Indication B-Indication
, O O
his O O
TSH B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
. O O
  
He O O
is O O
only O O
taking O O
gabapentin B-Drug B-Drug
at O O
125 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
perhaps O O
it O O
can O O
be O O
increased O O
over O O
to O O
150 B-Dose B-Dose
mcg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
This O O
may O O
need O O
to O O
be O O
done O O
through O O
his O O
primary O O
care O O
physician O O
, O O
who O O
can O O
followup O O
. O O
  
6. O O
History O O
of O O
hypertriglyceridemia B-Indication B-Indication
. O O
  
He O O
may O O
need O O
to O O
be O O
on O O
statins B-Drug B-Drug
for O O
the O O
same O O
. O O
  
We O O
will O O
have O O
a O O
discussion O O
with O O
him O O
during O O
his O O
next O O
visit O O
with O O
me O O
. O O
  
I O O
have O O
asked O O
him O O
to O O
follow O O
up O O
with O O
me O O
in O O
2 O O
weeks O O
. O O
  
At O O
that O O
time O O
, O O
we O O
will O O
have O O
a O O
discussion O O
about O O
his O O
staging O O
and O O
results O O
and O O
immune O O
recovery O O
. O O
  
At O O
that O O
time O O
, O O
we O O
will O O
give O O
him O O
his O O
vaccination O O
, O O
which O O
I O O
do O O
at O O
1 O O
year O O
post O O
- O O
transplant O O
and O O
will O O
be O O
repeating O O
those O O
vaccinations O O
in O O
2 O O
months O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
MD O O
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
10 O O
: O O
41PM O O
EST O O
Author O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
M.D. O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
10 O O
: O O
54 O O
AM O O
Clinic O O
Note O O
DIAGNOSES O O
: O O
  
1. O O
Mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
status O O
post O O
donor O O
stem O O
cell O O
transplant O O
5 O O
months O O
ago O O
. O O
  
2. O O
Chronic O O
upper B-SSLIF B-SSLIF
respiration I-SSLIF I-SSLIF
tract I-SSLIF I-SSLIF
infection I-SSLIF I-SSLIF
with O O
rhinovirus B-SSLIF B-SSLIF
with O O
persistent O O
cough B-SSLIF B-SSLIF
. O O
  
3. O O
History O O
of O O
exposure B-Indication B-Indication
to I-Indication I-Indication
hepatitis I-Indication I-Indication
B I-Indication I-Indication
. O O
  
Currently O O
, O O
on O O
therapy O O
with O O
Baraclude B-Drug B-Drug
. O O
  
4. O O
Hyperthyroidism B-SSLIF B-SSLIF
. O O
  
5. O O
Neuropathy B-SSLIF B-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
Name O O
comes O O
back O O
for O O
followup O O
examination O O
. O O
  
Today O O
is O O
approximately O O
5 O O
months O O
status O O
post O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
. O O
  
His O O
major O O
complaint O O
has O O
been O O
that O O
of O O
some B-Severity B-Severity
dry B-SSLIF B-SSLIF
cough I-SSLIF I-SSLIF
. O O
  
He O O
had O O
upper B-Indication B-Indication
respiratory I-Indication I-Indication
symptoms I-Indication I-Indication
in O O
middle O O
of O O
Date O O
and O O
at O O
that O O
time O O
, O O
respiratory B-Indication B-Indication
viral I-Indication I-Indication
infection I-Indication I-Indication
had O O
shown O O
a O O
rhinovirus B-SSLIF B-SSLIF
. O O
  
He O O
has O O
since O O
been O O
put O O
on O O
some O O
Augmentin B-Drug B-Drug
by O O
his O O
primary O O
care O O
physician O O
and O O
has O O
completed O O
the O O
same O O
. O O
  
He O O
comes O O
back O O
for O O
followup O O
examination O O
today O O
. O O
  
He O O
tells O O
me O O
that O O
he O O
is O O
still O O
having O O
some B-Severity B-Severity
cough B-SSLIF B-SSLIF
. O O
  
As O O
I O O
was O O
reviewing O O
his O O
medication O O
, O O
he O O
had O O
actually O O
stopped O O
his O O
dapsone B-Drug B-Drug
, O O
but O O
had O O
continued O O
on O O
Rapamune B-Drug B-Drug
. O O
  
He O O
was O O
supposed O O
to O O
stop O O
his O O
Rapamune B-Drug B-Drug
, O O
but O O
continue O O
the O O
dapsone B-Drug B-Drug
. O O
  
He O O
comes O O
back O O
for O O
followup O O
. O O
  
He O O
denies O O
any O O
other O O
complaints O O
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
. O O
  
Again O O
he O O
taking O O
Rapamune B-Drug B-Drug
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
, O O
which O O
he O O
was O O
supposed O O
to O O
stop O O
, O O
and O O
on O O
the O O
same O O
token O O
, O O
he O O
was O O
not O O
taking O O
his O O
dapsone B-Drug B-Drug
, O O
which O O
he O O
was O O
supposed O O
to O O
take O O
100 B-Dose B-Dose
mg I-Dose I-Dose
daily I-Dose I-Dose
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
a O O
slimly O O
built O O
male O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Are O O
noted O O
. O O
  
He O O
is O O
afebrile B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
and O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
There O O
are O O
no O O
changes O O
consistent O O
with O O
graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
Thyroid B-SSLIF B-SSLIF
gland I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
HEART O O
: O O
Heart O O
sounds O O
are O O
normal O O
. O O
  
There O O
is O O
no O O
murmur B-SSLIF B-SSLIF
, O O
rub B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
reveal O O
a O O
white O O
count O O
of O O
5000 O O
, O O
hemoglobin O O
of O O
11.8 O O
and O O
a O O
platelet O O
count O O
of O O
132 O O
, O O
000 O O
. O O
  
Segs O O
46% O O
, O O
lymphocytes O O
38% O O
, O O
giving O O
him O O
an O O
absolute O O
neutrophil O O
count O O
of O O
3213 O O
and O O
an O O
absolute O O
lymphocyte O O
count O O
of O O
1900 O O
. O O
  
Comprehensive O O
metabolic O O
panel O O
reveals O O
a O O
BUN O O
of O O
24 O O
, O O
creatinine O O
of O O
1.15 O O
, O O
albumin O O
of O O
4.1 O O
. O O
  
Total O O
cholesterol O O
is O O
292 O O
, O O
triglycerides O O
are O O
275 O O
, O O
HDL O O
is O O
37 O O
, O O
LDL O O
is O O
200 O O
. O O
  
C B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
reactive I-SSLIF I-SSLIF
protein I-SSLIF I-SSLIF
cardiac I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
high I-SSLIF I-SSLIF
at O O
4.6 O O
. O O
  
Her O O
total O O
_____ O O
free O O
T4 O O
and O O
TSH O O
levels O O
are O O
still O O
pending O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Graft O O
: O O
The O O
patient O O
is O O
well O O
engrafted O O
off O O
growth B-Drug B-Drug
factors I-Drug I-Drug
and O O
transfusion O O
independent O O
. O O
  
2. O O
Graft B-Indication B-Indication
versus I-Indication I-Indication
host I-Indication I-Indication
disease I-Indication I-Indication
: O O
There O O
is O O
no O O
active O O
graft B-SSLIF B-SSLIF
versus I-SSLIF I-SSLIF
host I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
was O O
supposed O O
to O O
be O O
on O O
stopping O O
his O O
sirolimus B-Drug B-Drug
, O O
but O O
he O O
had O O
been O O
continuing O O
it O O
as O O
of O O
right O O
now O O
. O O
  
I O O
asked O O
him O O
to O O
stop O O
both O O
his O O
sirolimus B-Drug B-Drug
and O O
prednisone B-Drug B-Drug
today O O
. O O
  
3. O O
Infectious O O
disease O O
: O O
The O O
patient O O
has O O
persistent O O
mild B-Severity B-Severity
cough B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
infection B-SSLIF B-SSLIF
with O O
a O O
rhinovirus B-SSLIF B-SSLIF
. O O
  
I O O
think O O
it O O
is O O
lingering O O
of O O
the O O
same O O
. O O
  
At O O
the O O
current O O
time O O
, O O
I O O
am O O
going O O
to O O
stop O O
both O O
prednisone B-Drug B-Drug
and O O
sirolimus B-Drug B-Drug
and O O
see O O
if O O
there O O
is O O
an O O
improvement O O
in O O
his O O
infection B-SSLIF B-SSLIF
or O O
whether O O
his O O
symptoms O O
persist O O
. O O
  
In O O
this O O
regard O O
, O O
I O O
am O O
going O O
to O O
follow O O
him O O
up O O
in O O
about O O
6 O O
weeks O O
, O O
but O O
he O O
can O O
call O O
if O O
his O O
symptoms O O
persist O O
. O O
  
4. O O
Nutritional O O
status O O
: O O
His O O
nutritional O O
status O O
is O O
good O O
. O O
  
5. O O
Disease O O
staging O O
: O O
We O O
will O O
stage O O
him O O
with O O
a O O
bone O O
marrow O O
aspiration O O
and O O
biopsy O O
and O O
a O O
PET O O
scan O O
6 O O
months O O
post O O
- O O
transplant O O
. O O
  
Next O O
time O O
when O O
aspirin B-Drug B-Drug
see O O
him O O
, O O
he O O
will O O
get O O
a O O
bone O O
marrow O O
and O O
a O O
staging O O
PET O O
scan O O
will O O
be O O
ordered O O
. O O
  
6. O O
Neuropathy B-SSLIF B-SSLIF
: O O
Stable O O
. O O
  
7. O O
Hypothyroidism B-Indication B-Indication
: O O
Continues O O
on O O
thyroid B-Drug B-Drug
replacement I-Drug I-Drug
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
9 O O
: O O
08PM O O
EST O O
Author O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
, O O
PA O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
8 O O
: O O
36 O O
P O O
HISTORY O O
AND O O
PHYSICAL O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
60 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
a O O
past O O
medical O O
history O O
significant O O
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
He O O
is O O
receiving O O
  
Rituxan B-Drug B-Drug
which O O
each O O
cycle O O
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
treatment O O
as O O
an O O
OP O O
. O O
  
He O O
is O O
being O O
admitted O O
today O O
for O O
his O O
fourth O O
cycle O O
of O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
part O O
A O O
. O O
  
On O O
presentation O O
, O O
the O O
patient O O
is O O
feeling O O
well O O
. O O
  
He O O
denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
breath I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
and O O
cold B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
constipation B-SSLIF B-SSLIF
, O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
, O O
bleeding B-SSLIF B-SSLIF
or O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
does O O
have O O
diarrhea B-SSLIF B-SSLIF
, O O
he O O
goes O O
3 O O
- O O
4 O O
times O O
a O O
day O O
. O O
  
This O O
has O O
been O O
going O O
on O O
for O O
the O O
past O O
several O O
weeks O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Remaining O O
10 O O
- O O
point O O
review O O
of O O
systems O O
is O O
negative O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Remarkable O O
for O O
hypothyroidism B-SSLIF B-SSLIF
secondary O O
to O O
thyroidectomy O O
more O O
than O O
30 O O
years O O
ago O O
, O O
acid B-SSLIF B-SSLIF
reflux I-SSLIF I-SSLIF
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
is O O
married O O
, O O
lives O O
with O O
his O O
wife O O
. O O
  
He O O
has O O
a O O
  
50 O O
- O O
pack O O
- O O
year O O
smoking O O
history O O
, O O
but O O
quit O O
a O O
few O O
years O O
ago O O
. O O
  
He O O
drinks O O
1 O O
- O O
2 O O
alcoholic O O
drinks O O
daily O O
prior O O
to O O
becoming O O
sick O O
; O O
he O O
has O O
now O O
not O O
had O O
any O O
alcoholic O O
beverages O O
since O O
starting O O
chemotherapy B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
Remarkable O O
for O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
One O O
brother O O
died B-SSLIF B-SSLIF
of O O
an O O
MI B-SSLIF B-SSLIF
at O O
age O O
68 O O
and O O
another O O
brother O O
had O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
and O O
diabetes B-SSLIF B-SSLIF
, O O
sister O O
died B-SSLIF B-SSLIF
of O O
stroke B-SSLIF B-SSLIF
and O O
another O O
sister O O
died B-SSLIF B-SSLIF
at O O
age O O
84 O O
of O O
an O O
aneurysm B-SSLIF B-SSLIF
of O O
some O O
type O O
. O O
  
Another O O
sister O O
had O O
some O O
form O O
of O O
leukemia B-SSLIF B-SSLIF
and O O
one O O
other O O
sister O O
died B-SSLIF B-SSLIF
of O O
colorectal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
He O O
has O O
2 O O
daughters O O
, O O
one O O
of O O
whom O O
has O O
issues O O
with O O
substance O O
abuse O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
This O O
is O O
an O O
elderly O O
male O O
who O O
appears O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Reviewed O O
and O O
within O O
normal O O
limits O O
. O O
  
HEENT O O
: O O
Sclerae O O
are O O
anicteric B-SSLIF B-SSLIF
. O O
  
Oropharynx O O
is O O
pink O O
. O O
  
No O O
mucositis B-SSLIF B-SSLIF
or O O
thrush B-SSLIF B-SSLIF
. O O
  
Head O O
is O O
normocephalic O O
, O O
atraumatic B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
midline O O
. O O
  
LUNGS O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
No O O
crackles B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
HEART O O
: O O
Regular O O
rate O O
and O O
rhythm O O
, O O
normal O O
S1 O O
, O O
S2 O O
, O O
no O O
murmurs B-SSLIF B-SSLIF
, O O
rubs B-SSLIF B-SSLIF
or O O
gallops B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
nondistended B-SSLIF B-SSLIF
, O O
normoactive O O
. O O
  
EXTREMITIES O O
: O O
No O O
clubbing B-SSLIF B-SSLIF
, O O
cyanosis B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
noted O O
. O O
  
SKIN O O
: O O
No O O
rash B-SSLIF B-SSLIF
noted O O
. O O
  
NEUROLOGIC O O
: O O
Cranial O O
nerves O O
II O O
through O O
XII O O
grossly O O
normal O O
. O O
  
LABORATORY O O
DATA O O
: O O
Sodium O O
140 O O
, O O
potassium O O
3.9 O O
, O O
chloride O O
106 O O
, O O
carbon O O
dioxide O O
26 O O
, O O
glucose O O
121 O O
, O O
BUN O O
10 O O
, O O
creatinine O O
0.98 O O
, O O
phosphorus O O
5.2 O O
, O O
magnesium O O
1.9 O O
, O O
T O O
- O O
bili O O
  
0.4 O O
, O O
alkaline O O
phosphatase O O
75 O O
, O O
AST O O
21 O O
, O O
ALT O O
17 O O
, O O
INR O O
0.9 O O
. O O
  
WBC O O
9.4 O O
, O O
hemoglobin O O
  
10.4 O O
, O O
platelets O O
331 O O
, O O
000 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
This O O
is O O
a O O
68 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
past O O
medical O O
history O O
significant O O
for O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
who O O
is O O
being O O
admitted O O
for O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
part O O
  
A O O
. O O
  
1. O O
Mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
: O O
The O O
patient O O
will O O
be O O
receiving O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
part I-Drug I-Drug
A I-Drug I-Drug
. O O
  
He O O
received O O
Rituxan B-Drug B-Drug
in O O
the O O
clinic O O
prior O O
to O O
admission O O
. O O
  
He O O
will O O
receive O O
dexamethasone B-Drug B-Drug
  
40 B-Dose B-Dose
mg I-Dose I-Dose
IV B-Route B-Route
on O O
days B-Frequency B-Frequency
1 I-Frequency I-Frequency
, I-Frequency I-Frequency
2 I-Frequency I-Frequency
3 I-Frequency I-Frequency
, I-Frequency I-Frequency
4 I-Frequency I-Frequency
, I-Frequency I-Frequency
11 I-Frequency I-Frequency
, I-Frequency I-Frequency
12 I-Frequency I-Frequency
, I-Frequency I-Frequency
13 I-Frequency I-Frequency
and I-Frequency I-Frequency
14 I-Frequency I-Frequency
. O O
  
He O O
will O O
receive O O
mesna B-Drug B-Drug
720 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
for I-Dose I-Dose
a I-Dose I-Dose
total I-Dose I-Dose
of I-Dose I-Dose
1300 I-Dose I-Dose
mg I-Dose I-Dose
on O O
days B-Frequency B-Frequency
1 I-Frequency I-Frequency
, I-Frequency I-Frequency
2 I-Frequency I-Frequency
and I-Frequency I-Frequency
3 I-Frequency I-Frequency
. O O
  
He O O
received O O
cyclophosphamide B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
for I-Dose I-Dose
a I-Dose I-Dose
total I-Dose I-Dose
dose I-Dose I-Dose
of I-Dose I-Dose
550 I-Dose I-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
12 I-Frequency I-Frequency
hours I-Frequency I-Frequency
on I-Frequency I-Frequency
days I-Frequency I-Frequency
1 I-Frequency I-Frequency
, I-Frequency I-Frequency
2 I-Frequency I-Frequency
and I-Frequency I-Frequency
3 I-Frequency I-Frequency
. O O
  
vincristine B-Drug B-Drug
2 B-Dose B-Dose
mg I-Dose I-Dose
on O O
days B-Frequency B-Frequency
4 I-Frequency I-Frequency
and I-Frequency I-Frequency
11 I-Frequency I-Frequency
and O O
doxorubicin B-Drug B-Drug
31 B-Dose B-Dose
mg I-Dose I-Dose
over B-Duration B-Duration
24 I-Duration I-Duration
hours I-Duration I-Duration
x3 I-Duration I-Duration
days I-Duration I-Duration
starting B-Frequency B-Frequency
on I-Frequency I-Frequency
day I-Frequency I-Frequency
4 I-Frequency I-Frequency
. O O
  
Neulasta B-Drug B-Drug
6 B-Dose B-Dose
mg I-Dose I-Dose
24 B-Frequency B-Frequency
hours I-Frequency I-Frequency
after I-Frequency I-Frequency
last I-Frequency I-Frequency
dose I-Frequency I-Frequency
of I-Frequency I-Frequency
chemotherapy I-Frequency I-Frequency
. O O
  
The O O
patient's O O
hemoglobin O O
is O O
kept O O
above O O
8 O O
and O O
platelets O O
kept O O
above O O
10 O O
, O O
000 O O
. O O
  
2. O O
Infectious O O
disease O O
: O O
The O O
patient O O
with O O
no O O
signs O O
of O O
acute O O
infection B-SSLIF B-SSLIF
on O O
admission O O
. O O
  
He O O
does O O
have O O
some B-Severity B-Severity
diarrhea B-SSLIF B-SSLIF
, O O
will O O
check O O
stool O O
for O O
C. B-SSLIF B-SSLIF
diff I-SSLIF I-SSLIF
. O O
  
He O O
will O O
be O O
continued O O
on O O
his O O
Valtrex B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d B-Frequency B-Frequency
given O O
h O O
/ O O
o O O
shingles B-Indication B-Indication
in O O
the O O
past O O
. O O
  
He O O
will O O
be O O
started O O
on O O
Noxafil B-Drug B-Drug
and O O
Levaquin B-Drug B-Drug
on O O
discharge O O
. O O
  
He O O
will O O
be O O
monitored O O
for O O
any O O
signs O O
of O O
acute O O
infection B-SSLIF B-SSLIF
. O O
  
3. O O
Fluid O O
, O O
electrolytes O O
and O O
nutrition O O
: O O
The O O
patient O O
will O O
be O O
started O O
on O O
normal B-Drug B-Drug
saline I-Drug I-Drug
at O O
150 B-Dose B-Dose
mL I-Dose I-Dose
/ I-Dose I-Dose
hour I-Dose I-Dose
and O O
this O O
will O O
be O O
continued O O
throughout O O
his O O
chemotherapy B-Drug B-Drug
. O O
  
His O O
potassium O O
will O O
be O O
kept O O
above O O
4 O O
and O O
magnesium O O
kept O O
above O O
2 O O
. O O
  
He O O
will O O
undergo O O
standard O O
neutropenic O O
precautions O O
and O O
have O O
neutropenic O O
diet O O
. O O
  
4. O O
Hypothyroidism B-Indication B-Indication
: O O
The O O
patient O O
will O O
continue O O
on O O
his O O
Synthroid B-Drug B-Drug
150 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
5. O O
Code O O
: O O
The O O
patient O O
is O O
full O O
code O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
Last O O
Edited O O
By O O
... O O
  
Name O O
Name O O
, O O
MD O O
# O O
Medical_Record_Number O O
Elec O O
. O O
  
Signed O O
By O O
on O O
Date O O
11 O O
: O O
54 O O
Name O O
Name O O
, O O
MD O O
# O O
Medical_Record_Number O O
Revision O O
Number O O
- O O
2 O O
on O O
Date O O
11 O O
: O O
54 O O
DATE O O
OF O O
SERVICE O O
: O O
Date O O
NAME O O
OF O O
THE O O
PROCEDURE O O
: O O
Bone O O
marrow O O
aspiration O O
, O O
biopsy O O
. O O
  
DIAGNOSIS O O
: O O
mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
INDICATIONS O O
: O O
disease O O
restaging O O
OPERATOR O O
: O O
Name O O
Name O O
PA O O
- O O
C O O
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
After O O
obtaining O O
informed O O
consent O O
, O O
the O O
patient O O
was O O
identified O O
by O O
name O O
and O O
medical O O
record O O
number O O
. O O
  
During O O
informed O O
consent O O
the O O
risks O O
of O O
procedure O O
were O O
explained O O
. O O
  
They O O
include O O
but O O
are O O
not O O
limited O O
to O O
bleeding B-SSLIF B-SSLIF
, O O
infection B-SSLIF B-SSLIF
, O O
pain B-SSLIF B-SSLIF
, O O
allergic B-ADE B-ADE
reaction I-ADE I-ADE
to O O
lidocaine B-Drug B-Drug
. O O
  
The O O
patient O O
signed O O
informed O O
consent O O
as O O
he O O
was O O
willing O O
to O O
proceed O O
. O O
  
Timeout O O
was O O
taken O O
during O O
which O O
equipment O O
was O O
checked O O
. O O
  
Landmarks O O
were O O
identified O O
, O O
medical O O
records O O
reviewed O O
for O O
relevant O O
information O O
. O O
  
The O O
patient's O O
right O O
posterior O O
superior O O
iliac O O
spine O O
was O O
marked O O
and O O
cleansed O O
with O O
Betadine O O
and O O
sterile O O
field O O
was O O
established O O
. O O
  
After O O
that O O
, O O
2% B-Dose B-Dose
lidocaine B-Drug B-Drug
was O O
used O O
for O O
local O O
anesthesia O O
and O O
aspiration O O
needle O O
was O O
inserted O O
into O O
the O O
area O O
. O O
  
Then O O
approximately O O
8 O O
- O O
10 O O
mL O O
of O O
bone O O
marrow O O
aspirate O O
was O O
obtained O O
without O O
difficulty O O
and O O
was O O
used O O
for O O
preparation O O
of O O
bone O O
marrow O O
smears O O
, O O
flow O O
cytometry O O
, O O
cytogenetics O O
and O O
molecular O O
genetics O O
. O O
  
After O O
that O O
, O O
bone O O
marrow O O
aspiration O O
needle O O
was O O
removed O O
and O O
bone O O
marrow O O
biopsy O O
needle O O
was O O
placed O O
into O O
the O O
same O O
area O O
and O O
bone O O
marrow O O
biopsy O O
was O O
obtained O O
without O O
difficulty O O
. O O
  
Pressure O O
was O O
applied O O
to O O
minimize O O
bleeding O O
. O O
  
Band O O
- O O
Aid O O
was O O
applied O O
to O O
the O O
same O O
area O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
and O O
was O O
discharged O O
home O O
without O O
significant O O
problems O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
PA O O
Date O O
8 O O
: O O
54AM O O
EST O O
Author O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
11 O O
: O O
04AM O O
EST O O
Hospital O O
Patient O O
Discharge O O
Instructions O O
Medications O O
It O O
is O O
the O O
responsibility O O
of O O
the O O
patient O O
or O O
patient O O
representative O O
to O O
confirm O O
the O O
list O O
of O O
medications O O
with O O
either O O
the O O
patient's O O
personal O O
care O O
provider O O
or O O
the O O
patient's O O
follow O O
- O O
up O O
care O O
provider O O
to O O
ensure O O
the O O
patient O O
has O O
an O O
appropriate O O
list O O
of O O
medications O O
to O O
take O O
at O O
home O O
. O O
  
Preliminary O O
list O O
- O O
medication O O
reconciliation O O
not O O
completed O O
. O O
  
Discharge O O
medications O O
acyclovir B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
docusate B-Drug B-Drug
sodium I-Drug I-Drug
( I-Drug I-Drug
DOK I-Drug I-Drug
) O O
100 B-Dose B-Dose
mg I-Dose I-Dose
Capsule I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
capsule I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
levothyroxine B-Drug B-Drug
( I-Drug I-Drug
Synthroid I-Drug I-Drug
) O O
150 B-Dose B-Dose
mcg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
  
MULTIVITAMINS B-Drug B-Drug
( I-Drug I-Drug
TAB I-Drug I-Drug
- I-Drug I-Drug
A I-Drug I-Drug
- I-Drug I-Drug
VITE I-Drug I-Drug
) O O
1 B-Dose B-Dose
TABLET I-Dose I-Dose
= O O
1 O O
TABLET O O
Oral B-Route B-Route
TABLET O O
DAILY B-Frequency B-Frequency
STAT O O
and O O
then O O
Routine O O
for O O
30 B-Duration B-Duration
Days I-Duration I-Duration
Directions O O
: O O
1 O O
tablet O O
oral O O
DAILY O O
prochlorperazine B-Drug B-Drug
maleate I-Drug I-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
NAUSEA B-Indication B-Indication
/ O O
VOMITING B-Indication B-Indication
sennosides B-Drug B-Drug
8.6 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
2 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
PRN I-Frequency I-Frequency
CONSTIPATION B-Indication B-Indication
simethicone B-Drug B-Drug
80 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, I-Dose I-Dose
Chewable I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
dispersible I-Dose I-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
four B-Frequency B-Frequency
times I-Frequency I-Frequency
daily I-Frequency I-Frequency
PRN I-Frequency I-Frequency
GAS B-Indication B-Indication
omeprazole B-Drug B-Drug
20 I-Drug I-Drug
mg I-Drug I-Drug
Capsule I-Drug I-Drug
, I-Drug I-Drug
Delayed I-Drug I-Drug
Release I-Drug I-Drug
( O O
E.C. O O
) O O
Directions O O
: O O
1 B-Dose B-Dose
capsule I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
levofloxacin B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
posaconazole B-Drug B-Drug
200 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
5 I-Dose I-Dose
mL I-Dose I-Dose
( I-Dose I-Dose
40 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
mL I-Dose I-Dose
) I-Dose I-Dose
Suspension I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
5 B-Dose B-Dose
mL I-Dose I-Dose
oral B-Route B-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
dayAdditional O O
Instructions O O
: O O
Please O O
DO O O
NOT O O
take O O
on O O
Date O O
, O O
Date O O
and O O
Date O O
  
LORazepam B-Drug B-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
NAUSEA B-Indication B-Indication
/ O O
VOMITING B-Indication B-Indication
Stopped O O
medications O O
None O O
Detailed O O
Instructions O O
Discharge O O
Instructions O O
Discharge O O
Instructions O O
from O O
Date O O
2 O O
: O O
16 O O
PM O O
: O O
  
PRN O O
Statement O O
/ O O
Explanation O O
: O O
In O O
the O O
Medications O O
section O O
above O O
, O O
you O O
may O O
see O O
the O O
term O O
"PRN." O O
This O O
term O O
means O O
"as O O
needed." O O
You O O
do O O
not O O
need O O
to O O
take O O
these O O
medications O O
unless O O
you O O
are O O
having O O
that O O
specific O O
symptom O O
. O O
  
You O O
are O O
being O O
discharged O O
from O O
: O O
Hospital O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Diagnoses O O
/ O O
Problems O O
During O O
this O O
Admission O O
: O O
Chemotherapy B-Drug B-Drug
for O O
Mantle B-Indication B-Indication
Cell I-Indication I-Indication
Lymphoma I-Indication I-Indication
Why O O
You O O
Were O O
Admitted O O
: O O
You O O
were O O
admitted O O
for O O
chemotherapy B-Drug B-Drug
. O O
  
You O O
tolerated O O
it O O
well O O
and O O
will O O
be O O
discharged O O
home O O
. O O
  
Attending O O
Physician O O
: O O
Name O O
Name O O
Attending O O
MSI O O
Number O O
: O O
Identifiers O O
Primary O O
Care O O
Provider O O
: O O
Name O O
Name O O
, O O
MD O O
Primary O O
Care O O
MSI O O
Number O O
: O O
Identifiers O O
Health O O
Care O O
Proxy O O
Name O O
: O O
Name O O
Name O O
  
HCP O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Heme O O
/ O O
Onc O O
clinic O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Fri O O
Date O O
@ O O
10 O O
: O O
30 O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
labs O O
/ O O
Neulasta B-Drug B-Drug
injection B-Route B-Route
Follow O O
Up O O
Appointment O O
With O O
: O O
Heme O O
/ O O
Onc O O
clinic O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Mon O O
Date O O
@ O O
10 O O
: O O
30 O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
labs O O
/ O O
? O O
transfusion O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Heme O O
/ O O
Onc O O
clnic O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Wed O O
Date O O
@ O O
10 O O
: O O
30 O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
labs O O
/ O O
? O O
transfusion B-Route B-Route
/ O O
rituxan B-Drug B-Drug
/ I-Drug I-Drug
vincristine I-Drug I-Drug
Other O O
Discharge O O
Instructions O O
: O O
Please O O
call O O
if O O
you O O
develop O O
fever B-SSLIF B-SSLIF
>100.4 O O
, O O
persistent O O
nausea B-SSLIF B-SSLIF
/ O O
vomiting B-SSLIF B-SSLIF
/ O O
diarrhea B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
cold O O
symptoms O O
, O O
or O O
any O O
other O O
concerns O O
Hospital O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Hospital O O
( O O
after O O
5pm O O
) O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Notify O O
MD O O
For O O
Any O O
of O O
the O O
Following O O
: O O
Increased O O
Trouble B-SSLIF B-SSLIF
Breathing I-SSLIF I-SSLIF
or O O
Chest B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
, O O
Fever B-SSLIF B-SSLIF
- O O
Temperature O O
Higher O O
Than O O
101 O O
Degrees O O
, O O
Any O O
Other O O
New O O
or O O
Concerning O O
Symptom O O
Discharge O O
Disposition O O
: O O
Home O O
- O O
No O O
Services O O
Discharge O O
Activity O O
: O O
As O O
Tolerated O O
Special O O
Diet O O
Instructions O O
: O O
Neutropenic O O
IV O O
Supplies O O
: O O
Yes O O
IV O O
Supplies O O
Vendor O O
: O O
Critical O O
Care O O
IV O O
Supplier O O
Vendor O O
Address O O
and O O
Phone O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Other O O
: O O
Picc O O
line O O
supplies O O
Case O O
Manager O O
/ O O
Social O O
Worker O O
Discharge O O
Note O O
: O O
SN O O
Discharge O O
Planning O O
Coordinator O O
: O O
Name O O
Name O O
RN O O
Planning O O
Coordinator O O
Contact O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Smoking O O
Statement O O
: O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die B-SSLIF B-SSLIF
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory O O
problems O O
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Discharge O O
Medication O O
Reconciliation O O
Statement O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
Authorization O O
Statement O O
: O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plans O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
Translator O O
Signature O O
/ O O
Relationship O O
: O O
______________________________________________________________________ O O
  
RN O O
Signature O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
Patient O O
/ O O
Responsible O O
Party O O
Signature O O
, O O
Relationship O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
General O O
Instructions O O
HOSPITAL O O
: O O
Hospital O O
PULMONARY O O
CONSULT O O
NOTE O O
Date O O
: O O
Date O O
Time O O
: O O
16 O O
: O O
23 O O
Hospital O O
Day O O
# O O
: O O
28 O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Name O O
Admission O O
Date O O
: O O
Date O O
Location O O
: O O
Location O O
Resident O O
Name O O
: O O
Name O O
, O O
Name O O
Resident O O
Pager O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Attending O O
MD O O
Name O O
: O O
Name O O
, O O
Name O O
Account O O
# O O
: O O
Medical_Record_Number O O
Medical O O
Record O O
# O O
: O O
Medical_Record_Number O O
  
DOB O O
: O O
Date O O
Age O O
: O O
69 O O
Sex O O
: O O
M O O
CHIEF O O
COMPLAINT O O
/ O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
Chief O O
Complaint O O
: O O
pleural B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
History O O
of O O
Present O O
Illness O O
: O O
69 O O
- O O
year O O
- O O
old O O
male O O
who O O
was O O
diagnosed O O
with O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
in O O
Date O O
. O O
  
He O O
then O O
completed O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
Hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
based O O
therapy O O
with O O
still O O
persistent O O
disease O O
at O O
least O O
at O O
the O O
molecular O O
level O O
in O O
the O O
bone O O
marrow O O
. O O
  
S O O
/ O O
p O O
BMT O O
on O O
Date O O
and O O
now O O
treated O O
for O O
LLL B-Indication B-Indication
pneumonia I-Indication I-Indication
starting O O
on O O
Date O O
with O O
vanc B-Drug B-Drug
and O O
zosyn B-Drug B-Drug
. O O
  
Pt O O
now O O
with O O
left B-SSLIF B-SSLIF
sided I-SSLIF I-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
as O O
seen O O
on O O
CXR O O
from O O
Date O O
film O O
and O O
CT O O
Scan O O
of O O
the O O
Chest O O
Date O O
. O O
  
Pt O O
states O O
that O O
he O O
is O O
not O O
SOB B-SSLIF B-SSLIF
, O O
no O O
cough B-SSLIF B-SSLIF
, O O
no O O
fever B-SSLIF B-SSLIF
, O O
no O O
diarrhea B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
all O O
symptoms O O
except O O
for O O
some B-Severity B-Severity
nausea B-SSLIF B-SSLIF
which O O
has O O
been O O
chronic O O
in O O
nature O O
and O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
has O O
been O O
neutropenic B-SSLIF B-SSLIF
for O O
the O O
last O O
2 O O
weeks O O
and O O
spiked O O
a O O
fever B-SSLIF B-SSLIF
Date O O
of O O
38.8 O O
. O O
  
In O O
addition O O
to O O
his O O
neutropenia B-SSLIF B-SSLIF
, O O
he O O
also O O
has O O
profound B-Severity B-Severity
thrombocytopenia B-SSLIF B-SSLIF
. O O
  
Treatment O O
Received O O
: O O
Vancomycin B-Drug B-Drug
and O O
zosyn B-Drug B-Drug
PAST O O
MEDICAL O O
/ O O
SURGICAL O O
HISTORY O O
Significant O O
for O O
hypothyroidism B-SSLIF B-SSLIF
secondary O O
to O O
thyroidectomy O O
over O O
30 O O
years O O
ago O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
status O O
post O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
Hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
based O O
therapy O O
followed O O
by O O
2 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
bendamustine B-Drug B-Drug
, O O
bortezomib B-Drug B-Drug
, O O
rituximab B-Drug B-Drug
based O O
therapy O O
and O O
S O O
/ O O
P O O
allogenic O O
stem O O
cell O O
transplant O O
on O O
Date O O
. O O
  
peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
vincristine B-Drug B-Drug
and O O
bortezomib B-Drug B-Drug
; O O
hepatitis B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
core I-SSLIF I-SSLIF
antibody I-SSLIF I-SSLIF
positivity I-SSLIF I-SSLIF
. O O
  
Surgical O O
History O O
: O O
  
Significant O O
for O O
thyroidectomy O O
over O O
30 O O
years O O
ago O O
inguinal O O
hernia O O
surgery O O
Date O O
lymph O O
node O O
biopsy O O
Date O O
. O O
  
MEDICATIONS O O
/ O O
ALLERGIES O O
Current O O
Medication O O
Orders O O
: O O
ONDANSETRON B-Drug B-Drug
( I-Drug I-Drug
ZOFRAN I-Drug I-Drug
) O O
8 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q8HPRN B-Frequency B-Frequency
  
ONDANSETRON B-Drug B-Drug
( I-Drug I-Drug
ZOFRAN I-Drug I-Drug
) O O
8 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
Q8HPRN B-Frequency B-Frequency
HEPARIN B-Drug B-Drug
FLUSH I-Drug I-Drug
10 B-Dose B-Dose
UNIT I-Dose I-Dose
/ I-Dose I-Dose
ML I-Dose I-Dose
( O O
HEPARIN O O
FLUSH O O
10 O O
UNIT O O
/ O O
ML O O
) O O
50 B-Dose B-Dose
UNIT I-Dose I-Dose
INTRALUMIN B-Route B-Route
PER O O
PROTOCOL O O
  
POSACONAZOLE B-Drug B-Drug
( I-Drug I-Drug
NOXAFIL I-Drug I-Drug
) O O
200 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
TID B-Frequency B-Frequency
W I-Frequency I-Frequency
MEALS I-Frequency I-Frequency
  
NYSTATIN B-Drug B-Drug
( I-Drug I-Drug
MYCOSTATIN I-Drug I-Drug
) O O
500000 B-Dose B-Dose
UNIT I-Dose I-Dose
ORAL B-Route B-Route
QID B-Frequency B-Frequency
SODIUM B-Drug B-Drug
FLUORIDE I-Drug I-Drug
( I-Drug I-Drug
PHOS I-Drug I-Drug
- I-Drug I-Drug
FLUR I-Drug I-Drug
) O O
5 B-Dose B-Dose
ML I-Dose I-Dose
MUCOUS B-Route B-Route
MEM I-Route I-Route
QHS B-Frequency B-Frequency
  
URSODIOL B-Drug B-Drug
( I-Drug I-Drug
ACTIGALL I-Drug I-Drug
) O O
300 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
TID B-Frequency B-Frequency
LANOLIN B-Drug B-Drug
/ I-Drug I-Drug
MINERAL I-Drug I-Drug
OIL I-Drug I-Drug
( I-Drug I-Drug
EUCERIN I-Drug I-Drug
) O O
1 B-Dose B-Dose
APP I-Dose I-Dose
TOPICAL B-Route B-Route
Q2HPRN B-Frequency B-Frequency
BACITRACIN B-Drug B-Drug
( O O
BACITRACIN O O
) O O
1 B-Dose B-Dose
APP I-Dose I-Dose
TOPICAL B-Route B-Route
Q2HPRN B-Frequency B-Frequency
ZINC B-Drug B-Drug
OXIDE I-Drug I-Drug
20% B-Dose B-Dose
( O O
ZINC O O
OXIDE O O
20% O O
) O O
1 B-Dose B-Dose
APP I-Dose I-Dose
TOPICAL B-Route B-Route
Q2HPRN B-Frequency B-Frequency
MENTHOL B-Drug B-Drug
/ I-Drug I-Drug
CAMPHOR I-Drug I-Drug
/ I-Drug I-Drug
PHENOL I-Drug I-Drug
( I-Drug I-Drug
SARNA I-Drug I-Drug
) O O
1 B-Dose B-Dose
APP I-Dose I-Dose
TOPICAL B-Route B-Route
Q2HPRN B-Frequency B-Frequency
  
KCL B-Drug B-Drug
20 B-Dose B-Dose
MEQ I-Dose I-Dose
/ I-Dose I-Dose
50 I-Dose I-Dose
ML I-Dose I-Dose
( O O
KCL O O
20 O O
MEQ O O
/ O O
50 O O
ML O O
) O O
See O O
MAR O O
INTRAVENOU B-Route B-Route
PER O O
PROTOCOL O O
MAGNESIUM B-Drug B-Drug
SULF I-Drug I-Drug
2 B-Dose B-Dose
G I-Dose I-Dose
/ I-Dose I-Dose
50 I-Dose I-Dose
ML I-Dose I-Dose
NS O O
( O O
MAGNESIUM O O
SULF O O
2 O O
G O O
/ O O
50 O O
ML O O
NS O O
) O O
See O O
MAR O O
INTRAVENOU B-Route B-Route
PER O O
PROTOCOL O O
diphenhydrAMINE B-Drug B-Drug
HCl I-Drug I-Drug
( I-Drug I-Drug
BENADRYL I-Drug I-Drug
) O O
25 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
PREMED O O
  
HYDROCORTISONE B-Drug B-Drug
SOD I-Drug I-Drug
SUCCINATE I-Drug I-Drug
( I-Drug I-Drug
SOLU I-Drug I-Drug
- I-Drug I-Drug
CORTEF I-Drug I-Drug
) O O
50 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
PREMED O O
levothyroxine B-Drug B-Drug
( I-Drug I-Drug
SYNTHROID I-Drug I-Drug
) O O
150 B-Dose B-Dose
MCG I-Dose I-Dose
ORAL B-Route B-Route
DAILY B-Frequency B-Frequency
  
PROCHLORPERAZINE B-Drug B-Drug
( I-Drug I-Drug
COMPAZINE I-Drug I-Drug
) O O
10 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q6HPRN B-Frequency B-Frequency
  
ZOLPIDEM B-Drug B-Drug
( I-Drug I-Drug
AMBIEN I-Drug I-Drug
) O O
5 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
QHSPRN B-Frequency B-Frequency
  
SIMETHICONE B-Drug B-Drug
( I-Drug I-Drug
MYLICON I-Drug I-Drug
) O O
80 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
QIDPRN B-Frequency B-Frequency
  
LORazepam B-Drug B-Drug
( I-Drug I-Drug
ATIVAN I-Drug I-Drug
) O O
0.5 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
Q6HPRN B-Frequency B-Frequency
  
LORazepam B-Drug B-Drug
( I-Drug I-Drug
ATIVAN I-Drug I-Drug
) O O
0.5 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q6HPRN B-Frequency B-Frequency
  
CLOTRIMAZOLE B-Drug B-Drug
( I-Drug I-Drug
MYCELEX I-Drug I-Drug
) O O
10 B-Dose B-Dose
MG I-Dose I-Dose
MUCOUS B-Route B-Route
MEM I-Route I-Route
QID B-Frequency B-Frequency
  
FUROSEMIDE B-Drug B-Drug
( I-Drug I-Drug
LASIX I-Drug I-Drug
) O O
20 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
DAILYPRN B-Frequency B-Frequency
  
ZOLPIDEM B-Drug B-Drug
( I-Drug I-Drug
AMBIEN I-Drug I-Drug
) O O
10 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
QHSPRN B-Frequency B-Frequency
  
LORazepam B-Drug B-Drug
( I-Drug I-Drug
ATIVAN I-Drug I-Drug
) O O
1 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q6HPRN B-Frequency B-Frequency
  
LORazepam B-Drug B-Drug
( I-Drug I-Drug
ATIVAN I-Drug I-Drug
) O O
1 B-Dose B-Dose
MG I-Dose I-Dose
INTRAVENOU B-Route B-Route
Q6HPRN B-Frequency B-Frequency
MIRACLE B-Drug B-Drug
MOUTHWASH I-Drug I-Drug
( O O
MIRACLE O O
MOUTHWASH O O
) O O
5 B-Dose B-Dose
ML I-Dose I-Dose
MUCOUS B-Route B-Route
MEM I-Route I-Route
TID B-Frequency B-Frequency
  
OXYCODONE B-Drug B-Drug
IR I-Drug I-Drug
( O O
OXYCODONE O O
IR O O
) O O
5 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q4HPRN B-Frequency B-Frequency
  
OXYCODONE B-Drug B-Drug
IR I-Drug I-Drug
( O O
OXYCODONE O O
IR O O
) O O
10 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q4HPRN B-Frequency B-Frequency
  
PIPERACILLIN O O
/ O O
TAZOBACTAM O O
( O O
ZOSYN O O
) O O
3.375 B-Dose B-Dose
G I-Dose I-Dose
INTRAVENOU B-Route B-Route
Q8H B-Frequency B-Frequency
  
URSODIOL B-Drug B-Drug
50 I-Drug I-Drug
MG I-Drug I-Drug
/ I-Drug I-Drug
ML I-Drug I-Drug
( I-Drug I-Drug
ACTIGALL I-Drug I-Drug
50 O O
MG O O
/ O O
ML O O
) O O
300 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
TID B-Frequency B-Frequency
chlorproMAZINE B-Drug B-Drug
( I-Drug I-Drug
THORAZINE I-Drug I-Drug
) O O
12.5 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q6HPRN B-Frequency B-Frequency
  
PANTOPRAZOLE B-Drug B-Drug
DR I-Drug I-Drug
( I-Drug I-Drug
Protonix I-Drug I-Drug
) O O
40 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
BID B-Frequency B-Frequency
MIRACLE O O
MOUTHWASH O O
( O O
MIRACLE O O
MOUTHWASH O O
) O O
5 O O
ML O O
MUCOUS O O
MEM O O
TIDPRN O O
  
GABAPENTIN B-Drug B-Drug
( I-Drug I-Drug
NEURONTIN I-Drug I-Drug
) O O
200 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
TID B-Frequency B-Frequency
  
LOPERAMIDE B-Drug B-Drug
( I-Drug I-Drug
IMODIUM I-Drug I-Drug
) O O
4 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
QIDPRN B-Frequency B-Frequency
  
LOPERAMIDE O O
( O O
IMODIUM O O
) O O
4 O O
MG O O
ORAL O O
QID O O
  
VANCOMYCIN B-Drug B-Drug
1 B-Dose B-Dose
G I-Dose I-Dose
/ I-Dose I-Dose
200 I-Dose I-Dose
ML I-Dose I-Dose
D5W O O
( O O
VANCOMYCIN O O
1 O O
G O O
/ O O
200 O O
ML O O
D5W O O
) O O
See O O
MAR O O
INTRAVENOU B-Route B-Route
Q24H B-Frequency B-Frequency
  
ENOXAPARIN B-Drug B-Drug
( I-Drug I-Drug
LOVENOX I-Drug I-Drug
) O O
30 B-Dose B-Dose
MG I-Dose I-Dose
SUBCUTAN B-Route B-Route
DAILY B-Frequency B-Frequency
  
ENTECAVIR B-Drug B-Drug
( I-Drug I-Drug
BARACLUDE I-Drug I-Drug
) O O
0.5 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
Q48H B-Frequency B-Frequency
  
SIROLIMUS B-Drug B-Drug
( I-Drug I-Drug
RAPAMUNE I-Drug I-Drug
) O O
1 B-Dose B-Dose
MG I-Dose I-Dose
ORAL B-Route B-Route
DAILY B-Frequency B-Frequency
Drug O O
Allergies O O
/ O O
ADR O O
from O O
Pharmacy O O
: O O
No O O
Known O O
Allergies O O
, O O
No O O
Known O O
Drug B-SSLIF B-SSLIF
Allergies I-SSLIF I-SSLIF
, O O
No O O
Known O O
Food O O
Allergies O O
FAMILY O O
HISTORY O O
/ O O
SOCIAL O O
HISTORY O O
Family O O
History O O
: O O
Significant O O
for O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
had O O
a O O
brother O O
who O O
died B-SSLIF B-SSLIF
of O O
myocardial B-SSLIF B-SSLIF
infarction I-SSLIF I-SSLIF
at O O
the O O
age O O
of O O
58 O O
. O O
  
He O O
had O O
another O O
brother O O
who O O
has O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
and O O
diabetes B-SSLIF B-SSLIF
mellitus I-SSLIF I-SSLIF
. O O
  
He O O
had O O
a O O
sister O O
who O O
died B-SSLIF B-SSLIF
of O O
stroke B-SSLIF B-SSLIF
at O O
the O O
age O O
of O O
85 O O
and O O
another O O
sister O O
who O O
had O O
some O O
leukemia B-SSLIF B-SSLIF
. O O
  
His O O
son O O
died B-SSLIF B-SSLIF
of O O
colorectal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
Social O O
History O O
: O O
Married O O
, O O
lives O O
with O O
wife O O
. O O
  
Smoking O O
Status O O
: O O
Former O O
smoker O O
, O O
quit O O
3 O O
years O O
ago O O
REVIEW O O
OF O O
SYSTEMS O O
  
ROS O O
: O O
All O O
systems O O
reviewed O O
and O O
negative O O
, O O
except O O
as O O
noted O O
below O O
and O O
in O O
HPI O O
: O O
  
GENERAL O O
: O O
COMMENTS O O
: O O
chills B-SSLIF B-SSLIF
ABDOMINAL O O
: O O
REPORTS O O
: O O
Nausea B-SSLIF B-SSLIF
SKIN O O
: O O
REPORTS O O
: O O
Rashes B-SSLIF B-SSLIF
VITALS O O
Date O O
Date O O
Date O O
Name O O
14 O O
: O O
49 O O
12 O O
: O O
09 O O
11 O O
: O O
31 O O
Temp O O
37.90 O O
36.70 O O
Temp O O
Site O O
Oral O O
Oral O O
Pulse O O
80 O O
84 O O
Pulse O O
Site O O
1 O O
Monitor O O
Pulse O O
Site O O
2 O O
  
BP O O
122 O O
/ O O
66 O O
  
BP O O
Site O O
Left O O
Arm O O
  
BP O O
Position O O
Lying O O
  
RR O O
18 O O
Pulse O O
Ox O O
94 O O
  
O2 O O
LPM O O
  
O2 O O
Delivery O O
Device O O
Room O O
Air O O
Room O O
Air O O
Admission O O
Weight O O
LINES O O
, O O
TUBES O O
, O O
AND O O
DRAINS O O
IV O O
Line O O
: O O
# O O
: O O
1 O O
; O O
Type O O
: O O
PICC O O
; O O
Location O O
: O O
Right O O
PHYSICAL O O
EXAM O O
GENERAL O O
: O O
No O O
apparent O O
distress B-SSLIF B-SSLIF
EYES O O
/ O O
ENT O O
: O O
Pupils O O
equal O O
, O O
round O O
, O O
and O O
react O O
to O O
light O O
; O O
Extraocular O O
movements O O
intact O O
; O O
Conjunctivae B-SSLIF B-SSLIF
non I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
ictereric I-SSLIF I-SSLIF
; O O
No O O
oral B-SSLIF B-SSLIF
thrush I-SSLIF I-SSLIF
; O O
Moist O O
oral O O
mucosa O O
, O O
no O O
lesions B-SSLIF B-SSLIF
LYMPHATIC O O
: O O
No O O
lymphadenopathy B-SSLIF B-SSLIF
neck I-SSLIF I-SSLIF
; O O
No O O
lymphadenopathy B-SSLIF B-SSLIF
axillae I-SSLIF I-SSLIF
RESPIRATORY O O
: O O
Clear O O
to O O
auscultation O O
, O O
no O O
wheezing B-SSLIF B-SSLIF
, O O
rales B-SSLIF B-SSLIF
or O O
rhonchi B-SSLIF B-SSLIF
; O O
decreased B-SSLIF B-SSLIF
breath I-SSLIF I-SSLIF
sounds I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
lung I-SSLIF I-SSLIF
field O O
; O O
Good O O
air O O
movement O O
, O O
normal O O
expansion O O
; O O
Normal O O
respiratory O O
effort O O
CARDIOVASCULAR O O
: O O
Regular O O
rate O O
rhythm O O
; O O
No O O
murmurs B-SSLIF B-SSLIF
, O O
rubs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
; O O
No O O
JVD B-SSLIF B-SSLIF
SKIN O O
: O O
maculopapular B-SSLIF B-SSLIF
erthymatous B-SSLIF B-SSLIF
blanching B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
anterier I-SSLIF I-SSLIF
chest I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
post I-SSLIF I-SSLIF
. I-SSLIF I-SSLIF
  
thorax O O
as O O
well O O
as O O
the O O
neck O O
. O O
  
ABDOMINAL O O
: O O
Normoactive O O
bowel O O
sounds O O
; O O
Non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
tender I-SSLIF I-SSLIF
, O O
no O O
masses B-SSLIF B-SSLIF
, O O
not O O
distended B-SSLIF B-SSLIF
, O O
no O O
rebound B-SSLIF B-SSLIF
, O O
no O O
guarding B-SSLIF B-SSLIF
MUSCULOSKELETAL O O
: O O
No O O
clubbing B-SSLIF B-SSLIF
or O O
cyanosis B-SSLIF B-SSLIF
; O O
No O O
joint B-SSLIF B-SSLIF
swelling I-SSLIF I-SSLIF
, O O
tenderness B-SSLIF B-SSLIF
, O O
effusions B-SSLIF B-SSLIF
; O O
2+ B-Severity B-Severity
pitting B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
up I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
patella I-SSLIF I-SSLIF
b I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
l I-SSLIF I-SSLIF
  
NEUROLOGIC O O
: O O
Alert O O
oriented O O
x O O
3 O O
; O O
No O O
gross O O
deficits O O
PSYCH O O
: O O
Normal O O
mood O O
and O O
affect O O
Attending O O
Comments O O
( O O
physical O O
exam O O
) O O
: O O
Agree O O
; O O
bedside O O
ultrasound O O
reveals O O
moderate B-Severity B-Severity
sized I-Severity I-Severity
left B-SSLIF B-SSLIF
sided I-SSLIF I-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
amenable O O
to O O
thoracentesis O O
LABORATORY O O
/ O O
STUDIES O O
  
Metabolics O O
Common O O
: O O
Date O O
Date O O
Date O O
Name O O
Units O O
Range O O
03 O O
: O O
00 O O
02 O O
: O O
00 O O
05 O O
: O O
00 O O
  
NA O O
mmol O O
/ O O
L O O
135 O O
- O O
145 O O
143 O O
144 O O
145 O O
  
K O O
mmol O O
/ O O
l O O
3.5 O O
- O O
5.3 O O
3.1* O O
3.1* O O
3.3* O O
  
CL O O
mmol O O
/ O O
L O O
97 O O
- O O
110 O O
110 O O
112* O O
113* O O
  
CO2 O O
mmol O O
/ O O
L O O
24 O O
- O O
32 O O
26 O O
26 O O
25 O O
Anion O O
Gap O O
5 O O
- O O
15 O O
7 O O
6 O O
7 O O
  
Glu O O
mg O O
/ O O
dL O O
70 O O
- O O
99 O O
105* O O
100* O O
94 O O
BUN O O
mg O O
/ O O
dL O O
7 O O
- O O
23 O O
9 O O
6* O O
6* O O
  
Creat O O
mg O O
/ O O
dL O O
0.60 O O
- O O
1.30 O O
1.63* O O
1.51* O O
1.13 O O
  
GFR O O
>60 O O
42* O O
46* O O
60 O O
  
CA O O
mg O O
/ O O
dL O O
8.7 O O
- O O
10.7 O O
8.1* O O
8.2* O O
8.4* O O
  
Mag O O
mg O O
/ O O
dL O O
1.6 O O
- O O
2.4 O O
1.7 O O
1.9 O O
2.1 O O
  
Phos O O
mg O O
/ O O
dL O O
2.5 O O
- O O
4.5 O O
3.0 O O
  
CBC O O
/ O O
Diff O O
: O O
Date O O
Date O O
Date O O
Name O O
Units O O
Range O O
03 O O
: O O
00 O O
02 O O
: O O
00 O O
05 O O
: O O
00 O O
  
WBC O O
th O O
/ O O
mm3 O O
4.3 O O
- O O
10.3 O O
0.2** O O
0.2** O O
0.2** O O
  
RBC O O
mil O O
/ O O
mm3 O O
4.40 O O
- O O
6.00 O O
2.74* O O
2.78* O O
2.98* O O
  
HGB O O
g O O
/ O O
dL O O
14.0 O O
- O O
18.0 O O
8.7* O O
8.9* O O
9.5* O O
  
HCT O O
% O O
42.0 O O
- O O
52.0 O O
25.6* O O
26.0* O O
28.1* O O
  
MCV O O
fl O O
82.0 O O
- O O
101.0 O O
93.5 O O
93.4 O O
94.1 O O
  
PLT O O
th O O
/ O O
mm3 O O
140 O O
- O O
440 O O
8** O O
12** O O
26** O O
NE O O
  
LY O O
  
MO O O
  
EO O O
  
BA O O
  
Coag O O
: O O
Date O O
Date O O
Name O O
Units O O
Range O O
03 O O
: O O
00 O O
02 O O
: O O
00 O O
  
PT O O
seconds O O
9.6 O O
- O O
12.4 O O
11.4 O O
10.8 O O
  
INR O O
2.0 O O
- O O
3.5 O O
1.1* O O
1.0* O O
  
PTT O O
seconds O O
22.3 O O
- O O
34.0 O O
27.7 O O
28.0 O O
Other O O
General O O
Labs O O
: O O
Name O O
Value O O
Flags O O
Units O O
Range O O
Date O O
11 O O
: O O
04 O O
AM O O
  
CREATININE O O
RANDOM O O
URINE O O
41 O O
mg O O
/ O O
dL O O
22 O O
- O O
328 O O
CHLORIDE O O
URINE O O
RANDOM O O
81 O O
mmol O O
/ O O
CHLORIDE O O
/ O O
CREATININE O O
UR O O
RANDOM O O
198 O O
mmol O O
/ O O
25 O O
- O O
253 O O
  
CREATININE O O
RANDOM O O
URINE O O
41 O O
mg O O
/ O O
dL O O
22 O O
- O O
328 O O
POTASSIUM O O
RANDOM O O
URINE O O
25 O O
mmol O O
/ O O
POTASSIUM O O
/ O O
CREATININE O O
UR O O
, O O
RANDOM O O
61.0 O O
mmol O O
/ O O
13 O O
- O O
116 O O
  
CREATININE O O
RANDOM O O
URINE O O
41 O O
mg O O
/ O O
dL O O
22 O O
- O O
328 O O
SODIUM O O
URINE O O
71 O O
mmol O O
/ O O
SODIUM O O
/ O O
CREATININE O O
URINE O O
, O O
RANDOM O O
173 O O
mmol O O
/ O O
23 O O
- O O
229 O O
Date O O
07 O O
: O O
27 O O
AM O O
  
SIROLIMUS B-Drug B-Drug
( I-Drug I-Drug
RAPAMYCIN I-Drug I-Drug
) O O
6.1 O O
ng O O
/ O O
mL O O
4.0 O O
- O O
20.0 O O
Date O O
04 O O
: O O
00 O O
AM O O
COLOR O O
URINE O O
Yellow O O
Yellow O O
APPEARANCE O O
URINE O O
Clear O O
Clear O O
SPEC O O
GRAVITY O O
, O O
URINE O O
1.007 O O
1.005 O O
- O O
1.03 O O
pH O O
URINE O O
6.5 O O
4.6 O O
- O O
8.0 O O
PROTEIN O O
URINE O O
Negative O O
Negative O O
GLUCOSE O O
URINE O O
Negative O O
Negative O O
  
KETONES O O
URINE O O
Negative O O
Negative O O
  
BILIRUBIN O O
URINE O O
Negative O O
Negative O O
OCCULT O O
BLOOD O O
URINE O O
Negative O O
Negative O O
NITRITE O O
URINE O O
Negative O O
Negative O O
  
UROBILINOGEN O O
URINE O O
Normal O O
Normal O O
  
LEUKO O O
ESTERASE O O
UR O O
Negative O O
Negative O O
MICROSCOPIC O O
? O O
Not O O
Indicated O O
  
VANCOMYCIN B-Drug B-Drug
TROUGH O O
20.8* O O
( O O
H O O
) O O
mcg O O
/ O O
mL O O
5 O O
- O O
20 O O
Microbiology O O
: O O
Date O O
3 O O
: O O
00 O O
: O O
00 O O
AM O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULT O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
PATIENT O O
: O O
Name O O
, O O
Name O O
Name O O
ACCT O O
# O O
: O O
Medical_Record_Number O O
U O O
# O O
: O O
Medical_Record_Number O O
  
LOC O O
: O O
Location O O
ROOM O O
: O O
Location O O
BED O O
: O O
Location O O
AGE O O
/ O O
SX O O
: O O
69 O O
/ O O
M O O
REG O O
: O O
Date O O
  
REG O O
DR O O
: O O
Name O O
, O O
Name O O
DOB O O
: O O
Date O O
DIS O O
: O O
  
STATUS O O
: O O
ADM O O
IN O O
TLOC O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
SPEC# O O
: O O
Medical_Record_Number O O
REQ# O O
: O O
Medical_Record_Number O O
STATUS O O
: O O
RES O O
COLL O O
: O O
Date O O
- O O
0300 O O
RECV O O
: O O
Date O O
- O O
0346 O O
SOURCE O O
: O O
BLOOD O O
ORDERED O O
: O O
AER O O
/ O O
ANA O O
BC O O
COMMENTS O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Procedure O O
Result O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULTURE O O
  
> O O
RESIN O O
AEROBIC O O
BOTTLE O O
: O O
Preliminary O O
NO O O
GROWTH O O
TO O O
DATE O O
  
> O O
ANAEROBIC O O
BOTTLE O O
: O O
Preliminary O O
NO O O
GROWTH O O
TO O O
DATE O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Date O O
2 O O
: O O
59 O O
: O O
00 O O
AM O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULT O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
PATIENT O O
: O O
Name O O
, O O
Name O O
Name O O
ACCT O O
# O O
: O O
Medical_Record_Number O O
U O O
# O O
: O O
Medical_Record_Number O O
  
LOC O O
: O O
Location O O
ROOM O O
: O O
Location O O
BED O O
: O O
Location O O
AGE O O
/ O O
SX O O
: O O
69 O O
/ O O
M O O
REG O O
: O O
Date O O
  
REG O O
DR O O
: O O
Name O O
, O O
Name O O
DOB O O
: O O
Date O O
DIS O O
: O O
  
STATUS O O
: O O
ADM O O
IN O O
TLOC O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
SPEC# O O
: O O
Medical_Record_Number O O
REQ# O O
: O O
Medical_Record_Number O O
STATUS O O
: O O
RES O O
COLL O O
: O O
Date O O
- O O
0259 O O
RECV O O
: O O
Date O O
- O O
0347 O O
SOURCE O O
: O O
BLOOD O O
ORDERED O O
: O O
AER O O
/ O O
ANA O O
BC O O
COMMENTS O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Procedure O O
Result O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULTURE O O
  
> O O
RESIN O O
AEROBIC O O
BOTTLE O O
: O O
Preliminary O O
NO O O
GROWTH O O
TO O O
DATE O O
  
> O O
ANAEROBIC O O
BOTTLE O O
: O O
Preliminary O O
NO O O
GROWTH O O
TO O O
DATE O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Date O O
11 O O
: O O
30 O O
: O O
00 O O
PM O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULT O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
PATIENT O O
: O O
Name O O
, O O
Name O O
Name O O
ACCT O O
# O O
: O O
Medical_Record_Number O O
U O O
# O O
: O O
Medical_Record_Number O O
  
LOC O O
: O O
Location O O
ROOM O O
: O O
Location O O
BED O O
: O O
Location O O
AGE O O
/ O O
SX O O
: O O
69 O O
/ O O
M O O
REG O O
: O O
Date O O
  
REG O O
DR O O
: O O
Name O O
, O O
Name O O
DOB O O
: O O
Date O O
DIS O O
: O O
  
STATUS O O
: O O
ADM O O
IN O O
TLOC O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
SPEC# O O
: O O
Medical_Record_Number O O
REQ# O O
: O O
Medical_Record_Number O O
STATUS O O
: O O
COMP O O
COLL O O
: O O
Date O O
- O O
2330 O O
RECV O O
: O O
Date O O
- O O
2336 O O
SOURCE O O
: O O
BLOOD O O
ORDERED O O
: O O
AER O O
/ O O
ANA O O
BC O O
COMMENTS O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Procedure O O
Result O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULTURE O O
  
> O O
RESIN O O
AEROBIC O O
BOTTLE O O
: O O
Final O O
No O O
growth O O
. O O
  
> O O
ANAEROBIC O O
BOTTLE O O
: O O
Final O O
No O O
growth O O
. O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Date O O
10 O O
: O O
59 O O
: O O
00 O O
PM O O
URINE O O
CULTURE O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
PATIENT O O
: O O
Name O O
, O O
Name O O
Name O O
ACCT O O
# O O
: O O
Medical_Record_Number O O
U O O
# O O
: O O
Medical_Record_Number O O
  
LOC O O
: O O
Location O O
ROOM O O
: O O
Location O O
BED O O
: O O
Location O O
AGE O O
/ O O
SX O O
: O O
69 O O
/ O O
M O O
REG O O
: O O
Date O O
  
REG O O
DR O O
: O O
Name O O
, O O
Name O O
DOB O O
: O O
Date O O
DIS O O
: O O
  
STATUS O O
: O O
ADM O O
IN O O
TLOC O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
SPEC# O O
: O O
Medical_Record_Number O O
REQ# O O
: O O
Medical_Record_Number O O
STATUS O O
: O O
COMP O O
COLL O O
: O O
Date O O
- O O
2259 O O
RECV O O
: O O
Date O O
- O O
0033 O O
SOURCE O O
: O O
CLEAN O O
CATCH O O
URINE O O
ORDERED O O
: O O
URINE O O
CULTURE O O
COMMENTS O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Procedure O O
Result O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
> O O
URINE O O
CULTURE O O
Final O O
NO O O
GROWTH O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Date O O
10 O O
: O O
45 O O
: O O
00 O O
PM O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULT O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
PATIENT O O
: O O
Name O O
, O O
Name O O
Name O O
ACCT O O
# O O
: O O
Medical_Record_Number O O
U O O
# O O
: O O
Medical_Record_Number O O
  
LOC O O
: O O
Location O O
ROOM O O
: O O
Location O O
BED O O
: O O
Location O O
AGE O O
/ O O
SX O O
: O O
69 O O
/ O O
M O O
REG O O
: O O
Date O O
  
REG O O
DR O O
: O O
Name O O
, O O
Name O O
DOB O O
: O O
Date O O
DIS O O
: O O
  
STATUS O O
: O O
ADM O O
IN O O
TLOC O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
  
SPEC# O O
: O O
Medical_Record_Number O O
REQ# O O
: O O
Medical_Record_Number O O
STATUS O O
: O O
COMP O O
COLL O O
: O O
Date O O
- O O
2245 O O
RECV O O
: O O
Date O O
- O O
2304 O O
SOURCE O O
: O O
BLOOD O O
ORDERED O O
: O O
AER O O
/ O O
ANA O O
BC O O
COMMENTS O O
: O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Procedure O O
Result O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
AEROBIC O O
/ O O
ANAEROBIC O O
BLOOD O O
CULTURE O O
  
> O O
RESIN O O
AEROBIC O O
BOTTLE O O
: O O
Final O O
No O O
growth O O
. O O
  
> O O
ANAEROBIC O O
BOTTLE O O
: O O
Final O O
No O O
growth O O
. O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Radiology O O
images O O
personally O O
reviewed O O
by O O
attending O O
  
ECG O O
IMPRESSION O O
  
69 O O
y O O
/ O O
o O O
male O O
s O O
/ O O
p O O
BMT O O
for O O
MAntel B-SSLIF B-SSLIF
Cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
pleural B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
in O O
the O O
setting O O
of O O
pneumonia B-SSLIF B-SSLIF
PROBLEM O O
LIST O O
/ O O
PLAN O O
OF O O
CARE O O
  
1 O O
; O O
pleural B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
ASSESSMENT O O
/ O O
PLAN O O
: O O
Pt O O
is O O
asymptomatic O O
at O O
this O O
time O O
and O O
saturating O O
well O O
on O O
room O O
air O O
. O O
  
Differential O O
Dx O O
for O O
the O O
etiology O O
of O O
the O O
pleural B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
is O O
parapneumonic B-SSLIF B-SSLIF
vs. O O
medication B-Drug B-Drug
induced O O
vs. O O
hemothorax B-SSLIF B-SSLIF
. O O
  
This O O
is O O
most O O
likely O O
a O O
parapneumonic B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
as O O
the O O
patient O O
is O O
currently O O
being O O
treated O O
for O O
pneumonia B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
. O O
  
Sirolimus B-Drug B-Drug
has O O
been O O
shown O O
to O O
cause O O
pleural B-ADE B-ADE
effusions I-ADE I-ADE
in O O
some O O
patients O O
, O O
although O O
rare O O
, O O
and O O
should O O
be O O
considered O O
as O O
well O O
. O O
  
Given O O
the O O
patient's O O
thrombocytopenia B-SSLIF B-SSLIF
, O O
the O O
possibility O O
of O O
a O O
hemothorax B-SSLIF B-SSLIF
may O O
also O O
be O O
entertained O O
. O O
  
Would O O
recommend O O
a O O
thoracentesis O O
, O O
however O O
, O O
patient O O
has O O
profound B-Severity B-Severity
thrombocytopenia B-SSLIF B-SSLIF
and O O
will O O
require O O
platelet O O
infusion O O
in O O
order O O
to O O
obtain O O
a O O
platelet O O
level O O
of O O
ideally O O
30 O O
, O O
000 O O
prior O O
to O O
the O O
thoracentesis O O
. O O
  
Would O O
also O O
recommend O O
daily O O
CXR O O
in O O
order O O
to O O
monitor O O
the O O
effusion B-Indication B-Indication
. O O
  
Would O O
continue O O
with O O
the O O
antibiotics B-Drug B-Drug
and O O
monitoring O O
of O O
the O O
vancomycin B-Drug B-Drug
trough O O
. O O
  
Thank O O
you O O
for O O
this O O
interesting O O
consult O O
and O O
allowing O O
us O O
to O O
participate O O
in O O
the O O
care O O
of O O
your O O
patient O O
. O O
  
ATTENDING O O
COMMENTS O O
: O O
Agree O O
with O O
thoracentesis O O
; O O
likely O O
parapneumonic B-SSLIF B-SSLIF
effusion I-SSLIF I-SSLIF
but O O
medication B-SSLIF B-SSLIF
effect I-SSLIF I-SSLIF
, O O
opportunistic B-SSLIF B-SSLIF
infections I-SSLIF I-SSLIF
, O O
etc O O
must O O
be O O
considered O O
. O O
  
Plan O O
for O O
thoracentesis O O
if O O
PLT O O
>30 O O
, O O
000 O O
GLOBAL O O
PLAN O O
OF O O
CARE O O
Limitations O O
of O O
Treatment O O
: O O
Full O O
Code O O
Fluids O O
/ O O
Electrolytes O O
/ O O
Nutrition O O
: O O
neutropenic O O
diet O O
COMMUNICATION O O
Discussed O O
Plan O O
of O O
Care O O
with O O
Patient O O
/ O O
Family O O
: O O
Yes O O
Discussed O O
plan O O
of O O
care O O
with O O
nursing O O
staff O O
: O O
Yes O O
Referring O O
Physician O O
: O O
Name O O
, O O
Name O O
Primary O O
Care O O
MD O O
: O O
Name O O
, O O
Name O O
ATTENDING O O
PHYSICIAN O O
BILLING O O
DOCUMENTATION O O
Billing O O
Documentation O O
: O O
Type O O
of O O
Service O O
Billed O O
: O O
Inpatient O O
Consultation O O
Date O O
of O O
Service O O
: O O
Date O O
SIGNATURES O O
Resident O O
Signature O O
: O O
Electronically O O
signed O O
by O O
Name O O
Name O O
, O O
DO O O
at O O
17 O O
: O O
43 O O
Date O O
of O O
Resident O O
Signature O O
: O O
Date O O
Attending O O
Attestation O O
: O O
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
. O O
  
I O O
agree O O
with O O
or O O
have O O
edited O O
the O O
findings O O
and O O
the O O
plan O O
of O O
care O O
as O O
documented O O
in O O
the O O
resident's O O
note O O
. O O
  
: O O
  
GC O O
Attending O O
Signature O O
: O O
Electronically O O
signed O O
by O O
Name O O
Name O O
, O O
MD O O
at O O
19 O O
: O O
47 O O
Date O O
of O O
Attending O O
Signature O O
: O O
Date O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Service O O
: O O
Date O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Date O O
Name O O
, O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
9 O O
: O O
59 O O
P O O
  
MD O O
SPECIAL O O
PROCEDURES O O
DIAGNOSIS O O
: O O
Mantle B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
bone O O
marrow O O
involvement O O
. O O
  
NAME O O
OF O O
PROCEDURE O O
: O O
Bone O O
marrow O O
aspiration O O
and O O
biopsy O O
for O O
restaging O O
. O O
  
SITE O O
OF O O
PROCEDURE O O
: O O
Right O O
posterior O O
iliac O O
crest O O
. O O
  
PRECEPTOR O O
: O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
After O O
an O O
informed O O
consent O O
and O O
timeout O O
, O O
bone O O
marrow O O
aspiration O O
and O O
biopsy O O
was O O
performed O O
under O O
local O O
anesthesia O O
and O O
sterile O O
condition O O
with O O
the O O
patient O O
in O O
left O O
lateral O O
position O O
. O O
  
Approximately O O
12 O O
mL O O
of O O
bone O O
marrow O O
was O O
aspirated O O
from O O
the O O
right O O
posterior O O
superior O O
iliac O O
spine O O
. O O
  
Subsequently O O
, O O
bone O O
marrow O O
biopsy O O
was O O
performed O O
using O O
the O O
Jamshidi O O
needle O O
from O O
the O O
same O O
incision O O
site O O
, O O
1 O O
inch O O
core O O
biopsy O O
was O O
obtained O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
without O O
any O O
pain B-SSLIF B-SSLIF
or O O
bleeding B-SSLIF B-SSLIF
. O O
  
He O O
was O O
asked O O
to O O
lie O O
down O O
flat O O
for O O
20 O O
min O O
after O O
the O O
procedure O O
. O O
  
I O O
was O O
present O O
during O O
the O O
entire O O
procedure O O
. O O
  
Reviewed O O
Name O O
Name O O
, O O
MD O O
Date O O
08 O O
: O O
28 O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
10 O O
: O O
42 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
NUTRITION O O
NOTE O O
: O O
  
Pt O O
seen O O
and O O
assessed O O
today O O
for O O
pre O O
- O O
BMT O O
nutrition O O
eval. O O
68 O O
- O O
year O O
- O O
old O O
male O O
diagnosed O O
with O O
mantle B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
, O O
initial O O
diagnosis O O
in O O
Date O O
. O O
  
Awaiting O O
allo O O
transplant O O
. O O
  
Pt O O
is O O
status O O
post O O
7 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
chemotherapy B-Drug B-Drug
on O O
the O O
hyper B-Drug B-Drug
- I-Drug I-Drug
CVAD I-Drug I-Drug
protocol O O
. O O
  
Reports O O
during O O
chemotherapy B-Drug B-Drug
he O O
had O O
issues O O
with O O
taste B-ADE B-ADE
changes I-ADE I-ADE
and O O
a O O
poor B-ADE B-ADE
appetite I-ADE I-ADE
but O O
these O O
issues O O
are O O
now O O
resolving O O
and O O
he O O
feells O O
well O O
and O O
is O O
eating O O
good O O
. O O
  
Typical O O
diet O O
includes O O
Cheerios O O
or O O
scrambled O O
eggs O O
with O O
peanut O O
butter O O
toast O O
and O O
coffee O O
for O O
breakfast O O
, O O
lunch O O
of O O
a O O
tuna O O
sandwich O O
, O O
dinner O O
of O O
chicken O O
, O O
canned O O
vegetables O O
and O O
a O O
cookie O O
for O O
dinner O O
, O O
snack O O
of O O
jello O O
or O O
ice O O
cream O O
, O O
drinks O O
coke O O
or O O
iced O O
tea O O
. O O
  
Pt O O
is O O
67 O O
? O O
? O O
? O O
tall O O
and O O
155lb O O
, O O
reports O O
his O O
usual O O
between O O
150 O O
and O O
160lb O O
. O O
  
Noted O O
weight O O
documented O O
at O O
172lb O O
on O O
11 O O
Date O O
ndicating O O
some B-Severity B-Severity
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
. O O
  
Current O O
BMI O O
24.3 O O
, O O
normal O O
. O O
  
Drinks O O
one O O
Boost O O
daily O O
, O O
encouraged O O
to O O
continue O O
and O O
increase O O
if O O
difficulty O O
with O O
regular O O
dietary O O
intake O O
occurs O O
or O O
if O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
seen O O
.. O O
Pt O O
has O O
been O O
previously O O
educated O O
on O O
low O O
bacteria O O
diet O O
and O O
has O O
been O O
following O O
since O O
initial O O
diagnoses O O
in O O
October O O
. O O
  
Reviewed O O
with O O
pt O O
in O O
further O O
detail O O
to O O
assure O O
good O O
understanding O O
. O O
  
Also O O
educated O O
on O O
sources O O
of O O
protein O O
and O O
importance O O
of O O
adequate O O
intake O O
. O O
  
Pt O O
denied O O
further O O
questions O O
at O O
this O O
time O O
. O O
  
RD O O
contact O O
info O O
provided O O
. O O
  
Will O O
f O O
/ O O
u O O
as O O
needed O O
post O O
- O O
transplant O O
. O O
  
Electronically O O
signed O O
by O O
: O O
VE O O
Name O O
RA O O
Name O O
Ap O O
Date O O
2 O O
: O O
25PM O O
EST O O
Author O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Service O O
: O O
Date O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
12 O O
: O O
04 O O
P O O
SPECIAL O O
PROCEDURES O O
NAME O O
OF O O
THE O O
PROCEDURE O O
: O O
Bone O O
marrow O O
aspiration O O
. O O
  
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
After O O
informed O O
consent O O
and O O
timeout O O
, O O
bone O O
marrow O O
aspiration O O
was O O
performed O O
under O O
local O O
anesthesia O O
in O O
sterile O O
condition O O
with O O
the O O
patient O O
in O O
left O O
lateral O O
position O O
. O O
  
Approximately O O
4 O O
mL O O
of O O
bone O O
marrow O O
was O O
aspirated O O
from O O
the O O
right O O
posterior O O
superior O O
iliac O O
crest O O
without O O
problems O O
. O O
  
It O O
was O O
sent O O
for O O
flow O O
cytometry O O
and O O
molecular O O
studies O O
. O O
  
Eight O O
slides O O
were O O
made O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
, O O
no O O
biopsy O O
was O O
performed O O
during O O
this O O
procedure O O
. O O
  
He O O
was O O
asked O O
to O O
lie O O
down O O
flat O O
for O O
half O O
an O O
hour O O
after O O
the O O
procedure O O
and O O
then O O
subsequently O O
discharged O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
21 O O
: O O
07 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
SSN O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
M.D. O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
12 O O
: O O
35 O O
PM O O
Clinic O O
Note O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
This O O
is O O
an O O
unscheduled O O
visit O O
with O O
Mr O O
. O O
  
Name O O
after O O
I O O
was O O
called O O
by O O
the O O
lab O O
today O O
that O O
patient O O
had O O
a O O
low B-SSLIF B-SSLIF
neutrophil I-SSLIF I-SSLIF
count I-SSLIF I-SSLIF
of O O
200 O O
along O O
with O O
dropping B-SSLIF B-SSLIF
platelet I-SSLIF I-SSLIF
count I-SSLIF I-SSLIF
of O O
68 O O
, O O
000 O O
. O O
  
Mr O O
. O O
  
Name O O
comes O O
back O O
for O O
evaluation O O
today O O
. O O
  
He O O
is O O
approximately O O
70 O O
days O O
status O O
post O O
unrelated O O
donor O O
stem O O
cell O O
transplant O O
. O O
  
He O O
had O O
received O O
post O O
- O O
transplant O O
cyclophosphamide B-Drug B-Drug
as O O
a O O
part O O
of O O
the O O
preparative O O
regimen O O
. O O
  
Overall O O
, O O
he O O
has O O
been O O
doing O O
well O O
as O O
usual O O
. O O
  
He O O
denies O O
any O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
or O O
diarrhea B-SSLIF B-SSLIF
. O O
  
In O O
the O O
past O O
, O O
he O O
has O O
not O O
been O O
complaining O O
of O O
any O O
fever B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
, O O
but O O
on O O
further O O
questioning O O
today O O
, O O
he O O
said O O
he O O
is O O
intermittently O O
getting O O
chills B-SSLIF B-SSLIF
for O O
a O O
few O O
minutes O O
which O O
go O O
away O O
. O O
  
He O O
denies O O
any O O
fever B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
is O O
concerned O O
about O O
his O O
drop O O
in O O
his O O
white O O
count O O
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
updated O O
in O O
Company O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
a O O
leanly O O
built O O
male O O
in O O
no O O
obvious O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Noted O O
. O O
  
He O O
is O O
afebrile B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Sclerae B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
, O O
not O O
pale B-SSLIF B-SSLIF
. O O
  
HEENT O O
is O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
mucositis B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
thrush B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
Trachea O O
is O O
central O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
Sounds O O
are O O
normal O O
. O O
  
ABDOMEN O O
: O O
Soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
There O O
is O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
Lab O O
tests O O
done O O
today O O
reveal O O
a O O
white O O
count O O
of O O
1000 O O
, O O
hemoglobin O O
of O O
9.7 O O
and O O
a O O
platelet O O
count O O
of O O
62 O O
, O O
000 O O
. O O
  
Absolute O O
neutrophil O O
count O O
is O O
220 O O
and O O
absolute O O
lymphocyte O O
count O O
is O O
500 O O
. O O
  
LDH O O
is O O
338 O O
, O O
reticulocyte O O
count O O
is O O
1.3% O O
, O O
giving O O
him O O
an O O
approximate O O
absolute O O
reticulocyte O O
count O O
of O O
about O O
45 O O
, O O
000 O O
. O O
  
BUN O O
is O O
14 O O
, O O
creatinine O O
1.12 O O
and O O
his O O
LFTs O O
are O O
within O O
normal O O
limits O O
. O O
  
PROBLEMS O O
: O O
  
1. O O
Graft O O
: O O
The O O
patient O O
is O O
dropping B-SSLIF B-SSLIF
blood I-SSLIF I-SSLIF
counts I-SSLIF I-SSLIF
of O O
uncertain O O
etiology O O
. O O
  
A O O
bone O O
marrow O O
aspiration O O
and O O
biopsy O O
was O O
performed O O
today O O
to O O
evaluate O O
the O O
etiology O O
of O O
the O O
same O O
. O O
  
Looking O O
back O O
at O O
his O O
records O O
, O O
some O O
of O O
the O O
etiologies O O
could O O
be O O
an O O
infection B-SSLIF B-SSLIF
, O O
for O O
example O O
, O O
with O O
CMV B-SSLIF B-SSLIF
or O O
any O O
additional O O
bacterial B-SSLIF B-SSLIF
infection I-SSLIF I-SSLIF
that O O
has O O
been O O
ruled O O
out O O
. O O
  
2. O O
Infectious O O
disease O O
: O O
The O O
patient O O
does O O
not O O
have O O
any O O
obvious O O
infection B-SSLIF B-SSLIF
and O O
for O O
this O O
reason O O
, O O
symptomatology O O
of O O
intermittent O O
chills B-SSLIF B-SSLIF
is O O
being O O
worked O O
up O O
with O O
blood O O
cultures O O
. O O
  
He O O
has O O
CMV B-SSLIF B-SSLIF
quant O O
PCR O O
, O O
which O O
is O O
barely B-Severity B-Severity
detectable I-Severity I-Severity
and O O
we O O
will O O
be O O
having O O
following O O
up O O
on O O
the O O
results O O
of O O
these O O
today O O
. O O
  
3. O O
GVHD B-Indication B-Indication
: O O
He O O
does O O
not O O
have O O
any O O
active O O
GVHD B-SSLIF B-SSLIF
, O O
is O O
on O O
sirolimus B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
Monday B-Frequency B-Frequency
, I-Frequency I-Frequency
Wednesday I-Frequency I-Frequency
and I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, O O
which O O
is O O
being O O
tapered O O
off O O
and O O
also O O
prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
, O O
#4 O O
. O O
  
4. O O
Nutritional O O
status O O
is O O
good O O
. O O
  
5. O O
Disease O O
status O O
: O O
He O O
was O O
in O O
remission O O
when O O
he O O
was O O
evaluated O O
day O O
#30 O O
posttransplant O O
. O O
  
I O O
am O O
going O O
to O O
give O O
him O O
a O O
dose O O
of O O
Neupogen B-Drug B-Drug
today O O
and O O
he O O
will O O
be O O
evaluated O O
on O O
Wednesday O O
and O O
have O O
a O O
check O O
on O O
his O O
counts O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
3 O O
: O O
40PM O O
EST O O
Attending O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
3 O O
: O O
36 O O
P O O
  
11 O O
: O O
11 O O
A O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
returns O O
for O O
routine O O
follow O O
- O O
up O O
examination O O
1 O O
month O O
after O O
the O O
end O O
of O O
radiation O O
therapy O O
to O O
the O O
left O O
groin O O
for O O
his O O
stage B-Severity B-Severity
I I-Severity I-Severity
follicular B-SSLIF B-SSLIF
low I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
grade I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
left B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
, O O
felt O O
to O O
be O O
secondary O O
to O O
the O O
groin O O
mass O O
. O O
  
He O O
is O O
doing O O
very O O
well O O
. O O
  
There O O
is O O
some O O
minimal B-Severity B-Severity
residual O O
edema B-SSLIF B-SSLIF
in O O
the O O
left O O
ankle O O
, O O
but O O
he O O
stopped O O
wearing O O
his O O
edema O O
stockings O O
. O O
  
He O O
denies O O
any O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
other O O
symptoms O O
. O O
  
He O O
has O O
noted O O
no O O
new O O
masses B-SSLIF B-SSLIF
. O O
  
MEDICATIONS O O
: O O
Tylenol B-Drug B-Drug
650 B-Dose B-Dose
mg I-Dose I-Dose
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
, O O
aspirin B-Drug B-Drug
81 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
atenolol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
doxazosin B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
simvastatin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
ALLERGIES O O
: O O
He O O
is O O
reported O O
to O O
be O O
allergic B-ADE B-ADE
to O O
lisinopril B-Drug B-Drug
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
Today O O
, O O
he O O
remains O O
an O O
obese B-SSLIF B-SSLIF
, O O
alert O O
, O O
oriented O O
gentleman O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
He O O
weighs O O
249 O O
pounds O O
, O O
his O O
temperature O O
is O O
97.3 O O
degrees O O
, O O
his O O
seated O O
blood O O
pressure O O
148 O O
/ O O
71 O O
, O O
pulse O O
49 O O
, O O
respirations O O
18 O O
, O O
pulse O O
oximetry O O
is O O
94% O O
on O O
room O O
air O O
. O O
  
HEENT O O
: O O
He O O
is O O
normocephalic O O
. O O
  
His O O
hearing O O
is O O
intact O O
to O O
speech O O
and O O
vision O O
seems O O
to O O
be O O
intact O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
There O O
is O O
no O O
palpable O O
cervical B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
, O O
although O O
the O O
rest O O
of O O
the O O
examination O O
is O O
restricted O O
by O O
obesity O O
. O O
  
I O O
could O O
not O O
appreciate O O
the O O
thyroid O O
. O O
  
SPINE O O
: O O
His O O
spine O O
, O O
costovertebral O O
angles O O
and O O
SI O O
joints O O
are O O
nontender O O
to O O
percussion O O
. O O
  
LUNGS O O
: O O
Clear O O
to O O
auscultation O O
and O O
percussion O O
. O O
  
HEART O O
: O O
Heart O O
sounds O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
No O O
carotid B-SSLIF B-SSLIF
bruits I-SSLIF I-SSLIF
appreciated O O
, O O
but O O
quite O O
distant O O
. O O
  
ABDOMEN O O
: O O
Bowel O O
sounds O O
are O O
present O O
. O O
  
There O O
is O O
no O O
abdominal B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
Organomegaly O O
cannot O O
be O O
assessed O O
because O O
of O O
body O O
habitus O O
. O O
  
There O O
is O O
no O O
inguinal B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
The O O
left O O
inguinal O O
incision O O
is O O
well O O
healed O O
. O O
  
EXTREMITIES O O
: O O
Femoral O O
pulses O O
are O O
barely O O
palpable O O
bilaterally O O
. O O
  
He O O
has O O
1+ O O
pitting B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
ankle I-SSLIF I-SSLIF
, O O
greatest O O
over O O
the O O
medial O O
malleolus O O
with O O
some O O
telangiectasias B-SSLIF B-SSLIF
. O O
  
There O O
is O O
, O O
however O O
, O O
a O O
bit O O
less O O
edema B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
. O O
  
His O O
gait O O
is O O
wide O O
base O O
, O O
but O O
probably O O
normal O O
for O O
his O O
size O O
. O O
  
IMPRESSION O O
: O O
Mr O O
. O O
  
Name O O
has O O
had O O
a O O
good O O
clinical O O
response O O
to O O
the O O
radiation O O
therapy O O
. O O
  
His O O
primary O O
concern O O
at O O
this O O
point O O
is O O
whether O O
he O O
can O O
drive O O
to O O
Named_Sites O O
. O O
  
Actually O O
, O O
this O O
is O O
his O O
wife's O O
concern O O
. O O
  
He O O
has O O
no O O
intention O O
of O O
not O O
driving O O
. O O
  
I O O
discussed O O
the O O
importance O O
of O O
being O O
aware O O
of O O
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
calves I-SSLIF I-SSLIF
and O O
of O O
getting O O
out O O
and O O
walking O O
around O O
about O O
every O O
hour O O
. O O
  
He O O
plans O O
one O O
stop O O
for O O
overnight O O
. O O
  
He O O
prefers O O
to O O
follow O O
primarily O O
with O O
Dr O O
. O O
  
Name O O
. O O
  
I O O
will O O
see O O
him O O
again O O
only O O
on O O
request O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
12 O O
: O O
43 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
MR# O O
: O O
SSN O O
Admit O O
: O O
Date O O
Surgery O O
: O O
Date O O
Loc O O
: O O
Named_Sites O O
  
Dict O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
Dict O O
Date O O
Trans O O
: O O
Date O O
12 O O
: O O
13 O O
A O O
Date O O
: O O
  
REPORT O O
OF O O
OPERATION O O
PROCEDURE O O
: O O
Left O O
inguinal O O
lymph O O
node O O
biopsy O O
, O O
excisional O O
. O O
  
SURGEON O O
: O O
Dr O O
. O O
  
Name O O
Name O O
  
ASSITANTS O O
: O O
Dr O O
. O O
  
Name O O
Name O O
PGY O O
- O O
2 O O
ANESTHESIA O O
: O O
Local O O
with O O
conscious O O
sedation O O
monitored O O
. O O
  
ESTIMATED O O
BLOOD O O
LOSS O O
: O O
Minimal O O
. O O
  
FLUIDS O O
: O O
500 O O
mL O O
of O O
crystalloid O O
. O O
  
URINE O O
OUTPUT O O
: O O
Not O O
applicable O O
. O O
  
SPECIMENS O O
: O O
4 O O
cm O O
left O O
inguinal O O
lymph O O
node O O
sent O O
to O O
pathology O O
. O O
  
INDICATIONS O O
: O O
The O O
patient O O
is O O
a O O
78 O O
- O O
year O O
- O O
old O O
gentleman O O
who O O
presented O O
to O O
clinic O O
on O O
Date O O
for O O
6 O O
- O O
week O O
history O O
of O O
left B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
He O O
was O O
found O O
to O O
have O O
4.5 O O
x O O
2.5 O O
x O O
1.5 O O
cm O O
lymph O O
node O O
in O O
the O O
left O O
groin O O
that O O
has O O
enlarged O O
. O O
  
The O O
patient O O
underwent O O
fine O O
needle O O
aspiration O O
that O O
did O O
not O O
reveal O O
any O O
diagnosis O O
. O O
  
The O O
patient O O
presents O O
today O O
for O O
excisional O O
biopsy O O
and O O
diagnosis O O
of O O
the O O
enlarged B-SSLIF B-SSLIF
lymph I-SSLIF I-SSLIF
node I-SSLIF I-SSLIF
. O O
  
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
The O O
patient O O
was O O
placed O O
in O O
the O O
supine O O
position O O
and O O
his O O
left O O
groin O O
was O O
cleansed O O
and O O
draped O O
in O O
usual O O
sterile O O
fashion O O
under O O
conscious O O
sedation O O
. O O
  
At O O
this O O
point O O
, O O
a O O
3 O O
- O O
cm O O
previous O O
scar O O
was O O
identified O O
and O O
a O O
marking O O
pen O O
was O O
used O O
to O O
mark O O
out O O
the O O
incision O O
along O O
the O O
scar O O
. O O
  
Time O O
- O O
out O O
was O O
performed O O
prior O O
to O O
introduction O O
of O O
10 B-Dose B-Dose
mL I-Dose I-Dose
of O O
Marcaine B-Drug B-Drug
with I-Drug I-Drug
epinephrine I-Drug I-Drug
, O O
and O O
a O O
10 O O
- O O
blade O O
was O O
used O O
to O O
make O O
3cm O O
incision O O
. O O
  
At O O
this O O
point O O
, O O
Bovie O O
electrocautery O O
was O O
used O O
to O O
extend O O
the O O
incision O O
deep O O
; O O
meanwhile O O
, O O
palpating O O
the O O
area O O
for O O
the O O
enlarged O O
lymph O O
node O O
. O O
  
Meticulous O O
hemostasis O O
was O O
maintained O O
while O O
dissection O O
continued O O
down O O
into O O
the O O
subcutaneous O O
planes O O
until O O
a O O
large O O
3 O O
cm O O
lymph O O
node O O
was O O
identified O O
. O O
  
A O O
Kelly O O
clamp O O
was O O
used O O
to O O
grasp O O
the O O
lymph O O
node O O
firmly O O
and O O
the O O
tissue O O
surrounding O O
it O O
was O O
dissected O O
. O O
  
At O O
this O O
point O O
, O O
an O O
incisional O O
biopsy O O
was O O
taken O O
of O O
the O O
lymph O O
node O O
, O O
tying O O
off O O
the O O
remaining O O
stump O O
with O O
a O O
2 O O
- O O
0 O O
silk O O
suture O O
. O O
  
This O O
was O O
taken O O
to O O
pathology O O
. O O
  
During O O
this O O
time O O
, O O
hemostasis O O
was O O
maintained O O
and O O
pressure O O
was O O
applied O O
to O O
the O O
groin O O
wound O O
. O O
  
Pathology O O
returned O O
with O O
a O O
message O O
to O O
remove O O
more O O
tissue O O
at O O
which O O
point O O
the O O
suture O O
was O O
identified O O
. O O
  
The O O
remaining O O
lymph O O
node O O
was O O
then O O
completely O O
dissected O O
free O O
and O O
the O O
area O O
was O O
inspected O O
for O O
sources O O
of O O
bleeding O O
and O O
lymphatic O O
drainage O O
. O O
  
All O O
sources O O
were O O
identified O O
and O O
electrocauterized O O
. O O
  
The O O
wound O O
was O O
thoroughly O O
irrigated O O
and O O
closed O O
in O O
3 O O
layers O O
using O O
2 O O
- O O
0 O O
Vicryl O O
, O O
3 O O
- O O
0 O O
Vicryl O O
and O O
4 O O
- O O
0 O O
Monocryl O O
in O O
that O O
order O O
is O O
subcuticular O O
closure O O
was O O
performed O O
using O O
the O O
4 O O
- O O
0 O O
Monocryl O O
. O O
  
The O O
wound O O
was O O
then O O
cleansed O O
again O O
with O O
normal O O
saline O O
and O O
dried O O
and O O
Dermabond O O
was O O
placed O O
over O O
the O O
wound O O
. O O
  
The O O
patient O O
was O O
weaned O O
off O O
sedation O O
without O O
event O O
and O O
was O O
taken O O
to O O
the O O
PACU O O
. O O
  
Lymph O O
node O O
was O O
sent O O
for O O
pathologic O O
examination O O
. O O
  
Attending O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
Last O O
Edited O O
By O O
Name O O
Name O O
, O O
MD O O
# O O
Identifiers O O
on O O
Date O O
10 O O
: O O
23 O O
Revision O O
Number O O
- O O
2 O O
Last O O
Edited O O
By O O
I O O
was O O
present O O
for O O
the O O
key O O
portions O O
of O O
this O O
surgery O O
Name O O
Name O O
MD O O
# O O
Identifiers O O
and O O
I O O
or O O
another O O
attending O O
was O O
available O O
for O O
all O O
on O O
Date O O
07 O O
: O O
04 O O
other O O
portions O O
of O O
the O O
surgery O O
. O O
  
Revision O O
Number O O
- O O
3 O O
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
MD O O
# O O
Identifiers O O
on O O
Date O O
07 O O
: O O
04 O O
Name O O
Name O O
, O O
MD O O
# O O
Identifiers O O
on O O
Date O O
10 O O
: O O
23 O O
CHIEF O O
COMPLAINT O O
: O O
This O O
is O O
a O O
78 O O
- O O
year O O
- O O
old O O
patient O O
of O O
mine O O
who O O
is O O
here O O
with O O
chief O O
complaint O O
for O O
followup O O
of O O
hypertension B-SSLIF B-SSLIF
and O O
hyperlipidemia B-SSLIF B-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
currently O O
under O O
followup O O
from O O
Dr O O
. O O
  
Name O O
Name O O
, O O
nephrologist O O
and O O
has O O
a O O
diagnosis O O
of O O
stage B-Severity B-Severity
III I-Severity I-Severity
kidney B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
with O O
hypertensive B-SSLIF B-SSLIF
nephrosclerosis I-SSLIF I-SSLIF
. O O
  
He O O
was O O
started O O
on O O
chlorthalidone B-Drug B-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
daily B-Frequency B-Frequency
for O O
better O O
control O O
of O O
hypertension B-Indication B-Indication
about O O
two O O
months O O
ago O O
; O O
however O O
, O O
he O O
never O O
filled O O
the O O
medication O O
and O O
has O O
not O O
been O O
on O O
chlorthalidone B-Drug B-Drug
. O O
  
He O O
reports O O
adherence O O
to O O
atenolol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
daily B-Frequency B-Frequency
and O O
reports O O
having O O
done O O
many O O
dietary O O
changes O O
towards O O
positive O O
healthy O O
lifestyle O O
. O O
  
He O O
feels O O
better O O
now O O
that O O
he O O
has O O
lost O O
10 O O
pounds O O
in O O
weight O O
through O O
dieting O O
alone O O
for O O
the O O
past O O
two O O
months O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Otherwise O O
, O O
feels O O
well O O
. O O
  
Denies O O
any O O
symptoms O O
of O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
or O O
palpitations B-SSLIF B-SSLIF
or O O
tachycardia B-SSLIF B-SSLIF
or O O
orthopnea B-SSLIF B-SSLIF
or O O
paroxysmal B-SSLIF B-SSLIF
nocturnal I-SSLIF I-SSLIF
dyspnea I-SSLIF I-SSLIF
, O O
dysphagia B-SSLIF B-SSLIF
, O O
heartburn B-SSLIF B-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
joint B-SSLIF B-SSLIF
swelling I-SSLIF I-SSLIF
, O O
depression B-SSLIF B-SSLIF
, O O
anxiety B-SSLIF B-SSLIF
, O O
panic B-SSLIF B-SSLIF
attacks I-SSLIF I-SSLIF
or O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
denies O O
any O O
headache B-SSLIF B-SSLIF
, O O
dizziness B-SSLIF B-SSLIF
, O O
earache B-SSLIF B-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Reviewed O O
and O O
noncontributory O O
. O O
  
SOCIAL O O
/ O O
PERSONAL O O
HISTORY O O
: O O
Former O O
smoker O O
. O O
  
Lives O O
at O O
home O O
with O O
wife O O
. O O
  
Mostly O O
sedentary O O
lifestyle O O
. O O
  
Retired O O
. O O
  
Has O O
grown O O
- O O
up O O
children O O
. O O
  
MEDICATIONS O O
: O O
As O O
on O O
Company O O
. O O
  
ALLERGIES B-SSLIF B-SSLIF
: O O
Not O O
true O O
allergy O O
to O O
lisinopril B-Drug B-Drug
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Positive O O
for O O
impaired B-SSLIF B-SSLIF
fasting I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
, O O
obesity B-SSLIF B-SSLIF
, O O
hyperlipidemia B-SSLIF B-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
On O O
physical O O
examination O O
, O O
the O O
patient O O
is O O
a O O
pleasant O O
, O O
well O O
- O O
nourished O O
78 O O
- O O
year O O
- O O
old O O
obese O O
Caucasian O O
man O O
in O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
. O O
  
Alert O O
, O O
oriented O O
x3 O O
. O O
  
Blood O O
pressure O O
158 O O
/ O O
82 O O
mmHg O O
, O O
heart O O
rate O O
of O O
54 O O
/ O O
minute O O
, O O
regular O O
. O O
  
Pulse O O
oximetry O O
on O O
room O O
air O O
of O O
97% O O
. O O
  
Weighs O O
247 O O
pounds O O
and O O
a O O
BMI O O
of O O
37 O O
. O O
  
Head O O
, O O
neck O O
, O O
ENT O O
: O O
MMM O O
. O O
  
EOMI O O
. O O
  
JVP O O
not O O
raised O O
. O O
  
Legs O O
: O O
No O O
edema B-SSLIF B-SSLIF
. O O
  
Musculoskeletal O O
and O O
neurological O O
system O O
exam O O
grossly O O
normal O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
  
1. O O
Hypertension B-Indication B-Indication
. O O
  
Poorly O O
- O O
controlled O O
at O O
this O O
time O O
. O O
  
Reviewed O O
with O O
him O O
the O O
need O O
to O O
start O O
on O O
the O O
diuretic B-Drug B-Drug
as O O
advised O O
by O O
nephrologist O O
. O O
  
At O O
this O O
time O O
, O O
chlorthalidone B-Drug B-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
called O O
in O O
to O O
his O O
local O O
pharmacy O O
for O O
two O O
months' O O
supply O O
only O O
. O O
  
I O O
told O O
him O O
that O O
once O O
the O O
dose O O
gets O O
stabilized O O
, O O
it O O
will O O
be O O
called O O
in O O
for O O
a O O
longer O O
duration O O
of O O
supply O O
at O O
Company O O
mail O O
ordered O O
where O O
he O O
wishes O O
his O O
medication O O
to O O
go O O
to O O
. O O
  
Followup O O
rescheduled O O
with O O
Dr O O
. O O
  
Name O O
's O O
office O O
in O O
order O O
to O O
give O O
the O O
new O O
medication O O
sufficient O O
time O O
to O O
work O O
, O O
and O O
patient O O
will O O
see O O
him O O
in O O
about O O
six O O
weeks' O O
time O O
from O O
the O O
start O O
of O O
taking O O
this O O
medication O O
. O O
  
He O O
agrees O O
with O O
the O O
plan O O
and O O
voices O O
his O O
understanding O O
. O O
  
His O O
electrolytes O O
checked O O
yesterday O O
were O O
within O O
normal O O
limits O O
with O O
a O O
return O O
of O O
creatinine O O
to O O
1.03 O O
. O O
  
These O O
results O O
were O O
discussed O O
with O O
the O O
patient O O
. O O
  
2. O O
Hyperlipidemia B-Indication B-Indication
. O O
  
Improvement O O
in O O
hypertriglyceridemia B-SSLIF B-SSLIF
, O O
292 O O
compared O O
to O O
his O O
last O O
laboratory O O
work O O
done O O
about O O
three O O
months O O
ago O O
. O O
  
Continue O O
with O O
fish B-Drug B-Drug
oil I-Drug I-Drug
and O O
simvastatin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
daily B-Frequency B-Frequency
along O O
with O O
the O O
lifestyle O O
modification O O
changes O O
. O O
  
Six O O
months O O
followup O O
now O O
towards O O
fasting O O
lipid O O
profile O O
arranged O O
for O O
. O O
  
No O O
other O O
intervention O O
needed O O
at O O
this O O
time O O
. O O
  
3. O O
Impaired B-SSLIF B-SSLIF
fasting I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
. O O
  
This O O
has O O
now O O
settled O O
down O O
with O O
improvement O O
of O O
HbA1c O O
to O O
5.5 O O
. O O
  
That O O
is O O
within O O
normal O O
limits O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
10 O O
: O O
39AM O O
EST O O
Author O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
9 O O
: O O
49 O O
P O O
  
2 O O
: O O
30 O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
78 O O
- O O
year O O
- O O
old O O
man O O
with O O
a O O
history O O
of O O
an O O
apparent O O
stage B-Severity B-Severity
I I-Severity I-Severity
follicular B-SSLIF B-SSLIF
low I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
grade I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
He O O
presented O O
with O O
left B-SSLIF B-SSLIF
inguinal I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
and O O
left B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
secondary O O
to O O
that O O
. O O
  
An O O
ultrasound O O
ruled O O
out O O
a O O
DVT B-SSLIF B-SSLIF
. O O
  
He O O
has O O
stage O O
I O O
disease O O
based O O
on O O
CT O O
scanning O O
, O O
but O O
did O O
not O O
undergo O O
a O O
bone O O
marrow O O
biopsy O O
. O O
  
He O O
completed O O
radiation O O
therapy O O
to O O
his O O
left O O
inguinal O O
region O O
, O O
under O O
the O O
care O O
of O O
Dr O O
. O O
  
Name O O
Name O O
approximately O O
10 O O
days O O
ago O O
. O O
  
He O O
received O O
a O O
total O O
of O O
30 O O
Gy O O
in O O
15 O O
fractions O O
and O O
completed O O
treatment O O
in O O
Date O O
. O O
  
He O O
reports O O
that O O
he O O
is O O
generally O O
doing O O
well O O
. O O
  
He O O
still O O
has O O
some O O
residual B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
ankle I-SSLIF I-SSLIF
. O O
  
He O O
wonders O O
that O O
if O O
he O O
can O O
stop O O
using O O
his O O
edema O O
stockings O O
at O O
this O O
point O O
. O O
  
Otherwise O O
, O O
he O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
rigors B-SSLIF B-SSLIF
or O O
sweats B-SSLIF B-SSLIF
, O O
coughing B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
other O O
adenopathy B-SSLIF B-SSLIF
, O O
anorexia B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
or O O
rash B-SSLIF B-SSLIF
. O O
  
A O O
comprehensive O O
review O O
of O O
all O O
remaining O O
systems O O
is O O
otherwise O O
entirely O O
negative O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
The O O
patient's O O
medications O O
are O O
unchanged O O
. O O
  
They O O
include O O
Tylenol B-Drug B-Drug
650 B-Dose B-Dose
mg I-Dose I-Dose
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
for O O
headache B-Indication B-Indication
, O O
aspirin B-Drug B-Drug
81 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
atenolol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
doxazosin B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
and O O
simvastatin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
ALLERGIES B-ADE B-ADE
: O O
He O O
reportedly O O
has O O
a O O
sensitivity B-ADE B-ADE
to O O
lisinopril B-Drug B-Drug
, O O
which O O
caused O O
dyspnea B-ADE B-ADE
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
Today O O
, O O
he O O
is O O
a O O
well O O
- O O
developed O O
obese O O
man O O
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
His O O
weight O O
is O O
112.7 O O
kg O O
, O O
blood O O
pressure O O
166 O O
/ O O
80 O O
, O O
temperature O O
is O O
36.5 O O
, O O
pulse O O
61 O O
, O O
respiratory O O
rate O O
is O O
18 O O
and O O
room O O
air O O
oxygen O O
saturation O O
is O O
95% O O
. O O
  
HEENT O O
: O O
Inspection O O
of O O
his O O
mouth O O
reveals O O
moist O O
mucous O O
membranes O O
without O O
mucositis B-SSLIF B-SSLIF
or O O
thrush B-SSLIF B-SSLIF
. O O
  
Sclerae O O
are O O
anicteric O O
. O O
  
HEENT O O
examination O O
is O O
otherwise O O
unremarkable O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
LYMPH O O
NODE O O
: O O
Entirely O O
negative O O
, O O
the O O
lymphadenopathy O O
in O O
the O O
left O O
inguinal O O
region O O
has O O
resolved O O
. O O
  
LUNGS O O
: O O
On O O
auscultation O O
, O O
his O O
lungs O O
are O O
clear O O
. O O
  
CARDIOVASCULAR O O
: O O
Reveals O O
a O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmur B-SSLIF B-SSLIF
, O O
rub B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
The O O
patient O O
is O O
obese O O
. O O
  
No O O
hepatosplenomegaly B-SSLIF B-SSLIF
is O O
easily O O
palpable O O
. O O
  
EXTREMITY O O
: O O
Reveals O O
residual O O
1+ O O
edema B-SSLIF B-SSLIF
predominantly I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
patient's I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
ankle I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
is O O
entirely O O
normal O O
with O O
a O O
white O O
count O O
of O O
7.1 O O
, O O
hemoglobin O O
15.6 O O
and O O
platelets O O
168 O O
, O O
000 O O
. O O
  
Electrolytes O O
are O O
normal O O
, O O
BUN O O
12 O O
and O O
creatinine O O
  
1.13 O O
. O O
  
ASSESSMENT O O
: O O
The O O
patient O O
appears O O
to O O
be O O
doing O O
well O O
. O O
  
He O O
has O O
tolerated O O
the O O
radiation O O
without O O
difficulty O O
. O O
  
His O O
lymphadenopathy B-SSLIF B-SSLIF
has O O
resolved O O
. O O
  
I O O
am O O
not O O
certain O O
whether O O
his O O
edema B-SSLIF B-SSLIF
will O O
recur O O
or O O
not O O
. O O
  
PLAN O O
: O O
The O O
patient O O
will O O
follow O O
up O O
with O O
me O O
in O O
3 O O
months O O
, O O
and O O
after O O
that O O
, O O
if O O
everything O O
is O O
stable O O
, O O
we O O
will O O
begin O O
every O O
6 O O
months' O O
followup O O
. O O
  
I O O
will O O
not O O
plan O O
any O O
imaging O O
for O O
the O O
patient O O
unless O O
he O O
develops O O
symptoms O O
or O O
palpable O O
adenopathy B-SSLIF B-SSLIF
. O O
  
We O O
did O O
discuss O O
the O O
fact O O
that O O
for O O
follicular B-SSLIF B-SSLIF
low I-SSLIF I-SSLIF
grade I-SSLIF I-SSLIF
lymphomas I-SSLIF I-SSLIF
an O O
observation O O
period O O
of O O
several O O
years O O
can O O
often O O
be O O
entertained O O
prior O O
to O O
the O O
patients O O
requiring O O
treatments O O
and O O
the O O
patient O O
is O O
comfortable O O
with O O
this O O
recommendation O O
especially O O
in O O
light O O
of O O
his O O
age O O
of O O
79 O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
21 O O
: O O
29 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
1 O O
: O O
38 O O
P O O
  
11 O O
: O O
37 O O
A O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
79 O O
- O O
year O O
- O O
old O O
man O O
with O O
a O O
history O O
of O O
an O O
apparent O O
stage B-Severity B-Severity
I I-Severity I-Severity
follicular B-SSLIF B-SSLIF
low I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
grade I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
was O O
staged O O
with O O
CT O O
scanning O O
, O O
but O O
did O O
not O O
undergo O O
bone O O
marrow O O
biopsy O O
. O O
  
His O O
only O O
apparent O O
site O O
of O O
disease O O
was O O
his O O
left B-SSLIF B-SSLIF
inguinal I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
received O O
30 O O
Gy O O
of O O
radiation O O
therapy O O
to O O
his O O
left B-SSLIF B-SSLIF
inguinal I-SSLIF I-SSLIF
lymph I-SSLIF I-SSLIF
node I-SSLIF I-SSLIF
, O O
which O O
was O O
completed O O
on O O
Date O O
. O O
  
Since O O
then O O
, O O
he O O
has O O
been O O
followed O O
without O O
evidence O O
of O O
recurrent O O
disease B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
and O O
his O O
wife O O
returned O O
from O O
Named_Sites O O
relatively O O
recently O O
. O O
  
He O O
has O O
been O O
doing O O
well O O
. O O
  
He O O
denies O O
any O O
adenopathy B-SSLIF B-SSLIF
. O O
  
His O O
left B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
has O O
diminished O O
somewhat O O
, O O
but O O
remains O O
roughly O O
stable O O
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
rigors B-SSLIF B-SSLIF
or O O
sweats B-SSLIF B-SSLIF
, O O
coughing B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
anorexia B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
or O O
rash B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
some O O
urinary B-SSLIF B-SSLIF
tract I-SSLIF I-SSLIF
infections I-SSLIF I-SSLIF
and O O
is O O
being O O
followed O O
by O O
urology O O
for O O
that O O
. O O
  
A O O
comprehensive O O
review O O
of O O
all O O
remaining O O
systems O O
is O O
otherwise O O
entirely O O
negative O O
. O O
  
He O O
is O O
being O O
bothered O O
by O O
bilateral B-SSLIF B-SSLIF
knee I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
secondary O O
to O O
DJD B-SSLIF B-SSLIF
but O O
is O O
reluctant O O
to O O
consider O O
the O O
possibility O O
of O O
knee O O
replacement O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Otherwise O O
, O O
remarkable O O
for O O
hypertension B-SSLIF B-SSLIF
and O O
dyslipidemia B-SSLIF B-SSLIF
. O O
  
MEDICATIONS O O
: O O
Include O O
aspirin B-Drug B-Drug
81 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
atenolol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
doxazosin B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
oxybutynin B-Drug B-Drug
extended O O
release O O
5 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
simvastatin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
ALLERGIES B-ADE B-ADE
: O O
The O O
patient O O
reportedly O O
has O O
a O O
history O O
of O O
dyspnea B-ADE B-ADE
when O O
he O O
took O O
lisinopril B-Drug B-Drug
in O O
the O O
past O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
He O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Weight O O
is O O
117.8 O O
kg O O
, O O
blood O O
pressure O O
132 O O
/ O O
72 O O
, O O
temp O O
36.1 O O
, O O
pulse O O
45 O O
, O O
respiratory O O
rate O O
is O O
16 O O
and O O
his O O
room O O
air O O
oxygen O O
saturation O O
is O O
95% O O
. O O
  
NECK O O
: O O
On O O
examination O O
, O O
his O O
neck O O
is O O
supple O O
without O O
any O O
palpable O O
cervical B-SSLIF B-SSLIF
deformity I-SSLIF I-SSLIF
or O O
tenderness B-SSLIF B-SSLIF
. O O
  
LYMPH O O
NODE O O
: O O
Negative O O
in O O
the O O
cervical O O
, O O
supraclavicular O O
, O O
axillary O O
and O O
inguinal O O
femoral O O
regions O O
. O O
  
LUNGS O O
: O O
On O O
auscultation O O
, O O
lungs O O
are O O
clear O O
. O O
  
CHEST O O
: O O
Examination O O
reveals O O
no O O
use O O
of O O
accessory O O
muscles O O
. O O
  
CARDIOVASCULAR O O
: O O
Examination O O
reveals O O
a O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmur B-SSLIF B-SSLIF
, O O
rub B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Obese O O
, O O
but O O
otherwise O O
benign O O
without O O
evidence O O
of O O
mass B-SSLIF B-SSLIF
, O O
tenderness B-SSLIF B-SSLIF
or O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITY O O
: O O
Reveals O O
trace O O
to O O
1+ O O
edema B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
, O O
which O O
is O O
improved O O
, O O
but O O
does O O
persist O O
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
count O O
is O O
6.3 O O
, O O
hemoglobin O O
14.9 O O
, O O
platelets O O
159 O O
, O O
000 O O
. O O
  
LDH O O
is O O
230 O O
, O O
which O O
is O O
within O O
normal O O
limits O O
. O O
  
ASSESSMENT O O
: O O
The O O
patient O O
appears O O
to O O
be O O
doing O O
well O O
. O O
  
He O O
has O O
no O O
clinical O O
evidence O O
of O O
recurrent O O
disease B-SSLIF B-SSLIF
now O O
approximately O O
7 O O
months O O
after O O
completion O O
of O O
radiation O O
therapy O O
. O O
  
PLAN O O
: O O
I O O
did O O
spend O O
some O O
time O O
with O O
the O O
patient O O
and O O
his O O
wife O O
discussing O O
the O O
utility O O
of O O
serial O O
CT O O
scanning O O
. O O
  
I O O
discussed O O
with O O
them O O
the O O
potential O O
for O O
false O O
positive O O
results O O
and O O
the O O
fact O O
that O O
serial O O
CT O O
scanning O O
has O O
not O O
been O O
shown O O
to O O
improve O O
survival O O
in O O
these O O
circumstances O O
. O O
  
Given O O
that O O
the O O
patient O O
is O O
comfortable O O
proceeding O O
with O O
the O O
policy O O
of O O
clinical O O
observation O O
alone O O
without O O
serial O O
CT O O
scanning O O
unless O O
his O O
clinical O O
condition O O
changes O O
. O O
  
The O O
patient O O
is O O
to O O
follow O O
up O O
with O O
me O O
in O O
6 O O
months O O
for O O
repeat O O
evaluation O O
. O O
  
Total O O
time O O
spent O O
with O O
the O O
patient O O
and O O
his O O
wife O O
today O O
was O O
30 O O
minutes O O
, O O
of O O
that O O
time O O
25 O O
minutes O O
were O O
spent O O
in O O
face O O
- O O
to O O
- O O
face O O
counseling O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
18 O O
: O O
06 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
SUBJECTIVE O O
: O O
This O O
is O O
a O O
76 O O
- O O
year O O
- O O
old O O
patient O O
of O O
mine O O
who O O
comes O O
in O O
with O O
a O O
chief O O
complaint O O
of O O
followup O O
of O O
lab O O
work O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
was O O
found O O
to O O
have O O
fasting O O
blood O O
glucose O O
of O O
124 O O
upon O O
initial O O
random O O
testing O O
. O O
  
However O O
, O O
he O O
underwent O O
two O O
hour O O
fasting O O
glucose O O
tolerance O O
test O O
which O O
revealed O O
his O O
fasting O O
blood O O
sugar O O
to O O
be O O
112 O O
. O O
  
His O O
two O O
hour O O
postprandial O O
was O O
100 O O
. O O
  
He O O
feels O O
well O O
. O O
  
He O O
is O O
currently O O
waiting O O
to O O
see O O
a O O
nutritionist O O
in O O
a O O
couple O O
of O O
weeks' O O
time O O
. O O
  
He O O
continues O O
to O O
have O O
tears B-Indication B-Indication
in I-Indication I-Indication
his I-Indication I-Indication
eyes I-Indication I-Indication
that O O
are O O
painless B-SSLIF B-SSLIF
and O O
do O O
not O O
bother O O
him O O
. O O
  
He O O
denies O O
any O O
itching B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
eyes I-SSLIF I-SSLIF
. O O
  
He O O
was O O
started O O
on O O
antihistamine B-Drug B-Drug
eyedrops B-Route B-Route
which O O
he O O
has O O
been O O
using O O
for O O
the O O
past O O
three B-Duration B-Duration
to I-Duration I-Duration
four I-Duration I-Duration
weeks I-Duration I-Duration
. O O
  
However O O
, O O
they O O
do O O
not O O
seem O O
to O O
have O O
affected O O
him O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Head O O
, O O
neck O O
, O O
ENT O O
: O O
He O O
denies O O
any O O
headache B-SSLIF B-SSLIF
, O O
dizziness B-SSLIF B-SSLIF
, O O
earache B-SSLIF B-SSLIF
or O O
decreased B-SSLIF B-SSLIF
hearing I-SSLIF I-SSLIF
. O O
  
Derm O O
: O O
He O O
denies O O
any O O
worrisome O O
lesions B-SSLIF B-SSLIF
. O O
  
Cardiopulmonary O O
: O O
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
palpitations B-SSLIF B-SSLIF
or O O
tachycardia B-SSLIF B-SSLIF
. O O
  
GI O O
: O O
He O O
denies O O
dysphagia B-SSLIF B-SSLIF
, O O
heartburn B-SSLIF B-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
or O O
diarrhea B-SSLIF B-SSLIF
. O O
  
GU O O
: O O
He O O
denies O O
dysuria B-SSLIF B-SSLIF
, O O
urgency B-SSLIF B-SSLIF
, O O
frequency B-SSLIF B-SSLIF
, O O
urgency B-SSLIF B-SSLIF
, O O
or O O
incontinence B-SSLIF B-SSLIF
. O O
  
Musculoskeletal O O
: O O
He O O
denies O O
joint B-SSLIF B-SSLIF
swelling I-SSLIF I-SSLIF
/ O O
myalgias B-SSLIF B-SSLIF
. O O
  
Psych O O
: O O
He O O
denies O O
any O O
symptoms O O
of O O
depression B-SSLIF B-SSLIF
or O O
anxiety B-SSLIF B-SSLIF
. O O
  
Systemic O O
: O O
He O O
denies O O
fever B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Positive O O
for O O
obesity B-SSLIF B-SSLIF
, O O
hyperlipidemia B-SSLIF B-SSLIF
and O O
hypertension B-SSLIF B-SSLIF
. O O
  
ALLERGIES B-SSLIF B-SSLIF
: O O
To O O
no O O
known O O
drugs O O
. O O
  
SOCIAL O O
/ O O
PERSONAL O O
HISTORY O O
: O O
Nonsmoker O O
. O O
  
He O O
lives O O
at O O
home O O
with O O
wife O O
. O O
  
Mostly O O
sedentary O O
lifestyle O O
. O O
  
Alcohol O O
habits O O
, O O
he O O
currently O O
drinks O O
about O O
once O O
every O O
month O O
and O O
he O O
has O O
done O O
this O O
for O O
the O O
past O O
four O O
years O O
. O O
  
However O O
, O O
before O O
those O O
four O O
years O O
, O O
he O O
was O O
drinking O O
two O O
six O O
packs O O
every O O
month O O
basis O O
. O O
  
He O O
reports O O
he O O
has O O
never O O
had O O
any O O
more O O
alcohol O O
than O O
that O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
is O O
a O O
pleasant O O
obese O O
76 O O
- O O
year O O
- O O
old O O
Caucasian O O
man O O
in O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
. O O
  
Weight O O
268 O O
pounds O O
. O O
  
Blood O O
pressure O O
128 O O
/ O O
76 O O
mmHg O O
. O O
  
Heart O O
rate O O
of O O
56 O O
per O O
minute O O
, O O
regular O O
. O O
  
Head O O
, O O
neck O O
, O O
ENT O O
: O O
MMM O O
. O O
  
EOMI O O
. O O
  
No O O
cervical B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
present O O
. O O
  
Lungs O O
: O O
Bilateral O O
clear O O
to O O
auscultation O O
. O O
  
Heart O O
: O O
Sounds O O
normal O O
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender O O
, O O
no O O
masses B-SSLIF B-SSLIF
. O O
  
Extremities O O
: O O
Mild B-Severity B-Severity
peripheral O O
1+ O O
edema B-SSLIF B-SSLIF
present I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
. O O
  
Calf O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
Spinal O O
anatomy O O
and O O
range O O
of O O
motion O O
normal O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
  
1. O O
Hypertension B-Indication B-Indication
within O O
reasonable O O
control O O
today O O
. O O
  
Continue O O
with O O
current O O
medication O O
. O O
  
Advised O O
an O O
emphasis O O
placed O O
upon O O
low O O
- O O
salt O O
diet O O
. O O
  
He O O
is O O
currently O O
on O O
triamterene B-Drug B-Drug
/ I-Drug I-Drug
HCTZ I-Drug I-Drug
combination O O
and O O
reports O O
complete O O
adherence O O
to O O
medication O O
regimen O O
. O O
  
2. O O
Impaired B-SSLIF B-SSLIF
fasting I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
. O O
  
His O O
two O O
hour O O
glucose O O
tolerance O O
test O O
was O O
within O O
normal O O
limits O O
. O O
  
Gave O O
him O O
the O O
results O O
and O O
advised O O
him O O
to O O
keep O O
an O O
eye O O
on O O
his O O
diet O O
and O O
also O O
try O O
to O O
continue O O
efforts O O
towards O O
losing O O
weight O O
. O O
  
Repeat O O
fasting O O
lab O O
work O O
will O O
be O O
in O O
six O O
months' O O
time O O
. O O
  
His O O
HbA1c O O
was O O
6.0 O O
. O O
  
3. O O
Hyperlipidemia B-Indication B-Indication
. O O
  
Continue O O
on O O
Lipitor B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
Repeat O O
fasting O O
lipid O O
testing O O
in O O
first O O
week O O
of O O
Date O O
next O O
year O O
prior O O
to O O
office O O
visit O O
with O O
me O O
. O O
  
4. O O
Watery B-Indication B-Indication
eyes I-Indication I-Indication
. O O
  
Unclear O O
etiology O O
at O O
this O O
time O O
, O O
however O O
, O O
likely O O
secondary O O
to O O
bilateral B-SSLIF B-SSLIF
dacryocystitis I-SSLIF I-SSLIF
. O O
  
He O O
declines O O
ophthalmology O O
appointment O O
at O O
this O O
time O O
. O O
  
Discontinued O O
antihistaminic B-Drug B-Drug
eye B-Route B-Route
drops I-Route I-Route
at O O
this O O
point O O
. O O
  
5. O O
Hepatomegaly B-SSLIF B-SSLIF
. O O
  
This O O
was O O
a O O
clinical O O
finding O O
upon O O
last O O
office O O
visit O O
. O O
  
In O O
absence O O
of O O
significant O O
alcohol O O
habits O O
, O O
this O O
is O O
likely O O
fatty B-SSLIF B-SSLIF
liver I-SSLIF I-SSLIF
. O O
  
However O O
, O O
I O O
will O O
get O O
an O O
ultrasound O O
of O O
right O O
upper O O
quadrant O O
. O O
  
Normal O O
LFTs O O
. O O
  
Follow O O
up O O
with O O
a O O
right O O
upper O O
quadrant O O
ultrasound O O
results O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
4 O O
: O O
25PM O O
EST O O
Author O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
NP O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
12 O O
: O O
47 O O
PM O O
Clinic O O
Note O O
DIAGNOSES O O
: O O
  
1. O O
Mr O O
. O O
  
Name O O
is O O
a O O
53 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
history O O
of O O
a O O
non B-Indication B-Indication
- I-Indication I-Indication
Hodgkin's I-Indication I-Indication
lymphoma I-Indication I-Indication
, O O
original O O
diagnosis O O
established O O
as O O
a O O
subtype B-Indication B-Indication
mixed I-Indication I-Indication
follicular I-Indication I-Indication
large I-Indication I-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
involving I-Indication I-Indication
the I-Indication I-Indication
T I-Indication I-Indication
- I-Indication I-Indication
spine I-Indication I-Indication
, O O
stage B-Severity B-Severity
IAE I-Severity I-Severity
. O O
  
Original O O
diagnosis O O
established O O
in O O
Date O O
. O O
  
2. O O
Chronic O O
arthritis B-Indication B-Indication
and O O
left B-Indication B-Indication
shoulder I-Indication I-Indication
pain I-Indication I-Indication
, O O
utilizing O O
Vicodin B-Drug B-Drug
2 B-Dose B-Dose
tablets I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
managed O O
by O O
primary O O
care O O
doctor O O
. O O
  
CURRENT O O
THERAPY O O
: O O
Maintenance O O
rituximab B-Drug B-Drug
375 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
kg I-Dose I-Dose
once B-Frequency B-Frequency
every I-Frequency I-Frequency
2 I-Frequency I-Frequency
months I-Frequency I-Frequency
. O O
  
This O O
was O O
initiated O O
in O O
Date O O
. O O
  
He O O
is O O
here O O
for O O
an O O
evaluation O O
prior O O
to O O
receiving O O
Rituxan B-Drug B-Drug
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
, O O
overall O O
, O O
feels O O
well O O
. O O
  
He O O
just O O
returned O O
from O O
a O O
cruise O O
from O O
Location O O
. O O
  
He O O
reports O O
that O O
he O O
gained B-SSLIF B-SSLIF
approximately I-SSLIF I-SSLIF
10 I-SSLIF I-SSLIF
pounds I-SSLIF I-SSLIF
since O O
his O O
trip O O
to O O
Location O O
because O O
of O O
the O O
buffets O O
and O O
low O O
- O O
cost O O
food O O
. O O
  
He O O
was O O
trying O O
to O O
exercise O O
, O O
but O O
does O O
experience O O
some B-Severity B-Severity
pain B-Indication B-Indication
. O O
  
He O O
usually O O
tries O O
to O O
take O O
his O O
Vicodin B-Drug B-Drug
2 B-Dose B-Dose
tablets I-Dose I-Dose
after O O
he O O
exercises O O
. O O
  
He O O
has O O
not O O
had O O
any O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
He O O
has O O
not O O
had O O
any O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
or O O
any O O
recent O O
infections B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
no O O
bleeding B-SSLIF B-SSLIF
or O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
new O O
lumps B-SSLIF B-SSLIF
or O O
bumps B-SSLIF B-SSLIF
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
reconciled O O
in O O
Company O O
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
, O O
unknown O O
reaction O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Nonsmoker O O
, O O
nondrinker O O
, O O
exercise O O
is O O
minimal O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
Temperature O O
is O O
36.6 O O
degrees O O
Celsius O O
, O O
blood O O
pressure O O
is O O
133 O O
/ O O
81 O O
, O O
heart O O
rate O O
is O O
85 O O
, O O
respiratory O O
rate O O
is O O
18 O O
, O O
O2 O O
saturation O O
95 O O
percent O O
on O O
room O O
air O O
, O O
weight O O
is O O
159.3 O O
kg O O
. O O
  
This O O
is O O
up O O
approximately O O
5 O O
kg O O
from O O
his O O
prior O O
visit O O
back O O
in O O
Date O O
. O O
  
GENERAL O O
: O O
Mr O O
. O O
  
Name O O
appears O O
well O O
. O O
  
He O O
is O O
alert O O
and O O
oriented O O
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
The O O
sclerae O O
are O O
anicteric B-SSLIF B-SSLIF
. O O
  
The O O
oropharyngeal O O
cavity O O
is O O
clear O O
. O O
  
NECK O O
: O O
The O O
thyroid O O
is O O
nonpalpable O O
. O O
  
LYMPHATICS O O
: O O
No O O
cervical B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
or O O
inguinal B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
SPINE O O
: O O
Nontender B-SSLIF B-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
bilaterally O O
without O O
any O O
rales B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
or O O
wheezes B-SSLIF B-SSLIF
. O O
  
CARDIAC O O
: O O
S1 O O
, O O
S2 O O
, O O
regular O O
rate O O
and O O
rhythm O O
. O O
  
There O O
are O O
no O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Exam O O
is O O
very O O
limited O O
due O O
to O O
habitus O O
. O O
  
There O O
is O O
no O O
gross B-Severity B-Severity
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rash B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Alert O O
and O O
oriented O O
, O O
nonfocal O O
. O O
  
MUSCULOSKELETAL O O
: O O
Nonataxic B-SSLIF B-SSLIF
gait I-SSLIF I-SSLIF
, O O
but O O
requires O O
a O O
cane B-SSLIF B-SSLIF
for I-SSLIF I-SSLIF
ambulation I-SSLIF I-SSLIF
. O O
  
ECOG O O
performance O O
status O O
is O O
1 O O
. O O
  
LABORATORY O O
DATA O O
: O O
Normal O O
CBC O O
, O O
LDH O O
is O O
normal O O
at O O
228 O O
, O O
elevated O O
AST O O
of O O
126 O O
, O O
an O O
ALT O O
of O O
299 O O
with O O
a O O
normal O O
bilirubin O O
. O O
  
ASSESSMENT O O
: O O
  
1. O O
Mr O O
. O O
  
Name O O
is O O
a O O
53 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
history O O
of O O
non B-Indication B-Indication
- I-Indication I-Indication
Hodgkin I-Indication I-Indication
lymphoma I-Indication I-Indication
subtype I-Indication I-Indication
mixed I-Indication I-Indication
follicular I-Indication I-Indication
large I-Indication I-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
involving I-Indication I-Indication
the I-Indication I-Indication
T I-Indication I-Indication
- I-Indication I-Indication
spine I-Indication I-Indication
, O O
stage B-Severity B-Severity
IAE I-Severity I-Severity
, O O
who O O
is O O
receiving O O
maintenance O O
rituximab B-Drug B-Drug
at O O
375 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
kg I-Dose I-Dose
once B-Frequency B-Frequency
every I-Frequency I-Frequency
2 I-Frequency I-Frequency
months I-Frequency I-Frequency
. O O
  
No O O
evidence O O
of O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
2. O O
Health O O
maintenance O O
, O O
again O O
encouraged O O
to O O
weight O O
loss O O
and O O
exercise O O
and O O
limit O O
portion O O
size O O
. O O
  
PLAN O O
: O O
Return O O
to O O
see O O
Dr O O
. O O
  
Name O O
in O O
2 O O
months O O
. O O
  
Repeat O O
blood O O
counts O O
. O O
  
Of O O
note O O
, O O
elevated B-SSLIF B-SSLIF
liver I-SSLIF I-SSLIF
transaminase I-SSLIF I-SSLIF
levels I-SSLIF I-SSLIF
being O O
followed O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
NP O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
MD O O
Name O O
Name O O
, O O
MD O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
N.P. O O
Date O O
1 O O
: O O
28PM O O
EST O O
Attending O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
, O O
PA O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
11 O O
: O O
22 O O
A O O
DISCHARGE O O
SUMMARY O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
DATE O O
OF O O
DISCHARGE O O
: O O
Date O O
DISCHARGE O O
DIAGNOSES O O
: O O
  
1. O O
Lymphoma B-SSLIF B-SSLIF
. O O
  
2. O O
Status O O
post O O
T10 O O
laminectomy O O
with O O
T8 O O
- O O
T12 O O
posterolateral O O
instrumentation O O
. O O
  
That O O
procedure O O
was O O
performed O O
on O O
Date O O
. O O
  
3. O O
Brachial B-SSLIF B-SSLIF
artery I-SSLIF I-SSLIF
thrombus I-SSLIF I-SSLIF
status O O
post O O
thrombectomy O O
. O O
  
That O O
procedure O O
was O O
performed O O
on O O
Date O O
. O O
  
4. O O
Pulmonary B-SSLIF B-SSLIF
embolus I-SSLIF I-SSLIF
. O O
  
DISCHARGE O O
MEDICATIONS O O
: O O
Tylenol B-Drug B-Drug
650 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
hours I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
, O O
Colace B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
b.i.d. B-Frequency B-Frequency
, O O
Lovenox B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
subcutaneous B-Route B-Route
b.i.d. B-Frequency B-Frequency
until O O
appropriate O O
therapeutic O O
  
INR O O
is O O
reached O O
with O O
warfarin B-Drug B-Drug
with O O
a O O
goal O O
INR O O
of O O
2 O O
- O O
3 O O
, O O
Nexium B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
Percocet B-Drug B-Drug
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
mg I-Dose I-Dose
1 I-Dose I-Dose
- I-Dose I-Dose
2 I-Dose I-Dose
tabs I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
hours I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
, O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
b.i.d. B-Frequency B-Frequency
, O O
Senokot B-Drug B-Drug
17.2 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
warfarin B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
adjust O O
to O O
INR O O
of O O
2 O O
- O O
3 O O
. O O
  
REASON O O
FOR O O
ADMISSION O O
: O O
The O O
patient O O
is O O
a O O
51 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
prior O O
history O O
of O O
T10 B-SSLIF B-SSLIF
vertebral I-SSLIF I-SSLIF
compression I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
of O O
unclear O O
etiology O O
. O O
  
He O O
had O O
had O O
a O O
kyphoplasty O O
done O O
in O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
he O O
had O O
had O O
a O O
biopsy O O
of O O
the O O
bone O O
, O O
which O O
was O O
equivocal O O
and O O
a O O
subsequent O O
hematology O O
and O O
oncology O O
consult O O
to O O
evaluate O O
for O O
a O O
possible O O
malignancy B-SSLIF B-SSLIF
as O O
there O O
was O O
no O O
clear O O
evidence O O
of O O
trauma B-SSLIF B-SSLIF
that O O
led O O
to O O
that O O
fracture B-SSLIF B-SSLIF
at O O
that O O
time O O
. O O
  
Subsequent O O
workups O O
including O O
biopsy O O
of O O
lymph B-SSLIF B-SSLIF
nodes I-SSLIF I-SSLIF
and O O
a O O
pericardial B-SSLIF B-SSLIF
cyst I-SSLIF I-SSLIF
were O O
negative O O
and O O
the O O
patient O O
was O O
subsequently O O
cleared O O
from O O
an O O
oncology O O
standpoint O O
. O O
  
The O O
patient O O
presented O O
back O O
to O O
our O O
emergency O O
room O O
on O O
Date O O
, O O
with O O
progressive O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
strength I-SSLIF I-SSLIF
weakness I-SSLIF I-SSLIF
x3 O O
days O O
in O O
the O O
setting O O
of O O
progressively O O
worsening O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
over O O
the O O
period O O
of O O
a O O
few O O
weeks O O
. O O
  
He O O
had O O
an O O
MRI O O
done O O
in O O
the O O
emergency O O
room O O
showing O O
cord B-SSLIF B-SSLIF
compression I-SSLIF I-SSLIF
and O O
ongoing O O
fracture B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
retropulsion I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
level O O
with O O
what O O
appeared O O
to O O
be O O
a O O
pathologic B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
. O O
  
He O O
was O O
subsequently O O
taken O O
to O O
the O O
operating O O
room O O
late O O
that O O
day O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Significant O O
for O O
hypertension B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
bilateral B-SSLIF B-SSLIF
hydroceles I-SSLIF I-SSLIF
, O O
tonsillectomy O O
as O O
a O O
child O O
, O O
kyphoplasty O O
in O O
Date O O
as O O
mentioned O O
with O O
prior O O
oncology O O
workup O O
which O O
was O O
negative O O
at O O
that O O
time O O
for O O
tumor B-SSLIF B-SSLIF
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
is O O
divorced O O
. O O
  
He O O
was O O
working O O
as O O
a O O
welder O O
. O O
  
He O O
has O O
3 O O
children O O
. O O
  
He O O
lives O O
alone O O
. O O
  
He O O
smokes O O
1 O O
pack O O
per O O
day O O
. O O
  
He O O
denies O O
any O O
alcohol O O
use O O
. O O
  
HOSPITAL O O
COURSE O O
: O O
He O O
was O O
admitted O O
to O O
Dr O O
. O O
  
Name O O
' O O
service O O
on O O
Date O O
. O O
  
He O O
underwent O O
urgent O O
decompression O O
of O O
the O O
spinal O O
cord O O
at O O
the O O
T10 O O
level O O
with O O
instrumentation O O
T8 O O
- O O
T12 O O
at O O
that O O
time O O
. O O
  
The O O
patient O O
was O O
brought O O
to O O
the O O
ICU O O
postoperatively O O
where O O
he O O
was O O
observed O O
for O O
a O O
day O O
. O O
  
In O O
his O O
first O O
postoperative O O
day O O
, O O
he O O
was O O
noted O O
to O O
have O O
some B-Severity B-Severity
low B-SSLIF B-SSLIF
blood I-SSLIF I-SSLIF
pressure I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
cool I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
. O O
  
There O O
was O O
some B-Severity B-Severity
discoloration B-SSLIF B-SSLIF
and O O
a O O
general O O
surgery O O
consult O O
was O O
placed O O
. O O
  
The O O
patient O O
was O O
ultimately O O
found O O
to O O
have O O
a O O
acute O O
thrombus B-Indication B-Indication
in I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
brachial I-Indication I-Indication
artery I-Indication I-Indication
and O O
was O O
taken O O
for O O
an O O
urgent O O
evacuation O O
of O O
that O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
He O O
was O O
placed O O
on O O
heparin B-Drug B-Drug
postoperatively B-Indication B-Indication
for O O
a O O
number O O
of O O
days O O
and O O
had O O
no O O
issues O O
thereafter O O
. O O
  
He O O
was O O
started O O
on O O
subcutaneous B-Route B-Route
heparin B-Drug B-Drug
as O O
well O O
. O O
  
While O O
in O O
the O O
ICU O O
, O O
the O O
patient O O
was O O
also O O
noted O O
to O O
have O O
some B-Severity B-Severity
elevated B-SSLIF B-SSLIF
creatinine I-SSLIF I-SSLIF
, O O
which O O
improved O O
with O O
gentle O O
IV O O
hydration O O
. O O
  
The O O
patient O O
generally O O
did O O
well O O
and O O
was O O
discharged O O
out O O
of O O
the O O
ICU O O
on O O
Date O O
. O O
  
The O O
following O O
morning O O
, O O
there O O
was O O
a O O
call O O
placed O O
that O O
the O O
patient O O
was O O
complaining O O
of O O
acute O O
left B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
sided I-SSLIF I-SSLIF
chest I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
EKG O O
was O O
done O O
which O O
was O O
negative O O
and O O
enzymes O O
were O O
done O O
which O O
was O O
negative O O
. O O
  
The O O
patient O O
had O O
a O O
CT O O
of O O
the O O
chest O O
revealing O O
acute O O
left B-Indication B-Indication
lower I-Indication I-Indication
lobe I-Indication I-Indication
pulmonary I-Indication I-Indication
embolus I-Indication I-Indication
. O O
  
The O O
patient O O
was O O
subsequently O O
brought O O
back O O
to O O
the O O
ICU O O
, O O
started O O
on O O
heparin B-Drug B-Drug
drip B-Route B-Route
and O O
eventually O O
bridged O O
to O O
Lovenox B-Drug B-Drug
with O O
an O O
eye O O
towards O O
getting O O
him O O
onto O O
warfarin B-Drug B-Drug
with O O
a O O
therapeutic O O
goal O O
of O O
2 O O
- O O
3 O O
. O O
  
We O O
are O O
still O O
working O O
on O O
this O O
at O O
that O O
time O O
. O O
  
In O O
the O O
interim O O
, O O
the O O
patient O O
was O O
slowly O O
mobilized O O
and O O
allowed O O
to O O
get O O
up O O
and O O
walk O O
around O O
. O O
  
His O O
leg O O
strength O O
gradually O O
improved O O
. O O
  
Ultimately O O
pathology O O
workup O O
returned O O
showing O O
evidence O O
of O O
lymphoma B-Indication B-Indication
. O O
  
The O O
patient O O
was O O
made O O
aware O O
of O O
the O O
diagnosis O O
and O O
Dr O O
. O O
  
Name O O
was O O
reconsulted O O
and O O
is O O
aware O O
and O O
feels O O
that O O
the O O
patient O O
will O O
need O O
an O O
aggressive O O
course O O
of O O
chemotherapy B-Drug B-Drug
and O O
radiation O O
. O O
  
She O O
would O O
like O O
to O O
see O O
him O O
next O O
week O O
in O O
followup O O
. O O
  
We O O
will O O
schedule O O
that O O
before O O
his O O
discharge O O
. O O
  
Dr O O
. O O
  
Name O O
will O O
see O O
him O O
back O O
in O O
a O O
few O O
weeks O O
. O O
  
In O O
light O O
of O O
the O O
fact O O
that O O
the O O
patient O O
is O O
hemodynamically O O
stable O O
, O O
has O O
no O O
acute O O
medical O O
issues O O
to O O
address O O
, O O
we O O
will O O
plan O O
on O O
discharging O O
him O O
out O O
to O O
rehab O O
today O O
, O O
if O O
possible O O
. O O
  
CONDITION O O
ON O O
DISCHARGE O O
: O O
Afebrile B-SSLIF B-SSLIF
. O O
  
His O O
vital O O
signs O O
are O O
stable O O
. O O
  
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
Motor O O
exam O O
reveals O O
he O O
has O O
some B-Severity B-Severity
mild I-Severity I-Severity
left B-SSLIF B-SSLIF
iliopsoas I-SSLIF I-SSLIF
weakness I-SSLIF I-SSLIF
, O O
otherwise O O
strength O O
is O O
full O O
. O O
  
Reflexes O O
are O O
2+ O O
and O O
symmetric O O
in O O
the O O
lower O O
extremities O O
. O O
  
Sensation O O
is O O
mildly B-Severity B-Severity
reduced B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
bottom I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
foot I-SSLIF I-SSLIF
, O O
otherwise O O
intact O O
throughout O O
the O O
lower O O
extremities O O
. O O
  
He O O
is O O
voiding O O
on O O
his O O
own O O
. O O
  
His O O
wound O O
is O O
clean O O
and O O
dry O O
. O O
  
He O O
also O O
has O O
an O O
incision B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
forearm I-SSLIF I-SSLIF
region B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
antecubital I-SSLIF I-SSLIF
space I-SSLIF I-SSLIF
, O O
which O O
is O O
clean O O
and O O
dry O O
as O O
well O O
. O O
  
Last O O
set O O
of O O
laboratory O O
data O O
I O O
have O O
on O O
this O O
gentleman O O
is O O
sodium O O
133 O O
, O O
potassium O O
  
3.7 O O
, O O
chloride O O
96 O O
, O O
CO2 O O
of O O
29 O O
, O O
glucose O O
105 O O
, O O
BUN O O
10 O O
, O O
creatinine O O
0.81 O O
. O O
  
INR O O
1.1 O O
today O O
and O O
that O O
was O O
on O O
7.5 B-Dose B-Dose
mg I-Dose I-Dose
of O O
Coumadin B-Drug B-Drug
. O O
  
White O O
count O O
of O O
5.8 O O
, O O
hematocrit O O
of O O
24 O O
and O O
platelet O O
of O O
216 O O
, O O
000 O O
. O O
  
The O O
patient O O
can O O
be O O
out O O
of O O
bed O O
as O O
tolerated O O
. O O
  
As O O
mentioned O O
, O O
we O O
would O O
like O O
him O O
to O O
have O O
his O O
Coumadin B-Drug B-Drug
up O O
to O O
a O O
level O O
with O O
therapeutic O O
INR O O
of O O
2 O O
- O O
3 O O
. O O
  
Please O O
call O O
our O O
office O O
if O O
there O O
are O O
any O O
questions O O
, O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
. O O
  
Attending O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
  
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
Name O O
MD O O
# O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
on O O
Date O O
16 O O
: O O
20 O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Consult O O
: O O
Date O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
7 O O
: O O
12 O O
P O O
CONSULTATION O O
REPORT O O
CONSULTANT O O
SERVICE O O
: O O
Vascular O O
. O O
  
REQUESTING O O
PROVIDER O O
: O O
ICU O O
, O O
Location O O
. O O
  
TIME O O
OF O O
CONSULTATION O O
: O O
1545 O O
hours O O
. O O
  
REASON O O
FOR O O
CONSULT O O
: O O
Numb B-SSLIF B-SSLIF
, O O
white B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
. O O
  
PRESENTING O O
COMPLAINT O O
: O O
Numb B-SSLIF B-SSLIF
, O O
white B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENTING O O
COMPLAINT O O
: O O
This O O
is O O
a O O
51 O O
- O O
year O O
- O O
old O O
male O O
who O O
is O O
now O O
postop O O
day O O
#1 O O
, O O
status O O
post O O
laminectomy O O
T8 O O
- O O
T10 O O
for O O
spinal B-SSLIF B-SSLIF
cord I-SSLIF I-SSLIF
compression I-SSLIF I-SSLIF
. O O
  
He O O
was O O
noted O O
to O O
have O O
a O O
tumor B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
vertebral I-SSLIF I-SSLIF
body I-SSLIF I-SSLIF
on O O
presentation O O
. O O
  
He O O
is O O
presenting O O
with O O
sudden B-SSLIF B-SSLIF
onset I-SSLIF I-SSLIF
numbness I-SSLIF I-SSLIF
and O O
discoloration B-SSLIF B-SSLIF
( I-SSLIF I-SSLIF
white I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
) I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
occurring O O
at O O
03 O O
: O O
40 O O
p.m. O O
today O O
. O O
  
He O O
also O O
initially O O
had O O
mild B-Severity B-Severity
pain B-SSLIF B-SSLIF
associated O O
with O O
this O O
, O O
and O O
in O O
the O O
course O O
of O O
the O O
examination O O
period O O
, O O
his O O
pain B-SSLIF B-SSLIF
seemed O O
to O O
intensify O O
. O O
  
He O O
denies O O
any O O
palpitations B-SSLIF B-SSLIF
or O O
any O O
history O O
of O O
atrial B-SSLIF B-SSLIF
fibrillation I-SSLIF I-SSLIF
. O O
  
He O O
also O O
denies O O
any O O
obvious O O
vascular O O
history O O
such O O
as O O
claudication B-SSLIF B-SSLIF
. O O
  
He O O
does O O
, O O
however O O
, O O
smoke O O
heavily O O
and O O
is O O
obese B-SSLIF B-SSLIF
. O O
  
He O O
last O O
ate O O
about O O
12 O O
: O O
00 O O
p.m. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Hypertension B-SSLIF B-SSLIF
and O O
bilateral B-SSLIF B-SSLIF
hydroceles I-SSLIF I-SSLIF
. O O
  
PAST O O
SURGICAL O O
HISTORY O O
: O O
Tonsillectomy O O
in O O
childhood O O
, O O
kyphoplasty O O
in O O
Date O O
and O O
T8 O O
through O O
T10 O O
laminectomy O O
in O O
Date O O
. O O
  
MEDICATIONS O O
: O O
Medications O O
include O O
lisinopril B-Drug B-Drug
, O O
hydrochlorothiazide B-Drug B-Drug
, O O
Zofran B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
magnesium B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
Combivent B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
and O O
vancomycin B-Drug B-Drug
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
Family O O
history O O
is O O
noncontributory O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
is O O
divorced O O
. O O
  
He O O
worked O O
as O O
a O O
welder O O
. O O
  
He O O
has O O
three O O
children O O
. O O
  
He O O
lives O O
alone O O
. O O
  
He O O
smokes O O
one O O
pack O O
per O O
day O O
. O O
  
He O O
currently O O
denies O O
any O O
alcohol O O
use O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Review O O
of O O
systems O O
is O O
positive O O
for O O
weakness B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
bilateral I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
post O O
- O O
surgery O O
, O O
which O O
is O O
stable O O
. O O
  
Aside O O
from O O
this O O
, O O
review O O
of O O
systems O O
was O O
negative O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
His O O
heart O O
rate O O
is O O
99 O O
, O O
blood O O
pressure O O
is O O
111 O O
/ O O
55 O O
and O O
respiratory O O
rate O O
is O O
16 O O
. O O
  
He O O
is O O
satting O O
97% O O
on O O
3 O O
L O O
nasal O O
cannula O O
. O O
  
GENERAL O O
APPEARANCE O O
: O O
On O O
general O O
examination O O
, O O
he O O
is O O
in O O
some O O
distress B-SSLIF B-SSLIF
. O O
  
He O O
is O O
obese B-SSLIF B-SSLIF
. O O
  
NEUROLOGICAL O O
EXAMINATION O O
: O O
He O O
is O O
awake O O
, O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
Cranial O O
nerves O O
are O O
grossly O O
intact O O
. O O
  
He O O
is O O
able O O
to O O
move O O
all O O
4 O O
extremities O O
; O O
however O O
, O O
the O O
power B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
about I-SSLIF I-SSLIF
3 I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
5 I-SSLIF I-SSLIF
( O O
he O O
is O O
able B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
hold I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
up I-SSLIF I-SSLIF
against I-SSLIF I-SSLIF
gravity I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
but I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
too I-SSLIF I-SSLIF
long I-SSLIF I-SSLIF
) O O
. O O
  
CARDIOVASCULAR O O
EXAM O O
: O O
Heart O O
sounds O O
1 O O
and O O
2 O O
were O O
present O O
with O O
no O O
added O O
sounds O O
. O O
  
He O O
has O O
a O O
regular O O
rate O O
and O O
rhythm O O
. O O
  
EXTREMITIES O O
: O O
His O O
right B-SSLIF B-SSLIF
hand I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
cool I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
white I-SSLIF I-SSLIF
. O O
  
His O O
thumb B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
middle I-SSLIF I-SSLIF
finger I-SSLIF I-SSLIF
were I-SSLIF I-SSLIF
more I-SSLIF I-SSLIF
numb I-SSLIF I-SSLIF
compared O O
to O O
the O O
rest O O
of O O
his O O
other O O
fingers O O
. O O
  
He O O
had O O
no O O
dopplerable B-SSLIF B-SSLIF
signals I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
radial I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
ulnar I-SSLIF I-SSLIF
arch I-SSLIF I-SSLIF
. O O
  
He O O
did O O
have O O
, O O
however O O
, O O
a O O
palpable O O
brachial O O
artery O O
pulse O O
. O O
  
In O O
his O O
left O O
hand O O
, O O
pulses O O
were O O
intact O O
including O O
radial O O
and O O
ulnar O O
. O O
  
In O O
his O O
left O O
leg O O
, O O
he O O
had O O
a O O
palpable O O
DP O O
and O O
PT O O
. O O
  
In O O
his O O
right B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
pulse I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
unable I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
be I-SSLIF I-SSLIF
palpated I-SSLIF I-SSLIF
, O O
but O O
he O O
did O O
have O O
a O O
palpable O O
DP O O
and O O
PT O O
. O O
  
RESPIRATORY O O
EXAMINATION O O
: O O
His O O
chest O O
was O O
clear O O
to O O
auscultation O O
. O O
  
ABDOMINAL O O
EXAMINATION O O
: O O
His O O
abdomen O O
was O O
distended B-SSLIF B-SSLIF
. O O
  
It O O
is O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
with O O
no O O
rebound B-SSLIF B-SSLIF
and O O
no O O
guarding B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
His O O
extremities O O
, O O
aside O O
from O O
his O O
right O O
hand O O
, O O
warm O O
and O O
well O O
perfused O O
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
cells O O
are O O
12.1 O O
, O O
hemoglobin O O
11.9 O O
and O O
platelets O O
242 O O
, O O
000 O O
. O O
  
INR O O
1.0 O O
. O O
  
This O O
is O O
from O O
Date O O
, O O
panel O O
136 O O
/ O O
4.3 O O
, O O
chloride O O
is O O
103 O O
/ O O
25 O O
, O O
BUN O O
is O O
31 O O
and O O
creatinine O O
is O O
2.20 O O
. O O
  
ASSESSMENT O O
AND O O
PLANNING O O
: O O
This O O
is O O
a O O
51 O O
- O O
year O O
- O O
old O O
man O O
who O O
is O O
postop O O
day O O
#1 O O
, O O
status O O
post O O
laminectomy O O
who O O
is O O
presenting O O
with O O
acutely O O
ischemic B-SSLIF B-SSLIF
right I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
, O O
postop O O
. O O
  
I O O
discussed O O
this O O
with O O
the O O
fellow O O
on O O
call O O
, O O
Dr O O
. O O
  
Name O O
who O O
reviewed O O
with O O
the O O
patient O O
and O O
discussed O O
it O O
with O O
her O O
attending O O
the O O
plan O O
as O O
follows O O
is O O
to O O
proceed O O
urgently O O
to O O
the O O
operating O O
room O O
. O O
  
CC O O
: O O
ICU O O
, O O
Location O O
. O O
  
Attending O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
. O O
  
I O O
discussed O O
the O O
case O O
with O O
the O O
resident O O
and O O
agree O O
with O O
the O O
findings O O
and O O
plan O O
as O O
documented O O
in O O
the O O
residents O O
note O O
. O O
  
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
MD O O
# O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
on O O
Date O O
11 O O
: O O
50 O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
10 O O
: O O
52 O O
A O O
Transcribed O O
Date O O
11 O O
: O O
38 O O
  
: O O
: O O
A O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
here O O
today O O
in O O
followup O O
for O O
his O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
has O O
a O O
history O O
of O O
hypertension B-Indication B-Indication
and O O
was O O
currently O O
on O O
hydrochlorothiazide B-Drug B-Drug
and I-Drug I-Drug
lisinopril I-Drug I-Drug
combination O O
and O O
a O O
second O O
dose O O
of O O
hydrochlorothiazide B-Drug B-Drug
, O O
which O O
was O O
added O O
to O O
help O O
with O O
his O O
lower B-Indication B-Indication
extremity I-Indication I-Indication
edema I-Indication I-Indication
from O O
his O O
previous O O
physician O O
. O O
  
He O O
reports O O
this O O
has O O
not O O
been O O
effective O O
. O O
  
His O O
second O O
dose O O
of O O
HCTZ B-Drug B-Drug
was O O
replaced O O
with O O
Lasix B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
. O O
  
He O O
started O O
out O O
with O O
the O O
10 B-Dose B-Dose
- I-Dose I-Dose
mg I-Dose I-Dose
tablet I-Dose I-Dose
and O O
then O O
was O O
increased O O
to O O
20 B-Dose B-Dose
mg I-Dose I-Dose
most O O
recently O O
last O O
week O O
. O O
  
He O O
does O O
report O O
this O O
does O O
not O O
get O O
as O O
swollen B-SSLIF B-SSLIF
throughout O O
the O O
day O O
, O O
but O O
it O O
is O O
still O O
somewhat O O
uncomfortable B-SSLIF B-SSLIF
. O O
  
He O O
does O O
report O O
he O O
gets O O
a B-Severity B-Severity
little I-Severity I-Severity
winded B-SSLIF B-SSLIF
with O O
increased O O
walking O O
, O O
although O O
he O O
has O O
put B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
weight I-SSLIF I-SSLIF
due O O
to O O
the O O
inactivity O O
secondary O O
to O O
his O O
new O O
diagnosis O O
of O O
lymphoma B-Indication B-Indication
at I-Indication I-Indication
T10 I-Indication I-Indication
status O O
post O O
laminectomy O O
, O O
T8 O O
through O O
T12 O O
, O O
currently O O
undergoing O O
chemotherapy B-Drug B-Drug
and O O
now O O
into O O
radiation O O
therapy O O
. O O
  
He O O
states O O
with O O
the O O
low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
discomfort I-SSLIF I-SSLIF
, O O
he O O
has O O
been O O
inactive O O
and O O
has O O
put B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
weight I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
palpitations B-SSLIF B-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Hypertension B-SSLIF B-SSLIF
, O O
obesity B-SSLIF B-SSLIF
, O O
bilateral B-SSLIF B-SSLIF
hydroceles I-SSLIF I-SSLIF
, O O
lymphoma B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
. O O
  
MEDICATIONS O O
: O O
Calcium B-Drug B-Drug
500 B-Dose B-Dose
- I-Dose I-Dose
mg I-Dose I-Dose
tablets I-Dose I-Dose
, O O
multivitamins B-Drug B-Drug
, O O
furosemide B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
gabapentin B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
1 I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
, O O
lisinopril B-Drug B-Drug
/ I-Drug I-Drug
hydrochlorothiazide I-Drug I-Drug
20 B-Dose B-Dose
/ I-Dose I-Dose
25 I-Dose I-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
tramadol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
p.r.n. O O
and O O
warfarin B-Drug B-Drug
as O O
directed O O
by O O
hematology O O
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
palpitations B-SSLIF B-SSLIF
. O O
  
Some B-Severity B-Severity
slight I-Severity I-Severity
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
discomfort I-SSLIF I-SSLIF
. O O
  
He O O
does O O
report O O
some O O
low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
as O O
well O O
as O O
extremity B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
He O O
is O O
sitting O O
comfortably O O
. O O
  
VITAL O O
SIGNS O O
: O O
His O O
blood O O
pressure O O
is O O
rechecked O O
at O O
136 O O
/ O O
86 O O
, O O
heart O O
rate O O
84 O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
HEART O O
: O O
Regular O O
rate O O
and O O
rhythm O O
. O O
  
No O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Obese B-SSLIF B-SSLIF
and O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Lower B-SSLIF B-SSLIF
extremities I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
1+ I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
it I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
nonpitting I-SSLIF I-SSLIF
bilaterally I-SSLIF I-SSLIF
. O O
  
ASSESSMENT O O
: O O
Hypertension B-Indication B-Indication
, O O
in O O
moderate B-Severity B-Severity
control O O
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
He O O
will O O
continue O O
the O O
lisinopril B-Drug B-Drug
/ I-Drug I-Drug
hydrochlorothiazide I-Drug I-Drug
20 B-Dose B-Dose
/ I-Dose I-Dose
25 I-Dose I-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
EKG O O
done O O
in O O
Date O O
, O O
which O O
was O O
normal O O
sinus O O
rhythm O O
. O O
  
2. O O
Lower B-Indication B-Indication
extremity I-Indication I-Indication
edema I-Indication I-Indication
. O O
  
We O O
will O O
increase O O
his O O
Lasix B-Drug B-Drug
from O O
20 B-Dose B-Dose
to I-Dose I-Dose
40 I-Dose I-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
3. O O
Obesity B-SSLIF B-SSLIF
- O O
we O O
did O O
discuss O O
weight O O
loss O O
with O O
the O O
patient O O
, O O
especially O O
in O O
his O O
abdomen O O
, O O
which O O
can O O
be O O
related O O
to O O
his O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
will O O
try O O
to O O
get O O
out O O
and O O
do O O
a O O
bit O O
more O O
walking O O
. O O
  
3. O O
Lymphoma B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
. O O
  
He O O
currently O O
is O O
going O O
through O O
radiation O O
treatments O O
in O O
City O O
with O O
Dr O O
. O O
  
Name O O
. O O
  
We O O
will O O
check O O
a O O
BMP O O
and O O
his O O
lipids O O
were O O
to O O
be O O
checked O O
today O O
. O O
  
We O O
will O O
have O O
him O O
follow O O
up O O
in O O
2 O O
to O O
3 O O
weeks' O O
time O O
for O O
a O O
weight O O
check O O
, O O
blood O O
pressure O O
check O O
, O O
otherwise O O
call O O
sooner O O
p.r.n. O O
  
Addendum O O
: O O
warfarin B-Drug B-Drug
followed O O
by O O
hematology O O
clinic O O
. O O
  
has O O
visit O O
scheduled O O
Date O O
. O O
  
I O O
discussed O O
the O O
case O O
with O O
the O O
nurse O O
practitioner O O
and O O
/ O O
or O O
physician O O
assistant O O
and O O
agree O O
with O O
the O O
findings O O
and O O
plan O O
as O O
documented O O
in O O
the O O
note O O
. O O
  
Reviewed O O
Name O O
Name O O
, O O
PA O O
- O O
C O O
Date O O
14 O O
: O O
48 O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
16 O O
: O O
19 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
PA O O
- O O
C O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B. O O
Date O O
Consult O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
Date O O
9 O O
: O O
02 O O
A O O
Transcribe O O
Date O O
  
: O O
d O O
: O O
9 O O
: O O
39 O O
A O O
OUTPATIENT O O
CONSULTATION O O
REPORT O O
REFERRING O O
PHYSICIAN O O
: O O
Name O O
Name O O
Name O O
M.D. O O
  
PRIMARY O O
CARE O O
PHYSICIAN O O
: O O
Name O O
Name O O
M.D. O O
  
REASON O O
FOR O O
VISIT O O
: O O
Low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
with O O
radiculopathy B-SSLIF B-SSLIF
. O O
  
DIAGNOSIS O O
: O O
Spondylolisthesis B-SSLIF B-SSLIF
grade I-SSLIF I-SSLIF
I I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
L5 I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
S1 I-SSLIF I-SSLIF
with O O
radiculopathy B-SSLIF B-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
gentleman O O
who O O
is O O
unfortunate O O
to O O
have O O
a O O
multisite B-Indication B-Indication
lymphoma I-Indication I-Indication
in O O
his O O
body O O
, O O
status O O
post O O
chemotherapy B-Drug B-Drug
and O O
treatment O O
on O O
numerous O O
times O O
and O O
he O O
was O O
presented O O
with O O
low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
and O O
radiculopathy B-SSLIF B-SSLIF
that O O
has O O
been O O
affecting O O
him O O
for O O
some O O
time O O
. O O
  
He O O
has O O
been O O
having O O
this O O
problem O O
on O O
and O O
off O O
. O O
  
He O O
had O O
an O O
MRI O O
, O O
which O O
showed O O
a O O
grade B-Severity B-Severity
I I-Severity I-Severity
L5 B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
S1 I-SSLIF I-SSLIF
spondylolisthesis I-SSLIF I-SSLIF
. O O
  
Also O O
the O O
flexion B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
extension I-SSLIF I-SSLIF
did I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
show I-SSLIF I-SSLIF
signs I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
instability I-SSLIF I-SSLIF
. O O
  
This O O
pain B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
mostly I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
with I-SSLIF I-SSLIF
radiation I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
a O O
history O O
of O O
DVT B-Indication B-Indication
for O O
which O O
he O O
was O O
on O O
Coumadin B-Drug B-Drug
for O O
a O O
long O O
time O O
; O O
however O O
, O O
this O O
was O O
stopped O O
last O O
week O O
as O O
per O O
Dr O O
. O O
  
Name O O
, O O
who O O
showed O O
no O O
evidence O O
of O O
further O O
clotting B-SSLIF B-SSLIF
, O O
even O O
though O O
he O O
has O O
swelling B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
, O O
but O O
that O O
was O O
thought O O
to O O
be O O
non O O
- O O
DVT B-SSLIF B-SSLIF
related O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Significant O O
for O O
benign B-SSLIF B-SSLIF
essential I-SSLIF I-SSLIF
hypertension I-SSLIF I-SSLIF
, O O
edema B-SSLIF B-SSLIF
, O O
hyperlipidemia B-SSLIF B-SSLIF
, O O
low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
, O O
and O O
lymphoma B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
multiple I-SSLIF I-SSLIF
sites I-SSLIF I-SSLIF
, O O
peripheral B-SSLIF B-SSLIF
neuropathy I-SSLIF I-SSLIF
, O O
spinal B-SSLIF B-SSLIF
cord I-SSLIF I-SSLIF
compression I-SSLIF I-SSLIF
, O O
and O O
history O O
of O O
deep B-SSLIF B-SSLIF
vein I-SSLIF I-SSLIF
thrombosis I-SSLIF I-SSLIF
. O O
  
PAST O O
SURGICAL O O
HISTORY O O
: O O
Upper O O
back O O
surgery O O
and O O
lumbar O O
injections O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
He O O
is O O
on O O
atorvastatin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
, O O
furosemide B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
hydrocodone B-Drug B-Drug
/ I-Drug I-Drug
acetaminophen I-Drug I-Drug
, O O
and O O
warfarin B-Drug B-Drug
which O O
he O O
stopped O O
last O O
week O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
is O O
a O O
smoker O O
and O O
he O O
is O O
unemployed O O
at O O
present O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Vital O O
signs O O
: O O
Blood O O
pressure O O
is O O
156 O O
/ O O
98 O O
, O O
heart O O
rate O O
88 O O
, O O
temperature O O
is O O
97 O O
, O O
saturations O O
98 O O
, O O
and O O
pain B-SSLIF B-SSLIF
score O O
7 O O
- O O
8 O O
. O O
  
Generally O O
, O O
he O O
looks O O
his O O
stated O O
age O O
. O O
  
He O O
is O O
morbidly B-Severity B-Severity
obese B-SSLIF B-SSLIF
. O O
  
Height O O
and O O
weight O O
; O O
5 O O
feet O O
10 O O
inches O O
for O O
height O O
, O O
356 O O
pounds O O
for O O
weight O O
. O O
  
Generally O O
, O O
he O O
looks O O
pleasant O O
, O O
good O O
historian O O
. O O
  
No O O
signs O O
of O O
depression B-SSLIF B-SSLIF
. O O
  
Brief O O
mental O O
examination O O
showed O O
normal O O
speech O O
and O O
concentration O O
. O O
  
Examination O O
of O O
the O O
back O O
showed O O
upper O O
back O O
scar O O
. O O
  
There O O
were O O
no O O
scars B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
lumbar I-SSLIF I-SSLIF
region I-SSLIF I-SSLIF
, O O
no O O
specific O O
tenderness B-SSLIF B-SSLIF
over I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
paraspinal I-SSLIF I-SSLIF
facet I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
sacroiliac I-SSLIF I-SSLIF
joints I-SSLIF I-SSLIF
. O O
  
Straight O O
leg O O
raising O O
was O O
positive O O
on O O
the O O
left O O
. O O
  
Neurologically O O
, O O
lower O O
extremity O O
motor O O
power O O
in O O
the O O
hip O O
flexion O O
, O O
knee O O
extension O O
, O O
ankle O O
dorsiflexion O O
, O O
and O O
plantar O O
flexion O O
was O O
5 O O
/ O O
5 O O
bilaterally O O
. O O
  
Cardiovascular O O
: O O
Regular O O
rate O O
and O O
rhythm O O
. O O
  
Abdomen O O
: O O
Softly O O
distended B-SSLIF B-SSLIF
. O O
  
Extremities O O
: O O
He O O
was O O
found O O
to O O
have O O
leg B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
pitting B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
with O O
redness B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
. O O
  
The O O
rest O O
of O O
the O O
extremities O O
were O O
unremarkable O O
. O O
  
IMAGING O O
: O O
Lumbar O O
MRI O O
showed O O
spondylolisthesis B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
L5 I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
S1 I-SSLIF I-SSLIF
with O O
irritating B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
nerve I-SSLIF I-SSLIF
roots I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
gentleman O O
who O O
is O O
known O O
to O O
have O O
lymphomas B-SSLIF B-SSLIF
and O O
being O O
treated O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
However O O
, O O
he O O
developed O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
No O O
history O O
of O O
trauma B-SSLIF B-SSLIF
or O O
fall B-SSLIF B-SSLIF
, O O
evident O O
by O O
x O O
- O O
ray O O
and O O
MRI O O
that O O
he O O
has O O
spondylolisthesis B-Indication B-Indication
, O O
was O O
referred O O
for O O
consideration O O
of O O
lumbar O O
epidural B-Route B-Route
steroid B-Drug B-Drug
injections O O
, O O
which O O
is O O
going O O
to O O
be O O
done O O
on O O
the O O
day O O
of O O
service O O
, O O
which O O
is O O
Date O O
. O O
  
I O O
spent O O
30 O O
minutes O O
during O O
this O O
visit O O
; O O
25 O O
min O O
was O O
face O O
- O O
to O O
- O O
face O O
counseling O O
and O O
coordinating O O
plan O O
of O O
care O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
09 O O
: O O
46 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
ST O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
11 O O
: O O
16 O O
A O O
Transcribed O O
Date O O
1 O O
: O O
53 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
This O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
man O O
who O O
presents O O
today O O
for O O
followup O O
of O O
multiple O O
issues O O
including O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
obesity B-SSLIF B-SSLIF
. O O
  
He O O
has O O
an O O
acute O O
issue O O
that O O
he O O
wishes O O
to O O
today O O
as O O
well O O
. O O
  
He O O
is O O
complaining O O
of O O
left B-SSLIF B-SSLIF
arm I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
for O O
about O O
two O O
weeks O O
. O O
  
He O O
has O O
been O O
trying O O
to O O
exercise O O
more O O
and O O
says O O
he O O
got O O
himself O O
some O O
kind O O
of O O
walking O O
machine O O
, O O
but O O
he O O
is O O
heavier O O
than O O
the O O
maximum O O
weight O O
, O O
so O O
he O O
has O O
been O O
leaning O O
forward O O
on O O
something O O
trying O O
to O O
take O O
some O O
of O O
his O O
weight O O
off O O
of O O
that O O
while O O
he O O
uses O O
it O O
. O O
  
He O O
thinks O O
that O O
maybe O O
helpful O O
his O O
left B-Indication B-Indication
arm I-Indication I-Indication
pain I-Indication I-Indication
started I-Indication I-Indication
as I-Indication I-Indication
well I-Indication I-Indication
as I-Indication I-Indication
left I-Indication I-Indication
neck I-Indication I-Indication
, I-Indication I-Indication
shoulder I-Indication I-Indication
and I-Indication I-Indication
elbow I-Indication I-Indication
and O O
he O O
has O O
point B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
in O O
these O O
areas O O
. O O
  
He O O
has O O
been O O
using O O
Icy O O
Hot O O
and O O
took O O
a O O
few O O
extra O O
Vicodin B-Drug B-Drug
, O O
but O O
he O O
says O O
it O O
is O O
still O O
at O O
8 B-Severity B-Severity
- I-Severity I-Severity
10 I-Severity I-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
He O O
did O O
sit O O
in O O
a O O
tub O O
for O O
couple O O
of O O
days O O
last O O
week O O
and O O
said O O
that O O
helped O O
. O O
  
He O O
says O O
his O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
is O O
stable O O
at O O
about O O
5 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
MEDICATIONS O O
: O O
Include O O
calcium B-Drug B-Drug
, O O
multivitamins B-Drug B-Drug
, O O
furosemide B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
gabapentin B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
3 B-Frequency B-Frequency
times I-Frequency I-Frequency
daily I-Frequency I-Frequency
, O O
hydrocodone B-Drug B-Drug
/ I-Drug I-Drug
acetaminophen I-Drug I-Drug
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
mg I-Dose I-Dose
, O O
losartan B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
multivitamin B-Drug B-Drug
, O O
and O O
omega B-Drug B-Drug
- I-Drug I-Drug
3 I-Drug I-Drug
1000 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
and O O
tramadol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
daily I-Frequency I-Frequency
p.r.n. O O
  
ALLERGIES B-ADE B-ADE
: O O
He O O
has O O
an O O
adverse B-ADE B-ADE
reaction I-ADE I-ADE
to O O
penicillin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
Noncontributory O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
continues O O
to O O
smoke O O
, O O
trying O O
to O O
exercise O O
more O O
as O O
above O O
. O O
  
He O O
is O O
not O O
working O O
due O O
to O O
disability O O
with O O
the O O
pain B-SSLIF B-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
He O O
denies O O
any O O
unusual O O
headaches B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
focal B-SSLIF B-SSLIF
weakness I-SSLIF I-SSLIF
. O O
  
Otherwise O O
review O O
of O O
systems O O
is O O
negative O O
except O O
per O O
the O O
HPI O O
above O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
Blood O O
pressure O O
150 O O
/ O O
94 O O
, O O
pulse O O
94 O O
, O O
pain B-SSLIF B-SSLIF
4 I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
8 I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
10 I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
arm I-SSLIF I-SSLIF
and O O
weight O O
360 O O
pounds O O
. O O
  
BMI O O
is O O
50.4 O O
. O O
  
GENERAL O O
: O O
He O O
is O O
a O O
well O O
- O O
appearing O O
obese B-SSLIF B-SSLIF
man O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
with O O
good O O
air O O
movement O O
. O O
  
No O O
wheezing B-SSLIF B-SSLIF
. O O
  
CV O O
: O O
Regular O O
. O O
  
ABDOMEN O O
: O O
Obese B-SSLIF B-SSLIF
and O O
positive O O
bowel O O
sounds O O
. O O
  
Neck B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
palpation I-SSLIF I-SSLIF
over I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
paraspinous I-SSLIF I-SSLIF
muscles I-SSLIF I-SSLIF
. O O
  
Range O O
of O O
motion O O
to O O
about O O
80 O O
degrees O O
to O O
the O O
left O O
, O O
limited O O
by O O
subjective O O
pain B-SSLIF B-SSLIF
. O O
  
Left B-SSLIF B-SSLIF
shoulder I-SSLIF I-SSLIF
point I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
posteriorly I-SSLIF I-SSLIF
and O O
left B-SSLIF B-SSLIF
elbow I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
near I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
malleolar I-SSLIF I-SSLIF
joint I-SSLIF I-SSLIF
medially I-SSLIF I-SSLIF
. O O
  
Bilateral O O
upper O O
extremity O O
strength O O
is O O
5 O O
/ O O
5 O O
and O O
equal O O
throughout O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
A O O
52 O O
- O O
year O O
- O O
old O O
man O O
with O O
multiple O O
medical O O
problems O O
presenting O O
for O O
followup O O
. O O
  
1. O O
Big O O
issue O O
today O O
is O O
left B-Indication B-Indication
neck I-Indication I-Indication
, I-Indication I-Indication
shoulder I-Indication I-Indication
and I-Indication I-Indication
elbow I-Indication I-Indication
pain I-Indication I-Indication
. O O
  
He O O
does O O
have O O
point B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
, O O
which O O
makes O O
it O O
seem O O
that O O
this O O
is O O
more O O
inflammatory B-SSLIF B-SSLIF
. O O
  
I O O
asked O O
him O O
to O O
take O O
some O O
ibuprofen B-Drug B-Drug
, O O
which O O
he O O
has O O
at O O
home O O
and O O
use O O
a O O
heating O O
pad O O
and O O
I O O
am O O
also O O
referring O O
him O O
to O O
physical O O
therapy O O
. O O
  
2. O O
Obesity B-SSLIF B-SSLIF
. O O
  
This O O
is O O
his O O
major O O
problem O O
. O O
  
I O O
talked O O
with O O
him O O
extensively O O
about O O
diet O O
, O O
exercise O O
and O O
weight O O
loss O O
, O O
trying O O
to O O
keep O O
active O O
. O O
  
Even O O
though O O
he O O
feels O O
uncomfortable O O
exercising O O
given O O
this O O
left O O
arm O O
issue O O
currently O O
. O O
  
3. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
His O O
blood B-SSLIF B-SSLIF
pressure I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
little I-SSLIF I-SSLIF
bit I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
today O O
. O O
  
I O O
am O O
going O O
to O O
have O O
him O O
come O O
back O O
in O O
about O O
a O O
month O O
so O O
that O O
we O O
can O O
reassess O O
that O O
given O O
that O O
he O O
is O O
complaining O O
of O O
severe B-Severity B-Severity
pain B-SSLIF B-SSLIF
at O O
this O O
time O O
. O O
  
4. O O
Back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
is O O
stable O O
. O O
  
Again O O
, O O
counseled O O
regarding O O
weight O O
loss O O
in O O
order O O
to O O
try O O
to O O
improve O O
that O O
. O O
  
5. O O
Elevated B-SSLIF B-SSLIF
blood I-SSLIF I-SSLIF
sugar I-SSLIF I-SSLIF
. O O
  
He O O
does O O
not O O
yet O O
meet O O
diabetic O O
criteria O O
, O O
but O O
we O O
continue O O
to O O
talk O O
about O O
diet O O
, O O
exercise O O
and O O
weight O O
loss O O
. O O
  
The O O
patient O O
will O O
see O O
me O O
again O O
in O O
about O O
one O O
month O O
, O O
as O O
noted O O
in O O
physical O O
therapy O O
before O O
he O O
has O O
agreed O O
to O O
Fit O O
testing O O
today O O
and O O
he O O
will O O
drop O O
off O O
his O O
most O O
recent O O
colonoscopy O O
report O O
with O O
me O O
when O O
he O O
comes O O
for O O
his O O
next O O
visit O O
. O O
  
I O O
will O O
see O O
him O O
earlier O O
if O O
necessary O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
10 O O
: O O
03 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Patient O O
: O O
Name O O
, O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
3 O O
: O O
57 O O
  
1 O O
: O O
00 O O
P O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
B B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
Name O O
is O O
a O O
50 O O
- O O
year O O
- O O
old O O
male O O
who O O
was O O
diagnosed O O
with O O
T10 B-SSLIF B-SSLIF
compression I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
on O O
Date O O
and O O
underwent O O
kyphoplasty O O
. O O
  
Pathology O O
showed O O
immunostains O O
positive O O
for O O
CD20 O O
and O O
CD45 O O
suggesting O O
a O O
B B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
; O O
however O O
, O O
samples O O
were O O
in O O
_____ O O
. O O
  
Since O O
that O O
time O O
, O O
he O O
has O O
had O O
CT O O
scan O O
of O O
the O O
chest O O
, O O
abdomen O O
and O O
pelvis O O
which O O
showed O O
right B-SSLIF B-SSLIF
cardiophrenic I-SSLIF I-SSLIF
angle I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
, O O
which O O
is O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
He O O
also O O
has O O
had O O
a O O
bone O O
marrow O O
biopsy O O
for O O
staging O O
workup O O
. O O
  
The O O
results O O
of O O
which O O
are O O
pending O O
at O O
this O O
time O O
. O O
  
He O O
is O O
in O O
today O O
actually O O
to O O
discuss O O
results O O
of O O
bone O O
marrow O O
biopsy O O
, O O
which O O
had O O
not O O
yet O O
returned O O
. O O
  
The O O
flow O O
cytometry O O
is O O
back O O
and O O
did O O
not O O
show O O
any O O
evidence O O
of O O
lymphoma B-SSLIF B-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
He O O
denies O O
any O O
history O O
of O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
remains O O
good O O
. O O
  
He O O
denies O O
any O O
history O O
of O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
He O O
has O O
some B-Severity B-Severity
back B-Indication B-Indication
pain I-Indication I-Indication
for O O
which O O
he O O
is O O
on O O
Lidoderm B-Drug B-Drug
patch B-Route B-Route
and O O
gabapentin B-Drug B-Drug
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
He O O
is O O
alert O O
and O O
oriented O O
. O O
  
VITAL O O
SIGNS O O
: O O
Stable O O
. O O
  
HEENT O O
: O O
No O O
pallor B-SSLIF B-SSLIF
, O O
no O O
icterus B-SSLIF B-SSLIF
, O O
no O O
cervical B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
CARDIOVASCULAR O O
: O O
S1 O O
, O O
S2 O O
present O O
, O O
regular O O
. O O
  
No O O
murmurs B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
nondistended B-SSLIF B-SSLIF
, O O
good O O
bowel O O
sounds O O
. O O
  
Hepatosplenomegaly B-SSLIF B-SSLIF
is O O
palpable O O
. O O
  
ABDOMEN O O
: O O
Obese B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
There O O
is O O
no O O
edema B-SSLIF B-SSLIF
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
Name O O
Name O O
is O O
a O O
50 O O
- O O
year O O
- O O
old O O
male O O
with O O
recent O O
T10 B-SSLIF B-SSLIF
compression I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
status O O
post O O
kyphoplasty O O
. O O
  
He O O
has O O
a O O
right B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
sided I-SSLIF I-SSLIF
cardiophrenic I-SSLIF I-SSLIF
angle I-SSLIF I-SSLIF
lung I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
, O O
which O O
is O O
adenopathy B-SSLIF B-SSLIF
and O O
is O O
probably O O
a O O
non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
Hodgkin I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
He O O
is O O
due O O
to O O
undergo O O
VATs O O
, O O
video O O
assisted O O
thoracoscopic O O
procedure O O
for O O
biopsy O O
of O O
this O O
mass B-SSLIF B-SSLIF
under O O
the O O
care O O
of O O
Dr O O
. O O
  
Name O O
Name O O
in O O
thoracic O O
surgery O O
. O O
  
This O O
is O O
scheduled O O
for O O
Date O O
. O O
  
His O O
bone O O
marrow O O
biopsy O O
results O O
are O O
not O O
back O O
yet O O
; O O
however O O
, O O
the O O
flow O O
cytometry O O
was O O
negative O O
. O O
  
I O O
will O O
see O O
him O O
in O O
2 O O
weeks O O
on O O
Date O O
and O O
hopefully O O
by O O
that O O
time O O
, O O
he O O
would O O
have O O
had O O
lung O O
biopsy O O
and O O
we O O
will O O
have O O
the O O
results O O
of O O
both O O
lung O O
biopsy O O
specimen O O
and O O
the O O
bone O O
marrow O O
biopsy O O
. O O
  
He O O
has O O
given O O
me O O
some O O
paperwork O O
for O O
workman's O O
comp O O
. O O
  
I O O
am O O
unable O O
to O O
decide O O
at O O
this O O
time O O
whether O O
this O O
thoracic B-SSLIF B-SSLIF
spine I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
was O O
related O O
to O O
lymphoma B-SSLIF B-SSLIF
. O O
  
It O O
is O O
unusual O O
for O O
non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
Hodgkin I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
to O O
cause O O
pathological B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
; O O
however O O
, O O
it O O
is O O
not O O
impossible O O
. O O
  
He O O
will O O
return O O
to O O
see O O
me O O
on O O
Date O O
. O O
  
Dictated O O
, O O
but O O
not O O
reviewed O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
fi O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Print O O
on O O
Date O O
at O O
4 O O
: O O
46pm O O
Hospital O O
PATIENT O O
DISCHARGE O O
CARE O O
FORM O O
Discharged O O
From O O
: O O
Hospital O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Location O O
: O O
Location O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Patient O O
DOB O O
: O O
Date O O
Address O O
Street_Address O O
City O O
State O O
/ O O
Zipcode O O
NOK O O
Name O O
, O O
Name O O
Patient O O
Phone O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Next O O
of O O
Kin O O
Phone O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
CELL O O
Patient O O
Medical O O
Record# O O
Medical_Record_Number O O
Patient O O
Account# O O
: O O
Medical_Record_Number O O
ADMIT O O
DATE O O
Date O O
DISCHARGE O O
DATE O O
DISCHARGE O O
TIME O O
Insurance O O
Information O O
Company O O
PARTS O O
A O O
& O O
B O O
PATIENT'S O O
PHYSICIANS O O
PHONE# O O
FAX O O
PRIMARY O O
: O O
Name O O
, O O
Name O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
REFERRING O O
: O O
Name O O
, O O
Name O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
ATTENDING O O
: O O
Name O O
, O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
HEMATOLOGY O O
/ O O
ONCOLOGY O O
Health O O
Proxy O O
Info O O
- O O
Agent O O
Name O O
: O O
Name O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
PRIMARY O O
DIAGNOSIS O O
DIFFUSE B-SSLIF B-SSLIF
LARGE I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
CELL I-SSLIF I-SSLIF
LYMPHOMA I-SSLIF I-SSLIF
SECONDARY O O
DIAGNOSIS O O
CLOSTRIDIUM B-SSLIF B-SSLIF
DIFFICILE I-SSLIF I-SSLIF
COLITIS I-SSLIF I-SSLIF
DEEP B-SSLIF B-SSLIF
VEIN I-SSLIF I-SSLIF
THROMBOSIS I-SSLIF I-SSLIF
PNEUMONIA B-SSLIF B-SSLIF
END B-Severity B-Severity
STAGE I-Severity I-Severity
RENAL B-SSLIF B-SSLIF
DISEASE I-SSLIF I-SSLIF
PROCEDURES O O
AND O O
DATES O O
NONE O O
CONDITION O O
ON O O
DISCHARGE O O
BRIEF O O
SUMMARY O O
OF O O
HOSPITALIZATION O O
  
( O O
INCLUDE O O
PROCEDURE O O
( O O
S O O
) O O
/ O O
SIGNIFICANT O O
EVENTS O O
/ O O
FINDINGS O O
/ O O
RESULTS O O
& O O
DATES O O
) O O
YOU O O
WERE O O
ADMITTED O O
FOR O O
WEAKNESS B-SSLIF B-SSLIF
, O O
DECREASED B-SSLIF B-SSLIF
ENERGY I-SSLIF I-SSLIF
, O O
INCREASED O O
PAIN B-SSLIF B-SSLIF
AT O O
THE O O
SITE O O
OF O O
YOUR O O
NECK B-SSLIF B-SSLIF
TUMOR I-SSLIF I-SSLIF
, O O
AND O O
A O O
CHANGE B-SSLIF B-SSLIF
IN I-SSLIF I-SSLIF
YOUR I-SSLIF I-SSLIF
MENTAL I-SSLIF I-SSLIF
STATUS I-SSLIF I-SSLIF
. O O
  
YOU O O
WERE O O
FOUND O O
TO O O
HAVE O O
CLOSTRIDIUM B-Indication B-Indication
DIFFICILE I-Indication I-Indication
( I-Indication I-Indication
C I-Indication I-Indication
DIFF I-Indication I-Indication
) I-Indication I-Indication
COLITIS I-Indication I-Indication
/ O O
DIARRHEA B-SSLIF B-SSLIF
AND O O
STARTED O O
TREATMENT O O
WITH O O
AN O O
ANTIBIOTIC B-Drug B-Drug
. O O
  
YOUR O O
DIARRHEA B-SSLIF B-SSLIF
IMPROVED O O
SIGNIFICANTLY O O
AND O O
THIS O O
ISSUE O O
WAS O O
NEARLY O O
RESOLVED O O
BY O O
TIME O O
OF O O
DISCHARGE O O
. O O
  
WE O O
TREATED O O
YOU O O
FOR O O
A O O
PNEUMONIA B-SSLIF B-SSLIF
WITH O O
SYMPTOMS O O
OF O O
A O O
PRODUCTIVE O O
COUGH B-SSLIF B-SSLIF
, O O
CHEST O O
X O O
- O O
RAY O O
FINDINGS O O
, O O
AND O O
LOW B-SSLIF B-SSLIF
OXYGEN I-SSLIF I-SSLIF
LEVEL I-SSLIF I-SSLIF
. O O
  
YOU O O
COMPLETED O O
A O O
COURSE O O
OF O O
ANTIBIOTICS B-Drug B-Drug
FOR O O
YOUR O O
PNEUMONIA B-Indication B-Indication
AND O O
YOUR O O
SYMPTOMS O O
IMPROVED O O
. O O
  
FINALLY O O
, O O
YOU O O
HAD O O
AN O O
AREA O O
OF O O
DISCOLORATION B-SSLIF B-SSLIF
AT I-SSLIF I-SSLIF
THE I-SSLIF I-SSLIF
TIP I-SSLIF I-SSLIF
OF I-SSLIF I-SSLIF
YOUR I-SSLIF I-SSLIF
PENIS I-SSLIF I-SSLIF
THAT O O
WE O O
FOUND O O
ON O O
THE O O
DAY O O
PRIOR O O
TO O O
ADMISSION O O
. O O
  
OUR O O
  
UROLOGISTS O O
EVALUATED O O
YOU O O
AND O O
FELT O O
THERE O O
WAS O O
NO O O
NEED O O
FOR O O
URGENT O O
SURGERY O O
AT O O
THIS O O
TIME O O
. O O
  
THEY O O
RECOMMENDED O O
A O O
FOLLOW O O
- O O
UP O O
APPOINTMENT O O
IN O O
TWO O O
WEEKS O O
TIME O O
AND O O
THAT O O
IT O O
MAY O O
BE O O
DUE O O
TO O O
A O O
SMALL B-Severity B-Severity
BLOOD B-Indication B-Indication
CLOT I-Indication I-Indication
. O O
  
WE O O
RESTARTED O O
YOU O O
ON O O
COUMADIN B-Drug B-Drug
. O O
  
YOUR O O
RECENT O O
INR O O
HAVE O O
BEEN O O
BETWEEN O O
2 O O
- O O
3 O O
. O O
  
WE O O
WOULD O O
RECOMMEND O O
REGULAR O O
FOLLOW O O
- O O
UP O O
OF O O
THE O O
INR O O
AND O O
PT O O
. O O
  
BLOOD O O
DRAWS O O
WILL O O
BE O O
DONE O O
AT O O
THE O O
HOME O O
BY O O
THE O O
VISITING O O
NURSE O O
AND O O
THE O O
RESULTS O O
WILL O O
BE O O
TRANSMITTED O O
TO O O
THE O O
ANTICOAGULATION O O
CLINIC O O
. O O
  
HEALTH O O
CARE O O
PROVIDER O O
FOLLOW O O
UP O O
APPOINTMENTS O O
Physician O O
Date O O
and O O
Time O O
Location O O
Clinic O O
Phone O O
# O O
  
1 O O
) O O
: O O
Name O O
, O O
Name O O
Named_Sites O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
  
2 O O
) O O
: O O
Name O O
, O O
Name O O
Name O O
Date O O
11 O O
AM O O
Named_Sites O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
CLINIC O O
APPT O O
/ O O
DATE O O
& O O
TIME O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
2 O O
Date O O
at O O
4 O O
: O O
46pm O O
YOU O O
SHALL O O
BE O O
CONTACTED O O
BY O O
THE O O
CLINIC O O
REGARDING O O
THE O O
FOLLOW O O
UP O O
APPOINTMENT O O
WITH O O
Dr O O
Name O O
LATER O O
THIS O O
WEEK O O
. O O
  
ACTIVITY O O
ASTOL O O
Shower O O
: O O
Yes O O
If O O
no O O
, O O
when O O
? O O
WEIGHT O O
BEARING O O
ASTOL O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die O O
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
PRE O O
- O O
EXISTING O O
ALLERGIES O O
NO O O
KNOWN B-SSLIF B-SSLIF
DRUG I-SSLIF I-SSLIF
ALLERGIES I-SSLIF I-SSLIF
GENERAL O O
DISCHARGE O O
INSTRUCTIONS O O
( O O
eg O O
. O O
  
Wound O O
care O O
, O O
avoid O O
, O O
return O O
if O O
) O O
  
1. O O
PLEASE O O
TAKE O O
YOUR O O
MEDICATIONS O O
AS O O
DIRECTED O O
  
2. O O
PLEASE O O
MAKE O O
YOUR O O
FOLLOW O O
- O O
UP O O
APPOINTMENTS O O
WITH O O
BOTH O O
ONCOLOGY O O
AND O O
UROLOGY O O
  
3. O O
PLEASE O O
SEEK O O
MEDICAL O O
ATTENTION O O
IF O O
YOU O O
DEVELOP O O
A O O
FEVER B-SSLIF B-SSLIF
, O O
SHORTNESS B-SSLIF B-SSLIF
OF I-SSLIF I-SSLIF
BREATH I-SSLIF I-SSLIF
, O O
ABDOMINAL B-SSLIF B-SSLIF
PAIN I-SSLIF I-SSLIF
, O O
UNCONTROLLABLE O O
DIARRHEA B-SSLIF B-SSLIF
, O O
OR O O
ANY O O
OTHER O O
SYMPTOMS O O
THAT O O
BROUGHT O O
YOU O O
INTO O O
THE O O
HOSPITAL O O
ON O O
THIS O O
ADMISSION O O
  
** O O
LAB O O
/ O O
MIC O O
/ O O
PATH O O
RESULTS O O
PENDING O O
... O O
  
POTASSIUM O O
BLOOD O O
Date O O
1500 O O
RESULTS O O
PENDING O O
AT O O
TIME O O
OF O O
DISCHARGE O O
NONE O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
COMMUNITY O O
SERVICES O O
/ O O
DISPOSITION O O
: O O
  
Pt O O
discharged O O
to O O
: O O
  
HWS O O
Name O O
of O O
Agency O O
: O O
  
Hospital O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Care O O
Coordinator O O
/ O O
Social O O
Worker O O
: O O
Name O O
Phone O O
: O O
U O O
Patient O O
to O O
receive O O
: O O
SN O O
  
PT O O
  
HH O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
3 O O
Date O O
at O O
4 O O
: O O
46pm O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
4 O O
Date O O
at O O
4 O O
: O O
46pm O O
DISCHARGE O O
MEDICATIONS O O
: O O
  
Brand O O
Name O O
Dose O O
Route O O
  
( O O
Generic O O
) O O
Name O O
How O O
to O O
Take O O
  
ROCALTROL B-Drug B-Drug
0.25 B-Dose B-Dose
MCG I-Dose I-Dose
PO B-Route B-Route
  
( O O
CALCITRIOL B-Drug B-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
NEXIUM B-Drug B-Drug
40 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
ESOMEPRAZOLE B-Drug B-Drug
MAG I-Drug I-Drug
TRIHYDRATE I-Drug I-Drug
) O O
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
Reason O O
for O O
this O O
Medication O O
: O O
HEARTBURN B-Indication B-Indication
New O O
Med O O
? O O
Yes O O
Is O O
Med O O
replacing O O
another O O
? O O
No O O
FISH B-Drug B-Drug
OIL I-Drug I-Drug
1000 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
FISH B-Drug B-Drug
OIL I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
RENAL B-Drug B-Drug
CAPS I-Drug I-Drug
1 B-Dose B-Dose
CAP I-Dose I-Dose
PO B-Route B-Route
  
( O O
FOLIC B-Drug B-Drug
ACID I-Drug I-Drug
/ I-Drug I-Drug
VITAMIN I-Drug I-Drug
B I-Drug I-Drug
COMP I-Drug I-Drug
W I-Drug I-Drug
- I-Drug I-Drug
C I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
FLORANEX B-Drug B-Drug
1 B-Dose B-Dose
TAB I-Dose I-Dose
PO B-Route B-Route
  
( O O
LACTOBACILLUS B-Drug B-Drug
ACIDOPHILUS I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
METHADONE B-Drug B-Drug
HCL I-Drug I-Drug
10 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
METHADONE B-Drug B-Drug
HCL I-Drug I-Drug
) O O
Three B-Frequency B-Frequency
Times I-Frequency I-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
METRONIDZAOLE B-Drug B-Drug
500 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
METRONIDAZOLE B-Drug B-Drug
) O O
Every B-Frequency B-Frequency
Eight I-Frequency I-Frequency
Hours I-Frequency I-Frequency
Reason O O
for O O
this O O
Medication O O
: O O
CLOSTRIDIUM B-Indication B-Indication
DIFFICLE I-Indication I-Indication
COLITIS I-Indication I-Indication
Comment O O
: O O
TAKE O O
FOR O O
A O O
TOTAL O O
OF O O
14 B-Duration B-Duration
DAYS I-Duration I-Duration
FIRST O O
DOSE O O
ON O O
Date O O
, O O
LAST O O
DOSE O O
ON O O
Date O O
New O O
Med O O
? O O
Yes O O
Is O O
Med O O
replacing O O
another O O
? O O
No O O
  
MICATIN B-Drug B-Drug
POWDER B-Dose B-Dose
TP O O
  
( O O
MICONAZOLE B-Drug B-Drug
NITRATE I-Drug I-Drug
) O O
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
NYSTATIN B-Drug B-Drug
500000 B-Dose B-Dose
UNIT I-Dose I-Dose
PO B-Route B-Route
  
( O O
NYSTATIN B-Drug B-Drug
) O O
Four B-Frequency B-Frequency
Times I-Frequency I-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
OXYCODONE B-Drug B-Drug
HCL I-Drug I-Drug
30 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
OXYCODONE B-Drug B-Drug
HCL I-Drug I-Drug
) O O
Q3H B-Frequency B-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
Reason O O
for O O
this O O
Medication O O
: O O
prn O O
pain B-Indication B-Indication
  
OXYCONTIN B-Drug B-Drug
60 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
OXYCODONE B-Drug B-Drug
HCL I-Drug I-Drug
SR I-Drug I-Drug
) O O
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
K B-Drug B-Drug
- I-Drug I-Drug
DUR I-Drug I-Drug
10 B-Dose B-Dose
MEQ I-Dose I-Dose
PO B-Route B-Route
  
( O O
POTASSIUM B-Drug B-Drug
CHLORIDE I-Drug I-Drug
SR I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
WARFARIN B-Drug B-Drug
SODIUM I-Drug I-Drug
UD O O
TABLET B-Dose B-Dose
7.5 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
WARFARIN B-Drug B-Drug
SODIUM I-Drug I-Drug
) O O
As O O
Directed O O
Your O O
next O O
INR O O
should O O
be O O
checked O O
on O O
Date O O
  
INR O O
results O O
should O O
be O O
sent O O
to O O
your O O
facility's O O
physician O O
New O O
Med O O
? O O
No O O
Is O O
Med O O
replacing O O
another O O
? O O
No O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
5 O O
Date O O
at O O
4 O O
: O O
46pm O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
6 O O
Date O O
at O O
4 O O
: O O
46pm O O
PHYSICAL O O
THERAPY O O
INSTRUCTIONS O O
: O O
  
Evaluation O O
Date O O
: O O
Date O O
Rehabilitation O O
Diagnosis O O
: O O
  
LYMPHOMA` B-SSLIF B-SSLIF
CURRENT O O
PROBLEM O O
LIST O O
DISCHARGE O O
STATUS O O
DECREASED B-SSLIF B-SSLIF
BALANCE I-SSLIF I-SSLIF
USE O O
ROLLING O O
WALKER O O
DECREASED B-SSLIF B-SSLIF
MOBILITY I-SSLIF I-SSLIF
ASSIST O O
ON O O
STAIRS O O
PATIENT O O
/ O O
FAMILY O O
EDUCATION O O
  
Excercise O O
Program O O
: O O
  
LEG O O
EXERCISES O O
Compensation O O
Strategies O O
: O O
  
PACING O O
WITH O O
ACTIVITY O O
. O O
  
Safety O O
Recommendations O O
: O O
  
USE O O
ROLLING O O
WALKER O O
AT O O
ALL O O
TIMES O O
. O O
  
HAVE O O
WIFE O O
ASSIST O O
ON O O
STAIRS O O
. O O
  
Recommendations O O
: O O
  
SEE O O
ABOVE O O
. O O
  
HOME O O
PHYSICAL O O
THERAPY O O
. O O
  
Therapist O O
: O O
Phone O O
: O O
Date O O
: O O
Date O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
DIAGNOSIS O O
BASED O O
PATIENT O O
EDUCATION O O
: O O
  
Patient O O
Information O O
for O O
Warfarin B-Drug B-Drug
Therapy O O
Generic O O
Name O O
: O O
Warfarin B-Drug B-Drug
Brand O O
Name O O
: O O
Coumadin B-Drug B-Drug
or O O
Jantoven B-Drug B-Drug
Why O O
am O O
I O O
taking O O
this O O
medication O O
? O O
To O O
prevent O O
and O O
treat O O
blood B-Indication B-Indication
clots I-Indication I-Indication
. O O
  
How O O
do O O
I O O
take O O
warfarin B-Drug B-Drug
? O O
  
Warfarin B-Drug B-Drug
comes O O
as O O
a O O
tablet B-Dose B-Dose
to O O
take O O
by B-Route B-Route
mouth I-Route I-Route
. O O
  
It O O
is O O
usually O O
taken O O
once B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
Your O O
doctor O O
will O O
prescribe O O
your O O
exact O O
dose O O
and O O
tell O O
you O O
how O O
often O O
and O O
when O O
it O O
should O O
be O O
taken O O
. O O
  
Take O O
warfarin B-Drug B-Drug
exactly O O
as O O
directed O O
. O O
  
Do O O
not O O
take O O
more O O
or O O
less O O
of O O
it O O
or O O
take O O
it O O
more O O
often O O
than O O
prescribed O O
by O O
your O O
doctor O O
. O O
  
How O O
often O O
do O O
I O O
need O O
to O O
have O O
my O O
blood O O
tested O O
? O O
It O O
is O O
important O O
that O O
you O O
have O O
your O O
blood O O
test O O
taken O O
for O O
your O O
INR O O
( O O
International O O
Normalized O O
Ratio O O
) O O
as O O
instructed O O
by O O
your O O
doctor O O
. O O
  
You O O
should O O
have O O
your O O
blood O O
tested O O
within O O
1 O O
week O O
of O O
discharge O O
from O O
the O O
hospital O O
. O O
  
Your O O
blood O O
will O O
be O O
tested O O
frequently O O
in O O
the O O
beginning O O
but O O
at O O
least O O
monthly O O
once O O
the O O
INR O O
is O O
stable O O
and O O
within O O
goal O O
INR O O
range O O
. O O
  
You O O
will O O
be O O
informed O O
of O O
your O O
goal O O
INR O O
range O O
by O O
your O O
doctor O O
. O O
  
This O O
blood O O
test O O
allows O O
your O O
doctor O O
to O O
monitor O O
your O O
warfarin B-Drug B-Drug
therapy O O
and O O
helps O O
him O O
or O O
her O O
to O O
adjust O O
your O O
dosage O O
. O O
  
The O O
INR O O
will O O
help O O
your O O
doctor O O
know O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
7 O O
Date O O
at O O
4 O O
: O O
46pm O O
if O O
you O O
might O O
be O O
at O O
risk O O
for O O
bleeding B-SSLIF B-SSLIF
. O O
  
What O O
if O O
I O O
miss O O
a O O
dose O O
? O O
If O O
you O O
miss O O
a O O
dose O O
or O O
forget O O
to O O
take O O
your O O
medication O O
, O O
take O O
it O O
as O O
soon O O
as O O
you O O
can O O
. O O
  
If O O
it O O
is O O
almost O O
time O O
for O O
your O O
next O O
dose O O
, O O
wait O O
until O O
then O O
to O O
take O O
the O O
medication O O
and O O
skip O O
the O O
missed O O
dose O O
. O O
  
Do O O
not O O
double O O
the O O
dose O O
to O O
make O O
up O O
for O O
a O O
missed O O
dose O O
. O O
  
If O O
you O O
feel O O
unsure O O
, O O
call O O
your O O
doctor O O
or O O
pharmacist O O
for O O
instructions O O
. O O
  
When O O
should O O
warfarin B-Drug B-Drug
NOT O O
be O O
used O O
? O O
You O O
should O O
not O O
use O O
this O O
medication O O
if O O
you O O
have O O
had O O
an O O
allergic B-SSLIF B-SSLIF
reaction I-SSLIF I-SSLIF
to O O
warfarin B-Drug B-Drug
or O O
if O O
you O O
are O O
pregnant B-SSLIF B-SSLIF
. O O
  
You O O
should O O
not O O
use O O
this O O
medication O O
if O O
you O O
have O O
had O O
recent O O
surgery O O
, O O
if O O
you O O
have O O
certain O O
heart B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
, O O
or O O
if O O
you O O
have O O
a O O
condition O O
that O O
may O O
cause O O
uncontrolled O O
bleeding B-SSLIF B-SSLIF
. O O
  
Make O O
sure O O
any O O
doctor O O
or O O
dentist O O
who O O
treats O O
you O O
knows O O
that O O
you O O
are O O
using O O
this O O
medication O O
. O O
  
You O O
may O O
need O O
to O O
stop O O
using O O
this O O
medication O O
several O O
days O O
or O O
weeks O O
before O O
having O O
surgery O O
or O O
medical O O
tests O O
. O O
  
Always O O
check O O
with O O
the O O
provider O O
who O O
manages O O
the O O
warfarin B-Drug B-Drug
before O O
stopping O O
warfarin B-Drug B-Drug
. O O
  
Which O O
drugs O O
might O O
interact O O
with O O
warfarin B-Drug B-Drug
? O O
Many O O
medications O O
interact O O
with O O
warfarin B-Drug B-Drug
resulting O O
in O O
an O O
increased O O
risk O O
of O O
clotting B-SSLIF B-SSLIF
or O O
bleeding B-SSLIF B-SSLIF
. O O
  
Check O O
with O O
your O O
doctor O O
or O O
pharmacist O O
before O O
using O O
any O O
other O O
medication O O
including O O
over B-Drug B-Drug
- I-Drug I-Drug
the I-Drug I-Drug
counter I-Drug I-Drug
medications I-Drug I-Drug
, O O
vitamins B-Drug B-Drug
, O O
and O O
herbal O O
products O O
. O O
  
You O O
should O O
not O O
take O O
over B-Drug B-Drug
the I-Drug I-Drug
counter I-Drug I-Drug
pain I-Drug I-Drug
medication I-Drug I-Drug
except O O
Tylenol B-Drug B-Drug
  
( O O
acetaminophen B-Drug B-Drug
) O O
while O O
taking O O
warfarin B-Drug B-Drug
. O O
  
If O O
you O O
do O O
have O O
to O O
use O O
acetaminophen B-Drug B-Drug
for O O
more O O
than O O
a O O
few O O
days O O
, O O
please O O
let O O
your O O
doctor O O
and O O
/ O O
or O O
anticoagulation O O
clinic O O
know O O
since O O
this O O
can O O
increase O O
the O O
INR O O
. O O
  
Make O O
sure O O
that O O
if O O
you O O
are O O
prescribed O O
antibiotics B-Drug B-Drug
that O O
your O O
physician O O
knows O O
that O O
you O O
are O O
taking O O
warfarin B-Drug B-Drug
. O O
  
Make O O
sure O O
your O O
doctor O O
knows O O
all O O
other O O
medications O O
you O O
are O O
using O O
. O O
  
Do O O
I O O
need O O
to O O
follow O O
a O O
special O O
diet O O
? O O
Follow O O
your O O
doctor's O O
instructions O O
about O O
any O O
special O O
diet O O
. O O
  
This O O
medication O O
works O O
best O O
when O O
you O O
eat O O
about O O
the O O
same O O
amount O O
of O O
vitamin O O
K O O
in O O
your O O
food O O
every O O
day O O
. O O
  
Avoid O O
big O O
changes O O
in O O
how O O
much O O
vitamin O O
K O O
you O O
eat O O
. O O
  
Some O O
foods O O
that O O
have O O
a O O
high O O
amount O O
of O O
vitamin O O
K O O
are O O
broccoli O O
, O O
brussel O O
sprouts O O
, O O
cabbage O O
, O O
and O O
green O O
leafy O O
vegetables O O
such O O
as O O
spinach O O
and O O
salad O O
greens O O
. O O
  
Will O O
alcoholic O O
beverages O O
affect O O
warfarin B-Drug B-Drug
? O O
Excessive O O
alcohol O O
intake O O
( O O
more O O
than O O
2 O O
glasses O O
of O O
wine O O
or O O
beer O O
per O O
night O O
) O O
may O O
increase O O
your O O
risk O O
for O O
bleeding B-SSLIF B-SSLIF
. O O
  
Warnings O O
while O O
using O O
warfarin B-Drug B-Drug
: O O
  
Using O O
warfarin B-Drug B-Drug
while O O
you O O
are O O
pregnant B-SSLIF B-SSLIF
can O O
harm O O
your O O
unborn O O
baby O O
. O O
  
If O O
you O O
think O O
you O O
have O O
become O O
pregnant B-SSLIF B-SSLIF
while O O
using O O
warfarin B-Drug B-Drug
, O O
tell O O
your O O
doctor O O
. O O
  
You O O
may O O
bleed B-SSLIF B-SSLIF
more O O
easily O O
while O O
you O O
are O O
using O O
this O O
medication O O
. O O
  
Stay O O
away O O
from O O
rough O O
sports O O
or O O
other O O
situations O O
where O O
you O O
could O O
be O O
bruised B-SSLIF B-SSLIF
, O O
cut B-SSLIF B-SSLIF
, O O
or O O
injured B-SSLIF B-SSLIF
. O O
  
Brush O O
and O O
floss O O
your O O
teeth O O
gently O O
. O O
  
Be O O
careful O O
when O O
using O O
sharp O O
objects O O
, O O
including O O
razors O O
and O O
clippers O O
. O O
  
When O O
should O O
I O O
call O O
my O O
doctor O O
? O O
Call O O
your O O
doctor O O
immediately O O
if O O
you O O
notice O O
any O O
of O O
these O O
side O O
effects O O
: O O
  
* O O
Unusual O O
bleeding B-SSLIF B-SSLIF
or O O
bruising B-SSLIF B-SSLIF
  
* O O
Black B-SSLIF B-SSLIF
or O O
bloody B-SSLIF B-SSLIF
stools I-SSLIF I-SSLIF
  
* O O
Blood B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
your I-SSLIF I-SSLIF
urine I-SSLIF I-SSLIF
  
* O O
Unexplained O O
fever B-SSLIF B-SSLIF
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
8 O O
Date O O
at O O
4 O O
: O O
46pm O O
How O O
do O O
I O O
store O O
and O O
dispose O O
of O O
warfarin B-Drug B-Drug
? O O
Keep O O
this O O
medication O O
at O O
room O O
temperature O O
, O O
away O O
from O O
heat O O
and O O
direct O O
light O O
. O O
  
Keep O O
all O O
medication O O
away O O
from O O
children O O
and O O
pets O O
and O O
never O O
share O O
your O O
medication O O
with O O
anyone O O
. O O
  
Ask O O
your O O
pharmacist O O
, O O
doctor O O
, O O
or O O
health O O
caregiver O O
about O O
the O O
best O O
way O O
to O O
dispose O O
of O O
any O O
outdated O O
medication O O
or O O
medication O O
no O O
longer O O
needed O O
. O O
  
Revised O O
Date O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
DIETARY O O
INSTRUCTIONS O O
: O O
  
DIET O O
: O O
REGULAR O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
DISCHARGE O O
MEDICATION O O
RECONCILIATION O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
. O O
  
___________________ O O
_______________________ O O
____________________________________ O O
  
MD O O
/ O O
NP O O
/ O O
PA O O
Signature O O
Print O O
Name O O
Attending O O
Cosignature O O
if O O
LOS O O
< O O
48hrs O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plan O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
__ O O
Translator O O
Used O O
: O O
( O O
Name O O
& O O
Relationship O O
to O O
patient O O
) O O
___________________________ O O
  
_________________________________ O O
_____________________________________________ O O
Nurse O O
Signature O O
Patient O O
/ O O
Responsible O O
Person O O
Signature O O
REMINDER O O
: O O
RETRIEVE O O
ALL O O
VALUABLES O O
FROM O O
PATIENT O O
ROOM O O
AND O O
/ O O
OR O O
ADMITTING O O
DEPARTMENT O O
SAFE O O
Patient O O
: O O
Please O O
bring O O
these O O
instructions O O
to O O
ALL O O
follow O O
- O O
up O O
appointments O O
. O O
  
Form O O
finalized O O
by O O
: O O
Name O O
, O O
Name O O
MD O O
on O O
Date O O
at O O
04 O O
: O O
38pm O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
Date O O
Discharge O O
Surgery O O
Date O O
Date O O
: O O
Date O O
: O O
Date O O
: O O
  
Dictated O O
: O O
Date O O
4 O O
: O O
17 O O
P O O
Transcribed O O
: O O
Date O O
Location O O
: O O
Location O O
  
4 O O
: O O
57 O O
P O O
REPORT O O
OF O O
OPERATION O O
PREOPERATIVE O O
DIAGNOSIS O O
: O O
Chronic O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
POSTOPERATIVE O O
DIAGNOSIS O O
: O O
Chronic O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
NAME O O
OF O O
PROCEDURE O O
: O O
Insertion O O
of O O
a O O
right O O
jugular O O
Perm O O
- O O
A O O
- O O
Cath O O
using O O
ultrasound O O
guidance O O
and O O
fluoroscopy O O
plus O O
construction O O
of O O
a O O
left O O
radiocephalic O O
AV O O
fistula O O
. O O
  
SURGEON O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
ASSISTANT O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
ANESTHESIA O O
: O O
General O O
sedation O O
with O O
local B-Drug B-Drug
anesthesia I-Drug I-Drug
. O O
  
INDICATIONS O O
: O O
The O O
patient O O
is O O
a O O
60 O O
- O O
year O O
- O O
old O O
year O O
old O O
white O O
male O O
in O O
need O O
of O O
chronic O O
dialysis O O
for O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
SURGICAL O O
PROCEDURE O O
: O O
Under O O
adequate O O
sedation O O
, O O
the O O
patient's O O
right O O
neck O O
was O O
prepped O O
with O O
ChloraPrep B-Drug B-Drug
and O O
draped O O
in O O
a O O
sterile O O
manner O O
. O O
  
A O O
needle O O
was O O
inserted O O
into O O
the O O
right O O
internal O O
jugular O O
vein O O
low O O
in O O
the O O
neck O O
using O O
ultrasound O O
guidance O O
. O O
  
The O O
skin O O
was O O
infiltrated O O
with O O
1% B-Dose B-Dose
Xylocaine B-Drug B-Drug
for O O
anesthesia B-Indication B-Indication
. O O
  
A O O
wire O O
was O O
placed O O
through O O
the O O
needle O O
into O O
the O O
superior O O
vena O O
cava O O
under O O
fluoroscopic O O
guidance O O
. O O
  
A O O
stab O O
wound O O
incision O O
was O O
then O O
made O O
below O O
the O O
clavicle O O
and O O
a O O
Palindrome O O
Perm O O
- O O
A O O
- O O
Cath O O
was O O
placed O O
through O O
the O O
stab O O
wound O O
in O O
a O O
gentle O O
arcs O O
through O O
the O O
subcutaneous O O
tissue O O
to O O
the O O
neck O O
wound O O
. O O
  
The O O
cuff O O
of O O
the O O
catheter O O
was O O
left O O
just O O
inside O O
the O O
skin O O
. O O
  
Dilators O O
were O O
placed O O
over O O
the O O
wire O O
and O O
then O O
the O O
trocar O O
introducer O O
was O O
placed O O
over O O
the O O
wire O O
. O O
  
The O O
trocar O O
and O O
wire O O
were O O
removed O O
and O O
the O O
tip O O
of O O
the O O
catheter O O
was O O
placed O O
through O O
the O O
bivalve O O
device O O
, O O
which O O
was O O
then O O
removed O O
. O O
  
Fluoroscopy O O
revealed O O
good O O
position O O
of O O
the O O
catheter O O
with O O
no O O
kink O O
and O O
good O O
flow O O
of O O
the O O
dye O O
into O O
the O O
superior O O
vena O O
cava O O
and O O
upper O O
atrium O O
. O O
  
The O O
neck O O
wound O O
was O O
closed O O
with O O
4 O O
- O O
0 O O
Vicryl O O
and O O
the O O
subcutaneous O O
tissue O O
with O O
4 O O
- O O
0 O O
nylon O O
on O O
the O O
skin O O
. O O
  
The O O
catheter O O
was O O
secured O O
to O O
the O O
anterior O O
chest O O
wall O O
with O O
3 O O
- O O
0 O O
nylon O O
sutures O O
x3 O O
. O O
  
A O O
bilobed O O
disk O O
was O O
placed O O
around O O
the O O
entry O O
site O O
and O O
the O O
catheter O O
was O O
covered O O
with O O
a O O
Tegaderm O O
dressing O O
. O O
  
The O O
left O O
arm O O
was O O
then O O
prepped O O
with O O
ChloraPrep B-Drug B-Drug
and O O
draped O O
in O O
a O O
sterile O O
manner O O
. O O
  
The O O
skin O O
was O O
infiltrated O O
with O O
1% B-Dose B-Dose
Xylocaine B-Drug B-Drug
plain O O
and O O
a O O
longitudinal O O
incision O O
was O O
made O O
halfway O O
between O O
the O O
radial O O
artery O O
and O O
the O O
cephalic O O
vein O O
at O O
the O O
wrist O O
. O O
  
The O O
cephalic O O
vein O O
was O O
dissected O O
out O O
and O O
ligated O O
distally O O
and O O
filled O O
with O O
heparinized B-Drug B-Drug
saline I-Drug I-Drug
. O O
  
The O O
radial O O
artery O O
was O O
dissected O O
out O O
. O O
  
Several O O
small O O
tributaries O O
were O O
divided O O
between O O
ligatures O O
of O O
5 O O
- O O
0 O O
silk O O
. O O
  
The O O
artery O O
was O O
opened O O
and O O
heparinized B-Drug B-Drug
saline I-Drug I-Drug
was O O
placed O O
in O O
both O O
directions O O
. O O
  
The O O
arteriotomy O O
was O O
increased O O
to O O
about O O
8 O O
mm O O
and O O
then O O
the O O
end O O
of O O
the O O
cephalic O O
vein O O
was O O
spatulated O O
and O O
anastomosed O O
in O O
end O O
- O O
to O O
- O O
side O O
fashion O O
to O O
this O O
arteriotomy O O
using O O
a O O
running O O
6 O O
- O O
0 O O
Prolene O O
suture O O
. O O
  
A O O
good O O
pulse O O
was O O
felt O O
in O O
the O O
fistula O O
up O O
into O O
the O O
forearm O O
. O O
  
Having O O
established O O
adequate O O
hemostasis O O
, O O
the O O
wound O O
was O O
closed O O
with O O
4 O O
- O O
0 O O
Vicryl O O
in O O
the O O
subcutaneous O O
tissue O O
and O O
with O O
4 O O
- O O
0 O O
nylon O O
mattress O O
sutures O O
on O O
the O O
skin O O
. O O
  
A O O
dry O O
dressing O O
was O O
applied O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
and O O
there O O
were O O
no O O
complications O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
14 O O
: O O
02 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
8 O O
: O O
02 O O
A O O
Transcribed O O
Date O O
8 O O
: O O
21 O O
  
: O O
: O O
A O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Progressive O O
follicular B-Indication B-Indication
lymphoma I-Indication I-Indication
with O O
symptomatic O O
posterior B-SSLIF B-SSLIF
mediastinal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
invading O O
the O O
epidural O O
space O O
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
has O O
recently O O
completed O O
radiation O O
to O O
the O O
posterior O O
mediastinum O O
encompassing O O
T1 O O
through O O
T8 O O
to O O
a O O
total O O
dose O O
of O O
3000 O O
cGy O O
. O O
  
Disease O O
progression O O
in O O
this O O
area O O
had O O
occurred O O
while O O
patient O O
was O O
receiving O O
weekly B-Frequency B-Frequency
doxorubicin B-Drug B-Drug
with O O
the O O
weekly O O
schedule O O
resulting O O
from O O
the O O
patient's O O
strong O O
desire O O
to O O
avoid O O
conspicuous O O
hair B-ADE B-ADE
loss I-ADE I-ADE
. O O
  
INTERIM O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
is O O
nearly O O
off O O
Decadron B-Drug B-Drug
. O O
  
Appetite O O
is O O
mediocre O O
. O O
  
He O O
has O O
had O O
a O O
"cold" B-SSLIF B-SSLIF
for O O
about O O
three O O
weeks O O
, O O
still O O
has O O
a O O
runny B-SSLIF B-SSLIF
nose I-SSLIF I-SSLIF
. O O
  
In O O
spite O O
of O O
his O O
runny B-SSLIF B-SSLIF
nose I-SSLIF I-SSLIF
and O O
mediocre B-SSLIF B-SSLIF
appetite I-SSLIF I-SSLIF
, O O
he O O
feels O O
mentally O O
quite O O
alert O O
and O O
far O O
better O O
than O O
he O O
has O O
recently O O
and O O
than O O
he O O
did O O
just O O
prior O O
to O O
his O O
radiation O O
. O O
  
He O O
is O O
not O O
aware O O
of O O
any O O
new B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
bone B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
he O O
has O O
had O O
nearly O O
total O O
relief O O
of O O
the O O
severe B-Severity B-Severity
back B-SSLIF B-SSLIF
/ I-SSLIF I-SSLIF
interscapular I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
, O O
which O O
prompted O O
investigation O O
and O O
subsequent O O
radiation O O
therapy O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Medical O O
history O O
has O O
changed O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Today O O
, O O
weight O O
stable O O
125 O O
pounds O O
down O O
from O O
his O O
baseline O O
weight O O
of O O
140 O O
- O O
150 O O
pounds O O
, O O
blood O O
pressure O O
160 O O
/ O O
80 O O
, O O
pulse O O
76 O O
and O O
regular O O
, O O
and O O
temperature O O
98.3 O O
. O O
  
He O O
looks O O
well O O
. O O
  
He O O
has O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
and O O
nothing O O
to O O
suggest O O
a O O
lymphomatous B-SSLIF B-SSLIF
infiltration I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
. O O
  
Mouth O O
and O O
pharynx O O
are O O
unremarkable O O
without O O
abnormal B-SSLIF B-SSLIF
lymphoid I-SSLIF I-SSLIF
tissue I-SSLIF I-SSLIF
. O O
  
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
spine B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
Lungs O O
are O O
clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
Abdomen O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
, O O
liver O O
not O O
enlarged O O
, O O
spleen O O
not O O
palpable O O
, O O
no O O
other O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
. O O
  
There O O
is O O
trace O O
to O O
1+ O O
bilateral B-SSLIF B-SSLIF
pretibial I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
count O O
7100 O O
, O O
hemoglobin O O
9.4 O O
grams O O
, O O
hematocrit O O
29% O O
, O O
and O O
platelets O O
59 O O
, O O
000 O O
. O O
  
Serum O O
creatinine O O
is O O
2.1 O O
, O O
calcium O O
is O O
11.5 O O
, O O
potassium O O
is O O
5.5 O O
, O O
magnesium O O
1.5 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
The O O
patient O O
is O O
persistently O O
hypercalcemic B-Indication B-Indication
and O O
he O O
will O O
have O O
another O O
dose O O
of O O
pamidronate B-Drug B-Drug
on O O
Date O O
, O O
Date O O
. O O
  
He O O
will O O
have O O
a O O
noncontrast O O
CT O O
the O O
week O O
of O O
Date O O
and O O
we O O
will O O
assess O O
the O O
current O O
extent O O
of O O
disease O O
and O O
, O O
more O O
importantly O O
, O O
response O O
to O O
radiation O O
therapy O O
. O O
  
Clinically O O
, O O
we O O
can O O
already O O
infer O O
that O O
he O O
has O O
had O O
a O O
dramatic O O
response O O
to O O
radiation O O
since O O
his O O
pain O O
has O O
substantially O O
resolved O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
09 O O
: O O
12 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Location O O
: O O
Location O O
Dictated O O
Date O O
1 O O
: O O
10 O O
P O O
Transcribed O O
Date O O
  
: O O
: O O
2 O O
: O O
29 O O
P O O
DISCHARGE O O
SUMMARY O O
SERVICE O O
: O O
Hematology O O
/ O O
Oncology O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
DATE O O
OF O O
DISCHARGE O O
: O O
Date O O
CHIEF O O
COMPLAINT O O
: O O
Shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
ADMITTING O O
DIAGNOSIS O O
: O O
Pneumonia B-SSLIF B-SSLIF
. O O
  
DISCHARGE O O
DIAGNOSIS O O
: O O
Pneumonia B-SSLIF B-SSLIF
. O O
  
Other O O
discharge O O
diagnoses O O
that O O
were O O
addressed O O
during O O
hospitalization O O
: O O
  
1. O O
Left B-SSLIF B-SSLIF
upper I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
. O O
  
2. O O
End B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
3. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
4. O O
Anemia B-SSLIF B-SSLIF
. O O
  
CONSULTATIONS O O
: O O
None O O
. O O
  
PROCEDURES O O
: O O
Peritoneal O O
dialysis O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
a O O
61 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
past O O
medical O O
history O O
significant O O
for O O
follicular B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
end B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
who O O
presents O O
with O O
4 O O
- O O
day O O
duration O O
of O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
and O O
weakness B-SSLIF B-SSLIF
. O O
  
Of O O
note O O
, O O
the O O
patient O O
was O O
recently O O
discharged O O
on O O
Date O O
, O O
for O O
left B-Indication B-Indication
upper I-Indication I-Indication
extremity I-Indication I-Indication
DVT I-Indication I-Indication
and O O
sent O O
home O O
with O O
Coumadin B-Drug B-Drug
. O O
  
The O O
patient O O
was O O
in O O
his O O
usual O O
state O O
of O O
health O O
until O O
4 O O
days O O
prior O O
to O O
admission O O
. O O
  
He O O
reports O O
URI O O
symptoms O O
including O O
cough B-SSLIF B-SSLIF
and O O
subjective B-SSLIF B-SSLIF
fevers I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
the O O
patient O O
denies O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
or O O
constipation B-SSLIF B-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
  
1. O O
Follicular B-Indication B-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
diagnosed O O
in O O
Date O O
, O O
last O O
chemotherapy B-Drug B-Drug
x O O
3 O O
months O O
prior O O
to O O
admission O O
. O O
  
The O O
patient O O
is O O
followed O O
by O O
Dr O O
. O O
  
Name O O
as O O
an O O
outpatient O O
. O O
  
2. O O
End B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
secondary O O
to O O
milk B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
alkali I-SSLIF I-SSLIF
syndrome I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
been O O
on O O
peritoneal O O
dialysis O O
since O O
Date O O
, O O
and O O
follows O O
by O O
Dr O O
. O O
  
Name O O
as O O
an O O
outpatient O O
. O O
  
3. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
4. O O
Peripheral B-SSLIF B-SSLIF
vascular I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
5. O O
History O O
of O O
left B-Indication B-Indication
subclavian I-Indication I-Indication
DVT I-Indication I-Indication
on O O
Coumadin B-Drug B-Drug
therapy O O
followed O O
by O O
anticoagulation O O
clinic O O
on O O
Street_Address O O
. O O
  
MEDICATIONS O O
ON O O
ADMISSION O O
: O O
Include O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
Percocet B-Drug B-Drug
, O O
OxyContin B-Drug B-Drug
, O O
renal B-Drug B-Drug
caps I-Drug I-Drug
, O O
Renvela B-Drug B-Drug
, O O
vitamin B-Drug B-Drug
B I-Drug I-Drug
complex I-Drug I-Drug
, O O
verapamil B-Drug B-Drug
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
and O O
Coumadin B-Drug B-Drug
. O O
  
HOSPITAL O O
COURSE O O
: O O
  
1. O O
Hospital O O
- O O
acquired O O
pneumonia B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
had O O
a O O
chest O O
x O O
- O O
ray O O
and O O
CT O O
done O O
that O O
showed O O
bilateral B-SSLIF B-SSLIF
consolidations I-SSLIF I-SSLIF
and O O
given O O
recent O O
hospitalization O O
, O O
the O O
patient O O
was O O
started O O
on O O
empiric O O
coverage O O
for O O
hospital O O
- O O
acquired O O
pneumonia B-Indication B-Indication
with O O
IV B-Route B-Route
antibiotics B-Drug B-Drug
. O O
  
The O O
patient O O
has O O
received O O
4 B-Duration B-Duration
days I-Duration I-Duration
of O O
IV B-Route B-Route
vancomycin B-Drug B-Drug
and O O
Zosyn B-Drug B-Drug
. O O
  
The O O
patient's O O
symptoms O O
of O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
and O O
cough B-SSLIF B-SSLIF
has O O
resolved O O
with O O
the O O
IV B-Route B-Route
antibiotics B-Drug B-Drug
. O O
  
The O O
patient O O
has O O
remained O O
afebrile B-SSLIF B-SSLIF
during O O
the O O
course O O
of O O
the O O
admission O O
. O O
  
The O O
patient's O O
blood O O
cultures O O
have O O
remained O O
no O O
growth O O
to O O
date O O
and O O
the O O
sputum O O
cultures O O
were O O
done O O
that O O
ruled O O
out O O
PCP B-SSLIF B-SSLIF
. O O
  
Given O O
clinical O O
improvement O O
on O O
IV B-Route B-Route
antibiotics B-Drug B-Drug
, O O
the O O
patient O O
was O O
transitioned O O
to O O
oral B-Route B-Route
antibiotics B-Drug B-Drug
with O O
azithromycin B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
, O O
which O O
he O O
is O O
to O O
continue O O
at O O
discharge O O
with O O
last O O
dose O O
scheduled O O
on O O
Date O O
. O O
  
The O O
patient O O
had O O
a O O
repeat O O
chest O O
x O O
- O O
ray O O
done O O
one O O
day O O
prior O O
to O O
discharge O O
that O O
showed O O
stable O O
consolidations O O
with O O
no O O
indication O O
of O O
worsening O O
disease O O
. O O
  
The O O
patient O O
initially O O
was O O
maintaining O O
his O O
oxygen B-Drug B-Drug
saturations O O
on O O
4 B-Dose B-Dose
L I-Dose I-Dose
nasal B-Route B-Route
cannula I-Route I-Route
with O O
treatment O O
of O O
his O O
pneumonia B-Indication B-Indication
. O O
  
The O O
patient O O
was O O
able O O
to O O
improve O O
to O O
maintain O O
his O O
oxygen B-Drug B-Drug
saturations O O
on O O
1 B-Dose B-Dose
L I-Dose I-Dose
nasal B-Route B-Route
cannula I-Route I-Route
. O O
  
He O O
had O O
a O O
trending O O
pulse O O
oximetry O O
done O O
that O O
was O O
normal O O
. O O
  
The O O
patient O O
already O O
has O O
home O O
oxygen B-Drug B-Drug
set O O
up O O
by O O
his O O
PCP O O
. O O
  
The O O
patient O O
will O O
likely O O
need O O
supplemental O O
oxygen B-Drug B-Drug
with O O
further O O
improvement O O
in O O
his O O
pneumonia B-Indication B-Indication
and O O
eventually O O
will O O
be O O
able O O
to O O
wean O O
off O O
the O O
oxygen O O
since O O
the O O
patient O O
should O O
follow O O
up O O
with O O
his O O
PCP O O
for O O
a O O
repeat O O
chest O O
x O O
- O O
ray O O
to O O
evaluate O O
for O O
resolution O O
of O O
his O O
pneumonia B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
at O O
the O O
time O O
of O O
discharge O O
is O O
able O O
to O O
ambulate O O
in O O
the O O
hallway O O
without O O
any O O
respiratory O O
difficulty O O
. O O
  
He O O
has O O
remained O O
afebrile B-SSLIF B-SSLIF
for O O
the O O
past O O
48 O O
hours O O
, O O
tolerating O O
p.o. O O
and O O
maintaining O O
oxygen B-Drug B-Drug
saturations O O
on O O
1 B-Dose B-Dose
L I-Dose I-Dose
nasal B-Route B-Route
cannula I-Route I-Route
. O O
  
2. O O
Left B-SSLIF B-SSLIF
upper I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
was O O
diagnosed O O
with O O
left B-Indication B-Indication
upper I-Indication I-Indication
extremity I-Indication I-Indication
DVT I-Indication I-Indication
on O O
last O O
admission O O
in O O
Date O O
. O O
  
The O O
patient O O
was O O
discharged O O
on O O
Date O O
, O O
on O O
Coumadin B-Drug B-Drug
therapy O O
. O O
  
The O O
patient's O O
coags O O
were O O
followed O O
throughout O O
this O O
admission O O
with O O
INR O O
remaining O O
subtherapeutic B-ADE B-ADE
. O O
  
INR O O
at O O
the O O
time O O
of O O
discharge O O
was O O
at O O
1.2 O O
. O O
  
The O O
patient O O
is O O
to O O
follow O O
at O O
the O O
anticoagulation O O
clinic O O
on O O
Street_Address O O
and O O
he O O
will O O
continue O O
to O O
follow O O
as O O
an O O
outpatient O O
to O O
continue O O
monitoring O O
his O O
INR O O
and O O
have O O
his O O
Coumadin B-Drug B-Drug
dose O O
adjusted O O
accordingly O O
. O O
  
3. O O
End B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
was O O
evaluated O O
by O O
the O O
renal O O
team O O
during O O
the O O
admission O O
and O O
continued O O
on O O
his O O
peritoneal O O
dialysis O O
and O O
maintained O O
on O O
his O O
outpatient O O
medications O O
including O O
sevelamer B-Drug B-Drug
, O O
which O O
was O O
increased O O
to O O
800 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
  
The O O
patient O O
is O O
to O O
follow O O
up O O
with O O
Dr O O
. O O
  
Name O O
this O O
week O O
on O O
Date O O
, O O
Date O O
at O O
2 O O
: O O
00 O O
p.m. O O
  
4. O O
Hypertension B-Indication B-Indication
. O O
  
The O O
patient O O
initially O O
admitted O O
on O O
verapamil B-Drug B-Drug
for O O
his O O
blood O O
pressures O O
. O O
  
The O O
patient's O O
blood O O
pressures O O
have O O
remained O O
normotensive O O
during O O
the O O
admission O O
and O O
so O O
this O O
medication O O
was O O
held O O
. O O
  
The O O
patient O O
is O O
to O O
discontinue O O
this O O
medication O O
as O O
of O O
now O O
and O O
we O O
will O O
restart O O
after O O
his O O
blood O O
pressures O O
checked O O
by O O
Dr O O
. O O
  
Name O O
at O O
his O O
followup O O
appointment O O
on O O
whether O O
he O O
needs O O
to O O
restart O O
this O O
medication O O
. O O
  
5. O O
Anemia B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
has O O
history O O
of O O
anemia B-SSLIF B-SSLIF
secondary O O
to O O
his O O
chronic B-SSLIF B-SSLIF
kidney I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
His O O
hematocrit O O
has O O
remained O O
stable O O
during O O
this O O
admission O O
and O O
no O O
other O O
signs O O
or O O
symptoms O O
of O O
bleed B-SSLIF B-SSLIF
and O O
no O O
further O O
interventions O O
were O O
needed O O
. O O
  
DISCHARGE O O
PLAN O O
: O O
The O O
patient O O
is O O
to O O
be O O
discharged O O
home O O
with O O
home O O
oxygen B-Drug B-Drug
. O O
  
CONDITION O O
UPON O O
DISCHARGE O O
: O O
Much O O
improved O O
. O O
  
The O O
patient O O
is O O
able O O
to O O
ambulate O O
in O O
the O O
hallway O O
without O O
any O O
respiratory O O
difficulties O O
. O O
  
The O O
patient O O
has O O
remained O O
afebrile B-SSLIF B-SSLIF
, O O
tolerating O O
p.o. O O
and O O
able O O
to O O
maintain O O
his O O
oxygen O O
saturations O O
at O O
minimal O O
settings O O
at O O
this O O
time O O
and O O
will O O
likely O O
be O O
able O O
to O O
wean O O
off O O
his O O
supplemental O O
oxygen B-Drug B-Drug
entirely O O
soon O O
. O O
  
DISCHARGE O O
MEDICATIONS O O
: O O
Azithromycin B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
with O O
last O O
dose O O
scheduled O O
on O O
Date O O
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
1000 B-Dose B-Dose
units I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
1000 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
Renal B-Drug B-Drug
Caps I-Drug I-Drug
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
nicotine B-Drug B-Drug
patch B-Route B-Route
7 I-Route I-Route
mg I-Route I-Route
transdermal I-Route I-Route
daily B-Frequency B-Frequency
, O O
Percocet B-Drug B-Drug
1 B-Dose B-Dose
- I-Dose I-Dose
2 I-Dose I-Dose
tabs I-Dose I-Dose
p.o. B-Route B-Route
q.6 B-Frequency B-Frequency
hours I-Frequency I-Frequency
p.r.n. I-Frequency I-Frequency
, O O
OxyContin B-Drug B-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
q.a.m. B-Frequency B-Frequency
, O O
OxyContin B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
sevelamer B-Drug B-Drug
800 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
t.i.d. B-Frequency B-Frequency
and O O
vitamin B-Drug B-Drug
B I-Drug I-Drug
complex I-Drug I-Drug
capsule B-Dose B-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
FOLLOWUP O O
APPOINTMENT O O
: O O
The O O
patient O O
is O O
to O O
follow O O
up O O
with O O
Dr O O
. O O
  
Name O O
, O O
his O O
nephrologist O O
this O O
Date O O
, O O
Date O O
, O O
at O O
2 O O
: O O
00 O O
p.m. O O
  
The O O
patient O O
is O O
to O O
follow O O
up O O
with O O
Dr O O
. O O
  
Name O O
, O O
his O O
oncologist O O
sometime O O
this O O
month O O
in O O
the O O
clinic O O
. O O
  
We O O
will O O
call O O
him O O
with O O
his O O
appointment O O
date O O
and O O
time O O
. O O
  
The O O
patient O O
should O O
follow O O
up O O
in O O
the O O
anticoagulation O O
clinic O O
to O O
have O O
his O O
INR O O
monitored O O
and O O
Coumadin B-Drug B-Drug
dose O O
adjusted O O
and O O
Coumadin O O
clinic O O
forms O O
have O O
been O O
faxed O O
on O O
date O O
of O O
discharge O O
and O O
the O O
patient O O
should O O
have O O
his O O
INR O O
checked O O
on O O
Date O O
. O O
  
CC O O
: O O
PCP O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
12 O O
: O O
44 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Physician O O
Copy O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
6 O O
: O O
35 O O
P O O
Transcribed O O
Date O O
6 O O
: O O
47 O O
  
: O O
: O O
A O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Intermediate B-Severity B-Severity
grade I-Severity I-Severity
follicular B-Indication B-Indication
lymphoma I-Indication I-Indication
with O O
associated O O
hypercalcemia B-Indication B-Indication
; O O
diagnosis O O
established O O
Date O O
. O O
  
CURRENT O O
THERAPY O O
: O O
Doxorubicin B-Drug B-Drug
given O O
weekly B-Frequency B-Frequency
or O O
every B-Frequency B-Frequency
other I-Frequency I-Frequency
week I-Frequency I-Frequency
based O O
on O O
blood O O
counts O O
; O O
the O O
unorthodox O O
dosing O O
schedule O O
has O O
been O O
driven O O
by O O
the O O
patient's O O
strong O O
desire O O
to O O
minimize O O
hair B-ADE B-ADE
loss I-ADE I-ADE
in O O
an O O
effort O O
to O O
deflect O O
the O O
attention O O
of O O
business O O
colleagues O O
and O O
family O O
from O O
his O O
battle O O
with O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
receives O O
pamidronate B-Drug B-Drug
as O O
needed O O
to O O
control O O
calcium O O
. O O
  
INTERIM O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
is O O
feeling O O
well O O
. O O
  
No O O
systemic O O
symptoms O O
. O O
  
He O O
is O O
unaware O O
of O O
any O O
lymphadenopathy B-SSLIF B-SSLIF
, O O
no O O
recurrence O O
of O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
genital I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
No O O
symptoms O O
of O O
congestive B-SSLIF B-SSLIF
heart I-SSLIF I-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
He O O
notes O O
some B-Severity B-Severity
thinning B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
hair I-SSLIF I-SSLIF
but O O
also O O
reports O O
that O O
this O O
has O O
not O O
attracted O O
any O O
attention O O
among O O
business O O
colleagues O O
or O O
in O O
deed O O
from O O
his O O
family O O
, O O
from O O
whom O O
he O O
continues O O
to O O
try O O
to O O
conceal O O
a O O
good O O
deal O O
of O O
what O O
is O O
going O O
on O O
with O O
his O O
illness O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
No O O
change O O
in O O
medical O O
history O O
since O O
the O O
patient O O
was O O
seen O O
here O O
on O O
Date O O
. O O
  
FAMILY O O
HISTORY O O
/ O O
SOCIAL O O
HISTORY O O
: O O
No O O
change O O
in O O
family O O
history O O
or O O
social O O
history O O
. O O
  
The O O
patient O O
continues O O
to O O
work O O
full O O
time O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Please O O
see O O
outpatient O O
visit O O
note O O
for O O
review O O
of O O
systems O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Today O O
, O O
Mr O O
. O O
  
Name O O
, O O
as O O
always O O
. O O
  
looks O O
quite O O
well O O
. O O
  
His O O
hair B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
thinned I-SSLIF I-SSLIF
. O O
  
Weight O O
is O O
stable O O
139 O O
pounds O O
. O O
  
Blood O O
pressure O O
126 O O
/ O O
74 O O
, O O
temperature O O
36.8 O O
. O O
  
No O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
Mouth O O
and O O
pharynx O O
unremarkable O O
. O O
  
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
spine B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
Lungs O O
clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
Abdomen O O
soft O O
and O O
nontender O O
, O O
liver O O
not O O
enlarged O O
, O O
spleen O O
not O O
palpable O O
, O O
no O O
other O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
count O O
6200 O O
, O O
hemoglobin O O
10.2 O O
grams O O
, O O
hematocrit O O
  
30 O O
- O O
30% O O
, O O
platelets O O
99 O O
, O O
000 O O
. O O
  
Serum O O
creatinine O O
1.6 O O
, O O
serum O O
calcium O O
is O O
10.3 O O
. O O
  
IMAGING O O
: O O
CT O O
scan O O
of O O
chest O O
, O O
abdomen O O
and O O
pelvis O O
without O O
IV O O
contrast O O
shows O O
decrease O O
in O O
size O O
of O O
the O O
dominant O O
anterior B-SSLIF B-SSLIF
mediastinal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
compared O O
to O O
the O O
study O O
of O O
Date O O
. O O
  
The O O
mass B-SSLIF B-SSLIF
currently O O
measures O O
7x3.1 B-Severity B-Severity
cm I-Severity I-Severity
; O O
previously O O
was O O
  
7.7 O O
x O O
4.6 O O
. O O
  
In O O
addition O O
, O O
a O O
left B-SSLIF B-SSLIF
pleural I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
has O O
resolved O O
. O O
  
There O O
are O O
other O O
mediastinal B-SSLIF B-SSLIF
lymph I-SSLIF I-SSLIF
nodes I-SSLIF I-SSLIF
, O O
which O O
are O O
unchanged O O
. O O
  
No O O
evidence O O
of O O
lymphoma B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
abdomen I-SSLIF I-SSLIF
is O O
noted O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
The O O
patient O O
is O O
having O O
a O O
modest O O
response O O
to O O
his O O
current O O
Adriamycin B-Drug B-Drug
regimen O O
in O O
the O O
form O O
of O O
a O O
gradually O O
diminishing O O
bulk O O
of O O
his O O
mediastinal B-Indication B-Indication
mass I-Indication I-Indication
. O O
  
In O O
point O O
of O O
fact O O
, O O
because O O
of O O
his O O
thrombocytopenia B-ADE B-ADE
, O O
it O O
would O O
probably O O
be O O
impossible O O
to O O
treat O O
him O O
much O O
more O O
vigorously O O
in O O
any O O
case O O
, O O
since O O
a O O
severe B-Severity B-Severity
and O O
prolonged O O
thrombocytopenia B-ADE B-ADE
has O O
been O O
a O O
longstanding O O
problem O O
. O O
  
The O O
patient O O
will O O
be O O
treated O O
today O O
, O O
Date O O
, O O
and O O
again O O
on O O
Date O O
, O O
and O O
we O O
will O O
continue O O
to O O
work O O
with O O
him O O
as O O
best O O
we O O
can O O
to O O
coordinate O O
chemotherapy B-Drug B-Drug
with O O
his O O
business O O
schedule O O
, O O
as O O
well O O
as O O
a O O
vacation O O
schedule O O
. O O
  
He O O
is O O
aware O O
that O O
the O O
plan O O
may O O
need O O
to O O
change O O
should O O
he O O
have O O
evidence O O
of O O
disease O O
getting O O
out O O
of O O
control O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
18 O O
: O O
32 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
7 O O
: O O
05 O O
P O O
Transcribed O O
Date O O
8 O O
: O O
58 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Follicular B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
history O O
of O O
mediastinal B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
invading O O
mid O O
thoracic O O
spine O O
epidural O O
space O O
. O O
  
The O O
patient O O
has O O
also O O
had O O
peripheral B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Diagnosis O O
established O O
in O O
Date O O
. O O
  
Other O O
medical O O
problems O O
, O O
persistent O O
, O O
intractable B-Severity B-Severity
hypercalcemia B-SSLIF B-SSLIF
of O O
uncertain O O
etiology O O
which O O
has O O
not O O
been O O
consistently O O
related O O
to O O
activity O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
has O O
chronic B-SSLIF B-SSLIF
renal I-SSLIF I-SSLIF
insufficiency I-SSLIF I-SSLIF
which O O
is O O
due O O
in O O
significant O O
part O O
to O O
his O O
hypercalcemia B-SSLIF B-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
No O O
lymphoma B-SSLIF B-SSLIF
treatment O O
. O O
  
He O O
requires O O
frequent O O
pamidronate B-Drug B-Drug
to O O
treat O O
his O O
hypercalcemia B-Indication B-Indication
. O O
  
INTERIM O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
feels O O
much O O
better O O
since O O
his O O
hospitalization O O
of O O
Date O O
through O O
Date O O
, O O
which O O
was O O
prompted O O
by O O
arise B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
serum I-SSLIF I-SSLIF
calcium I-SSLIF I-SSLIF
to O O
nearly O O
6 O O
in O O
concert O O
with O O
a O O
serum O O
calcium O O
that O O
was O O
14.5 O O
. O O
  
With O O
hospitalization O O
, O O
his O O
serum O O
creatinine O O
dropped O O
down O O
to O O
about O O
5.3 O O
, O O
but O O
his O O
calcium O O
responded O O
dramatically O O
to O O
11.4 O O
by O O
discharge O O
. O O
  
He O O
was O O
not O O
uremic B-SSLIF B-SSLIF
. O O
  
At O O
this O O
point O O
, O O
he O O
feels O O
much O O
better O O
than O O
he O O
did O O
2 O O
weeks O O
ago O O
. O O
  
Energy O O
is O O
improved O O
as O O
is O O
his O O
appetite O O
, O O
although O O
neither O O
is O O
normal O O
. O O
  
No O O
bone B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
no O O
constipation B-SSLIF B-SSLIF
. O O
  
He O O
has O O
no O O
new B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
He O O
feels O O
that O O
his O O
mental O O
status O O
is O O
normal O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Medical O O
history O O
has O O
changed O O
since O O
the O O
visit O O
here O O
on O O
Date O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
No O O
change O O
in O O
family O O
history O O
or O O
social O O
history O O
. O O
  
I O O
should O O
note O O
that O O
the O O
patient O O
is O O
interviewed O O
and O O
examined O O
today O O
with O O
Dr O O
. O O
  
Name O O
Name O O
, O O
medical O O
resident O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Please O O
see O O
outpatient O O
visit O O
note O O
for O O
review O O
of O O
systems O O
. O O
  
MEDICATIONS O O
: O O
Medication O O
list O O
is O O
reviewed O O
and O O
no O O
changes O O
are O O
made O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Today O O
, O O
the O O
patient's O O
weight O O
is O O
55 O O
kilograms O O
( O O
121 O O
- O O
1 O O
/ O O
2 O O
pounds O O
) O O
, O O
stable O O
, O O
blood O O
pressure O O
122 O O
/ O O
56 O O
, O O
pulse O O
88 O O
and O O
regular O O
and O O
temperature O O
36.7 O O
. O O
  
He O O
looks O O
a B-Severity B-Severity
little I-Severity I-Severity
thin B-SSLIF B-SSLIF
and O O
a B-Severity B-Severity
little I-Severity I-Severity
pale B-SSLIF B-SSLIF
, O O
but O O
otherwise O O
okay O O
and O O
is O O
basically O O
unchanged O O
in O O
his O O
appearance O O
. O O
  
He O O
has O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
and O O
no O O
lesions B-SSLIF B-SSLIF
suspicious O O
for O O
lymphomatous B-SSLIF B-SSLIF
infiltration I-SSLIF I-SSLIF
. O O
  
Mouth O O
and O O
pharynx O O
unremarkable O O
without O O
abnormal B-SSLIF B-SSLIF
lymphoid I-SSLIF I-SSLIF
tissue I-SSLIF I-SSLIF
. O O
  
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
percussion B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
. O O
  
Lungs O O
are O O
clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
, O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
Abdomen O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
, O O
liver O O
not O O
enlarged O O
, O O
spleen O O
not O O
palpable O O
, O O
no O O
other B-SSLIF B-SSLIF
abdominal I-SSLIF I-SSLIF
masses I-SSLIF I-SSLIF
and O O
no O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
count O O
5700 O O
, O O
hemoglobin O O
9.6 O O
grams O O
, O O
hematocrit O O
28% O O
, O O
platelets O O
are O O
204 O O
, O O
000 O O
. O O
  
Serum O O
creatinine O O
on O O
Date O O
was O O
5.44 O O
and O O
serum O O
calcium O O
of O O
11.4 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
Collateral O O
history O O
was O O
obtained O O
from O O
the O O
patient's O O
wife O O
at O O
the O O
time O O
of O O
the O O
patient's O O
admission O O
to O O
the O O
hospital O O
on O O
Date O O
. O O
  
It O O
is O O
her O O
impression O O
that O O
he O O
may O O
be O O
consuming O O
large O O
numbers O O
of O O
Tums B-Drug B-Drug
and O O
she O O
has O O
in O O
fact O O
seen O O
them O O
coming O O
from O O
his O O
mouth O O
during O O
sleep O O
. O O
  
I O O
have O O
questioned O O
the O O
patient O O
about O O
this O O
today O O
and O O
he O O
somewhat O O
reluctantly O O
admits O O
that O O
there O O
may O O
be O O
times O O
when O O
he O O
takes O O
some O O
Tums B-Drug B-Drug
to O O
treat O O
reflux B-Indication B-Indication
, O O
although O O
he O O
denies O O
taking O O
large O O
numbers O O
of O O
Tums B-Drug B-Drug
. O O
  
I O O
am O O
not O O
sure O O
what O O
to O O
think O O
about O O
this O O
, O O
but O O
certainly O O
it O O
is O O
a O O
clue O O
that O O
is O O
worth O O
pursuing O O
and O O
I O O
have O O
asked O O
him O O
to O O
entirely O O
discontinue O O
using O O
Tums B-Drug B-Drug
in O O
an O O
effort O O
to O O
test O O
the O O
hypothesis O O
that O O
his O O
hypercalcemia B-SSLIF B-SSLIF
may O O
represent O O
something O O
like O O
milk B-ADE B-ADE
alkali I-ADE I-ADE
syndrome I-ADE I-ADE
. O O
  
We O O
will O O
recheck O O
serum O O
calcium O O
, O O
serum O O
creatinine O O
a O O
week O O
. O O
  
He O O
will O O
continue O O
to O O
be O O
followed O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
There O O
is O O
no O O
clinical O O
suggestion O O
of O O
reactivation O O
of O O
his O O
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
Finally O O
, O O
if O O
his O O
renal O O
function O O
does O O
not O O
return O O
to O O
normal O O
, O O
I O O
would O O
expect O O
that O O
he O O
will O O
remain O O
significantly B-Severity B-Severity
anemic B-Indication B-Indication
with O O
hemoglobin O O
below O O
10 O O
grams O O
and O O
will O O
need O O
to O O
address O O
the O O
issue O O
of O O
Procrit B-Drug B-Drug
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
17 O O
: O O
28 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
2 O O
: O O
27 O O
P O O
Transcribed O O
Date O O
4 O O
: O O
25 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
59 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
progressive O O
follicular B-Indication B-Indication
lymphoma I-Indication I-Indication
with O O
mediastinal B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
invading O O
the O O
epidural O O
space O O
. O O
  
Has O O
had O O
peripheral B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
as O O
well O O
as O O
axillary B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Original O O
diagnosis O O
was O O
established O O
Date O O
. O O
  
CURRENT O O
THERAPY O O
: O O
Observation O O
. O O
  
Most O O
recently O O
completed O O
Rituxan B-Drug B-Drug
with O O
the O O
last O O
dose O O
being O O
on O O
Date O O
. O O
  
Prior O O
therapy O O
consisted O O
of O O
cyclophosphamide B-Drug B-Drug
, O O
doxorubicin B-Drug B-Drug
, O O
fludarabine B-Drug B-Drug
, O O
prednisone B-Drug B-Drug
and O O
vincristine B-Drug B-Drug
. O O
  
Previously O O
he O O
has O O
also O O
received O O
Zometa B-Drug B-Drug
, O O
but O O
has O O
been O O
discontinued O O
due O O
to O O
renal B-ADE B-ADE
insufficiency I-ADE I-ADE
. O O
  
Is O O
receiving O O
pamidronate B-Drug B-Drug
intermittently O O
for O O
hypercalcemia B-Indication B-Indication
associated O O
with O O
lymphoma B-SSLIF B-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
here O O
for O O
a O O
routine O O
visit O O
. O O
  
Name O O
is O O
alone O O
today O O
. O O
  
He O O
comes O O
in O O
for O O
his O O
check O O
for O O
his O O
CBC O O
and O O
chemistry O O
panel O O
. O O
  
Again O O
, O O
it O O
is O O
noted O O
that O O
he O O
has O O
hypercalcemia B-SSLIF B-SSLIF
with O O
a O O
calcium O O
13.1 O O
. O O
  
He O O
reports O O
he O O
continues O O
to O O
feel O O
quite O O
well O O
. O O
  
He O O
has O O
not O O
had O O
any O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
any O O
fevers B-SSLIF B-SSLIF
or O O
any O O
shaking B-SSLIF B-SSLIF
chills I-SSLIF I-SSLIF
. O O
  
He O O
has O O
not O O
had O O
any O O
recent O O
infections B-SSLIF B-SSLIF
. O O
  
He O O
does O O
report O O
that O O
his O O
energy O O
is O O
good O O
. O O
  
He O O
continues O O
to O O
be O O
in O O
retirement O O
and O O
is O O
enjoying O O
that O O
. O O
  
For O O
activities O O
he O O
is O O
setting O O
up O O
his O O
Company O O
train O O
set O O
and O O
he O O
does O O
not O O
routinely O O
exercise O O
, O O
but O O
is O O
independent O O
of O O
all O O
normal O O
activities O O
of O O
daily O O
living O O
. O O
  
He O O
does O O
report O O
he O O
is O O
eating O O
, O O
but O O
his O O
appetite O O
is O O
not O O
the O O
way O O
it O O
used O O
to O O
be O O
, O O
he O O
does O O
have O O
some O O
diminished B-SSLIF B-SSLIF
appetite I-SSLIF I-SSLIF
. O O
  
His O O
pain B-SSLIF B-SSLIF
continues O O
to O O
be O O
well O O
controlled O O
, O O
his O O
pain B-Indication B-Indication
is O O
located O O
in O O
the O O
back O O
. O O
  
It O O
is O O
unchanged O O
. O O
  
He O O
is O O
on O O
with O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
12 I-Frequency I-Frequency
hours I-Frequency I-Frequency
and O O
Percocet B-Drug B-Drug
  
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
. O O
  
He O O
reports O O
he O O
has O O
good O O
pain O O
control O O
, O O
some O O
days O O
he O O
does O O
take O O
an O O
average O O
of O O
5 B-Dose B-Dose
- I-Dose I-Dose
6 I-Dose I-Dose
tablets I-Dose I-Dose
of O O
the O O
Percocet B-Drug B-Drug
per B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
continues O O
to O O
sleep O O
well O O
. O O
  
He O O
has O O
not O O
experienced O O
any O O
constipation B-SSLIF B-SSLIF
or O O
diarrhea B-SSLIF B-SSLIF
and O O
he O O
has O O
not O O
had O O
any O O
urinary B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
or O O
weakness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
lymphadenopathy B-SSLIF B-SSLIF
of O O
the O O
legs O O
or O O
swelling B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
coughing B-SSLIF B-SSLIF
, O O
or O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
has O O
had O O
no O O
new O O
bony B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
MEDICATIONS O O
: O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
, O O
Percocet B-Drug B-Drug
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
1 B-Dose B-Dose
- I-Dose I-Dose
6 I-Dose I-Dose
tablets I-Dose I-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
, I-Frequency I-Frequency
aspirin B-Drug B-Drug
325 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
verapamil B-Drug B-Drug
240 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
pamidronate B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
for O O
hypercalcemia B-Indication B-Indication
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
1000 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
magnesium B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
and O O
vitamin B-Drug B-Drug
  
C O O
500 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
  
1. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
2. O O
Renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
has O O
continued O O
to O O
smoke O O
. O O
  
He O O
is O O
smoking O O
roughly O O
about O O
8 O O
- O O
9 O O
cigarettes O O
per O O
day O O
. O O
  
He O O
is O O
continuing O O
to O O
wean O O
off O O
as O O
he O O
does O O
have O O
motivation O O
to O O
stop O O
. O O
  
He O O
is O O
married O O
and O O
lives O O
with O O
his O O
wife O O
. O O
  
He O O
does O O
have O O
a O O
daughter O O
who O O
is O O
in O O
her O O
freshman O O
year O O
at O O
City O O
. O O
  
FAMILY O O
HISTORY O O
: O O
There O O
have O O
been O O
no O O
recent O O
cancers B-SSLIF B-SSLIF
diagnosed O O
in O O
the O O
family O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Vital O O
signs O O
are O O
located O O
in O O
the O O
flow O O
sheet O O
. O O
  
He O O
is O O
afebrile O O
. O O
  
Sclera O O
is O O
anicteric O O
. O O
  
The O O
oropharyngeal O O
cavity O O
clear O O
. O O
  
Neck O O
: O O
  
There O O
is O O
no O O
cervical B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
His O O
original O O
axillary B-SSLIF B-SSLIF
node I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
deep I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
area I-SSLIF I-SSLIF
which O O
is O O
roughly O O
about O O
1 B-Severity B-Severity
cm I-Severity I-Severity
x I-Severity I-Severity
1 I-Severity I-Severity
cm I-Severity I-Severity
is O O
firm O O
and O O
nonmobile O O
. O O
  
It O O
is O O
nonpainful B-SSLIF B-SSLIF
with O O
palpation O O
. O O
  
There O O
is O O
no O O
ulceration B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
other O O
lymphadenopathy B-SSLIF B-SSLIF
palpated O O
, O O
though O O
the O O
inguinal O O
area O O
was O O
not O O
examined O O
as O O
he O O
was O O
in O O
the O O
chemotherapy B-Drug B-Drug
infusion O O
area O O
today O O
receiving O O
his O O
fluids B-Drug B-Drug
. O O
  
Spine O O
is O O
nontender B-SSLIF B-SSLIF
to O O
palpation O O
. O O
  
The O O
lungs O O
are O O
clear O O
to O O
percussion O O
and O O
auscultation O O
bilaterally O O
without O O
any O O
rales B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
, O O
wheezes B-SSLIF B-SSLIF
. O O
  
Cardiac O O
: O O
S1 O O
, O O
S2 O O
, O O
regular O O
rate O O
and O O
rhythm O O
without O O
any O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender O O
, O O
no O O
gross O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
Extremities O O
reveal O O
no O O
edema B-SSLIF B-SSLIF
. O O
  
Skin O O
exam O O
does O O
not O O
reveal O O
any O O
rash B-SSLIF B-SSLIF
or O O
petechiae B-SSLIF B-SSLIF
. O O
  
Neurologically O O
alert O O
and O O
oriented O O
and O O
nonfocal O O
. O O
  
ECOG O O
performance O O
status O O
is O O
a O O
1 O O
. O O
  
LABORATORY O O
DATA O O
: O O
Chemistry O O
panel O O
reveals O O
a O O
creatinine O O
of O O
2.93 O O
. O O
  
Calcium O O
is O O
  
13.1 O O
with O O
liver O O
transaminase O O
levels O O
normal O O
. O O
  
WBCs O O
are O O
7.2 O O
, O O
hemoglobin O O
11 O O
, O O
hematocrit O O
32.4 O O
and O O
platelet O O
count O O
is O O
188 O O
, O O
000 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
59 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
at O O
this O O
time O O
is O O
under O O
observation O O
. O O
  
He O O
has O O
no O O
bulky B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
palpated O O
on O O
exam O O
with O O
the O O
exception O O
of O O
a O O
small B-Severity B-Severity
left B-SSLIF B-SSLIF
axillary I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
He O O
continues O O
to O O
be O O
hypercalcemic B-SSLIF B-SSLIF
. O O
  
2. O O
Hypercalcemia B-Indication B-Indication
. O O
  
Received O O
normal B-Drug B-Drug
saline I-Drug I-Drug
500 B-Dose B-Dose
mL I-Dose I-Dose
intravenously B-Route B-Route
over B-Dose B-Dose
one I-Dose I-Dose
hour I-Dose I-Dose
followed O O
by O O
pamidronate B-Drug B-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
over B-Dose B-Dose
2 I-Dose I-Dose
hours I-Dose I-Dose
. O O
  
3. O O
Pain B-SSLIF B-SSLIF
control O O
. O O
  
His O O
pain B-Indication B-Indication
is O O
adequately O O
controlled O O
, O O
he O O
is O O
given O O
a O O
prescription O O
for O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
tablets O O
to O O
take O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
every B-Frequency B-Frequency
12 I-Frequency I-Frequency
hours I-Frequency I-Frequency
, O O
dispense O O
60 O O
with O O
no O O
refills O O
plus O O
a O O
prescription O O
for O O
Percocet B-Drug B-Drug
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
to O O
take O O
  
1 B-Dose B-Dose
- I-Dose I-Dose
2 I-Dose I-Dose
tablets I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
hours I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
for O O
breakthrough O O
pain B-Indication B-Indication
, O O
dispense O O
180 O O
tablets O O
with O O
no O O
refills O O
. O O
  
4. O O
Renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
continues O O
to O O
be O O
followed O O
by O O
nephrology O O
. O O
  
5 O O
. O O
  
The O O
plan O O
is O O
that O O
Mr O O
. O O
  
Name O O
received O O
normal B-Drug B-Drug
saline I-Drug I-Drug
plus O O
pamidronate B-Drug B-Drug
today O O
. O O
  
He O O
will O O
follow O O
up O O
with O O
Dr O O
. O O
  
Name O O
Name O O
within O O
three O O
weeks' O O
time O O
for O O
further O O
evaluation O O
and O O
monitoring O O
as O O
well O O
as O O
monitoring O O
of O O
his O O
pain B-SSLIF B-SSLIF
. O O
  
Mr O O
. O O
  
Name O O
will O O
call O O
sooner O O
if O O
he O O
experiences O O
any O O
problems O O
prior O O
to O O
next O O
followup O O
visit O O
. O O
  
SUPERVISING O O
PHYSICIAN O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
NP O O
Date O O
15 O O
: O O
43 O O
  
____________________________ O O
Name O O
Name O O
, O O
NP O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
NP O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
3 O O
: O O
48 O O
P O O
Transcribed O O
Date O O
2 O O
: O O
49 O O
  
: O O
: O O
A O O
CLINIC O O
NOTE O O
DIAGNOSES O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
60 O O
- O O
year O O
- O O
old O O
male O O
with O O
: O O
  
1. O O
A O O
history O O
of O O
a O O
follicular B-Indication B-Indication
B I-Indication I-Indication
- I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
with O O
mediastinal B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
invading O O
the O O
mid O O
thoracic O O
spine O O
in O O
epidural O O
space O O
as O O
well O O
as O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
Original O O
diagnosis O O
established O O
in O O
Date O O
. O O
  
2. O O
Hypercalcemia B-SSLIF B-SSLIF
of O O
uncertain O O
etiology O O
. O O
  
3. O O
Chronic B-SSLIF B-SSLIF
renal I-SSLIF I-SSLIF
insufficiency I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
Observation O O
, O O
pamidronate B-Drug B-Drug
for O O
hypercalcemia B-Indication B-Indication
. O O
  
Prior O O
treatment O O
consisted O O
of O O
cyclophosphamide B-Drug B-Drug
, O O
doxorubicin B-Drug B-Drug
, O O
fludarabine B-Drug B-Drug
, O O
mitoxantrone B-Drug B-Drug
, O O
Rituxan B-Drug B-Drug
, O O
and O O
vincristine B-Drug B-Drug
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
alone O O
today O O
. O O
  
He O O
reports O O
over O O
the O O
course O O
of O O
the O O
week O O
, O O
he O O
has O O
noted O O
bilateral B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
starting O O
from O O
the O O
inguinal O O
area O O
down O O
to O O
the O O
toes O O
. O O
  
He O O
has O O
had O O
no O O
pain B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
ambulation I-SSLIF I-SSLIF
and O O
has O O
had O O
no O O
discomfort O O
. O O
  
He O O
denies O O
any O O
erythema B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
or O O
any O O
warmth B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
no O O
fevers B-SSLIF B-SSLIF
or O O
shaking B-SSLIF B-SSLIF
chills I-SSLIF I-SSLIF
. O O
  
He O O
reports O O
he O O
has O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
palpitations B-SSLIF B-SSLIF
and O O
he O O
is O O
able O O
to O O
ambulate O O
up O O
2 O O
flights O O
of O O
stairs O O
without O O
stopping O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
. O O
  
He O O
reports O O
he O O
is O O
still O O
urinating O O
and O O
there O O
has O O
been O O
no O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
urine I-SSLIF I-SSLIF
color I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
hematuria B-SSLIF B-SSLIF
, O O
bleeding B-SSLIF B-SSLIF
or O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
no O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
Clinically O O
, O O
what O O
he O O
does O O
report O O
besides O O
the O O
bilateral B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
, O O
is O O
increased O O
fatigue B-SSLIF B-SSLIF
. O O
  
He O O
does O O
report O O
his O O
energy B-SSLIF B-SSLIF
has I-SSLIF I-SSLIF
continued I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
decline I-SSLIF I-SSLIF
since O O
he O O
has O O
seen O O
Dr O O
. O O
  
Name O O
on O O
the O O
Date O O
. O O
  
He O O
does O O
report O O
that O O
his O O
appetite O O
has O O
been O O
okay O O
and O O
notes O O
no O O
significant O O
change O O
. O O
  
He O O
reports O O
for O O
activities O O
, O O
he O O
has O O
been O O
trying O O
to O O
golf O O
, O O
he O O
has O O
gone O O
a O O
couple O O
of O O
vacations O O
and O O
he O O
is O O
working O O
in O O
the O O
yard O O
. O O
  
He O O
continues O O
to O O
be O O
independent O O
of O O
his O O
normal O O
activities O O
of O O
daily O O
living O O
. O O
  
He O O
is O O
retired O O
. O O
  
With O O
regard O O
to O O
his O O
chronic O O
pain B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
this I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
located I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
. O O
  
He O O
reports O O
that O O
he O O
is O O
currently O O
taking O O
his O O
long O O
acting O O
pain B-Drug B-Drug
medication I-Drug I-Drug
as O O
well O O
as O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
1 B-Dose B-Dose
tablet I-Dose I-Dose
every B-Frequency B-Frequency
12 I-Frequency I-Frequency
hours I-Frequency I-Frequency
. O O
  
He O O
reports O O
the O O
Percocet B-Drug B-Drug
he O O
is O O
taking O O
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
anywhere O O
from O O
5 B-Dose B-Dose
- I-Dose I-Dose
6 I-Dose I-Dose
tablets I-Dose I-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
reports O O
this O O
pain B-Indication B-Indication
is O O
fairly O O
well O O
controlled O O
and O O
is O O
0 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
scale O O
. O O
  
He O O
reports O O
he O O
has O O
no O O
difficulty B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
walking I-SSLIF I-SSLIF
or O O
any O O
bowel B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
bladder I-SSLIF I-SSLIF
dysfunction I-SSLIF I-SSLIF
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Aspirin B-Drug B-Drug
325 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
lasix B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
OxyContin B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
1 B-Dose B-Dose
tablet I-Dose I-Dose
every B-Frequency B-Frequency
12 I-Frequency I-Frequency
hours I-Frequency I-Frequency
, O O
Percocet B-Drug B-Drug
5 B-Dose B-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
and O O
verapamil B-Drug B-Drug
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
  
1. O O
Carotid B-SSLIF B-SSLIF
artery I-SSLIF I-SSLIF
stenosis I-SSLIF I-SSLIF
. O O
  
2. O O
Stage B-Severity B-Severity
IV I-Severity I-Severity
kidney B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
3. O O
Hypercalcemia B-SSLIF B-SSLIF
, O O
unknown O O
etiology O O
. O O
  
4. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
5. O O
Peripheral B-SSLIF B-SSLIF
vascular I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
6. O O
Right B-SSLIF B-SSLIF
carotid I-SSLIF I-SSLIF
bruit I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
does O O
continue O O
to O O
smoke O O
. O O
  
He O O
has O O
cut O O
down O O
to O O
12 O O
cigarettes O O
per O O
day O O
from O O
a O O
pack O O
and O O
a O O
half O O
. O O
  
At O O
this O O
time O O
, O O
he O O
would O O
like O O
to O O
stop O O
smoking O O
but O O
is O O
not O O
motivated O O
enough O O
to O O
completely O O
stop O O
or O O
initiate O O
any O O
other O O
therapy O O
. O O
  
He O O
will O O
try O O
to O O
continue O O
to O O
wean O O
himself O O
off O O
the O O
cigarettes O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
Temperature O O
is O O
97.7 O O
degrees O O
Fahrenheit O O
; O O
blood O O
pressure O O
is O O
  
118 O O
/ O O
60 O O
; O O
heart O O
rate O O
is O O
88 O O
; O O
weight O O
is O O
127.8 O O
pounds O O
, O O
up O O
from O O
122 O O
pounds O O
on O O
Date O O
, O O
and O O
Date O O
, O O
was O O
119 O O
pounds O O
. O O
  
GENERAL O O
: O O
Mr O O
. O O
  
Name O O
appears O O
cachectic B-SSLIF B-SSLIF
and O O
chronically O O
ill O O
. O O
  
HEENT O O
: O O
The O O
sclerae O O
are O O
anicteric B-SSLIF B-SSLIF
. O O
  
The O O
oropharyngeal O O
cavity O O
is O O
moist O O
and O O
clear O O
without O O
lesions B-SSLIF B-SSLIF
or O O
thrush B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
The O O
thyroid O O
is O O
nonpalpable O O
. O O
  
LYMPHATICS O O
: O O
There O O
is O O
no O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Under O O
the O O
left O O
axilla O O
, O O
there O O
are O O
2 B-SSLIF B-SSLIF
lymph I-SSLIF I-SSLIF
nodes I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
one I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
at O O
least O O
2 B-Severity B-Severity
x I-Severity I-Severity
2 I-Severity I-Severity
cm I-Severity I-Severity
, O O
firm O O
and O O
slightly O O
mobile O O
in O O
the O O
deep O O
axilla O O
. O O
  
It O O
is O O
hard O O
to O O
ascertain O O
the O O
size O O
but O O
estimated O O
at O O
least O O
2 O O
x O O
2 O O
cm O O
. O O
  
The O O
right B-SSLIF B-SSLIF
axilla I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
without I-SSLIF I-SSLIF
any I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
BACK O O
: O O
Spine O O
is O O
nontender O O
to O O
palpation O O
. O O
  
LUNGS O O
: O O
A O O
few O O
wheezes B-SSLIF B-SSLIF
inspiratory O O
bilaterally O O
otherwise O O
clear O O
without O O
any O O
rales B-SSLIF B-SSLIF
or O O
rhonchi B-SSLIF B-SSLIF
. O O
  
CARDIAC O O
: O O
S1 O O
, O O
S2 O O
. O O
  
Regular O O
rate O O
and O O
rhythm O O
. O O
  
Uncertain O O
if O O
question O O
murmur B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Positive O O
bowel O O
sounds O O
throughout O O
. O O
  
Questionable O O
some B-Severity B-Severity
fullness B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
suprapubic I-SSLIF I-SSLIF
area I-SSLIF I-SSLIF
, O O
question O O
ascites B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
distinct O O
lymphadenopathy B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
area I-SSLIF I-SSLIF
bilaterally I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
There O O
is O O
at O O
least O O
4+ O O
pitting B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
pretibial I-SSLIF I-SSLIF
on O O
the O O
left O O
and O O
3+ O O
on O O
the O O
right O O
. O O
  
Circulation O O
is O O
intact O O
. O O
  
Femoral O O
, O O
popliteal O O
and O O
pedal O O
pulses O O
are O O
adequately O O
palpated O O
on O O
both O O
extremities O O
. O O
  
There O O
is O O
no O O
erythema B-SSLIF B-SSLIF
. O O
  
Some B-Severity B-Severity
chronic B-SSLIF B-SSLIF
venous I-SSLIF I-SSLIF
changes I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
. O O
  
No O O
indication O O
of O O
infections B-SSLIF B-SSLIF
or O O
ulcerations B-SSLIF B-SSLIF
. O O
  
Temperature O O
is O O
with O O
warm O O
and O O
normal O O
. O O
  
NEUROLOGIC O O
: O O
Alert O O
and O O
oriented O O
, O O
nonfocal O O
and O O
displays O O
a O O
nonataxic O O
gait O O
. O O
  
ECOG O O
performance O O
status O O
is O O
2 O O
. O O
  
LABORATORY O O
DATA O O
: O O
BUN O O
and O O
creatinine O O
are O O
pending O O
. O O
  
LDH O O
is O O
normal O O
. O O
  
Liver O O
transaminase O O
levels O O
are O O
normal O O
. O O
  
Total O O
protein O O
is O O
4 O O
, O O
albumin O O
is O O
1.9 O O
and O O
calcium O O
is O O
9.9 O O
. O O
  
Platelet O O
count O O
is O O
153 O O
, O O
000 O O
, O O
hemoglobin O O
10.5 O O
, O O
hematocrit O O
  
31% O O
, O O
MCV O O
is O O
102 O O
, O O
WBCs O O
of O O
4 O O
and O O
INR O O
is O O
0.9 O O
. O O
  
ASSESSMENT O O
: O O
Ms O O
. O O
  
Name O O
is O O
a O O
60 O O
- O O
year O O
- O O
old O O
male O O
with O O
: O O
  
1. O O
Follicular B-SSLIF B-SSLIF
B I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
a O O
prior O O
history O O
of O O
mediastinal B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
thoracic I-SSLIF I-SSLIF
involvement I-SSLIF I-SSLIF
, O O
has O O
been O O
on O O
treatment O O
hiatus O O
. O O
  
2. O O
New O O
bilateral B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
3. O O
Stage B-Severity B-Severity
IV I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
4. O O
Hypoalbuminemia B-SSLIF B-SSLIF
. O O
  
PLAN O O
: O O
Mr O O
. O O
  
Name O O
bilateral B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
certainly O O
could O O
be O O
due O O
to O O
his O O
chronic B-SSLIF B-SSLIF
renal I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
and O O
also O O
significant B-Severity B-Severity
hypoalbuminemia B-SSLIF B-SSLIF
related O O
to O O
his O O
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
In O O
order O O
to O O
rule O O
out O O
worsening O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
, O O
he O O
is O O
sent O O
for O O
a O O
CT O O
scan O O
of O O
the O O
chest O O
, O O
abdomen O O
and O O
pelvis O O
without O O
contrast O O
due O O
to O O
his O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
some O O
clinical O O
palpable O O
nodes B-SSLIF B-SSLIF
under I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
axilla I-SSLIF I-SSLIF
, O O
which O O
have O O
been O O
present O O
on O O
prior O O
exams O O
. O O
  
In O O
addition O O
, O O
question O O
whether O O
or O O
not O O
new O O
murmur B-SSLIF B-SSLIF
was O O
auscultated O O
, O O
I O O
will O O
be O O
sending O O
him O O
for O O
an O O
echocardiogram O O
also O O
, O O
to O O
rule O O
out O O
any O O
cardiac O O
cause O O
for O O
the O O
bilateral B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
After O O
Mr O O
. O O
  
Name O O
scans O O
, O O
he O O
will O O
return O O
to O O
see O O
Dr O O
. O O
  
Name O O
Name O O
for O O
discussions O O
of O O
these O O
scans O O
within O O
two O O
weeks O O
. O O
  
He O O
will O O
need O O
to O O
have O O
another O O
followup O O
with O O
his O O
renal O O
physician O O
for O O
further O O
evaluation O O
for O O
worsening O O
of O O
his O O
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
SUPERVISING O O
PHYSICIAN O O
: O O
Name O O
Name O O
, O O
MD O O
. O O
  
ADDENDUM O O
: O O
BUN O O
/ O O
CRT O O
in O O
Company O O
. O O
  
CRT O O
6.74 O O
/ O O
BUN O O
77 O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
NP O O
Date O O
13 O O
: O O
19 O O
  
____________________________ O O
Name O O
Name O O
, O O
NP O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
NP O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
9 O O
: O O
34 O O
A O O
  
7 O O
: O O
41 O O
A O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Follicular B-Indication B-Indication
B I-Indication I-Indication
- I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
with O O
significant B-Severity B-Severity
peripheral B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
mediastinal I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
since O O
Date O O
when O O
he O O
was O O
diagnosed O O
. O O
  
Currently O O
, O O
he O O
has O O
bilateral O O
bulky O O
supraclavicular B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
He O O
has O O
a O O
history O O
of O O
bulky O O
posterior B-SSLIF B-SSLIF
mediastinal I-SSLIF I-SSLIF
nodal I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
involving O O
the O O
epidural O O
space O O
at O O
the O O
level O O
of O O
the O O
mid O O
thoracic O O
spine O O
. O O
  
Most O O
recently O O
, O O
he O O
manifests O O
an O O
SVC B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
like I-SSLIF I-SSLIF
syndrome I-SSLIF I-SSLIF
as O O
a O O
result O O
of O O
extrinsic B-SSLIF B-SSLIF
compression I-SSLIF I-SSLIF
/ O O
thrombosis B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
left I-Indication I-Indication
subclavian I-Indication I-Indication
vein I-Indication I-Indication
. O O
  
He O O
is O O
on O O
warfarin B-Drug B-Drug
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
has O O
received O O
an O O
initial O O
dose O O
of O O
radiation O O
to O O
the O O
left O O
supraclavicular O O
fossa O O
on O O
Date O O
, O O
and O O
will O O
be O O
reevaluated O O
by O O
Dr O O
. O O
  
Name O O
on O O
Date O O
. O O
  
Most O O
recently O O
, O O
he O O
has O O
been O O
treated O O
with O O
3 B-Duration B-Duration
courses I-Duration I-Duration
of O O
CVP B-Drug B-Drug
with O O
little O O
response O O
. O O
  
He O O
has O O
never O O
been O O
exposed O O
to O O
doxorubicin B-Drug B-Drug
. O O
  
OTHER O O
MEDICAL O O
PROBLEMS O O
His O O
dominant O O
medical O O
comorbidity O O
is O O
end B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
and O O
he O O
is O O
on O O
home O O
peritoneal O O
dialysis O O
. O O
  
Etiology O O
of O O
his O O
end B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-ADE B-ADE
disease I-ADE I-ADE
is O O
milk B-ADE B-ADE
- I-ADE I-ADE
alkali I-ADE I-ADE
syndrome I-ADE I-ADE
resulting O O
from O O
compulsive O O
use O O
of O O
calcium B-Drug B-Drug
containing I-Drug I-Drug
antacids I-Drug I-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Mr O O
. O O
  
Name O O
notes O O
a O O
significant O O
decrease O O
in O O
the O O
size O O
of O O
his O O
left B-SSLIF B-SSLIF
supraclavicular I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
since O O
his O O
initial O O
radiation O O
treatment O O
, O O
but O O
also O O
notes O O
persistent O O
swelling B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
and O O
the O O
appearance O O
of O O
more O O
prominent B-Severity B-Severity
superficial B-SSLIF B-SSLIF
veins I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
chest I-SSLIF I-SSLIF
wall I-SSLIF I-SSLIF
. O O
  
Overall O O
, O O
he O O
feels O O
tired B-SSLIF B-SSLIF
. O O
  
He O O
does O O
, O O
however O O
, O O
continue O O
to O O
go O O
about O O
his O O
usual O O
activities O O
, O O
which O O
includes O O
some O O
light O O
jobs O O
around O O
the O O
house O O
, O O
and O O
traveling O O
and O O
socializing O O
. O O
  
He O O
is O O
retired O O
from O O
work O O
. O O
  
He O O
has O O
had O O
no O O
fever B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
no O O
sweats B-SSLIF B-SSLIF
and O O
describes O O
his O O
appetite O O
as O O
stable O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Medical O O
history O O
has O O
changed O O
since O O
his O O
visit O O
here O O
on O O
Date O O
, O O
in O O
that O O
he O O
has O O
undergone O O
fine O O
needle O O
aspiration O O
of O O
a O O
left B-SSLIF B-SSLIF
supraclavicular I-SSLIF I-SSLIF
nodal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
, O O
which O O
was O O
unsuccessful O O
in O O
distinguishing O O
between O O
persistent O O
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
and O O
conversion O O
to O O
high B-Severity B-Severity
- I-Severity I-Severity
grade I-Severity I-Severity
lymphoma B-SSLIF B-SSLIF
. O O
  
It O O
did O O
as O O
expected O O
confirmed O O
that O O
this O O
is O O
a O O
follicular B-SSLIF B-SSLIF
center I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
in O O
family O O
history O O
or O O
social O O
history O O
. O O
  
As O O
noted O O
above O O
, O O
the O O
patient O O
is O O
retired O O
, O O
lives O O
at O O
home O O
with O O
his O O
wife O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Ten O O
- O O
item O O
review O O
of O O
systems O O
is O O
negative O O
in O O
detail O O
except O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
I O O
should O O
add O O
that O O
the O O
patient O O
really O O
describes O O
his O O
overall O O
energy O O
level O O
as O O
"exhausted." B-SSLIF B-SSLIF
MEDICATIONS O O
: O O
List O O
is O O
reconciled O O
in O O
Company O O
. O O
  
No O O
changes O O
made O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
On O O
examination O O
today O O
, O O
weight O O
58.8 O O
kg O O
( O O
130 O O
pounds O O
) O O
, O O
blood O O
pressure O O
147 O O
/ O O
86 O O
, O O
pulse O O
80 O O
and O O
regular O O
, O O
temperature O O
98.1 O O
and O O
O2 O O
saturation O O
98% O O
on O O
room O O
air O O
. O O
  
He O O
has O O
a O O
puffy B-SSLIF B-SSLIF
face I-SSLIF I-SSLIF
, O O
and O O
very B-Severity B-Severity
swollen B-SSLIF B-SSLIF
left I-SSLIF I-SSLIF
arm I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
. O O
  
No O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
Mouth O O
and O O
pharynx O O
are O O
unremarkable O O
without O O
abnormal B-SSLIF B-SSLIF
lymphoid I-SSLIF I-SSLIF
tissue I-SSLIF I-SSLIF
. O O
  
There O O
is O O
persistence O O
of O O
a O O
7 B-Severity B-Severity
x I-Severity I-Severity
4 I-Severity I-Severity
cm I-Severity I-Severity
left B-SSLIF B-SSLIF
supraclavicular I-SSLIF I-SSLIF
nodal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
There O O
is O O
a O O
3 B-Severity B-Severity
x I-Severity I-Severity
4 I-Severity I-Severity
cm I-Severity I-Severity
right B-SSLIF B-SSLIF
supraclavicular I-SSLIF I-SSLIF
nodal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
, O O
which O O
is O O
quite O O
firm O O
and O O
fixed O O
. O O
  
There O O
is O O
a O O
1.5 B-Severity B-Severity
cm I-Severity I-Severity
node B-SSLIF B-SSLIF
just I-SSLIF I-SSLIF
behind I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
pectoralis I-SSLIF I-SSLIF
major I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
axilla I-SSLIF I-SSLIF
and O O
the O O
suggestion O O
of O O
a O O
bulky O O
adenopathy B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
apex I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
axilla I-SSLIF I-SSLIF
. O O
  
No O O
other O O
axillary B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
percussion B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
. O O
  
Lungs O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
. O O
  
No O O
murmur B-SSLIF B-SSLIF
, O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
Abdomen O O
: O O
Soft O O
and O O
nontender B-SSLIF B-SSLIF
, O O
liver O O
not O O
enlarged O O
, O O
spleen O O
not O O
palpable O O
, O O
no O O
other O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
and O O
no O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
The O O
fine O O
needle O O
aspiration O O
was O O
not O O
successful O O
in O O
confirming O O
that O O
the O O
patient O O
has O O
not O O
experienced O O
a O O
conversion O O
from O O
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
to O O
a O O
higher B-Severity B-Severity
grade I-Severity I-Severity
lymphoma B-SSLIF B-SSLIF
and O O
I O O
will O O
arrange O O
for O O
a O O
biopsy O O
. O O
  
The O O
patient O O
was O O
not O O
biopsied O O
in O O
the O O
first O O
place O O
because O O
he O O
has O O
a O O
real O O
fear O O
of O O
lymph O O
node O O
biopsy O O
because O O
of O O
a O O
painful B-SSLIF B-SSLIF
episode I-SSLIF I-SSLIF
early O O
in O O
the O O
course O O
of O O
his O O
illness O O
and O O
he O O
expresses O O
the O O
strong O O
preference O O
to O O
undergo O O
fine O O
needle O O
aspiration O O
. O O
  
He O O
is O O
due O O
to O O
see O O
Dr O O
. O O
  
Name O O
on O O
Date O O
. O O
  
Clinically O O
, O O
it O O
would O O
appear O O
that O O
his O O
shrinkage O O
so O O
far O O
is O O
only O O
modest O O
and O O
I O O
think O O
he O O
will O O
need O O
more O O
radiation O O
to O O
relieve O O
a O O
persistent O O
degree O O
of O O
venous B-SSLIF B-SSLIF
obstruction I-SSLIF I-SSLIF
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
07 O O
: O O
43 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B. O O
Date O O
Consult O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
Date O O
4 O O
: O O
28 O O
P O O
Transcribe O O
Date O O
  
: O O
d O O
: O O
1 O O
: O O
31 O O
A O O
OUTPATIENT O O
CONSULTATION O O
REPORT O O
IDENTIFICATION O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
61 O O
- O O
year O O
- O O
old O O
gentleman O O
seen O O
in O O
reconsultation O O
at O O
the O O
request O O
of O O
Dr O O
. O O
  
Name O O
Name O O
for O O
consideration O O
of O O
radiation O O
therapy O O
to O O
the O O
bilateral O O
low O O
neck O O
, O O
supraclavicular O O
fossa O O
and O O
left O O
axilla O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
well O O
known O O
to O O
this O O
service O O
from O O
previous O O
radiation O O
therapy O O
in O O
Date O O
to O O
3000 O O
cGy O O
in O O
10 O O
fractions O O
to O O
the O O
T1 O O
- O O
T8 O O
spine O O
and O O
paraaortic O O
field O O
in O O
Date O O
for O O
right O O
pelvic O O
and O O
groin O O
radiation O O
for O O
significant B-Severity B-Severity
lymphedema B-SSLIF B-SSLIF
. O O
  
Since O O
then O O
, O O
he O O
has O O
been O O
on O O
multiple O O
chemotherapies B-Drug B-Drug
, O O
most O O
recently O O
a O O
CVP B-Drug B-Drug
, O O
which O O
did O O
demonstrate O O
some O O
response O O
in O O
the O O
mediastinum O O
as O O
an O O
SVC B-Indication B-Indication
syndrome I-Indication I-Indication
has O O
resolved O O
, O O
but O O
the O O
supraclavicular B-Indication B-Indication
masses I-Indication I-Indication
have O O
not O O
responded O O
at O O
all O O
. O O
  
Since O O
I O O
last O O
saw O O
him O O
, O O
he O O
has O O
developed O O
end B-Severity B-Severity
- I-Severity I-Severity
stage I-Severity I-Severity
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
and O O
is O O
on O O
home O O
peritoneal O O
dialysis O O
. O O
  
Dr O O
. O O
  
Name O O
is O O
also O O
wondering O O
again O O
whether O O
the O O
patient's O O
tumor B-SSLIF B-SSLIF
has O O
converted O O
from O O
follicular O O
to O O
more O O
aggressive O O
histology O O
. O O
  
His O O
primary O O
complaints O O
at O O
this O O
time O O
are O O
the O O
neck B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
which O O
are O O
really O O
interfering O O
with O O
his O O
quality O O
of O O
life O O
and O O
the O O
swelling B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
arm I-SSLIF I-SSLIF
, O O
which O O
seems O O
to O O
be O O
getting O O
worse O O
. O O
  
He O O
has O O
had O O
no O O
fevers B-SSLIF B-SSLIF
, O O
sweats B-SSLIF B-SSLIF
, O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
no O O
nausea B-SSLIF B-SSLIF
or O O
headache B-SSLIF B-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Unchanged O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
is O O
retired O O
now O O
and O O
is O O
happy O O
about O O
that O O
no O O
changes O O
in O O
family O O
situation O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Otherwise O O
negative O O
. O O
  
All O O
other O O
systems O O
are O O
negative O O
. O O
  
MEDICATIONS O O
: O O
Reviewed O O
from O O
the O O
Company O O
list O O
. O O
  
The O O
only O O
change O O
is O O
that O O
he O O
is O O
not O O
taking O O
ondansetron B-Drug B-Drug
at O O
the O O
moment O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Today O O
, O O
GENERAL O O
: O O
He O O
is O O
alert O O
, O O
oriented O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
He O O
weighs O O
56.4 O O
kilograms O O
. O O
  
His O O
temperature O O
is O O
36.9 O O
degrees O O
, O O
his O O
seated O O
blood O O
pressure O O
is O O
135 O O
/ O O
79 O O
, O O
pulse O O
80 O O
and O O
respirations O O
16 O O
. O O
  
Pulse O O
oximetry O O
is O O
98% O O
on O O
room O O
air O O
. O O
  
HEENT O O
: O O
He O O
is O O
normocephalic O O
, O O
but O O
has O O
significant B-Severity B-Severity
rounded B-SSLIF B-SSLIF
face I-SSLIF I-SSLIF
. O O
  
He O O
is O O
alert O O
, O O
oriented O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
His O O
hearing O O
is O O
intact O O
to O O
normal O O
speech O O
. O O
  
Vision O O
seems O O
to O O
be O O
intact O O
. O O
  
Oral O O
mucosa O O
is O O
moist O O
. O O
  
Tongue O O
protrudes O O
midline O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
He O O
has O O
good O O
range O O
of O O
motion O O
. O O
  
There O O
is O O
a O O
mass B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
neck I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
fossa I-SSLIF I-SSLIF
, O O
which O O
extends O O
all O O
the O O
way O O
posteriorly O O
to O O
the O O
back O O
of O O
the O O
neck O O
. O O
  
It O O
is O O
at O O
least O O
10 B-Severity B-Severity
x I-Severity I-Severity
4 I-Severity I-Severity
cm I-Severity I-Severity
in O O
greatest O O
dimension O O
, O O
extends O O
into O O
the O O
supraclavicular O O
fossa O O
. O O
  
Theone O O
on O O
the O O
right O O
is O O
somewhat O O
smaller O O
and O O
does O O
not O O
appear O O
to O O
be O O
extending O O
over O O
his O O
lower O O
back O O
. O O
  
There O O
is O O
left B-SSLIF B-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
, O O
which O O
is O O
somewhat B-Severity B-Severity
smaller I-Severity I-Severity
, O O
but O O
actually O O
the O O
top O O
of O O
this O O
seems O O
to O O
be O O
contiguous O O
with O O
supraclavicular B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
The O O
right O O
axilla O O
is O O
unremarkable O O
. O O
  
There O O
is O O
no O O
spinal O O
costovertebral B-SSLIF B-SSLIF
angle I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
sacroiliac I-SSLIF I-SSLIF
joint I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Actually O O
clear O O
to O O
auscultation O O
and O O
percussion O O
. O O
  
HEART O O
: O O
Heart O O
sounds O O
normal O O
S1 O O
, O O
S2 O O
, O O
with O O
regular O O
rate O O
rhythm O O
without O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
No O O
carotid B-SSLIF B-SSLIF
bruits I-SSLIF I-SSLIF
appreciated O O
. O O
  
ABDOMEN O O
: O O
Bowel O O
sounds O O
present O O
. O O
  
There O O
is O O
no O O
abdominal B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
NEUROLOGIC O O
: O O
His O O
gait O O
is O O
normal O O
. O O
  
Neurologically O O
, O O
his O O
extremity O O
examination O O
is O O
dominated O O
by O O
3 O O
- O O
4+ O O
pitting B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
forearm I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
elbow I-SSLIF I-SSLIF
. O O
  
Interestingly O O
, O O
the O O
hand O O
is O O
not O O
swollen B-SSLIF B-SSLIF
. O O
  
IMPRESSION O O
: O O
Mr O O
. O O
  
Name O O
has O O
progressive O O
lymphadenopathy B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
fossa I-SSLIF I-SSLIF
, O O
which O O
is O O
very O O
symptomatic O O
. O O
  
Low B-Severity B-Severity
grade I-Severity I-Severity
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
may O O
well O O
respond O O
to O O
very O O
low O O
- O O
dose O O
radiation O O
therapy O O
. O O
  
I O O
have O O
discussed O O
his O O
situation O O
with O O
Dr O O
. O O
  
Name O O
. O O
  
We O O
are O O
both O O
aware O O
that O O
if O O
radiation O O
was O O
delivered O O
before O O
the O O
biopsy O O
, O O
it O O
may O O
destroy O O
any O O
possibility O O
of O O
making O O
a O O
diagnosis O O
at O O
this O O
time O O
and O O
therefore O O
we O O
will O O
arrange O O
for O O
fine O O
needle O O
aspiration O O
soon O O
. O O
  
The O O
cytologist O O
feels O O
this O O
will O O
give O O
him O O
the O O
answer O O
prior O O
to O O
starting O O
radiation O O
therapy O O
. O O
  
However O O
, O O
it O O
is O O
reasonable O O
to O O
simulate O O
the O O
field O O
prior O O
to O O
this O O
procedure O O
. O O
  
I O O
reviewed O O
the O O
rationale O O
for O O
, O O
acute O O
side O O
effects O O
and O O
long O O
- O O
term O O
risks O O
of O O
this O O
radiation O O
with O O
the O O
patient O O
. O O
  
I O O
explained O O
that O O
we O O
would O O
attempt O O
initially O O
given O O
low O O
- O O
dose O O
radiation O O
therapy O O
with O O
single O O
fraction O O
. O O
  
If O O
this O O
fails O O
to O O
control O O
to O O
shrink O O
his O O
disease O O
dramatically O O
, O O
we O O
can O O
give O O
him O O
a O O
course O O
of O O
traditional O O
radiation O O
therapy O O
a O O
week O O
or O O
two O O
later O O
. O O
  
He O O
appeared O O
to O O
understand O O
and O O
requested O O
treatment O O
as O O
soon O O
as O O
possible O O
. O O
  
He O O
was O O
sent O O
over O O
to O O
the O O
CT O O
simulator O O
for O O
a O O
simulation O O
and O O
then O O
asked O O
to O O
go O O
to O O
Dr O O
. O O
  
Name O O
office O O
for O O
aspiration O O
biopsy O O
this O O
afternoon O O
. O O
  
We O O
will O O
treat O O
him O O
next O O
week O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
15 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B. O O
Date O O
Consult O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
Date O O
5 O O
: O O
52 O O
P O O
Transcribe O O
Date O O
  
: O O
d O O
: O O
8 O O
: O O
03 O O
P O O
OUTPATIENT O O
CONSULTATION O O
REPORT O O
DATE O O
OF O O
BIRTH O O
: O O
Date O O
IDENTIFICATION O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
58 O O
- O O
year O O
- O O
old O O
gentleman O O
seen O O
in O O
reconsultation O O
at O O
request O O
of O O
Dr O O
. O O
  
Name O O
for O O
consideration O O
of O O
palliative O O
radiation O O
therapy O O
to O O
his O O
thoracic O O
spine O O
for O O
his O O
now O O
extensive B-Severity B-Severity
metastatic B-SSLIF B-SSLIF
follicular I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
which O O
appears O O
to O O
be O O
undergoing O O
a O O
Richter's B-SSLIF B-SSLIF
transformation I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
well O O
known O O
to O O
this O O
service O O
from O O
previous O O
radiation O O
therapy O O
to O O
the O O
right O O
pelvis O O
and O O
groin O O
for O O
stage B-Severity B-Severity
III I-Severity I-Severity
follicular B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
significant B-Severity B-Severity
lymphedema B-SSLIF B-SSLIF
in O O
Date O O
and O O
early O O
Date O O
. O O
  
He O O
had O O
excellent O O
complete O O
response O O
to O O
2400 O O
cGy O O
in O O
12 O O
fractions O O
. O O
  
However O O
, O O
he O O
had O O
problems O O
with O O
counts O O
before O O
the O O
treatment O O
was O O
interrupted O O
early O O
. O O
  
His O O
diagnosis O O
originally O O
was O O
made O O
in O O
Date O O
. O O
  
Recently O O
he O O
has O O
been O O
on O O
doxorubicin B-Drug B-Drug
weekly B-Frequency B-Frequency
or O O
every B-Frequency B-Frequency
other I-Frequency I-Frequency
week I-Frequency I-Frequency
, O O
depending O O
on O O
blood O O
counts O O
, O O
with O O
pamidronate B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
to O O
control B-Indication B-Indication
calcium I-Indication I-Indication
. O O
  
Today O O
, O O
he O O
has O O
received O O
10 B-Dose B-Dose
doses I-Dose I-Dose
of O O
doxorubicin B-Drug B-Drug
since O O
Date O O
but O O
he O O
came O O
in O O
Date O O
complaining O O
of O O
new O O
progressive B-SSLIF B-SSLIF
interscapular I-SSLIF I-SSLIF
thoracic I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
, O O
without O O
any O O
associated O O
neurologic B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
sweats B-SSLIF B-SSLIF
or O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
CT O O
scan O O
of O O
the O O
chest O O
demonstrated O O
increased O O
lymphadenopathy B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
axilla I-SSLIF I-SSLIF
and O O
a O O
left B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
paratracheal I-SSLIF I-SSLIF
nodal I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
but O O
in O O
addition O O
, O O
at O O
the O O
left O O
side O O
of O O
the O O
upper O O
thoracic O O
region O O
, O O
a O O
paraspinous B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
is O O
enlarged O O
. O O
  
The O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
was O O
felt O O
to O O
be O O
due O O
to O O
the O O
paraspinous B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
and O O
magnetic O O
resonance O O
imaging O O
was O O
obtained O O
Date O O
. O O
  
I O O
have O O
reviewed O O
these O O
images O O
personally O O
. O O
  
Post O O
- O O
contrast O O
images O O
demonstrate O O
diffuse O O
marked O O
enhancement O O
of O O
an O O
abnormal B-SSLIF B-SSLIF
epidural I-SSLIF I-SSLIF
soft I-SSLIF I-SSLIF
tissue I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
and O O
extending O O
from O O
T3 O O
to O O
T7 O O
, O O
which O O
enters O O
through O O
the O O
neural O O
foramen O O
, O O
T3 O O
, O O
T4 O O
and O O
T5 O O
. O O
  
A O O
broad O O
abnormal B-SSLIF B-SSLIF
left I-SSLIF I-SSLIF
subpleural I-SSLIF I-SSLIF
mass I-SSLIF I-SSLIF
is O O
noted O O
in O O
the O O
paravertebral O O
soft O O
tissues O O
extending O O
into O O
the O O
spinal O O
canal O O
. O O
  
In O O
addition O O
, O O
the O O
bone O O
marrow O O
of O O
T4 O O
, O O
T5 O O
and O O
T6 O O
are O O
mildly O O
enhancing O O
. O O
  
There O O
is O O
compromising O O
spinal O O
canal O O
with O O
some O O
slight O O
impression O O
on O O
the O O
spinal O O
cord O O
without O O
severe B-Severity B-Severity
spinal B-SSLIF B-SSLIF
cord I-SSLIF I-SSLIF
compression I-SSLIF I-SSLIF
. O O
  
Based O O
on O O
this O O
, O O
Dr O O
. O O
  
Name O O
asked O O
me O O
to O O
see O O
the O O
patient O O
today O O
urgently O O
. O O
  
He O O
was O O
in O O
being O O
treated O O
with O O
magnesium B-Drug B-Drug
for O O
his O O
hypercalcemia B-Indication B-Indication
today O O
. O O
  
His O O
interval O O
medical O O
history O O
is O O
not O O
significantly O O
changed O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Unchanged O O
. O O
  
He O O
is O O
still O O
managing O O
a O O
manufacturing O O
company O O
as O O
he O O
lives O O
at O O
home O O
with O O
his O O
wife O O
and O O
child O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Remarkable O O
for O O
the O O
aforementioned O O
severe B-Severity B-Severity
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
which O O
she O O
states O O
is O O
, O O
without O O
pain O O
medicine O O
, O O
10 B-Severity B-Severity
on I-Severity I-Severity
a I-Severity I-Severity
scale I-Severity I-Severity
of I-Severity I-Severity
1 I-Severity I-Severity
- I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
At O O
the O O
moment O O
, O O
it O O
is O O
down O O
to O O
8 O O
. O O
  
All O O
other O O
systems O O
are O O
all O O
negative O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
He O O
is O O
alert O O
, O O
oriented O O
and O O
not O O
in O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
His O O
temperature O O
is O O
36.8 O O
, O O
seated O O
blood O O
pressure O O
84 O O
/ O O
42 O O
, O O
pulse O O
80 O O
, O O
respirations O O
16 O O
. O O
  
He O O
is O O
normocephalic O O
. O O
  
Hearing O O
is O O
intact O O
to O O
finger O O
rub O O
. O O
  
Vision O O
is O O
intact O O
to O O
finger O O
count O O
. O O
  
Extraocular O O
motions O O
intact O O
. O O
  
Pupils O O
equal O O
, O O
round O O
, O O
react O O
to O O
light O O
and O O
accommodate O O
. O O
  
No O O
arcus B-SSLIF B-SSLIF
cornealis I-SSLIF I-SSLIF
, O O
no O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Oral O O
mucosa O O
is O O
moist O O
. O O
  
Tongue O O
protrudes O O
midline O O
, O O
no O O
lesions B-SSLIF B-SSLIF
visible I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
mouth I-SSLIF I-SSLIF
. O O
  
Neck O O
is O O
supple O O
. O O
  
I O O
appreciate O O
no O O
palpable O O
cervical B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
circular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Spine O O
, O O
costovertebral O O
angles O O
and O O
SI O O
joints O O
are O O
entirely O O
nontender B-SSLIF B-SSLIF
to O O
percussion O O
. O O
  
Lungs O O
: O O
Clear O O
to O O
auscultation O O
and O O
percussion O O
. O O
  
Heart O O
sounds O O
: O O
regular O O
rate O O
and O O
rhythm O O
. O O
  
No O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
No O O
carotid B-SSLIF B-SSLIF
bruits I-SSLIF I-SSLIF
appreciated O O
. O O
  
Bowel O O
sounds O O
present O O
. O O
  
There O O
is O O
no O O
abdominal B-SSLIF B-SSLIF
tenderness I-SSLIF I-SSLIF
or O O
organomegaly B-SSLIF B-SSLIF
and O O
no O O
adenopathy B-SSLIF B-SSLIF
is O O
noted O O
. O O
  
Femoral O O
pulses O O
are O O
strong O O
. O O
  
Extremities O O
are O O
without O O
cyanosis B-SSLIF B-SSLIF
, O O
clubbing B-SSLIF B-SSLIF
, O O
or O O
edema B-SSLIF B-SSLIF
. O O
  
Calves O O
nontender O O
. O O
  
Dorsalis O O
pedis O O
and O O
posterior O O
tibial O O
pulses O O
are O O
palpable O O
. O O
  
Neurologically O O
, O O
gait O O
is O O
normal O O
. O O
  
Motor O O
strength O O
and O O
light O O
touch O O
intact O O
throughout O O
. O O
  
Deep B-SSLIF B-SSLIF
tendon I-SSLIF I-SSLIF
reflexes I-SSLIF I-SSLIF
essentially O O
absent O O
throughout O O
. O O
  
He O O
has O O
about O O
six O O
beats O O
of O O
clonus B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
, O O
none O O
on O O
the O O
right O O
, O O
toes O O
downgoing O O
bilaterally O O
. O O
  
His O O
laboratory O O
results O O
of O O
today O O
demonstrate O O
this O O
white O O
count O O
as O O
21.3 O O
, O O
his O O
hemoglobin O O
12.0 O O
, O O
hematocrit O O
35.0 O O
, O O
platelets O O
193 O O
, O O
000 O O
. O O
  
Radiographs O O
are O O
as O O
above O O
. O O
  
IMPRESSION O O
: O O
This O O
patient O O
has O O
clear O O
- O O
cut O O
evidence O O
of O O
malignant B-SSLIF B-SSLIF
involvement I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
spinal I-SSLIF I-SSLIF
canal I-SSLIF I-SSLIF
which O O
needs O O
reasonably O O
urgent O O
treatment O O
. O O
  
Dr O O
. O O
  
Name O O
and O O
I O O
have O O
discussed O O
with O O
the O O
patient O O
in O O
detail O O
. O O
  
He O O
is O O
hoping O O
to O O
obtain O O
a O O
biopsy O O
tomorrow O O
at O O
some O O
point O O
but O O
treatment O O
needs O O
to O O
start O O
. O O
  
I O O
reviewed O O
the O O
rationale O O
for O O
acute O O
side B-SSLIF B-SSLIF
effects I-SSLIF I-SSLIF
and O O
long B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
term I-SSLIF I-SSLIF
risks I-SSLIF I-SSLIF
of O O
this O O
treatment O O
with O O
the O O
patient O O
. O O
  
He O O
appeared O O
to O O
understand O O
and O O
requested O O
treatment O O
. O O
  
I O O
booked O O
him O O
for O O
simulation O O
first O O
thing O O
tomorrow O O
so O O
we O O
can O O
start O O
treatment O O
at O O
the O O
end O O
of O O
the O O
day O O
tomorrow O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Date O O
08 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Recorded O O
as O O
Task O O
Date O O
: O O
Date O O
03 O O
: O O
26 O O
PM O O
, O O
Created O O
By O O
: O O
Name O O
, O O
Name O O
Task O O
Name O O
: O O
FYI O O
Assigned O O
To O O
: O O
Name O O
, O O
Name O O
Regarding O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
, O O
Status O O
: O O
Active O O
Comment O O
: O O
  
Name O O
, O O
Name O O
- O O
Date O O
3 O O
: O O
26 O O
PM O O
TASK O O
CREATED O O
Caller O O
: O O
Self O O
; O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Home O O
) O O
; O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Work O O
) O O
MESSAGE O O
FOR O O
DR O O
Name O O
FOR O O
THURSDAY O O
- O O
PT O O
IS O O
CALLING O O
TO O O
LEAVE O O
YOU O O
THE O O
PHONE O O
# O O
OF O O
Company O O
- O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
THAT O O
YOU O O
NEED O O
TO O O
CALL O O
TO O O
SEE O O
IF O O
THEY O O
WILL O O
COVER O O
HIS O O
VISITS O O
FOR O O
ACUPUNCTURE O O
Name O O
RN O O
, O O
Name O O
- O O
Date O O
3 O O
: O O
44 O O
PM O O
TASK O O
EDITED O O
DIDN'T O O
KNOW O O
IF O O
THIS O O
GOES O O
TO O O
YOU O O
OR O O
Name O O
. O O
  
Pt O O
aware O O
that O O
I O O
have O O
called O O
the O O
number O O
multiple O O
times O O
and O O
havenot O O
been O O
able O O
to O O
reach O O
a O O
person O O
. O O
  
He O O
would O O
like O O
to O O
have O O
acupuncture O O
visits O O
for O O
his O O
psoriasis B-SSLIF B-SSLIF
and O O
chemo B-Drug B-Drug
detox O O
covered O O
. O O
  
They O O
were O O
done O O
in O O
State O O
/ O O
Zipcode O O
over O O
three O O
weeks O O
. O O
  
I O O
have O O
left O O
a O O
message O O
for O O
him O O
to O O
leave O O
me O O
his O O
insurance O O
ID O O
number O O
and O O
claim O O
number O O
as O O
I O O
need O O
those O O
to O O
go O O
throught O O
the O O
prompt O O
system O O
to O O
reach O O
a O O
live O O
person O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
Date O O
9 O O
: O O
44AM O O
EST O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Electronic_Identifiers O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
5 O O
: O O
33 O O
P O O
  
3 O O
: O O
07 O O
P O O
CLINIC O O
NOTE O O
CHIEF O O
COMPLAINT O O
: O O
Weight O O
check O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
a O O
generally O O
healthy O O
12 O O
- O O
year O O
- O O
old O O
female O O
who O O
presents O O
today O O
for O O
follow O O
- O O
up O O
of O O
disordered B-SSLIF B-SSLIF
eating I-SSLIF I-SSLIF
. O O
  
Name O O
initially O O
presented O O
with O O
this O O
issue O O
in O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
she O O
had O O
had O O
5 B-Severity B-Severity
kg I-Severity I-Severity
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
in O O
a O O
month's O O
time O O
due O O
to O O
caloric B-SSLIF B-SSLIF
restriction I-SSLIF I-SSLIF
. O O
  
Name O O
admitted O O
to O O
body B-SSLIF B-SSLIF
image I-SSLIF I-SSLIF
distortion I-SSLIF I-SSLIF
but O O
denied O O
any O O
purging B-SSLIF B-SSLIF
behaviors I-SSLIF I-SSLIF
. O O
  
Her O O
electrolytes O O
and O O
vital O O
signs O O
were O O
within O O
normal O O
limits O O
at O O
that O O
time O O
. O O
  
Name O O
was O O
counseled O O
extensively O O
on O O
the O O
negative O O
health O O
implications O O
of O O
severe B-Severity B-Severity
caloric B-SSLIF B-SSLIF
restriction I-SSLIF I-SSLIF
and O O
she O O
was O O
then O O
seen O O
a O O
week O O
later O O
. O O
  
Name O O
had O O
already O O
started O O
to O O
make O O
improvements O O
in O O
terms O O
of O O
her O O
nutritional O O
habits O O
. O O
  
She O O
was O O
referred O O
for O O
evaluation O O
with O O
Name O O
Name O O
in O O
Nutrition O O
, O O
but O O
unfortunately O O
had O O
to O O
cancel O O
several O O
appointments O O
with O O
Name O O
and O O
has O O
never O O
seen O O
her O O
. O O
  
Since O O
I O O
last O O
saw O O
Name O O
, O O
she O O
reports O O
doing O O
extremely O O
well O O
in O O
terms O O
of O O
her O O
nutritional O O
habits O O
. O O
  
When O O
she O O
was O O
last O O
seen O O
in O O
Date O O
, O O
her O O
weight O O
was O O
44 O O
kg O O
and O O
her O O
BMI O O
was O O
17.6 O O
. O O
  
At O O
today's O O
visit O O
, O O
her O O
weight O O
is O O
45.8 O O
kg O O
and O O
her O O
BMI O O
is O O
increased O O
to O O
18 O O
. O O
  
This O O
places O O
her O O
BMI O O
close O O
to O O
the O O
50th O O
percentile O O
for O O
her O O
age O O
. O O
  
In O O
private O O
conversation O O
, O O
Name O O
reports O O
being O O
much O O
less O O
concerned B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
body I-SSLIF I-SSLIF
image I-SSLIF I-SSLIF
, O O
although O O
she O O
does O O
tend O O
to O O
worry O O
sometimes O O
about O O
the O O
appearance O O
of O O
her O O
stomach O O
. O O
  
She O O
denies O O
that O O
these O O
concerns O O
about O O
her O O
body O O
ever O O
lead O O
her O O
to O O
restrict B-SSLIF B-SSLIF
calories I-SSLIF I-SSLIF
or O O
to O O
refrain O O
from O O
behaviors O O
such O O
as O O
wearing O O
a O O
bathing O O
suit O O
. O O
  
She O O
regularly O O
has O O
been O O
eating O O
three O O
meals O O
per O O
day O O
along O O
with O O
several O O
snacks O O
. O O
  
For O O
breakfast O O
, O O
she O O
typically O O
has O O
cereal O O
and O O
juice O O
. O O
  
For O O
lunch O O
, O O
she O O
has O O
a O O
peanut O O
butter O O
and O O
jelly O O
sandwich O O
. O O
  
Her O O
mother O O
cooks O O
dinner O O
which O O
typically O O
consist O O
of O O
a O O
chicken O O
dish O O
and O O
salad O O
. O O
  
Name O O
will O O
also O O
have O O
a O O
couple O O
of O O
snacks O O
throughout O O
the O O
day O O
, O O
such O O
as O O
goldfish O O
, O O
granola O O
bars O O
or O O
yogurt O O
with O O
granola O O
. O O
  
She O O
drinks O O
water O O
throughout O O
the O O
day O O
and O O
admittedly O O
does O O
not O O
drink O O
any O O
milk O O
. O O
  
As O O
stated O O
, O O
she O O
is O O
no O O
longer O O
counting B-SSLIF B-SSLIF
any I-SSLIF I-SSLIF
calories I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
self B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
induced I-SSLIF I-SSLIF
vomiting I-SSLIF I-SSLIF
. O O
  
Regarding O O
her O O
mood O O
, O O
she O O
states O O
that O O
her O O
mood O O
is O O
"normal." O O
She O O
denies O O
any O O
depression B-SSLIF B-SSLIF
or O O
suicidality B-SSLIF B-SSLIF
. O O
  
Name O O
was O O
also O O
recently O O
evaluated O O
by O O
my O O
colleague O O
, O O
Dr O O
. O O
  
Name O O
several O O
weeks O O
ago O O
for O O
a O O
pruritic B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
Prior O O
to O O
be O O
seen O O
by O O
Dr O O
. O O
  
Name O O
, O O
she O O
was O O
seen O O
and O O
Name O O
clinic O O
and O O
was O O
prescribed O O
prednisone B-Drug B-Drug
for O O
a O O
presumed O O
diagnosis O O
of O O
poison B-Indication B-Indication
ivy I-Indication I-Indication
. O O
  
When O O
Dr O O
. O O
  
Name O O
evaluated O O
Name O O
rash B-SSLIF B-SSLIF
, O O
she O O
noted O O
closed O O
small B-Severity B-Severity
areas B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
purpura I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
clusters I-SSLIF I-SSLIF
. O O
  
Name O O
was O O
instructed O O
to O O
finish O O
her O O
prednisone B-Drug B-Drug
course O O
and O O
to O O
followup O O
. O O
  
Blood O O
work O O
was O O
obtained O O
at O O
that O O
visit O O
on O O
Date O O
and O O
showed O O
a O O
white O O
blood O O
cell O O
count O O
of O O
9.5 O O
, O O
hemoglobin O O
of O O
12.4 O O
, O O
hematocrit B-SSLIF B-SSLIF
slightly I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
at O O
35.3 O O
and O O
platelet O O
count O O
of O O
266 O O
, O O
000 O O
. O O
  
Name O O
reports O O
that O O
overall O O
her O O
rash B-SSLIF B-SSLIF
has O O
improved O O
. O O
  
She O O
continues O O
to O O
have O O
several O O
erythematous B-SSLIF B-SSLIF
bumpy I-SSLIF I-SSLIF
patches I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
thigh I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
thigh I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
around I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
knee I-SSLIF I-SSLIF
. O O
  
She O O
said O O
that O O
these O O
areas O O
are O O
mostly O O
fading O O
and O O
she O O
denies O O
any O O
new O O
lesions B-SSLIF B-SSLIF
. O O
  
These O O
lesions B-SSLIF B-SSLIF
are O O
no O O
longer O O
itchy B-SSLIF B-SSLIF
and O O
do O O
not O O
cause O O
her O O
any O O
pain B-SSLIF B-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
No O O
dizziness B-SSLIF B-SSLIF
. O O
  
No O O
fainting B-SSLIF B-SSLIF
. O O
  
No O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
No O O
palpitations B-SSLIF B-SSLIF
, O O
no O O
diarrhea B-SSLIF B-SSLIF
, O O
no O O
constipation B-SSLIF B-SSLIF
. O O
  
Name O O
is O O
having O O
regular O O
monthly O O
menses O O
. O O
  
No O O
depression B-SSLIF B-SSLIF
and O O
no O O
suicidality B-SSLIF B-SSLIF
. O O
  
Review O O
of O O
systems O O
is O O
positive O O
for O O
recent O O
dermatologic B-SSLIF B-SSLIF
issues I-SSLIF I-SSLIF
as O O
per O O
HPI O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
  
1. O O
Separation B-SSLIF B-SSLIF
anxiety I-SSLIF I-SSLIF
/ O O
school B-SSLIF B-SSLIF
anxiety I-SSLIF I-SSLIF
as O O
a O O
younger O O
child O O
. O O
  
Name O O
saw O O
Dr O O
. O O
  
Name O O
in O O
Hospital O O
for O O
this O O
issue O O
in O O
Date O O
. O O
  
2. O O
Lymphadenitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
neck I-SSLIF I-SSLIF
in O O
Date O O
  
3. O O
Disordered B-SSLIF B-SSLIF
eating I-SSLIF I-SSLIF
as O O
per O O
HPI O O
. O O
  
MEDICATIONS O O
: O O
None O O
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Amoxicillin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
There O O
is O O
a O O
family O O
history O O
of O O
hypertension B-SSLIF B-SSLIF
, O O
hypercholesterolemia B-SSLIF B-SSLIF
in O O
maternal O O
grandparents O O
. O O
  
There O O
is O O
also O O
a O O
history O O
of O O
type B-SSLIF B-SSLIF
2 I-SSLIF I-SSLIF
diabetes I-SSLIF I-SSLIF
in O O
maternal O O
grandfather O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Name O O
lives O O
with O O
her O O
mother O O
, O O
father O O
and O O
younger O O
brother O O
. O O
  
She O O
just O O
completed O O
her O O
sixth O O
grade O O
year O O
Name O O
Middle O O
School O O
and O O
is O O
a O O
very O O
good O O
student O O
. O O
  
She O O
is O O
planning O O
on O O
participating O O
in O O
cheerleading O O
over O O
the O O
summer O O
, O O
but O O
is O O
not O O
currently O O
participating O O
in O O
any O O
regular O O
exercise O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Height O O
159 O O
cm O O
, O O
weight O O
45.8 O O
kg O O
, O O
BMI O O
is O O
18.1 O O
, O O
blood O O
pressure O O
100 O O
/ O O
68 O O
and O O
heart O O
rate O O
94 O O
. O O
  
General O O
: O O
Well O O
- O O
appearing O O
Caucasian O O
female O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
Skin O O
: O O
Multiple O O
clusters O O
of O O
dry O O
erythematous B-SSLIF B-SSLIF
rough I-SSLIF I-SSLIF
patches I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
. O O
  
These O O
lesions B-SSLIF B-SSLIF
do O O
blanch O O
. O O
  
There O O
is O O
no O O
weeping B-SSLIF B-SSLIF
or O O
crusting B-SSLIF B-SSLIF
. O O
  
These O O
lesions B-SSLIF B-SSLIF
are I-SSLIF I-SSLIF
located I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
clusters I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
thigh I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
outer I-SSLIF I-SSLIF
thigh I-SSLIF I-SSLIF
. O O
  
Around O O
the O O
knee O O
area O O
, O O
there O O
are O O
scattered B-SSLIF B-SSLIF
pinpoint I-SSLIF I-SSLIF
erythematous I-SSLIF I-SSLIF
papules I-SSLIF I-SSLIF
. O O
  
As O O
stated O O
all O O
lesions B-SSLIF B-SSLIF
blanch O O
to O O
the O O
touch O O
. O O
  
HEENT O O
: O O
Normocephalic O O
and O O
atraumatic B-SSLIF B-SSLIF
. O O
  
Mucous O O
membranes O O
moist O O
. O O
  
No O O
oral B-SSLIF B-SSLIF
lesions I-SSLIF I-SSLIF
. O O
  
Sclerae B-SSLIF B-SSLIF
are I-SSLIF I-SSLIF
noninjected I-SSLIF I-SSLIF
and O O
nonicteric B-SSLIF B-SSLIF
. O O
  
Neck O O
: O O
Supple O O
, O O
with O O
no O O
lymphadenopathy B-SSLIF B-SSLIF
and O O
no O O
thyromegaly B-SSLIF B-SSLIF
. O O
  
Cardiovascular O O
: O O
Regular O O
rate O O
and O O
rhythm O O
with O O
no O O
murmurs B-SSLIF B-SSLIF
, O O
rubs B-SSLIF B-SSLIF
or O O
gallops B-SSLIF B-SSLIF
. O O
  
Pulmonary O O
: O O
No O O
grunting B-SSLIF B-SSLIF
, O O
flaring B-SSLIF B-SSLIF
or O O
retractions B-SSLIF B-SSLIF
. O O
  
Lungs O O
are O O
clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
nondistended B-SSLIF B-SSLIF
with O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
and O O
no O O
masses B-SSLIF B-SSLIF
. O O
  
Mental O O
status O O
: O O
Name O O
made O O
appropriate O O
eye O O
contact O O
and O O
affect O O
was O O
appropriate O O
to O O
conversation O O
. O O
  
She O O
denied O O
any O O
depression B-SSLIF B-SSLIF
or O O
suicidality B-SSLIF B-SSLIF
. O O
  
IMPRESSION O O
AND O O
PLAN O O
: O O
Name O O
is O O
a O O
12 O O
- O O
year O O
- O O
old O O
female O O
who O O
is O O
generally O O
healthy O O
, O O
who O O
presents O O
today O O
with O O
the O O
following O O
issues O O
: O O
  
1. O O
Follow O O
- O O
up O O
disordered B-SSLIF B-SSLIF
eating I-SSLIF I-SSLIF
patterns I-SSLIF I-SSLIF
: O O
Name O O
has O O
made O O
excellent O O
progress O O
in O O
terms O O
of O O
improving O O
her O O
nutritional O O
habits O O
and O O
maintaining O O
a O O
healthy O O
weight O O
. O O
  
She O O
has O O
responded O O
very O O
well O O
to O O
motivational O O
counseling O O
. O O
  
She O O
currently O O
denies O O
any O O
body B-SSLIF B-SSLIF
image I-SSLIF I-SSLIF
distortion I-SSLIF I-SSLIF
and O O
says O O
that O O
her O O
preoccupation B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
body I-SSLIF I-SSLIF
has O O
decreased O O
significantly O O
. O O
  
I O O
explained O O
to O O
Name O O
and O O
her O O
mother O O
that O O
monitoring O O
her O O
nutritional O O
habits O O
in O O
relationship O O
to O O
her O O
body O O
image O O
is O O
something O O
that O O
will O O
have O O
to O O
be O O
ongoing O O
. O O
  
It O O
is O O
clear O O
that O O
Name O O
is O O
sensitive O O
to O O
issues O O
related O O
to O O
body O O
image O O
and O O
as O O
she O O
progresses O O
through O O
her O O
teenage O O
years O O
, O O
patterns O O
of O O
disordered B-SSLIF B-SSLIF
eating I-SSLIF I-SSLIF
will O O
have O O
to O O
be O O
closely O O
monitored O O
for O O
. O O
  
However O O
, O O
at O O
the O O
current O O
time O O
, O O
she O O
has O O
normal O O
vital O O
signs O O
, O O
improved O O
weight O O
, O O
and O O
adequate O O
caloric O O
intake O O
. O O
  
Name O O
is O O
very O O
much O O
uninterested O O
in O O
seeing O O
a O O
nutritionist O O
at O O
this O O
point O O
. O O
  
Given O O
her O O
progress O O
, O O
I O O
do O O
not O O
think O O
it O O
is O O
necessary O O
to O O
push O O
the O O
issue O O
currently O O
. O O
  
We O O
did O O
discuss O O
that O O
she O O
has O O
inadequate O O
dietary O O
intake O O
of O O
calcium O O
and O O
vitamin O O
D O O
and O O
she O O
will O O
begin O O
Viactiv B-Drug B-Drug
2 B-Dose B-Dose
chews I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
She O O
will O O
follow O O
up O O
with O O
me O O
in O O
several O O
months O O
for O O
her O O
routine O O
physical O O
and O O
we O O
will O O
check O O
in O O
on O O
her O O
weight O O
and O O
nutritional O O
habits O O
at O O
that O O
point O O
. O O
  
2. O O
Mild B-Severity B-Severity
anemia B-Indication B-Indication
: O O
When O O
Name O O
was O O
seen O O
by O O
Dr O O
. O O
  
Name O O
on O O
Date O O
, O O
her O O
hematocrit B-SSLIF B-SSLIF
was I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
to O O
35 O O
. O O
  
Name O O
has O O
a O O
history O O
of O O
low B-SSLIF B-SSLIF
ferritin I-SSLIF I-SSLIF
and O O
thus O O
was O O
started O O
on O O
ferrous B-Drug B-Drug
sulfate I-Drug I-Drug
325 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
3. O O
Dermatitis B-Indication B-Indication
: O O
At O O
this O O
point O O
, O O
Name O O
rash B-SSLIF B-SSLIF
appeared O O
more O O
consistent O O
with O O
a O O
contact B-SSLIF B-SSLIF
reaction I-SSLIF I-SSLIF
, O O
although O O
I O O
am O O
a O O
bit O O
unclear O O
as O O
to O O
why O O
her O O
symptoms O O
have O O
persisted O O
so O O
long O O
following O O
the O O
initial O O
outbreak O O
. O O
  
She O O
was O O
prescribed O O
hydrocortisone B-Drug B-Drug
valerate I-Drug I-Drug
ointment B-Dose B-Dose
to O O
be O O
applied O O
two B-Frequency B-Frequency
to I-Frequency I-Frequency
three I-Frequency I-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
and O O
also O O
was O O
provided O O
mupirocin B-Drug B-Drug
ointment B-Dose B-Dose
to O O
be O O
applied O O
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
for O O
the O O
next B-Duration B-Duration
week I-Duration I-Duration
to O O
cover O O
for O O
any O O
possible O O
bacterial B-Indication B-Indication
contamination I-Indication I-Indication
from I-Indication I-Indication
her I-Indication I-Indication
frequent I-Indication I-Indication
scratching I-Indication I-Indication
. O O
  
Name O O
was O O
instructed O O
to O O
make O O
an O O
appointment O O
with O O
Dermatology O O
should O O
her O O
rash O O
not O O
resolve O O
with O O
these O O
measures O O
. O O
  
She O O
and O O
her O O
mother O O
were O O
clearly O O
instructed O O
to O O
seek O O
medical O O
attention O O
should O O
these O O
ointments O O
not O O
relieve O O
her O O
symptoms O O
. O O
  
She O O
was O O
also O O
instructed O O
to O O
seek O O
medical O O
attention O O
for O O
any O O
worsening O O
complaints O O
. O O
  
4. O O
Healthcare O O
maintenance O O
: O O
Name O O
received O O
her O O
Tdap O O
varicella O O
#2 O O
and O O
Menactra O O
vaccines O O
at O O
today's O O
visit O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
11 O O
: O O
29 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
HCG O O
Electronic_Identifiers O O
cc O O
: O O
DOB O O
: O O
Date O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
Name O O
, O O
a O O
57 O O
- O O
year O O
- O O
old O O
male O O
, O O
is O O
here O O
for O O
his O O
annual O O
physical O O
. O O
  
He O O
is O O
overall O O
doing O O
well O O
. O O
  
No O O
active O O
issues O O
to O O
discuss O O
. O O
  
He O O
had O O
a O O
right B-SSLIF B-SSLIF
forefoot I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
was O O
referred O O
to O O
Dr O O
. O O
  
Name O O
at O O
that O O
time O O
, O O
sometime O O
in O O
Date O O
. O O
  
He O O
said O O
that O O
he O O
was O O
given O O
a O O
steroid B-Drug B-Drug
injection B-Route B-Route
. O O
  
He O O
felt O O
good O O
with O O
it O O
. O O
  
Symptoms O O
started O O
after O O
a O O
couple O O
of O O
weeks O O
. O O
  
Otherwise O O
, O O
he O O
had O O
no O O
issues O O
to O O
discuss O O
today O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Right O O
hip O O
THR O O
in O O
Date O O
, O O
right O O
knee O O
surgery O O
. O O
  
MEDICATIONS O O
: O O
None O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
is O O
divorced O O
. O O
  
He O O
is O O
a O O
machinist O O
. O O
  
He O O
does O O
not O O
use O O
alcohol O O
, O O
does O O
not O O
smoke O O
cigarettes O O
. O O
  
FAMILY O O
HISTORY O O
: O O
He O O
is O O
adopted O O
. O O
  
He O O
does O O
not O O
have O O
information O O
about O O
his O O
biological O O
parents O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Review O O
of O O
systems O O
is O O
only O O
significant O O
for O O
the O O
right B-SSLIF B-SSLIF
forefoot I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
no O O
cardiac B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
respiratory I-SSLIF I-SSLIF
issues I-SSLIF I-SSLIF
. O O
  
The O O
questionnaire O O
was O O
reviewed O O
with O O
him O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
On O O
examination O O
, O O
he O O
is O O
alert O O
and O O
oriented O O
. O O
  
Vital O O
signs O O
are O O
reviewed O O
which O O
are O O
within O O
normal O O
limits O O
. O O
  
Examination O O
pertinent O O
to O O
HEENT O O
, O O
thyroid O O
, O O
lungs O O
, O O
heart O O
, O O
abdomen O O
, O O
and O O
neuro O O
are O O
within O O
normal O O
limits O O
. O O
  
Dermatologic O O
revealed O O
congenital B-SSLIF B-SSLIF
nevi I-SSLIF I-SSLIF
. O O
  
No O O
abnormal B-SSLIF B-SSLIF
nevi I-SSLIF I-SSLIF
noted O O
. O O
  
Musculoskeletal O O
: O O
Normal O O
neck O O
, O O
upper O O
and O O
lower O O
extremity O O
range O O
of O O
motion O O
. O O
  
Normal O O
foot O O
exam O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
  
1. O O
Normal O O
physical O O
examination O O
. O O
  
2. O O
Right B-SSLIF B-SSLIF
foot I-SSLIF I-SSLIF
metatarsalgia I-SSLIF I-SSLIF
. O O
  
3. O O
Congenital B-SSLIF B-SSLIF
nevi I-SSLIF I-SSLIF
. O O
  
ABCDs O O
discussed O O
. O O
  
I O O
suggested O O
him O O
to O O
see O O
Dr O O
. O O
  
Name O O
in O O
the O O
past O O
for O O
multiple O O
nevi B-SSLIF B-SSLIF
. O O
  
He O O
was O O
not O O
able O O
to O O
make O O
it O O
. O O
  
Will O O
give O O
the O O
information O O
again O O
. O O
  
Metatarsalgia B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
foot I-SSLIF I-SSLIF
. O O
  
Right O O
now O O
he O O
is O O
asymptomatic O O
. O O
  
Exam O O
is O O
benign O O
. O O
  
Gave O O
him O O
foot O O
exercises O O
. O O
  
I O O
told O O
him O O
that O O
if O O
his O O
symptoms O O
are O O
not O O
any O O
better O O
, O O
he O O
should O O
see O O
Dr O O
. O O
  
Name O O
again O O
. O O
  
4. O O
Status O O
post O O
right O O
THR O O
. O O
  
He O O
is O O
doing O O
well O O
with O O
regards O O
to O O
that O O
. O O
  
5. O O
Right B-Indication B-Indication
knee I-Indication I-Indication
pain I-Indication I-Indication
. O O
  
He O O
gets O O
the O O
right O O
knee O O
pain O O
on O O
and O O
off O O
. O O
  
Physical O O
exam O O
is O O
unremarkable O O
. O O
  
I O O
suggested O O
him O O
to O O
take O O
Tylenol B-Drug B-Drug
on O O
a O O
p.r.n. B-Frequency B-Frequency
basis O O
. O O
  
He O O
finds O O
that O O
once O O
when O O
he O O
does O O
the O O
bike O O
exercises O O
, O O
he O O
feels O O
better O O
. O O
  
Continue O O
to O O
monitor O O
at O O
this O O
time O O
. O O
  
6. O O
Preventive O O
exams O O
. O O
  
He O O
had O O
a O O
colonoscopy O O
in O O
Date O O
, O O
which O O
was O O
unremarkable O O
. O O
  
Next O O
check O O
will O O
be O O
in O O
ten O O
years O O
from O O
Date O O
. O O
  
His O O
tetanus O O
shot O O
is O O
up O O
- O O
to O O
- O O
date O O
. O O
  
His O O
last O O
one O O
was O O
in O O
Date O O
. O O
  
I O O
will O O
do O O
baseline O O
blood O O
work O O
including O O
PSA O O
today O O
. O O
  
I O O
will O O
see O O
him O O
back O O
in O O
one O O
year O O
or O O
early O O
, O O
as O O
needed O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
9 O O
: O O
00PM O O
EST O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
11 O O
: O O
14 O O
P O O
  
4 O O
: O O
30 O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
This O O
is O O
day O O
15 O O
of O O
cycle O O
6 O O
of O O
chemotherapy B-Drug B-Drug
with O O
ABVD B-Drug B-Drug
, O O
for O O
this O O
59 O O
- O O
year O O
- O O
old O O
man O O
with O O
stage B-Severity B-Severity
IIIA I-Severity I-Severity
classic B-Indication B-Indication
Hodgkin I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
This O O
is O O
planned O O
to O O
be O O
the O O
patient's O O
final O O
chemotherapy B-Drug B-Drug
. O O
  
A O O
PET O O
scan O O
obtained O O
after O O
2 O O
cycles O O
of O O
chemotherapy B-Drug B-Drug
revealed O O
essentially O O
a O O
complete O O
response O O
. O O
  
Mr O O
. O O
  
Name O O
continues O O
to O O
feel O O
quite O O
well O O
. O O
  
He O O
is O O
without O O
complaint O O
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
rigors B-SSLIF B-SSLIF
or O O
sweats B-SSLIF B-SSLIF
, O O
coughing B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
adenopathy B-SSLIF B-SSLIF
, O O
anorexia B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
, O O
pedal B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
or O O
rash B-SSLIF B-SSLIF
. O O
  
Comprehensive O O
review O O
of O O
all O O
remaining O O
systems O O
is O O
otherwise O O
negative O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Include O O
Klonopin B-Drug B-Drug
0.5 B-Dose B-Dose
- I-Dose I-Dose
1 I-Dose I-Dose
mg I-Dose I-Dose
orally B-Route B-Route
at O O
h.s. B-Frequency B-Frequency
or I-Frequency I-Frequency
every I-Frequency I-Frequency
8 I-Frequency I-Frequency
hours I-Frequency I-Frequency
on I-Frequency I-Frequency
an I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
basis O O
for O O
anxiety B-Indication B-Indication
, O O
omeprazole B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
daily B-Frequency B-Frequency
, O O
Zofran B-Drug B-Drug
8 B-Dose B-Dose
mg I-Dose I-Dose
orally B-Route B-Route
every B-Frequency B-Frequency
8 I-Frequency I-Frequency
hours I-Frequency I-Frequency
on I-Frequency I-Frequency
an I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
basis O O
for O O
nausea B-Indication B-Indication
and I-Indication I-Indication
vomiting I-Indication I-Indication
and O O
a O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
supplement O O
. O O
  
ALLERGIES O O
: O O
He O O
has O O
no O O
known O O
medication B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
Today O O
, O O
he O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
His O O
height O O
is O O
166.5 O O
cm O O
. O O
  
His O O
weight O O
is O O
77.2 O O
kg O O
, O O
temperature O O
is O O
36.3 O O
, O O
blood O O
pressure O O
129 O O
/ O O
81 O O
, O O
pulse O O
76 O O
, O O
respiratory O O
rate O O
is O O
16 O O
and O O
is O O
unlabored O O
. O O
  
HEENT O O
: O O
Inspection O O
of O O
his O O
mouth O O
reveals O O
moist O O
mucous O O
membranes O O
without O O
mucositis B-SSLIF B-SSLIF
or O O
thrush B-SSLIF B-SSLIF
. O O
  
Sclerae O O
are O O
anicteric B-SSLIF B-SSLIF
. O O
  
HEENT O O
examination O O
is O O
otherwise O O
unremarkable O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
LYMPH O O
NODE O O
: O O
Negative O O
. O O
  
CARDIOVASCULAR O O
: O O
Reveals O O
a O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmur B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Benign O O
without O O
evidence O O
of O O
mass B-SSLIF B-SSLIF
, O O
tenderness B-SSLIF B-SSLIF
or O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
clubbing B-SSLIF B-SSLIF
, O O
cyanosis B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
Unremarkable O O
. O O
  
LABORATORY O O
DATA O O
: O O
His O O
white O O
count O O
is O O
1500 O O
. O O
  
His O O
neutrophil B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
500 I-SSLIF I-SSLIF
. O O
  
His O O
neutrophil O O
count O O
is O O
actually O O
higher O O
than O O
it O O
was O O
2 O O
weeks O O
ago O O
when O O
he O O
began O O
his O O
sixth O O
cycle O O
of O O
chemotherapy B-Drug B-Drug
. O O
  
On O O
that O O
date O O
, O O
his O O
neutrophil B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
400 I-SSLIF I-SSLIF
. O O
  
His O O
hemoglobin O O
is O O
11.8 O O
. O O
  
His O O
platelets O O
are O O
207 O O
, O O
000 O O
. O O
  
His O O
electrolytes O O
are O O
normal O O
, O O
glucose O O
is O O
82 O O
, O O
BUN O O
is O O
17 O O
, O O
creatinine O O
is O O
0.85 O O
, O O
calcium O O
is O O
8.8 O O
, O O
albumin O O
is O O
3.6 O O
. O O
  
Liver O O
functions O O
are O O
normal O O
. O O
  
LDH O O
is O O
normal O O
at O O
190 O O
. O O
  
ASSESSMENT O O
: O O
Mr O O
. O O
  
Name O O
is O O
doing O O
well O O
. O O
  
He O O
is O O
tolerating O O
his O O
chemotherapy B-Drug B-Drug
without O O
difficulty O O
. O O
  
Despite O O
the O O
fact O O
that O O
he O O
has O O
been O O
neutropenic B-ADE B-ADE
for O O
the O O
last O O
several O O
cycles O O
of O O
chemotherapy B-Drug B-Drug
, O O
he O O
has O O
tolerated O O
it O O
well O O
and O O
has O O
no O O
evidence O O
of O O
infection B-SSLIF B-SSLIF
at O O
this O O
point O O
. O O
  
PLAN O O
: O O
Proceed O O
with O O
day O O
15 O O
, O O
cycle O O
6 O O
of O O
chemotherapy B-Drug B-Drug
. O O
  
The O O
patient O O
will O O
follow O O
up O O
with O O
Dr O O
. O O
  
Name O O
in O O
approximately O O
2 O O
weeks O O
for O O
repeat O O
evaluation O O
and O O
for O O
a O O
final O O
staging O O
CT O O
scan O O
. O O
  
The O O
patient O O
will O O
continue O O
his O O
p.r.n. O O
medications O O
as O O
well O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
11 O O
: O O
46 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
3 O O
: O O
03 O O
P O O
  
2 O O
: O O
49 O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
This O O
is O O
day O O
11 O O
of O O
cycle O O
1 O O
of O O
ABVD B-Drug B-Drug
chemotherapy I-Drug I-Drug
, O O
for O O
this O O
59 O O
- O O
year O O
- O O
old O O
man O O
with O O
stage B-Severity B-Severity
IIIa I-Severity I-Severity
Hodgkin B-Indication B-Indication
disease I-Indication I-Indication
. O O
  
Mr O O
. O O
  
Name O O
reports O O
that O O
he O O
is O O
doing O O
fine O O
. O O
  
He O O
is O O
without O O
complaint O O
. O O
  
He O O
has O O
had O O
no O O
difficulty O O
with O O
his O O
chemotherapy B-Drug B-Drug
and O O
he O O
is O O
feeling O O
generally O O
well O O
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
rigors B-SSLIF B-SSLIF
or O O
sweats B-SSLIF B-SSLIF
, O O
coughing B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
The O O
patient's O O
comprehensive O O
review O O
of O O
systems O O
is O O
otherwise O O
negative O O
. O O
  
The O O
patient O O
reports O O
that O O
he O O
is O O
using O O
a O O
very O O
few O O
of O O
his O O
medications O O
at O O
this O O
point O O
. O O
  
He O O
remains O O
on O O
Klonopin B-Drug B-Drug
on O O
an O O
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
basis O O
as O O
well O O
as O O
a O O
clotrimazole B-Drug B-Drug
cream B-Dose B-Dose
. O O
  
He O O
uses O O
Reglan B-Drug B-Drug
, O O
ondansetron B-Drug B-Drug
and O O
Compazine B-Drug B-Drug
on O O
an O O
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
basis O O
and O O
he O O
does O O
the O O
same O O
with O O
omeprazole B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
. O O
  
ALLERGIES O O
: O O
He O O
has O O
no O O
known O O
medication B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
Today O O
, O O
he O O
is O O
a O O
well O O
- O O
developed O O
and O O
well O O
- O O
nourished O O
man O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Temperature O O
is O O
36.4 O O
, O O
blood O O
pressure O O
is O O
137 O O
/ O O
87 O O
, O O
pulse O O
is O O
72 O O
, O O
respiratory O O
rate O O
is O O
20 O O
. O O
  
His O O
weight O O
is O O
77.1 O O
kg O O
. O O
  
NECK O O
: O O
Supple O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
LYMPH O O
NODE O O
: O O
Negative O O
. O O
  
CARDIOVASCULAR O O
: O O
Reveals O O
a O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmur B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Benign O O
without O O
evidence O O
of O O
mass B-SSLIF B-SSLIF
, O O
tenderness B-SSLIF B-SSLIF
or O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITY O O
: O O
Reveals O O
no O O
clubbing B-SSLIF B-SSLIF
, O O
cyanosis B-SSLIF B-SSLIF
or O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
Unremarkable O O
. O O
  
LABORATORY O O
DATA O O
: O O
Electrolytes O O
are O O
normal O O
today O O
, O O
BUN O O
17 O O
, O O
creatinine O O
0.97 O O
. O O
  
LDH O O
is O O
198 O O
. O O
  
White O O
count O O
is O O
1.6 O O
, O O
hemoglobin O O
12.5 O O
and O O
platelets O O
207 O O
, O O
000 O O
. O O
  
ASSESSMENT O O
: O O
The O O
patient O O
appears O O
to O O
be O O
doing O O
quite O O
well O O
and O O
tolerating O O
his O O
chemotherapy B-Drug B-Drug
without O O
difficulty O O
. O O
  
He O O
does O O
have O O
the O O
expected O O
degree O O
of O O
neutropenia B-ADE B-ADE
. O O
  
PLAN O O
: O O
I O O
discussed O O
neutropenic O O
precautions O O
with O O
the O O
patient O O
. O O
  
He O O
will O O
follow O O
up O O
in O O
the O O
oncology O O
clinic O O
on O O
Wednesday O O
, O O
Date O O
, O O
for O O
his O O
day O O
15 O O
chemotherapy B-Drug B-Drug
. O O
  
He O O
will O O
follow O O
up O O
two O O
weeks O O
after O O
that O O
with O O
either O O
Dr O O
. O O
  
Name O O
or O O
with O O
our O O
nurse O O
practitioner O O
, O O
Name O O
Name O O
, O O
for O O
evaluation O O
prior O O
to O O
cycle O O
#2 O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
17 O O
: O O
29 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
PATIENT O O
DISCHARGE O O
: O O
  
Allergies B-ADE B-ADE
: O O
  
Contrast B-Drug B-Drug
Penicillin B-Drug B-Drug
V I-Drug I-Drug
PROBLEMS O O
/ O O
REASON O O
FOR O O
ADMISSION O O
: O O
  
Diagnosis O O
/ O O
Problem O O
During O O
This O O
Admission O O
: O O
Fever B-SSLIF B-SSLIF
, O O
h O O
/ O O
o O O
relapsed B-SSLIF B-SSLIF
NK I-SSLIF I-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
Why O O
You O O
Were O O
Admitted O O
: O O
Admitted O O
w O O
/ O O
recurrent O O
fever B-Indication B-Indication
and O O
underwent O O
infectious O O
disease O O
consultation O O
. O O
  
You O O
started O O
IV B-Route B-Route
antibiotics B-Drug B-Drug
and O O
remained O O
afebrile B-SSLIF B-SSLIF
during O O
your O O
stay O O
. O O
  
An O O
MRI O O
was O O
performed O O
which O O
showed O O
sinusitis B-SSLIF B-SSLIF
( O O
likely O O
chronic O O
) O O
Procedures O O
Performed O O
During O O
This O O
Hospitalization O O
: O O
s O O
/ O O
p O O
ENT O O
debridement O O
Attending O O
Physician O O
: O O
Name O O
Name O O
, O O
MD O O
Primary O O
Care O O
Provider O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
PCP O O
MSI O O
Number O O
: O O
Identifiers O O
Health O O
Care O O
Proxy O O
Name O O
/ O O
Relationship O O
: O O
Name O O
Name O O
( O O
wife O O
) O O
Phone O O
Number O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Follow O O
Up O O
Appointments O O
: O O
  
With O O
: O O
Keep O O
appt O O
@ O O
Hospital O O
- O O
ENT O O
When O O
: O O
Mon O O
Date O O
With O O
: O O
Heme O O
/ O O
Onc O O
Hospital O O
- O O
call O O
for O O
f O O
/ O O
u O O
appt O O
after O O
seen O O
by O O
Hospital O O
Pending O O
Studies O O
at O O
Time O O
of O O
Discharge O O
? O O
: O O
No O O
Other O O
Discharge O O
Instructions O O
: O O
Monitor O O
for O O
fever B-SSLIF B-SSLIF
greater O O
than O O
or O O
equal O O
to O O
100.5 O O
, O O
persistent O O
nausea B-SSLIF B-SSLIF
/ O O
vomiting B-SSLIF B-SSLIF
/ O O
diarrhea B-SSLIF B-SSLIF
and O O
call O O
if O O
these O O
occur O O
or O O
with O O
any O O
other O O
questions O O
/ O O
concerns O O
. O O
  
Heme O O
/ O O
Onc O O
clinic O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
, O O
after O O
hours O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
and O O
ask O O
to O O
speak O O
w O O
/ O O
MD O O
on O O
- O O
call O O
for O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
Restrictions O O
: O O
  
Activity O O
: O O
As O O
Tolerated O O
Diet O O
: O O
  
Diet O O
: O O
Neutropenic O O
Completed O O
By O O
: O O
Name O O
Name O O
Date O O
/ O O
Time O O
: O O
Date O O
11 O O
: O O
34 O O
: O O
00 O O
Vital O O
Signs O O
: O O
  
Last O O
Bowel O O
Movement O O
: O O
Date O O
Temperature O O
: O O
98.1 O O
Fahrenheit O O
Pulse O O
: O O
85 O O
Respiration O O
: O O
18 O O
Blood O O
Pressure O O
: O O
108 O O
/ O O
75 O O
Pulse O O
Ox O O
% O O
: O O
100 O O
IV O O
Access O O
Care O O
: O O
  
Central O O
Line O O
Care O O
: O O
Yes O O
Comments O O
: O O
PAC O O
flushed O O
1630 O O
Date O O
Discharge O O
Instructions O O
: O O
Reviewed O O
Discharge O O
Instructions O O
with O O
Patient O O
/ O O
Authorized O O
Representative O O
, O O
Patient O O
/ O O
Authorized O O
Representative O O
Verbalized O O
Understanding O O
of O O
Discharge O O
Instructions O O
, O O
Patient O O
/ O O
Authorized O O
Representative O O
Received O O
Written O O
Instructions O O
, O O
and O O
Prescription O O
( O O
s O O
) O O
Provided O O
to O O
Patient O O
/ O O
Authorized O O
Representative O O
. O O
  
Smoking O O
: O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die B-SSLIF B-SSLIF
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer O O
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
' O O
Helpline O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Discharge O O
Medication O O
Reconciliation O O
Statement O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
. O O
  
Please O O
refer O O
to O O
the O O
companion O O
Discharge O O
Medication O O
Instruction O O
document O O
. O O
  
Completed O O
By O O
: O O
Name O O
Name O O
Name O O
RN O O
Date O O
/ O O
Time O O
: O O
Date O O
16 O O
: O O
03 O O
: O O
00 O O
Community O O
Referrals O O
: O O
  
Home O O
Health O O
Agency O O
: O O
Company O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Equipment O O
: O O
  
IV O O
Supplies O O
: O O
Yes O O
Provider O O
Name O O
: O O
Company O O
Address O O
/ O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Additional O O
Case O O
Manager O O
/ O O
Social O O
Worker O O
Discharge O O
Note O O
: O O
Plan O O
for O O
delivery O O
tomorrow O O
and O O
visit O O
in O O
afternoon O O
around O O
3 O O
- O O
4 O O
pm O O
by O O
nursing O O
for O O
IV B-Route B-Route
antibiotic B-Drug B-Drug
administration O O
. O O
  
Discharge O O
Planning O O
Coordinator O O
Name O O
: O O
Name O O
Name O O
R.N. O O
  
Planning O O
Coordinator O O
Contact O O
Phone O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Completed O O
By O O
: O O
Name O O
Name O O
Name O O
RN O O
Date O O
/ O O
Time O O
: O O
Date O O
16 O O
: O O
07 O O
: O O
00 O O
Discharge O O
Disposition O O
: O O
Home O O
with O O
Services O O
Authorization O O
: O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plans O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
DISCHARGE O O
MEDICATION O O
INSTRUCTIONS O O
Results O O
of O O
Medication O O
List O O
query O O
DISCHARGE O O
MEDICATION O O
INSTRUCTIONS O O
Collected O O
Date O O
/ O O
Time O O
: O O
Date O O
15 O O
: O O
10 O O
: O O
33 O O
Medication O O
Name O O
, O O
Dose O O
, O O
Route O O
, O O
Instructions O O
acyclovir B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
esomeprazole B-Drug B-Drug
magnesium I-Drug I-Drug
( I-Drug I-Drug
NexIUM I-Drug I-Drug
Packet I-Drug I-Drug
) I-Drug I-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
Granules I-Dose I-Dose
DR I-Dose I-Dose
for I-Dose I-Dose
susp I-Dose I-Dose
in I-Dose I-Dose
Packet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
each I-Dose I-Dose
gastro B-Route B-Route
- I-Route I-Route
intestinal I-Route I-Route
stoma I-Route I-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
mirtazapine B-Drug B-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
at I-Frequency I-Frequency
bedtime I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
oxyCODONE B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
5 I-Dose I-Dose
mL I-Dose I-Dose
Solution I-Dose I-Dose
Directions O O
: O O
5 B-Dose B-Dose
- I-Dose I-Dose
10ml I-Dose I-Dose
= I-Dose I-Dose
5 I-Dose I-Dose
- I-Dose I-Dose
10mg I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
four I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
pain B-Indication B-Indication
Continued O O
By O O
: O O
Name O O
Name O O
predniSONE B-Drug B-Drug
5mg B-Dose B-Dose
/ I-Dose I-Dose
5ml I-Dose I-Dose
Concentrate I-Dose I-Dose
Directions O O
: O O
5 B-Dose B-Dose
mL I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
prochlorperazine B-Drug B-Drug
maleate I-Drug I-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
NAUSEA B-Indication B-Indication
Continued O O
By O O
: O O
Name O O
Name O O
  
MULTIVITAMINS B-Drug B-Drug
( I-Drug I-Drug
TAB I-Drug I-Drug
- I-Drug I-Drug
A I-Drug I-Drug
- I-Drug I-Drug
VITE I-Drug I-Drug
) O O
1 B-Dose B-Dose
TABLET I-Dose I-Dose
= I-Dose I-Dose
1 I-Dose I-Dose
TABLET I-Dose I-Dose
Gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
TABLET B-Dose B-Dose
DAILY B-Frequency B-Frequency
( O O
900 B-Dose B-Dose
) O O
for O O
30 B-Duration B-Duration
Days I-Duration I-Duration
posaconazole B-Drug B-Drug
200 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
5 I-Dose I-Dose
mL I-Dose I-Dose
( I-Dose I-Dose
40 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
mL I-Dose I-Dose
) I-Dose I-Dose
Suspension I-Dose I-Dose
Directions O O
: O O
5 B-Dose B-Dose
mL I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
cholecalciferol B-Drug B-Drug
( I-Drug I-Drug
vitamin I-Drug I-Drug
D3 I-Drug I-Drug
) I-Drug I-Drug
( I-Drug I-Drug
Vitamin I-Drug I-Drug
D3 I-Drug I-Drug
) I-Drug I-Drug
1 B-Dose B-Dose
, I-Dose I-Dose
000 I-Dose I-Dose
unit I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
2 B-Dose B-Dose
tablet I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
cefTRIAXone B-Drug B-Drug
2 B-Dose B-Dose
gram I-Dose I-Dose
Recon I-Dose I-Dose
Soln I-Dose I-Dose
Directions O O
: O O
5 B-Dose B-Dose
mL I-Dose I-Dose
intravenous B-Route B-Route
daily B-Frequency B-Frequency
Extended O O
Instructions O O
: O O
x10days B-Duration B-Duration
Continued O O
By O O
: O O
Name O O
Name O O
metroNIDAZOLE B-Drug B-Drug
( I-Drug I-Drug
Flagyl I-Drug I-Drug
) I-Drug I-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
gastrostomy B-Route B-Route
( I-Route I-Route
PEG I-Route I-Route
) I-Route I-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
Extended O O
Instructions O O
: O O
x10days B-Duration B-Duration
Continued O O
By O O
: O O
Name O O
Name O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
9 O O
: O O
49 O O
P O O
  
2 O O
: O O
27 O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Extranodal B-SSLIF B-SSLIF
nonsmall I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
natural I-SSLIF I-SSLIF
killer I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
subtype I-SSLIF I-SSLIF
nodule I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
Initial O O
diagnosis O O
in O O
Date O O
, O O
treated O O
with O O
definitive O O
radiation O O
management O O
. O O
  
Treatment O O
was O O
delivered O O
to O O
paranasal O O
sinus O O
region O O
. O O
  
Relapse O O
documented O O
biopsy O O
- O O
proven O O
in O O
Date O O
with O O
disease B-Indication B-Indication
extension I-Indication I-Indication
into I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
maxillary I-Indication I-Indication
sinus I-Indication I-Indication
. O O
  
The O O
patient O O
received O O
CHOP B-Drug B-Drug
chemotherapy I-Drug I-Drug
for O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
followed O O
by O O
consolidation O O
radiation O O
management O O
delivered O O
to O O
an O O
identical O O
target O O
volume O O
including O O
right O O
maxillary O O
sinus O O
. O O
  
There O O
was O O
overlap O O
of O O
treatment O O
field O O
including O O
overlap O O
of O O
optic O O
structures O O
. O O
  
The O O
patient O O
returns O O
today O O
for O O
a O O
followup O O
appointment O O
. O O
  
The O O
patient O O
feels O O
well O O
, O O
he O O
offers O O
no O O
focal O O
complaint O O
. O O
  
MEDICATIONS O O
AND O O
ALLERGIES O O
: O O
Reviewed O O
and O O
reconciled O O
. O O
  
The O O
patient O O
recently O O
saw O O
Dr O O
. O O
  
Name O O
, O O
ophthalmology O O
service O O
, O O
who O O
reported O O
stable O O
visual O O
field O O
findings O O
. O O
  
The O O
patient O O
was O O
recently O O
evaluated O O
by O O
Dr O O
. O O
  
Name O O
Name O O
and O O
is O O
doing O O
well O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
full O O
14 O O
- O O
point O O
system O O
review O O
is O O
performed O O
. O O
  
The O O
patient O O
has O O
no O O
constitutional O O
symptoms O O
. O O
  
He O O
continues O O
to O O
work O O
and O O
feels O O
well O O
. O O
  
There O O
are O O
no O O
changes B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
visual I-SSLIF I-SSLIF
field I-SSLIF I-SSLIF
. O O
  
He O O
does O O
use O O
reading O O
glasses O O
; O O
however O O
, O O
there O O
is O O
no O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
moisture I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
visual I-SSLIF I-SSLIF
field I-SSLIF I-SSLIF
. O O
  
Ear O O
, O O
Nose O O
and O O
Throat O O
: O O
There O O
is O O
continued O O
improvement O O
as O O
he O O
has O O
not O O
had O O
sinus B-SSLIF B-SSLIF
infection I-SSLIF I-SSLIF
for O O
an O O
extended O O
period O O
of O O
time O O
. O O
  
Dr O O
. O O
  
Name O O
reported O O
stable O O
physical O O
exam O O
findings O O
. O O
  
Respiratory O O
: O O
No O O
change O O
in O O
status O O
. O O
  
Cardiovascular O O
: O O
No O O
change O O
in O O
status O O
. O O
  
Gastrointestinal O O
: O O
No O O
change O O
in O O
status O O
. O O
  
Genitourinary O O
: O O
No O O
change O O
in O O
status O O
. O O
  
Musculoskeletal O O
: O O
The O O
patient O O
reports O O
no O O
focal B-SSLIF B-SSLIF
bony I-SSLIF I-SSLIF
discomfort I-SSLIF I-SSLIF
. O O
  
Neurologic O O
: O O
No O O
change O O
in O O
status O O
. O O
  
Hematologic O O
: O O
No O O
change O O
in O O
status O O
. O O
  
General O O
: O O
Otherwise O O
noncontributory O O
. O O
  
The O O
patient O O
presents O O
in O O
no O O
cardiac B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
respiratory I-SSLIF I-SSLIF
distress I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
Revealed O O
the O O
patient O O
to O O
be O O
afebrile B-SSLIF B-SSLIF
. O O
  
The O O
pulse O O
is O O
76 O O
, O O
respirations O O
14 O O
and O O
blood O O
pressure O O
136 O O
/ O O
86 O O
. O O
  
Weight O O
208 O O
pounds O O
. O O
  
NEUROLOGIC O O
: O O
Speech O O
and O O
affect O O
are O O
appropriate O O
for O O
situation O O
. O O
  
Karnofsky O O
status O O
100% O O
. O O
  
There O O
is O O
no O O
papilledema B-SSLIF B-SSLIF
. O O
  
Funduscopic O O
examination O O
reveals O O
no O O
specific O O
abnormality O O
. O O
  
Extraocular O O
movements O O
intact O O
. O O
  
Cranial O O
nerves O O
function O O
within O O
normal O O
limits O O
. O O
  
Detailed O O
examination O O
of O O
nasal O O
cavity O O
reveals O O
healing B-SSLIF B-SSLIF
changes I-SSLIF I-SSLIF
with O O
minimal B-Severity B-Severity
mucosal B-SSLIF B-SSLIF
irritation I-SSLIF I-SSLIF
noted O O
at O O
this O O
time O O
. O O
  
Tympanic O O
membranes O O
intact O O
without O O
abnormality O O
. O O
  
Intraoral O O
examination O O
reveals O O
mucosa O O
to O O
be O O
intact O O
without O O
visible O O
abnormality O O
. O O
  
A O O
tongue O O
extends O O
to O O
the O O
midline O O
. O O
  
The O O
soft O O
palate O O
elevates O O
in O O
a O O
symmetric O O
fashion O O
. O O
  
Examination O O
of O O
the O O
larynx O O
reveals O O
no O O
abnormality O O
. O O
  
There O O
is O O
no O O
occipital B-SSLIF B-SSLIF
preauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
retroauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
submandibular I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
neck I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
posterior I-SSLIF I-SSLIF
cervical I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
infraclavicular I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
Carotid O O
pulses O O
are O O
symmetric O O
. O O
  
There O O
is O O
no O O
jugular B-SSLIF B-SSLIF
venous I-SSLIF I-SSLIF
distention I-SSLIF I-SSLIF
. O O
  
Trachea O O
is O O
in O O
the O O
midline O O
. O O
  
Thyroid B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
enlarged I-SSLIF I-SSLIF
. O O
  
IMPRESSION O O
: O O
Stable O O
clinical O O
status O O
at O O
this O O
juncture O O
. O O
  
The O O
patient O O
is O O
doing O O
well O O
. O O
  
I O O
will O O
see O O
the O O
patient O O
again O O
in O O
1 O O
year O O
or O O
sooner O O
if O O
indicated O O
. O O
  
We O O
did O O
discuss O O
removal O O
of O O
the O O
Port O O
- O O
A O O
- O O
Cath O O
. O O
  
He O O
has O O
an O O
appointment O O
with O O
Dr O O
. O O
  
Name O O
in O O
Date O O
and O O
we O O
will O O
rediscuss O O
this O O
issue O O
at O O
that O O
time O O
. O O
  
More O O
than O O
40 O O
minutes O O
were O O
spent O O
in O O
reviewing O O
information O O
on O O
this O O
patient O O
, O O
of O O
this O O
time O O
25 O O
minutes O O
were O O
spent O O
in O O
face O O
to O O
face O O
interaction O O
including O O
examination O O
, O O
discussion O O
, O O
review O O
of O O
care O O
plan O O
and O O
generation O O
of O O
note O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
10 O O
: O O
43 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI B-PHI B-PHI
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
, O O
PA O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
2 O O
: O O
01 O O
P O O
HISTORY O O
AND O O
PHYSICAL O O
ADMISSION O O
DIAGNOSIS O O
: O O
Nasal B-Indication B-Indication
NK I-Indication I-Indication
/ I-Indication I-Indication
T I-Indication I-Indication
- I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
Admitted O O
for O O
mobilization O O
chemotherapy B-Drug B-Drug
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Mr O O
. O O
  
Name O O
is O O
a O O
53 O O
- O O
year O O
- O O
old O O
Caucasian O O
male O O
with O O
a O O
past O O
medical O O
history O O
for O O
hypertension B-SSLIF B-SSLIF
as O O
well O O
as O O
T B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
was O O
first O O
diagnosed O O
with O O
NK B-SSLIF B-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
in O O
Date O O
, O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
he O O
was O O
staged O O
as O O
stage B-Severity B-Severity
I I-Severity I-Severity
and O O
received O O
radiation O O
by O O
Dr O O
. O O
  
Name O O
locally O O
. O O
  
The O O
patient O O
has O O
been O O
in O O
remission O O
for O O
approximately O O
6 O O
years O O
in O O
Date O O
, O O
had O O
recurrent B-Indication B-Indication
disease I-Indication I-Indication
in I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
maxillary I-Indication I-Indication
sinus I-Indication I-Indication
and O O
received O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
CHOP B-Drug B-Drug
followed O O
by O O
3500 O O
centigrade O O
radiation O O
therapy O O
. O O
  
The O O
patient O O
remained O O
in O O
remission O O
for O O
the O O
next O O
9 O O
years O O
and O O
then O O
in O O
Date O O
of O O
last O O
year O O
, O O
he O O
began O O
to O O
have O O
new O O
symptoms O O
of O O
being O O
hoarsed B-SSLIF B-SSLIF
and O O
increased O O
postnasal B-SSLIF B-SSLIF
drip I-SSLIF I-SSLIF
. O O
  
At O O
that O O
time O O
, O O
the O O
patient O O
was O O
seen O O
and O O
assessed O O
by O O
Dr O O
. O O
  
Name O O
from O O
ENT O O
and O O
a O O
CT O O
scan O O
of O O
the O O
neck O O
and O O
sinuses O O
obtained O O
in O O
Date O O
, O O
was O O
felt O O
to O O
only O O
____ O O
changes B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
maxillary I-SSLIF I-SSLIF
sinus I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
nasal I-SSLIF I-SSLIF
fossa I-SSLIF I-SSLIF
. O O
  
CT O O
of O O
the O O
neck O O
at O O
that O O
time O O
did O O
not O O
demonstrate O O
any O O
increased O O
adenopathy B-SSLIF B-SSLIF
. O O
  
Subsequently O O
, O O
the O O
patient O O
had O O
a O O
biopsy O O
of O O
a O O
vocal O O
cord O O
in O O
Date O O
, O O
which O O
revealed O O
nasal B-Indication B-Indication
NK I-Indication I-Indication
/ I-Indication I-Indication
T I-Indication I-Indication
- I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
The O O
patient O O
most O O
recently O O
has O O
been O O
receiving O O
radiation O O
therapy O O
, O O
which O O
he O O
completed O O
on O O
Date O O
. O O
  
The O O
patient O O
is O O
admitted O O
at O O
the O O
current O O
time O O
for O O
mobilization O O
chemotherapy B-Drug B-Drug
with O O
etoposide B-Drug B-Drug
, O O
cyclophosphamide B-Drug B-Drug
, O O
and O O
cisplatin B-Drug B-Drug
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
states O O
that O O
he O O
has O O
been O O
feeling O O
well O O
. O O
  
Denies O O
any O O
recent O O
fevers B-SSLIF B-SSLIF
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
Does O O
state O O
that O O
over O O
the O O
past O O
2 O O
weeks O O
, O O
his O O
appetite B-SSLIF B-SSLIF
has I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
, O O
but O O
states O O
his O O
weight O O
has O O
been O O
stable O O
. O O
  
The O O
patient O O
denied O O
any O O
upper B-SSLIF B-SSLIF
respiratory I-SSLIF I-SSLIF
symptoms I-SSLIF I-SSLIF
. O O
  
He O O
states O O
he O O
has O O
chronic O O
postnasal B-SSLIF B-SSLIF
drip I-SSLIF I-SSLIF
, O O
which O O
is O O
at O O
its O O
baseline O O
. O O
  
The O O
patient O O
denied O O
any O O
cough B-SSLIF B-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
or O O
chest B-SSLIF B-SSLIF
discomfort I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
states O O
that O O
his O O
bowels B-SSLIF B-SSLIF
last I-SSLIF I-SSLIF
week I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
loose I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
, O O
but O O
he O O
was O O
seen O O
and O O
evaluated O O
in O O
clinic O O
. O O
  
Had O O
the O O
stool O O
studies O O
done O O
, O O
which O O
were O O
negative O O
for O O
C. B-SSLIF B-SSLIF
diff I-SSLIF I-SSLIF
and O O
since O O
that O O
time O O
, O O
his O O
bowels O O
have O O
been O O
back O O
at O O
baseline O O
. O O
  
The O O
patient O O
had O O
normal O O
bowel O O
movement O O
within O O
the O O
last O O
24 O O
hours O O
. O O
  
The O O
patient O O
denies O O
any O O
nausea B-SSLIF B-SSLIF
and O O
vomiting B-SSLIF B-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
Hypertension B-SSLIF B-SSLIF
. O O
  
NK B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
as O O
described O O
above O O
, O O
original O O
diagnosis O O
in O O
Date O O
, O O
Date O O
. O O
  
Hernia O O
repair O O
in O O
Date O O
. O O
  
Tonsillectomy O O
at O O
the O O
age O O
of O O
30. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
is O O
married O O
. O O
  
He O O
has O O
a O O
very O O
supportive O O
son O O
. O O
  
He O O
has O O
  
2 O O
sons O O
, O O
ages O O
18 O O
and O O
20 O O
. O O
  
Denies O O
any O O
history O O
of O O
tobacco O O
use O O
, O O
was O O
a O O
social O O
drinker O O
in O O
the O O
past O O
but O O
has O O
cut O O
down O O
considerably O O
since O O
the O O
Date O O
. O O
  
MEDICATIONS O O
AT O O
THE O O
TIME O O
OF O O
ADMISSION O O
: O O
Enalapril B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
oxycodone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
  
1 O O
- O O
2 O O
tabs O O
q.4h. B-Frequency B-Frequency
p.r.n. I-Frequency I-Frequency
for O O
pain B-Indication B-Indication
, O O
tobramycin B-Drug B-Drug
/ I-Drug I-Drug
dexamethasone I-Drug I-Drug
0.3 B-Dose B-Dose
- I-Dose I-Dose
0.1% I-Dose I-Dose
eyedrops B-Route B-Route
in O O
the O O
left O O
eye O O
. O O
  
The O O
patient O O
states O O
that O O
he O O
has O O
been O O
on O O
these O O
for O O
over O O
a O O
month O O
, O O
it O O
has O O
not O O
been O O
utilizing O O
regularly O O
, O O
originally O O
prescribed O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Penicillin B-Drug B-Drug
, O O
patient O O
states O O
he O O
gets O O
hives B-ADE B-ADE
as O O
a O O
child O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
37 O O
, O O
56 O O
, O O
18 O O
, O O
132 O O
/ O O
82 O O
, O O
satting O O
99% O O
on O O
room O O
air O O
. O O
  
GENERAL O O
: O O
This O O
is O O
a O O
pleasant O O
52 O O
- O O
year O O
- O O
old O O
Caucasian O O
male O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
, O O
alert O O
and O O
oriented O O
x3 O O
, O O
accompanied O O
by O O
his O O
wife O O
. O O
  
HEENT O O
: O O
Oral O O
mucosa O O
is O O
pink O O
and O O
moist O O
. O O
  
There O O
are O O
no O O
oral B-SSLIF B-SSLIF
lesions I-SSLIF I-SSLIF
noted O O
. O O
  
There O O
is O O
no O O
gross B-Severity B-Severity
foul B-SSLIF B-SSLIF
odor I-SSLIF I-SSLIF
noted I-SSLIF I-SSLIF
from I-SSLIF I-SSLIF
patient's I-SSLIF I-SSLIF
oropharynx I-SSLIF I-SSLIF
nor I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
nares I-SSLIF I-SSLIF
. O O
  
Patient O O
has O O
abnormality O O
noted O O
secondary O O
to O O
nasal B-SSLIF B-SSLIF
NK I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
septal B-SSLIF B-SSLIF
deviation I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
no O O
pain B-SSLIF B-SSLIF
or O O
discomfort B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
palpation I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rate O O
and O O
rhythm O O
. O O
  
There O O
is O O
no O O
murmur B-SSLIF B-SSLIF
auscultated O O
. O O
  
RESPIRATORY O O
: O O
Lung O O
sounds O O
are O O
clear O O
bilaterally O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
with O O
normal O O
bowel O O
sounds O O
. O O
  
No O O
guarding B-SSLIF B-SSLIF
or O O
rebound B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Without O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
Warm O O
, O O
dry O O
and O O
intact O O
. O O
  
The O O
patient O O
has O O
a O O
single O O
lumen O O
Port O O
- O O
A O O
- O O
Cath O O
in O O
the O O
right O O
upper O O
chest O O
wall O O
, O O
which O O
has O O
been O O
accessed O O
. O O
  
There O O
are O O
no O O
signs O O
and O O
symptoms O O
of O O
infection B-SSLIF B-SSLIF
around O O
insertion O O
site O O
. O O
  
NEUROLOGIC O O
: O O
Cranial O O
nerves O O
are O O
grossly O O
intact O O
. O O
  
Push O O
- O O
pull O O
strength O O
in O O
upper O O
and O O
lower O O
extremities O O
5 O O
/ O O
5 O O
and O O
equal O O
bilaterally O O
. O O
  
LABORATORY O O
DATA O O
: O O
Sodium O O
is O O
138 O O
, O O
potassium O O
is O O
4.1 O O
, O O
chloride O O
is O O
103 O O
, O O
CO2 O O
is O O
26 O O
, O O
BUN O O
is O O
16 O O
, O O
creatinine O O
is O O
0.87 O O
. O O
  
T O O
- O O
bili O O
is O O
0.4 O O
, O O
AST O O
is O O
15 O O
, O O
ALT O O
is O O
17 O O
. O O
  
White O O
count O O
7.3 O O
, O O
H O O
H O O
is O O
13.3 O O
and O O
40.3 O O
, O O
platelet O O
count O O
is O O
240 O O
, O O
000 O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
This O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
Caucasian O O
male O O
with O O
NK B-Indication B-Indication
/ I-Indication I-Indication
T I-Indication I-Indication
- I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
who O O
was O O
completed O O
, O O
most O O
recently O O
radiation O O
on O O
Date O O
. O O
  
The O O
patient O O
is O O
admitted O O
at O O
this O O
time O O
for O O
mobilization O O
chemotherapy B-Drug B-Drug
with O O
cyclophosphamide B-Drug B-Drug
, O O
etoposide B-Drug B-Drug
and O O
cisplatin B-Drug B-Drug
. O O
  
The O O
patient O O
will O O
be O O
started O O
on O O
IV O O
fluids O O
prior O O
to O O
initiation O O
of O O
chemotherapy B-Drug B-Drug
and O O
will O O
continue O O
with O O
continuous O O
mesna B-Drug B-Drug
during O O
his O O
chemotherapy B-Drug B-Drug
regimen O O
. O O
  
The O O
patient O O
will O O
be O O
provided O O
with O O
a O O
calendar O O
at O O
the O O
time O O
of O O
discharge O O
to O O
review O O
his O O
upcoming O O
clinic O O
appointments O O
as O O
well O O
as O O
Neupogen B-Drug B-Drug
and O O
Neulasta B-Drug B-Drug
followups O O
. O O
  
We O O
will O O
complete O O
patient's O O
pretransplant O O
workup O O
during O O
this O O
hospital O O
stay O O
. O O
  
We O O
will O O
plan O O
for O O
apheresis O O
line O O
placement O O
on O O
Thursday O O
morning O O
. O O
  
The O O
patient O O
will O O
be O O
made O O
n.p.o. O O
after O O
midnight O O
. O O
  
We O O
will O O
also O O
plan O O
on O O
obtaining O O
patient's O O
pulmonary O O
function O O
test O O
during O O
this O O
hospital O O
stay O O
. O O
  
We O O
have O O
reviewed O O
with O O
the O O
patient O O
his O O
current O O
regimen O O
as O O
well O O
as O O
the O O
plans O O
for O O
apheresis O O
catheter O O
placement O O
and O O
pulmonary O O
function O O
testing O O
during O O
this O O
hospital O O
stay O O
. O O
  
We O O
have O O
also O O
discussed O O
with O O
patient O O
the O O
need O O
to O O
live O O
in O O
a O O
close O O
proximity O O
to O O
the O O
clinic O O
during O O
his O O
neutropenic B-SSLIF B-SSLIF
phase O O
and O O
during O O
the O O
time O O
of O O
collection O O
. O O
  
The O O
patient O O
as O O
well O O
as O O
his O O
wife O O
have O O
looked O O
at O O
the O O
Company O O
and O O
they O O
plan O O
to O O
reside O O
at O O
the O O
Company O O
following O O
this O O
discharge O O
. O O
  
Hypertension B-Indication B-Indication
: O O
The O O
patient O O
will O O
continue O O
on O O
his O O
ACE B-Drug B-Drug
inhibitor I-Drug I-Drug
at O O
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
Infectious O O
disease O O
: O O
At O O
the O O
current O O
time O O
, O O
the O O
patient O O
has O O
no O O
signs O O
or O O
symptoms O O
of O O
infection B-Indication B-Indication
. O O
  
He O O
will O O
start O O
his O O
prophylactic B-Indication B-Indication
acyclovir B-Drug B-Drug
at O O
the O O
time O O
of O O
admission O O
, O O
which O O
he O O
will O O
continue O O
in O O
the O O
outpatient O O
setting O O
. O O
  
Upon O O
discharge O O
, O O
the O O
patient O O
will O O
be O O
started O O
on O O
his O O
prophylactic B-Indication B-Indication
posaconazole B-Drug B-Drug
and O O
Levaquin B-Drug B-Drug
in O O
addition O O
to O O
his O O
acyclovir B-Drug B-Drug
. O O
  
Prophylactic O O
: O O
Patient O O
will O O
be O O
started O O
on O O
PPI B-Drug B-Drug
daily B-Frequency B-Frequency
as O O
well O O
as O O
Lovenox B-Drug B-Drug
40 B-Dose B-Dose
daily B-Frequency B-Frequency
for O O
DVT B-Indication B-Indication
prophylaxis I-Indication I-Indication
. O O
  
ADVANCE O O
DIRECTIVES O O
: O O
The O O
patient O O
is O O
a O O
full O O
code O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
. O O
  
I O O
discussed O O
the O O
case O O
with O O
the O O
fellow O O
and O O
agree O O
with O O
the O O
findings O O
and O O
plan O O
as O O
documented O O
in O O
the O O
fellows O O
note O O
. O O
  
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
MD O O
# O O
Identifiers O O
on O O
Date O O
18 O O
: O O
25 O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
9 O O
: O O
14 O O
A O O
  
8 O O
: O O
03 O O
A O O
CLINIC O O
NOTE O O
RADIATION O O
ONCOLOGY O O
IDENTIFICATION O O
NUMBER O O
: O O
Identifiers O O
DIAGNOSIS O O
: O O
Extranodal B-SSLIF B-SSLIF
nonsmall I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
natural I-SSLIF I-SSLIF
killer I-SSLIF I-SSLIF
type I-SSLIF I-SSLIF
subtype I-SSLIF I-SSLIF
nodular I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
initial O O
diagnosis O O
Date O O
, O O
treated O O
with O O
definitive O O
radiation O O
management O O
. O O
  
Therapy O O
was O O
delivered O O
to O O
paranasal O O
sinus O O
region O O
. O O
  
Biopsy O O
proven O O
relapse O O
in O O
Date O O
with O O
disease B-Indication B-Indication
extension I-Indication I-Indication
to I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
maxillary I-Indication I-Indication
sinus I-Indication I-Indication
. O O
  
The O O
patient O O
received O O
CHOP B-Drug B-Drug
chemotherapy I-Drug I-Drug
with O O
supplemental O O
radiation O O
therapy O O
delivered O O
to O O
essentially O O
identical O O
target O O
volume O O
, O O
which O O
included O O
right O O
maxillary O O
sinus O O
. O O
  
There O O
was O O
intentional O O
overlap O O
of O O
therapy O O
including O O
overlap O O
of O O
optic O O
structures O O
. O O
  
NARRATIVE O O
: O O
The O O
patient O O
returns O O
today O O
for O O
a O O
scheduled O O
followup O O
visit O O
. O O
  
The O O
patient O O
feels O O
well O O
. O O
  
He O O
reports O O
no O O
change O O
in O O
his O O
general O O
medical O O
status O O
. O O
  
He O O
has O O
done O O
well O O
during O O
the O O
past O O
year O O
with O O
respect O O
to O O
paranasal B-SSLIF B-SSLIF
sinus I-SSLIF I-SSLIF
infection I-SSLIF I-SSLIF
. O O
  
He O O
reports O O
no O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
visual I-SSLIF I-SSLIF
field I-SSLIF I-SSLIF
. O O
  
MEDICATIONS O O
AND O O
ALLERGIES O O
: O O
Reviewed O O
and O O
reconciled O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
full O O
14 O O
- O O
point O O
system O O
review O O
is O O
noted O O
. O O
  
The O O
patient O O
continues O O
to O O
work O O
. O O
  
He O O
reports O O
no O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
visual I-SSLIF I-SSLIF
field I-SSLIF I-SSLIF
. O O
  
He O O
continues O O
to O O
be O O
actively O O
followed O O
by O O
ophthalmology O O
. O O
  
There O O
are O O
no O O
constitutional O O
symptoms O O
. O O
  
He O O
reports O O
no O O
limitation B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
activity I-SSLIF I-SSLIF
. O O
  
General O O
system O O
review O O
is O O
otherwise O O
noncontributory O O
in O O
all O O
remaining O O
site O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
GENERAL O O
: O O
The O O
patient O O
presents O O
in O O
no O O
cardiac B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
respiratory I-SSLIF I-SSLIF
distress I-SSLIF I-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Reveal O O
the O O
patient O O
to O O
be O O
afebrile B-SSLIF B-SSLIF
. O O
  
Pulse O O
60 O O
, O O
respirations O O
16 O O
, O O
blood O O
pressure O O
138 O O
/ O O
94 O O
, O O
weight O O
215 O O
pounds O O
. O O
  
Speech O O
and O O
affect O O
are O O
appropriate O O
for O O
situation O O
. O O
  
Karnofsky O O
status O O
100% O O
. O O
  
Extraocular O O
movements O O
full O O
. O O
  
Cranial O O
nerves O O
function O O
within O O
normal O O
limits O O
. O O
  
There O O
is O O
no O O
visual B-SSLIF B-SSLIF
field I-SSLIF I-SSLIF
defect I-SSLIF I-SSLIF
noted O O
. O O
  
HEENT O O
: O O
Funduscopic O O
examination O O
details O O
no O O
abnormality O O
. O O
  
Mucous O O
membranes O O
moist O O
and O O
intact O O
without O O
abnormality O O
. O O
  
Membranes O O
, O O
nasal O O
cavity O O
intact O O
without O O
abnormality O O
. O O
  
There O O
is O O
no O O
occipital B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
preauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
retroauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
submandibular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
neck I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
posterior I-SSLIF I-SSLIF
cervical I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
infraclavicular I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
noted O O
. O O
  
Carotid O O
pulses O O
are O O
symmetric O O
. O O
  
There O O
is O O
no O O
jugular B-SSLIF B-SSLIF
venous I-SSLIF I-SSLIF
distention I-SSLIF I-SSLIF
. O O
  
Trachea O O
is O O
in O O
the O O
midline O O
. O O
  
There O O
is O O
no O O
occipital B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
preauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
retroauricular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
submandibular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
neck I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
posterior I-SSLIF I-SSLIF
cervical I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
infraclavicular I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
noted O O
. O O
  
Carotid O O
pulses O O
are O O
symmetric O O
. O O
  
There O O
is O O
no O O
jugular B-SSLIF B-SSLIF
venous I-SSLIF I-SSLIF
distention I-SSLIF I-SSLIF
. O O
  
Trachea O O
is O O
in O O
the O O
midline O O
and O O
the O O
thyroid B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
not I-SSLIF I-SSLIF
enlarged I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Chest O O
wall O O
contour O O
symmetric O O
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
HEART O O
: O O
Reveals O O
no O O
adventitious O O
sound O O
. O O
  
ABDOMEN B-SSLIF B-SSLIF
: I-SSLIF I-SSLIF
Nontender I-SSLIF I-SSLIF
without O O
ascites B-SSLIF B-SSLIF
or O O
organomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
There O O
is O O
no O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
Peripheral O O
pulses O O
are O O
symmetric O O
and O O
intact O O
. O O
  
Neuromuscular O O
challenge O O
reveals O O
no O O
sensory O O
or O O
motor O O
asymmetry O O
. O O
  
There O O
is O O
no O O
specific O O
area O O
of O O
focal B-SSLIF B-SSLIF
bony I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
noted O O
. O O
  
There O O
is O O
good O O
range O O
of O O
motion O O
of O O
all O O
joint O O
surfaces O O
evaluated O O
. O O
  
MUSCULOSKELETAL O O
: O O
The O O
gait O O
remains O O
normal O O
. O O
  
IMPRESSION O O
: O O
Stable O O
clinical O O
status O O
. O O
  
The O O
patient O O
is O O
doing O O
well O O
at O O
this O O
juncture O O
. O O
  
The O O
patient O O
will O O
continue O O
to O O
be O O
carefully O O
monitored O O
by O O
Dr O O
. O O
  
Name O O
and O O
Dr O O
. O O
  
Name O O
. O O
  
I O O
will O O
see O O
him O O
in O O
1 O O
year O O
or O O
sooner O O
if O O
indicated O O
. O O
  
Forty O O
minutes O O
were O O
spent O O
reviewing O O
information O O
on O O
this O O
patient O O
with O O
30 O O
minutes O O
spent O O
in O O
face O O
- O O
to O O
- O O
face O O
interaction O O
including O O
examination O O
, O O
discussion O O
, O O
generation O O
of O O
note O O
, O O
review O O
of O O
care O O
plan O O
. O O
  
cc O O
: O O
Name O O
Name O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
11 O O
: O O
22 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
FI B-PHI B-PHI
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Physician O O
Copy O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
1 O O
: O O
44 O O
P O O
Transcribed O O
Date O O
3 O O
: O O
42 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
feeling O O
well O O
. O O
  
He O O
has O O
noted O O
a O O
significant O O
decrease O O
in O O
crusting B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinus I-SSLIF I-SSLIF
cavities I-SSLIF I-SSLIF
and O O
has O O
had O O
no O O
bleeding B-SSLIF B-SSLIF
. O O
  
He O O
has O O
no O O
complaints O O
of O O
difficulty B-SSLIF B-SSLIF
breathing I-SSLIF I-SSLIF
through I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
. O O
  
He O O
has O O
no O O
visual B-SSLIF B-SSLIF
disturbances I-SSLIF I-SSLIF
. O O
  
He O O
has O O
no O O
pain B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
, O O
dysphagia B-SSLIF B-SSLIF
, O O
or O O
odynophagia B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
excellent O O
and O O
his O O
weight O O
has O O
been O O
stable O O
. O O
  
He O O
has O O
no O O
cardiac B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
pulmonary I-SSLIF I-SSLIF
problems I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
His O O
voice O O
is O O
normal O O
, O O
without O O
hoarseness B-SSLIF B-SSLIF
or O O
stridor B-SSLIF B-SSLIF
. O O
  
He O O
is O O
well O O
developed O O
and O O
well O O
nourished O O
. O O
  
EACs O O
are O O
clean O O
and O O
TMs O O
are O O
intact O O
. O O
  
Vision O O
and O O
extraocular O O
motions O O
are O O
intact O O
without O O
orbital B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
cellulitis B-SSLIF B-SSLIF
, O O
or O O
pain B-SSLIF B-SSLIF
. O O
  
Nasal O O
exam O O
shows O O
a O O
surprisingly O O
normal O O
appearing O O
mucosa O O
in O O
the O O
remaining O O
portions O O
. O O
  
The O O
septum B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
essentially I-SSLIF I-SSLIF
all I-SSLIF I-SSLIF
gone I-SSLIF I-SSLIF
along I-SSLIF I-SSLIF
with I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
walls I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
maxillary I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
. O O
  
He O O
has O O
one B-SSLIF B-SSLIF
big I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
. O O
  
Minimal B-Severity B-Severity
dryness B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
noted I-SSLIF I-SSLIF
laterally I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
bleeding B-SSLIF B-SSLIF
. O O
  
No O O
abnormal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
are O O
appreciated O O
. O O
  
The O O
choanae O O
are O O
clean O O
. O O
  
There O O
is O O
no O O
paranasal B-SSLIF B-SSLIF
sinus I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
Nasopharynx O O
is O O
clean O O
and O O
eustachian O O
tubes O O
are O O
intact O O
. O O
  
Oral O O
cavity O O
and O O
oropharynx O O
are O O
normal O O
. O O
  
Gums O O
and O O
lips O O
are O O
clean O O
. O O
  
Trachea O O
is O O
midline O O
. O O
  
There O O
is O O
no O O
thyromegaly B-SSLIF B-SSLIF
or O O
cervical B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
IMPRESSION O O
: O O
Status O O
post O O
radiation O O
therapy O O
for O O
lymphoma B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
evidence O O
of O O
recurrent O O
disease O O
. O O
  
PLAN O O
: O O
Return O O
in O O
6 O O
months O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
14 O O
: O O
51 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
PR B-PHI B-PHI
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
Discharge O O
Instructions O O
Medications O O
It O O
is O O
the O O
responsibility O O
of O O
the O O
patient O O
or O O
patient O O
representative O O
to O O
confirm O O
the O O
list O O
of O O
medications O O
with O O
either O O
the O O
patient's O O
personal O O
care O O
provider O O
or O O
the O O
patient's O O
follow O O
- O O
up O O
care O O
provider O O
to O O
ensure O O
the O O
patient O O
has O O
an O O
appropriate O O
list O O
of O O
medications O O
to O O
take O O
at O O
home O O
. O O
  
Preliminary O O
list O O
- O O
medication O O
reconciliation O O
not O O
completed O O
. O O
  
Discharge O O
medications O O
acyclovir B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
enalapril B-Drug B-Drug
maleate I-Drug I-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
Additional O O
Instructions O O
: O O
HOLD O O
IF O O
SBP O O
< O O
___ O O
oxyCODONE B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
four I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
Pain B-Indication B-Indication
pantoprazole B-Drug B-Drug
( I-Drug I-Drug
ProTONIX I-Drug I-Drug
) I-Drug I-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, I-Dose I-Dose
Delayed I-Dose I-Dose
Release I-Dose I-Dose
( I-Dose I-Dose
E.C. I-Dose I-Dose
) I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
Additional O O
Instructions O O
: O O
THERAPEUTIC O O
INTERCHANGE O O
FOR O O
ESOMEPRAZOLE B-Drug B-Drug
prochlorperazine I-Drug I-Drug
maleate I-Drug I-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
Nausea B-Indication B-Indication
/ O O
Vomiting B-Indication B-Indication
levofloxacin B-Drug B-Drug
( I-Drug I-Drug
LevaQUIN I-Drug I-Drug
) I-Drug I-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
posaconazole B-Drug B-Drug
200 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
5 I-Dose I-Dose
mL I-Dose I-Dose
( I-Dose I-Dose
40 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
mL I-Dose I-Dose
) I-Dose I-Dose
Suspension I-Dose I-Dose
Directions O O
: O O
5 B-Dose B-Dose
mL I-Dose I-Dose
oral B-Route B-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
dayAdditional I-Frequency I-Frequency
Instructions O O
: O O
with O O
meals O O
ondansetron B-Drug B-Drug
HCl I-Drug I-Drug
( I-Drug I-Drug
Zofran I-Drug I-Drug
) I-Drug I-Drug
8 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
PRN I-Frequency I-Frequency
nausea B-Indication B-Indication
or O O
vomiting B-Indication B-Indication
Stopped O O
medications O O
None O O
Detailed O O
Instructions O O
Discharge O O
Instructions O O
Discharge O O
Instructions O O
from O O
Date O O
11 O O
: O O
37 O O
AM O O
: O O
  
PRN O O
Statement O O
/ O O
Explanation O O
: O O
In O O
the O O
Medications O O
section O O
above O O
, O O
you O O
may O O
see O O
the O O
term O O
"PRN." O O
This O O
term O O
means O O
"as O O
needed." O O
You O O
do O O
not O O
need O O
to O O
take O O
these O O
medications O O
unless O O
you O O
are O O
having O O
that O O
specific O O
symptom O O
. O O
  
You O O
are O O
being O O
discharged O O
from O O
: O O
Hospital O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Diagnoses O O
/ O O
Problems O O
During O O
this O O
Admission O O
: O O
lymphoma B-Indication B-Indication
Why O O
You O O
Were O O
Admitted O O
: O O
You O O
where O O
admitted O O
for O O
stem O O
cell O O
mobilization O O
chemotherapy B-Drug B-Drug
. O O
  
Attending O O
Physician O O
: O O
Name O O
Name O O
Attending O O
MSI O O
Number O O
: O O
Identifiers O O
Primary O O
Care O O
Provider O O
: O O
Name O O
Name O O
Primary O O
Care O O
MSI O O
Number O O
: O O
Identifiers O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
11am O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
clinic O O
for O O
neulasta B-Drug B-Drug
; O O
labs O O
? O O
transfusion O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Date O O
10 O O
: O O
30 O O
am O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
labs O O
/ O O
? O O
transusion O O
support O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Location O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Date O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
9 O O
: O O
30am O O
labs O O
? O O
transfusion O O
support O O
Provider O O
visit O O
10am O O
Other O O
Discharge O O
Instructions O O
: O O
call O O
with O O
fever B-SSLIF B-SSLIF
gerater O O
than O O
or O O
equal O O
to O O
100.5 O O
, O O
persistant O O
diarhea B-SSLIF B-SSLIF
, O O
vomitting B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
or O O
unable B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
tolerate I-SSLIF I-SSLIF
po I-SSLIF I-SSLIF
liquids I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
solids I-SSLIF I-SSLIF
. O O
  
Clinic O O
number O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
; O O
after O O
5pm O O
call O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
the O O
hospital O O
main O O
number O O
and O O
ask O O
to O O
speak O O
wit O O
the O O
provider O O
covering O O
for O O
Dr O O
. O O
  
Name O O
. O O
  
Discharge O O
Disposition O O
: O O
Home O O
- O O
No O O
Services O O
Discharge O O
to O O
Other O O
Facility O O
: O O
Company O O
Discharge O O
Activity O O
: O O
As O O
Tolerated O O
Special O O
Diet O O
Instructions O O
: O O
Neutropenic O O
Case O O
Manager O O
/ O O
Social O O
Worker O O
Discharge O O
Note O O
: O O
No O O
services O O
Discharge O O
Planning O O
Coordinator O O
: O O
Name O O
Name O O
RN O O
Planning O O
Coordinator O O
Contact O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Smoking O O
Statement O O
: O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability B-SSLIF B-SSLIF
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die B-SSLIF B-SSLIF
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
' O O
Helpline O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Discharge O O
Medication O O
Reconciliation O O
Statement O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
Authorization O O
Statement O O
: O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plans O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
Translator O O
Signature O O
/ O O
Relationship O O
: O O
______________________________________________________________________ O O
  
RN O O
Signature O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
Patient O O
/ O O
Responsible O O
Party O O
Signature O O
, O O
Relationship O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
General O O
Instructions O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
03 O O
: O O
30 O O
AM O O
Clinic O O
Note O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
approximately O O
4 O O
weeks O O
status O O
post O O
autologous O O
stem O O
cell O O
transplant O O
for O O
NK B-SSLIF B-SSLIF
/ I-SSLIF I-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
lacrimal I-SSLIF I-SSLIF
system I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinonasal I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
. O O
  
He O O
is O O
7 O O
weeks O O
status O O
post O O
completion O O
of O O
radiation O O
therapy O O
for O O
extranodal B-SSLIF B-SSLIF
NK I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
of O O
the O O
same O O
area O O
. O O
  
He O O
is O O
also O O
over O O
5 O O
years O O
status O O
post O O
radiation O O
therapy O O
for O O
lymphoma B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
, O O
and O O
more O O
recently O O
radiation O O
therapy O O
for O O
laryngeal B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
vocal I-SSLIF I-SSLIF
cords I-SSLIF I-SSLIF
. O O
  
He O O
continues O O
to O O
have O O
significant B-Severity B-Severity
crusting B-SSLIF B-SSLIF
and O O
scabbing B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
sinonasal I-SSLIF I-SSLIF
cavity O O
, O O
which O O
makes O O
it O O
very B-Severity B-Severity
difficult B-SSLIF B-SSLIF
for I-SSLIF I-SSLIF
him I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
breathe I-SSLIF I-SSLIF
. O O
  
He O O
has O O
some B-Severity B-Severity
pain B-SSLIF B-SSLIF
in O O
that O O
region O O
as O O
well O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
His O O
voice O O
is O O
normal O O
without O O
hoarseness B-SSLIF B-SSLIF
or O O
stridor B-SSLIF B-SSLIF
. O O
  
He O O
is O O
adequately O O
developed O O
and O O
nourished O O
and O O
is O O
oriented O O
x3 O O
. O O
  
He O O
has O O
normal O O
skin O O
turgor O O
and O O
texture O O
. O O
  
Vision O O
and O O
extraocular O O
motions O O
are O O
grossly O O
intact O O
. O O
  
There O O
is O O
some B-Severity B-Severity
discoloration B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
over I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lacrimal I-SSLIF I-SSLIF
system I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
cheek I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
well I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
nasal I-SSLIF I-SSLIF
region I-SSLIF I-SSLIF
. O O
  
There O O
is O O
a O O
small B-Severity B-Severity
scab B-SSLIF B-SSLIF
over I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
bridge I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
measuring O O
approximately O O
0.5 B-Severity B-Severity
cm I-Severity I-Severity
in I-Severity I-Severity
diameter I-Severity I-Severity
. O O
  
There O O
is O O
no O O
evidence O O
of O O
acute O O
infection B-SSLIF B-SSLIF
, O O
but O O
there O O
is O O
a O O
small B-Severity B-Severity
ulcer B-SSLIF B-SSLIF
on O O
which O O
the O O
scab B-SSLIF B-SSLIF
sits O O
. O O
  
Intranasally O O
, O O
the O O
patient O O
has O O
1 B-SSLIF B-SSLIF
large I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
sides I-SSLIF I-SSLIF
with O O
absence B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
septum I-SSLIF I-SSLIF
. O O
  
The O O
entire O O
cavity O O
is O O
covered O O
with O O
a O O
thick B-Severity B-Severity
layer I-Severity I-Severity
of O O
dry B-SSLIF B-SSLIF
crust I-SSLIF I-SSLIF
and O O
scabs B-SSLIF B-SSLIF
. O O
  
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
Local O O
anesthesia O O
was O O
obtained O O
with O O
topical B-Route B-Route
lidocaine B-Drug B-Drug
sprayed O O
into O O
the O O
nostrils O O
bilaterally O O
. O O
  
The O O
large B-Severity B-Severity
scabs B-SSLIF B-SSLIF
and O O
crusts B-SSLIF B-SSLIF
were O O
removed O O
piecemeal O O
with O O
the O O
cup O O
forceps O O
and O O
Hartmann O O
forceps O O
. O O
  
The O O
entire O O
cavity O O
was O O
cleaned O O
completely O O
. O O
  
There O O
was O O
no O O
evidence O O
of O O
bleeding B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
. O O
  
Nasopharynx O O
was O O
clean O O
thereafter O O
. O O
  
Oral O O
cavity O O
and O O
oropharynx O O
are O O
within O O
normal O O
limits O O
. O O
  
Trachea O O
is O O
midline O O
. O O
  
There O O
is O O
no O O
thyromegaly B-SSLIF B-SSLIF
or O O
cervical B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
IMPRESSION O O
: O O
Four O O
weeks O O
status O O
post O O
autologous O O
stem O O
cell O O
transplant O O
for O O
NK B-SSLIF B-SSLIF
/ I-SSLIF I-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
He O O
is O O
also O O
7 O O
weeks O O
status O O
post O O
completion O O
of O O
radiation O O
therapy O O
for O O
extranodal B-SSLIF B-SSLIF
NK I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
T I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lacrimal I-SSLIF I-SSLIF
system I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinonasal I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
with O O
dehiscence B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
lamina I-SSLIF I-SSLIF
papyracea I-SSLIF I-SSLIF
. O O
  
He O O
is O O
over O O
5 O O
years O O
status O O
post O O
radiation O O
therapy O O
for O O
lymphoma B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
sinonasal I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
and O O
more O O
recently O O
, O O
radiation O O
therapy O O
for O O
laryngeal B-SSLIF B-SSLIF
carcinoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
vocal I-SSLIF I-SSLIF
cords I-SSLIF I-SSLIF
. O O
  
PLAN O O
: O O
Return O O
in O O
2 O O
weeks O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
MD O O
Name O O
Name O O
Name O O
MD O O
Name O O
Name O O
M.D. O O
  
Name O O
Name O O
Name O O
MD O O
Name O O
Name O O
Name O O
, O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
2 O O
: O O
28PM O O
EST O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
2 O O
: O O
21 O O
P O O
Transcribed O O
Date O O
3 O O
: O O
44 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
doing O O
quite O O
well O O
. O O
  
He O O
has O O
no O O
significant B-Severity B-Severity
complaints B-SSLIF B-SSLIF
related I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
at O O
this O O
time O O
. O O
  
He O O
has O O
not O O
noted O O
significant B-Severity B-Severity
crusting B-SSLIF B-SSLIF
and O O
when O O
there O O
is O O
, O O
it O O
comes O O
out O O
quite O O
readily O O
by O O
blowing O O
his O O
nose O O
. O O
  
He O O
has O O
no O O
visual B-SSLIF B-SSLIF
disturbances I-SSLIF I-SSLIF
. O O
  
He O O
has O O
no O O
cardiac B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
pulmonary I-SSLIF I-SSLIF
issues I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Negative O O
. O O
  
His O O
appetite O O
is O O
excellent O O
and O O
his O O
weight O O
has O O
been O O
stable O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
and O O
his O O
voice O O
is O O
normal O O
, O O
without O O
hoarseness B-SSLIF B-SSLIF
or O O
stridor B-SSLIF B-SSLIF
. O O
  
He O O
is O O
well O O
developed O O
and O O
well O O
nourished O O
and O O
is O O
oriented O O
to O O
time O O
, O O
place O O
and O O
person O O
. O O
  
Ears O O
are O O
normal O O
. O O
  
TMs O O
are O O
intact O O
. O O
  
Vision O O
and O O
extraocular O O
motions O O
are O O
grossly O O
intact O O
without O O
orbital B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
or O O
cellulitis B-SSLIF B-SSLIF
. O O
  
Nasal O O
exam O O
shows O O
widely B-SSLIF B-SSLIF
open I-SSLIF I-SSLIF
cavity I-SSLIF I-SSLIF
encompassing I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
nasal I-SSLIF I-SSLIF
cavities I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
maxillary I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
. O O
  
Septum B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
completely I-SSLIF I-SSLIF
absent I-SSLIF I-SSLIF
. O O
  
The O O
medial B-SSLIF B-SSLIF
walls I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
maxillary I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
also I-SSLIF I-SSLIF
completely I-SSLIF I-SSLIF
absent I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
sides I-SSLIF I-SSLIF
. O O
  
There O O
is O O
good O O
and O O
appearing O O
mucosa O O
covering O O
the O O
entire O O
cavity O O
. O O
  
Minimal B-Severity B-Severity
mucusy B-SSLIF B-SSLIF
discharge I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
noted I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
. O O
  
Choanae O O
are O O
clear O O
bilaterally O O
. O O
  
Superior O O
aspects O O
of O O
the O O
nasal O O
cavity O O
is O O
also O O
clean O O
. O O
  
There O O
is O O
no O O
paranasal B-SSLIF B-SSLIF
sinus I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
moderate B-Severity B-Severity
saddle B-SSLIF B-SSLIF
nose I-SSLIF I-SSLIF
deformity I-SSLIF I-SSLIF
from O O
the O O
lymphoma B-SSLIF B-SSLIF
and O O
treatment O O
. O O
  
Lips O O
and O O
gums O O
are O O
normal O O
. O O
  
Tongue O O
mobility O O
is O O
full O O
and O O
floor O O
of O O
mouth O O
is O O
clean O O
and O O
soft O O
. O O
  
Nasopharynx O O
is O O
clear O O
. O O
  
Eustachian O O
tubes O O
are O O
intact O O
and O O
patent O O
. O O
  
Base O O
of O O
tongue O O
and O O
epiglottis O O
normal O O
and O O
vallecula O O
was O O
clear O O
. O O
  
Vocal O O
cords O O
are O O
fully O O
mobile O O
without O O
lesions B-SSLIF B-SSLIF
or O O
masses B-SSLIF B-SSLIF
. O O
  
Airway O O
is O O
widely O O
patent O O
. O O
  
Trachea O O
is O O
midline O O
. O O
  
There O O
is O O
no O O
thyromegaly B-SSLIF B-SSLIF
or O O
cervical B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
Salivary O O
glands O O
are O O
normal O O
. O O
  
IMPRESSION O O
: O O
The O O
patient O O
is O O
status O O
post O O
radiation O O
therapy O O
for O O
lymphoma B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
nose I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
sinuses I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
evidence O O
of O O
recurrent B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
PLAN O O
: O O
Return O O
in O O
one O O
year O O
. O O
  
CC O O
: O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
13 O O
: O O
14 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
SG B-PHI B-PHI
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Physician O O
Copy O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Location O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
6 O O
: O O
31 O O
P O O
HISTORY O O
AND O O
PHYSICAL O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
REASON O O
FOR O O
ADMISSION O O
: O O
Facial B-Indication B-Indication
cellulitis I-Indication I-Indication
x48 O O
hours O O
. O O
  
PRIMARY O O
CARE O O
PHYSICIAN O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
ADMITTING O O
ATTENDING O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
was O O
in O O
his O O
usual O O
state O O
of O O
health O O
until O O
  
48 O O
hours O O
ago O O
when O O
he O O
began O O
to O O
note O O
some B-Severity B-Severity
redness B-SSLIF B-SSLIF
and O O
swelling B-SSLIF B-SSLIF
around I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
eye I-SSLIF I-SSLIF
. O O
  
He O O
also O O
had O O
a O O
small B-Severity B-Severity
papule B-SSLIF B-SSLIF
that O O
then O O
became O O
larger O O
and O O
started O O
to O O
express O O
pus B-SSLIF B-SSLIF
. O O
  
He O O
did O O
call O O
the O O
hematology O O
fellow O O
on O O
- O O
call O O
, O O
who O O
was O O
Dr O O
. O O
  
Name O O
Name O O
and O O
was O O
started O O
on O O
cephalexin B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
The O O
patient O O
was O O
febrile B-SSLIF B-SSLIF
to O O
approximately O O
101 O O
degrees O O
Fahrenheit O O
on O O
Saturday O O
. O O
  
He O O
states O O
that O O
after O O
he O O
took O O
the O O
antibiotic O O
, O O
he O O
felt O O
that O O
his O O
periorbital O O
area O O
started O O
to O O
improve O O
, O O
but O O
this O O
morning O O
he O O
states O O
it O O
started O O
to O O
worsen O O
once O O
again O O
and O O
a O O
low B-Severity B-Severity
- I-Severity I-Severity
grade I-Severity I-Severity
fever B-SSLIF B-SSLIF
was O O
noted O O
. O O
  
He O O
denied O O
any O O
associated O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
has O O
no O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
eyesight I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
he O O
has O O
no O O
systemic O O
symptoms O O
such O O
as O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
shaking B-SSLIF B-SSLIF
chills I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
comes O O
today O O
to O O
be O O
seen O O
and O O
since O O
the O O
cellulitis B-SSLIF B-SSLIF
appears O O
to O O
be O O
worsening O O
, O O
admission O O
is O O
indicated O O
. O O
  
The O O
patient O O
does O O
have O O
a O O
preexisting O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
diagnosed O O
initially O O
in O O
Date O O
and O O
associated O O
with O O
a O O
progressively O O
increasing O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
The O O
lymphoma B-Indication B-Indication
currently O O
is O O
acting O O
more O O
like O O
multiple B-Indication B-Indication
myeloma I-Indication I-Indication
. O O
  
He O O
has O O
had O O
significant B-Severity B-Severity
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
and O O
kyphoplasty O O
specimens O O
have O O
revealed O O
infiltration O O
with O O
lymphoplasmacytoid O O
cells O O
. O O
  
The O O
patient O O
is O O
currently O O
receiving O O
reduced O O
doses O O
of O O
Velcade B-Drug B-Drug
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
or I-Frequency I-Frequency
2 I-Frequency I-Frequency
out I-Frequency I-Frequency
of I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
. O O
  
The O O
doses O O
are O O
reduced O O
secondary O O
to O O
peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
. O O
  
He O O
is O O
also O O
on O O
thalidomide B-Drug B-Drug
for O O
the O O
same O O
problem O O
and O O
is O O
also O O
receiving O O
intermittent O O
pamidronate B-Drug B-Drug
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Please O O
see O O
the O O
dictations O O
in O O
Company O O
. O O
  
The O O
past O O
medical O O
history O O
involves O O
mainly O O
issues O O
around O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
did O O
have O O
an O O
extensive O O
hospitalization O O
in O O
Date O O
where O O
he O O
was O O
admitted O O
initially O O
for O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
because O O
of O O
septic B-SSLIF B-SSLIF
shock I-SSLIF I-SSLIF
developed O O
cardiac B-SSLIF B-SSLIF
/ I-SSLIF I-SSLIF
respiratory I-SSLIF I-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
with O O
intubation O O
and O O
acute O O
dialysis O O
as O O
needed O O
. O O
  
He O O
has O O
residual O O
peripheral B-SSLIF B-SSLIF
neuropathy I-SSLIF I-SSLIF
from O O
this O O
hospitalization O O
as O O
well O O
as O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
from O O
this O O
hospitalization O O
. O O
  
The O O
patient O O
has O O
bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
the O O
left B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
occurring O O
most O O
recently O O
in O O
Date O O
. O O
  
He O O
is O O
currently O O
on O O
Coumadin B-Drug B-Drug
for O O
this O O
. O O
  
He O O
is O O
also O O
status O O
post O O
IVC O O
filter O O
. O O
  
The O O
patient O O
has O O
hypertension B-SSLIF B-SSLIF
, O O
hypothyroidism B-SSLIF B-SSLIF
, O O
chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
which O O
is O O
multifactorial O O
and O O
a O O
history O O
of O O
psoriasis B-SSLIF B-SSLIF
. O O
  
PAST O O
SURGICAL O O
HISTORY O O
: O O
The O O
patient O O
did O O
have O O
debridement O O
of O O
the O O
right O O
gastrocnemius O O
muscle O O
because O O
of O O
the O O
fasciitis B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
no O O
recent O O
surgeries O O
. O O
  
The O O
patient O O
has O O
had O O
multiple O O
blood O O
and O O
platelet O O
transfusions O O
in O O
the O O
past O O
, O O
but O O
none O O
recently O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
These O O
are O O
listed O O
in O O
Company O O
and O O
include O O
alprazolam B-Drug B-Drug
, O O
low B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
aspirin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
and I-Drug I-Drug
vitamin I-Drug I-Drug
D I-Drug I-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
Lasix B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
gabapentin B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
, O O
glucosamine B-Drug B-Drug
, O O
Levoxyl B-Drug B-Drug
, O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
1 I-Dose I-Dose
tablet I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
and O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
45 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
morning I-Frequency I-Frequency
and O O
15 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
, O O
which O O
he O O
takes O O
regularly O O
. O O
  
He O O
is O O
also O O
on O O
pantoprazole B-Drug B-Drug
, O O
prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
and O O
Coumadin B-Drug B-Drug
. O O
  
ALLERGIES O O
: O O
The O O
patient O O
has O O
no O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
His O O
father O O
died B-SSLIF B-SSLIF
of O O
acute O O
leukemia B-SSLIF B-SSLIF
at O O
an O O
advanced O O
age O O
and O O
also O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
He O O
has O O
1 O O
brother O O
who O O
is O O
well O O
, O O
but O O
is O O
unfortunately O O
not O O
an O O
HLA O O
match O O
. O O
  
He O O
has O O
several O O
children O O
who O O
are O O
well O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
As O O
noted O O
above O O
, O O
the O O
patient O O
has O O
had O O
a O O
low O O
- O O
grade O O
fever O O
. O O
  
He O O
denies O O
any O O
pain B-SSLIF B-SSLIF
over O O
the O O
lesions B-SSLIF B-SSLIF
. O O
  
He O O
has O O
not O O
had O O
any O O
pain B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
side I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
face I-SSLIF I-SSLIF
and O O
his O O
eyesight O O
is O O
normal O O
. O O
  
He O O
denies O O
any O O
headache B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
or O O
increased O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
chronic O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
problems O O
with O O
his O O
skin O O
, O O
but O O
has O O
had O O
no O O
significant O O
problems O O
recently O O
. O O
  
He O O
does O O
have O O
chronic O O
musculoskeletal B-Indication B-Indication
pain I-Indication I-Indication
, O O
especially O O
in O O
the O O
back O O
. O O
  
This O O
is O O
well O O
controlled O O
by O O
his O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
as O O
well O O
as O O
his O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
lives O O
at O O
home O O
by O O
himself O O
. O O
  
His O O
performance O O
status O O
of O O
ECOG O O
0 O O
- O O
1 O O
. O O
  
He O O
is O O
on O O
disability O O
currently O O
. O O
  
He O O
was O O
in O O
the O O
IT O O
industry O O
. O O
  
He O O
does O O
do O O
all O O
activities O O
of O O
daily O O
living O O
including O O
driving O O
. O O
  
Unfortunately O O
, O O
he O O
has O O
minimal O O
family O O
support O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
The O O
patient O O
had O O
a O O
low B-Severity B-Severity
- I-Severity I-Severity
grade I-Severity I-Severity
fever B-SSLIF B-SSLIF
of O O
37.6 O O
degrees O O
centigrade O O
. O O
  
Blood O O
pressure O O
158 O O
/ O O
81 O O
, O O
pulse O O
94 O O
and O O
regular O O
and O O
his O O
weight O O
is O O
120.3 O O
kg O O
, O O
which O O
is O O
basically O O
stable O O
. O O
  
HEENT O O
: O O
There O O
is O O
reddening B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
conjunctiva I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
eye I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
a O O
raised B-SSLIF B-SSLIF
weeping I-SSLIF I-SSLIF
3 I-SSLIF I-SSLIF
x I-SSLIF I-SSLIF
2 I-SSLIF I-SSLIF
erythematous I-SSLIF I-SSLIF
lesion I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
middle I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
forehead I-SSLIF I-SSLIF
. O O
  
There O O
is O O
a O O
papule B-SSLIF B-SSLIF
, O O
which O O
is O O
crusted B-SSLIF B-SSLIF
, O O
but O O
also O O
leaking O O
pus B-SSLIF B-SSLIF
right I-SSLIF I-SSLIF
above I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
eye I-SSLIF I-SSLIF
on O O
the O O
medial O O
aspect O O
above O O
the O O
eyebrow O O
. O O
  
There O O
is O O
erythema B-SSLIF B-SSLIF
around I-SSLIF I-SSLIF
both I-SSLIF I-SSLIF
eyes I-SSLIF I-SSLIF
. O O
  
Pharynx O O
benign O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
I O O
cannot O O
palpate O O
any O O
organomegaly B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
The O O
patient O O
wears O O
bilateral O O
compression O O
stockings O O
. O O
  
He O O
has O O
no O O
other O O
significant B-Severity B-Severity
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
revealed O O
a O O
white B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
1700 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
little I-SSLIF I-SSLIF
bit I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
than O O
he O O
usually O O
runs O O
with O O
55 O O
polys O O
, O O
19.2 O O
lymphs O O
, O O
21.4 O O
monocytes O O
, O O
3.6 O O
eos O O
, O O
  
0.8 O O
basophils O O
, O O
a O O
platelet B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
130 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
000 I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
again I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
than O O
he O O
usually O O
runs O O
and O O
a O O
hemoglobin O O
of O O
9.7 O O
with O O
hematocrit O O
of O O
28.9 O O
, O O
which O O
is O O
basically O O
stable O O
. O O
  
Electrolytes O O
reveal O O
serum O O
sodium O O
of O O
134 O O
. O O
  
BUN O O
is O O
29 O O
, O O
creatinine O O
is O O
  
1.65 O O
, O O
which O O
is O O
stable O O
. O O
  
A O O
total O O
protein O O
is O O
9.6 O O
, O O
which O O
is O O
stable O O
with O O
an O O
albumin O O
of O O
2.9 O O
, O O
which O O
is O O
also O O
stable O O
. O O
  
AST O O
is O O
28 O O
, O O
ALT O O
is O O
30 O O
and O O
an O O
LDH O O
is O O
178 O O
. O O
  
A O O
prothrombin O O
time O O
was O O
done O O
approximately O O
3 O O
weeks O O
ago O O
and O O
was O O
1.7 O O
. O O
  
ASSESSMENT O O
: O O
  
1. O O
Name O O
Name O O
is O O
a O O
54 O O
- O O
year O O
- O O
old O O
male O O
with O O
an O O
acute O O
problem O O
which O O
is O O
facial B-Indication B-Indication
cellulitis I-Indication I-Indication
. O O
  
The O O
patient O O
should O O
get O O
intravenous O O
fluids O O
. O O
  
I O O
had O O
considered O O
treating O O
him O O
as O O
an O O
outpatient O O
but O O
I O O
am O O
not O O
sure O O
what O O
bacteria O O
if O O
any O O
this O O
is O O
due O O
to O O
. O O
  
The O O
lesion B-SSLIF B-SSLIF
should O O
be O O
cultured O O
. O O
  
I O O
have O O
drawn O O
blood O O
cultures O O
. O O
  
Additionally O O
, O O
he O O
has O O
received O O
1 B-Dose B-Dose
g I-Dose I-Dose
of O O
vancomycin B-Drug B-Drug
in O O
the O O
clinic O O
. O O
  
Since O O
we O O
do O O
not O O
know O O
what O O
this O O
is O O
probably O O
vancomycin B-Drug B-Drug
should O O
be O O
included O O
in O O
the O O
antibiotic B-Drug B-Drug
mix I-Drug I-Drug
until O O
culture O O
is O O
obtained O O
, O O
but O O
I O O
will O O
leave O O
this O O
decision O O
to O O
the O O
inpatient O O
attending O O
as O O
well O O
perhaps O O
ID O O
to O O
sort O O
this O O
out O O
. O O
  
2. O O
Lymphoplasmacytoid B-Indication B-Indication
lymphoma I-Indication I-Indication
: O O
The O O
patient O O
is O O
under O O
treatment O O
. O O
  
His O O
thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
should O O
be O O
continued O O
. O O
  
3. O O
Pancytopenia B-ADE B-ADE
: O O
The O O
patient O O
is O O
a O O
little O O
more O O
pancytopenic B-ADE B-ADE
than O O
usual O O
. O O
  
This O O
could O O
be O O
from O O
his O O
Velcade B-Drug B-Drug
and O O
thalidomide B-Drug B-Drug
. O O
  
If O O
the O O
white B-SSLIF B-SSLIF
blood I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
count I-SSLIF I-SSLIF
continues I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
fall I-SSLIF I-SSLIF
, O O
then O O
I O O
would O O
hold O O
the O O
thalidomide B-Drug B-Drug
. O O
  
4. O O
Bilateral B-Indication B-Indication
DVT I-Indication I-Indication
: O O
The O O
patient O O
does O O
need O O
PT O O
/ O O
INR O O
checked O O
. O O
  
I O O
would O O
continue O O
him O O
on O O
the O O
same O O
dose O O
of O O
Coumadin B-Drug B-Drug
, O O
although O O
it O O
may O O
have O O
to O O
be O O
increased O O
if O O
the O O
PT O O
comes O O
back O O
in O O
a O O
nontherapeutic O O
range O O
. O O
  
5. O O
Chronic O O
back B-Indication B-Indication
pain I-Indication I-Indication
: O O
The O O
patient O O
should O O
continue O O
on O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
45 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
morning I-Frequency I-Frequency
and O O
15 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
. O O
  
He O O
should O O
also O O
get O O
30 B-Dose B-Dose
mg I-Dose I-Dose
MSIR B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
every I-Frequency I-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
. O O
  
He O O
should O O
be O O
allowed O O
to O O
ambulate O O
ad O O
lib O O
. O O
  
RECOMMENDATIONS O O
: O O
As O O
above O O
. O O
  
1 O O
. O O
  
The O O
patient O O
will O O
need O O
antibiotics B-Drug B-Drug
including O O
vancomycin B-Drug B-Drug
at O O
least O O
until O O
cultures O O
are O O
obtained O O
. O O
  
2. O O
Cultures O O
should O O
be O O
obtained O O
of O O
the O O
weeping B-SSLIF B-SSLIF
lesion I-SSLIF I-SSLIF
above I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
eye I-SSLIF I-SSLIF
. O O
  
Blood O O
cultures O O
have O O
been O O
drawn O O
and O O
are O O
pending O O
. O O
  
3 O O
. O O
  
The O O
patient O O
is O O
extremely O O
nervous O O
about O O
this O O
hospitalization O O
, O O
so O O
if O O
there O O
is O O
an O O
indication O O
that O O
the O O
cellulitis B-SSLIF B-SSLIF
is O O
improving O O
, O O
I O O
would O O
just O O
let O O
him O O
go O O
home O O
and O O
we O O
can O O
treat O O
him O O
as O O
an O O
outpatient O O
. O O
  
Attending O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
  
===================== O O
END O O
OF O O
DOCUMENT O O
/ O O
CHANGE O O
LOG O O
FOLLOWS O O
===================== O O
Last O O
Edited O O
By O O
Elec O O
. O O
  
Signed O O
By O O
Name O O
Name O O
MD O O
# O O
Identifiers O O
Name O O
Name O O
MD O O
# O O
Identifiers O O
on O O
Date O O
18 O O
: O O
37 O O
on O O
Date O O
18 O O
: O O
37 O O
Revision O O
Number O O
- O O
2 O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
3 O O
: O O
09 O O
P O O
  
12 O O
: O O
44 O O
P O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
returns O O
today O O
for O O
followup O O
visit O O
for O O
his O O
epistaxis B-SSLIF B-SSLIF
. O O
  
This O O
patient O O
was O O
followed O O
while O O
inpatient O O
by O O
Dr O O
. O O
  
Name O O
and O O
myself O O
. O O
  
I O O
have O O
replaced O O
his O O
inflatable O O
Rhinorocket O O
with O O
an O O
8 O O
cm O O
Merocel O O
on O O
Friday O O
. O O
  
The O O
patient O O
returns O O
today O O
for O O
removal O O
of O O
the O O
aforementioned O O
packing O O
. O O
  
He O O
is O O
treated O O
with O O
anticoagulation B-Drug B-Drug
and O O
aspirin B-Drug B-Drug
for O O
underlying O O
coagulopathy B-Indication B-Indication
and O O
previous O O
DVT B-Indication B-Indication
. O O
  
That O O
has O O
been O O
discontinued O O
. O O
  
His O O
current O O
INR O O
is O O
running O O
about O O
1.0 O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
On O O
examination O O
today O O
, O O
the O O
patient O O
is O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
There O O
was O O
no O O
bleeding B-SSLIF B-SSLIF
in O O
the O O
oropharynx O O
. O O
  
The O O
nasal O O
packing O O
was O O
removed O O
without O O
difficulty O O
. O O
  
The O O
nasal O O
vault O O
was O O
then O O
suctioned O O
and O O
there O O
was O O
no O O
further O O
bleeding B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
was O O
kept O O
in O O
the O O
office O O
for O O
about O O
15 O O
minutes O O
with O O
no O O
further O O
bleeding B-SSLIF B-SSLIF
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
I O O
have O O
extensively O O
discussed O O
nosebleed B-SSLIF B-SSLIF
precautions O O
with O O
him O O
, O O
particularly O O
those O O
involving O O
decreased O O
activity O O
, O O
humidification O O
, O O
hydration O O
and O O
abstaining O O
from O O
nasal O O
projectiles O O
. O O
  
I O O
discussed O O
the O O
case O O
with O O
the O O
nurse O O
practitioner O O
and O O
/ O O
or O O
physician O O
assistant O O
and O O
agree O O
with O O
the O O
findings O O
and O O
plan O O
as O O
documented O O
in O O
the O O
note O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
09 O O
: O O
39 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
PA O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Print O O
on O O
Date O O
at O O
11 O O
: O O
42am O O
Hospital O O
PATIENT O O
DISCHARGE O O
CARE O O
FORM O O
Discharged O O
From O O
: O O
Hospital O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Location O O
: O O
Location O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Patient O O
DOB O O
: O O
Date O O
Address O O
Street_Address O O
City O O
State O O
/ O O
Zipcode O O
Patient O O
Next O O
of O O
Kin O O
Name O O
, O O
Name O O
Patient O O
Phone O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Next O O
of O O
Kin O O
Phone O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Patient O O
Medical O O
Record# O O
Medical_Record_Number O O
Patient O O
Account# O O
: O O
Medical_Record_Number O O
ADMIT O O
DATE O O
Date O O
DISCHARGE O O
DATE O O
DISCHARGE O O
TIME O O
Insurance O O
Information O O
Company O O
PATIENT'S O O
PHYSICIANS O O
SPECIALTY O O
PHONE# O O
FAX O O
PRIMARY O O
: O O
Name O O
, O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
REFERRING O O
: O O
Name O O
, O O
Name O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
ATTENDING O O
: O O
Name O O
, O O
Name O O
Name O O
HEMATOLOGY O O
/ O O
ONCOLOGY O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Health O O
Proxy O O
Info O O
- O O
Agent O O
Name O O
: O O
Name O O
, O O
Name O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
PRIMARY O O
DIAGNOSIS O O
CELLULITIS B-SSLIF B-SSLIF
SECONDARY O O
DIAGNOSIS O O
DVT B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
BILATERAL I-SSLIF I-SSLIF
LOWER I-SSLIF I-SSLIF
EXT I-SSLIF I-SSLIF
LYMPHOMA B-SSLIF B-SSLIF
ACUTE B-SSLIF B-SSLIF
ON I-SSLIF I-SSLIF
CHRONIC I-SSLIF I-SSLIF
RENAL I-SSLIF I-SSLIF
INSUFF I-SSLIF I-SSLIF
  
HYPONATREMIA B-SSLIF B-SSLIF
ANEMIA B-SSLIF B-SSLIF
, O O
CHRONIC O O
CHRONIC O O
BACK B-SSLIF B-SSLIF
PAIN I-SSLIF I-SSLIF
CONDITION O O
ON O O
DISCHARGE O O
BRIEF O O
SUMMARY O O
OF O O
HOSPITALIZATION O O
  
( O O
INCLUDE O O
PROCEDURE O O
( O O
S O O
) O O
/ O O
SIGNIFICANT O O
EVENTS O O
/ O O
FINDINGS O O
/ O O
RESULTS O O
& O O
DATES O O
) O O
PATIENT O O
ADMITTED O O
FOR O O
RT B-SSLIF B-SSLIF
LEG I-SSLIF I-SSLIF
CELLULITIS I-SSLIF I-SSLIF
. O O
  
ALSO O O
FOUND O O
TO O O
HAVE O O
BILATERALLY B-SSLIF B-SSLIF
LOWER I-SSLIF I-SSLIF
EXT I-SSLIF I-SSLIF
DVT'S I-SSLIF I-SSLIF
. O O
  
STARTED O O
ON O O
ABX B-Drug B-Drug
FOR O O
CELLULITIS B-Indication B-Indication
; O O
SEEN O O
BY O O
ID O O
SPECIALISTS O O
WHO O O
RECOMMENDED O O
7 B-Duration B-Duration
- I-Duration I-Duration
10 I-Duration I-Duration
DAY I-Duration I-Duration
COURSE O O
OF O O
VANCOMYCIN B-Drug B-Drug
. O O
  
DVT'S B-Indication B-Indication
TREATED O O
WITH O O
HEPARIN B-Drug B-Drug
GTT B-Route B-Route
AND O O
COUMADIN B-Drug B-Drug
; O O
TRANSITIONED O O
TO O O
LOVENOX B-Drug B-Drug
& O O
COUMADIN B-Drug B-Drug
FOR O O
D O O
/ O O
C O O
. O O
  
EXPERIENCED O O
ACUTE B-SSLIF B-SSLIF
ON I-SSLIF I-SSLIF
CHRONIC I-SSLIF I-SSLIF
RENAL I-SSLIF I-SSLIF
INSUFF I-SSLIF I-SSLIF
; O O
SEEN O O
BY O O
DR O O
Name O O
OF O O
NEPHROLOGY O O
. O O
  
NSAID'S B-Drug B-Drug
  
D O O
/ O O
C'D O O
FOR O O
SUSPECTED O O
ETIOLOGY O O
OF O O
ARF B-SSLIF B-SSLIF
. O O
  
CREATININE O O
IMPROVED O O
TOWARD O O
BASELINE O O
. O O
  
HEALTH O O
CARE O O
PROVIDER O O
FOLLOW O O
UP O O
APPOINTMENTS O O
Physician O O
Date O O
and O O
Time O O
Location O O
Clinic O O
Phone O O
# O O
  
1 O O
) O O
: O O
Name O O
, O O
Name O O
Name O O
CALL O O
FOR O O
APPT O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
CLINIC O O
APPT O O
/ O O
DATE O O
& O O
TIME O O
PLEASE O O
F O O
/ O O
U O O
WITH O O
DR O O
Name O O
IN O O
1 O O
- O O
2 O O
WEEKS O O
AFTER O O
D O O
/ O O
C O O
. O O
  
ACTIVITY O O
ASTOL O O
WEIGHT O O
BEARING O O
ASTOL O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
2 O O
Date O O
at O O
11 O O
: O O
42am O O
Education O O
on O O
smoking O O
cessation O O
completed O O
? O O
Y O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die B-SSLIF B-SSLIF
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
NEW O O
MEDICATIONS O O
ALLERGIES O O
/ O O
REACTIONS O O
THIS O O
ADMISSION O O
: O O
  
NONE O O
PRE O O
- O O
EXISTING O O
ALLERGIES O O
Medication O O
name O O
Generic O O
name O O
Reaction O O
Date O O
LATEX O O
LATEX O O
SKIN O O
RASH O O
; O O
"MILD O O
? O O
  
RASH" O O
GENERAL O O
DISCHARGE O O
INSTRUCTIONS O O
( O O
eg O O
. O O
  
Wound O O
care O O
, O O
avoid O O
, O O
return O O
if O O
) O O
TAKE O O
ALL O O
MEDS O O
AS O O
DIRECTED O O
. O O
  
F O O
/ O O
U O O
WITH O O
DR O O
Name O O
WITHIN O O
1 O O
- O O
2 O O
WEEKS O O
OF O O
D O O
/ O O
C O O
; O O
CALL O O
FOR O O
APPT O O
. O O
  
RETURN O O
TO O O
HOSPITAL O O
OR O O
CALL O O
YOUR O O
DOCTOR O O
FOR O O
FEVER B-SSLIF B-SSLIF
, O O
WORSENING O O
REDNESS B-SSLIF B-SSLIF
OR O O
SWELLING B-SSLIF B-SSLIF
OF I-SSLIF I-SSLIF
RT I-SSLIF I-SSLIF
LEG I-SSLIF I-SSLIF
, O O
PAIN B-SSLIF B-SSLIF
IN I-SSLIF I-SSLIF
LEGS I-SSLIF I-SSLIF
, O O
SHORTNESS B-SSLIF B-SSLIF
OF I-SSLIF I-SSLIF
BREATH I-SSLIF I-SSLIF
, O O
CHEST B-SSLIF B-SSLIF
PAIN I-SSLIF I-SSLIF
, O O
OR O O
ANY O O
OTHER O O
WORRISOME O O
SYMPTOMS O O
. O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
COMMUNITY O O
SERVICES O O
/ O O
DISPOSITION O O
: O O
  
Pt O O
discharged O O
to O O
: O O
HWS O O
Name O O
of O O
Agency O O
: O O
Company O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Company O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Care O O
Coordinator O O
/ O O
Social O O
Worker O O
: O O
Name O O
Phone O O
: O O
M O O
Patient O O
to O O
receive O O
: O O
HOME O O
IV B-Route B-Route
ABX B-Drug B-Drug
  
BID B-Frequency B-Frequency
LOVENOX B-Drug B-Drug
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
3 O O
Date O O
at O O
11 O O
: O O
42am O O
DISCHARGE O O
MEDICATIONS O O
: O O
  
Brand O O
Name O O
Dose O O
Route O O
Time O O
of O O
( O O
Generic O O
) O O
Name O O
How O O
to O O
Take O O
Last O O
Dose O O
  
XANAX B-Drug B-Drug
0.25 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
ALPRAZOLAM B-Drug B-Drug
) O O
Four B-Frequency B-Frequency
Times I-Frequency I-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
AS O O
NEEDED O O
FOR O O
ANXIETY B-Indication B-Indication
ASPIRIN B-Drug B-Drug
81 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
ASPIRIN B-Drug B-Drug
CHEWABLE B-Dose B-Dose
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
OYSTER B-Drug B-Drug
SHELL I-Drug I-Drug
CA I-Drug I-Drug
/ I-Drug I-Drug
VIT I-Drug I-Drug
D I-Drug I-Drug
TAB B-Dose B-Dose
500 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
CALCIUM B-Drug B-Drug
CARBONATE I-Drug I-Drug
/ I-Drug I-Drug
VITAMIN I-Drug I-Drug
D I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
CLARITIN B-Drug B-Drug
- I-Drug I-Drug
D I-Drug I-Drug
1 B-Dose B-Dose
TAB I-Dose I-Dose
PO B-Route B-Route
One B-Frequency B-Frequency
Time I-Frequency I-Frequency
Per I-Frequency I-Frequency
Day I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
AS O O
NEEDED O O
FOR O O
ALLERGIC B-Indication B-Indication
RHINITIS I-Indication I-Indication
  
CYCLOBENZAPRINE B-Drug B-Drug
HCL I-Drug I-Drug
10 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
CYCLOBENZAPRINE B-Drug B-Drug
HCL I-Drug I-Drug
) O O
Three B-Frequency B-Frequency
Times I-Frequency I-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
DILTIAZEM B-Drug B-Drug
HCL I-Drug I-Drug
XR I-Drug I-Drug
240MG B-Dose B-Dose
240 O O
MG O O
PO B-Route B-Route
  
( O O
DILTIAZEM B-Drug B-Drug
HCL I-Drug I-Drug
XR I-Drug I-Drug
240MG B-Dose B-Dose
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
COLACE B-Drug B-Drug
100 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
DOCUSATE B-Drug B-Drug
SODIUM I-Drug I-Drug
) O O
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
CARDURA B-Drug B-Drug
4 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
DOXAZOSIN B-Drug B-Drug
MESYLATE I-Drug I-Drug
) O O
At B-Frequency B-Frequency
Bedtime I-Frequency I-Frequency
  
DOXYCYCLINE B-Drug B-Drug
HYCLATE I-Drug I-Drug
UD O O
CAPSULE B-Dose B-Dose
100 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
DOXYCYCLINE B-Drug B-Drug
HYCLATE I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
12 I-Frequency I-Frequency
Hours I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
TAKE O O
THROUGH O O
Date O O
  
NEXIUM B-Drug B-Drug
40 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
ESOMEPRAZOLE B-Drug B-Drug
MAG I-Drug I-Drug
TRIHYDRATE I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
DURAGESIC B-Drug B-Drug
2.5 B-Dose B-Dose
MG I-Dose I-Dose
TP B-Route B-Route
  
( O O
FENTANYL B-Drug B-Drug
PATCH B-Route B-Route
) O O
Q3D B-Frequency B-Frequency
GLUCOSAMINE B-Drug B-Drug
  
LOVENOX B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
SQ B-Route B-Route
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
TAKE O O
UNTIL O O
COUMADIN B-Drug B-Drug
IS O O
THERAPEUTIC O O
MULTIPLE B-Drug B-Drug
VITAMIN I-Drug I-Drug
1 B-Dose B-Dose
UDCAP B-Dose B-Dose
PO B-Route B-Route
  
( O O
MULTIVITAMINS B-Drug B-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
4 O O
Date O O
at O O
11 O O
: O O
42am O O
  
PANTOPROZOLE B-Drug B-Drug
40 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
One B-Frequency B-Frequency
Time I-Frequency I-Frequency
Per I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
PREDNISONE B-Drug B-Drug
10 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
PREDNISONE B-Drug B-Drug
) O O
Every B-Frequency B-Frequency
Day I-Frequency I-Frequency
  
PROCHLORPERAZINE B-Drug B-Drug
MALEATE I-Drug I-Drug
UD O O
TABLET B-Dose B-Dose
10 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
PROCHLORPERAZINE B-Drug B-Drug
MALEATE I-Drug I-Drug
) O O
Every B-Frequency B-Frequency
Six I-Frequency I-Frequency
Hours I-Frequency I-Frequency
as I-Frequency I-Frequency
Needed I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
AS O O
NEEDED O O
FOR O O
NAUSEA B-Indication B-Indication
  
SENOKOT B-Drug B-Drug
374 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
SENNA B-Drug B-Drug
) O O
Twice B-Frequency B-Frequency
a I-Frequency I-Frequency
Day I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
TAKE O O
AS O O
NEEDED O O
FOR O O
CONSTIPATION B-Indication B-Indication
THALIDOMIDE B-Drug B-Drug
CAPSULE B-Dose B-Dose
100 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
THALIDOMIDE B-Drug B-Drug
) O O
One B-Frequency B-Frequency
Time I-Frequency I-Frequency
Per I-Frequency I-Frequency
Day I-Frequency I-Frequency
  
COUMADIN B-Drug B-Drug
5 B-Dose B-Dose
MG I-Dose I-Dose
PO B-Route B-Route
  
( O O
WARFARIN B-Drug B-Drug
SODIUM I-Drug I-Drug
) O O
Daily B-Frequency B-Frequency
at I-Frequency I-Frequency
5 I-Frequency I-Frequency
pm I-Frequency I-Frequency
Comment O O
for O O
this O O
Medication O O
: O O
monitor O O
inr O O
levels O O
and O O
adjust O O
dose O O
as O O
needed O O
. O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
VACCINATIONS O O
DURING O O
THIS O O
HOSPITAL O O
STAY O O
: O O
  
PNEUMOCOCCAL O O
VACCINE O O
Date O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Med O O
Rec# O O
Medical_Record_Number O O
Page O O
5 O O
Date O O
at O O
11 O O
: O O
42am O O
DIETARY O O
INSTRUCTIONS O O
: O O
  
DIET O O
: O O
REGULAR O O
  
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
DISCHARGE O O
MEDICATION O O
RECONCILIATION O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
. O O
  
______________________ O O
_______________________ O O
____________________________________ O O
  
MD O O
/ O O
NP O O
/ O O
PA O O
Signature O O
Print O O
Name O O
Attending O O
Cosignature O O
if O O
LOS O O
< O O
48hrs O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plan O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
__ O O
Translator O O
Used O O
: O O
( O O
Name O O
& O O
Relationship O O
to O O
patient O O
) O O
__________________________________ O O
  
_________________________________ O O
____________________________________________________ O O
Nurse O O
Signature O O
Patient O O
/ O O
Responsible O O
Person O O
Signature O O
REMINDER O O
: O O
RETRIEVE O O
ALL O O
VALUABLES O O
FROM O O
PATIENT O O
ROOM O O
AND O O
/ O O
OR O O
ADMITTING O O
DEPARTMENT O O
SAFE O O
Patient O O
: O O
Please O O
bring O O
these O O
instructions O O
to O O
ALL O O
follow O O
- O O
up O O
appointments O O
. O O
  
Form O O
finalized O O
by O O
: O O
Name O O
, O O
Name O O
MD O O
on O O
Date O O
at O O
04 O O
: O O
43pm O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
2 O O
: O O
41 O O
P O O
  
11 O O
: O O
33 O O
A O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Disseminated B-SSLIF B-SSLIF
herpes I-SSLIF I-SSLIF
zoster I-SSLIF I-SSLIF
in O O
Date O O
, O O
now O O
resolved O O
. O O
  
2. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
initially O O
diagnosed O O
in O O
Date O O
associated O O
with O O
a O O
progressively O O
increasing O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
3. O O
Compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
status O O
post O O
3 O O
kyphoplasties O O
with O O
the O O
first O O
being O O
done O O
in O O
Date O O
and O O
the O O
second O O
in O O
Date O O
. O O
  
With O O
the O O
first O O
procedure O O
, O O
he O O
developed O O
acute O O
hemoglobin B-SSLIF B-SSLIF
decrease I-SSLIF I-SSLIF
for O O
which O O
he O O
was O O
hospitalized O O
and O O
found O O
to O O
have O O
a O O
hemorrhagic B-SSLIF B-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
. O O
  
This O O
was O O
drained O O
and O O
was O O
found O O
to O O
be O O
nonmalignant B-SSLIF B-SSLIF
. O O
  
At O O
that O O
time O O
, O O
he O O
received O O
5 O O
units O O
of O O
red O O
blood O O
cells O O
. O O
  
The O O
etiology O O
of O O
the O O
effusion B-SSLIF B-SSLIF
was O O
never O O
clarified O O
. O O
  
4. O O
Extensive O O
hospitalization O O
in O O
Date O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
then O O
developed O O
a O O
cardiorespiratory B-SSLIF B-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
with O O
intubation O O
as O O
well O O
as O O
acute O O
hemodialysis O O
. O O
  
Because O O
of O O
the O O
debridement O O
of O O
the O O
calf O O
muscle O O
, O O
a O O
residual O O
ulcer B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
developed O O
which O O
has O O
now O O
healed O O
. O O
  
He O O
was O O
hospitalized O O
several O O
more O O
times O O
for O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
, O O
most O O
recently O O
in O O
Date O O
. O O
  
5. O O
Bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
the O O
right B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
occurring O O
in O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
he O O
was O O
treated O O
with O O
6 B-Duration B-Duration
months I-Duration I-Duration
of O O
Coumadin B-Drug B-Drug
and O O
Coumadin B-Drug B-Drug
was O O
then O O
discontinued O O
. O O
  
He O O
is O O
status O O
post O O
an O O
IVC O O
filter O O
placement O O
. O O
  
In O O
Date O O
, O O
he O O
developed O O
swelling B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
and O O
a O O
left B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
was O O
diagnosed O O
. O O
  
He O O
continues O O
on O O
Coumadin B-Drug B-Drug
currently O O
. O O
  
6. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
7. O O
Hypothyroidism B-SSLIF B-SSLIF
. O O
  
8. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
which O O
is O O
multifactorial O O
. O O
  
9. O O
Psoriasis B-SSLIF B-SSLIF
, O O
which O O
is O O
not O O
a O O
problem O O
currently O O
. O O
  
10. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
both O O
thalidomide B-Drug B-Drug
and O O
the O O
use O O
of O O
vasoconstrictors B-Drug B-Drug
while O O
he O O
was O O
in O O
the O O
ICU. O O
11 O O
. O O
  
Hypogonadism B-SSLIF B-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
  
1. O O
Thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
2. O O
Prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
once B-Frequency B-Frequency
a I-Frequency I-Frequency
month I-Frequency I-Frequency
, O O
which O O
has O O
been O O
discontinued O O
. O O
  
4. O O
Velcade B-Drug B-Drug
1.3 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
for I-Frequency I-Frequency
2 I-Frequency I-Frequency
/ I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
, O O
which O O
is O O
on O O
hold O O
. O O
  
5. O O
Prophylactic B-Indication B-Indication
valacyclovir B-Drug B-Drug
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1. O O
Six B-Duration B-Duration
cycles I-Duration I-Duration
of O O
RCVP B-Drug B-Drug
completed O O
in O O
Date O O
and O O
maintenance O O
Rituxan B-Drug B-Drug
completed O O
in O O
Date O O
. O O
  
2. O O
Revlimid B-Drug B-Drug
which O O
was O O
discontinued O O
secondary O O
to O O
rash B-ADE B-ADE
. O O
  
3. O O
Fludarabine B-Drug B-Drug
given O O
in O O
Date O O
. O O
  
He O O
received O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
, O O
but O O
it O O
caused O O
profound B-Severity B-Severity
pancytopenic B-ADE B-ADE
and O O
this O O
was O O
not O O
repeated O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Alprazolam B-Drug B-Drug
, O O
Androderm B-Drug B-Drug
, O O
aspirin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
, O O
Claritin B-Drug B-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
furosemide B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
Levoxyl B-Drug B-Drug
, O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
for O O
which O O
I O O
write O O
, O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
45 B-Dose B-Dose
mg I-Dose I-Dose
in O O
the O O
a.m. B-Frequency B-Frequency
and O O
15 B-Dose B-Dose
mg I-Dose I-Dose
in O O
the O O
p.m. B-Frequency B-Frequency
which O O
I O O
write O O
for O O
, O O
pantoprazole B-Drug B-Drug
, O O
Compazine B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
, O O
Coumadin B-Drug B-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
says O O
he O O
is O O
doing O O
reasonably O O
well O O
. O O
  
He O O
is O O
more O O
active O O
. O O
  
He O O
continues O O
to O O
ride O O
a O O
recumbent O O
bicycle O O
and O O
get O O
some O O
exercise O O
. O O
  
He O O
has O O
lost O O
a O O
bit O O
of O O
weight O O
. O O
  
He O O
has O O
had O O
no O O
interim O O
hospitalizations O O
. O O
  
His O O
zoster B-SSLIF B-SSLIF
lesions I-SSLIF I-SSLIF
have O O
cleared O O
. O O
  
He O O
does O O
tell O O
me O O
that O O
he O O
does O O
have O O
significant B-Severity B-Severity
numbness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
feet I-SSLIF I-SSLIF
and O O
he O O
has O O
started O O
to O O
cut O O
himself O O
, O O
cutting O O
his O O
toenails B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
growing I-SSLIF I-SSLIF
abnormally I-SSLIF I-SSLIF
. O O
  
He O O
does O O
continue O O
to O O
wear O O
bilateral O O
compression O O
stockings O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
any O O
excessive B-Severity B-Severity
fatigue B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
has O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
PND B-SSLIF B-SSLIF
or O O
orthopnea B-SSLIF B-SSLIF
. O O
  
He O O
has O O
chronic O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
especially O O
when O O
he O O
stands O O
or O O
sits O O
for O O
too O O
long O O
. O O
  
He O O
says O O
, O O
however O O
, O O
that O O
his O O
pain B-SSLIF B-SSLIF
is O O
reasonably O O
well O O
controlled O O
. O O
  
He O O
denies O O
any O O
significant B-Severity B-Severity
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
acute O O
leukemia B-SSLIF B-SSLIF
in O O
his O O
father O O
. O O
  
His O O
father O O
was O O
elderly O O
when O O
he O O
got O O
the O O
leukemia B-SSLIF B-SSLIF
. O O
  
His O O
father O O
also O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
1 O O
brother O O
who O O
is O O
unfortunately O O
not O O
an O O
HLA O O
match O O
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
unchanged O O
. O O
  
He O O
lives O O
independently O O
and O O
does O O
all O O
activities O O
of O O
daily O O
living O O
. O O
  
He O O
is O O
able O O
to O O
drive O O
. O O
  
He O O
cannot B-SSLIF B-SSLIF
walk I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
stand I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
long I-SSLIF I-SSLIF
periods I-SSLIF I-SSLIF
of O O
time O O
. O O
  
He O O
uses O O
a O O
cane O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
was O O
151 O O
/ O O
81 O O
, O O
pulse O O
93 O O
and O O
regular O O
and O O
weight O O
266 O O
pounds O O
, O O
which O O
is O O
basically O O
stable O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
without O O
lesions B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
no O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
The O O
patient O O
has O O
bilateral O O
compression O O
stockings O O
on O O
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
has O O
a O O
broad B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
based I-SSLIF I-SSLIF
gait I-SSLIF I-SSLIF
. O O
  
He O O
walks O O
with O O
a O O
cane O O
. O O
  
He O O
is O O
alert O O
and O O
oriented O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
; O O
white O O
blood O O
cell O O
count O O
is O O
2200 O O
which O O
has O O
decreased O O
with O O
42.8 O O
polys O O
, O O
33.6 O O
lymphs O O
, O O
17.3 O O
monos O O
, O O
5.3 O O
eos O O
, O O
1 O O
basophil O O
. O O
  
A O O
platelet O O
count O O
of O O
163 O O
, O O
000 O O
and O O
a O O
hemoglobin O O
of O O
10.6 O O
with O O
hematocrit O O
of O O
30.5 O O
, O O
which O O
is O O
stable O O
. O O
  
MCV O O
is O O
90.6 O O
. O O
  
Electrolytes O O
are O O
within O O
normal O O
limits O O
. O O
  
A O O
nonfasting O O
blood O O
sugar O O
is O O
94 O O
. O O
  
A O O
BUN O O
is O O
26 O O
with O O
a O O
creatinine O O
of O O
1.61 O O
, O O
which O O
is O O
stable O O
. O O
  
A O O
total O O
protein O O
is O O
9.9 O O
with O O
an O O
albumin O O
of O O
2.9 O O
. O O
  
AST O O
is O O
18 O O
, O O
ALT O O
is O O
20 O O
, O O
an O O
LDH O O
is O O
119 O O
. O O
  
An O O
IgG O O
level O O
is O O
5960 O O
, O O
which O O
is O O
stable O O
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
743 O O
. O O
  
Free O O
lambda O O
light O O
chains O O
are O O
1.3 O O
with O O
a O O
kappa B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
lambda I-SSLIF I-SSLIF
ratio I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
554 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
very I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
, O O
but O O
his O O
lambda B-SSLIF B-SSLIF
light I-SSLIF I-SSLIF
chains I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
suppressed I-SSLIF I-SSLIF
today O O
for O O
unknown O O
reasons O O
. O O
  
The O O
patient's O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
continues O O
to O O
show O O
the O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
monoclonal I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
. O O
  
On O O
the O O
serum O O
protein O O
electrophoresis O O
, O O
it O O
is O O
stable O O
at O O
3600 O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
54 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
a O O
large B-Severity B-Severity
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
, O O
which O O
seems O O
to O O
be O O
currently O O
the O O
main O O
issue O O
. O O
  
His O O
paraprotein B-SSLIF B-SSLIF
level O O
is O O
stable O O
, O O
although O O
his O O
kappa B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
lambda I-SSLIF I-SSLIF
light I-SSLIF I-SSLIF
chain I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
quite I-SSLIF I-SSLIF
abnormal I-SSLIF I-SSLIF
today O O
, O O
although O O
this O O
may O O
be O O
a O O
spurious O O
value O O
. O O
  
Additional O O
problems O O
include O O
: O O
  
1. O O
Leukopenia B-ADE B-ADE
. O O
  
This O O
is O O
probably O O
secondary O O
from O O
the O O
Velcade B-Drug B-Drug
and O O
thalidomide B-Drug B-Drug
. O O
  
I O O
will O O
hold O O
these O O
drugs O O
currently O O
. O O
  
2. O O
Peripheral B-SSLIF B-SSLIF
neuropathy I-SSLIF I-SSLIF
with O O
problems B-SSLIF B-SSLIF
walking I-SSLIF I-SSLIF
as O O
well O O
as O O
numbness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
feet I-SSLIF I-SSLIF
. O O
  
I O O
will O O
make O O
a O O
referral O O
to O O
Dr O O
. O O
  
Name O O
Name O O
so O O
he O O
can O O
have O O
help O O
with O O
cutting O O
his O O
nails O O
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
The O O
patient O O
will O O
have O O
a O O
referral O O
to O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
2. O O
I O O
will O O
hold O O
thalidomide B-Drug B-Drug
and O O
Velcade B-Drug B-Drug
. O O
  
3. O O
I O O
will O O
discontinue O O
pamidronate B-Drug B-Drug
since O O
it O O
should O O
be O O
a O O
2 B-Duration B-Duration
- I-Duration I-Duration
year I-Duration I-Duration
infusion B-Route B-Route
and O O
he O O
has O O
clearly O O
been O O
infused O O
much O O
longer O O
than O O
that O O
. O O
  
4. O O
I O O
will O O
see O O
him O O
in O O
followup O O
in O O
2 O O
months O O
. O O
  
Greater O O
than O O
50% O O
of O O
this O O
40 O O
- O O
minute O O
visit O O
was O O
spent O O
discussing O O
these O O
changes O O
in O O
care O O
and O O
also O O
the O O
referral O O
to O O
a O O
podiatrist O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
16 O O
: O O
00 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
16 O O
: O O
03 O O
PM O O
Clinic O O
Note O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
originally O O
diagnosed O O
in O O
Date O O
associated O O
with O O
a O O
progressively O O
increasing O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
He O O
did O O
have O O
bony B-SSLIF B-SSLIF
involvement I-SSLIF I-SSLIF
and O O
has O O
had O O
3 O O
kyphoplasties O O
in O O
Date O O
. O O
  
He O O
has O O
significant B-Severity B-Severity
pancytopenia B-SSLIF B-SSLIF
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
. O O
  
2. O O
Prolonged O O
hospitalization O O
in O O
Date O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
presenting O O
as O O
excruciating B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
then O O
developed O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
sustained O O
a O O
cardiopulmonary B-SSLIF B-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
requiring O O
intubation O O
as O O
well O O
as O O
acute O O
hemodialysis O O
. O O
  
He O O
then O O
developed O O
an O O
ulceration B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
, O O
which O O
has O O
healed O O
. O O
  
He O O
has O O
had O O
several O O
episodes O O
of O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
with O O
the O O
most O O
recent O O
episode O O
in O O
Date O O
. O O
  
3. O O
Pancytopenia B-SSLIF B-SSLIF
secondary O O
to O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
4. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
, O O
which O O
is O O
multifactorial O O
. O O
  
5. O O
Bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
the O O
right B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
in O O
Date O O
, O O
at O O
which O O
time O O
an O O
IVC O O
filter O O
was O O
placed O O
and O O
then O O
a O O
left B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
in O O
Date O O
. O O
  
He O O
is O O
on O O
chronic O O
Coumadin B-Drug B-Drug
. O O
  
6. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
7. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
both O O
the O O
chemotherapy B-Drug B-Drug
and O O
vasoconstrictors B-Drug B-Drug
, O O
which O O
were O O
used O O
while O O
he O O
was O O
hypotensive B-Indication B-Indication
in O O
the O O
ICU O O
in O O
Date O O
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
is O O
here O O
to O O
receive O O
his O O
second O O
cycle O O
of O O
bendamustine B-Drug B-Drug
and O O
Rituxan B-Drug B-Drug
. O O
  
He O O
had O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
of O O
bendamustine B-Drug B-Drug
and O O
Rituxan B-Drug B-Drug
with O O
the O O
bendamustine B-Drug B-Drug
at O O
very O O
reduced O O
dose O O
of O O
45 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m I-Dose I-Dose
squared I-Dose I-Dose
x1 B-Duration B-Duration
day I-Duration I-Duration
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1. O O
Thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
and O O
Velcade B-Drug B-Drug
1.3 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m I-Dose I-Dose
squared I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
for I-Frequency I-Frequency
2 I-Frequency I-Frequency
out I-Frequency I-Frequency
of I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
. O O
  
This O O
was O O
discontinued O O
secondary O O
to O O
increasing O O
pancytopenia B-ADE B-ADE
and O O
neuropathy B-ADE B-ADE
. O O
  
2. O O
Revlimid B-Drug B-Drug
, O O
which O O
was O O
discontinued O O
secondary O O
to O O
skin B-ADE B-ADE
rash I-ADE I-ADE
. O O
  
3. O O
Six B-Duration B-Duration
cycles I-Duration I-Duration
of O O
RCVP B-Drug B-Drug
completed O O
in O O
Date O O
with O O
maintenance O O
Rituxan B-Drug B-Drug
for O O
1 B-Duration B-Duration
year I-Duration I-Duration
. O O
  
4. O O
Fludarabine B-Drug B-Drug
x1 B-Duration B-Duration
cycle I-Duration I-Duration
in O O
Date O O
, O O
which O O
caused O O
profound B-Severity B-Severity
pancytopenia B-ADE B-ADE
, O O
which O O
was O O
discontinued O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Androderm B-Drug B-Drug
, O O
low B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
aspirin B-Drug B-Drug
, O O
clonazepam B-Drug B-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
Lasix B-Drug B-Drug
, O O
lactulose B-Drug B-Drug
, O O
Levoxyl B-Drug B-Drug
, O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
and O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
a.m. O O
and O O
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
mid I-Frequency I-Frequency
day I-Frequency I-Frequency
and O O
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
. O O
  
He O O
is O O
on O O
pantoprazole B-Drug B-Drug
and O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
as O O
well O O
as O O
Compazine B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
has O O
chronic O O
low B-Indication B-Indication
back I-Indication I-Indication
pain I-Indication I-Indication
about O O
5 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
He O O
says O O
that O O
the O O
morphine B-Drug B-Drug
dosing O O
helps O O
him O O
and O O
he O O
does O O
not O O
feel O O
he O O
needs O O
increase O O
in O O
pain B-Drug B-Drug
medication I-Drug I-Drug
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
currently O O
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
leg B-SSLIF B-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
He O O
has O O
had O O
no O O
problems O O
with O O
skin B-SSLIF B-SSLIF
ulceration I-SSLIF I-SSLIF
recently O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
As O O
above O O
. O O
  
The O O
patient O O
has O O
chronic O O
low B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
acute O O
leukemia B-SSLIF B-SSLIF
in O O
his O O
father O O
who O O
developed O O
acute O O
leukemia B-SSLIF B-SSLIF
in O O
his O O
80s O O
. O O
  
His O O
father O O
also O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
He O O
has O O
one O O
brother O O
who O O
is O O
living O O
, O O
but O O
is O O
not O O
an O O
HLA O O
match O O
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
1 O O
- O O
2 O O
. O O
  
He O O
does O O
live O O
independently O O
by O O
himself O O
. O O
  
He O O
does O O
all O O
activities O O
of O O
daily O O
living O O
including O O
driving O O
. O O
  
However O O
, O O
he O O
does O O
not O O
do O O
very O O
much O O
activity O O
secondary O O
to O O
his O O
back O O
issues O O
. O O
  
He O O
sits O O
in O O
a O O
chair O O
and O O
does O O
not O O
leave O O
his O O
apartment O O
too O O
much O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
137 O O
/ O O
70 O O
, O O
pulse O O
82 O O
and O O
regular O O
and O O
his O O
weight O O
is O O
98.5 O O
, O O
which O O
has O O
stabilized O O
. O O
  
He O O
has O O
lost O O
a O O
fair O O
amount O O
of O O
weight O O
for O O
unclear O O
reasons O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
benign O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
. O O
  
There O O
is O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
EXTREMITIES O O
: O O
No O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
petechiae B-SSLIF B-SSLIF
or O O
ecchymoses B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rashes B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
walks O O
with O O
a O O
cane O O
. O O
  
He O O
is O O
quite B-Severity B-Severity
hunched B-SSLIF B-SSLIF
over I-SSLIF I-SSLIF
secondary O O
to O O
his O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
and O O
kyphoplasties O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
is O O
1600 O O
with O O
34 O O
polys O O
, O O
34.8 O O
lymphs O O
, O O
29 O O
monos O O
, O O
1.8 O O
eos O O
, O O
0.3 O O
basophils O O
, O O
a O O
platelet O O
count O O
is O O
85 O O
, O O
000 O O
and O O
a O O
hemoglobin O O
is O O
8.7 O O
with O O
hematocrit O O
of O O
24.4 O O
, O O
which O O
is O O
stable O O
. O O
  
MCV O O
is O O
92.5 O O
. O O
  
His O O
absolute O O
neutrophil B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
530 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
. O O
  
He O O
did O O
receive O O
bendamustine B-Drug B-Drug
approximately O O
1 O O
month O O
ago O O
and O O
this O O
is O O
probably O O
the O O
result O O
. O O
  
LDH O O
is O O
110 O O
. O O
  
A O O
BUN O O
is O O
49 O O
and O O
a O O
creatinine O O
is O O
2.62 O O
, O O
which O O
has O O
been O O
stable O O
over O O
the O O
last O O
6 O O
months O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
56 O O
- O O
year O O
- O O
old O O
male O O
with O O
: O O
  
1. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
an O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
His O O
paraprotein B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
still I-SSLIF I-SSLIF
very I-SSLIF I-SSLIF
high I-SSLIF I-SSLIF
. O O
  
I O O
had O O
tried O O
him O O
on O O
various O O
myeloma B-Drug B-Drug
medications I-Drug I-Drug
. O O
  
I O O
cannot O O
go O O
to O O
high B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
because O O
of O O
various O O
side B-ADE B-ADE
effects I-ADE I-ADE
and O O
cytopenias B-ADE B-ADE
. O O
  
He O O
has O O
received O O
1 B-Dose B-Dose
dose O O
of O O
bendamustine B-Drug B-Drug
at O O
a O O
reduced O O
dose O O
. O O
  
He O O
continues O O
to O O
get O O
Rituxan B-Drug B-Drug
. O O
  
2. O O
Pancytopenia B-ADE B-ADE
secondary O O
to O O
chemotherapy B-Drug B-Drug
and O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
PLAN O O
: O O
  
1. O O
I O O
will O O
hold O O
bendamustine B-Drug B-Drug
today O O
as O O
his O O
white B-ADE B-ADE
blood I-ADE I-ADE
cell I-ADE I-ADE
count I-ADE I-ADE
is I-ADE I-ADE
low I-ADE I-ADE
. O O
  
2 O O
. O O
  
He O O
will O O
receive O O
Rituxan B-Drug B-Drug
375 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m I-Dose I-Dose
squared O O
after O O
premedication O O
with O O
Tylenol B-Drug B-Drug
, O O
Benadryl B-Drug B-Drug
, O O
hydrocortisone B-Drug B-Drug
, O O
and O O
Pepcid B-Drug B-Drug
. O O
  
3. O O
I O O
will O O
see O O
him O O
in O O
followup O O
in O O
one O O
month O O
. O O
  
The O O
patient O O
is O O
also O O
receiving O O
pamidronate B-Drug B-Drug
every B-Frequency B-Frequency
other I-Frequency I-Frequency
month I-Frequency I-Frequency
. O O
  
Greater O O
than O O
20 O O
minutes O O
of O O
this O O
40 O O
- O O
minute O O
visit O O
was O O
spent O O
reviewing O O
his O O
current O O
therapy O O
and O O
his O O
blood O O
counts O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
MD O O
Name O O
Name O O
, O O
MD O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
6 O O
: O O
24AM O O
EST O O
Acknowledgement O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
4 O O
: O O
54 O O
P O O
Transcribed O O
Date O O
6 O O
: O O
42 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
. O O
  
This O O
is O O
associated O O
with O O
an O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
, O O
which O O
in O O
the O O
past O O
has O O
been O O
quite O O
large B-Severity B-Severity
. O O
  
2. O O
Anemia B-SSLIF B-SSLIF
and O O
hypercalcemia B-SSLIF B-SSLIF
secondary O O
to O O
problem O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
3. O O
Compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
. O O
  
In O O
the O O
past O O
, O O
this O O
has O O
been O O
associated O O
with O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
is O O
status O O
post O O
3 O O
kyphoplasties O O
the O O
first O O
in O O
Date O O
and O O
2 O O
in O O
Date O O
. O O
  
The O O
initial O O
procedure O O
in O O
Date O O
was O O
complicated O O
by O O
an O O
acute O O
drop B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
hemoglobin I-SSLIF I-SSLIF
, O O
for O O
which O O
he O O
was O O
hospitalized O O
. O O
  
A O O
hemorrhagic B-SSLIF B-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
was O O
noted O O
and O O
drained O O
. O O
  
This O O
was O O
not O O
malignant B-SSLIF B-SSLIF
. O O
  
He O O
received O O
4 O O
- O O
5 O O
units O O
of O O
red O O
blood O O
cells O O
this O O
at O O
that O O
time O O
. O O
  
There O O
have O O
been O O
no O O
recurrences O O
of O O
this O O
problem O O
, O O
but O O
the O O
etiology O O
remains O O
unexplained O O
. O O
  
4. O O
Hospitalization O O
in O O
Date O O
, O O
which O O
was O O
prolonged O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
subsequently O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
of O O
the O O
right O O
calf O O
muscle O O
. O O
  
He O O
did O O
have O O
a O O
residual O O
ulcer B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
, O O
which O O
has O O
now O O
fully O O
healed O O
. O O
  
He O O
has O O
required O O
several O O
hospitalizations O O
since O O
that O O
time O O
for O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
, O O
the O O
most O O
recent O O
being O O
in O O
Date O O
. O O
  
Also O O
during O O
the O O
hospitalization O O
in O O
Date O O
, O O
he O O
had O O
respiratory B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
and O O
required O O
intubation O O
. O O
  
5. O O
Bilateral B-SSLIF B-SSLIF
DVT I-SSLIF I-SSLIF
with O O
right B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
being O O
found O O
most O O
recently O O
in O O
Date O O
. O O
  
He O O
finished O O
a O O
6 B-Duration B-Duration
- I-Duration I-Duration
month I-Duration I-Duration
course O O
of O O
Coumadin B-Drug B-Drug
after O O
initially O O
being O O
treated O O
with O O
Lovenox B-Drug B-Drug
. O O
  
6. O O
Psoriasis B-SSLIF B-SSLIF
. O O
  
7. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
8. O O
Hypothyroidism B-SSLIF B-SSLIF
. O O
  
9. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
  
1 O O
. O O
  
The O O
patient O O
has O O
been O O
on O O
Velcade B-Drug B-Drug
2 B-Frequency B-Frequency
weeks I-Frequency I-Frequency
out I-Frequency I-Frequency
of I-Frequency I-Frequency
each I-Frequency I-Frequency
month I-Frequency I-Frequency
with O O
the O O
reduced O O
dosing O O
schedule O O
1 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
2. O O
Prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
3 B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Monthly B-Frequency B-Frequency
pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
. O O
  
4. O O
Thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
which O O
has O O
been O O
discontinued O O
because O O
of O O
neuropathy B-ADE B-ADE
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1 O O
. O O
  
The O O
patient O O
received O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
Rituxan B-Drug B-Drug
plus I-Drug I-Drug
CVP I-Drug I-Drug
completed O O
in O O
Date O O
. O O
  
2 O O
. O O
  
He O O
received O O
maintenance O O
Rituxan B-Drug B-Drug
alone O O
, O O
which O O
was O O
completed O O
in O O
Date O O
. O O
  
3 O O
. O O
  
He O O
received O O
Revlimid B-Drug B-Drug
, O O
which O O
was O O
discontinued O O
secondary O O
to O O
a O O
severe B-Severity B-Severity
skin B-ADE B-ADE
rash I-ADE I-ADE
. O O
  
4 O O
. O O
  
He O O
received O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
of O O
fludarabine B-Drug B-Drug
in O O
Date O O
, O O
which O O
renders O O
him O O
profoundly B-Severity B-Severity
pancytopenic B-ADE B-ADE
and O O
has O O
not O O
been O O
repeated O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
for O O
pain B-Indication B-Indication
with O O
Dilaudid B-Drug B-Drug
  
4 B-Dose B-Dose
mg I-Dose I-Dose
for O O
breakthrough O O
pain B-Indication B-Indication
. O O
  
He O O
is O O
also O O
on O O
Cartia B-Drug B-Drug
XT I-Drug I-Drug
, O O
doxazosin B-Drug B-Drug
, O O
Protonix B-Drug B-Drug
, O O
Lasix B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
Levoxyl B-Drug B-Drug
and O O
multivitamins B-Drug B-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoplasmacytoid B-Indication B-Indication
lymphoma I-Indication I-Indication
. O O
  
His O O
IgG B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
had I-SSLIF I-SSLIF
been I-SSLIF I-SSLIF
decreasing I-SSLIF I-SSLIF
. O O
  
Unfortunately O O
, O O
I O O
had O O
to O O
stop O O
the O O
thalidomide B-Drug B-Drug
secondary O O
to O O
neuropathy B-ADE B-ADE
and O O
thus O O
his O O
IgG O O
level O O
seems O O
to O O
have O O
stabilized O O
. O O
  
Unfortunately O O
, O O
his O O
neuropathy B-SSLIF B-SSLIF
is O O
worsening O O
. O O
  
It O O
is O O
now O O
affecting O O
his O O
hands O O
. O O
  
His O O
feet O O
are O O
also O O
affected O O
. O O
  
He O O
says O O
sometimes O O
his O O
walking B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
difficult I-SSLIF I-SSLIF
and O O
he O O
is O O
worried O O
that O O
he O O
may O O
start O O
to O O
have O O
difficulty B-SSLIF B-SSLIF
driving I-SSLIF I-SSLIF
because O O
of O O
the O O
neuropathy B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
hands I-SSLIF I-SSLIF
. O O
  
He O O
also O O
said O O
that O O
with O O
the O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
in O O
the O O
morning O O
, O O
he O O
is O O
having O O
significant B-Severity B-Severity
fatigue B-ADE B-ADE
during O O
the O O
day O O
. O O
  
He O O
did O O
try O O
to O O
take O O
60 B-Dose B-Dose
mg I-Dose I-Dose
at O O
night O O
and O O
woke O O
up O O
several O O
times O O
very B-Severity B-Severity
short B-ADE B-ADE
of I-ADE I-ADE
breath I-ADE I-ADE
. O O
  
He O O
says O O
that O O
the O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
helps O O
his O O
pain B-Indication B-Indication
at O O
night O O
, O O
but O O
he O O
cannot O O
take O O
too O O
much O O
of O O
it O O
. O O
  
He O O
does O O
not O O
like O O
taking O O
it O O
during O O
the O O
day O O
because O O
of O O
the O O
fatigue B-ADE B-ADE
. O O
  
The O O
patient O O
has O O
had O O
no O O
interim O O
hospitalizations O O
since O O
last O O
seen O O
. O O
  
His O O
thyroid O O
is O O
still O O
being O O
investigated O O
. O O
  
He O O
has O O
gone O O
up O O
on O O
the O O
Levoxyl B-Drug B-Drug
dose O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
has O O
significant B-Severity B-Severity
fatigue B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysphasia B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
, O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
. O O
  
He O O
does O O
have O O
edema B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
has O O
significant B-Severity B-Severity
neuropathy B-SSLIF B-SSLIF
, O O
which O O
is O O
worsening O O
both O O
in O O
his O O
hands O O
and O O
feet O O
with O O
pain B-SSLIF B-SSLIF
as O O
well O O
as O O
numbness B-SSLIF B-SSLIF
and O O
tingling B-SSLIF B-SSLIF
. O O
  
He O O
does O O
walk O O
with O O
a O O
cane O O
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
known O O
glucose B-SSLIF B-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
has O O
6 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
back B-Indication B-Indication
pain I-Indication I-Indication
. O O
  
The O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
does O O
help O O
him O O
. O O
  
He O O
does O O
have O O
intermittent O O
eczematous B-SSLIF B-SSLIF
skin I-SSLIF I-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
leukemia B-SSLIF B-SSLIF
and O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
in O O
his O O
father O O
. O O
  
It O O
is O O
negative O O
for O O
any O O
other O O
history O O
of O O
blood B-SSLIF B-SSLIF
dyscrasias I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
family O O
history O O
of O O
lymphoma B-SSLIF B-SSLIF
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
1 O O
. O O
  
He O O
lives O O
at O O
home O O
independently O O
. O O
  
He O O
does O O
walk O O
with O O
a O O
cane O O
. O O
  
He O O
is O O
able O O
to O O
do O O
all O O
activities O O
of O O
daily O O
living O O
. O O
  
He O O
is O O
still O O
driving O O
. O O
  
He O O
is O O
very O O
worried O O
about O O
his O O
neuropathy B-SSLIF B-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
looked O O
unchanged O O
, O O
afebrile B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Blood O O
pressure O O
is O O
150 O O
/ O O
80 O O
, O O
pulse O O
is O O
92 O O
and O O
regular O O
, O O
and O O
his O O
weight B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
121 I-SSLIF I-SSLIF
kilograms I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
268 I-SSLIF I-SSLIF
pounds I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
gone I-SSLIF I-SSLIF
up I-SSLIF I-SSLIF
slightly B-Severity B-Severity
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
without O O
lesions B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
I O O
did O O
not O O
get O O
him O O
on O O
to O O
the O O
examining O O
table O O
as O O
he O O
is O O
having O O
pain B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
notable O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
although O O
it O O
has O O
been O O
difficult O O
for O O
me O O
to O O
feel O O
a O O
spleen O O
palpable O O
, O O
even O O
when O O
one O O
is O O
present O O
by O O
scans O O
. O O
  
EXTREMITIES O O
: O O
The O O
patient O O
has O O
edema B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
hands I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
. O O
  
There O O
are O O
scattered B-SSLIF B-SSLIF
ecchymoses I-SSLIF I-SSLIF
. O O
  
SKIN O O
: O O
His O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
has O O
basically O O
again O O
resolved O O
. O O
  
NEUROLOGICAL O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
He O O
uses O O
a O O
cane O O
to O O
walk O O
and O O
his O O
gait B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
abnormal I-SSLIF I-SSLIF
secondary O O
to O O
his O O
back O O
issues O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
revealed O O
a O O
white O O
blood O O
cell O O
count O O
of O O
2800 O O
with O O
72 O O
polys O O
, O O
9 O O
bands O O
, O O
6 O O
lymphs O O
, O O
2 O O
atypical O O
lymphs O O
, O O
10 O O
monos O O
and O O
2 O O
eos O O
, O O
a O O
platelet O O
count O O
of O O
148 O O
, O O
000 O O
and O O
a O O
hemoglobin O O
of O O
11.8 O O
with O O
hematocrit O O
of O O
33.7 O O
. O O
  
MCV O O
is O O
  
90.6 O O
. O O
  
An O O
IgG O O
level O O
has O O
decreased O O
to O O
2030 O O
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
  
31.4 O O
. O O
  
Free O O
lambda O O
light O O
chains O O
are O O
4.34 O O
with O O
a O O
kappa O O
to O O
lambda O O
ratio O O
that O O
is O O
basically O O
stable O O
at O O
7.22 O O
. O O
  
Electrolytes O O
are O O
within O O
normal O O
limits O O
. O O
  
A O O
nonfasting O O
blood O O
sugar O O
is O O
119 O O
. O O
  
A O O
BUN O O
is O O
25 O O
, O O
a O O
creatinine O O
is O O
1.44 O O
, O O
which O O
is O O
stable O O
. O O
  
AST O O
is O O
21 O O
, O O
ALT O O
is O O
28 O O
. O O
  
LDH O O
is O O
normal O O
at O O
109 O O
. O O
  
A O O
total O O
protein O O
is O O
  
7.2 O O
with O O
an O O
albumin O O
of O O
3.8 O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
that O O
is O O
really O O
acting O O
more O O
like O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
and O O
thus O O
he O O
has O O
been O O
treated O O
as O O
if O O
it O O
were O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
. O O
  
Currently O O
, O O
he O O
does O O
have O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
We O O
are O O
still O O
working O O
out O O
his O O
pain B-Drug B-Drug
medications I-Drug I-Drug
. O O
  
He O O
was O O
taking O O
MS B-Drug B-Drug
  
Contin O O
30 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
then O O
did O O
not O O
take O O
the O O
morning O O
dose O O
, O O
but O O
took O O
  
2 B-Dose B-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
and O O
that O O
was O O
problematic O O
for O O
him O O
. O O
  
He O O
is O O
having O O
significant B-Severity B-Severity
problems O O
with O O
neuropathy B-SSLIF B-SSLIF
. O O
  
Neurontin B-Drug B-Drug
may O O
help O O
the O O
neuropathy B-Indication B-Indication
as O O
well O O
as O O
his O O
pain B-Indication B-Indication
. O O
  
Thus O O
, O O
he O O
and O O
I O O
have O O
decided O O
that O O
he O O
will O O
take O O
the O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
, O O
but O O
also O O
take O O
200 B-Dose B-Dose
mg I-Dose I-Dose
of O O
Neurontin B-Drug B-Drug
at B-Frequency B-Frequency
night I-Frequency I-Frequency
to O O
see O O
if O O
this O O
might O O
help O O
and O O
then O O
take O O
100 B-Dose B-Dose
mg I-Dose I-Dose
of O O
Neurontin B-Drug B-Drug
during O O
the O O
day B-Frequency B-Frequency
. O O
  
The O O
Neurontin B-Drug B-Drug
certainly O O
can O O
be O O
increased O O
and O O
perhaps O O
it O O
would O O
be O O
helpful O O
for O O
his O O
neuropathy B-Indication B-Indication
. O O
  
Because O O
of O O
the O O
progressive O O
neuropathy B-SSLIF B-SSLIF
, O O
I O O
have O O
stopped O O
the O O
Velcade B-Drug B-Drug
as O O
this O O
could O O
be O O
a O O
side B-ADE B-ADE
effect I-ADE I-ADE
of O O
Velcade B-Drug B-Drug
as O O
well O O
. O O
  
PLAN O O
: O O
  
1. O O
Velcade B-Drug B-Drug
will O O
be O O
discontinued O O
. O O
  
He O O
will O O
continue O O
to O O
hold O O
the O O
thalidomide B-Drug B-Drug
. O O
  
2 O O
. O O
  
The O O
patient O O
needs O O
to O O
receive O O
pamidronate B-Drug B-Drug
. O O
  
By O O
oversight O O
he O O
did O O
not O O
stay O O
today O O
and O O
he O O
will O O
need O O
to O O
be O O
called O O
back O O
to O O
receive O O
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
next O O
week O O
. O O
  
3. O O
I O O
have O O
given O O
him O O
a O O
prescription O O
for O O
Neurontin B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
200 B-Dose B-Dose
at O O
night B-Frequency B-Frequency
and O O
1 O O
mg O O
in O O
100 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
morning I-Frequency I-Frequency
. O O
  
4 O O
. O O
  
He O O
will O O
continue O O
on O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
but O O
will O O
take O O
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
only O O
. O O
  
There O O
is O O
15 B-Dose B-Dose
mg I-Dose I-Dose
tablet I-Dose I-Dose
of O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
as O O
well O O
and O O
I O O
will O O
consider O O
writing O O
15 B-Dose B-Dose
mg I-Dose I-Dose
for O O
him O O
so O O
that O O
perhaps O O
he O O
could O O
take O O
45 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
if O O
his O O
pain B-Indication B-Indication
is O O
really O O
quite O O
severe B-Severity B-Severity
. O O
  
He O O
does O O
not O O
want O O
to O O
take O O
any O O
during O O
the O O
day O O
. O O
  
He O O
does O O
have O O
  
Dilaudid B-Drug B-Drug
at O O
home O O
and O O
I O O
have O O
not O O
refilled O O
this O O
prescription O O
. O O
  
5 O O
. O O
  
The O O
patient O O
will O O
return O O
for O O
followup O O
in O O
4 O O
weeks O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
22 O O
: O O
30 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
10 O O
: O O
46 O O
P O O
  
2 O O
: O O
56 O O
P O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
initially O O
diagnosed O O
in O O
Date O O
, O O
associated O O
with O O
progressively O O
increasing O O
IgA B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
Disseminated B-SSLIF B-SSLIF
herpes I-SSLIF I-SSLIF
zoster I-SSLIF I-SSLIF
, O O
requiring O O
hospitalization O O
in O O
Date O O
, O O
now O O
resolved O O
. O O
  
3. O O
Compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
status O O
post O O
3 O O
kyphoplasty O O
in O O
Date O O
. O O
  
With O O
the O O
first O O
procedure O O
, O O
he O O
developed O O
an O O
acute O O
hemoglobin B-SSLIF B-SSLIF
decrease I-SSLIF I-SSLIF
for O O
which O O
he O O
was O O
hospitalized O O
and O O
found O O
to O O
have O O
a O O
hemorrhagic B-SSLIF B-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
, O O
which O O
was O O
drained O O
and O O
found O O
to O O
be O O
nonmalignant B-SSLIF B-SSLIF
. O O
  
At O O
that O O
time O O
, O O
he O O
received O O
5 O O
units O O
of O O
red O O
blood O O
cells O O
. O O
  
The O O
etiology O O
of O O
the O O
effusion B-SSLIF B-SSLIF
was O O
never O O
clarified O O
. O O
  
4. O O
Extensive O O
hospitalization O O
in O O
Date O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
subsequently O O
developed O O
a O O
cardiorespiratory B-SSLIF B-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
with O O
intubation O O
as O O
well O O
as O O
acute O O
hemodialysis O O
. O O
  
He O O
developed O O
an O O
ulceration B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
, O O
which O O
has O O
now O O
healed O O
. O O
  
He O O
was O O
hospitalized O O
several O O
more O O
times O O
for O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
. O O
  
His O O
most O O
recent O O
recurrence O O
of O O
cellulitis B-SSLIF B-SSLIF
was O O
in O O
Date O O
, O O
but O O
this O O
was O O
treated O O
as O O
an O O
outpatient O O
. O O
  
5. O O
Bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
a O O
right B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
in O O
Date O O
, O O
at O O
which O O
time O O
an O O
IVC O O
filter O O
was O O
placed O O
. O O
  
In O O
Date O O
, O O
he O O
had O O
a O O
DVT B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
left I-Indication I-Indication
leg I-Indication I-Indication
and O O
he O O
is O O
now O O
on O O
chronic O O
Coumadin B-Drug B-Drug
. O O
  
6. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
7. O O
Hypothyroidism B-SSLIF B-SSLIF
. O O
  
8. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
, O O
which O O
is O O
multifactorial O O
. O O
  
9. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
both O O
to O O
medication O O
and O O
the O O
use O O
of O O
vasoconstrictors B-Drug B-Drug
while O O
he O O
was O O
in O O
the O O
ICU O O
in O O
Date O O
. O O
  
CURRENT O O
THERAPY O O
: O O
  
1. O O
Currently O O
, O O
the O O
patient O O
is O O
off O O
all O O
therapy O O
. O O
  
Most O O
recently O O
, O O
he O O
was O O
on O O
thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
and O O
Velcade B-Drug B-Drug
1 B-Dose B-Dose
- I-Dose I-Dose
1.3 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
for I-Frequency I-Frequency
2 I-Frequency I-Frequency
/ I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
. O O
  
I O O
have O O
discontinued O O
this O O
because O O
his O O
neuropathy B-ADE B-ADE
was O O
worsening O O
. O O
  
2. O O
Prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Prophylactic B-Indication B-Indication
valacyclovir B-Drug B-Drug
. O O
  
4. O O
Chronic O O
Coumadin B-Drug B-Drug
. O O
  
5. O O
Pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
every B-Frequency B-Frequency
other I-Frequency I-Frequency
month I-Frequency I-Frequency
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1. O O
Six B-Duration B-Duration
cycles I-Duration I-Duration
of O O
R B-Drug B-Drug
- I-Drug I-Drug
CVP I-Drug I-Drug
completed O O
in O O
Date O O
and O O
Rituxan B-Drug B-Drug
given O O
for O O
maintenance O O
completed O O
in O O
Date O O
. O O
  
2. O O
Revlimid B-Drug B-Drug
discontinued O O
secondary O O
to O O
skin B-ADE B-ADE
rash I-ADE I-ADE
. O O
  
3. O O
Fludarabine B-Drug B-Drug
monotherapy O O
in O O
Date O O
. O O
  
He O O
developed O O
profound B-Severity B-Severity
pancytopenia B-ADE B-ADE
with O O
only O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
and O O
has O O
not O O
had O O
any O O
further O O
therapy O O
with O O
this O O
drug O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Alprazolam B-Drug B-Drug
, O O
low B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
aspirin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
furosemide B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
lactulose B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
, O O
Levoxyl B-Drug B-Drug
, O O
morphine B-Drug B-Drug
sulfate I-Drug I-Drug
that O O
is O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
and O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
a.m. O O
and O O
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
for O O
which O O
I O O
am O O
writing O O
. O O
  
He O O
is O O
also O O
on O O
pantoprazole B-Drug B-Drug
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoma B-Indication B-Indication
. O O
  
He O O
is O O
basically O O
stable O O
. O O
  
I O O
have O O
stopped O O
the O O
thalidomide B-Drug B-Drug
and O O
Velcade B-Drug B-Drug
because O O
he O O
was O O
having O O
increasing O O
problems O O
with O O
neuropathy B-ADE B-ADE
. O O
  
He O O
says O O
that O O
once O O
the O O
thalidomide B-Drug B-Drug
was O O
stopped O O
, O O
he O O
felt B-SSLIF B-SSLIF
even I-SSLIF I-SSLIF
more I-SSLIF I-SSLIF
poorly I-SSLIF I-SSLIF
, O O
but O O
now O O
is O O
feeling O O
back O O
to O O
his O O
baseline O O
. O O
  
He O O
continues O O
to O O
have O O
significant B-Severity B-Severity
issues O O
with O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
cannot B-SSLIF B-SSLIF
stand I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
walk I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
any I-SSLIF I-SSLIF
long I-SSLIF I-SSLIF
periods I-SSLIF I-SSLIF
of O O
time O O
. O O
  
He O O
is O O
able O O
to O O
drive O O
short O O
distances O O
. O O
  
He O O
continues O O
to O O
live O O
independently O O
. O O
  
He O O
is O O
actively O O
again O O
trying O O
to O O
lose O O
weight O O
, O O
but O O
it O O
is O O
difficult O O
for O O
him O O
to O O
exercise O O
because O O
of O O
his O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
has O O
fatigue B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
breathing I-SSLIF I-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
or O O
cough B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
significant B-Severity B-Severity
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
He O O
is O O
trying O O
to O O
lose O O
weight O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
history O O
of O O
stroke B-SSLIF B-SSLIF
or O O
seizure B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
continues O O
to O O
have O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
about O O
4 B-Severity B-Severity
- I-Severity I-Severity
5 I-Severity I-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
He O O
denies O O
any O O
current O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Negative O O
for O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
. O O
  
His O O
father O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
and O O
then O O
developed O O
AML B-SSLIF B-SSLIF
when O O
he O O
was O O
quite O O
elderly O O
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
1 O O
. O O
  
He O O
does O O
live O O
independently O O
. O O
  
He O O
uses O O
a O O
cane O O
to O O
walk O O
. O O
  
He O O
is O O
able O O
to O O
drive O O
. O O
  
He O O
does O O
all O O
activities O O
of O O
daily O O
living O O
, O O
but O O
is O O
unable O O
to O O
work O O
and O O
is O O
on O O
disability O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
is O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
is O O
138 O O
/ O O
71 O O
, O O
pulse O O
is O O
89 O O
and O O
regular O O
and O O
his O O
weight O O
is O O
258 O O
pounds O O
, O O
which O O
is O O
decreased O O
by O O
7 O O
pounds O O
since O O
last O O
seen O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx B-SSLIF B-SSLIF
without I-SSLIF I-SSLIF
lesions I-SSLIF I-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
EXTREMITIES O O
: O O
Reveal O O
1+ O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
usually O O
wears O O
compressions O O
stockings O O
, O O
but O O
is O O
not O O
wearing O O
them O O
currently O O
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
He O O
has O O
a O O
slow B-SSLIF B-SSLIF
gait I-SSLIF I-SSLIF
and O O
uses O O
a O O
cane O O
to O O
walk O O
. O O
  
He O O
has O O
developed O O
a O O
significant B-Severity B-Severity
kyphoscoliosis B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rashes B-SSLIF B-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
is O O
3300 O O
with O O
71 O O
polys O O
, O O
16.3 O O
lymphs O O
, O O
10.6 O O
monos O O
, O O
1.7 O O
eos O O
, O O
0.4 O O
basophils O O
, O O
a O O
platelet O O
count O O
of O O
138 O O
, O O
000 O O
and O O
hemoglobin O O
of O O
9.2 O O
with O O
hematocrit O O
of O O
27.1 O O
. O O
  
MCV O O
is O O
90.5 O O
. O O
  
A O O
BUN O O
is O O
13 O O
, O O
creatinine O O
is O O
1.78 O O
, O O
which O O
has O O
improved O O
. O O
  
AST O O
is O O
46 O O
, O O
ALT O O
is O O
20 O O
, O O
LDH O O
is O O
195 O O
. O O
  
An O O
IgG O O
level O O
is O O
stable O O
at O O
6850 O O
. O O
  
Free B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
light I-SSLIF I-SSLIF
chains I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
2050 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
increased I-SSLIF I-SSLIF
. O O
  
Free B-SSLIF B-SSLIF
lambda I-SSLIF I-SSLIF
light I-SSLIF I-SSLIF
chains I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
5.1 I-SSLIF I-SSLIF
with I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
kappa I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
lambda I-SSLIF I-SSLIF
ratio I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
404 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
which I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
significantly I-SSLIF I-SSLIF
increased I-SSLIF I-SSLIF
. O O
  
A O O
serum O O
protein O O
electrophoresis O O
reveals O O
an O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
that I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
increased I-SSLIF I-SSLIF
as O O
well O O
and O O
is O O
now O O
5200 O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
55 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
and O O
an O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
monoclonal I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
. O O
  
He O O
is O O
acting O O
more O O
like O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
and O O
I O O
have O O
treated O O
him O O
as O O
such O O
. O O
  
He O O
has O O
been O O
on O O
Velcade B-Drug B-Drug
and O O
thalidomide B-Drug B-Drug
. O O
  
However O O
, O O
he O O
has O O
increasing O O
peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
and O O
thus O O
I O O
have O O
held O O
his O O
medication O O
now O O
for O O
the O O
last O O
several O O
months O O
. O O
  
His O O
neuropathy B-SSLIF B-SSLIF
is O O
again O O
improving O O
, O O
although O O
the O O
neuropathy B-SSLIF B-SSLIF
has O O
multiple O O
causes O O
. O O
  
However O O
, O O
his O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
kappa I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
lambda I-SSLIF I-SSLIF
ratio I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
clearly I-SSLIF I-SSLIF
risen I-SSLIF I-SSLIF
. O O
  
I O O
was O O
thinking O O
of O O
alternative O O
chemotherapy B-Drug B-Drug
. O O
  
I O O
will O O
present O O
him O O
again O O
to O O
lymphoma B-Indication B-Indication
conference O O
, O O
but O O
I O O
am O O
wondering O O
whether O O
bendamustine B-Drug B-Drug
and O O
Rituxan B-Drug B-Drug
might O O
be O O
worth O O
a O O
try O O
. O O
  
He O O
did O O
respond O O
very O O
well O O
to O O
R B-Drug B-Drug
- I-Drug I-Drug
CVP I-Drug I-Drug
in O O
the O O
distant O O
past O O
, O O
although O O
his O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
that I-SSLIF I-SSLIF
time I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
much I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
. O O
  
PLAN O O
: O O
  
1. O O
I O O
will O O
get O O
prior O O
authorization O O
for O O
bendamustine B-Drug B-Drug
and O O
Rituxan B-Drug B-Drug
. O O
  
2 O O
. O O
  
He O O
will O O
receive O O
pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
today O O
over O O
2 O O
hours O O
. O O
  
3 O O
. O O
  
His O O
prednisone B-Drug B-Drug
will O O
be O O
decreased O O
to O O
5 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
week I-Frequency I-Frequency
. O O
  
4. O O
I O O
will O O
see O O
him O O
in O O
followup O O
in O O
1 O O
month O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
10 O O
: O O
36 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
12 O O
: O O
07 O O
A O O
  
10 O O
: O O
38 O O
P O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Plasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
initially O O
diagnosed O O
in O O
Date O O
associated O O
with O O
a O O
progressively O O
increasing O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
Disseminated B-SSLIF B-SSLIF
herpes I-SSLIF I-SSLIF
zoster I-SSLIF I-SSLIF
, O O
requiring O O
hospitalization O O
in O O
Date O O
, O O
now O O
resolved O O
. O O
  
3. O O
Compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
status O O
post O O
3 O O
kyphoplasties O O
, O O
one O O
in O O
Date O O
in O O
Date O O
and O O
the O O
second O O
and O O
third O O
1 O O
month O O
later O O
. O O
  
With O O
the O O
first O O
procedure O O
developed O O
an O O
acute O O
hemoglobin B-SSLIF B-SSLIF
decrease I-SSLIF I-SSLIF
for O O
which O O
he O O
was O O
hospitalized O O
and O O
found O O
to O O
have O O
hemorrhagic B-SSLIF B-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
. O O
  
This O O
was O O
drained O O
and O O
found O O
to O O
be O O
nonmalignant B-SSLIF B-SSLIF
. O O
  
At O O
that O O
time O O
, O O
he O O
received O O
5 O O
units O O
of O O
red O O
blood O O
cells O O
. O O
  
The O O
etiology O O
of O O
the O O
effusion B-SSLIF B-SSLIF
was O O
never O O
clarified O O
. O O
  
4. O O
Extensive O O
hospitalization O O
in O O
Date O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
subsequently O O
developed O O
a O O
cardio B-SSLIF B-SSLIF
respiratory I-SSLIF I-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
within O O
the O O
patient O O
as O O
well O O
as O O
acute O O
hemodialysis O O
. O O
  
He O O
developed O O
an O O
ulceration B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
, O O
which O O
has O O
now O O
healed O O
. O O
  
He O O
was O O
hospitalized O O
several O O
more O O
times O O
for O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
. I-SSLIF I-SSLIF
  
His O O
most O O
recent O O
recurrence O O
of O O
cellulitis B-SSLIF B-SSLIF
was O O
in O O
Date O O
, O O
but O O
this O O
was O O
treated O O
as O O
an O O
outpatient O O
. O O
  
5. O O
Bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
right B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
occurring O O
in O O
Date O O
, O O
at O O
which O O
time O O
an O O
IVC O O
filter O O
was O O
placed O O
. O O
  
In O O
Date O O
, O O
he O O
had O O
a O O
DVT B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
left I-Indication I-Indication
leg I-Indication I-Indication
and O O
he O O
is O O
now O O
on O O
chronic O O
Coumadin B-Drug B-Drug
. O O
  
6. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
7. O O
Hypothyroid B-SSLIF B-SSLIF
. O O
  
8. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
, O O
which O O
is O O
multifactorial O O
. O O
  
9. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
secondary O O
to O O
both O O
thalidomide B-Drug B-Drug
and O O
the O O
use O O
of O O
Vasoconstrictors B-Drug B-Drug
while O O
he O O
was O O
in O O
the O O
ICU O O
and O O
in O O
Date O O
. O O
  
10. O O
Bilateral B-SSLIF B-SSLIF
conjunctivitis I-SSLIF I-SSLIF
, O O
either O O
viral B-SSLIF B-SSLIF
or O O
bacterial B-SSLIF B-SSLIF
, O O
which O O
has O O
now O O
resolved O O
. O O
  
This O O
occurred O O
1 O O
month O O
ago O O
in O O
Date O O
. O O
  
CURRENT O O
THERAPY O O
: O O
  
1. O O
Thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
2. O O
Prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
every B-Frequency B-Frequency
other I-Frequency I-Frequency
month I-Frequency I-Frequency
. O O
  
4. O O
Velcade B-Drug B-Drug
1 B-Dose B-Dose
- I-Dose I-Dose
1.3 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
for I-Frequency I-Frequency
2 I-Frequency I-Frequency
/ I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
. I-Frequency I-Frequency
  
5. O O
Prophylactic B-Indication B-Indication
valacyclovir B-Drug B-Drug
. O O
  
6. O O
Chronic O O
Coumadin B-Drug B-Drug
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1. O O
Six B-Duration B-Duration
cycles I-Duration I-Duration
of O O
RCVP B-Drug B-Drug
completed O O
in O O
Date O O
and O O
then O O
maintenance O O
Rituxan B-Drug B-Drug
completed O O
in O O
Date O O
. O O
  
2. O O
Revlimid B-Drug B-Drug
, O O
which O O
was O O
discontinued O O
secondary O O
to O O
skin B-ADE B-ADE
rash I-ADE I-ADE
. O O
  
3. O O
Fludarabine B-Drug B-Drug
monotherapy O O
given O O
in O O
Date O O
. O O
  
He O O
developed O O
profound B-Severity B-Severity
pancytopenia B-ADE B-ADE
with O O
only O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
and O O
has O O
not O O
had O O
any O O
further O O
therapy O O
with O O
this O O
drug O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Alprazolam B-Drug B-Drug
, O O
low B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
aspirin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
and I-Drug I-Drug
vitamin I-Drug I-Drug
D I-Drug I-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
furosemide B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
glucosamine B-Drug B-Drug
, O O
lactulose B-Drug B-Drug
, O O
Levoxyl B-Drug B-Drug
, O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
4 I-Frequency I-Frequency
- I-Frequency I-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
and O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
a.m. O O
and O O
30 B-Dose B-Dose
mg I-Dose I-Dose
12 B-Frequency B-Frequency
hours I-Frequency I-Frequency
later I-Frequency I-Frequency
, O O
pantoprazole B-Drug B-Drug
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
. I-Drug I-Drug
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
basically O O
stable O O
. O O
  
He O O
continues O O
to O O
have O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
but O O
is O O
trying O O
to O O
be O O
active O O
. O O
  
He O O
does O O
a O O
stationary O O
bike O O
, O O
but O O
only O O
for O O
a O O
few O O
minutes O O
because O O
it O O
does O O
bother B-SSLIF B-SSLIF
his I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
. O O
  
He O O
is O O
trying O O
to O O
get O O
out O O
and O O
is O O
going O O
to O O
large O O
meetings O O
, O O
which O O
he O O
enjoys O O
. O O
  
He O O
, O O
however O O
, O O
continues O O
to O O
have O O
issues O O
with O O
his O O
back O O
. O O
  
He O O
would O O
very O O
much O O
like O O
to O O
lose O O
weight O O
because O O
he O O
feels O O
that O O
with O O
weight O O
loss O O
, O O
his O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
would O O
improve O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
any O O
fatigue B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
, O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
. O O
  
He O O
does O O
have O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
focal O O
neurological O O
changes O O
. O O
  
He O O
does O O
have O O
chronic B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
about O O
6 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
It O O
is O O
difficult B-SSLIF B-SSLIF
for I-SSLIF I-SSLIF
him I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
sit I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
stand I-SSLIF I-SSLIF
for O O
any O O
long O O
period O O
of O O
time O O
. O O
  
He O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
currently O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
in O O
his O O
father O O
. O O
  
His O O
father O O
also O O
developed O O
AML B-SSLIF B-SSLIF
at O O
an O O
elderly O O
age O O
. O O
  
He O O
has O O
1 O O
brother O O
who O O
is O O
not O O
an O O
HLA O O
match O O
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
1 O O
- O O
2 O O
. O O
  
He O O
lives O O
independently O O
and O O
does O O
activities O O
of O O
daily O O
living O O
. O O
  
He O O
is O O
able O O
to O O
drive O O
. O O
  
He O O
does O O
walk B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
cane I-SSLIF I-SSLIF
. O O
  
He O O
is O O
on O O
disability O O
and O O
is O O
unable O O
to O O
work O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
152 O O
/ O O
77 O O
, O O
pulse O O
83 O O
and O O
regular O O
and O O
weight O O
265 O O
pounds O O
, O O
which O O
is O O
stable O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx B-SSLIF B-SSLIF
without I-SSLIF I-SSLIF
lesions I-SSLIF I-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
There O O
is O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
The O O
patient O O
has O O
compression O O
stockings O O
on O O
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
He O O
is O O
quite O O
kyphotic O O
and O O
walks O O
with O O
a O O
cane O O
. O O
  
SKIN O O
: O O
No O O
rashes B-SSLIF B-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
revealed O O
a O O
white O O
count O O
of O O
2700 O O
with O O
53.4 O O
polys O O
, O O
26.7 O O
lymphs O O
, O O
15.5 O O
monos O O
, O O
3.9 O O
eos O O
, O O
0.5 O O
basophils O O
, O O
a O O
platelet O O
count O O
of O O
164 O O
, O O
000 O O
and O O
hemoglobin O O
of O O
8.9 O O
with O O
hematocrit O O
of O O
26.2 O O
, O O
which O O
is O O
stable O O
. O O
  
MCV O O
is O O
90.2 O O
. O O
  
BUN O O
is O O
29 O O
, O O
creatinine O O
is O O
1.85 O O
, O O
which O O
is O O
stable O O
. O O
  
LDH B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
at O O
325 O O
. O O
  
An O O
IgG O O
level O O
is O O
7340 O O
, O O
which O O
is O O
stable O O
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
1068 O O
. O O
  
Free O O
lambda O O
light O O
chains O O
are O O
6 O O
with O O
a O O
kappa O O
to O O
lambda O O
ratio O O
of O O
177 O O
, O O
which O O
is O O
basically O O
stable O O
. O O
  
A O O
serum O O
protein O O
electrophoresis O O
reveals O O
an O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
of O O
5100 O O
, O O
which O O
is O O
quite O O
elevated O O
, O O
but O O
stable O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
55 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
a O O
significant B-Severity B-Severity
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
M I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
. O O
  
He O O
is O O
being O O
treated O O
as O O
a O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
, O O
although O O
this O O
is O O
not O O
his O O
disease O O
. O O
  
His O O
disease O O
is O O
stable O O
, O O
but O O
certainly O O
treatment O O
is O O
not O O
making O O
a O O
great O O
impact O O
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
The O O
patient O O
will O O
receive O O
Velcade B-Drug B-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
today O O
and O O
in O O
1 O O
week O O
. O O
  
2. O O
I O O
will O O
decrease O O
his O O
prednisone B-Drug B-Drug
to O O
15 B-Dose B-Dose
mg I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
instead O O
of O O
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
I O O
will O O
try O O
to O O
taper O O
back O O
the O O
prednisone B-Drug B-Drug
. O O
  
3 O O
. O O
  
The O O
patient O O
will O O
return O O
for O O
followup O O
in O O
1 O O
month O O
. O O
  
4. O O
I O O
have O O
written O O
prescriptions O O
for O O
the O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
morning I-Frequency I-Frequency
and O O
30 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
as O O
well O O
as O O
the O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
1 I-Dose I-Dose
every B-Frequency B-Frequency
3 I-Frequency I-Frequency
- I-Frequency I-Frequency
4 I-Frequency I-Frequency
hours I-Frequency I-Frequency
. O O
  
He O O
says O O
that O O
his O O
pain B-Indication B-Indication
control O O
is O O
reasonable O O
and O O
he O O
does O O
not O O
want O O
this O O
increase O O
currently O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
06 O O
: O O
21 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Date O O
Name O O
Name O O
, O O
M.D. O O
  
Street_Address O O
City O O
, O O
State O O
/ O O
Zipcode O O
RE O O
: O O
Name O O
, O O
Name O O
Hospital O O
# O O
: O O
Medical_Record_Number O O
DATE O O
OF O O
SERVICE O O
: O O
Date O O
Dear O O
Dr O O
. O O
  
Name O O
: O O
  
I O O
had O O
the O O
pleasure O O
of O O
seeing O O
Mr O O
. O O
  
Name O O
in O O
the O O
renal O O
clinic O O
today O O
. O O
  
As O O
you O O
know O O
, O O
this O O
is O O
a O O
57 O O
- O O
year O O
- O O
old O O
gentleman O O
who O O
has O O
a O O
history O O
of O O
stage B-Severity B-Severity
V I-Severity I-Severity
chronic O O
kidney B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
due O O
to O O
monoclonal B-SSLIF B-SSLIF
gammopathy I-SSLIF I-SSLIF
. O O
  
His O O
renal B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
has O O
been O O
progressive O O
over O O
the O O
last O O
6 O O
months O O
with O O
more O O
significant O O
acceleration O O
in O O
the O O
last O O
two O O
months O O
. O O
  
He O O
says O O
that O O
he O O
is O O
completely O O
asymptomatic O O
, O O
has O O
no O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
, O O
no O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
, O O
no O O
increasing O O
fatigue B-SSLIF B-SSLIF
. O O
  
He O O
was O O
last O O
seen O O
at O O
your O O
office O O
last O O
week O O
where O O
he O O
was O O
noted O O
to O O
have O O
significant B-Severity B-Severity
anemia B-SSLIF B-SSLIF
with O O
a O O
hemoglobin O O
in O O
the O O
6 O O
range O O
and O O
was O O
given O O
transfusion O O
. O O
  
At O O
that O O
time O O
, O O
he O O
also O O
had O O
worsening B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
creatinine I-SSLIF I-SSLIF
up O O
to O O
7.16 O O
from O O
6.3 O O
previously O O
. O O
  
Again O O
, O O
he O O
feels O O
that O O
he O O
is O O
doing O O
well O O
. O O
  
He O O
has O O
no O O
signs O O
or O O
symptoms O O
of O O
uremia B-SSLIF B-SSLIF
. O O
  
He O O
has O O
seen O O
Dr O O
. O O
  
Name O O
from O O
vascular O O
surgery O O
, O O
who O O
is O O
planning O O
on O O
placing O O
an O O
AV O O
fistula O O
. O O
  
He O O
also O O
has O O
seen O O
the O O
dialysis O O
educator O O
at O O
Location O O
and O O
has O O
decided O O
to O O
pursue O O
in O O
- O O
center O O
hemodialysis O O
as O O
his O O
modality O O
. O O
  
All O O
other O O
systems O O
are O O
reviewed O O
and O O
are O O
negative O O
. O O
  
MEDICATIONS O O
: O O
Androderm B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
patch I-Dose I-Dose
, O O
clonazepam B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
, O O
diltiazem B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
, O O
doxazosin B-Drug B-Drug
8 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
garlic B-Drug B-Drug
, O O
glucosamine B-Drug B-Drug
supplement O O
, O O
lactulose B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
constipation B-Indication B-Indication
, O O
levothyroxine B-Drug B-Drug
150 B-Dose B-Dose
mcg I-Dose I-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
magnesium B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
morphine B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
, O O
multivitamin B-Drug B-Drug
1 B-Dose B-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
per O O
Hem O O
/ O O
Onc O O
, O O
pantoprazole B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
per B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
prochlorperazine B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
  
PHYSICAL O O
EXAMINATION O O
: O O
This O O
is O O
a O O
pleasant O O
gentleman O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
He O O
is O O
alert O O
and O O
oriented O O
x3 O O
. O O
  
His O O
blood O O
pressure O O
is O O
147 O O
/ O O
75 O O
. O O
  
Heart O O
rate O O
70 O O
, O O
temperature O O
98 O O
degrees O O
Fahrenheit O O
. O O
  
His O O
weight O O
is O O
199 O O
pounds O O
, O O
which O O
is O O
unchanged O O
from O O
previously O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
In O O
conclusion O O
, O O
this O O
is O O
a O O
57 O O
- O O
year O O
- O O
old O O
gentleman O O
with O O
history O O
of O O
stage B-Severity B-Severity
V I-Severity I-Severity
CKD B-SSLIF B-SSLIF
due O O
to O O
lymphoma B-SSLIF B-SSLIF
and O O
monoclonal B-SSLIF B-SSLIF
gammopathy I-SSLIF I-SSLIF
. O O
  
He O O
is O O
approaching O O
the O O
need O O
for O O
renal O O
replacement O O
therapy O O
. O O
  
He O O
will O O
pursue O O
in O O
- O O
center O O
hemodialysis O O
and O O
is O O
awaiting O O
a O O
fistula O O
placement O O
by O O
Dr O O
. O O
  
Name O O
from O O
our O O
vascular O O
surgery O O
. O O
  
He O O
has O O
several O O
concerns O O
about O O
the O O
actual O O
procedure O O
and O O
wants O O
to O O
see O O
her O O
again O O
before O O
scheduling O O
a O O
date O O
. O O
  
The O O
patient O O
has O O
a O O
history O O
of O O
hypertension B-SSLIF B-SSLIF
, O O
but O O
his O O
blood O O
pressure O O
is O O
acceptable O O
and O O
at O O
this O O
point O O
I O O
am O O
not O O
making O O
any O O
changes O O
in O O
his O O
medications O O
. O O
  
He O O
has O O
a O O
history O O
of O O
anemia B-SSLIF B-SSLIF
and O O
is O O
receiving O O
transfusions O O
through O O
Dr O O
. O O
  
Name O O
Name O O
office O O
. O O
  
From O O
the O O
standpoint O O
of O O
renal B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
, O O
the O O
patient's O O
PTH O O
and O O
vitamin O O
D O O
are O O
at O O
goal O O
. O O
  
As O O
far O O
as O O
renal O O
replacement O O
therapy O O
, O O
again O O
patient O O
will O O
be O O
scheduling O O
his O O
procedure O O
soon O O
. O O
  
We O O
also O O
discussed O O
the O O
fact O O
that O O
his O O
renal B-SSLIF B-SSLIF
function I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
deteriorated I-SSLIF I-SSLIF
significantly B-Severity B-Severity
and O O
that O O
he O O
may O O
require O O
temporary O O
Tesio O O
placement O O
in O O
order O O
to O O
wait O O
for O O
the O O
fistula O O
to O O
mature O O
. O O
  
Depending O O
on O O
when O O
he O O
decides O O
to O O
have O O
his O O
procedure O O
done O O
, O O
we O O
may O O
arrange O O
for O O
simultaneous O O
placement O O
of O O
both O O
the O O
fistula O O
and O O
his O O
catheter O O
. O O
  
Alternately O O
, O O
he O O
may O O
require O O
having O O
graft O O
placement O O
, O O
which O O
can O O
be O O
used O O
much O O
earlier O O
. O O
  
I O O
will O O
communicate O O
this O O
with O O
Dr O O
. O O
  
Name O O
. O O
  
Sincerely O O
, O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
Dictation O O
Date O O
/ O O
Time O O
: O O
Date O O
09 O O
: O O
53 O O
: O O
55 O O
Transcription O O
Date O O
/ O O
Time O O
: O O
Date O O
11 O O
: O O
47 O O
: O O
20 O O
cc O O
: O O
Name O O
Name O O
MD O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
4 O O
: O O
08PM O O
EST O O
Author O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Location O O
: O O
Location O O
Dictated O O
Date O O
6 O O
: O O
20 O O
P O O
Transcribed O O
Date O O
  
: O O
: O O
7 O O
: O O
24 O O
P O O
HISTORY O O
AND O O
PHYSICAL O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
Name O O
is O O
a O O
51 O O
- O O
year O O
- O O
old O O
male O O
who O O
is O O
a O O
patient O O
of O O
Dr O O
. O O
  
Name O O
Name O O
and O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
He O O
has O O
an O O
unfortunate O O
history O O
with O O
having O O
lymphoplasmacytic B-Indication B-Indication
lymphoma I-Indication I-Indication
involving I-Indication I-Indication
the I-Indication I-Indication
bone I-Indication I-Indication
marrow I-Indication I-Indication
and I-Indication I-Indication
spleen I-Indication I-Indication
, O O
which O O
was O O
diagnosed O O
in O O
Date O O
with O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
He O O
has O O
had O O
multiple O O
complications O O
from O O
this O O
and O O
is O O
followed O O
by O O
Dr O O
. O O
  
Name O O
Name O O
in O O
the O O
hematology O O
clinic O O
. O O
  
Apparently O O
, O O
Mr O O
. O O
  
Name O O
has O O
been O O
having O O
severe B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
has O O
multiple O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
. O O
  
He O O
was O O
seen O O
today O O
in O O
the O O
operating O O
room O O
by O O
Dr O O
. O O
  
Name O O
Name O O
for O O
kyphoplasty O O
of O O
L1 O O
and O O
L3 O O
where O O
they O O
put O O
cement O O
into O O
the O O
vertebral O O
bodies O O
. O O
  
Dr O O
. O O
  
Name O O
said O O
that O O
the O O
case O O
went O O
well O O
and O O
there O O
was O O
minimal B-Severity B-Severity
bleeding B-SSLIF B-SSLIF
, O O
which O O
he O O
felt O O
was O O
about O O
100 O O
mL O O
in O O
the O O
operating O O
room O O
. O O
  
The O O
patient O O
had O O
a O O
CBC O O
preop O O
on O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
his O O
hemoglobin O O
was O O
9.5 O O
and O O
hematocrit O O
26.9 O O
. O O
  
Postop O O
CBC O O
showed O O
hemoglobin O O
of O O
6.4 O O
and O O
hematocrit O O
of O O
18.4 O O
. O O
  
The O O
patient O O
also O O
finished O O
some O O
chemotherapy B-Drug B-Drug
last O O
week O O
and O O
regularly O O
gets O O
Velcade B-Drug B-Drug
and O O
Doxil B-Drug B-Drug
. O O
  
Patient O O
states O O
he O O
has O O
had O O
no O O
blood B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
stools I-SSLIF I-SSLIF
, O O
no O O
black B-SSLIF B-SSLIF
tarry I-SSLIF I-SSLIF
stools I-SSLIF I-SSLIF
, O O
no O O
stomach B-SSLIF B-SSLIF
upset I-SSLIF I-SSLIF
. O O
  
He O O
did O O
have O O
an O O
MRI O O
scan O O
done O O
last O O
week O O
under O O
general B-Drug B-Drug
anesthesia I-Drug I-Drug
due O O
to O O
pain B-SSLIF B-SSLIF
problems O O
and O O
since O O
that O O
time O O
has O O
had O O
some B-Severity B-Severity
flu B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
like I-SSLIF I-SSLIF
symptoms I-SSLIF I-SSLIF
and O O
mild B-Severity B-Severity
cough B-SSLIF B-SSLIF
with O O
mild B-Severity B-Severity
sore B-SSLIF B-SSLIF
throat I-SSLIF I-SSLIF
. O O
  
He O O
was O O
not O O
intubated O O
at O O
that O O
time O O
apparently O O
. O O
  
That O O
is O O
his O O
only O O
other O O
complaint O O
. O O
  
He O O
really O O
has O O
no O O
complaints O O
of O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
does O O
have O O
chronic O O
severe B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Extensive O O
and O O
includes O O
lymphoma B-SSLIF B-SSLIF
as O O
mentioned O O
above O O
, O O
hypercalcemia B-Indication B-Indication
where O O
he O O
regularly O O
gets O O
pamidronate B-Drug B-Drug
. O O
  
He O O
has O O
a O O
history O O
of O O
severe B-Severity B-Severity
cellulitis B-SSLIF B-SSLIF
and O O
actually O O
had O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
that O O
was O O
debrided O O
in O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
he O O
also O O
had O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
. O O
  
He O O
has O O
a O O
history O O
of O O
psoriasis B-SSLIF B-SSLIF
and O O
hypertension B-SSLIF B-SSLIF
. O O
  
He O O
has O O
had O O
MRSA B-SSLIF B-SSLIF
on O O
previous O O
cultures O O
, O O
hypertension B-SSLIF B-SSLIF
, O O
compression B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
lymphoma B-SSLIF B-SSLIF
, O O
glucose B-SSLIF B-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
For O O
pain B-Indication B-Indication
control O O
, O O
he O O
is O O
on O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
50 B-Dose B-Dose
mcg I-Dose I-Dose
q.3 B-Frequency B-Frequency
days I-Frequency I-Frequency
. O O
  
He O O
received O O
his O O
last O O
dose O O
yesterday O O
. O O
  
He O O
has O O
chronic O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
Right O O
now O O
, O O
his O O
BUN O O
is O O
31 O O
, O O
creatinine O O
1.45 O O
which O O
is O O
around O O
his O O
baseline O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
acute O O
myelogenous B-SSLIF B-SSLIF
leukemia I-SSLIF I-SSLIF
in O O
his O O
father O O
who O O
died B-SSLIF B-SSLIF
in O O
his O O
80s O O
from O O
leukemia B-SSLIF B-SSLIF
. O O
  
His O O
father O O
also O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
does O O
not O O
drink O O
or O O
smoke O O
. O O
  
He O O
takes O O
care O O
of O O
all O O
activities O O
of O O
daily O O
living O O
but O O
is O O
on O O
disability O O
. O O
  
MEDICATIONS O O
: O O
Cartia B-Drug B-Drug
XT I-Drug I-Drug
240 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
50 B-Dose B-Dose
mcg I-Dose I-Dose
to O O
the O O
skin O O
every B-Frequency B-Frequency
3 I-Frequency I-Frequency
days I-Frequency I-Frequency
, O O
last O O
applied O O
yesterday O O
morning O O
, O O
Percocet B-Drug B-Drug
1 B-Dose B-Dose
tab I-Dose I-Dose
p.o. B-Route B-Route
t.i.d. B-Frequency B-Frequency
p.r.n. I-Frequency I-Frequency
, O O
extra O O
pain B-Indication B-Indication
, O O
Colace B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
b.i.d. B-Frequency B-Frequency
, O O
multivitamin B-Drug B-Drug
1 B-Dose B-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
doxazosin B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
q.p.m. B-Frequency B-Frequency
  
He O O
states O O
he O O
is O O
on O O
this O O
for O O
his O O
blood B-Indication B-Indication
pressure I-Indication I-Indication
. O O
  
Claritin B-Drug B-Drug
D I-Drug I-Drug
1 B-Dose B-Dose
tablet I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
prochlorperazine B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
p.r.n. I-Frequency I-Frequency
nausea B-Indication B-Indication
, O O
omeprazole B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
, O O
alprazolam B-Drug B-Drug
0.25 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
t.i.d. B-Frequency B-Frequency
p.r.n. I-Frequency I-Frequency
anxiety B-Indication B-Indication
, O O
prednisone B-Drug B-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
after O O
chemo B-Drug B-Drug
for O O
a O O
few O O
days O O
. O O
  
He O O
has O O
had O O
none O O
in O O
3 O O
weeks O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
fatigue B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
but O O
he O O
does O O
have O O
a O O
sore B-SSLIF B-SSLIF
throat I-SSLIF I-SSLIF
, O O
some O O
mild B-Severity B-Severity
cough B-SSLIF B-SSLIF
and O O
congestion B-SSLIF B-SSLIF
. O O
  
He O O
has O O
no O O
trouble B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
has O O
no O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
no O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
. O O
  
He O O
has O O
not O O
noticed O O
any O O
blood B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
stools I-SSLIF I-SSLIF
or O O
black B-SSLIF B-SSLIF
tarry I-SSLIF I-SSLIF
stools I-SSLIF I-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
complains O O
of O O
pain B-SSLIF B-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
site I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
G I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
tube I-SSLIF I-SSLIF
insertion I-SSLIF I-SSLIF
. O O
  
The O O
G O O
- O O
tube O O
has O O
been O O
removed O O
. O O
  
He O O
denies O O
diarrhea B-SSLIF B-SSLIF
, O O
melena B-SSLIF B-SSLIF
, O O
hematemesis B-SSLIF B-SSLIF
or O O
hematochezia B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
polyuria B-SSLIF B-SSLIF
or O O
dysuria B-SSLIF B-SSLIF
, O O
no O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
No O O
numbness B-SSLIF B-SSLIF
, O O
tingling B-SSLIF B-SSLIF
or O O
weakness B-SSLIF B-SSLIF
anywhere O O
. O O
  
He O O
has O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
some B-Severity B-Severity
rib B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
as O O
well O O
. O O
  
He O O
states O O
he O O
has O O
recently O O
lost B-SSLIF B-SSLIF
maybe I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
much I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
5 I-SSLIF I-SSLIF
inches I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
height I-SSLIF I-SSLIF
. O O
  
He O O
has O O
intermittent O O
skin B-SSLIF B-SSLIF
rashes I-SSLIF I-SSLIF
and O O
psoriasis B-SSLIF B-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
was O O
lying O O
in O O
bed O O
. O O
  
He O O
was O O
comfortable O O
when O O
lying O O
flat O O
but O O
as O O
soon O O
I O O
tried O O
to O O
sit O O
him O O
up O O
he O O
was O O
quite O O
uncomfortable O O
. O O
  
His O O
vital O O
signs O O
and O O
blood O O
pressure O O
141 O O
/ O O
58 O O
, O O
pulse O O
109 O O
, O O
respirations O O
20 O O
, O O
temperature O O
37.6 O O
p.o. O O
There O O
is O O
no O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
clear O O
. O O
  
Neck O O
was O O
supple O O
, O O
no O O
lymphadenopathy B-SSLIF B-SSLIF
noted O O
. O O
  
Lungs O O
are O O
clear O O
. O O
  
His O O
heart O O
is O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmur B-SSLIF B-SSLIF
. O O
  
Abdomen O O
was O O
soft O O
, O O
active O O
bowel O O
sounds O O
, O O
mild B-Severity B-Severity
tenderness B-SSLIF B-SSLIF
over I-SSLIF I-SSLIF
under I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
area I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
G I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
tube I-SSLIF I-SSLIF
. O O
  
I O O
did O O
not O O
feel O O
a O O
mass B-SSLIF B-SSLIF
there O O
. O O
  
Extremities O O
: O O
There O O
is O O
1+ O O
edema B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
legs I-SSLIF I-SSLIF
, O O
no O O
petechiae B-SSLIF B-SSLIF
noted O O
. O O
  
Skin O O
: O O
No O O
particular O O
rash B-SSLIF B-SSLIF
. O O
  
Neurologically O O
, O O
he O O
has O O
good O O
movement O O
of O O
his O O
legs O O
and O O
arms O O
. O O
  
His O O
reflexes O O
are O O
2+ O O
bilaterally O O
. O O
  
He O O
is O O
able O O
to O O
dorsiflex O O
feet O O
and O O
bend O O
his O O
knees O O
. O O
  
ASSESSMENT O O
: O O
  
1. O O
Anemia B-SSLIF B-SSLIF
postop O O
. O O
  
It O O
is O O
hard O O
to O O
say O O
if O O
this O O
all O O
caused O O
by O O
the O O
procedure O O
not O O
. O O
  
We O O
would O O
also O O
try O O
to O O
rule O O
out O O
a O O
cause O O
of O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
is O O
to O O
be O O
transfused O O
here O O
3 O O
units O O
. O O
  
We O O
will O O
follow O O
up O O
his O O
hemoglobin O O
and O O
hematocrit O O
. O O
  
2. O O
Past O O
medical O O
history O O
of O O
lymphoplasmacytic B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
with O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
3. O O
Hypercalcemia B-Indication B-Indication
on O O
pamidronate B-Drug B-Drug
. O O
  
4. O O
History O O
of O O
cellulitis B-SSLIF B-SSLIF
and O O
MRSA B-SSLIF B-SSLIF
infection I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
will O O
be O O
placed O O
in O O
a O O
private O O
room O O
. O O
  
5. O O
History O O
of O O
psoriasis B-SSLIF B-SSLIF
. O O
  
6. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
7. O O
Compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
secondary O O
to O O
lymphoma B-SSLIF B-SSLIF
, O O
followed O O
by O O
Dr O O
. O O
  
Name O O
and O O
now O O
Dr O O
. O O
  
Name O O
Name O O
. O O
  
The O O
patient O O
has O O
received O O
kyphoplasty O O
today O O
. O O
  
8. O O
Glucose B-SSLIF B-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
We O O
will O O
keep O O
track O O
of O O
his O O
blood O O
sugars O O
. O O
  
9 O O
. O O
  
For O O
pain B-Indication B-Indication
control O O
, O O
will O O
keep O O
him O O
on O O
his O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
. O O
  
He O O
has O O
some O O
percent O O
ordered O O
as O O
well O O
. O O
  
10. O O
Status O O
post O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
, O O
status O O
post O O
debridement O O
in O O
Date O O
. O O
  
11. O O
History O O
of O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
. O O
  
12 O O
. O O
  
His O O
EKG O O
is O O
abnormal O O
with O O
depression B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
PR I-SSLIF I-SSLIF
and O O
nonspecific O O
ST O O
changes O O
. O O
  
We O O
will O O
rule O O
out O O
a O O
myocardial B-SSLIF B-SSLIF
infarction I-SSLIF I-SSLIF
and O O
place O O
the O O
patient O O
on O O
tele O O
. O O
  
13. O O
Chronic O O
renal B-SSLIF B-SSLIF
failure I-SSLIF I-SSLIF
. O O
  
This O O
appears O O
to O O
be O O
at O O
his O O
baseline O O
. O O
  
PLAN O O
: O O
We O O
will O O
check O O
neuro O O
checks O O
every O O
4 O O
hours O O
. O O
  
In O O
discussion O O
with O O
Dr O O
. O O
  
Name O O
Name O O
, O O
the O O
plan O O
is O O
to O O
get O O
an O O
MRI O O
of O O
his O O
lumbar O O
spine O O
if O O
he O O
has O O
neurological O O
changes O O
to O O
make O O
sure O O
there O O
is O O
no O O
bleeding B-SSLIF B-SSLIF
. O O
  
We O O
will O O
order O O
the O O
  
3 O O
units O O
of O O
packed O O
red O O
blood O O
cells O O
Tylenol B-Drug B-Drug
and O O
Benadryl B-Drug B-Drug
as O O
premedication B-Indication B-Indication
. O O
  
Patient O O
will O O
be O O
on O O
tele O O
and O O
an O O
echo O O
was O O
ordered O O
. O O
  
We O O
will O O
recheck O O
his O O
EKG O O
tomorrow O O
and O O
his O O
labs O O
will O O
be O O
followed O O
, O O
as O O
well O O
as O O
a O O
chest O O
x O O
- O O
ray O O
because O O
he O O
does O O
have O O
this O O
cough B-SSLIF B-SSLIF
and O O
mild B-Severity B-Severity
congestion B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
is O O
a O O
full O O
code O O
patient O O
. O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
8 O O
: O O
48 O O
P O O
  
5 O O
: O O
07 O O
P O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
, O O
diagnosed O O
initially O O
in O O
Date O O
associated O O
with O O
progressively O O
increasing O O
IgA B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
Compression O O
fractures O O
of O O
the O O
spine O O
secondary O O
to O O
the O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
status O O
post O O
3 O O
kyphoplasties O O
, O O
the O O
first O O
in O O
Date O O
and O O
then O O
2 O O
in O O
Date O O
. O O
  
With O O
the O O
first O O
procedure O O
, O O
he O O
developed O O
an O O
acute O O
hemoglobin B-SSLIF B-SSLIF
decrease I-SSLIF I-SSLIF
for O O
which O O
he O O
was O O
hospitalized O O
and O O
found O O
to O O
have O O
hemorrhagic B-SSLIF B-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
, O O
which O O
was O O
subsequently O O
drained O O
and O O
was O O
found O O
not O O
to O O
be O O
malignant B-SSLIF B-SSLIF
. O O
  
At O O
that O O
time O O
, O O
he O O
received O O
5 O O
units O O
of O O
red O O
blood O O
cells O O
. O O
  
The O O
etiology O O
of O O
the O O
effusion B-SSLIF B-SSLIF
was O O
never O O
clarified O O
. O O
  
3. O O
Extensive O O
hospitalization O O
in O O
Date O O
. O O
  
He O O
was O O
initially O O
admitted O O
for O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
developed O O
Salmonella B-SSLIF B-SSLIF
sepsis I-SSLIF I-SSLIF
with O O
necrotizing B-SSLIF B-SSLIF
fasciitis I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
gastrocnemius I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
requiring O O
debridement O O
. O O
  
He O O
then O O
developed O O
cardiac B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
respiratory I-SSLIF I-SSLIF
arrest I-SSLIF I-SSLIF
and O O
had O O
a O O
prolonged O O
ICU O O
stay O O
with O O
intubation O O
and O O
acute O O
dialysis O O
. O O
  
Because O O
of O O
the O O
debridement O O
of O O
the O O
right O O
calf O O
muscle O O
, O O
a O O
residual O O
ulcer B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
medial I-SSLIF I-SSLIF
malleolus I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
ankle I-SSLIF I-SSLIF
developed O O
which O O
has O O
now O O
healed O O
. O O
  
He O O
was O O
hospitalized O O
several O O
times O O
after O O
this O O
for O O
recurrent O O
cellulitis B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
, O O
most O O
recently O O
in O O
Date O O
. O O
  
4. O O
Bilateral B-SSLIF B-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
DVT I-SSLIF I-SSLIF
with O O
the O O
right B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
occurring O O
in O O
Date O O
. O O
  
At O O
that O O
time O O
, O O
he O O
was O O
treated O O
with O O
a O O
6 B-Duration B-Duration
- I-Duration I-Duration
month I-Duration I-Duration
course O O
of O O
Coumadin B-Drug B-Drug
, O O
which O O
had O O
been O O
discontinued O O
and O O
he O O
is O O
status O O
post O O
an O O
IVC O O
filter O O
. O O
  
In O O
Date O O
, O O
he O O
developed O O
swelling B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
and O O
a O O
left B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
was O O
diagnosed O O
and O O
he O O
is O O
on O O
Coumadin B-Drug B-Drug
once O O
again O O
. O O
  
5. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
6. O O
Hypothyroidism B-SSLIF B-SSLIF
. O O
  
7. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
, O O
which O O
is O O
multifactorial O O
. O O
  
8. O O
Psoriasis B-SSLIF B-SSLIF
. O O
  
9. O O
Peripheral B-ADE B-ADE
neuropathy I-ADE I-ADE
, O O
which O O
is O O
attributed O O
to O O
the O O
use O O
of O O
vasoconstrictors B-Drug B-Drug
while O O
he O O
was O O
in O O
the O O
intensive O O
care O O
unit O O
. O O
  
CURRENT O O
THERAPY O O
: O O
  
1. O O
Thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
2. O O
Prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
on O O
mg O O
intravenously B-Route B-Route
once B-Frequency B-Frequency
a I-Frequency I-Frequency
month I-Frequency I-Frequency
. O O
  
4. O O
Velcade B-Drug B-Drug
1.3 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
once B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
for I-Frequency I-Frequency
2 I-Frequency I-Frequency
/ I-Frequency I-Frequency
4 I-Frequency I-Frequency
weeks I-Frequency I-Frequency
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1 O O
. O O
  
He O O
received O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
Rituxan B-Drug B-Drug
plus I-Drug I-Drug
CVP I-Drug I-Drug
completed O O
in O O
Date O O
and O O
then O O
maintenance O O
Rituxan B-Drug B-Drug
which O O
was O O
completed O O
in O O
Date O O
. O O
  
2. O O
Revlimid B-Drug B-Drug
, O O
which O O
was O O
discontinued O O
secondary O O
to O O
skin B-ADE B-ADE
rash I-ADE I-ADE
. O O
  
3. O O
Fludarabine B-Drug B-Drug
in O O
Date O O
. O O
  
He O O
received O O
1 B-Duration B-Duration
cycle I-Duration I-Duration
, O O
but O O
it O O
rendered O O
him O O
profoundly B-Severity B-Severity
pancytopenic B-ADE B-ADE
and O O
this O O
was O O
not O O
repeated O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
MS B-Drug B-Drug
Contin I-Drug I-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
in B-Frequency B-Frequency
the I-Frequency I-Frequency
morning I-Frequency I-Frequency
and O O
15 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
as O O
well O O
as O O
MSIR B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
6 I-Frequency I-Frequency
hours I-Frequency I-Frequency
for O O
breakthrough O O
pain B-Indication B-Indication
, O O
both O O
of O O
which O O
prescriptions O O
, O O
I O O
am O O
writing O O
. O O
  
He O O
is O O
also O O
on O O
alprazolam B-Drug B-Drug
, O O
low B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
aspirin B-Drug B-Drug
, O O
calcium B-Drug B-Drug
, O O
diltiazem B-Drug B-Drug
, O O
doxazosin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
gabapentin B-Drug B-Drug
, O O
Lasix B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
Levoxyl B-Drug B-Drug
, O O
magnesium B-Drug B-Drug
, O O
pantoprazole B-Drug B-Drug
, O O
and O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
. O O
  
He O O
is O O
on O O
Coumadin B-Drug B-Drug
currently O O
for O O
his O O
left B-Indication B-Indication
leg I-Indication I-Indication
DVT I-Indication I-Indication
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
his O O
lymphoma B-SSLIF B-SSLIF
. O O
  
He O O
is O O
doing O O
reasonably O O
well O O
. O O
  
His O O
pain B-SSLIF B-SSLIF
is O O
quite O O
well O O
controlled O O
. O O
  
It O O
is O O
at O O
most O O
4 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
He O O
did O O
walk O O
with O O
a O O
cane O O
down O O
to O O
the O O
clinic O O
area O O
, O O
which O O
is O O
quite O O
a O O
long O O
walk O O
. O O
  
He O O
did O O
not O O
need O O
a O O
wheelchair O O
. O O
  
He O O
says O O
he O O
has O O
developed O O
some B-Severity B-Severity
anxiety B-SSLIF B-SSLIF
and O O
panic B-SSLIF B-SSLIF
attacks I-SSLIF I-SSLIF
. O O
  
He O O
says O O
they O O
come O O
on O O
quite O O
suddenly O O
and O O
he O O
starts O O
to O O
get O O
very B-Severity B-Severity
short B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
He O O
feels O O
these O O
are O O
anxiety B-SSLIF B-SSLIF
because O O
he O O
can O O
actually O O
then O O
take O O
some O O
deep O O
breaths O O
they O O
pass O O
quite O O
quickly O O
. O O
  
Otherwise O O
, O O
he O O
has O O
had O O
no O O
specific O O
issues O O
. O O
  
He O O
continues O O
to O O
try O O
to O O
lose O O
weight O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
any O O
fatigue B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
cough B-SSLIF B-SSLIF
. O O
  
He O O
is O O
experiencing O O
some B-Severity B-Severity
intermittent O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
which O O
he O O
attributes O O
to O O
anxiety B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
or O O
increased O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
His O O
appetite O O
is O O
good O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
, O O
epistaxis B-SSLIF B-SSLIF
or O O
gingival B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
history O O
of O O
stroke B-SSLIF B-SSLIF
or O O
seizure B-SSLIF B-SSLIF
. O O
  
He O O
has O O
abnormal B-SSLIF B-SSLIF
gait I-SSLIF I-SSLIF
secondary O O
to O O
his O O
spine O O
issues O O
. O O
  
He O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
change O O
in O O
his O O
pain B-SSLIF B-SSLIF
status O O
. O O
  
It O O
is O O
at O O
most O O
4 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
and O O
this O O
is O O
related O O
to O O
his O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rashes I-SSLIF I-SSLIF
currently O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Positive O O
for O O
acute O O
leukemia B-SSLIF B-SSLIF
in O O
his O O
father O O
who O O
had O O
it O O
at O O
an O O
elderly O O
age O O
. O O
  
His O O
father O O
also O O
had O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
He O O
has O O
1 O O
brother O O
who O O
has O O
been O O
HLA O O
- O O
typed O O
and O O
is O O
not O O
a O O
match O O
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
unchanged O O
and O O
his O O
ECOG O O
is O O
1 O O
- O O
2 O O
. O O
  
He O O
does O O
do O O
all O O
activities O O
of O O
daily O O
living O O
including O O
driving O O
. O O
  
He O O
lives O O
independently O O
. O O
  
He O O
walks O O
with O O
a O O
cane O O
. O O
  
He O O
cannot O O
sit O O
or O O
stand O O
too O O
long O O
, O O
however O O
, O O
because O O
of O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
was O O
136 O O
/ O O
73 O O
, O O
pulse O O
is O O
79 O O
and O O
regular O O
and O O
his O O
weight O O
is O O
258 O O
pounds O O
, O O
which O O
is O O
slightly O O
decreased O O
from O O
when O O
last O O
seen O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
benign O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
no O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
1+ O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
with O O
no O O
petechiae B-SSLIF B-SSLIF
or O O
ecchymoses B-SSLIF B-SSLIF
. O O
  
He O O
wears O O
a O O
compression O O
stocking O O
on O O
the O O
right O O
leg O O
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
He O O
does O O
walk O O
with O O
a O O
cane O O
and O O
has O O
an O O
abnormal B-SSLIF B-SSLIF
gait I-SSLIF I-SSLIF
secondary O O
to O O
his O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
is O O
2400 O O
with O O
52.5 O O
polys O O
, O O
28.9 O O
lymphs O O
, O O
14 O O
monos O O
, O O
3.6 O O
eos O O
and O O
1 O O
basophil O O
, O O
a O O
platelet O O
count O O
of O O
175 O O
, O O
000 O O
and O O
a O O
hemoglobin O O
of O O
11.4 O O
with O O
hematocrit O O
of O O
33 O O
, O O
which O O
is O O
stable O O
. O O
  
MCV O O
is O O
91.2 O O
. O O
  
A O O
BUN O O
is O O
34 O O
and O O
a O O
creatinine O O
is O O
1.67 O O
, O O
which O O
is O O
stable O O
from O O
when O O
last O O
seen O O
, O O
but O O
it O O
has O O
gone O O
up O O
slightly O O
over O O
time O O
. O O
  
A O O
total B-SSLIF B-SSLIF
protein I-SSLIF I-SSLIF
continues I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
be I-SSLIF I-SSLIF
high I-SSLIF I-SSLIF
at O O
10 O O
with O O
an O O
albumin O O
of O O
3 O O
. O O
  
AST O O
is O O
18 O O
, O O
ALT O O
is O O
20 O O
and O O
an O O
LDH O O
is O O
113 O O
. O O
  
A O O
prothrombin O O
time O O
is O O
23.2 O O
seconds O O
with O O
an O O
INR O O
of O O
2.2 O O
, O O
which O O
is O O
in O O
reasonable O O
range O O
. O O
  
Quantitative O O
immunoglobulins O O
reveal O O
an O O
IgG O O
level O O
of O O
6510 O O
, O O
which O O
has O O
come O O
down O O
slightly O O
. O O
  
His O O
IgA O O
and O O
IgM O O
levels O O
are O O
depressed O O
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
954 O O
, O O
which O O
have O O
decreased O O
. O O
  
Free O O
lambda O O
light O O
chains O O
are O O
1.54 O O
with O O
a O O
kappa O O
to O O
lambda O O
ratio O O
of O O
619 O O
, O O
which O O
has O O
also O O
decreased O O
. O O
  
A O O
protein O O
electrophoresis O O
reveals O O
a O O
total O O
protein O O
of O O
11.3 O O
. O O
  
The O O
M B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
spike I-SSLIF I-SSLIF
is O O
4500 O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
53 O O
- O O
year O O
- O O
old O O
male O O
who O O
has O O
had O O
lymphoplasmacytoid B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
for O O
many O O
years O O
. O O
  
This O O
has O O
been O O
associated O O
with O O
a O O
rising O O
IgG B-SSLIF B-SSLIF
kappa I-SSLIF I-SSLIF
paraprotein I-SSLIF I-SSLIF
and O O
in O O
fact O O
his O O
disease O O
is O O
acting O O
more O O
like O O
multiple B-SSLIF B-SSLIF
myeloma I-SSLIF I-SSLIF
with O O
bony B-SSLIF B-SSLIF
mets I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
does O O
have O O
chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
which O O
is O O
multifactorial O O
secondary O O
to O O
his O O
hypotensive B-SSLIF B-SSLIF
crisis I-SSLIF I-SSLIF
now O O
some O O
years O O
ago O O
as O O
well O O
as O O
perhaps O O
his O O
underlying O O
lymphoma B-SSLIF B-SSLIF
. O O
  
At O O
least O O
his O O
pain B-SSLIF B-SSLIF
currently O O
is O O
under O O
reasonable O O
control O O
. O O
  
The O O
patient O O
continues O O
to O O
get O O
pamidronate B-Drug B-Drug
to O O
prevent B-Indication B-Indication
further I-Indication I-Indication
bony I-Indication I-Indication
fracture I-Indication I-Indication
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
The O O
patient O O
will O O
continue O O
thalidomide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
and O O
prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
2 O O
. O O
  
He O O
will O O
receive O O
Velcade B-Drug B-Drug
1.3 B-Dose B-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
m2 I-Dose I-Dose
today O O
and O O
in O O
1 O O
week O O
. O O
  
3 O O
. O O
  
He O O
will O O
receive O O
pamidronate B-Drug B-Drug
90 B-Dose B-Dose
mg I-Dose I-Dose
intravenously B-Route B-Route
over O O
2 O O
hours O O
today O O
. O O
  
4 O O
. O O
  
He O O
will O O
be O O
seen O O
in O O
followup O O
in O O
1 O O
month O O
. O O
  
Greater O O
than O O
50% O O
of O O
this O O
visit O O
was O O
spent O O
discussing O O
his O O
treatment O O
and O O
his O O
progress O O
. O O
  
It O O
should O O
be O O
noted O O
that O O
his O O
IgG O O
level O O
is O O
starting O O
to O O
come O O
down O O
once O O
again O O
and O O
hopefully O O
this O O
will O O
continue O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
21 O O
: O O
32 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
2 O O
: O O
59 O O
P O O
Transcribed O O
Date O O
11 O O
: O O
58 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
SUBJECTIVE O O
: O O
A O O
53 O O
- O O
year O O
- O O
old O O
female O O
returns O O
to O O
Plastic O O
Surgery O O
Wound O O
Clinic O O
at O O
Hospital O O
for O O
reevaluation O O
of O O
her O O
back B-SSLIF B-SSLIF
wound I-SSLIF I-SSLIF
. O O
  
She O O
is O O
status O O
post O O
back O O
fusion O O
surgery O O
in O O
Date O O
by O O
Dr O O
. O O
  
Name O O
Name O O
at O O
Hospital O O
in O O
the O O
Spine O O
Center O O
. O O
  
She O O
is O O
also O O
treated O O
by O O
Dr O O
. O O
  
Name O O
at O O
Hospital O O
, O O
who O O
is O O
an O O
anesthesiologist O O
for O O
steroid B-Drug B-Drug
injections B-Route B-Route
in O O
this O O
area O O
to O O
help O O
with O O
her O O
pain B-Indication B-Indication
issues O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Includes O O
radiation O O
treatments O O
to O O
this O O
area O O
for O O
a O O
Wilms B-SSLIF B-SSLIF
tumor I-SSLIF I-SSLIF
during O O
childhood O O
. O O
  
Recent O O
culture O O
results O O
from O O
Location O O
on O O
Date O O
revealed O O
Staph B-SSLIF B-SSLIF
coag I-SSLIF I-SSLIF
negative I-SSLIF I-SSLIF
with I-SSLIF I-SSLIF
sensitivities I-SSLIF I-SSLIF
. O O
  
Repeat O O
culture O O
was O O
performed O O
at O O
Hospital O O
on O O
Date O O
revealing O O
no O O
growth O O
. O O
  
Past O O
medical O O
history O O
, O O
medications O O
, O O
allergies O O
are O O
updated O O
, O O
signed O O
and O O
reviewed O O
on O O
the O O
PCHIS B-PHI B-PHI
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Denies O O
any O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
pain B-SSLIF B-SSLIF
, O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
OBJECTIVE O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
x3 O O
with O O
a O O
pleasant O O
affect O O
. O O
  
On O O
the O O
back O O
overlying O O
the O O
spine O O
near O O
the O O
surgical O O
incision O O
, O O
there O O
is O O
one O O
small O O
tiny B-Severity B-Severity
opening B-SSLIF B-SSLIF
approximately O O
2 B-Severity B-Severity
mm I-Severity I-Severity
in I-Severity I-Severity
diameter I-Severity I-Severity
, O O
still O O
undermining O O
around O O
the O O
edges O O
approximately O O
8 O O
mm O O
. O O
  
No O O
signs O O
of O O
infection B-SSLIF B-SSLIF
, O O
no O O
erythema B-SSLIF B-SSLIF
. O O
  
A O O
small B-Severity B-Severity
amount I-Severity I-Severity
of O O
serous B-SSLIF B-SSLIF
drainage I-SSLIF I-SSLIF
is O O
seen O O
if O O
direct O O
pressure O O
is O O
applied O O
to O O
this O O
area O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
At O O
this O O
point O O
in O O
time O O
, O O
the O O
patient O O
will O O
continue O O
washing O O
this O O
area O O
off O O
with O O
soap O O
and O O
water O O
daily O O
. O O
  
She O O
can O O
cover O O
it O O
with O O
one O O
dry O O
gauze O O
dressing O O
to O O
catch O O
any O O
drainage O O
issues O O
. O O
  
She O O
will O O
, O O
otherwise O O
, O O
followup O O
with O O
the O O
Wound O O
Center O O
in O O
8 O O
weeks O O
for O O
reevaluation O O
. O O
  
She O O
does O O
state O O
that O O
she O O
will O O
be O O
getting O O
her O O
steroid B-Drug B-Drug
injection B-Route B-Route
by O O
Dr O O
. O O
  
Name O O
after O O
the O O
first O O
of O O
the O O
new O O
year O O
. O O
  
CC O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
Hospital O O
Hospital O O
City O O
, O O
MA O O
Name O O
City O O
, O O
M.D. O O
  
Hospital O O
City O O
, O O
State O O
/ O O
Zipcode O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
PA O O
Date O O
16 O O
: O O
11 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
PA O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
PA O O
  
Medical_Record_Number O O
cc O O
: O O
Physician O O
Copy O O
Name O O
Name O O
Name O O
, O O
MD O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
a O O
52 O O
- O O
year O O
- O O
old O O
female O O
who O O
was O O
seen O O
on O O
Date O O
after O O
a O O
motor B-SSLIF B-SSLIF
vehicle I-SSLIF I-SSLIF
accident I-SSLIF I-SSLIF
, O O
leaving O O
her O O
with O O
neck B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
presents O O
today O O
with O O
continued O O
neck B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
The O O
pain B-SSLIF B-SSLIF
continues O O
to O O
be O O
an O O
8 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
She O O
has O O
had O O
no O O
significant O O
improvement O O
, O O
but O O
she O O
has O O
had O O
no O O
worsening O O
of O O
her O O
symptoms O O
. O O
  
She O O
has O O
been O O
seeing O O
a O O
chiropractor O O
regularly O O
and O O
states O O
that O O
has O O
been O O
helping O O
. O O
  
She O O
is O O
unable O O
to O O
drive O O
long O O
distances O O
due O O
to O O
her O O
neck B-Indication B-Indication
and I-Indication I-Indication
back I-Indication I-Indication
pain I-Indication I-Indication
. O O
  
She O O
finds O O
that O O
she O O
is O O
able O O
to O O
sleep O O
at O O
night O O
with O O
the O O
lorazepam B-Drug B-Drug
. O O
  
She O O
normally O O
would O O
take O O
1 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
, O O
but O O
finds O O
she O O
does O O
need O O
to O O
take O O
2 B-Dose B-Dose
mg I-Dose I-Dose
in O O
order O O
to O O
sleep O O
. O O
  
She O O
has O O
taken O O
an O O
occasional O O
Vicodin B-Drug B-Drug
at B-Frequency B-Frequency
night I-Frequency I-Frequency
and O O
is O O
using O O
Tylenol B-Drug B-Drug
and O O
a O O
heating O O
pad O O
. O O
  
She O O
is O O
unable O O
to O O
use O O
anti B-Drug B-Drug
- I-Drug I-Drug
inflammatories I-Drug I-Drug
. O O
  
She O O
has O O
been O O
seen O O
regularly O O
by O O
Dr O O
. O O
  
Name O O
Name O O
at O O
Location O O
who O O
is O O
an O O
orthopedist O O
. O O
  
Name O O
has O O
a O O
longstanding O O
history O O
of O O
spinal B-SSLIF B-SSLIF
stenosis I-SSLIF I-SSLIF
and O O
scoliosis B-SSLIF B-SSLIF
. O O
  
Her O O
medications O O
, O O
history O O
and O O
allergies O O
were O O
reviewed O O
and O O
updated O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Her O O
blood O O
pressure O O
this O O
morning O O
is O O
138 O O
/ O O
84 O O
with O O
a O O
heart O O
rate O O
of O O
100 O O
, O O
her O O
weight O O
is O O
139 O O
and O O
she O O
is O O
5 O O
feet O O
4 O O
inches O O
. O O
  
She O O
is O O
well O O
, O O
in O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
, O O
but O O
she O O
is O O
walking B-SSLIF B-SSLIF
around I-SSLIF I-SSLIF
stiffly I-SSLIF I-SSLIF
and O O
getting B-SSLIF B-SSLIF
out I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
chair I-SSLIF I-SSLIF
very I-SSLIF I-SSLIF
gingerly I-SSLIF I-SSLIF
. O O
  
Back B-SSLIF B-SSLIF
: I-SSLIF I-SSLIF
ROM I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
with O O
all O O
movement O O
. O O
  
Positive O O
toe O O
walk O O
, O O
positive O O
heel O O
walk O O
. O O
  
Neck B-SSLIF B-SSLIF
ROM I-SSLIF I-SSLIF
: I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
woth O O
all O O
movements O O
seconday O O
to O O
pain B-SSLIF B-SSLIF
. O O
  
ASSESSMENT O O
: O O
Neck B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
secondary O O
to O O
MVA B-SSLIF B-SSLIF
. O O
  
PLAN O O
: O O
Referral O O
to O O
Dr O O
. O O
  
Name O O
at O O
Location O O
to O O
evaluate O O
her O O
neck B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
is O O
to O O
continue O O
going O O
to O O
the O O
chiropractor O O
. O O
  
A O O
referral O O
was O O
given O O
for O O
physical O O
therapy O O
to O O
maximize O O
treatment O O
. O O
  
A O O
script O O
for O O
lorazepam B-Drug B-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
to O O
take O O
two B-Dose B-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
as I-Frequency I-Frequency
needed I-Frequency I-Frequency
and O O
she O O
was O O
instructed O O
to O O
use O O
to O O
the O O
two B-Dose B-Dose
at B-Frequency B-Frequency
night I-Frequency I-Frequency
to O O
help B-Indication B-Indication
her I-Indication I-Indication
sleep I-Indication I-Indication
secondary O O
to O O
the O O
increase O O
in O O
pain B-Indication B-Indication
. O O
  
She O O
will O O
continue O O
to O O
use O O
Vicodin B-Drug B-Drug
p.r.n. B-Frequency B-Frequency
, O O
Tylenol B-Drug B-Drug
and O O
heating O O
pads O O
. O O
  
No O O
lifting O O
, O O
no O O
activity O O
causing O O
any O O
pain B-SSLIF B-SSLIF
. O O
  
The O O
expectation O O
is O O
that O O
she O O
will O O
be O O
seen O O
by O O
Dr O O
. O O
  
Name O O
, O O
she O O
will O O
continue O O
chiropractor O O
and O O
physical O O
therapy O O
. O O
  
If O O
she O O
continues O O
to O O
have O O
problems O O
, O O
she O O
is O O
to O O
followup O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
N.P. O O
Date O O
1 O O
: O O
38PM O O
EST O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
9 O O
: O O
22PM O O
EST O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
3 O O
: O O
54 O O
P O O
  
1 O O
: O O
35 O O
P O O
CLINIC O O
NOTE O O
PROBLEM O O
LIST O O
: O O
Right B-SSLIF B-SSLIF
thumb I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
SUBJECTIVE O O
: O O
The O O
patient O O
returns O O
today O O
for O O
a O O
followup O O
visit O O
after O O
having O O
last O O
been O O
seen O O
a O O
couple O O
of O O
years O O
ago O O
. O O
  
She O O
is O O
concerned O O
that O O
the O O
cyst B-SSLIF B-SSLIF
she O O
had O O
in O O
her O O
carpal O O
tunnel O O
area O O
has O O
recurred O O
. O O
  
She O O
notes O O
that O O
she O O
has O O
been O O
having O O
some B-Severity B-Severity
pain B-SSLIF B-SSLIF
in O O
the O O
area O O
of O O
the O O
palmar O O
hand O O
. O O
  
She O O
, O O
of O O
note O O
, O O
underwent O O
a O O
spinal O O
fusion O O
, O O
which O O
was O O
complicated O O
by O O
an O O
infection B-SSLIF B-SSLIF
and O O
is O O
still O O
recovering O O
from O O
that O O
. O O
  
She O O
does O O
not O O
have O O
any O O
active O O
infection B-SSLIF B-SSLIF
at O O
this O O
time O O
. O O
  
OBJECTIVE O O
: O O
Exam O O
today O O
shows O O
a O O
well O O
- O O
appearing O O
woman O O
. O O
  
Evaluation O O
of O O
her O O
right O O
hand O O
shows O O
her O O
wound O O
is O O
well O O
healed O O
. O O
  
At O O
the O O
most O O
distal O O
portion O O
of O O
her O O
hand O O
, O O
she O O
does O O
have O O
a O O
lesion B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
, O O
which O O
is O O
approximately O O
three B-Severity B-Severity
mm I-Severity I-Severity
in O O
size O O
and O O
is O O
within O O
the O O
dermis O O
and O O
is O O
consistent O O
with O O
a O O
wart B-SSLIF B-SSLIF
. O O
  
She O O
has O O
full O O
motion O O
of O O
her O O
fingers O O
. O O
  
She O O
does O O
have O O
tenderness B-SSLIF B-SSLIF
over I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
thumb I-SSLIF I-SSLIF
CMC I-SSLIF I-SSLIF
joint I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
with O O
a O O
grind O O
test O O
. O O
  
RADIOLOGY O O
: O O
Review O O
of O O
radiographs O O
taken O O
today O O
do O O
show O O
thumb B-SSLIF B-SSLIF
CMC I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
STT I-SSLIF I-SSLIF
arthritis I-SSLIF I-SSLIF
. O O
  
She O O
has O O
no O O
evidence O O
of O O
a O O
continued O O
mass B-SSLIF B-SSLIF
. O O
  
ASSESSMENT O O
: O O
Right B-SSLIF B-SSLIF
thumb I-SSLIF I-SSLIF
CMC I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
STT I-SSLIF I-SSLIF
arthritis I-SSLIF I-SSLIF
, O O
right B-SSLIF B-SSLIF
hand I-SSLIF I-SSLIF
lesion I-SSLIF I-SSLIF
, O O
likely O O
wart B-SSLIF B-SSLIF
. O O
  
This O O
was O O
all O O
discussed O O
with O O
her O O
. O O
  
It O O
does O O
not O O
appear O O
that O O
her O O
ganglion B-SSLIF B-SSLIF
has O O
recurred O O
and O O
most O O
likely O O
her O O
symptoms O O
are O O
coming O O
from O O
the O O
arthritis B-Indication B-Indication
in I-Indication I-Indication
her I-Indication I-Indication
thumb I-Indication I-Indication
. O O
  
This O O
was O O
all O O
discussed O O
with O O
her O O
. O O
  
She O O
was O O
given O O
an O O
appointment O O
for O O
therapy O O
for O O
a O O
splint O O
and O O
small O O
joint O O
preservation O O
exercises O O
. O O
  
Risks O O
and O O
benefits O O
of O O
steroid B-Drug B-Drug
injection B-Route B-Route
, O O
including O O
the O O
risk O O
of O O
this O O
not O O
relieving O O
the O O
entirety O O
of O O
her O O
symptoms O O
, O O
were O O
discussed O O
, O O
and O O
she O O
chose O O
to O O
proceed O O
with O O
this O O
. O O
  
This O O
was O O
therefore O O
performed O O
under O O
sterile O O
conditions O O
and O O
after O O
appropriate O O
informed O O
consent O O
and O O
timeout O O
with O O
4 B-Dose B-Dose
mg I-Dose I-Dose
of O O
dexamethasone B-Drug B-Drug
phosphate I-Drug I-Drug
and O O
1 B-Dose B-Dose
mL I-Dose I-Dose
of O O
lidocaine B-Drug B-Drug
into O O
the O O
right O O
thumb O O
CMC O O
joint O O
. O O
  
She O O
will O O
see O O
how O O
this O O
goes O O
and O O
the O O
splint O O
and O O
will O O
follow O O
up O O
here O O
in O O
about O O
a O O
month O O
for O O
reevaluation O O
. O O
  
She O O
will O O
discuss O O
wart O O
removal O O
with O O
her O O
primary O O
doctor O O
who O O
can O O
refer O O
her O O
to O O
a O O
dermatologist O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
13 O O
: O O
30 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Admit O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
  
Loc O O
: O O
Named_Sites O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
00 O O
: O O
02 O O
AM O O
Clinic O O
Note O O
DIAGNOSIS O O
: O O
Stage B-Severity B-Severity
IIB I-Severity I-Severity
primary B-Indication B-Indication
mediastinal I-Indication I-Indication
large I-Indication I-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
Initial O O
diagnosis O O
was O O
in O O
Date O O
. O O
  
ONCOLOGICAL O O
THERAPY O O
: O O
Status O O
post O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
combination O O
biochemotherapy B-Drug B-Drug
with O O
R B-Drug B-Drug
- I-Drug I-Drug
CHOP I-Drug I-Drug
completed O O
in O O
Date O O
and O O
received O O
consolidation O O
radiation O O
therapy O O
to O O
the O O
mediastinum O O
. O O
  
A O O
total O O
of O O
3000 O O
cGy O O
in O O
20 O O
fractions O O
completed O O
in O O
Date O O
. O O
  
REASON O O
FOR O O
VISIT O O
: O O
Active O O
surveillance O O
of O O
her O O
non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
Hodgkin's I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
reports O O
that O O
since O O
her O O
last O O
visit O O
about O O
6 O O
months O O
ago O O
with O O
Name O O
Name O O
, O O
she O O
has O O
reported O O
some B-Severity B-Severity
progressive O O
dysphagia B-SSLIF B-SSLIF
. O O
  
Since O O
her O O
completion O O
of O O
radiation O O
therapy O O
, O O
she O O
always O O
has O O
some O O
mild B-Severity B-Severity
swallowing B-SSLIF B-SSLIF
difficulty I-SSLIF I-SSLIF
; O O
however O O
, O O
over O O
the O O
past O O
couple O O
of O O
months O O
this O O
has O O
progressively O O
got O O
worse O O
and O O
she O O
feels B-SSLIF B-SSLIF
like I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
tube I-SSLIF I-SSLIF
filling I-SSLIF I-SSLIF
up I-SSLIF I-SSLIF
when O O
she O O
is O O
drinking O O
water O O
. O O
  
On O O
further O O
questioning O O
, O O
she O O
admitted O O
dysphagia B-SSLIF B-SSLIF
to O O
both O O
solids O O
and O O
liquids O O
. O O
  
She O O
denies O O
having O O
any O O
loss B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
appetite I-SSLIF I-SSLIF
, O O
loss B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
weight I-SSLIF I-SSLIF
. O O
  
No O O
hematemesis B-SSLIF B-SSLIF
, O O
no O O
black B-SSLIF B-SSLIF
tarry I-SSLIF I-SSLIF
stools I-SSLIF I-SSLIF
. O O
  
No O O
reports O O
of O O
any O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
However O O
, O O
she O O
is O O
somewhat O O
bothered O O
by O O
the O O
progressive O O
dysphagia B-SSLIF B-SSLIF
. O O
  
She O O
does O O
not O O
have O O
any O O
prior O O
GI O O
evaluation O O
or O O
any O O
endoscopic O O
evaluation O O
in O O
the O O
past O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
No O O
reports O O
of O O
any O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
or O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
No O O
ongoing O O
fevers B-SSLIF B-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
No O O
new O O
onset B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
pains I-SSLIF I-SSLIF
. O O
  
No O O
lightheadedness B-SSLIF B-SSLIF
or O O
dizziness B-SSLIF B-SSLIF
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
As O O
noted O O
above O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
None O O
, O O
except O O
for O O
over O O
- O O
the O O
- O O
counter O O
multivitamins B-Drug B-Drug
. O O
  
SOCIAL O O
HISTORY O O
: O O
She O O
is O O
married O O
. O O
  
Since O O
her O O
last O O
visit O O
with O O
me O O
about O O
a O O
year O O
ago O O
, O O
she O O
had O O
delivered O O
a O O
baby O O
and O O
she O O
mentioned O O
she O O
has O O
named O O
him O O
as O O
Name O O
and O O
he O O
is O O
doing O O
fantastic O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
Pleasant O O
lady O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
Weight O O
is O O
82.5 O O
kg O O
, O O
which O O
is O O
down O O
from O O
91.1 O O
kg O O
in O O
Date O O
. O O
  
It O O
is O O
possible O O
that O O
she O O
has O O
lost O O
all O O
her O O
pregnancy O O
and O O
pregnancy O O
weight O O
from O O
before O O
. O O
  
VITAL O O
SIGNS O O
: O O
Temperature O O
of O O
36.8 O O
, O O
blood O O
pressure O O
105 O O
/ O O
68 O O
, O O
pulse O O
rate O O
of O O
74 O O
, O O
respirations O O
of O O
16 O O
, O O
pulse O O
ox O O
of O O
100% O O
on O O
room O O
air O O
. O O
  
Pain B-SSLIF B-SSLIF
level O O
0 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
. O O
  
HEENT O O
: O O
No O O
pallor B-SSLIF B-SSLIF
, O O
no O O
icterus B-SSLIF B-SSLIF
, O O
no O O
oral B-SSLIF B-SSLIF
thrush I-SSLIF I-SSLIF
. O O
  
NECK O O
: O O
Supple O O
neck O O
. O O
  
No O O
palpable O O
peripheral B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
. O O
  
HEART O O
: O O
Normal O O
heart O O
sounds O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
bowel O O
sounds O O
are O O
present O O
. O O
  
No O O
liver B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
enlargement I-SSLIF I-SSLIF
, O O
no O O
underlying O O
abnormal O O
palpable B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
abdomen I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
Without O O
any O O
edema B-SSLIF B-SSLIF
or O O
tenderness B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Nonfocal O O
for O O
any O O
gross O O
motor O O
deficits O O
. O O
  
LABORATORY O O
DATA O O
: O O
LDH O O
is O O
normal O O
at O O
139 O O
. O O
  
CBC O O
is O O
completely O O
normal O O
with O O
white O O
cells O O
of O O
5.2 O O
, O O
hemoglobin O O
of O O
13.3 O O
, O O
platelet O O
count O O
of O O
198 O O
, O O
000 O O
. O O
  
IMPRESSION O O
: O O
  
1. O O
Diagnosis O O
of O O
non B-Indication B-Indication
- I-Indication I-Indication
Hodgkin's I-Indication I-Indication
lymphoma I-Indication I-Indication
( O O
primary O O
mediastinal B-Indication B-Indication
lymphoma I-Indication I-Indication
, O O
stage B-Severity B-Severity
IIB I-Severity I-Severity
) O O
, O O
status O O
post O O
successful O O
completion O O
of O O
combination O O
biochemotherapy B-Drug B-Drug
with O O
R B-Drug B-Drug
- I-Drug I-Drug
CHOP I-Drug I-Drug
followed O O
by O O
consolidation O O
radiation O O
therapy O O
with O O
no O O
evidence O O
of O O
disease O O
recurrence B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
2. O O
Increasing O O
dysphagia B-SSLIF B-SSLIF
. O O
  
Likely O O
related O O
to O O
the O O
esophageal B-SSLIF B-SSLIF
stenosis I-SSLIF I-SSLIF
from O O
prior O O
radiation O O
therapy O O
. O O
  
Clinical O O
symptoms O O
not O O
suspicious O O
for O O
esophageal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
However O O
, O O
she O O
given O O
her O O
significant B-Severity B-Severity
dysphagia B-SSLIF B-SSLIF
, O O
she O O
needs O O
an O O
endoscopic O O
evaluation O O
and O O
if O O
there O O
is O O
any O O
stenosis B-SSLIF B-SSLIF
she O O
would O O
benefit O O
from O O
dilation O O
procedure O O
. O O
  
To O O
this O O
regard O O
, O O
I O O
am O O
making O O
a O O
referral O O
to O O
Dr O O
. O O
  
Name O O
for O O
the O O
patient O O
to O O
be O O
seen O O
at O O
the O O
earliest O O
possible O O
time O O
. O O
  
The O O
patient O O
was O O
explained O O
about O O
the O O
above O O
care O O
plan O O
and O O
she O O
is O O
appreciative O O
of O O
the O O
referral O O
to O O
the O O
GI O O
. O O
  
I O O
have O O
asked O O
the O O
patient O O
to O O
contact O O
me O O
if O O
any O O
issues O O
or O O
concerns O O
that O O
might O O
arise O O
rather O O
than O O
waiting O O
until O O
the O O
next O O
appointment O O
. O O
  
If O O
there O O
are O O
any O O
concerning O O
findings O O
on O O
the O O
EGD O O
and O O
if O O
I O O
need O O
to O O
see O O
her O O
back O O
in O O
the O O
clinic O O
sooner O O
than O O
her O O
scheduled O O
surveillance O O
appointment O O
and O O
see O O
in O O
6 O O
months O O
, O O
I O O
am O O
more O O
than O O
happy O O
to O O
bring O O
her O O
into O O
the O O
clinic O O
. O O
  
All O O
the O O
questions O O
and O O
concerns O O
raised O O
by O O
the O O
patient O O
were O O
addressed O O
to O O
her O O
satisfaction O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
NP O O
Name O O
Name O O
MD O O
Name O O
Name O O
MD O O
Name O O
Name O O
, O O
MD O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
9 O O
: O O
31AM O O
EST O O
Author O O
DIAGNOSES O O
: O O
Stage B-Severity B-Severity
IIB I-Severity I-Severity
primary B-Indication B-Indication
mediastinal I-Indication I-Indication
large I-Indication I-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
originally O O
diagnosed O O
in O O
Date O O
. O O
  
ONCOLOGICAL O O
THERAP O O
: O O
Completed O O
6 B-Duration B-Duration
cycles I-Duration I-Duration
of O O
chemotherapy B-Drug B-Drug
with O O
R B-Drug B-Drug
- I-Drug I-Drug
CHOP I-Drug I-Drug
completed O O
in O O
Date O O
. O O
  
Received O O
consolidation O O
radiation O O
therapy O O
to O O
the O O
mediastinum O O
for O O
a O O
total O O
of O O
3000 O O
Gy O O
in O O
20 O O
fractions O O
, O O
which O O
was O O
completed O O
in O O
Date O O
. O O
  
REASON O O
FOR O O
VISIT O O
: O O
Active O O
surveillance O O
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
reports O O
she O O
feels O O
quite O O
well O O
and O O
infact O O
conveyed O O
the O O
god O O
news O O
that O O
she O O
is O O
now O O
pregnant O O
and O O
is O O
due O O
in O O
Date O O
She O O
has O O
had O O
no O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
Her O O
energy O O
level O O
is O O
excellent O O
, O O
as O O
well O O
as O O
her O O
appetite O O
and O O
she O O
is O O
maintaining O O
her O O
weight O O
. O O
  
She O O
does O O
exercise O O
by O O
running O O
, O O
walking O O
or O O
doing O O
yoga O O
. O O
  
She O O
has O O
had O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
palpitations B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
discomfort B-SSLIF B-SSLIF
, O O
swelling B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
or O O
any O O
bowel B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
bladder I-SSLIF I-SSLIF
dysfunction I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
bleeding B-SSLIF B-SSLIF
or O O
bruising B-SSLIF B-SSLIF
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Include O O
albuterol B-Drug B-Drug
and O O
multivitamin B-Drug B-Drug
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Amoxicillin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
new O O
cancers B-SSLIF B-SSLIF
diagnosed O O
in O O
the O O
family O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Noncontributory O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
She O O
is O O
a O O
never O O
smoker O O
and O O
exercises O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
Temperature O O
is O O
36.6 O O
, O O
blood O O
pressure O O
is O O
98 O O
/ O O
64 O O
, O O
heart O O
rate O O
is O O
76 O O
, O O
respiratory O O
rate O O
is O O
16 O O
, O O
O2 O O
saturation O O
99% O O
on O O
room O O
air O O
, O O
weight O O
is O O
88.5 O O
kg O O
. O O
  
GENERAL O O
: O O
Ms O O
. O O
  
Name O O
does O O
look O O
well O O
. O O
  
She O O
is O O
alert O O
and O O
oriented O O
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
The O O
sclerae B-SSLIF B-SSLIF
are I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
. O O
  
The O O
oropharyngeal O O
cavity O O
is O O
clear O O
. O O
  
NECK O O
: O O
The O O
thyroid O O
is O O
nonpalpable O O
. O O
  
LYMPHATICS O O
: O O
There O O
is O O
no O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Spine O O
is O O
nontender O O
to O O
palpation O O
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
bilaterally O O
. O O
  
There O O
are O O
no O O
rales B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
or O O
wheezes B-SSLIF B-SSLIF
. O O
  
CARDIAC O O
: O O
S1 O O
and O O
S2 O O
, O O
regular O O
rate O O
and O O
rhythm O O
without O O
murmurs B-SSLIF B-SSLIF
, O O
gallops B-SSLIF B-SSLIF
or O O
rubs B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
distension O O
consistent O O
with O O
gestation O O
. O O
  
Positive O O
bowel O O
sounds O O
throughout O O
, O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
There O O
are O O
no O O
masses B-SSLIF B-SSLIF
or O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Reveal O O
no O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
There O O
are O O
no O O
rashes B-SSLIF B-SSLIF
, O O
petechia B-SSLIF B-SSLIF
or O O
ecchymosis B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Nonfocal O O
. O O
  
BREASTS O O
: O O
Exam O O
is O O
performed O O
upright O O
and O O
supine O O
. O O
  
There O O
are O O
no O O
palpable B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
either I-SSLIF I-SSLIF
breast I-SSLIF I-SSLIF
and O O
no O O
axillary B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
ECOG O O
performance O O
status O O
is O O
0 O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
is O O
normal O O
. O O
  
Chemistry O O
panel O O
1 O O
+ O O
hemolysis O O
on O O
the O O
sample O O
. O O
  
Relatively O O
normal O O
electrolytes O O
, O O
BUN O O
and O O
creatinine O O
. O O
  
LDH O O
is O O
pending O O
ASSESSMENT O O
: O O
  
History O O
of O O
stage B-Severity B-Severity
IIB I-Severity I-Severity
primary B-Indication B-Indication
mediastinal I-Indication I-Indication
large I-Indication I-Indication
B I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
No O O
B B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
. O O
  
No O O
evidence O O
of O O
any O O
disease O O
recurrence O O
clinically O O
. O O
  
Labs O O
very O O
reassuring O O
. O O
  
No O O
evidence O O
of O O
chemotherapy B-Drug B-Drug
related O O
delayed B-ADE B-ADE
side I-ADE I-ADE
effects I-ADE I-ADE
. O O
  
Second O O
Trimester O O
Gestation O O
: O O
No O O
acute O O
problems O O
from O O
OB O O
- O O
GYN O O
stand O O
point O O
. O O
  
Reassured O O
her O O
that O O
women O O
who O O
have O O
undergone O O
chemotherapy B-Drug B-Drug
for O O
their O O
lymphomas B-Indication B-Indication
and O O
got O O
cured O O
have O O
had O O
no O O
significant B-Severity B-Severity
pregnancy B-ADE B-ADE
or I-ADE I-ADE
fetal I-ADE I-ADE
complications I-ADE I-ADE
. O O
  
Babies O O
born O O
to O O
these O O
mothers O O
are O O
at O O
no O O
significantly O O
higher O O
for O O
any O O
developmental B-ADE B-ADE
delays I-ADE I-ADE
especially O O
if O O
women O O
conceived O O
after O O
a O O
reasonable O O
interval O O
after O O
completion O O
of O O
chemotherapy B-Drug B-Drug
. O O
  
PLAN O O
: O O
Stressed O O
the O O
importance O O
of O O
age O O
appropriate O O
cancer O O
screening O O
and O O
advised O O
to O O
get O O
mammograms O O
starting O O
from O O
age O O
40 O O
given O O
her O O
radiation O O
to O O
the O O
mediastinum O O
. O O
  
Return O O
to O O
clinic O O
for O O
6 O O
months O O
follow O O
- O O
up O O
with O O
Name O O
Name O O
, O O
NP O O
and O O
with O O
me O O
in O O
1 O O
year O O
. O O
  
cc O O
: O O
Physician O O
Copy O O
Name O O
Name O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
MD O O
Date O O
5 O O
: O O
31PM O O
EST O O
Author O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
7 O O
: O O
33 O O
A O O
Transcribed O O
Date O O
7 O O
: O O
57 O O
  
: O O
: O O
A O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Stage B-Severity B-Severity
II I-Severity I-Severity
follicular B-SSLIF B-SSLIF
small I-SSLIF I-SSLIF
cleaved I-SSLIF I-SSLIF
lymphocytic I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
diagnosed O O
Date O O
; O O
the O O
patient's O O
other O O
hematologic O O
diagnosis O O
is O O
hypercoagulable B-SSLIF B-SSLIF
state I-SSLIF I-SSLIF
due O O
to O O
double B-SSLIF B-SSLIF
heterozygosity I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
factor I-SSLIF I-SSLIF
V I-SSLIF I-SSLIF
Leiden I-SSLIF I-SSLIF
and O O
a O O
prothrombin B-SSLIF B-SSLIF
2210 I-SSLIF I-SSLIF
mutations I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
Observation O O
only O O
. O O
  
The O O
patient O O
receives O O
six B-Duration B-Duration
courses I-Duration I-Duration
of O O
cyclophosphamide B-Drug B-Drug
, O O
vincristine B-Drug B-Drug
and O O
prednisone B-Drug B-Drug
completed O O
Date O O
and O O
completed O O
two B-Duration B-Duration
years I-Duration I-Duration
of O O
maintenance O O
Rituxan B-Drug B-Drug
in O O
Date O O
. O O
  
She O O
is O O
on O O
lifelong B-Duration B-Duration
warfarin B-Drug B-Drug
because O O
of O O
her O O
hypercoagulable B-Indication B-Indication
state I-Indication I-Indication
. O O
  
INTERIM O O
HISTORY O O
: O O
Mrs O O
. O O
  
Name O O
is O O
feeling O O
well O O
. O O
  
Appetite O O
and O O
energy O O
are O O
good O O
. O O
  
No O O
systemic O O
symptoms O O
. O O
  
She O O
is O O
unaware O O
of O O
any O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
She O O
is O O
now O O
82 O O
years O O
old O O
and O O
feels O O
that O O
she O O
is O O
slowing B-SSLIF B-SSLIF
down I-SSLIF I-SSLIF
and O O
has B-SSLIF B-SSLIF
less I-SSLIF I-SSLIF
energy I-SSLIF I-SSLIF
. O O
  
She O O
has O O
noticed O O
a O O
few O O
soaking B-Severity B-Severity
nocturnal B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
It O O
is O O
difficult O O
to O O
be O O
sure O O
exactly O O
how O O
often O O
this O O
is O O
happening O O
, O O
but O O
my O O
sense O O
from O O
her O O
account O O
today O O
is O O
that O O
it O O
is O O
perhaps O O
once O O
a O O
week O O
. O O
  
She O O
has O O
had O O
no O O
symptoms O O
suggestive O O
of O O
repeat O O
deep B-SSLIF B-SSLIF
vein I-SSLIF I-SSLIF
thrombosis I-SSLIF I-SSLIF
. O O
  
About O O
a O O
month O O
ago O O
, O O
she O O
experienced O O
severe B-Severity B-Severity
aching B-Indication B-Indication
of I-Indication I-Indication
bones I-Indication I-Indication
and I-Indication I-Indication
muscles I-Indication I-Indication
from I-Indication I-Indication
her I-Indication I-Indication
shoulders I-Indication I-Indication
to I-Indication I-Indication
her I-Indication I-Indication
knees I-Indication I-Indication
and O O
her O O
primary O O
care O O
physician O O
, O O
Dr O O
. O O
  
Name O O
began O O
her O O
on O O
a O O
short B-Duration B-Duration
course I-Duration I-Duration
of O O
prednisone B-Drug B-Drug
, O O
which O O
was O O
rapidly O O
tapered O O
. O O
  
This O O
did O O
produce O O
improvement O O
. O O
  
She O O
is O O
currently O O
still O O
experiencing O O
intermittent O O
aching B-Indication B-Indication
and O O
is O O
on O O
prednisone B-Drug B-Drug
7 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
His O O
clinical O O
diagnosis O O
is O O
polymyalgia B-Indication B-Indication
rheumatica I-Indication I-Indication
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Has O O
not O O
changed O O
except O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
in O O
family O O
history O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
lives O O
alone O O
in O O
an O O
apartment O O
in O O
her O O
brother's O O
home O O
. O O
  
She O O
has O O
a O O
good O O
deal O O
of O O
family O O
support O O
and O O
her O O
daughter O O
is O O
with O O
her O O
today O O
as O O
usual O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Negative O O
in O O
detail O O
, O O
except O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
MEDICATIONS O O
: O O
Reviewed O O
as O O
outlined O O
in O O
Company O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
Today O O
, O O
weight O O
is O O
82.7 O O
kilograms O O
, O O
blood O O
pressure O O
150 O O
/ O O
90 O O
, O O
pulse O O
  
72 O O
and O O
regular O O
, O O
and O O
temperature O O
98 O O
. O O
  
SKIN O O
: O O
She O O
has O O
no O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
, O O
nothing O O
to O O
suggest O O
lymphomatous B-SSLIF B-SSLIF
infiltration I-SSLIF I-SSLIF
of O O
the O O
skin O O
. O O
  
HEENT O O
: O O
Mouth O O
and O O
pharynx O O
unremarkable O O
without O O
abnormal B-SSLIF B-SSLIF
lymphoid I-SSLIF I-SSLIF
tissue I-SSLIF I-SSLIF
. O O
  
LYMPHATICS O O
: O O
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
percussion O O
tenderness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
Liver B-SSLIF B-SSLIF
not I-SSLIF I-SSLIF
enlarged I-SSLIF I-SSLIF
. O O
  
Spleen B-SSLIF B-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
. O O
  
No O O
other O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
. O O
  
No O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
BREASTS O O
: O O
Examination O O
of O O
the O O
right O O
breast O O
reveals O O
an O O
old O O
biopsy O O
scar O O
over O O
the O O
upper O O
outer O O
quadrant O O
, O O
no O O
palpable O O
mass B-SSLIF B-SSLIF
. O O
  
No O O
mass B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
breast I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
White O O
count O O
9500 O O
, O O
hemoglobin O O
13.2 O O
grams O O
, O O
hematocrit O O
39% O O
with O O
MCV O O
93 O O
, O O
and O O
platelets O O
270 O O
, O O
000 O O
. O O
  
Automated O O
differential O O
83 O O
neutrophils O O
and O O
11 O O
lymphocytes O O
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
There O O
is O O
no O O
obvious O O
evidence O O
of O O
recurrent O O
lymphoma B-SSLIF B-SSLIF
, O O
although O O
I O O
am O O
a O O
little O O
concerned O O
about O O
her O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
We O O
will O O
do O O
a O O
CAT O O
scan O O
next O O
month O O
, O O
which O O
will O O
be O O
about O O
six O O
months O O
after O O
her O O
most O O
recent O O
CAT O O
scan O O
and O O
I O O
will O O
reassess O O
her O O
clinically O O
in O O
three O O
months O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
18 O O
: O O
47 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
FI O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
8 O O
: O O
23 O O
A O O
Transcribed O O
Date O O
9 O O
: O O
43 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
DIAGNOSIS O O
: O O
Stage B-Severity B-Severity
II I-Severity I-Severity
follicular B-SSLIF B-SSLIF
small I-SSLIF I-SSLIF
cleaved I-SSLIF I-SSLIF
lymphocytic I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
, O O
diagnosed O O
in O O
Date O O
; O O
the O O
patient's O O
other O O
hematologic O O
diagnosis O O
is O O
hypercoagulable B-SSLIF B-SSLIF
state I-SSLIF I-SSLIF
due O O
to O O
double B-SSLIF B-SSLIF
heterozygosity I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
factor I-SSLIF I-SSLIF
V I-SSLIF I-SSLIF
Leiden I-SSLIF I-SSLIF
and O O
prothrombin B-SSLIF B-SSLIF
2210 I-SSLIF I-SSLIF
mutations I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
For O O
her O O
lymphoma B-Indication B-Indication
, O O
observation O O
only O O
; O O
the O O
patient O O
is O O
status O O
post O O
6 B-Duration B-Duration
courses I-Duration I-Duration
of O O
CVP B-Drug B-Drug
completed O O
Date O O
and O O
completed O O
2 B-Duration B-Duration
years I-Duration I-Duration
of O O
maintenance O O
Rituxan B-Drug B-Drug
in O O
Date O O
; O O
she O O
is O O
on O O
indefinite B-Duration B-Duration
oral B-Route B-Route
anticoagulant B-Drug B-Drug
therapy O O
for O O
her O O
hypercoagulable B-Indication B-Indication
state I-Indication I-Indication
. O O
  
INTERIM O O
HISTORY O O
: O O
Mrs O O
. O O
  
Name O O
is O O
seen O O
back O O
here O O
a O O
month O O
after O O
her O O
visit O O
on O O
Date O O
at O O
which O O
she O O
described O O
decreased B-SSLIF B-SSLIF
appetite I-SSLIF I-SSLIF
, O O
decreased B-SSLIF B-SSLIF
energy I-SSLIF I-SSLIF
, O O
nothing B-SSLIF B-SSLIF
tasting I-SSLIF I-SSLIF
good I-SSLIF I-SSLIF
and O O
some B-Severity B-Severity
discomfort B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lateral I-SSLIF I-SSLIF
chest I-SSLIF I-SSLIF
. O O
  
She O O
had O O
a O O
CT O O
scan O O
of O O
chest O O
, O O
abdomen O O
and O O
pelvis O O
which O O
disclosed O O
no O O
significant B-Severity B-Severity
pathology B-SSLIF B-SSLIF
. O O
  
Her O O
complete O O
blood O O
count O O
at O O
that O O
time O O
was O O
normal O O
as O O
were O O
her O O
blood O O
chemistries O O
with O O
the O O
exception O O
of O O
a O O
slightly B-Severity B-Severity
elevated B-SSLIF B-SSLIF
glucose I-SSLIF I-SSLIF
at O O
112 O O
and O O
somewhat B-Severity B-Severity
decreased B-SSLIF B-SSLIF
total I-SSLIF I-SSLIF
protein I-SSLIF I-SSLIF
5.8 O O
g O O
/ O O
dL O O
. O O
  
In O O
the O O
month O O
since O O
we O O
saw O O
her O O
, O O
the O O
patient O O
has O O
continued O O
to O O
feel O O
weak B-SSLIF B-SSLIF
and O O
without B-SSLIF B-SSLIF
stamina I-SSLIF I-SSLIF
. O O
  
She O O
describes O O
total B-SSLIF B-SSLIF
body I-SSLIF I-SSLIF
aches I-SSLIF I-SSLIF
and O O
pains B-SSLIF B-SSLIF
and O O
even O O
on O O
careful O O
questioning O O
and O O
even O O
in O O
the O O
presence O O
of O O
her O O
daughter O O
is O O
with O O
her O O
today O O
, O O
she O O
cannot O O
localize O O
where O O
she O O
hurts B-SSLIF B-SSLIF
the O O
most O O
, O O
nor O O
even O O
whether O O
this O O
is O O
really O O
bone B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
muscle B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
is O O
taking O O
Percocet B-Drug B-Drug
twice B-Frequency B-Frequency
or I-Frequency I-Frequency
3 I-Frequency I-Frequency
times I-Frequency I-Frequency
daily I-Frequency I-Frequency
to O O
help O O
her O O
with O O
bone B-Indication B-Indication
pain I-Indication I-Indication
. O O
  
Apparently O O
, O O
the O O
question O O
of O O
polymyalgia B-Indication B-Indication
rheumatica I-Indication I-Indication
has O O
been O O
raised O O
in O O
the O O
past O O
and O O
the O O
patient O O
has O O
been O O
on O O
low B-Dose B-Dose
doses I-Dose I-Dose
of O O
steroid B-Drug B-Drug
in O O
the O O
past O O
under O O
the O O
direction O O
of O O
Dr O O
. O O
  
Name O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
No O O
change O O
in O O
medical O O
history O O
in O O
the O O
month O O
since O O
we O O
have O O
seen O O
her O O
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
change O O
in O O
family O O
history O O
or O O
social O O
history O O
. O O
  
The O O
patient's O O
daughter O O
and O O
daughter's O O
son O O
are O O
with O O
her O O
today O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Ten O O
- O O
item O O
review O O
of O O
systems O O
is O O
negative O O
in O O
detail O O
except O O
as O O
noted O O
in O O
the O O
present O O
illness O O
. O O
  
MEDICATIONS O O
: O O
Reviewed O O
and O O
include O O
Lidoderm B-Drug B-Drug
patch B-Route B-Route
, O O
Percocet B-Drug B-Drug
twice B-Frequency B-Frequency
or I-Frequency I-Frequency
3 I-Frequency I-Frequency
daily I-Frequency I-Frequency
, O O
Asacol B-Drug B-Drug
400 B-Dose B-Dose
mg I-Dose I-Dose
3 B-Dose B-Dose
tablets I-Dose I-Dose
3 B-Frequency B-Frequency
times I-Frequency I-Frequency
daily I-Frequency I-Frequency
, O O
Lipitor B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
Lasix B-Drug B-Drug
40 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
lisinopril B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
omeprazole B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
daily I-Frequency I-Frequency
, O O
warfarin B-Drug B-Drug
to O O
keep O O
her O O
INR O O
between O O
2 O O
and O O
3 O O
and O O
flecainide B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
daily I-Frequency I-Frequency
. O O
  
No O O
changes O O
are O O
made O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Today O O
, O O
weight O O
is O O
stable O O
79.8 O O
kg O O
( O O
176 O O
pounds O O
) O O
, O O
blood O O
pressure O O
124 O O
/ O O
70 O O
, O O
pulse O O
88 O O
and O O
regular O O
, O O
temperature O O
36.6 O O
. O O
  
No O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
, O O
nothing O O
suggestive O O
of O O
lymphomatous B-SSLIF B-SSLIF
infiltration I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
skin I-SSLIF I-SSLIF
. O O
  
Mouth O O
and O O
pharynx O O
are O O
unremarkable O O
. O O
  
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
inguinal I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
femoral I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
No O O
percussion O O
tenderness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
. O O
  
Lungs O O
are O O
clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
Regular O O
cardiac O O
rhythm O O
. O O
  
No O O
murmur B-SSLIF B-SSLIF
, O O
gallop B-SSLIF B-SSLIF
or O O
rub B-SSLIF B-SSLIF
. O O
  
Abdomen O O
is O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
, O O
liver B-SSLIF B-SSLIF
not I-SSLIF I-SSLIF
enlarged I-SSLIF I-SSLIF
, O O
spleen B-SSLIF B-SSLIF
not I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
, O O
no O O
other O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
and O O
no O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
ASSESSMENT O O
AND O O
PLAN O O
: O O
I O O
am O O
not O O
sure O O
what O O
to O O
make O O
of O O
her O O
complaints O O
. O O
  
There O O
is O O
no O O
evidence O O
either O O
clinically O O
or O O
by O O
imaging O O
of O O
recurrence O O
of O O
her O O
indolent B-Severity B-Severity
lymphoma B-SSLIF B-SSLIF
. O O
  
The O O
diagnosis O O
of O O
polymyalgia B-Indication B-Indication
rheumatica I-Indication I-Indication
or O O
something O O
like O O
it O O
is O O
worthy O O
of O O
further O O
consideration O O
and O O
certainly O O
it O O
was O O
considered O O
seriously O O
enough O O
a O O
few O O
years O O
ago O O
that O O
she O O
was O O
actually O O
treated O O
with O O
steroids B-Drug B-Drug
with O O
some O O
benefit O O
. O O
  
I O O
have O O
ordered O O
a O O
complete O O
blood O O
count O O
with O O
sedimentation O O
rate O O
today O O
, O O
CPK O O
, O O
LDH O O
, O O
serum O O
protein O O
electrophoresis O O
and O O
TSH O O
to O O
be O O
sure O O
that O O
we O O
are O O
not O O
dealing O O
with O O
thyroid B-SSLIF B-SSLIF
dysfunction I-SSLIF I-SSLIF
. O O
  
We O O
will O O
see O O
her O O
back O O
in O O
4 O O
- O O
6 O O
weeks O O
. O O
  
I O O
may O O
need O O
to O O
steer O O
this O O
to O O
Dr O O
. O O
  
Name O O
since O O
at O O
this O O
point O O
there O O
is O O
no O O
evidence O O
that O O
we O O
are O O
dealing O O
with O O
lymphoma B-SSLIF B-SSLIF
related O O
issues O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
07 O O
: O O
54 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
8 O O
: O O
27 O O
P O O
  
1 O O
: O O
07 O O
P O O
CLINIC O O
NOTE O O
DIAGNOSES O O
: O O
  
1. O O
Mr O O
. O O
  
Name O O
is O O
an O O
83 O O
- O O
year O O
- O O
old O O
female O O
with O O
a O O
history O O
of O O
a O O
stage B-Severity B-Severity
II I-Severity I-Severity
follicular B-SSLIF B-SSLIF
small I-SSLIF I-SSLIF
cleaved I-SSLIF I-SSLIF
lymphocytic I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
Original O O
diagnosis O O
established O O
in O O
Date O O
. O O
  
2. O O
Hypercholesteremia B-SSLIF B-SSLIF
. O O
  
3. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
4. O O
Deep B-SSLIF B-SSLIF
venous I-SSLIF I-SSLIF
thrombosis I-SSLIF I-SSLIF
in O O
Date O O
, O O
to O O
the O O
left O O
extremity O O
; O O
the O O
second O O
one O O
in O O
Date O O
, O O
to O O
the O O
right O O
extremity O O
. O O
  
The O O
patient O O
is O O
on O O
lifelong B-Duration B-Duration
warfarin B-Drug B-Drug
as O O
she O O
is O O
factor B-Indication B-Indication
V I-Indication I-Indication
Leiden I-Indication I-Indication
and O O
prothrombin B-Indication B-Indication
202010 I-Indication I-Indication
heterozygote I-Indication I-Indication
. O O
  
5. O O
Crohn B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
6. O O
Atrial B-SSLIF B-SSLIF
fibrillation I-SSLIF I-SSLIF
with O O
mitral B-SSLIF B-SSLIF
prolapse I-SSLIF I-SSLIF
. O O
  
7. O O
Coronary B-SSLIF B-SSLIF
artery I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
. O O
  
8. O O
GERD B-SSLIF B-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
Observation O O
. O O
  
She O O
has O O
received O O
monthly B-Frequency B-Frequency
rituximab B-Drug B-Drug
and O O
is O O
status O O
post O O
CVP B-Drug B-Drug
( O O
cyclophosphamide B-Drug B-Drug
, O O
vincristine B-Drug B-Drug
, O O
prednisone B-Drug B-Drug
) O O
for O O
6 B-Duration B-Duration
courses I-Duration I-Duration
, O O
completed O O
in O O
Date O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Ms O O
. O O
  
Name O O
is O O
accompanied O O
by O O
her O O
daughter O O
, O O
Name O O
, O O
today O O
. O O
  
Name O O
, O O
overall O O
, O O
feels O O
well O O
. O O
  
She O O
is O O
not O O
having O O
fevers B-SSLIF B-SSLIF
, O O
chills B-SSLIF B-SSLIF
or O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
. O O
  
She O O
has O O
had O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
palpitations B-SSLIF B-SSLIF
or O O
any O O
bowel B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
bladder I-SSLIF I-SSLIF
dysfunction I-SSLIF I-SSLIF
. O O
  
She O O
has O O
not O O
had O O
any O O
dizziness B-SSLIF B-SSLIF
or O O
lightheadedness B-SSLIF B-SSLIF
. O O
  
She O O
has O O
had O O
no O O
falls B-SSLIF B-SSLIF
. O O
  
She O O
is O O
hard B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
hearing I-SSLIF I-SSLIF
and O O
that O O
has O O
remained O O
unchanged O O
and O O
has O O
not O O
worsened O O
in O O
severity O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Reviewed O O
and O O
include O O
, O O
flecainide B-Drug B-Drug
, O O
Lidoderm B-Drug B-Drug
patch B-Dose B-Dose
, O O
Lipitor B-Drug B-Drug
, O O
lisinopril B-Drug B-Drug
, O O
Metamucil B-Drug B-Drug
, O O
omeprazole B-Drug B-Drug
, O O
oxycodone B-Drug B-Drug
with I-Drug I-Drug
acetaminophen I-Drug I-Drug
if B-Frequency B-Frequency
needed I-Frequency I-Frequency
, O O
Compazine B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
. O O
  
ALLERGIES O O
: O O
No O O
known O O
drug B-SSLIF B-SSLIF
allergies I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
No O O
new O O
cancers B-SSLIF B-SSLIF
diagnosed O O
in O O
the O O
family O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Does O O
not O O
smoke O O
or O O
drink O O
any O O
alcohol O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
Temperature O O
is O O
36.8 O O
, O O
blood O O
pressure O O
is O O
155 O O
/ O O
84 O O
, O O
heart O O
rate O O
is O O
71 O O
, O O
respiratory O O
rate O O
is O O
18 O O
and O O
weight O O
is O O
86 O O
kg O O
, O O
which O O
is O O
up O O
3 O O
kg O O
from O O
Date O O
. O O
  
GENERAL O O
: O O
Ms O O
. O O
  
Name O O
does O O
look O O
well O O
. O O
  
She O O
is O O
alert O O
and O O
oriented O O
and O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
The B-SSLIF B-SSLIF
sclerae I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
anicteric I-SSLIF I-SSLIF
. O O
  
Oropharyngeal O O
cavity O O
is O O
clear O O
. O O
  
NECK O O
: O O
Thyroid B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
nonpalpable I-SSLIF I-SSLIF
. O O
  
No O O
cervical B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
supraclavicular I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
palpated O O
. O O
  
Spine B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
nontender I-SSLIF I-SSLIF
to O O
palpation O O
. O O
  
LUNGS O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
bilaterally O O
with O O
no O O
rales B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
or O O
wheezes B-SSLIF B-SSLIF
. O O
  
CARDIAC O O
: O O
S1 O O
, O O
S2 O O
. O O
  
No O O
murmurs B-SSLIF B-SSLIF
auscultated O O
. O O
  
ABDOMEN O O
: O O
Positive O O
bowel O O
sounds O O
, O O
soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
There O O
are O O
no O O
masses B-SSLIF B-SSLIF
or O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
edema B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rash B-SSLIF B-SSLIF
, O O
petechia B-SSLIF B-SSLIF
or O O
ecchymosis B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Nonfocal O O
. O O
  
BREAST O O
: O O
Exam O O
is O O
deferred O O
today O O
. O O
  
She O O
reports O O
she O O
had O O
a O O
breast O O
exam O O
3 O O
months O O
ago O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
is O O
normal O O
. O O
  
ASSESSMENT O O
: O O
Ms O O
. O O
  
Name O O
is O O
an O O
83 O O
- O O
year O O
- O O
old O O
female O O
with O O
a O O
stage B-Severity B-Severity
II I-Severity I-Severity
follicular B-SSLIF B-SSLIF
small I-SSLIF I-SSLIF
cleaved I-SSLIF I-SSLIF
lymphocytic I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
, O O
continues O O
to O O
be O O
in O O
remission O O
. O O
  
PLAN O O
: O O
Ms O O
. O O
  
Name O O
will O O
see O O
Dr O O
. O O
  
Name O O
in O O
4 O O
months' O O
time O O
. O O
  
He O O
likes O O
to O O
repeat O O
CT O O
scans O O
about O O
every O O
6 O O
months O O
, O O
and O O
she O O
will O O
be O O
due O O
. O O
  
We O O
set O O
up O O
a O O
restaging O O
CT O O
scan O O
of O O
the O O
chest O O
, O O
abdomen O O
and O O
pelvis O O
with O O
contrast O O
. O O
  
Ms O O
. O O
  
Name O O
will O O
return O O
sooner O O
if O O
she O O
has O O
any O O
problems O O
prior O O
to O O
next O O
followup O O
visit O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
NP O O
Date O O
15 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
, O O
NP O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
NP O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
, O O
MD O O
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
PHYSICAL O O
  
MR# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
HOSPITAL O O
: O O
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
AND O O
PHYSICAL O O
Date O O
: O O
Date O O
Time O O
: O O
23 O O
: O O
33 O O
Hospital O O
Day O O
# O O
: O O
1 O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
  
DOB O O
: O O
Date O O
Age O O
: O O
75 O O
Sex O O
: O O
M O O
Account O O
# O O
: O O
Medical_Record_Number O O
Medical O O
Record O O
# O O
: O O
Medical_Record_Number O O
Admission O O
Date O O
: O O
Date O O
Location O O
: O O
Location O O
Attending O O
MD O O
Name O O
: O O
Name O O
, O O
Name O O
Pager O O
# O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Chief O O
Complaint O O
: O O
SOB B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
and O O
fever B-SSLIF B-SSLIF
History O O
of O O
Present O O
Illness O O
: O O
75 O O
yo O O
male O O
history O O
of O O
recurrent B-Indication B-Indication
follicular I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
, O O
s O O
/ O O
p O O
multiple O O
cycles O O
of O O
chemo B-Drug B-Drug
now O O
in O O
remission O O
, O O
history O O
of O O
mild B-Severity B-Severity
asthma B-SSLIF B-SSLIF
who O O
presents O O
with O O
cough B-SSLIF B-SSLIF
, O O
SOB B-SSLIF B-SSLIF
and O O
fever B-SSLIF B-SSLIF
x4 O O
days O O
. O O
  
He O O
complained O O
of O O
myalgias B-SSLIF B-SSLIF
but O O
it O O
was O O
fever B-SSLIF B-SSLIF
+ O O
delirium B-SSLIF B-SSLIF
"nearly O O
incoherent" O O
that O O
brought O O
him O O
in O O
. O O
  
He O O
was O O
recently O O
at O O
a O O
family O O
party O O
. O O
  
about O O
a O O
week O O
ago O O
. O O
  
His O O
brother O O
was O O
sick O O
with O O
an O O
upper B-SSLIF B-SSLIF
respiratory I-SSLIF I-SSLIF
illness I-SSLIF I-SSLIF
, O O
and O O
his O O
nephew O O
( O O
in O O
good O O
health O O
) O O
came O O
down O O
with O O
severe B-Severity B-Severity
pneumonia B-SSLIF B-SSLIF
and O O
was O O
hospitalized O O
in O O
City O O
. O O
  
Patient O O
did O O
have O O
a O O
flu O O
shot O O
this O O
year O O
. O O
  
He O O
has O O
no O O
history O O
of O O
recurrent O O
infections B-SSLIF B-SSLIF
, O O
asthma B-SSLIF B-SSLIF
exacerbations I-SSLIF I-SSLIF
, O O
chest O O
radiation O O
. O O
  
Only O O
other O O
symptom O O
is O O
loose B-SSLIF B-SSLIF
stools I-SSLIF I-SSLIF
. O O
  
Treatment O O
Received O O
: O O
ceft B-Drug B-Drug
/ O O
azithro B-Drug B-Drug
Past O O
Medical O O
/ O O
Surgical O O
History O O
: O O
Follicular B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
Date O O
, O O
recurrent O O
in O O
Date O O
, O O
Date O O
. O O
  
( O O
CHOP B-Drug B-Drug
tx O O
in O O
Date O O
, O O
then O O
cycles O O
of O O
Fludarabine B-Drug B-Drug
for O O
recurrent O O
disease O O
, O O
last O O
in O O
Date O O
) O O
  
Monoclonal B-SSLIF B-SSLIF
gammopathy I-SSLIF I-SSLIF
Mild B-Severity B-Severity
asthma B-SSLIF B-SSLIF
( O O
hasn't O O
used O O
inhaler B-Drug B-Drug
in O O
years O O
) O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
( O O
baseline O O
creatinine O O
1.2 O O
) O O
Elevated B-SSLIF B-SSLIF
PSA I-SSLIF I-SSLIF
Mild B-Severity B-Severity
leukopenia B-ADE B-ADE
since O O
tx O O
with O O
chemo B-Drug B-Drug
( O O
WBC O O
baseline O O
of O O
3.4 O O
) O O
MEDICATIONS O O
Current O O
Medication O O
Orders O O
: O O
  
ALLERGIES O O
Drug O O
Allergies O O
/ O O
ADR O O
from O O
Pharmacy O O
: O O
NO O O
KNOWN O O
DRUG B-SSLIF B-SSLIF
ALLERGIES I-SSLIF I-SSLIF
General O O
Allergies O O
from O O
Order O O
Entry O O
: O O
Allergies O O
: O O
NKDA O O
, O O
Food O O
Allergies O O
: O O
NKFA O O
FAMILY O O
HISTORY O O
/ O O
SOCIAL O O
HISTORY O O
Family O O
History O O
: O O
No O O
Reported O O
Family O O
History O O
Smoking O O
History O O
: O O
none O O
Alcohol O O
History O O
: O O
none O O
  
Illicits O O
History O O
: O O
none O O
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
PHYSICAL O O
  
MR# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
REVIEW O O
OF O O
SYSTEMS O O
Review O O
of O O
Systems O O
: O O
GENERAL O O
: O O
Fevers B-SSLIF B-SSLIF
; O O
Fatigue B-SSLIF B-SSLIF
; O O
Excercise B-SSLIF B-SSLIF
Intolerance I-SSLIF I-SSLIF
; O O
No_Sweats B-SSLIF B-SSLIF
; O O
No_Chills B-SSLIF B-SSLIF
; O O
No_Weight B-SSLIF B-SSLIF
Loss I-SSLIF I-SSLIF
; O O
No_Weight B-SSLIF B-SSLIF
Gain I-SSLIF I-SSLIF
NOSE O O
, O O
THROAT O O
: O O
No_Congestion B-SSLIF B-SSLIF
; O O
No_Sore B-SSLIF B-SSLIF
Throat I-SSLIF I-SSLIF
  
GENITOURINARY O O
: O O
No_Frequency O O
; O O
No_Urgency O O
; O O
No_Dysuria B-SSLIF B-SSLIF
; O O
No_Hematuria B-SSLIF B-SSLIF
SKIN O O
: O O
No_Rashes B-SSLIF B-SSLIF
MUSCULOSKELETAL O O
: O O
Muscle B-SSLIF B-SSLIF
Aches I-SSLIF I-SSLIF
; O O
No_Joint B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
; O O
No_Back B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
  
HEMATOPOIETIC O O
: O O
No_Anemia B-SSLIF B-SSLIF
RESPIRATORY O O
: O O
Cough B-SSLIF B-SSLIF
; O O
Dyspnea B-SSLIF B-SSLIF
; O O
No_Wheezing B-SSLIF B-SSLIF
CARDIOVASCULAR O O
: O O
No_Chest B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
; O O
No_Edema B-SSLIF B-SSLIF
; O O
No_Palpitations B-SSLIF B-SSLIF
PSYCHIATRIC O O
: O O
No_Depression B-SSLIF B-SSLIF
; O O
No_Anxiety B-SSLIF B-SSLIF
GASTROINTESTINAL O O
: O O
Diarrhea B-SSLIF B-SSLIF
; O O
No_Dysphagia B-SSLIF B-SSLIF
; O O
No_Abdominal B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
; O O
No_Nausea B-SSLIF B-SSLIF
; O O
No_Vomiting B-SSLIF B-SSLIF
; O O
No_Constipation B-SSLIF B-SSLIF
  
NEUROLOGIC O O
: O O
No_Paresthesias B-SSLIF B-SSLIF
; O O
No_Gait B-SSLIF B-SSLIF
Abnormalities I-SSLIF I-SSLIF
PHYSICAL O O
EXAM O O
Temp O O
: O O
100.2 O O
Pulse O O
: O O
93 O O
- O O
110 O O
  
Resp O O
: O O
18 O O
  
BP O O
: O O
134 O O
/ O O
73 O O
Pulse O O
Ox O O
: O O
95% O O
on O O
RA O O
( O O
as O O
low O O
as O O
90% O O
on O O
RA O O
) O O
Physical O O
Exam O O
Systems O O
: O O
GENERAL O O
: O O
well O O
alert O O
and O O
comfortable O O
with O O
HCP O O
at O O
bedside O O
  
HEENT O O
: O O
MMM O O
EOMI O O
NO O O
Icterus B-SSLIF B-SSLIF
LUNG O O
: O O
CTA O O
bilaterally O O
- O O
no O O
wheezes B-SSLIF B-SSLIF
/ O O
crackles B-SSLIF B-SSLIF
, O O
no O O
increased B-SSLIF B-SSLIF
work I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
breathing I-SSLIF I-SSLIF
CARDIOVASCULAR O O
: O O
Slightly B-Severity B-Severity
tachy B-SSLIF B-SSLIF
, O O
regular O O
no O O
murmur B-SSLIF B-SSLIF
NECK O O
/ O O
LYMPH O O
NODES O O
/ O O
SKIN O O
: O O
C O O
/ O O
D O O
/ O O
I O O
ABDOMEN O O
: O O
Soft O O
NT O O
ND O O
EXTREMITIES O O
/ O O
MUSCULOSKELETAL O O
: O O
no O O
edema B-SSLIF B-SSLIF
  
NEUROLOGIC O O
: O O
Alert O O
oriented O O
nonfocal O O
PSYCHOLOGICAL O O
: O O
appropriate O O
and O O
pleasant O O
LABORATORY O O
/ O O
STUDIES O O
  
Metabolics O O
Common O O
: O O
Date O O
Name O O
Units O O
Range O O
19 O O
: O O
35 O O
  
NA O O
mmol O O
/ O O
L O O
135 O O
- O O
145 O O
130* O O
  
K O O
mmol O O
/ O O
L O O
3.5 O O
- O O
5.3 O O
4.2 O O
  
CL O O
mmol O O
/ O O
L O O
97 O O
- O O
110 O O
97 O O
  
CO2 O O
mmol O O
/ O O
L O O
24 O O
- O O
32 O O
25 O O
Anion O O
Gap O O
5 O O
- O O
15 O O
8 O O
  
Glu O O
mg O O
/ O O
dL O O
70 O O
- O O
99 O O
101* O O
BUN O O
mg O O
/ O O
dL O O
7 O O
- O O
23 O O
17 O O
  
Creat O O
mg O O
/ O O
dL O O
0.60 O O
- O O
1.30 O O
1.19 O O
  
GFR O O
>60 O O
60 O O
  
CA O O
mg O O
/ O O
dL O O
8.7 O O
- O O
10.7 O O
8.7 O O
  
CBC O O
/ O O
Diff O O
: O O
Date O O
Name O O
Units O O
Range O O
19 O O
: O O
35 O O
  
WBC O O
th O O
/ O O
mm3 O O
4.3 O O
- O O
10.3 O O
2.9* O O
  
RBC O O
mil O O
/ O O
mm3 O O
4.40 O O
- O O
6.00 O O
4.36* O O
  
HGB O O
g O O
/ O O
dL O O
14.0 O O
- O O
18.0 O O
14.6 O O
  
HCT O O
% O O
42.0 O O
- O O
52.0 O O
40.8* O O
  
MCV O O
fl O O
82.0 O O
- O O
101.0 O O
93.7 O O
  
PLT O O
th O O
/ O O
mm3 O O
140 O O
- O O
440 O O
74* O O
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
PHYSICAL O O
  
MR# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
NE O O
% O O
43.0 O O
- O O
72.0 O O
81.4* O O
  
LY O O
% O O
18.0 O O
- O O
43.0 O O
10.6* O O
  
MO O O
% O O
4.0 O O
- O O
12.0 O O
7.3 O O
  
EO O O
% O O
0.0 O O
- O O
8.0 O O
0.5 O O
  
BA O O
% O O
0.0 O O
- O O
2.0 O O
0.2 O O
Cardiac O O
Enzymes O O
: O O
Date O O
Name O O
Units O O
Range O O
20 O O
: O O
23 O O
  
Troponin O O
I O O
  
BNP O O
pg O O
/ O O
mL O O
< O O
100 O O
10 O O
Radiology O O
: O O
Date O O
09 O O
: O O
49 O O
PM O O
  
CT O O
: O O
CHEST O O
- O O
PE O O
  
MR# O O
: O O
Medical_Record_Number O O
ACCT# O O
: O O
Medical_Record_Number O O
  
CT O O
chest O O
with O O
contrast O O
, O O
PE O O
protocol O O
History O O
: O O
Shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
Technique O O
: O O
Spiral O O
CT O O
of O O
the O O
chest O O
is O O
performed O O
after O O
the O O
administration O O
of O O
70 O O
cc O O
intravenous O O
Isovue O O
- O O
370 O O
per O O
standard O O
department O O
protocol O O
in O O
the O O
angiographic O O
phase O O
. O O
  
Findings O O
: O O
  
There O O
is O O
no O O
pulmonary B-SSLIF B-SSLIF
embolus I-SSLIF I-SSLIF
. O O
  
Minimal O O
platelike B-SSLIF B-SSLIF
atelectasis I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
present I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
inferior I-SSLIF I-SSLIF
lingula I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
the O O
lungs O O
are O O
essentially O O
clear O O
. O O
  
No O O
pulmonary B-SSLIF B-SSLIF
nodule I-SSLIF I-SSLIF
or O O
pulmonary B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
is O O
identified O O
. O O
  
There O O
is O O
no O O
significant B-Severity B-Severity
mediastinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
No O O
pleural B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
pericardial I-SSLIF I-SSLIF
effusion I-SSLIF I-SSLIF
. O O
  
No O O
pneumothorax B-SSLIF B-SSLIF
. O O
  
There O O
is O O
incomplete O O
visualization O O
of O O
a O O
hypodense O O
focus O O
along O O
the O O
subcapsular O O
region O O
of O O
the O O
right O O
lobe O O
of O O
the O O
liver O O
measuring O O
about O O
7 O O
mm O O
in O O
diameter O O
. O O
  
In O O
retrospect O O
, O O
this O O
was O O
present O O
on O O
the O O
prior O O
exam O O
from O O
Date O O
and O O
while O O
nonspecific O O
may O O
represent O O
a O O
small B-Severity B-Severity
cyst B-SSLIF B-SSLIF
. O O
  
Otherwise O O
, O O
the O O
limited O O
visualization O O
of O O
the O O
upper O O
abdominal O O
visceral O O
are O O
grossly O O
unremarkable O O
. O O
  
Degenerative O O
changes O O
are O O
noted O O
of O O
the O O
thoracic O O
spine O O
. O O
  
Otherwise O O
, O O
the O O
osseous O O
structures O O
are O O
grossly O O
unremarkable O O
. O O
  
Impression O O
: O O
  
No O O
pulmonary B-SSLIF B-SSLIF
embolus I-SSLIF I-SSLIF
. O O
  
Minimal O O
platelike B-SSLIF B-SSLIF
atelectasis I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lung I-SSLIF I-SSLIF
base I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
the O O
lungs O O
are O O
essentially O O
clear O O
. O O
  
7 B-Severity B-Severity
mm I-Severity I-Severity
probable O O
cyst B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
liver I-SSLIF I-SSLIF
. O O
  
ECG O O
Interpretation O O
: O O
NSR O O
rate O O
107 O O
, O O
no O O
ST O O
/ O O
Twave O O
changes O O
. O O
  
Essentially O O
unchanged O O
from O O
Date O O
  
ECG O O
Personally O O
Reviewed O O
: O O
True O O
IMPRESSION O O
  
75 O O
yo O O
male O O
history O O
of O O
follicular B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
presents O O
with O O
signs O O
and O O
symptoms O O
of O O
PNA B-SSLIF B-SSLIF
but O O
with O O
negative O O
CXR O O
/ O O
CT O O
scan O O
. O O
  
PROBLEM O O
LIST O O
/ O O
PLAN O O
OF O O
CARE O O
  
1 O O
) O O
Pneumonia B-SSLIF B-SSLIF
( O O
480.9 O O
VIRAL B-SSLIF B-SSLIF
PNEUMONIA I-SSLIF I-SSLIF
) O O
Plan O O
: O O
Patient O O
likely O O
has O O
viral B-Indication B-Indication
pneumonia I-Indication I-Indication
, O O
possibly O O
influenza B-Indication B-Indication
. O O
  
At O O
this O O
time O O
, O O
until O O
more O O
data O O
obtained O O
, O O
will O O
continue O O
antibiotics B-Drug B-Drug
Ceftriaxone B-Drug B-Drug
and O O
Azithro B-Drug B-Drug
, O O
but O O
start O O
Tamiflu B-Drug B-Drug
. O O
  
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
PHYSICAL O O
  
MR# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
Plan O O
: O O
  
Sputum O O
cultures O O
  
Legionella O O
/ O O
Strep O O
antigen O O
Flu O O
/ O O
RVP O O
swabs O O
  
Ceft B-Drug B-Drug
/ O O
Azithro B-Drug B-Drug
+Tamiflu B-Drug B-Drug
  
IVF O O
for O O
tachycardia B-SSLIF B-SSLIF
Last O O
Modified O O
: O O
Date O O
  
- O O
  
2 O O
) O O
Leukopenia B-SSLIF B-SSLIF
( O O
288.50 O O
LEUKOPENIA O O
) O O
Plan O O
: O O
Patient O O
is O O
not O O
neutropenic B-SSLIF B-SSLIF
but O O
WBC B-SSLIF B-SSLIF
decreased I-SSLIF I-SSLIF
from O O
baseline O O
of O O
3.4 O O
to O O
2.8 O O
. O O
  
This O O
may O O
be O O
related O O
to O O
infection B-SSLIF B-SSLIF
. O O
  
Will O O
monitor O O
. O O
  
Patient O O
is O O
followed O O
closely O O
by O O
Dr O O
Name O O
for O O
history O O
of O O
lymphoma B-SSLIF B-SSLIF
, O O
and O O
per O O
patient O O
he O O
has O O
required O O
chemo B-Drug B-Drug
for O O
treatment O O
of O O
his O O
recurrent O O
lymphoma B-Indication B-Indication
every O O
4 B-Frequency B-Frequency
years I-Frequency I-Frequency
or O O
so O O
( O O
now O O
going O O
on O O
5 O O
years O O
since O O
last O O
treatment O O
. O O
  
) O O
If O O
leukopenia B-SSLIF B-SSLIF
worsening O O
, O O
will O O
need O O
to O O
discuss O O
with O O
Heme O O
- O O
Onc O O
. O O
  
Last O O
Modified O O
: O O
Date O O
  
- O O
  
3 O O
) O O
thrombocytopenia B-SSLIF B-SSLIF
( O O
287.5 O O
THROMBOCYTOPENIA O O
) O O
Plan O O
: O O
Patient's O O
baseline O O
plt O O
around O O
100 O O
, O O
now O O
decreased O O
to O O
74 O O
. O O
  
Monitor O O
. O O
  
Last O O
Modified O O
: O O
Date O O
  
- O O
  
4 O O
) O O
asthma B-SSLIF B-SSLIF
( O O
493.90 O O
ASTHMA O O
) O O
Plan O O
: O O
Does O O
not O O
appear O O
to O O
have O O
signs O O
/ O O
symptoms O O
of O O
asthma B-SSLIF B-SSLIF
exacerbation I-SSLIF I-SSLIF
but O O
have O O
written O O
for O O
albuterol B-Drug B-Drug
nebs B-Route B-Route
in O O
case O O
of O O
wheezing B-SSLIF B-SSLIF
. O O
  
Last O O
Modified O O
: O O
Date O O
  
- O O
  
5 O O
) O O
PSA O O
( O O
602.9 O O
PROSTATE B-SSLIF B-SSLIF
DISORDERS I-SSLIF I-SSLIF
) O O
Plan O O
: O O
PSA O O
checked O O
by O O
Heme O O
Onc O O
on O O
Date O O
. O O
  
Would O O
refer O O
back O O
to O O
heme O O
- O O
onc O O
for O O
further O O
monitoring O O
. O O
  
Elevated O O
at O O
>4 O O
. O O
  
Last O O
Modified O O
: O O
Date O O
  
- O O
GLOBAL O O
PLAN O O
OF O O
CARE O O
Limitations O O
of O O
Treatment O O
: O O
Full O O
Code O O
Code O O
Status O O
Comments O O
: O O
confirmed O O
with O O
HCP O O
at O O
bedside O O
- O O
full O O
code O O
as O O
there O O
are O O
no O O
serious O O
chronic O O
illnesses O O
and O O
chance O O
of O O
recovery O O
from O O
respiratory O O
distress O O
/ O O
cardiac O O
arrest O O
could O O
be O O
fairly O O
good O O
Fluids O O
/ O O
Electrolytes O O
/ O O
Nutrition O O
: O O
NS O O
at O O
150cc O O
/ O O
hr O O
x2L O O
  
VTE O O
Prophylaxis O O
Status O O
: O O
Intermittent O O
Pneumatic O O
Compression O O
  
VTE B-Indication B-Indication
Prophylaxis I-Indication I-Indication
Comments O O
: O O
Will O O
hold O O
off O O
on O O
lovenox B-Drug B-Drug
as O O
plt B-SSLIF B-SSLIF
count I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
to O O
74 O O
: O O
watch O O
for O O
plt O O
trend O O
before O O
starting O O
COMMUNICATION O O
Discussed O O
Plan O O
of O O
Care O O
with O O
Patient O O
/ O O
Family O O
: O O
True O O
Referring O O
Physician O O
: O O
Name O O
, O O
Name O O
Primary O O
Care O O
MD O O
: O O
Name O O
, O O
Name O O
Forward O O
to O O
PCP O O
: O O
True O O
BILLING O O
DOCUMENTATION O O
Patient O O
Status O O
in O O
System O O
: O O
I O O
Billing O O
Documentation O O
: O O
Type O O
of O O
Service O O
Billed O O
: O O
Initial O O
Hospital O O
Care O O
Hospital O O
HOSPITAL O O
MEDICINE O O
HISTORY O O
PHYSICAL O O
  
MR# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
SIGNATURE O O
Attending O O
Signature O O
: O O
Electronically O O
signed O O
by O O
Name O O
Name O O
, O O
MD O O
at O O
23 O O
: O O
56 O O
Date O O
of O O
Attending O O
Signature O O
: O O
Date O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Recurrent B-SSLIF B-SSLIF
follicular I-SSLIF I-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
He O O
has O O
had O O
a O O
recent O O
relapse O O
in O O
his O O
bowel O O
. O O
  
Routine O O
surveillance O O
colonoscopy O O
with O O
numerous O O
biopsies O O
showed O O
polyps B-SSLIF B-SSLIF
as O O
well O O
as O O
a O O
nodular B-SSLIF B-SSLIF
mucosal I-SSLIF I-SSLIF
area I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
proximal I-SSLIF I-SSLIF
ascending I-SSLIF I-SSLIF
colon I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
cecum I-SSLIF I-SSLIF
. O O
  
Multiple O O
biopsies O O
revealed O O
a O O
low B-Severity B-Severity
- I-Severity I-Severity
grade I-Severity I-Severity
B B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
Polyps B-SSLIF B-SSLIF
revealed O O
tubular B-SSLIF B-SSLIF
adenoma I-SSLIF I-SSLIF
. O O
  
A O O
. O O
  
He O O
initially O O
presented O O
with O O
a O O
mass B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
large I-SSLIF I-SSLIF
bowel I-SSLIF I-SSLIF
in O O
the O O
early O O
Date O O
, O O
which O O
was O O
associated O O
with O O
diarrhea B-SSLIF B-SSLIF
and O O
iron B-SSLIF B-SSLIF
deficiency I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
. O O
  
Biopsy O O
of O O
the O O
mass B-SSLIF B-SSLIF
was O O
said O O
to O O
reveal O O
large B-Indication B-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
and O O
he O O
was O O
given O O
chemotherapy B-Drug B-Drug
at O O
that O O
time O O
. O O
  
B O O
. O O
  
He O O
had O O
a O O
recurrence O O
in O O
Date O O
and O O
was O O
retreated O O
. O O
  
C O O
. O O
  
In O O
Date O O
, O O
he O O
had O O
another O O
recurrence O O
with O O
diffuse B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
and O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
. O O
  
At O O
that O O
time O O
, O O
a O O
lymph O O
node O O
was O O
biopsied O O
and O O
it O O
was O O
follicular B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
D O O
. O O
  
A O O
recent O O
bone O O
marrow O O
aspirate O O
and O O
biopsy O O
in O O
Date O O
revealed O O
a O O
hypocellular B-SSLIF B-SSLIF
marrow I-SSLIF I-SSLIF
with O O
normal O O
trilineage O O
hematopoiesis O O
. O O
  
Lymphoma B-SSLIF B-SSLIF
was O O
noted O O
as O O
well O O
. O O
  
The O O
cells O O
were O O
CD5 O O
positive O O
, O O
CD20 O O
positive O O
and O O
PAX5 O O
positive O O
. O O
  
Cyclin O O
D1 O O
was O O
negative O O
as O O
well O O
as O O
BCL O O
- O O
6 O O
. O O
  
BCL O O
- O O
2 O O
was O O
positive O O
. O O
  
Flow O O
cytometry O O
revealed O O
the O O
lymphoma B-SSLIF B-SSLIF
cells I-SSLIF I-SSLIF
, O O
which O O
were O O
17% O O
. O O
  
They O O
were O O
CD5 O O
positive O O
, O O
CD10 O O
negative O O
, O O
FMC O O
- O O
7 O O
negative O O
. O O
  
Cytogenetics O O
revealed O O
trisomy B-SSLIF B-SSLIF
12 I-SSLIF I-SSLIF
. O O
  
There O O
was O O
no O O
deletion B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
13q I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
TP53 I-SSLIF I-SSLIF
. O O
  
There O O
may O O
have O O
been O O
an O O
MDS B-SSLIF B-SSLIF
related I-SSLIF I-SSLIF
clone I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
20q I-SSLIF I-SSLIF
- O O
. O O
  
2. O O
Mild B-Severity B-Severity
thrombocytopenia B-SSLIF B-SSLIF
, O O
present O O
since O O
Date O O
and O O
intermittent O O
leukopenia B-SSLIF B-SSLIF
. O O
  
This O O
could O O
be O O
secondary O O
to O O
MDS B-SSLIF B-SSLIF
as O O
well O O
as O O
lymphomatous B-SSLIF B-SSLIF
involvement I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
. O O
  
3. O O
Asthma B-SSLIF B-SSLIF
. O O
  
4. O O
Chronic O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
of O O
unclear O O
etiology O O
. O O
  
5. O O
Monoclonal B-SSLIF B-SSLIF
gammopathy I-SSLIF I-SSLIF
with O O
2 O O
IgG O O
monoclonal O O
bands O O
which O O
are O O
IgG O O
kappa O O
and O O
IgG O O
lambda O O
, O O
probably O O
secondary O O
to O O
his O O
underlying O O
lymphoma B-SSLIF B-SSLIF
. O O
  
6. O O
Increased B-SSLIF B-SSLIF
PSA I-SSLIF I-SSLIF
, O O
followed O O
by O O
urology O O
. O O
  
7. O O
Hospitalization O O
in O O
Date O O
for O O
pneumonia B-SSLIF B-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
has O O
been O O
on O O
no O O
chemotherapy B-Drug B-Drug
since O O
Date O O
. O O
  
He O O
is O O
on O O
no O O
chemotherapy B-Drug B-Drug
currently O O
and O O
has O O
been O O
followed O O
by O O
observation O O
only O O
. O O
  
PAST O O
CHEMOTHERAPY O O
: O O
  
1. O O
Four B-Duration B-Duration
cycles I-Duration I-Duration
of O O
fludarabine B-Drug B-Drug
, O O
which O O
ended O O
in O O
Date O O
. O O
  
2. O O
Three B-Duration B-Duration
cycles I-Duration I-Duration
of O O
fludarabine B-Drug B-Drug
in O O
Date O O
. O O
  
3. O O
Fludarabine B-Drug B-Drug
in O O
Date O O
. O O
  
4. O O
Six B-Duration B-Duration
cycles I-Duration I-Duration
of O O
CHOP B-Drug B-Drug
in O O
Date O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Inhalers B-Drug B-Drug
, O O
aspirin B-Drug B-Drug
, O O
fish B-Drug B-Drug
oil I-Drug I-Drug
, O O
multivitamins B-Drug B-Drug
and O O
vitamin B-Drug B-Drug
B12 I-Drug I-Drug
as O O
well O O
as O O
vitamin B-Drug B-Drug
C I-Drug I-Drug
and O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
and O O
to O O
discuss O O
initiating O O
rituximab B-Drug B-Drug
. O O
  
He O O
is O O
accompanied O O
today O O
by O O
his O O
nephew O O
. O O
  
He O O
himself O O
continues O O
to O O
feel O O
well O O
. O O
  
He O O
has O O
had O O
no O O
interim O O
issues O O
. O O
  
He O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
fatigue B-SSLIF B-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
. O O
  
He O O
continues O O
to O O
be O O
very O O
active O O
and O O
does O O
ballroom O O
dancing O O
with O O
his O O
girlfriend O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
complete O O
review O O
of O O
systems O O
is O O
negative O O
. O O
  
He O O
has O O
no O O
significant B-Severity B-Severity
complaints O O
of O O
pain B-SSLIF B-SSLIF
and O O
has O O
noted O O
no O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
change O O
in O O
bowel O O
or O O
bladder O O
habits O O
. O O
  
He O O
denies O O
any O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
or O O
dysuria B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Negative O O
for O O
lymphoma B-SSLIF B-SSLIF
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
0 O O
. O O
  
He O O
lives O O
independently O O
and O O
is O O
active O O
. O O
  
He O O
does O O
drive O O
. O O
  
He O O
does O O
have O O
a O O
significant O O
other O O
and O O
they O O
go O O
dancing O O
2 O O
- O O
3 O O
times O O
a O O
week O O
, O O
which O O
he O O
says O O
is O O
excellent O O
exercise O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
155 O O
/ O O
72 O O
, O O
pulse O O
66 O O
and O O
regular O O
and O O
weight O O
is O O
88.1kg O O
, O O
which O O
is O O
stable O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
without O O
lesions B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
. O O
  
There O O
is O O
no O O
anterior B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
posterior I-SSLIF I-SSLIF
cervical I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
axillary B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
no O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
petechiae B-SSLIF B-SSLIF
or O O
ecchymoses B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rashes B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
Strength O O
intact O O
and O O
gait O O
is O O
normal O O
. O O
  
LABORATORY O O
DATA O O
: O O
  
Test O O
Result O O
  
WBC O O
2.6 O O
th O O
/ O O
mm3 O O
  
RBC O O
3.79 O O
mil O O
/ O O
mm3 O O
  
HGB O O
13.1 O O
g O O
/ O O
dL O O
  
HCT O O
37.5 O O
% O O
  
MCV O O
98.8 O O
fl O O
  
MCH O O
34.6 O O
pg O O
  
MCHC O O
35.0 O O
g O O
/ O O
dL O O
  
RDW O O
15.4 O O
% O O
PLATELET O O
COUNT O O
79 O O
th O O
/ O O
mm3 O O
Date O O
Date O O
Date O O
Date O O
Date O O
Date O O
Date O O
Date O O
Date O O
Date O O
  
2 O O
: O O
36 O O
PM O O
1 O O
: O O
09 O O
PM O O
1 O O
: O O
27 O O
PM O O
1 O O
: O O
30 O O
PM O O
12 O O
: O O
59 O O
PM O O
1 O O
: O O
11 O O
PM O O
12 O O
: O O
39 O O
PM O O
12 O O
: O O
26 O O
PM O O
12 O O
: O O
01 O O
AM O O
1 O O
: O O
35 O O
PM O O
  
LDH O O
BLOOD O O
195 O O
207 O O
227 O O
231 O O
220 O O
277 O O
238 O O
286 O O
196 O O
206 O O
  
LFTs O O
and O O
renal O O
function O O
are O O
with O O
in O O
normal O O
limits O O
. O O
  
Pathology O O
: O O
  
DIAGNOSIS O O
Bone O O
Marrow O O
, O O
Site O O
Unspecified O O
, O O
Biopsy O O
and O O
Clot O O
: O O
  
- O O
CD5+ B-SSLIF B-SSLIF
LOW I-SSLIF I-SSLIF
GRADE I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
CELL I-SSLIF I-SSLIF
LYMPHOMA I-SSLIF I-SSLIF
, O O
MOST O O
CONSISTENT O O
WITH O O
SMALL B-SSLIF B-SSLIF
LYMPHOCYTIC I-SSLIF I-SSLIF
LYMPHOMA I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
CHRONIC I-SSLIF I-SSLIF
LYMPHOCYTIC I-SSLIF I-SSLIF
LEUKEMIA I-SSLIF I-SSLIF
, O O
COMPRISING O O
10 O O
- O O
20% O O
OF O O
THE O O
TOTAL O O
CELLS O O
. O O
  
BONE O O
MARROW O O
BIOPSY O O
: O O
  
Cellularity O O
: O O
30% O O
  
Megakaryocytes O O
: O O
Adequate O O
Myeloid O O
Series O O
: O O
Hypoplasia O O
; O O
normal O O
maturation O O
  
Erythroid O O
Series O O
: O O
Hyperplasia O O
; O O
normal O O
maturation O O
Myeloid B-SSLIF B-SSLIF
: I-SSLIF I-SSLIF
Erythroid I-SSLIF I-SSLIF
Ratio I-SSLIF I-SSLIF
: I-SSLIF I-SSLIF
Decreased I-SSLIF I-SSLIF
Infiltrative O O
process O O
: O O
Several O O
paratrabecular B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
non I-SSLIF I-SSLIF
- I-SSLIF I-SSLIF
paratrabecular I-SSLIF I-SSLIF
ymphoid I-SSLIF I-SSLIF
aggregates I-SSLIF I-SSLIF
, O O
comprising O O
10 O O
- O O
20% O O
of O O
the O O
total O O
cells O O
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
76 O O
- O O
year O O
- O O
old O O
male O O
with O O
recurrent B-Indication B-Indication
low I-Indication I-Indication
- I-Indication I-Indication
grade I-Indication I-Indication
follicular I-Indication I-Indication
cell I-Indication I-Indication
lymphoma I-Indication I-Indication
. O O
  
Recently O O
, O O
he O O
seems O O
to O O
have O O
relapsed O O
in O O
his O O
bowel O O
, O O
although O O
he O O
has O O
had O O
positive O O
biopsies O O
in O O
the O O
past O O
. O O
  
He O O
is O O
entirely O O
asymptomatic O O
. O O
  
His O O
iron O O
levels O O
are O O
normal O O
and O O
he O O
has O O
no O O
diarrhea B-SSLIF B-SSLIF
. O O
  
He O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
and O O
his O O
weight O O
is O O
stable O O
. O O
  
Full O O
body O O
CT O O
scan O O
and O O
PET O O
scan O O
revealed O O
no O O
PET O O
CT O O
evidence O O
of O O
malignancy B-SSLIF B-SSLIF
. O O
  
There O O
are O O
small B-Severity B-Severity
abdominal B-SSLIF B-SSLIF
lymph I-SSLIF I-SSLIF
nodes I-SSLIF I-SSLIF
, O O
but O O
they O O
are O O
not O O
PET O O
avid O O
. O O
  
He O O
also O O
has O O
evidence O O
of O O
lymphoma B-Indication B-Indication
in I-Indication I-Indication
the I-Indication I-Indication
bone I-Indication I-Indication
marrow I-Indication I-Indication
. O O
  
At O O
the O O
last O O
visit O O
, O O
single O O
agent O O
Rituxan B-Drug B-Drug
, O O
was O O
discussed O O
with O O
the O O
patient O O
after O O
discussion O O
took O O
place O O
in O O
lymphoma O O
tumor O O
board O O
. O O
  
Mr O O
. O O
  
Name O O
is O O
still O O
in O O
agreement O O
with O O
initiating O O
this O O
regimen O O
. O O
  
We O O
feel O O
that O O
he O O
will O O
be O O
able O O
to O O
tolerate O O
especially O O
given O O
that O O
he O O
tolerated O O
fludarabine B-Drug B-Drug
. O O
  
We O O
discussed O O
the O O
risks O O
and O O
benefits O O
again O O
with O O
the O O
patient O O
and O O
the O O
consent O O
was O O
signed O O
. O O
  
We O O
went O O
ahead O O
and O O
made O O
weekly B-Frequency B-Frequency
appointment O O
for O O
the O O
rituxan B-Drug B-Drug
. O O
  
All O O
of O O
his O O
questions O O
were O O
answered O O
to O O
his O O
satisfaction O O
. O O
  
PLAN O O
: O O
  
He O O
will O O
receive O O
Ritaxan B-Drug B-Drug
weekly B-Frequency B-Frequency
x O O
4 B-Duration B-Duration
weeks I-Duration I-Duration
and O O
then O O
in O O
6mos O O
time O O
for O O
a O O
total O O
of O O
2 B-Duration B-Duration
years I-Duration I-Duration
. O O
  
He O O
will O O
follow O O
back O O
with O O
Dr O O
. O O
  
Name O O
in O O
5 O O
weeks O O
time O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
D.O. O O
Date O O
4 O O
: O O
24PM O O
EST O O
Author O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
10 O O
: O O
29PM O O
EST O O
Acknowledgement O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
Date O O
  
Loc O O
: O O
Named_Sites O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
13 O O
: O O
10 O O
PM O O
Clinic O O
Note O O
PEDIATRIC O O
HEMATOLOGY O O
/ O O
ONCOLOGY O O
CLINIC O O
DIAGNOSIS O O
: O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
stage B-Severity B-Severity
III I-Severity I-Severity
abdominal O O
, O O
off O O
therapy O O
. O O
  
SUBJECTIVE O O
: O O
Name O O
is O O
a O O
21 O O
- O O
year O O
- O O
old O O
man O O
who O O
returns O O
to O O
clinic O O
for O O
followup O O
of O O
stage B-Severity B-Severity
III I-Severity I-Severity
abdominal B-Indication B-Indication
Burkitt I-Indication I-Indication
lymphoma I-Indication I-Indication
diagnosed O O
in O O
Date O O
and O O
treated O O
with O O
chemotherapy B-Drug B-Drug
per O O
COG B-PHI B-PHI
protocol I-PHI I-PHI
5961 I-PHI I-PHI
, I-PHI I-PHI
group I-PHI I-PHI
B I-PHI I-PHI
. O O
  
His O O
postoperative O O
course O O
was O O
complicated O O
by O O
wound B-ADE B-ADE
dehiscence I-ADE I-ADE
. O O
  
Otherwise O O
, O O
he O O
tolerated O O
the O O
treatment O O
well O O
except O O
for O O
continued O O
depression B-SSLIF B-SSLIF
. O O
  
Since O O
his O O
last O O
visit O O
on O O
Date O O
, O O
he O O
has O O
been O O
entirely O O
well O O
. O O
  
He O O
has O O
had O O
no O O
GI B-SSLIF B-SSLIF
, O O
neurological B-SSLIF B-SSLIF
or O O
systemic B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
A O O
12 O O
- O O
point O O
review O O
of O O
systems O O
is O O
negative O O
in O O
detail O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
, O O
PAST O O
SURGICAL O O
HISTORY O O
AND O O
FAMILY O O
HISTORY O O
: O O
Unchanged O O
from O O
note O O
on O O
Date O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Name O O
is O O
in O O
his O O
last O O
year O O
at O O
the O O
Named_Sites O O
and O O
expects O O
to O O
graduate O O
with O O
an O O
associate's O O
degree O O
in O O
Date O O
. O O
  
He O O
is O O
looking O O
into O O
jobs O O
at O O
5 O O
Star O O
restaurants O O
in O O
City O O
and O O
at O O
City O O
( O O
Company O O
) O O
. O O
  
He O O
is O O
very O O
enthusiastic O O
about O O
his O O
prospects O O
. O O
  
MEDICATIONS O O
: O O
Reconciled O O
with O O
the O O
patient O O
: O O
amitriptyline B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
and O O
enalapril B-Drug B-Drug
maleate I-Drug I-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Amoxicillin B-Drug B-Drug
, O O
rash B-ADE B-ADE
. O O
  
Reglan B-Drug B-Drug
, O O
agitation B-ADE B-ADE
. O O
  
OBJECTIVE O O
: O O
  
GENERAL O O
: O O
A O O
well O O
- O O
appearing O O
, O O
moderately B-Severity B-Severity
obese B-SSLIF B-SSLIF
young O O
man O O
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Weight O O
121.2 O O
kg O O
( O O
increased O O
from O O
113.8 O O
kg O O
on O O
Date O O
) O O
, O O
height O O
190.2 O O
cm O O
and O O
BMI O O
33.57 O O
. O O
  
HR O O
80 O O
and O O
BP O O
136 O O
/ O O
80 O O
. O O
  
Pain O O
level O O
0 O O
. O O
  
SKIN O O
: O O
No O O
pallor B-SSLIF B-SSLIF
, O O
jaundice B-SSLIF B-SSLIF
or O O
rash B-SSLIF B-SSLIF
; O O
striations O O
across O O
abdomen O O
. O O
  
HEENT O O
: O O
Normal O O
oral O O
mucosa O O
, O O
dentition O O
, O O
eyes O O
( O O
including O O
fundi O O
) O O
, O O
ears O O
and O O
nose O O
. O O
  
LYMPH O O
NODES O O
: O O
No O O
enlargement B-SSLIF B-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
CARDIAC O O
: O O
Regular O O
rhythm O O
, O O
normal O O
S1 O O
and O O
S2 O O
with O O
physiologic O O
split O O
. O O
  
No O O
murmur B-SSLIF B-SSLIF
or O O
gallop B-SSLIF B-SSLIF
. O O
  
ABDOMEN O O
: O O
No O O
organomegaly B-SSLIF B-SSLIF
, O O
mass B-SSLIF B-SSLIF
or O O
tenderness B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
bone B-SSLIF B-SSLIF
or O O
joint B-SSLIF B-SSLIF
deformity I-SSLIF I-SSLIF
or O O
tenderness B-SSLIF B-SSLIF
. O O
  
NEUROLOGICAL O O
: O O
Normal O O
mental O O
status O O
with O O
no O O
focal B-SSLIF B-SSLIF
deficits I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
: O O
WBC O O
5.6 O O
with O O
normal O O
differential O O
, O O
hemoglobin O O
15.8 O O
, O O
hematocrit O O
45.2 O O
, O O
MCV O O
88.2 O O
and O O
platelets O O
214 O O
, O O
000 O O
. O O
  
Creatinine O O
0.78 O O
. O O
  
Bilirubin O O
0.4 O O
total O O
. O O
  
ALT O O
20 O O
. O O
  
IMPRESSION O O
AND O O
PLAN O O
: O O
  
1. O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
, O O
stage B-Severity B-Severity
III I-Severity I-Severity
abdominal O O
, O O
in O O
continued O O
clinical O O
remission O O
3 O O
years O O
off O O
therapy O O
. O O
  
With O O
this O O
rapidly O O
growing O O
tumor O O
, O O
the O O
risk O O
of O O
relapse O O
is O O
now O O
extremely O O
low O O
. O O
  
2. O O
Depression B-SSLIF B-SSLIF
, O O
well O O
controlled O O
on O O
current O O
medication O O
. O O
  
3. O O
Obesity B-SSLIF B-SSLIF
: O O
The O O
rising O O
weight O O
and O O
BMI O O
( O O
now O O
>30 O O
) O O
are O O
of O O
concern O O
and O O
should O O
be O O
addressed O O
with O O
his O O
primary O O
care O O
physician O O
. O O
  
Name O O
will O O
return O O
to O O
clinic O O
in O O
6 O O
months O O
after O O
the O O
end O O
of O O
school O O
, O O
and O O
then O O
will O O
make O O
arrangements O O
for O O
followup O O
depending O O
on O O
where O O
he O O
is O O
living O O
. O O
  
Most O O
likely O O
, O O
he O O
will O O
continue O O
at O O
Hospital O O
with O O
visits O O
when O O
he O O
visits O O
his O O
family O O
in O O
this O O
area O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
Name O O
, O O
MD O O
patient O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
7 O O
: O O
24PM O O
EST O O
Author O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
Date O O
Discharge O O
Date O O
Surgery O O
Date O O
Date O O
: O O
Date O O
: O O
Date O O
: O O
  
Dictated O O
: O O
Date O O
4 O O
: O O
12 O O
P O O
Transcribed O O
: O O
Date O O
Location O O
: O O
Location O O
  
3 O O
: O O
01 O O
A O O
REPORT O O
OF O O
OPERATION O O
PREOPERATIVE O O
DIAGNOSIS O O
: O O
Burkitt's B-Indication B-Indication
lymphoma I-Indication I-Indication
group I-Indication I-Indication
B I-Indication I-Indication
. O O
  
POSTOPERATIVE O O
DIAGNOSIS O O
: O O
Burkitt's B-Indication B-Indication
lymphoma I-Indication I-Indication
group I-Indication I-Indication
B I-Indication I-Indication
. O O
  
NAME O O
OF O O
PROCEDURE O O
: O O
Administration O O
of O O
intrathecal B-Route B-Route
chemotherapy B-Drug B-Drug
with O O
methotrexate B-Drug B-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
and O O
hydrocortisone B-Drug B-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
and O O
10 O O
mL O O
of O O
normal O O
saline O O
. O O
  
SURGEON O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
ANESTHESIA O O
: O O
Moderate O O
sedation B-Indication B-Indication
with O O
Versed B-Drug B-Drug
and O O
fentanyl B-Drug B-Drug
. O O
  
ANESTHESIOLOGIST O O
: O O
Name O O
Name O O
, O O
MD O O
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
After O O
obtaining O O
consent O O
from O O
the O O
mother O O
, O O
the O O
patient O O
was O O
given O O
moderate O O
sedation O O
by O O
Dr O O
. O O
  
Name O O
, O O
which O O
he O O
tolerated O O
well O O
with O O
stable O O
vital O O
signs O O
and O O
oxygen O O
saturation O O
. O O
  
Using O O
strict O O
aseptic O O
technique O O
, O O
1% B-Dose B-Dose
lidocaine B-Drug B-Drug
was O O
infiltrated O O
in O O
L2 O O
- O O
L3 O O
for O O
local B-Indication B-Indication
anesthesia I-Indication I-Indication
. O O
  
Using O O
22 O O
- O O
gauge O O
3 O O
- O O
1 O O
/ O O
2 O O
inch O O
spinal O O
needle O O
, O O
lumbar O O
puncture O O
was O O
done O O
. O O
  
In O O
the O O
same O O
interspace O O
, O O
clear O O
CSF O O
was O O
obtained O O
, O O
which O O
was O O
collected O O
for O O
cell O O
count O O
, O O
protein O O
and O O
glucose O O
. O O
  
Chemotherapy B-Drug B-Drug
was O O
slowly O O
injected O O
through O O
the O O
spinal O O
needle O O
with O O
no O O
problems O O
. O O
  
Spinal O O
needle O O
was O O
removed O O
and O O
the O O
puncture O O
wound O O
was O O
covered O O
with O O
a O O
Band O O
- O O
Aid O O
. O O
  
The O O
patient O O
was O O
recovered O O
recumbent O O
for O O
30 O O
minutes O O
and O O
was O O
then O O
transferred O O
back O O
to O O
Named_Sites O O
for O O
his O O
continued O O
clinical O O
care O O
. O O
  
CSF O O
Analysis O O
: O O
3 O O
WBC O O
, O O
1 O O
RBC O O
, O O
2% O O
segs O O
, O O
64% O O
lymphs O O
, O O
14% O O
monos O O
. O O
  
CSF O O
protein O O
of O O
35 O O
, O O
CSF O O
glucose O O
of O O
54 O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
12 O O
: O O
49 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
Date O O
4 O O
: O O
51 O O
P O O
Transcribed O O
Date O O
  
: O O
: O O
5 O O
: O O
51 O O
P O O
DISCHARGE O O
SUMMARY O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
a O O
17 O O
- O O
year O O
- O O
old O O
male O O
with O O
a O O
history O O
of O O
Burkitt B-Indication B-Indication
lymphoma I-Indication I-Indication
group I-Indication I-Indication
B I-Indication I-Indication
diagnosed O O
in O O
Date O O
who O O
is O O
being O O
admitted O O
for O O
scheduled O O
chemotherapy B-Drug B-Drug
according O O
to O O
protocol B-PHI B-PHI
COG I-PHI I-PHI
5961 I-PHI I-PHI
. O O
  
In O O
general O O
, O O
Name O O
has O O
been O O
well O O
since O O
his O O
previous O O
admission O O
. O O
  
He O O
was O O
hospitalized O O
in O O
the O O
end O O
of O O
Date O O
for O O
an O O
acute O O
episode O O
of O O
mania B-ADE B-ADE
, O O
suicidal B-ADE B-ADE
ideation I-ADE I-ADE
and O O
rapid B-ADE B-ADE
cycling I-ADE I-ADE
, O O
which O O
was O O
thought O O
to O O
be O O
due O O
to O O
discontinuation O O
of O O
steroids B-Drug B-Drug
and O O
increased O O
Ativan B-Drug B-Drug
use O O
since O O
then O O
he O O
has O O
had O O
no O O
further O O
psychiatric O O
symptoms O O
and O O
has O O
been O O
feeling O O
well O O
. O O
  
At O O
present O O
, O O
he O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
any O O
URI B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
, O O
rashes B-SSLIF B-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
or O O
mouth B-SSLIF B-SSLIF
sores I-SSLIF I-SSLIF
. O O
  
There O O
were O O
no O O
sick O O
contacts O O
. O O
  
He O O
has O O
a O O
history O O
of O O
occasional O O
headaches B-Indication B-Indication
, O O
which O O
have O O
improved O O
since O O
he O O
was O O
started O O
on O O
Zyrtec B-Drug B-Drug
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Otherwise O O
, O O
negative O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
status O O
post O O
resection O O
of O O
mesenteric O O
mass O O
on O O
Date O O
, O O
status O O
post O O
double O O
lumen O O
Broviac O O
placement O O
Date O O
, O O
history O O
of O O
ADHD B-SSLIF B-SSLIF
. O O
  
DEVELOPMENTAL O O
HISTORY O O
: O O
No O O
issues O O
. O O
  
MEDICATIONS O O
: O O
Amitriptyline B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
Prilosec B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
Tylenol B-Drug B-Drug
#3 I-Drug I-Drug
p.r.n. B-Frequency B-Frequency
, O O
Bactrim B-Drug B-Drug
DS I-Drug I-Drug
one B-Dose B-Dose
tab I-Dose I-Dose
p.o. B-Route B-Route
b.i.d. B-Frequency B-Frequency
on I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, I-Frequency I-Frequency
Saturday I-Frequency I-Frequency
, I-Frequency I-Frequency
Sunday I-Frequency I-Frequency
; O O
Zyrtec B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
q.a.m. B-Frequency B-Frequency
, O O
Peridex B-Drug B-Drug
mouthwash B-Route B-Route
t.i.d. B-Frequency B-Frequency
  
ALLERGIES O O
: O O
Amoxicillin B-Drug B-Drug
- O O
rash B-ADE B-ADE
. O O
  
( O O
adverse B-ADE B-ADE
reaction I-ADE I-ADE
to O O
Reglan B-Drug B-Drug
; O O
lactose B-ADE B-ADE
intolerance I-ADE I-ADE
) O O
DIET O O
: O O
Regular O O
. O O
  
IMMUNIZATIONS O O
: O O
Up O O
- O O
to O O
- O O
date O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Father O O
with O O
a O O
history O O
of O O
melanoma B-SSLIF B-SSLIF
and O O
basal B-SSLIF B-SSLIF
cell I-SSLIF I-SSLIF
carcinoma I-SSLIF I-SSLIF
. O O
  
Otherwise O O
, O O
noncontributory O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
Name O O
lives O O
with O O
his O O
mother O O
, O O
father O O
, O O
16 O O
- O O
year O O
- O O
old O O
brother O O
, O O
an O O
11 O O
- O O
year O O
- O O
old O O
sister O O
in O O
City O O
, O O
State O O
/ O O
Zipcode O O
. O O
  
He O O
is O O
in O O
high O O
school O O
. O O
  
He O O
plans O O
to O O
attend O O
Named_Sites O O
after O O
graduation O O
.. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Upon O O
admission O O
; O O
temperature O O
36 O O
, O O
heart O O
rate O O
111 O O
, O O
respiratory O O
rate O O
18 O O
, O O
blood O O
pressure O O
121 O O
/ O O
87 O O
, O O
oxygen O O
saturation O O
97% O O
on O O
room O O
air O O
. O O
  
General O O
: O O
He O O
is O O
a O O
well O O
- O O
appearing O O
male O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Normocephalic O O
and O O
atraumatic B-SSLIF B-SSLIF
. O O
  
No O O
oral B-SSLIF B-SSLIF
lesions I-SSLIF I-SSLIF
noted O O
. O O
  
Mucous O O
membranes O O
moist O O
. O O
  
Neck O O
: O O
Supple O O
, O O
no O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
Heart O O
: O O
Regular O O
rate O O
and O O
rhythm O O
, O O
no O O
murmurs B-SSLIF B-SSLIF
. O O
  
Lungs O O
: O O
Clear O O
to O O
auscultation O O
bilaterally O O
. O O
  
Abdomen O O
: O O
Soft O O
, O O
surgical O O
scar O O
with O O
dressing O O
in O O
place O O
, O O
clean O O
, O O
dry O O
and O O
intact O O
. O O
  
GU O O
: O O
Deferred O O
. O O
  
Extremities O O
: O O
Warm O O
and O O
well O O
perfused O O
. O O
  
Neurologic O O
: O O
Grossly O O
intact O O
. O O
  
Skin O O
: O O
No O O
rashes B-SSLIF B-SSLIF
or O O
lesions B-SSLIF B-SSLIF
noted O O
. O O
  
LABORATORY O O
DATA O O
ON O O
ADMISSION O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
4.9 O O
, O O
hemoglobin O O
12.1 O O
, O O
hematocrit O O
35.3 O O
, O O
platelets O O
272 O O
, O O
000 O O
, O O
ANC O O
3600 O O
. O O
  
BMP O O
: O O
Sodium O O
140 O O
, O O
potassium O O
4.4 O O
, O O
chloride O O
106 O O
, O O
bicarbonate O O
27 O O
, O O
BUN O O
9 O O
, O O
creatinine O O
0.85 O O
, O O
glucose O O
111 O O
, O O
calcium O O
9.5 O O
, O O
phosphorus O O
5.1 O O
, O O
magnesium O O
2.3 O O
, O O
albumin O O
3.9 O O
, O O
total O O
bilirubin O O
0.5 O O
, O O
alkaline O O
phosphatase O O
102 O O
, O O
AST O O
18 O O
, O O
ALT O O
31 O O
, O O
LDH O O
192 O O
. O O
  
HISTORY O O
OF O O
HOSPITALIZATION O O
BY O O
ORGAN O O
SYSTEM O O
: O O
  
1. O O
Hematology O O
/ O O
oncology O O
: O O
Name O O
received O O
chemotherapy B-Drug B-Drug
according O O
to O O
protocol B-PHI B-PHI
COG I-PHI I-PHI
5961 I-PHI I-PHI
with O O
high B-Dose B-Dose
- I-Dose I-Dose
dose I-Dose I-Dose
methotrexate B-Drug B-Drug
on O O
day O O
1 O O
( O O
with O O
leucovorin B-Drug B-Drug
rescue O O
) O O
, O O
IT B-Route B-Route
chemotherapy B-Drug B-Drug
on O O
day O O
#2 O O
and O O
7 O O
, O O
and O O
cytarabine B-Drug B-Drug
on O O
days O O
2 O O
- O O
6 O O
. O O
  
There O O
were O O
no O O
complications O O
from O O
his O O
chemotherapy B-Drug B-Drug
. O O
  
2. O O
FEN O O
/ O O
GI O O
: O O
Name O O
was O O
kept O O
on O O
a O O
regular O O
diet O O
. O O
  
He O O
received O O
Zofran B-Drug B-Drug
and O O
scopolamine B-Drug B-Drug
for O O
nausea B-Indication B-Indication
. O O
  
He O O
received O O
Prilosec B-Drug B-Drug
for O O
reflux B-Indication B-Indication
. O O
  
He O O
was O O
continued O O
on O O
lactaid B-Drug B-Drug
for O O
lactose B-Indication B-Indication
intolerance I-Indication I-Indication
. O O
  
He O O
received O O
Peridex B-Drug B-Drug
t.i.d. B-Frequency B-Frequency
for O O
mouth B-Indication B-Indication
care I-Indication I-Indication
. O O
  
He O O
was O O
on O O
IV B-SSLIF B-SSLIF
hydration I-SSLIF I-SSLIF
with O O
D5W O O
+50 B-Dose B-Dose
mEq I-Dose I-Dose
of O O
sodium B-Drug B-Drug
bicarbonate I-Drug I-Drug
per O O
liter O O
at O O
270 B-Frequency B-Frequency
mL I-Frequency I-Frequency
/ I-Frequency I-Frequency
hour I-Frequency I-Frequency
. O O
  
3. O O
Infectious O O
diseases O O
. O O
  
Bactrim B-Drug B-Drug
prophylaxis B-Indication B-Indication
held O O
on O O
admission O O
due O O
to O O
methotrexate B-Drug B-Drug
. O O
  
He O O
was O O
started O O
on O O
fluconazole B-Drug B-Drug
200 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
x O O
1 B-Frequency B-Frequency
and O O
then O O
100 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
x O O
9 B-Duration B-Duration
days I-Duration I-Duration
as O O
well O O
as O O
nystatin B-Drug B-Drug
cream B-Dose B-Dose
to O O
his O O
groin O O
area O O
for O O
candidal B-Indication B-Indication
rash I-Indication I-Indication
  
4. O O
Neuro O O
: O O
Name O O
was O O
treated O O
with O O
Tylenol B-Drug B-Drug
for O O
pain B-Indication B-Indication
or O O
fevers B-Indication B-Indication
. O O
  
He O O
was O O
maintained O O
on O O
his O O
home O O
amitriptyline B-Drug B-Drug
  
5. O O
Renal O O
: O O
No O O
evidence O O
of O O
renal B-SSLIF B-SSLIF
insufficiency I-SSLIF I-SSLIF
. O O
  
6. O O
Cardiovascular O O
: O O
Name O O
was O O
hemodynamically O O
stable O O
throughout O O
this O O
admission O O
. O O
  
7. O O
Pulmonary O O
. O O
  
Name O O
had O O
no O O
respiratory B-SSLIF B-SSLIF
issues I-SSLIF I-SSLIF
during O O
this O O
admission O O
. O O
  
He O O
was O O
on O O
room O O
air O O
throughout O O
the O O
entire O O
hospitalization O O
. O O
  
DISCHARGE O O
diagnosis O O
: O O
Burkitt's B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
DISCHARGE O O
MEDICATIONS O O
: O O
  
1. O O
Amitriptyline B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
. O O
  
2. O O
Chlorhexidine B-Drug B-Drug
15 B-Dose B-Dose
mL I-Dose I-Dose
t.i.d. B-Frequency B-Frequency
  
3. O O
Tylenol B-Drug B-Drug
No. I-Drug I-Drug
3 I-Drug I-Drug
p.o. B-Route B-Route
q.4 B-Frequency B-Frequency
h. I-Frequency I-Frequency
p.r.n. I-Frequency I-Frequency
pain B-Indication B-Indication
. O O
  
4. O O
Fluconazole B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
through O O
Date O O
. O O
  
5. O O
Lactase B-Drug B-Drug
6000 B-Dose B-Dose
units I-Dose I-Dose
p.o. B-Route B-Route
t.i.d. B-Frequency B-Frequency
  
6. O O
Miconazole B-Drug B-Drug
powder O O
apply O O
to O O
groin O O
t.i.d. B-Frequency B-Frequency
  
7. O O
Omeprazole B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
8. O O
Bactrim B-Drug B-Drug
DS I-Drug I-Drug
1 B-Dose B-Dose
tablet I-Dose I-Dose
p.o. B-Route B-Route
b.i.d. B-Frequency B-Frequency
on I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, I-Frequency I-Frequency
Saturday I-Frequency I-Frequency
and I-Frequency I-Frequency
Sunday I-Frequency I-Frequency
. O O
  
9. O O
Zyrtec B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
q.a.m. B-Frequency B-Frequency
  
DISCHARGE O O
INSTRUCTIONS O O
: O O
Home O O
health O O
nurse O O
will O O
draw O O
Name O O
CBC O O
with O O
diff O O
on O O
Date O O
, O O
Date O O
and O O
Date O O
; O O
the O O
results O O
will O O
be O O
faxed O O
to O O
# O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
. O O
  
Name O O
next O O
plan O O
admission O O
will O O
be O O
Date O O
at O O
6 O O
: O O
00 O O
p.m. O O
pending O O
blood O O
count O O
recovery O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
16 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
Name O O
Name O O
, O O
MD O O
  
Named_Sites O O
  
Street_Address O O
City O O
, O O
State O O
/ O O
Zipcode O O
RE O O
: O O
Name O O
, O O
Name O O
Hospital O O
# O O
: O O
Medical_Record_Number O O
Dear O O
Dr O O
. O O
  
Name O O
: O O
  
I O O
had O O
the O O
pleasure O O
of O O
taking O O
care O O
of O O
your O O
patient O O
, O O
Name O O
Name O O
, O O
today O O
. O O
  
He O O
went O O
to O O
the O O
OR O O
and O O
underwent O O
removal O O
of O O
his O O
left O O
subclavian O O
Broviac O O
due O O
to O O
completion O O
of O O
his O O
chemotherapy B-Drug B-Drug
. O O
  
He O O
tolerated O O
the O O
procedure O O
without O O
any O O
difficulty O O
and O O
will O O
be O O
discharged O O
home O O
later O O
today O O
. O O
  
I O O
will O O
see O O
him O O
back O O
in O O
clinic O O
in O O
the O O
next O O
couple O O
of O O
weeks O O
. O O
  
I O O
have O O
enjoyed O O
taking O O
care O O
of O O
Name O O
. O O
  
Please O O
call O O
me O O
with O O
any O O
questions O O
regarding O O
his O O
care O O
. O O
  
Sincerely O O
, O O
Name O O
Name O O
, O O
MD O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
15 O O
: O O
28 O O
  
D O O
: O O
Date O O
  
T O O
: O O
Date O O
9 O O
: O O
13 O O
P O O
  
Medical_Record_Number O O
cc O O
: O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
Date O O
Discharge O O
Surgery O O
Date O O
Date O O
: O O
Date O O
: O O
Date O O
: O O
  
Dictated O O
: O O
Date O O
4 O O
: O O
17 O O
P O O
Transcribed O O
: O O
Date O O
Location O O
: O O
Location O O
  
5 O O
: O O
36 O O
P O O
REPORT O O
OF O O
OPERATION O O
PREOPERATIVE O O
DIAGNOSIS O O
: O O
Mesenteric B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
POSTOPERATIVE O O
DIAGNOSIS O O
: O O
Mesenteric B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
PROCEDURES O O
: O O
Exploratory O O
laparotomy O O
and O O
cecectomy O O
and O O
resection O O
of O O
mesenteric B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
. O O
  
SURGEON O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
ASSISTANT O O
: O O
Dr O O
. O O
  
Name O O
Name O O
, O O
PGY1 O O
. O O
  
ANESTHESIA O O
: O O
General O O
endotracheal O O
. O O
  
FINDINGS O O
: O O
Hard B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
mesentery I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
terminal I-SSLIF I-SSLIF
ileum I-SSLIF I-SSLIF
. O O
  
DESCRIPTION O O
OF O O
PROCEDURE O O
: O O
After O O
consent O O
was O O
obtained O O
, O O
the O O
patient O O
was O O
taken O O
to O O
the O O
OR O O
, O O
and O O
placed O O
on O O
the O O
table O O
. O O
  
Anesthesia O O
was O O
induced O O
, O O
an O O
NG O O
tube O O
was O O
placed O O
. O O
  
A O O
Foley O O
was O O
placed O O
. O O
  
His O O
abdomen O O
was O O
prepped O O
and O O
draped O O
in O O
sterile O O
fashion O O
. O O
  
After O O
proper O O
timeout O O
and O O
patient O O
safety O O
check O O
were O O
performed O O
, O O
an O O
incision O O
was O O
made O O
inferior O O
to O O
the O O
umbilicus O O
. O O
  
Dissection O O
continued O O
down O O
through O O
the O O
tissue O O
and O O
into O O
the O O
abdomen O O
. O O
  
A O O
12 O O
mm O O
trocar O O
was O O
entered O O
in O O
the O O
abdomen O O
. O O
  
The O O
abdomen O O
was O O
then O O
insufflated O O
to O O
50 O O
mm O O
of O O
pressure O O
. O O
  
Two O O
additional O O
trocars O O
were O O
placed O O
, O O
one O O
in O O
the O O
left O O
lower O O
quadrant O O
, O O
one O O
in O O
the O O
suprapubic O O
space O O
. O O
  
We O O
then O O
began O O
to O O
mobilize O O
the O O
bowel O O
. O O
  
We O O
identified O O
the O O
mass B-SSLIF B-SSLIF
; O O
it O O
was O O
hard O O
and O O
matted O O
. O O
  
It O O
did O O
not O O
look O O
like O O
lymph B-SSLIF B-SSLIF
nodes I-SSLIF I-SSLIF
. O O
  
Because O O
we O O
could O O
not O O
fully O O
characterize O O
the O O
mass B-SSLIF B-SSLIF
this O O
way O O
, O O
we O O
determined O O
that O O
we O O
should O O
open O O
. O O
  
We O O
then O O
made O O
a O O
lower O O
midline O O
incision O O
and O O
entered O O
into O O
the O O
abdomen O O
. O O
  
We O O
mobilized O O
the O O
right O O
colon O O
and O O
brought O O
the O O
terminal O O
ileum O O
and O O
the O O
right O O
colon O O
into O O
wound O O
. O O
  
The O O
mass B-SSLIF B-SSLIF
was I-SSLIF I-SSLIF
hard I-SSLIF I-SSLIF
noncystic I-SSLIF I-SSLIF
like O O
, O O
there O O
were O O
a O O
couple O O
of O O
other O O
enlarged B-Severity B-Severity
lymph B-SSLIF B-SSLIF
nodes I-SSLIF I-SSLIF
towards I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
base I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
mesentery I-SSLIF I-SSLIF
that O O
were O O
not O O
involved O O
in O O
the O O
mass B-SSLIF B-SSLIF
. O O
  
We O O
were O O
unable O O
to O O
fully O O
characterize O O
it O O
, O O
but O O
it O O
did O O
not O O
look O O
normal O O
and O O
did O O
look O O
somewhat O O
necrotic O O
so O O
at O O
this O O
point O O
, O O
we O O
decided O O
to O O
do O O
an O O
ileocecectomy O O
. O O
  
Prior O O
to O O
doing O O
this O O
, O O
we O O
ran O O
the O O
remainder O O
of O O
the O O
bowel O O
. O O
  
There O O
were O O
no O O
further O O
masses B-SSLIF B-SSLIF
or O O
evidence O O
for O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
We O O
then O O
palpated O O
the O O
liver O O
and O O
it O O
was O O
smooth O O
. O O
  
We O O
palpated O O
the O O
underside O O
of O O
the O O
peritoneum O O
and O O
it O O
was O O
smooth O O
with O O
no O O
evidence O O
of O O
implants O O
. O O
  
We O O
palpated O O
the O O
spleen O O
and O O
also O O
felt O O
normal O O
in O O
size O O
and O O
smooth O O
. O O
  
We O O
then O O
used O O
the O O
GIA O O
stapler O O
to O O
transect O O
the O O
ileum O O
about O O
5 O O
cm O O
from O O
the O O
ileocecal O O
valve O O
and O O
we O O
transected O O
the O O
right O O
colon O O
in O O
the O O
middle O O
of O O
its O O
aspect O O
. O O
  
The O O
mesentery O O
was O O
tied O O
off O O
using O O
3 O O
- O O
0 O O
silk O O
and O O
the O O
specimen O O
was O O
removed O O
from O O
the O O
wound O O
and O O
sent O O
to O O
pathology O O
for O O
frozen O O
section O O
. O O
  
In O O
frozen O O
section O O
, O O
they O O
determined O O
it O O
looked O O
mostly O O
like O O
a O O
lymphoid B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
of O O
undetermined O O
significance O O
that O O
would O O
require O O
further O O
staining O O
. O O
  
After O O
assurance O O
of O O
hemostasis O O
, O O
we O O
then O O
resected O O
both O O
staple O O
lines O O
and O O
used O O
a O O
GIA O O
stapler O O
to O O
perform O O
a O O
side O O
- O O
to O O
- O O
side O O
anastomosis O O
between O O
the O O
terminal O O
ileum O O
and O O
the O O
right O O
colon O O
. O O
  
After O O
this O O
, O O
we O O
closed O O
the O O
remaining O O
enterotomy O O
using O O
first O O
a O O
running O O
stitch O O
of O O
3 O O
- O O
0 O O
Vicryl O O
and O O
then O O
Lembert O O
stitches O O
of O O
3 O O
- O O
0 O O
silk O O
. O O
  
The O O
mesenteric O O
defect O O
was O O
closed O O
using O O
running O O
stitches O O
of O O
3 O O
- O O
0 O O
Vicryl O O
. O O
  
We O O
changed O O
gloves O O
and O O
then O O
irrigated O O
the O O
abdomen O O
with O O
copious O O
amounts O O
of O O
saline O O
. O O
  
The O O
bowel O O
was O O
returned O O
into O O
the O O
abdomen O O
. O O
  
The O O
fascia O O
was O O
then O O
closed O O
using O O
#1 O O
PDS O O
and O O
the O O
skin O O
was O O
closed O O
using O O
staples O O
. O O
  
The O O
wound O O
was O O
dressed O O
with O O
a O O
nylon O O
, O O
dressing O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
without O O
complications O O
, O O
transferred O O
to O O
PACU O O
. O O
  
All O O
counts O O
were O O
correct O O
at O O
the O O
end O O
of O O
case O O
. O O
  
I O O
was O O
present O O
and O O
scrubbed O O
for O O
the O O
entire O O
procedure O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
MD O O
Date O O
09 O O
: O O
42 O O
  
____________________________ O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
7 O O
: O O
20 O O
P O O
  
3 O O
: O O
29 O O
P O O
CLINIC O O
NOTE O O
PRIMARY O O
CARE O O
PHYSICIAN O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
an O O
18 O O
- O O
year O O
- O O
old O O
with O O
history O O
of O O
group O O
B O O
abdominal B-SSLIF B-SSLIF
Burkitt I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
who O O
is O O
11 O O
months O O
off O O
therapy O O
and O O
comes O O
to O O
Pediatric O O
Oncology O O
Survivor's O O
Clinic O O
for O O
interval O O
evaluation O O
. O O
  
Name O O
was O O
last O O
seen O O
in O O
Pediatric O O
Oncology O O
Clinic O O
on O O
Date O O
. O O
  
Since O O
that O O
clinic O O
visit O O
, O O
according O O
to O O
Name O O
and O O
his O O
mother O O
who O O
accompanies O O
him O O
, O O
he O O
is O O
doing O O
much O O
better O O
. O O
  
His O O
diarrhea B-SSLIF B-SSLIF
markedly O O
improved O O
after O O
Dr O O
. O O
  
Name O O
, O O
pediatric O O
GI O O
, O O
started O O
him O O
on O O
amitriptyline B-Drug B-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
for O O
functional B-Indication B-Indication
diarrhea I-Indication I-Indication
. O O
  
He O O
is O O
now O O
eating O O
normally O O
and O O
having O O
1 O O
- O O
2 O O
bowel O O
movements O O
a O O
day O O
. O O
  
According O O
to O O
him O O
, O O
he O O
is O O
now O O
able O O
to O O
lead O O
a O O
normal O O
life O O
. O O
  
In O O
the O O
last O O
three O O
months O O
, O O
he O O
has O O
been O O
diagnosed O O
with O O
bipolar B-Indication B-Indication
disorder I-Indication I-Indication
and O O
Ritalin B-Drug B-Drug
was O O
discontinued O O
and O O
Lamictal B-Drug B-Drug
was O O
added O O
. O O
  
According O O
to O O
the O O
mother O O
, O O
his O O
anger B-SSLIF B-SSLIF
has O O
improved O O
after O O
the O O
start O O
of O O
Lamictal B-Drug B-Drug
which O O
is O O
on O O
a O O
slow O O
escalation O O
. O O
  
He O O
is O O
much O O
more O O
social O O
, O O
currently O O
working O O
as O O
a O O
short O O
order O O
cook O O
preparing O O
desserts O O
and O O
salads O O
at O O
Named_Sites O O
and O O
he O O
is O O
looking O O
forward O O
to O O
starting O O
college O O
at O O
Named_Sites O O
in O O
Date O O
. O O
  
He O O
is O O
on O O
target O O
to O O
do O O
that O O
, O O
he O O
is O O
saving O O
up O O
money O O
to O O
get O O
a O O
car O O
. O O
  
No O O
history O O
of O O
fever B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
cold B-SSLIF B-SSLIF
, O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
, O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
, O O
dizziness B-SSLIF B-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
is O O
off O O
Bactrim B-Drug B-Drug
: O O
He O O
is O O
allergic B-ADE B-ADE
to O O
amoxicillin B-Drug B-Drug
and O O
Reglan B-Drug B-Drug
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
Negative O O
except O O
for O O
runny B-SSLIF B-SSLIF
stools I-SSLIF I-SSLIF
, O O
but O O
only O O
twice O O
a O O
day O O
and O O
occasional O O
outburst B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
anger I-SSLIF I-SSLIF
. O O
  
MEDICATIONS O O
: O O
  
1. O O
Clindamycin B-Drug B-Drug
300 B-Dose B-Dose
mg I-Dose I-Dose
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
that O O
he O O
is O O
taking O O
a O O
10 B-Duration B-Duration
- I-Duration I-Duration
day I-Duration I-Duration
course O O
for O O
folliculitis B-Indication B-Indication
on I-Indication I-Indication
his I-Indication I-Indication
legs I-Indication I-Indication
that O O
he O O
started O O
two O O
days O O
ago O O
. O O
  
2. O O
Lamictal B-Drug B-Drug
12.5 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
for O O
bipolar B-Indication B-Indication
disorder I-Indication I-Indication
. O O
  
3. O O
Divalproex B-Drug B-Drug
500 B-Dose B-Dose
mg I-Dose I-Dose
tablet O O
two B-Dose B-Dose
tablets I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
4. O O
Seroquel B-Drug B-Drug
200 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
5. O O
Amitriptyline B-Drug B-Drug
15 B-Dose B-Dose
mg I-Dose I-Dose
p.o. B-Route B-Route
daily B-Frequency B-Frequency
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Reveals O O
alert O O
, O O
active O O
, O O
cooperative O O
young O O
man O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
Weight O O
of O O
108.3 O O
kg O O
, O O
which O O
is O O
slightly O O
up O O
, O O
height O O
187.4 O O
cm O O
, O O
BMI O O
30.97 O O
, O O
stable O O
. O O
  
Blood O O
pressure O O
133 O O
/ O O
82 O O
, O O
heart O O
rate O O
of O O
133 O O
, O O
temperature O O
98 O O
. O O
  
HEENT O O
: O O
Head O O
normocephalic O O
, O O
atraumatic O O
. O O
  
PERRL O O
, O O
EOMI O O
. O O
  
Tympanic O O
membranes O O
are O O
clear O O
. O O
  
Nasopharynx O O
shows O O
no O O
injection B-SSLIF B-SSLIF
, O O
no O O
redness B-SSLIF B-SSLIF
, O O
no O O
exudate B-SSLIF B-SSLIF
. O O
  
Neck O O
: O O
Supple O O
, O O
no O O
lymphadenopathy B-SSLIF B-SSLIF
. O O
  
Chest O O
is O O
clear O O
to O O
auscultation O O
, O O
good O O
air O O
entry O O
bilaterally O O
. O O
  
Heart O O
sounds O O
regular O O
sinus O O
rhythm O O
, O O
no O O
murmur B-SSLIF B-SSLIF
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender O O
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
bowel O O
sounds O O
are O O
positive O O
. O O
  
Skin O O
is O O
clear O O
except O O
for O O
the O O
laparotomy O O
scar O O
and O O
the O O
wound O O
dehiscence O O
scar O O
over O O
the O O
anterior O O
abdomen O O
, O O
mild B-Severity B-Severity
case O O
of O O
folliculitis B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
seen I-SSLIF I-SSLIF
over I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
, O O
no O O
major B-Severity B-Severity
pustules B-SSLIF B-SSLIF
. O O
  
ASSESSMENT O O
: O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
abdominal I-SSLIF I-SSLIF
group I-SSLIF I-SSLIF
B I-SSLIF I-SSLIF
, O O
Off O O
- O O
therapy O O
for O O
11 O O
months O O
in O O
continued O O
clinical O O
remission O O
. O O
  
RECOMMENDATIONS O O
: O O
The O O
patient O O
is O O
close O O
to O O
one O O
year O O
off O O
therapy O O
. O O
  
We O O
will O O
continue O O
to O O
monitor O O
him O O
now O O
on O O
a O O
six O O
- O O
monthly O O
basis O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
18 O O
: O O
49 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
Name O O
Name O O
Name O O
, O O
MD O O
Hospital O O
  
Street_Address O O
City O O
, O O
State O O
/ O O
Zipcode O O
RE O O
: O O
Name O O
, O O
Name O O
Hospital O O
# O O
: O O
Medical_Record_Number O O
  
DOB O O
: O O
Date O O
  
DOS O O
: O O
Date O O
Dear O O
Name O O
: O O
  
I O O
saw O O
Name O O
Name O O
in O O
Pediatric O O
GI O O
Clinic O O
on O O
Date O O
. O O
  
Name O O
is O O
a O O
20 O O
- O O
year O O
- O O
old O O
who O O
is O O
status O O
post O O
resection O O
, O O
stage B-Severity B-Severity
III I-Severity I-Severity
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
as O O
well O O
as O O
recurring O O
abdominal B-Indication B-Indication
pain I-Indication I-Indication
, O O
which O O
seems O O
to O O
be O O
well O O
managed O O
on O O
20 B-Dose B-Dose
mg I-Dose I-Dose
amitriptyline B-Drug B-Drug
daily B-Frequency B-Frequency
. O O
  
He O O
also O O
is O O
on O O
fluoxetine B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
once B-Frequency B-Frequency
per I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
He O O
did O O
have O O
a O O
visit O O
with O O
Heme O O
- O O
Onc O O
at O O
the O O
Heme O O
- O O
Onc O O
Survivorship O O
Clinic O O
a O O
few O O
months O O
ago O O
. O O
  
He O O
is O O
doing O O
well O O
and O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
urgency B-SSLIF B-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
or O O
low B-SSLIF B-SSLIF
energy I-SSLIF I-SSLIF
. O O
  
He O O
noticeably O O
has O O
been O O
gaining O O
weight O O
. O O
  
He O O
is O O
up O O
to O O
117.8 O O
kg O O
. O O
  
He O O
attributes O O
this O O
as O O
part O O
in O O
that O O
he O O
is O O
going O O
to O O
culinary O O
school O O
at O O
this O O
present O O
time O O
and O O
is O O
enjoying O O
it O O
very O O
much O O
and O O
is O O
home O O
for O O
the O O
summer O O
presently O O
. O O
  
He O O
otherwise O O
is O O
doing O O
well O O
, O O
has O O
no O O
complaints O O
. O O
  
Review O O
of O O
systems O O
: O O
Negative O O
other O O
than O O
above O O
for O O
12 O O
points O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
His O O
height O O
was O O
188.3 O O
cm O O
, O O
blood O O
pressure O O
141 O O
/ O O
84 O O
, O O
pulse O O
  
81. O O
General O O
: O O
Appeared O O
somewhat O O
obese O O
, O O
awake O O
, O O
alert O O
, O O
in O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
, O O
cooperative O O
with O O
examination O O
. O O
  
General O O
: O O
Appeared O O
nourished O O
, O O
awake O O
, O O
alert O O
, O O
no O O
apparent O O
distress B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
  
ATNC O O
, O O
waering O O
glasses O O
, O O
PERRL O O
, O O
no O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
, O O
mucous O O
membranes O O
moist O O
, O O
no O O
pharyngeal B-SSLIF B-SSLIF
erythema I-SSLIF I-SSLIF
. O O
  
Neck O O
is O O
supple O O
, O O
no O O
cervical B-SSLIF B-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
. O O
  
Chest O O
: O O
  
Clear O O
to O O
auscultation O O
bilaterally O O
, O O
no O O
wheezes B-SSLIF B-SSLIF
, O O
crackle B-SSLIF B-SSLIF
, O O
crepitations B-SSLIF B-SSLIF
. O O
  
Heart O O
: O O
  
S1 O O
, O O
S2 O O
and O O
rhythm O O
, O O
no O O
murmurs B-SSLIF B-SSLIF
appreciated O O
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
nondistended B-SSLIF B-SSLIF
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
good O O
bowel O O
sounds O O
. O O
  
Abdomen O O
with O O
old O O
surgical O O
healed O O
scar O O
, O O
IMPRESSION O O
: O O
  
1. O O
Functional B-SSLIF B-SSLIF
abdominal I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
and O O
diarrhea B-SSLIF B-SSLIF
- O O
Given O O
his O O
weight O O
gain O O
, O O
I O O
do O O
feel O O
that O O
this O O
is O O
a O O
good O O
sign O O
that O O
his O O
GI O O
tract O O
is O O
functioning O O
and O O
much O O
of O O
the O O
weight O O
gain O O
must O O
be O O
due O O
to O O
the O O
fact O O
that O O
he O O
sampling O O
a O O
lot O O
of O O
his O O
own O O
foods O O
and O O
says O O
that O O
is O O
not O O
atypical O O
for O O
most O O
new O O
students O O
at O O
his O O
culinary O O
school O O
to O O
gain O O
quite O O
a O O
bit O O
of O O
weight O O
during O O
the O O
first O O
year O O
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
He O O
is O O
otherwise O O
doing O O
very O O
well O O
at O O
present O O
dose O O
of O O
Amitriptyline B-Drug B-Drug
, O O
of O O
which O O
I O O
do O O
not O O
want O O
to O O
change O O
currently O O
as O O
of O O
yet O O
since O O
it O O
is O O
working O O
well O O
. O O
  
2. O O
Follow O O
- O O
up O O
in O O
a O O
years' O O
time O O
. O O
  
Thank O O
you O O
for O O
allowing O O
me O O
to O O
see O O
this O O
patient O O
. O O
  
If O O
you O O
have O O
questions O O
or O O
concerns O O
, O O
please O O
do O O
not O O
hesitate O O
to O O
contact O O
me O O
. O O
  
Sincerely O O
, O O
Name O O
Name O O
Name O O
, O O
MD O O
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
16 O O
: O O
20 O O
  
D O O
: O O
Date O O
  
T O O
: O O
Date O O
3 O O
: O O
24 O O
P O O
  
Medical_Record_Number O O
cc O O
: O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
Discharge O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
Date O O
10 O O
: O O
54 O O
P O O
Transcribed O O
Date O O
  
: O O
: O O
11 O O
: O O
45 O O
P O O
DISCHARGE O O
SUMMARY O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
. O O
  
DATE O O
OF O O
DISCHARGE O O
: O O
Date O O
. O O
  
CHIEF O O
COMPLAINT O O
: O O
Routine O O
chemotherapy B-Drug B-Drug
for O O
Burkitt B-Indication B-Indication
lymphoma I-Indication I-Indication
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
is O O
an O O
18 O O
- O O
year O O
- O O
old O O
male O O
diagnosed O O
with O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
4 O O
months O O
ago O O
. O O
  
At O O
this O O
time O O
, O O
his O O
symptoms O O
include O O
1 O O
- O O
month O O
of O O
diarrhea B-SSLIF B-SSLIF
, O O
a O O
20 B-Severity B-Severity
- I-Severity I-Severity
pound I-Severity I-Severity
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
and O O
severe B-Severity B-Severity
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
He O O
was O O
worked O O
up O O
for O O
IBD B-SSLIF B-SSLIF
and O O
incidentally O O
found O O
to O O
have O O
an O O
abdominal B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
which O O
was O O
_____ O O
and O O
he O O
was O O
diagnosed O O
with O O
Burkitt B-Indication B-Indication
lymphoma I-Indication I-Indication
. O O
  
He O O
has O O
had O O
several O O
courses O O
of O O
chemotherapy B-Drug B-Drug
todate O O
, O O
the O O
last O O
was O O
Date O O
- O O
Date O O
. O O
  
He O O
has O O
had O O
no O O
problems O O
or O O
complications O O
since O O
that O O
time O O
and O O
reports O O
feeling O O
well O O
recently O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
He O O
denies O O
fever B-SSLIF B-SSLIF
, O O
weight B-SSLIF B-SSLIF
loss I-SSLIF I-SSLIF
or O O
headache B-SSLIF B-SSLIF
. O O
  
No O O
oral B-SSLIF B-SSLIF
ulcers I-SSLIF I-SSLIF
or O O
sore B-SSLIF B-SSLIF
throat I-SSLIF I-SSLIF
. O O
  
No O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
or O O
palpitations B-SSLIF B-SSLIF
. O O
  
No O O
nausea B-SSLIF B-SSLIF
, O O
vomiting B-SSLIF B-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
or O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
No O O
cough B-SSLIF B-SSLIF
, O O
no O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
No O O
dysuria B-SSLIF B-SSLIF
. O O
  
No O O
rashes B-SSLIF B-SSLIF
. O O
  
He O O
does O O
note O O
some O O
mild B-Severity B-Severity
shot B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
term I-SSLIF I-SSLIF
memory I-SSLIF I-SSLIF
loss I-SSLIF I-SSLIF
and O O
increased B-SSLIF B-SSLIF
sensation I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
hot I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
on O O
his O O
skin O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
He O O
has O O
no O O
medical O O
history O O
prior O O
to O O
his O O
Burkitt B-SSLIF B-SSLIF
diagnosis O O
. O O
  
PAST O O
SURGICAL O O
HISTORY O O
: O O
His O O
surgical O O
history O O
includes O O
an O O
ex O O
- O O
lap O O
resection O O
of O O
mesenteric B-SSLIF B-SSLIF
mass I-SSLIF I-SSLIF
and O O
ileocecostomy O O
on O O
Date O O
. O O
  
DEVELOPMENTAL O O
HISTORY O O
: O O
He O O
has O O
born O O
full O O
- O O
term O O
as O O
a O O
spontaneous O O
vaginal O O
delivery O O
and O O
had O O
normal O O
development O O
. O O
  
MEDICATIONS O O
: O O
He O O
takes O O
lactade B-Drug B-Drug
; O O
Prilosec B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
; O O
Zyrtec B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
; O O
amitriptyline B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
q.h.s. B-Frequency B-Frequency
; O O
Ritalin B-Drug B-Drug
daily B-Frequency B-Frequency
and O O
Bactrim B-Drug B-Drug
on O O
Monday B-Frequency B-Frequency
, I-Frequency I-Frequency
Wednesdays I-Frequency I-Frequency
, I-Frequency I-Frequency
and I-Frequency I-Frequency
Fridays I-Frequency I-Frequency
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Amoxicillin B-Drug B-Drug
where O O
he O O
gets O O
a O O
rash B-ADE B-ADE
and O O
Reglan B-Drug B-Drug
. O O
  
DIET O O
: O O
Normal O O
and O O
variant O O
. O O
  
IMMUNIZATIONS O O
: O O
Up O O
- O O
to O O
- O O
date O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Colitis B-SSLIF B-SSLIF
and O O
Crohn's B-SSLIF B-SSLIF
on O O
both O O
maternal O O
and O O
paternal O O
sides O O
. O O
  
No O O
other O O
significant O O
family O O
history O O
. O O
  
SOCIAL O O
HISTORY O O
: O O
He O O
lives O O
at O O
home O O
with O O
mom O O
, O O
dad O O
, O O
his O O
brother O O
who O O
is O O
16 O O
and O O
his O O
sister O O
who O O
is O O
11 O O
. O O
  
He O O
is O O
looking O O
on O O
finishing O O
the O O
11th O O
grade O O
currently O O
with O O
help O O
of O O
a O O
tutor O O
. O O
  
He O O
is O O
interested O O
in O O
attending O O
Named_Sites O O
. O O
  
HOSPITAL O O
COURSE O O
BY O O
SYSTEM O O
: O O
  
1. O O
Hem O O
- O O
Onc O O
: O O
He O O
denies O O
any O O
18 O O
- O O
year O O
- O O
old O O
male O O
with O O
Burkitt B-Indication B-Indication
lymphoma I-Indication I-Indication
. O O
  
He O O
was O O
admitted O O
for O O
scheduled O O
chemotherapy B-Drug B-Drug
with I-Drug I-Drug
methotrexate I-Drug I-Drug
and I-Drug I-Drug
cytarabine I-Drug I-Drug
. O O
  
His O O
protocol O O
is O O
CCG5961 B-PHI B-PHI
and O O
he O O
is O O
in O O
the O O
group O O
B O O
treatment O O
plan O O
and O O
is O O
currently O O
off O O
study O O
. O O
  
He O O
is O O
on O O
cycle O O
CYM O O
- O O
2 O O
. O O
  
A O O
spinal O O
tap O O
was O O
performed O O
on O O
Date O O
and O O
Date O O
for O O
enter O O
the O O
goal O O
chemotherapy B-Drug B-Drug
. O O
  
He O O
again O O
tolerated O O
both O O
procedures O O
well O O
and O O
also O O
tolerated O O
the O O
chemotherapy B-Drug B-Drug
. O O
  
His O O
methotrexate B-Drug B-Drug
levels O O
and O O
kidney O O
functions O O
were O O
monitored O O
daily O O
and O O
he O O
was O O
given O O
leucovorin B-Drug B-Drug
until O O
his O O
_____ O O
level O O
decrease O O
to O O
the O O
desired O O
amount O O
. O O
  
He O O
is O O
to O O
followup O O
in O O
Hem O O
- O O
Onc O O
Clinic O O
as O O
scheduled O O
. O O
  
2. O O
GI O O
: O O
Name O O
received O O
pre O O
and O O
continuing O O
hydration O O
throughout O O
his O O
chemotherapy B-Drug B-Drug
. O O
  
While O O
receiving O O
methotrexate B-Drug B-Drug
his O O
urine O O
was O O
also O O
monitored O O
. O O
  
Name O O
did O O
have O O
some B-Severity B-Severity
nausea B-Indication B-Indication
that O O
was O O
refractory O O
to O O
these O O
scopolamine B-Drug B-Drug
patch B-Route B-Route
and O O
Zofran B-Drug B-Drug
and O O
was O O
additionally O O
give O O
a O O
dose O O
of O O
Benadryl B-Drug B-Drug
and O O
Compazine B-Drug B-Drug
. O O
  
He O O
noted O O
feeling O O
very B-Severity B-Severity
jittery B-ADE B-ADE
after O O
this O O
and O O
did O O
not O O
receive O O
another O O
dose O O
. O O
  
3. O O
ID O O
: O O
On O O
Date O O
Name O O
spiked O O
a O O
fever B-Indication B-Indication
to O O
39 O O
degree O O
Celsius O O
. O O
  
Blood O O
cultures O O
were O O
obtained O O
from O O
both O O
lumens O O
and O O
he O O
was O O
started O O
on O O
ceftriaxone B-Drug B-Drug
. O O
  
Both O O
blood O O
cultures O O
were O O
negative O O
and O O
the O O
antibiotics B-Drug B-Drug
were O O
stopped O O
. O O
  
4. O O
Derm O O
. O O
  
It O O
was O O
noted O O
on O O
Date O O
that O O
Name O O
developed O O
a O O
rash B-SSLIF B-SSLIF
. O O
  
It O O
is O O
believed O O
that O O
this O O
is O O
a O O
methotrexate B-Drug B-Drug
rash B-Indication B-Indication
and O O
he O O
was O O
given O O
Benadryl B-Drug B-Drug
after O O
which O O
his O O
symptoms O O
resolved O O
. O O
  
Name O O
also O O
developed O O
a O O
sty B-SSLIF B-SSLIF
within I-SSLIF I-SSLIF
his I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
eye I-SSLIF I-SSLIF
around O O
this O O
time O O
that O O
was O O
relieved O O
by O O
warm O O
compresses O O
. O O
  
FINAL O O
DIAGNOSIS O O
: O O
Burkitt B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
CONDITION O O
OF O O
PATIENT O O
ON O O
DISCHARGE O O
: O O
Good O O
. O O
  
DISCHARGE O O
INSTRUCTIONS O O
: O O
Include O O
moisturizing O O
the O O
abdominal O O
scar O O
as O O
directed O O
by O O
surgery O O
, O O
taking O O
oral O O
medications O O
as O O
directed O O
and O O
a O O
CT O O
is O O
scheduled O O
on O O
Date O O
. O O
  
Please O O
arrive O O
at O O
3 O O
: O O
30 O O
p.m. O O
for O O
these O O
4 O O
: O O
30 O O
p.m. O O
scan O O
. O O
  
Name O O
should O O
have O O
nothing O O
to O O
eat O O
or O O
drink O O
afternoon O O
of O O
that O O
day O O
. O O
  
He O O
is O O
also O O
to O O
followup O O
in O O
a O O
Pediatric O O
Oncology O O
Clinic O O
with O O
Dr O O
. O O
  
Name O O
on O O
Date O O
at O O
10 O O
: O O
30 O O
a.m. O O
  
DISCHARGE O O
MEDICATIONS O O
: O O
Include O O
; O O
  
1. O O
Amitriptyline B-Drug B-Drug
HCL B-Dose B-Dose
50 I-Dose I-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
. O O
  
2. O O
Peridex B-Drug B-Drug
5 B-Dose B-Dose
mL I-Dose I-Dose
mouth B-Route B-Route
wash I-Route I-Route
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
. O O
  
3. O O
Lactade B-Drug B-Drug
1 B-Dose B-Dose
- I-Dose I-Dose
3 I-Dose I-Dose
tablets I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
before B-Frequency B-Frequency
meals I-Frequency I-Frequency
3 I-Frequency I-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
4. O O
Prilosec B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
everyday B-Frequency B-Frequency
. O O
  
5. O O
Sulfamethoxazole B-Drug B-Drug
trimethoprim I-Drug I-Drug
1 B-Dose B-Dose
tablet I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
on I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, I-Frequency I-Frequency
Saturday I-Frequency I-Frequency
and I-Frequency I-Frequency
Sunday I-Frequency I-Frequency
. O O
  
6. O O
Zyrtec B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
by B-Route B-Route
mouth I-Route I-Route
every B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
14 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
Call O O
to O O
daughter O O
Name O O
regarding O O
Name O O
results O O
drawn O O
today O O
. O O
  
Hgb O O
/ O O
Hct O O
were O O
12.1 O O
/ O O
37.0 O O
, O O
retic O O
is O O
1.7 O O
. O O
  
Name O O
is O O
currently O O
on O O
5mg B-Dose B-Dose
Prednisone B-Drug B-Drug
daily B-Frequency B-Frequency
and O O
Cyclophosphamide B-Drug B-Drug
100mg B-Dose B-Dose
twice B-Frequency B-Frequency
weekly I-Frequency I-Frequency
with O O
50mg B-Dose B-Dose
5 B-Frequency B-Frequency
times I-Frequency I-Frequency
weekly I-Frequency I-Frequency
. O O
  
Per O O
Dr O O
Name O O
, O O
Name O O
will O O
decrease O O
the O O
Cyclophosphamide B-Drug B-Drug
to O O
50mg B-Dose B-Dose
6 B-Frequency B-Frequency
times I-Frequency I-Frequency
weekly I-Frequency I-Frequency
and O O
100mg B-Dose B-Dose
once B-Frequency B-Frequency
weekly I-Frequency I-Frequency
. O O
  
The O O
Prednisone B-Drug B-Drug
will O O
remain O O
the O O
same O O
. O O
  
Labs O O
will O O
be O O
redrawn O O
in O O
1 O O
week O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
City O O
R.N. O O
Date O O
4 O O
: O O
55PM O O
EST O O
Date O O
Name O O
Name O O
Name O O
, O O
M.D. O O
  
Street_Address O O
City O O
, O O
State O O
/ O O
Zipcode O O
RE O O
: O O
Name O O
, O O
Name O O
Hospital O O
# O O
: O O
Medical_Record_Number O O
DATE O O
OF O O
SERVICE O O
: O O
Date O O
DATE O O
OF O O
BIRTH O O
: O O
Date O O
Dear O O
Dr O O
. O O
  
Name O O
: O O
  
I O O
had O O
the O O
pleasure O O
of O O
seeing O O
Name O O
Name O O
for O O
followup O O
today O O
in O O
the O O
Cardiovascular O O
Clinic O O
with O O
Name O O
Name O O
. O O
  
As O O
you O O
know O O
, O O
she O O
is O O
a O O
very O O
pleasant O O
76 O O
- O O
year O O
- O O
old O O
female O O
that O O
I O O
originally O O
met O O
on O O
Date O O
. O O
  
She O O
has O O
been O O
followed O O
by O O
Dr O O
. O O
  
Name O O
for O O
management O O
of O O
her O O
hypertension B-SSLIF B-SSLIF
. O O
  
She O O
has O O
also O O
been O O
followed O O
by O O
several O O
providers O O
and O O
did O O
undergo O O
a O O
splenectomy O O
following O O
a O O
diagnosis O O
of O O
lymphoma B-SSLIF B-SSLIF
. O O
  
She O O
also O O
had O O
a O O
previous O O
thrombocytopenia B-SSLIF B-SSLIF
and O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
and O O
is O O
followed O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
In O O
Date O O
, O O
she O O
presented O O
with O O
hematochezia B-SSLIF B-SSLIF
and O O
a O O
colonoscopy O O
at O O
this O O
time O O
was O O
suspicious O O
for O O
ischemic B-SSLIF B-SSLIF
colitis I-SSLIF I-SSLIF
. O O
  
Following O O
her O O
hospitalization O O
, O O
she O O
was O O
seen O O
by O O
Dr O O
. O O
  
Name O O
and O O
was O O
reporting O O
increased O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
along O O
with O O
dyspnea B-SSLIF B-SSLIF
and O O
fatigue B-SSLIF B-SSLIF
. O O
  
She O O
was O O
also O O
noted O O
to O O
have O O
a O O
more O O
prominent O O
heart B-SSLIF B-SSLIF
murmur I-SSLIF I-SSLIF
. O O
  
A O O
repeat O O
echocardiogram O O
was O O
recommended O O
. O O
  
Her O O
prior O O
study O O
in O O
Date O O
demonstrated O O
a O O
normal O O
ejection O O
fraction O O
of O O
65% O O
. O O
  
There O O
was O O
mild B-Severity B-Severity
calcification B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
aortic I-SSLIF I-SSLIF
valve I-SSLIF I-SSLIF
leaflets I-SSLIF I-SSLIF
with O O
no O O
significant O O
abnormalities O O
. O O
  
There O O
was O O
trace B-Severity B-Severity
MR B-SSLIF B-SSLIF
and O O
moderate B-Severity B-Severity
TR B-SSLIF B-SSLIF
. O O
  
In O O
light O O
of O O
an O O
element O O
of O O
volume B-Indication B-Indication
overload I-Indication I-Indication
, O O
she O O
was O O
placed O O
on O O
Lasix B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
There O O
was O O
also O O
concern O O
that O O
her O O
outflow B-SSLIF B-SSLIF
murmur I-SSLIF I-SSLIF
could O O
be O O
secondary O O
to O O
her O O
anemia B-SSLIF B-SSLIF
. O O
  
Her O O
hematocrit O O
had O O
stabilized O O
at O O
31.4 O O
with O O
a O O
platelet O O
count O O
of O O
300 O O
, O O
000 O O
. O O
  
Her O O
echocardiogram O O
performed O O
on O O
Date O O
, O O
demonstrated O O
normal O O
ejection O O
fraction O O
along O O
with O O
evidence O O
of O O
diastolic B-SSLIF B-SSLIF
dysfunction I-SSLIF I-SSLIF
. O O
  
There O O
was O O
no O O
  
PFO B-SSLIF B-SSLIF
. O O
  
The O O
PA O O
systolic O O
pressures O O
were O O
in O O
the O O
range O O
of O O
36 O O
- O O
60 O O
mm O O
, O O
the O O
aortic B-SSLIF B-SSLIF
valve I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
bicuspid I-SSLIF I-SSLIF
with O O
mild B-Severity B-Severity
stenosis B-SSLIF B-SSLIF
, O O
regurgitation B-SSLIF B-SSLIF
. O O
  
The O O
mitral B-SSLIF B-SSLIF
valve I-SSLIF I-SSLIF
showed I-SSLIF I-SSLIF
mild I-SSLIF I-SSLIF
prolapse I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
posterior I-SSLIF I-SSLIF
leaflet I-SSLIF I-SSLIF
with O O
evidence O O
of O O
moderate B-Severity B-Severity
regurgitation B-SSLIF B-SSLIF
and O O
also O O
moderate B-Severity B-Severity
tricuspid B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
. O O
  
In O O
followup O O
she O O
had O O
reported O O
continued O O
episodes O O
of O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
was O O
sleeping O O
on O O
several O O
pillows O O
. O O
  
The O O
edema B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
had O O
essentially O O
resolved O O
. O O
  
She O O
had O O
previously O O
reported O O
that O O
the O O
swelling B-SSLIF B-SSLIF
had O O
increased O O
up O O
her O O
left O O
leg O O
. O O
  
At O O
this O O
time O O
, O O
I O O
did O O
recommend O O
that O O
we O O
continue O O
diuresis O O
and O O
advanced O O
her O O
furosemide B-Drug B-Drug
to O O
40 B-Dose B-Dose
mg I-Dose I-Dose
once B-Frequency B-Frequency
daily I-Frequency I-Frequency
. O O
  
We O O
were O O
questioning O O
whether O O
her O O
diastolic B-SSLIF B-SSLIF
dysfunction I-SSLIF I-SSLIF
could O O
have O O
resulted O O
in O O
fluid B-SSLIF B-SSLIF
retention I-SSLIF I-SSLIF
. O O
  
She O O
was O O
also O O
on O O
fairly O O
high O O
doses O O
of O O
prednisone B-Drug B-Drug
which O O
could O O
further O O
add O O
to O O
fluid B-ADE B-ADE
retention I-ADE I-ADE
. O O
  
It O O
appears O O
that O O
she O O
presented O O
to O O
the O O
hospital O O
on O O
Date O O
, O O
with O O
acute O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
had O O
diuresed O O
over O O
7 O O
pounds O O
; O O
however O O
, O O
her O O
symptoms O O
of O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
did O O
not O O
resolve O O
. O O
  
A O O
CT O O
of O O
her O O
chest O O
was O O
performed O O
which O O
showed O O
evidence O O
of O O
multiple O O
subsegmental B-Indication B-Indication
pulmonary I-Indication I-Indication
emboli I-Indication I-Indication
. O O
  
She O O
was O O
placed O O
on O O
heparin B-Drug B-Drug
and O O
transitioned O O
to O O
Lovenox B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
. O O
  
I O O
had O O
seen O O
her O O
in O O
followup O O
once O O
again O O
on O O
Date O O
, O O
and O O
at O O
this O O
time O O
, O O
she O O
reported O O
that O O
she O O
was O O
less O O
short B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
; O O
however O O
, O O
she O O
had O O
significant B-Severity B-Severity
swelling B-Indication B-Indication
to I-Indication I-Indication
both I-Indication I-Indication
of I-Indication I-Indication
her I-Indication I-Indication
lower I-Indication I-Indication
extremities I-Indication I-Indication
. O O
  
Her O O
weight B-Indication B-Indication
had I-Indication I-Indication
increased I-Indication I-Indication
by I-Indication I-Indication
approximately I-Indication I-Indication
15 I-Indication I-Indication
pounds I-Indication I-Indication
. O O
  
I O O
did O O
recommend O O
that O O
we O O
reinitiate O O
the O O
20 B-Dose B-Dose
mg I-Dose I-Dose
of O O
furosemide B-Drug B-Drug
. O O
  
The O O
etiology O O
of O O
her O O
pulmonary B-SSLIF B-SSLIF
embolization I-SSLIF I-SSLIF
was O O
unclear O O
. O O
  
I O O
did O O
recommend O O
a O O
same O O
day O O
venous O O
duplex O O
to O O
rule O O
out O O
any O O
possible O O
obstructive O O
source O O
of O O
her O O
edema B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
pelvic I-SSLIF I-SSLIF
region I-SSLIF I-SSLIF
and O O
would O O
see O O
her O O
in O O
clinical O O
followup O O
. O O
  
On O O
presentation O O
today O O
, O O
Name O O
reports O O
at O O
this O O
time O O
that O O
she O O
has O O
no O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
palpitations B-SSLIF B-SSLIF
. O O
  
No O O
dizziness B-SSLIF B-SSLIF
or O O
lightheadedness B-SSLIF B-SSLIF
. O O
  
Her O O
weight O O
in O O
the O O
clinic O O
today O O
had O O
declined O O
by O O
approximately O O
7 O O
pounds O O
. O O
  
She O O
has O O
also O O
noted O O
a O O
significant O O
decrease O O
in O O
the O O
amount O O
of O O
her O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
She O O
has O O
had O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
orthopnea B-SSLIF B-SSLIF
or O O
PND B-SSLIF B-SSLIF
. O O
  
Of O O
note O O
, O O
the O O
prior O O
BNP O O
level O O
obtained O O
on O O
Date O O
, O O
was O O
295 O O
with O O
a O O
previous O O
reading O O
of O O
96 O O
. O O
  
She O O
has O O
been O O
therapeutic O O
on O O
her O O
warfarin B-Drug B-Drug
with O O
no O O
bleeding B-SSLIF B-SSLIF
issues O O
. O O
  
She O O
tells O O
me O O
that O O
her O O
only O O
other O O
issue O O
is O O
related O O
to O O
possible O O
spinal B-SSLIF B-SSLIF
stenosis I-SSLIF I-SSLIF
. O O
  
She O O
has O O
been O O
experiencing O O
significant B-Severity B-Severity
discomfort B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremity I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
Blood O O
pressure O O
152 O O
/ O O
67 O O
, O O
139 O O
/ O O
73 O O
. O O
  
GENERAL O O
: O O
Appears O O
well O O
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Alert O O
and O O
oriented O O
. O O
  
Mood O O
is O O
pleasant O O
. O O
  
SKIN O O
: O O
Color O O
skin O O
turgor O O
normal O O
. O O
  
Slight B-Severity B-Severity
pallor B-SSLIF B-SSLIF
. O O
  
HEENT O O
: O O
Mucous O O
membranes O O
moist O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
JVD B-SSLIF B-SSLIF
, O O
weight O O
164 O O
pounds O O
. O O
  
LUNGS O O
: O O
Respirations O O
20 O O
and O O
unlabored O O
. O O
  
Lungs O O
clear O O
to O O
auscultation O O
. O O
  
Room O O
air O O
saturation O O
was O O
95% O O
. O O
  
CARDIAC O O
: O O
Regular O O
rate O O
and O O
rhythm O O
, O O
normal O O
S1 O O
, O O
S2 O O
with O O
a O O
soft O O
grade B-Severity B-Severity
II I-Severity I-Severity
/ I-Severity I-Severity
VI I-Severity I-Severity
systolic B-SSLIF B-SSLIF
murmur I-SSLIF I-SSLIF
present O O
. O O
  
ABDOMEN O O
: O O
Soft O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
EXTREMITIES O O
: O O
Bilateral O O
lower O O
extremities O O
, O O
soft O O
to O O
palpation O O
with O O
1 O O
to O O
2+ O O
edema B-SSLIF B-SSLIF
extending I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
third I-SSLIF I-SSLIF
up I-SSLIF I-SSLIF
bilaterally I-SSLIF I-SSLIF
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Calcitonin B-Drug B-Drug
, O O
Celexa B-Drug B-Drug
, O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
, O O
folic B-Drug B-Drug
acid I-Drug I-Drug
, O O
furosemide B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
Lidoderm B-Drug B-Drug
, O O
lisinopril B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
lorazepam B-Drug B-Drug
, O O
metoprolol B-Drug B-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
prednisone B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
tramadol B-Drug B-Drug
, O O
Tylenol B-Drug B-Drug
and O O
warfarin B-Drug B-Drug
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Codeine B-Drug B-Drug
, O O
amlodipine B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
ibuprofen B-Drug B-Drug
, O O
latex O O
, O O
naproxen B-Drug B-Drug
, O O
nonsteroidals B-Drug B-Drug
and O O
shellfish O O
. O O
  
LABORATORY O O
DATA O O
: O O
Resting O O
EKG O O
: O O
Heart O O
rate O O
74 O O
beats O O
a O O
minute O O
, O O
normal O O
sinus O O
rhythm O O
, O O
no O O
acute O O
diagnostic O O
ST O O
- O O
T O O
wave O O
abnormalities O O
. O O
  
Most O O
recent O O
blood O O
work O O
obtained O O
today O O
, O O
Date O O
, O O
sodium O O
140 O O
, O O
potassium O O
  
3.7 O O
, O O
BUN O O
17 O O
, O O
creatinine O O
0.86 O O
. O O
  
BNP O O
212 O O
, O O
prior O O
reading O O
295 O O
. O O
  
PT O O
/ O O
INR O O
1.8 O O
. O O
  
Hemoglobin O O
11.2 O O
, O O
hematocrit O O
31 O O
, O O
platelet O O
278 O O
, O O
000 O O
. O O
  
IMPRESSION O O
AND O O
PLAN O O
: O O
At O O
this O O
time O O
, O O
in O O
discussion O O
with O O
Dr O O
. O O
  
Name O O
, O O
the O O
etiology O O
of O O
her O O
pulmonary B-SSLIF B-SSLIF
embolization I-SSLIF I-SSLIF
remains O O
unclear O O
. O O
  
We O O
did O O
obtain O O
a O O
venous O O
duplex O O
today O O
which O O
was O O
negative O O
for O O
any O O
evidence O O
of O O
DVT B-Indication B-Indication
, O O
however O O
, O O
she O O
will O O
need O O
to O O
remain O O
on O O
the O O
warfarin B-Drug B-Drug
long O O
- O O
term O O
. O O
  
She O O
was O O
reporting O O
today O O
that O O
she O O
is O O
anticipating O O
an O O
MRI O O
to O O
further O O
evaluate O O
her O O
spinal B-SSLIF B-SSLIF
stenosis I-SSLIF I-SSLIF
and O O
left B-SSLIF B-SSLIF
leg I-SSLIF I-SSLIF
weakness I-SSLIF I-SSLIF
/ O O
discomfort O O
. O O
  
We O O
feel O O
that O O
given O O
her O O
recent O O
diagnosis O O
of O O
pulmonary B-Indication B-Indication
embolization I-Indication I-Indication
that O O
she O O
will O O
need O O
to O O
ideally O O
remain O O
on O O
her O O
warfarin B-Drug B-Drug
for O O
a O O
minimum B-Duration B-Duration
of I-Duration I-Duration
6 I-Duration I-Duration
months I-Duration I-Duration
. O O
  
With O O
regards O O
to O O
her O O
edema B-SSLIF B-SSLIF
, O O
it O O
is O O
slowly O O
resolving O O
. O O
  
I O O
understand O O
that O O
her O O
prednisone B-Drug B-Drug
will O O
be O O
tapered O O
further O O
and O O
it O O
is O O
possible O O
that O O
she O O
has O O
some O O
evidence O O
for O O
fluid B-SSLIF B-SSLIF
retention I-SSLIF I-SSLIF
secondary O O
to O O
diastolic O O
function O O
. O O
  
Her O O
elevated B-SSLIF B-SSLIF
pulmonary I-SSLIF I-SSLIF
artery I-SSLIF I-SSLIF
pressures I-SSLIF I-SSLIF
on O O
echocardiogram O O
along O O
with O O
tricuspid B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
is O O
likely O O
secondary O O
to O O
her O O
pulmonary B-SSLIF B-SSLIF
embolization I-SSLIF I-SSLIF
. O O
  
We O O
anticipate O O
at O O
some O O
point O O
to O O
repeat O O
her O O
echocardiogram O O
to O O
reassess O O
in O O
this O O
regard O O
. O O
  
I O O
did O O
recommend O O
a O O
slight O O
downward O O
adjustment O O
in O O
her O O
furosemide B-Drug B-Drug
. O O
  
She O O
will O O
take O O
20 B-Dose B-Dose
mg I-Dose I-Dose
alternating I-Dose I-Dose
with I-Dose I-Dose
10 I-Dose I-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
She O O
still O O
has O O
edema B-SSLIF B-SSLIF
and O O
her O O
BNP B-SSLIF B-SSLIF
levels I-SSLIF I-SSLIF
are I-SSLIF I-SSLIF
still I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
. O O
  
She O O
understands O O
to O O
avoid O O
any O O
excess O O
sodium O O
in O O
her O O
diet O O
. O O
  
Her O O
blood B-SSLIF B-SSLIF
pressure I-SSLIF I-SSLIF
today I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
; O O
however O O
, O O
her O O
previous O O
readings O O
have O O
been O O
within O O
range O O
and O O
she O O
has O O
not O O
experienced O O
any O O
evidence O O
of O O
tachyarrhythmias B-SSLIF B-SSLIF
. O O
  
I O O
will O O
see O O
her O O
back O O
in O O
the O O
next O O
several O O
weeks O O
and O O
she O O
understands O O
to O O
call O O
in O O
the O O
interim O O
if O O
she O O
has O O
any O O
concerns O O
. O O
  
Sincerely O O
, O O
Name O O
Name O O
, O O
NP O O
Addendum O O
: O O
I O O
informed O O
her O O
of O O
labs O O
. O O
  
K O O
3.7 O O
creatinine O O
.86 O O
. O O
  
BNP O O
212 O O
prior O O
295 O O
. O O
  
She O O
will O O
also O O
start O O
KCL B-Drug B-Drug
10meq B-Dose B-Dose
daily B-Frequency B-Frequency
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
NP O O
Date O O
08 O O
: O O
42 O O
  
D O O
: O O
Date O O
  
T O O
: O O
Date O O
10 O O
: O O
57 O O
P O O
  
FI O O
  
Medical_Record_Number O O
cc O O
: O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
5 O O
: O O
52 O O
P O O
  
9 O O
: O O
09 O O
A O O
CLINIC O O
NOTE O O
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
a O O
75 O O
- O O
year O O
- O O
old O O
female O O
who O O
is O O
six O O
years O O
status O O
post O O
right O O
total O O
hip O O
replacement O O
. O O
  
The O O
patient's O O
hip O O
is O O
pain B-SSLIF B-SSLIF
free O O
. O O
  
Very O O
pleased O O
with O O
the O O
results O O
of O O
her O O
surgery O O
. O O
  
Occasional O O
pain B-SSLIF B-SSLIF
in O O
her O O
opposite O O
hip O O
. O O
  
Also O O
having O O
problems O O
with O O
her O O
low O O
back O O
. O O
  
Was O O
recently O O
shoveling O O
and O O
states O O
that O O
there O O
is O O
a O O
suspicion O O
she O O
may O O
have O O
suffered O O
a O O
stress B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
in O O
her O O
spine O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
The O O
patient O O
stands O O
5 O O
feet O O
5 O O
- O O
1 O O
/ O O
2 O O
inches O O
tall O O
and O O
weighs O O
175 O O
pounds O O
. O O
  
BMI O O
is O O
28.7 O O
. O O
  
The O O
patient O O
walks O O
with O O
a O O
satisfactory O O
gait O O
. O O
  
Passive O O
motion O O
of O O
the O O
right O O
hip O O
is O O
pain B-SSLIF B-SSLIF
free O O
. O O
  
No O O
limitation B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
motion I-SSLIF I-SSLIF
. O O
  
Calf O O
soft O O
, O O
supple O O
and O O
nontender B-SSLIF B-SSLIF
. O O
  
Distal O O
pulse O O
present O O
. O O
  
Diminished B-SSLIF B-SSLIF
internal I-SSLIF I-SSLIF
rotation I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
hip I-SSLIF I-SSLIF
with O O
pain B-SSLIF B-SSLIF
on O O
attempt O O
. O O
  
RADIOLOGY O O
: O O
  
1. O O
Excellent O O
position O O
of O O
right O O
THR O O
without O O
change O O
. O O
  
2. O O
Advanced B-Severity B-Severity
OA B-SSLIF B-SSLIF
, O O
left O O
hip O O
. O O
  
IMPRESSION O O
: O O
  
1. O O
Right O O
THR O O
, O O
Date O O
. O O
  
2. O O
Advanced B-Severity B-Severity
OA B-SSLIF B-SSLIF
, O O
left O O
hip O O
. O O
  
3. O O
Lumbar B-SSLIF B-SSLIF
spine I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
with O O
recent O O
injury O O
, O O
question O O
stress B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
. O O
  
4. O O
Non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
Hodgkin's I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
PLAN O O
: O O
  
1. O O
Continue O O
current O O
activity O O
level O O
. O O
  
2. O O
Conservative O O
treatment O O
of O O
left O O
hip O O
OA B-SSLIF B-SSLIF
. O O
  
3. O O
Follow O O
up O O
with O O
spine O O
team O O
regarding O O
spine B-SSLIF B-SSLIF
injury I-SSLIF I-SSLIF
. O O
  
4. O O
Follow O O
up O O
here O O
in O O
one O O
year O O
for O O
routine O O
check O O
of O O
the O O
right O O
hip O O
, O O
sooner O O
if O O
left B-SSLIF B-SSLIF
hip I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
increases O O
before O O
then O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
MD O O
Date O O
14 O O
: O O
50 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
  
SG B-PHI B-PHI
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Date O O
of O O
Service O O
: O O
Date O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
MD O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
23 O O
: O O
39 O O
PM O O
Inpatient O O
Consult O O
REASON O O
FOR O O
REFERRAL O O
: O O
Exacerbation O O
of O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
. O O
  
ATTENDING O O
PHYSICIAN O O
: O O
Named_Sites O O
at O O
Hospital O O
. O O
  
PRIMARY O O
CARE O O
PHYSICIAN O O
: O O
Name O O
Name O O
, O O
M.D. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
Name O O
Name O O
is O O
a O O
77 O O
- O O
year O O
- O O
old O O
female O O
who O O
is O O
well O O
known O O
to O O
me O O
who O O
was O O
admitted O O
on O O
Date O O
, O O
for O O
exacerbation O O
of O O
her O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
. O O
  
Please O O
see O O
my O O
office O O
transcriptions O O
. O O
  
The O O
patient O O
was O O
diagnosed O O
with O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
in O O
Date O O
and O O
was O O
treated O O
with O O
splenectomy O O
only O O
. O O
  
Subsequently O O
, O O
in O O
Date O O
, O O
she O O
developed O O
autoimmune B-Indication B-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
with O O
a O O
warm B-SSLIF B-SSLIF
IgG I-SSLIF I-SSLIF
autoantibody I-SSLIF I-SSLIF
. O O
  
It O O
has O O
been O O
difficult O O
to O O
treat O O
this O O
disease O O
. O O
  
She O O
did O O
have O O
initial O O
good O O
results O O
, O O
but O O
then O O
did O O
have O O
an O O
exacerbation O O
in O O
Date O O
. O O
  
However O O
, O O
recently O O
her O O
prednisone B-Drug B-Drug
dose O O
had O O
been O O
tapered O O
to O O
10 B-Dose B-Dose
mg I-Dose I-Dose
alternating O O
with O O
5 B-Dose B-Dose
mg I-Dose I-Dose
. O O
  
Her O O
cyclophosphamide B-Drug B-Drug
dose O O
was O O
also O O
tapered O O
. O O
  
Her O O
hemoglobins O O
had O O
been O O
running O O
in O O
the O O
11 O O
range O O
and O O
her O O
reticulocyte O O
count O O
and O O
LDH O O
had O O
been O O
normal O O
. O O
  
Unfortunately O O
, O O
approximately O O
2 O O
weeks O O
ago O O
, O O
the O O
patient O O
had O O
a O O
fall B-SSLIF B-SSLIF
in O O
the O O
bathroom O O
. O O
  
She O O
did O O
not O O
hit O O
her O O
head O O
, O O
but O O
she O O
did O O
fracture B-SSLIF B-SSLIF
her I-SSLIF I-SSLIF
elbow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
several I-SSLIF I-SSLIF
ribs I-SSLIF I-SSLIF
. I-SSLIF I-SSLIF
  
She O O
also O O
then O O
was O O
noted O O
to O O
be O O
orthostatic B-SSLIF B-SSLIF
and O O
also O O
had O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
was O O
hospitalized O O
in O O
the O O
intensive O O
care O O
unit O O
. O O
  
Pulmonary B-SSLIF B-SSLIF
embolus I-SSLIF I-SSLIF
was O O
ruled O O
out O O
with O O
a O O
CT O O
scan O O
. O O
  
The O O
patient's O O
hemoglobins O O
did O O
drop O O
into O O
the O O
8 O O
range O O
, O O
but O O
she O O
was O O
discharged O O
at O O
about O O
9 O O
to O O
Hospital O O
. O O
  
The O O
patient's O O
daughter O O
said O O
that O O
yesterday O O
she O O
did O O
have O O
a O O
very O O
good O O
day O O
. O O
  
She O O
was O O
active O O
and O O
interactive O O
. O O
  
However O O
, O O
subsequently O O
, O O
she O O
became O O
very B-Severity B-Severity
fatigued B-SSLIF B-SSLIF
. O O
  
A O O
CBC O O
that O O
was O O
done O O
revealed O O
a O O
hemoglobin O O
of O O
6.1 O O
and O O
thus O O
, O O
she O O
was O O
sent O O
to O O
the O O
hospital O O
where O O
blood O O
will O O
be O O
transfused O O
. O O
  
The O O
patient O O
has O O
had O O
a O O
persistent O O
Coombs B-SSLIF B-SSLIF
test I-SSLIF I-SSLIF
that I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
been I-SSLIF I-SSLIF
positive I-SSLIF I-SSLIF
. O O
  
Currently O O
, O O
the O O
patient O O
is O O
feeling O O
extremely B-Severity B-Severity
fatigued B-SSLIF B-SSLIF
. O O
  
She O O
does O O
have O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
. O O
  
She O O
has O O
some B-Severity B-Severity
degree O O
of O O
air B-SSLIF B-SSLIF
hunger I-SSLIF I-SSLIF
, O O
although O O
her O O
pulse O O
oximetry O O
is O O
reasonable O O
. O O
  
She O O
has O O
been O O
transferred O O
to O O
the O O
CCU O O
. O O
  
In O O
the O O
past O O
, O O
the O O
patient's O O
autoimmune B-Indication B-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
has O O
been O O
treated O O
with O O
higher O O
dose O O
prednisone B-Drug B-Drug
; O O
cyclophosphamide B-Drug B-Drug
, O O
which O O
she O O
remains O O
on O O
; O O
Rituxan B-Drug B-Drug
, O O
which O O
was O O
given O O
in O O
Date O O
. O O
  
Because O O
she O O
is O O
on O O
chronic O O
steroids B-Drug B-Drug
, O O
she O O
is O O
on O O
Bactrim B-Drug B-Drug
DS I-Drug I-Drug
1 B-Dose B-Dose
tablet I-Dose I-Dose
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
for O O
Pneumocystis B-Indication B-Indication
prophylaxis I-Indication I-Indication
. O O
  
She O O
also O O
is O O
on O O
folic B-Drug B-Drug
acid I-Drug I-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
The O O
patient's O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
has O O
been O O
exacerbated O O
by O O
falls B-SSLIF B-SSLIF
. O O
  
She O O
has O O
very B-Severity B-Severity
weak B-SSLIF B-SSLIF
bones I-SSLIF I-SSLIF
and O O
has O O
had O O
recurrent O O
fractures B-SSLIF B-SSLIF
. O O
  
She O O
did O O
have O O
a O O
sternal B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
and O O
has O O
multiple O O
rib B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
as O O
well O O
as O O
the O O
current O O
elbow B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
. O O
  
She O O
has O O
been O O
seen O O
by O O
endocrinology O O
who O O
have O O
her O O
on O O
calcitonin B-Drug B-Drug
and O O
high O O
doses O O
of O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
. O O
  
The O O
etiology O O
of O O
the O O
significant B-Severity B-Severity
osteoporosis B-Indication B-Indication
is O O
not O O
clear O O
. O O
  
Certainly O O
, O O
steroids B-Drug B-Drug
can O O
do O O
it O O
, O O
but O O
usually O O
it O O
is O O
not O O
show O O
acute O O
and O O
rapid O O
onset O O
. O O
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
The O O
patient O O
had O O
a O O
pulmonary B-Indication B-Indication
embolus I-Indication I-Indication
associated O O
with O O
bed O O
rest O O
in O O
Date O O
. O O
  
She O O
remains O O
on O O
Coumadin B-Drug B-Drug
. O O
  
She O O
has O O
had O O
numerous O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
L3 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
L4 I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
T8 I-SSLIF I-SSLIF
. O O
  
There O O
are O O
some O O
recent O O
new O O
ones O O
. O O
  
The O O
patient O O
has O O
been O O
worked O O
up O O
with O O
CT O O
scans O O
and O O
PET O O
scans O O
. O O
  
The O O
fractures O O
were O O
deemed O O
to O O
be O O
nonpathologic O O
. O O
  
The O O
PET O O
scan O O
did O O
not O O
light O O
up O O
to O O
denote O O
any O O
significant B-Severity B-Severity
lymphoma B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
has O O
been O O
hospitalized O O
for O O
hematochezia B-SSLIF B-SSLIF
. O O
  
PAST O O
SURGICAL O O
HISTORY O O
: O O
The O O
patient O O
has O O
had O O
a O O
right O O
total O O
hip O O
replacement O O
in O O
Date O O
. O O
  
She O O
had O O
a O O
splenectomy O O
as O O
treatment O O
for O O
her O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
For O O
her O O
autoimmune B-Indication B-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
, O O
she O O
was O O
on O O
prednisone B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
alternating O O
with O O
5 B-Dose B-Dose
mg I-Dose I-Dose
every B-Frequency B-Frequency
other I-Frequency I-Frequency
day I-Frequency I-Frequency
. O O
  
Currently O O
, O O
it O O
has O O
been O O
increased O O
to O O
60 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
She O O
is O O
on O O
folic B-Drug B-Drug
acid I-Drug I-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
She O O
is O O
on O O
cyclophosphamide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
5 I-Frequency I-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
, O O
100 B-Dose B-Dose
mg I-Dose I-Dose
2 B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Fentanyl B-Drug B-Drug
patch B-Route B-Route
, O O
which O O
has O O
been O O
decreased O O
to O O
25 B-Dose B-Dose
mcg I-Dose I-Dose
every B-Frequency B-Frequency
3 I-Frequency I-Frequency
days I-Frequency I-Frequency
; O O
calcitonin B-Drug B-Drug
; O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
50 B-Dose B-Dose
, I-Dose I-Dose
000 I-Dose I-Dose
units I-Dose I-Dose
weekly B-Frequency B-Frequency
; O O
Vicodin B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
; O O
Lasix B-Drug B-Drug
; O O
potassium B-Drug B-Drug
; O O
lisinopril B-Drug B-Drug
; O O
metoprolol B-Drug B-Drug
and O O
Coumadin B-Drug B-Drug
. O O
  
FAMILY O O
HISTORY O O
: O O
Negative O O
for O O
lymphoma B-SSLIF B-SSLIF
or O O
autoimmune B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
. O O
  
Her O O
brother O O
had O O
laryngeal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
Her O O
father O O
died B-SSLIF B-SSLIF
at O O
age O O
80 O O
of O O
COPD B-SSLIF B-SSLIF
and O O
her O O
mother O O
died B-SSLIF B-SSLIF
at O O
age O O
84 O O
of O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
has O O
significant B-Severity B-Severity
fatigue B-SSLIF B-SSLIF
and O O
has O O
had O O
some B-Severity B-Severity
delirium B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
or O O
chills B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
She O O
is O O
having O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
has O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
or O O
wheezing B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
Her O O
appetite B-SSLIF B-SSLIF
was I-SSLIF I-SSLIF
good I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
but I-SSLIF I-SSLIF
currently I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
. I-SSLIF I-SSLIF
  
She O O
denies O O
any O O
melena B-SSLIF B-SSLIF
, O O
hematemesis B-SSLIF B-SSLIF
or O O
hematochezia B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
hematuria B-SSLIF B-SSLIF
or O O
dysuria B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
change B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
bowel I-SSLIF I-SSLIF
or O O
bladder B-SSLIF B-SSLIF
habits I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
increased O O
bruising B-SSLIF B-SSLIF
, O O
epistaxis B-SSLIF B-SSLIF
or O O
gingival B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
history O O
of O O
stroke B-SSLIF B-SSLIF
or O O
seizure B-SSLIF B-SSLIF
. O O
  
She O O
has O O
an O O
abnormal B-SSLIF B-SSLIF
gait I-SSLIF I-SSLIF
secondary O O
to O O
her O O
bony B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
lives O O
at O O
home O O
with O O
her O O
husband O O
. O O
  
She O O
, O O
in O O
the O O
past O O
, O O
was O O
very O O
active O O
, O O
but O O
her O O
performance O O
status O O
has O O
deteriorated O O
over O O
the O O
last O O
month O O
to O O
month O O
and O O
a O O
half O O
. O O
  
When O O
I O O
had O O
seen O O
her O O
last O O
in O O
the O O
clinic O O
in O O
Date O O
, O O
she O O
was O O
in O O
a O O
wheelchair O O
, O O
but O O
was O O
walking O O
and O O
was O O
certainly O O
looking O O
more O O
robust O O
. O O
  
Since O O
her O O
hospitalization O O
2 O O
weeks O O
ago O O
and O O
now O O
in O O
rehab O O
, O O
she O O
has O O
clearly O O
deteriorated O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
looked O O
chronically O O
ill O O
and O O
cushingoid B-SSLIF B-SSLIF
. O O
  
VITAL O O
SIGNS O O
: O O
Blood O O
pressure O O
was O O
116 O O
/ O O
91 O O
, O O
pulse O O
was O O
103 O O
and O O
regular O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
without O O
lesions B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
without O O
wheezes B-SSLIF B-SSLIF
, O O
rales B-SSLIF B-SSLIF
or O O
rhonchi B-SSLIF B-SSLIF
. O O
  
CARDIOVASCULAR O O
: O O
Rapid O O
regular O O
rhythm O O
with O O
a O O
grade B-Severity B-Severity
II I-Severity I-Severity
/ I-Severity I-Severity
VI I-Severity I-Severity
systolic B-SSLIF B-SSLIF
ejection I-SSLIF I-SSLIF
murmur I-SSLIF I-SSLIF
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
There O O
is O O
diffuse B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
There O O
is O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
. O O
  
There O O
is O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
2+ O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
. O O
  
She O O
has O O
significant B-Severity B-Severity
ecchymoses B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
. O O
  
There O O
are O O
no O O
petechiae B-SSLIF B-SSLIF
. O O
  
SKIN O O
: O O
No O O
rashes B-SSLIF B-SSLIF
. O O
  
NEUROLOGICAL O O
: O O
The O O
patient O O
is O O
alert O O
, O O
but O O
somewhat B-Severity B-Severity
lethargic B-SSLIF B-SSLIF
. O O
  
She O O
is O O
lying O O
in O O
bed O O
, O O
but O O
is O O
entirely O O
responsive O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
revealed O O
a O O
white O O
blood O O
cell O O
count O O
of O O
5900 O O
with O O
82 O O
polys O O
, O O
3 O O
bands O O
, O O
2 O O
metamyelocytes O O
, O O
1 O O
myelocyte O O
, O O
1 O O
promyelocyte O O
, O O
2 O O
lymphs O O
, O O
9 O O
monos O O
, O O
9 O O
nucleated O O
red O O
blood O O
cells O O
. O O
  
A O O
hemoglobin O O
is O O
7.1 O O
and O O
a O O
platelet O O
count O O
is O O
150 O O
, O O
000 O O
. O O
  
Reticulocyte O O
count O O
is O O
3% O O
. O O
  
LDH B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
85 I-SSLIF I-SSLIF
. O O
  
Her O O
BNP B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
elevated I-SSLIF I-SSLIF
. O O
  
Her O O
peripheral O O
smear O O
reveals O O
no O O
schistocytes B-SSLIF B-SSLIF
. O O
  
There O O
is O O
left B-SSLIF B-SSLIF
shifting I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
myeloid I-SSLIF I-SSLIF
series I-SSLIF I-SSLIF
and O O
nucleated B-SSLIF B-SSLIF
red I-SSLIF I-SSLIF
blood I-SSLIF I-SSLIF
cells I-SSLIF I-SSLIF
are O O
evident O O
as O O
well O O
as O O
polychromatophilia B-SSLIF B-SSLIF
. O O
  
Electrolytes O O
reveal O O
a O O
decreased B-SSLIF B-SSLIF
serum I-SSLIF I-SSLIF
sodium I-SSLIF I-SSLIF
. O O
  
A O O
BUN O O
is O O
26 O O
and O O
a O O
creatinine O O
is O O
0.6 O O
. O O
  
Amylase O O
and O O
lipase O O
are O O
normal O O
. O O
  
B12 O O
and O O
folate O O
have O O
been O O
normal O O
in O O
the O O
past O O
. O O
  
The O O
patient O O
remains O O
on O O
Coumadin B-Drug B-Drug
and O O
her O O
INR O O
is O O
in O O
good O O
range O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
77 O O
- O O
year O O
- O O
old O O
female O O
with O O
: O O
  
1. O O
Recurrent B-Indication B-Indication
warm I-Indication I-Indication
autoimmune I-Indication I-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
with O O
an O O
IgG B-SSLIF B-SSLIF
autoantibody I-SSLIF I-SSLIF
. O O
  
She O O
has O O
been O O
somewhat O O
resistant O O
to O O
treatment O O
, O O
although O O
recently O O
I O O
had O O
been O O
tapering O O
her O O
prednisone B-Drug B-Drug
significantly O O
and O O
she O O
was O O
on O O
minimal O O
doses O O
with O O
a O O
stable O O
hemoglobin O O
. O O
  
Unfortunately O O
, O O
she O O
did O O
have O O
another O O
fall B-SSLIF B-SSLIF
. O O
  
She O O
had O O
an O O
acute O O
admission O O
to O O
the O O
hospital O O
and O O
was O O
in O O
the O O
CCU O O
. O O
  
She O O
was O O
discharged O O
to O O
Hospital O O
. O O
  
There O O
they O O
noted O O
that O O
she O O
was O O
lethargic B-SSLIF B-SSLIF
and O O
a O O
hemoglobin O O
was O O
in O O
the O O
6.8 O O
range O O
. O O
  
She O O
will O O
need O O
to O O
have O O
her O O
steroids B-Drug B-Drug
increased O O
. O O
  
I O O
will O O
keep O O
the O O
Cytoxan B-Drug B-Drug
dose O O
the O O
same O O
. O O
  
She O O
has O O
a O O
good O O
response O O
to O O
steroids B-Drug B-Drug
. O O
  
2. O O
Multiple O O
fractures B-Indication B-Indication
. O O
  
These O O
were O O
not O O
deemed O O
pathological O O
by O O
MRI O O
or O O
PET O O
scan O O
. O O
  
She O O
has O O
significant B-Severity B-Severity
osteoporosis B-ADE B-ADE
probably O O
secondary O O
to O O
prednisone B-Drug B-Drug
. O O
  
She O O
is O O
on O O
calcitonin B-Drug B-Drug
, O O
but O O
I O O
am O O
wondering O O
whether O O
she O O
should O O
not O O
be O O
put O O
on O O
a O O
drug O O
such O O
as O O
Forteo B-Drug B-Drug
. O O
  
An O O
endocrinology O O
should O O
be O O
consulted O O
. O O
  
3. O O
Marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
She O O
is O O
status O O
post O O
splenectomy O O
and O O
continues O O
to O O
have O O
no O O
evidence O O
of O O
disease O O
unless O O
the O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
is O O
a O O
precursor O O
. O O
  
PLAN O O
: O O
  
1. O O
I O O
agree O O
with O O
prednisone B-Drug B-Drug
60 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
Perhaps O O
this O O
could O O
be O O
given O O
as O O
a O O
hydrocortisone B-Drug B-Drug
equivalent I-Drug I-Drug
intravenously B-Route B-Route
. O O
  
She O O
also O O
does O O
need O O
a O O
protein B-Drug B-Drug
pump I-Drug I-Drug
inhibitor I-Drug I-Drug
or O O
H2 B-Drug B-Drug
blocker I-Drug I-Drug
for O O
the O O
prednisone B-Drug B-Drug
. O O
  
2. O O
Continue O O
the O O
Bactrim B-Drug B-Drug
DS I-Drug I-Drug
1 B-Dose B-Dose
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
3. O O
Please O O
obtain O O
a O O
serum O O
iron O O
, O O
TIBC O O
and O O
folate O O
as O O
well O O
as O O
vitamin O O
B12 O O
. O O
  
4. O O
Maintain O O
her O O
cyclophosphamide B-Drug B-Drug
at O O
the O O
same O O
dose O O
of O O
50 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
for I-Frequency I-Frequency
5 I-Frequency I-Frequency
days I-Frequency I-Frequency
out I-Frequency I-Frequency
of I-Frequency I-Frequency
the I-Frequency I-Frequency
week I-Frequency I-Frequency
and O O
1 B-Dose B-Dose
g I-Dose I-Dose
for O O
2 B-Frequency B-Frequency
days I-Frequency I-Frequency
out I-Frequency I-Frequency
of I-Frequency I-Frequency
the I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
5. O O
Continue O O
folic B-Drug B-Drug
acid I-Drug I-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
. O O
  
We O O
will O O
see O O
her O O
when O O
she O O
is O O
discharged O O
from O O
the O O
hospital O O
. O O
  
She O O
is O O
awaiting O O
blood O O
transfusions O O
, O O
but O O
it O O
is O O
a O O
difficult O O
crossmatch O O
. O O
  
Currently O O
, O O
she O O
does O O
appear B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
be I-SSLIF I-SSLIF
deteriorating I-SSLIF I-SSLIF
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
  
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
H O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Location O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
1 O O
: O O
32 O O
P O O
  
11 O O
: O O
08 O O
A O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
. O O
  
She O O
is O O
status O O
post O O
splenectomy O O
in O O
Date O O
. O O
  
She O O
had O O
an O O
associated O O
IgM B-SSLIF B-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
History O O
of O O
thrombocytopenia B-SSLIF B-SSLIF
secondary O O
to O O
problem O O
#1 O O
, O O
now O O
resolved O O
. O O
  
3. O O
Status O O
post O O
splenectomy O O
in O O
Date O O
, O O
which O O
was O O
complicated O O
by O O
postoperative O O
hemorrhage B-SSLIF B-SSLIF
requiring O O
intubation O O
, O O
and O O
an O O
ICU O O
stay O O
as O O
well O O
as O O
reoperation O O
and O O
numerous O O
units O O
of O O
blood O O
. O O
  
4. O O
History O O
of O O
diverticulitis B-SSLIF B-SSLIF
requiring O O
hospitalization O O
in O O
Date O O
with O O
intermittent O O
recurrences O O
. O O
  
5. O O
History O O
of O O
acute O O
pancreatitis B-SSLIF B-SSLIF
, O O
now O O
resolved O O
. O O
  
6. O O
Cellulitis B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
thigh I-Indication I-Indication
in O O
Date O O
requiring O O
antibiotics B-Drug B-Drug
, O O
now O O
resolved O O
. O O
  
7. O O
Status O O
post O O
right O O
total O O
hip O O
replacement O O
in O O
Date O O
with O O
postoperative O O
bleeding B-SSLIF B-SSLIF
. O O
  
8. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
9. O O
Carpal O O
tunnel O O
surgery O O
bilaterally O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems O O
. O O
  
10. O O
Hernia O O
repair O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems O O
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
is O O
status O O
post O O
splenectomy O O
for O O
her O O
lymphoma B-SSLIF B-SSLIF
and O O
has O O
had O O
no O O
further O O
therapy O O
. O O
  
I O O
am O O
following O O
her O O
with O O
observation O O
only O O
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Allegra B-Drug B-Drug
, O O
folic B-Drug B-Drug
acid I-Drug I-Drug
, O O
lisinopril B-Drug B-Drug
, O O
lorazepam B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
, O O
metoprolol B-Drug B-Drug
and O O
Tylenol B-Drug B-Drug
as B-Frequency B-Frequency
needed I-Frequency I-Frequency
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
her O O
lymphoma B-SSLIF B-SSLIF
. O O
  
She O O
is O O
doing O O
very O O
well O O
. O O
  
Her O O
performance O O
status O O
has O O
returned O O
to O O
baseline O O
and O O
is O O
ECOG O O
0 O O
. O O
  
She O O
is O O
very O O
active O O
. O O
  
She O O
continues O O
to O O
work O O
once O O
a O O
week O O
. O O
  
She O O
gardens O O
. O O
  
There O O
have O O
been O O
some O O
changes O O
in O O
her O O
blood B-Drug B-Drug
pressure I-Drug I-Drug
medications I-Drug I-Drug
. O O
  
Otherwise O O
, O O
she O O
has O O
had O O
no O O
interim O O
hospitalizations O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
any O O
fatigue B-SSLIF B-SSLIF
, O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
, O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
or O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
Her O O
appetite O O
is O O
good O O
. O O
  
She O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
increased B-SSLIF B-SSLIF
bruising I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
significant B-Severity B-Severity
musculoskeletal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
focal B-SSLIF B-SSLIF
neurological I-SSLIF I-SSLIF
changes I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Negative O O
for O O
lymphoma B-SSLIF B-SSLIF
. O O
  
Her O O
father O O
died B-SSLIF B-SSLIF
at O O
age O O
80 O O
of O O
COPD B-SSLIF B-SSLIF
and O O
her O O
mother O O
died B-SSLIF B-SSLIF
at O O
age O O
84 O O
of O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
One O O
brother O O
died B-SSLIF B-SSLIF
at O O
age O O
42 O O
of O O
laryngeal B-SSLIF B-SSLIF
carcinoma I-SSLIF I-SSLIF
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
0 O O
. O O
  
She O O
is O O
active O O
and O O
does O O
all O O
activities O O
of O O
daily O O
living O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
150 O O
/ O O
80 O O
, O O
pulse O O
is O O
77 O O
and O O
regular O O
, O O
and O O
her O O
weight O O
is O O
175 O O
pounds O O
, O O
which O O
is O O
increased O O
by O O
6 O O
pounds O O
since O O
last O O
seen O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
benign O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
no O O
increased B-SSLIF B-SSLIF
liver I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
palpable I-SSLIF I-SSLIF
, O O
no O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
petechiae B-SSLIF B-SSLIF
or O O
ecchymoses B-SSLIF B-SSLIF
. O O
  
NEUROLOGICAL O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
Strength O O
intact O O
and O O
gait O O
normal O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
4700 O O
with O O
35.5 O O
polys O O
, O O
33.3 O O
lymphs O O
, O O
20.6 O O
monos O O
, O O
9.9 O O
eos O O
, O O
0.7 O O
basophils O O
, O O
a O O
platelet O O
count O O
of O O
188 O O
, O O
000 O O
and O O
a O O
hemoglobin O O
of O O
12.9 O O
with O O
hematocrit O O
of O O
37.5 O O
. O O
  
MCV O O
is O O
92.3 O O
. O O
  
An O O
IgM B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
continues I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
be I-SSLIF I-SSLIF
very I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
20.4 I-SSLIF I-SSLIF
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
17 O O
. O O
  
Free O O
lambda O O
light O O
chains O O
are O O
15 O O
with O O
a O O
kappa O O
to O O
lambda O O
ratio O O
of O O
1.13 O O
, O O
which O O
is O O
normal O O
. O O
  
A O O
BUN O O
is O O
14 O O
, O O
a O O
creatinine O O
is O O
0.91 O O
. O O
  
AST O O
is O O
24 O O
, O O
ALT O O
is O O
16 O O
and O O
an O O
LDH O O
is O O
182 O O
. O O
  
A O O
serum O O
protein O O
electrophoresis O O
is O O
normal O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
75 O O
- O O
year O O
- O O
old O O
female O O
with O O
a O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
. O O
  
She O O
is O O
now O O
status O O
post O O
splenectomy O O
and O O
is O O
feeling O O
very O O
well O O
. O O
  
Her O O
peripheral O O
blood O O
counts O O
are O O
normal O O
except O O
for O O
a O O
monocytosis B-SSLIF B-SSLIF
, O O
which O O
has O O
persisted O O
since O O
splenectomy O O
. O O
  
She O O
is O O
asymptomatic O O
and O O
feels O O
well O O
. O O
  
PLAN O O
: O O
  
1 O O
. O O
  
At O O
this O O
time O O
, O O
no O O
intervention O O
will O O
be O O
made O O
. O O
  
She O O
will O O
be O O
followed O O
by O O
observation O O
only O O
. O O
  
2. O O
I O O
will O O
see O O
her O O
in O O
followup O O
in O O
4 O O
months O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Date O O
17 O O
: O O
06 O O
  
____________________________ O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Admit O O
: O O
Date O O
DOS O O
: O O
Date O O
Loc O O
: O O
Named_Sites O O
  
Dict O O
By O O
: O O
Name O O
Name O O
, O O
OTR O O
- O O
L O O
Dict O O
Date O O
: O O
Date O O
Trans O O
: O O
Date O O
9 O O
: O O
35 O O
P O O
REHABILITATION O O
SERVICES O O
HAND O O
THERAPY O O
REHABILITATION O O
DISCHARGE O O
NOTE O O
Date O O
: O O
Date O O
Patient O O
Name O O
: O O
Name O O
Name O O
Medical O O
Record O O
# O O
: O O
Medical_Record_Number O O
Referring O O
Physician O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
M.D. O O
Diagnosis O O
: O O
Right B-SSLIF B-SSLIF
CMC I-SSLIF I-SSLIF
joint I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
and O O
Dequervain's B-SSLIF B-SSLIF
. O O
  
ICD O O
- O O
9 O O
code O O
719.44 O O
, O O
715.94 O O
and O O
727.04 O O
. O O
  
Number O O
of O O
Visits O O
Completed O O
: O O
2 O O
. O O
  
Date O O
of O O
Evaluation O O
: O O
Date O O
. O O
  
Date O O
of O O
Discharge O O
: O O
Date O O
. O O
  
REASON O O
FOR O O
DISCHARGE O O
: O O
The O O
patient O O
has O O
adequately O O
met O O
goals O O
set O O
at O O
the O O
time O O
of O O
evaluation O O
and O O
feels O O
that O O
she O O
can O O
continue O O
with O O
pain O O
management O O
at O O
home O O
. O O
  
INITIAL O O
PROBLEM O O
LIST O O
: O O
  
1. O O
Pain B-SSLIF B-SSLIF
: O O
9 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
at O O
worst O O
, O O
0 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
at O O
best O O
. O O
  
2. O O
Function O O
: O O
The O O
patient O O
independent O O
with O O
substitution O O
secondary O O
to O O
pain B-SSLIF B-SSLIF
, O O
has O O
difficulty B-SSLIF B-SSLIF
hooking I-SSLIF I-SSLIF
bra I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
doing I-SSLIF I-SSLIF
buttons I-SSLIF I-SSLIF
. O O
  
The O O
patient O O
rated O O
hand O O
, O O
wrist O O
eval O O
64.5 O O
. O O
  
3. O O
Strength O O
: O O
Grip O O
strength O O
on O O
the O O
right O O
21 O O
, O O
30 O O
on O O
the O O
left O O
. O O
  
DISCHARGE O O
STATUS O O
: O O
Data O O
gathered O O
on O O
Date O O
at O O
last O O
visit O O
. O O
  
1. O O
Pain B-SSLIF B-SSLIF
: O O
4 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
in O O
CMC O O
area O O
at O O
worst O O
with O O
certain O O
movements O O
, O O
0 B-Severity B-Severity
/ I-Severity I-Severity
10 I-Severity I-Severity
at O O
best O O
. O O
  
2. O O
Function O O
: O O
The O O
patient O O
is O O
independent O O
with O O
splint O O
wear O O
and O O
care O O
for O O
pain O O
management O O
. O O
  
3. O O
Strength O O
: O O
Independent O O
with O O
home O O
exercise O O
program O O
for O O
isometric O O
strengthening O O
. O O
  
EDUCATION O O
: O O
The O O
patient O O
was O O
educated O O
in O O
diagnosis O O
and O O
prognosis O O
, O O
joint O O
protection O O
, O O
task O O
modification O O
, O O
splint O O
wear O O
and O O
care O O
and O O
isometric O O
exercises O O
. O O
  
HOME O O
EXERCISE O O
PROGRAM O O
: O O
The O O
patient O O
was O O
provided O O
with O O
a O O
written O O
home O O
exercise O O
program O O
for O O
isometric O O
strengthening O O
and O O
splinting O O
as O O
needed O O
for O O
pain B-SSLIF B-SSLIF
as O O
well O O
as O O
adaptive O O
equipment O O
, O O
task O O
modification O O
, O O
joint O O
protection O O
as O O
needed O O
. O O
  
PRECAUTIONS O O
: O O
The O O
patient O O
is O O
to O O
respect O O
pain O O
. O O
  
RECOMMENDATIONS O O
AT O O
DISCHARGE O O
: O O
Continue O O
with O O
adaptive O O
equipment O O
as O O
needed O O
and O O
splint O O
, O O
continue O O
with O O
home O O
exercise O O
program O O
. O O
  
Follow O O
up O O
with O O
physician O O
as O O
scheduled O O
and O O
contact O O
hand O O
therapy O O
with O O
any O O
questions O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
, O O
OTR O O
- O O
L O O
Date O O
08 O O
: O O
39 O O
  
____________________________ O O
Name O O
Name O O
, O O
OTR O O
- O O
L O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
, O O
OTR O O
- O O
L O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
CHIEF O O
COMPLAINT O O
: O O
Established O O
osteoporosis B-SSLIF B-SSLIF
, O O
vitamin B-SSLIF B-SSLIF
D I-SSLIF I-SSLIF
deficiency I-SSLIF I-SSLIF
, O O
elevated B-SSLIF B-SSLIF
calcium I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
76 O O
- O O
year O O
- O O
old O O
woman O O
who O O
comes O O
in O O
today O O
with O O
her O O
daughter O O
. O O
  
She O O
has O O
a O O
very O O
complex O O
history O O
. O O
  
Last O O
set O O
of O O
labs O O
were O O
done O O
in O O
Date O O
and O O
her O O
ionized B-SSLIF B-SSLIF
calcium I-SSLIF I-SSLIF
level I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
slightly I-SSLIF I-SSLIF
high I-SSLIF I-SSLIF
. O O
  
Her O O
vitamin O O
D O O
level O O
was O O
excellent O O
. O O
  
She O O
started O O
nasal B-Route B-Route
calcitonin B-Drug B-Drug
and O O
has O O
tolerated O O
that O O
well O O
. O O
  
No O O
problems O O
with O O
it O O
. O O
  
She O O
does O O
use O O
oxygen B-Drug B-Drug
at O O
night O O
, O O
which O O
dries B-ADE B-ADE
out I-ADE I-ADE
her I-ADE I-ADE
nasal I-ADE I-ADE
passages I-ADE I-ADE
. O O
  
Despite O O
this O O
, O O
she O O
denies O O
any O O
problems O O
nasally O O
except O O
occasional B-Severity B-Severity
stuffiness B-SSLIF B-SSLIF
. O O
  
Her O O
back O O
is O O
doing O O
a O O
lot O O
better O O
. O O
  
She O O
has O O
been O O
cut O O
back O O
on O O
her O O
prednisone B-Drug B-Drug
and O O
she O O
is O O
now O O
down O O
to O O
5 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
She O O
continues O O
to O O
use O O
a O O
wheelchair O O
as O O
her O O
leg O O
is O O
bothering O O
her O O
. O O
  
She O O
does O O
need O O
to O O
have O O
a O O
hip O O
replacement O O
, O O
but O O
that O O
will O O
be O O
"down O O
the O O
road" O O
as O O
she O O
would O O
have O O
to O O
come O O
off O O
her O O
warfarin B-Drug B-Drug
. O O
  
MEDICATIONS O O
: O O
( O O
Reviewed O O
and O O
updated O O
) O O
: O O
Celexa B-Drug B-Drug
. O O
  
Cyclophosphamide B-Drug B-Drug
. O O
  
Fentanyl B-Drug B-Drug
. O O
  
Lisinopril B-Drug B-Drug
. O O
  
Lorazepam B-Drug B-Drug
. O O
  
Metoprolol B-Drug B-Drug
. O O
  
MiraLax B-Drug B-Drug
. O O
  
Ondansetron B-Drug B-Drug
. O O
  
Prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
. O O
  
Sulfa B-Drug B-Drug
. O O
  
Vicodin B-Drug B-Drug
. O O
  
Warfarin B-Drug B-Drug
. O O
  
Folate B-Drug B-Drug
. O O
  
Calcitonin B-Drug B-Drug
. O O
  
Ergocalciferol B-Drug B-Drug
weekly B-Frequency B-Frequency
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Blood O O
pressure O O
108 O O
/ O O
62 O O
, O O
pulse O O
66 O O
, O O
weight O O
unable O O
. O O
  
General O O
: O O
No O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
Lungs O O
: O O
Clear O O
to O O
auscultation O O
. O O
  
Heart O O
: O O
Regular O O
rate O O
and O O
rhythm O O
. O O
  
Abdomen O O
: O O
Soft O O
, O O
nontender B-SSLIF B-SSLIF
, O O
nondistended B-SSLIF B-SSLIF
. O O
  
Back O O
: O O
Had O O
no O O
spinal B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
paraspinal I-SSLIF I-SSLIF
muscle I-SSLIF I-SSLIF
tenderness I-SSLIF I-SSLIF
. O O
  
Extremities O O
had O O
no O O
proximal B-SSLIF B-SSLIF
muscle I-SSLIF I-SSLIF
weakness I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
extremities I-SSLIF I-SSLIF
. O O
  
LABORATORY O O
DATA O O
( O O
Date O O
) O O
: O O
ICA O O
5.4 O O
, O O
25D O O
51 O O
, O O
NTX O O
67 O O
. O O
  
IMPRESSION O O
  
1. O O
Established O O
steroid B-Drug B-Drug
osteoporosis B-ADE B-ADE
. O O
  
Fractures B-SSLIF B-SSLIF
occurred O O
prior O O
to O O
starting O O
prednisone B-Drug B-Drug
and O O
after O O
prednisone B-Drug B-Drug
. O O
  
Question O O
of O O
whether O O
there O O
have O O
been O O
issues O O
with O O
bone O O
quality O O
. O O
  
Bone O O
alkaline B-SSLIF B-SSLIF
phosphatase I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
a I-SSLIF I-SSLIF
bit I-SSLIF I-SSLIF
high I-SSLIF I-SSLIF
, O O
but O O
it O O
is O O
coming O O
down O O
slowly O O
. O O
  
Back O O
, O O
she O O
states O O
she O O
is O O
overall O O
doing O O
well O O
. O O
  
She O O
does O O
not O O
know O O
when O O
she O O
will O O
have O O
surgery O O
on O O
her O O
back O O
and O O
therefore O O
we O O
could O O
consider O O
a O O
bisphosphonate B-Drug B-Drug
in O O
the O O
future O O
. O O
  
However O O
, O O
she O O
is O O
on O O
so O O
many O O
medications O O
, O O
she O O
is O O
concerned O O
about O O
being O O
on O O
another O O
one O O
, O O
which O O
may O O
cause O O
side O O
effects O O
. O O
  
She O O
is O O
tolerating O O
the O O
nasal B-Route B-Route
calcitonin B-Drug B-Drug
well O O
and O O
therefore O O
she O O
has O O
opted O O
to O O
stay O O
on O O
it O O
. O O
  
She O O
does O O
have O O
underlying O O
warfarin B-Drug B-Drug
use O O
and O O
therefore O O
, O O
we O O
need O O
to O O
be O O
concerned O O
about O O
nasal B-SSLIF B-SSLIF
irritation I-SSLIF I-SSLIF
. O O
  
Will O O
consider O O
intravenous B-Route B-Route
bisphosphonate B-Drug B-Drug
after O O
the O O
next O O
visit O O
. O O
  
2. O O
Hypercalcemia B-SSLIF B-SSLIF
. O O
  
Mildly B-Severity B-Severity
elevated B-SSLIF B-SSLIF
ionized I-SSLIF I-SSLIF
calcium I-SSLIF I-SSLIF
that O O
has O O
persisted O O
. O O
  
PTH B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
been I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
in O O
the O O
past O O
. O O
  
Will O O
recheck O O
. O O
  
Symptomatically O O
is O O
doing O O
well O O
. O O
  
3. O O
Elevated B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
alkaline I-SSLIF I-SSLIF
phosphatase I-SSLIF I-SSLIF
. O O
  
Has O O
improved O O
. O O
  
Will O O
reassess O O
. O O
  
4. O O
Vitamin B-Indication B-Indication
D I-Indication I-Indication
deficiency I-Indication I-Indication
. O O
  
Ergocalciferol B-Drug B-Drug
weekly B-Frequency B-Frequency
, O O
which O O
she O O
has O O
tolerated O O
well O O
and O O
her O O
vitamin O O
D O O
level O O
is O O
in O O
goal O O
range O O
. O O
  
Will O O
recheck O O
levels O O
today O O
. O O
  
PLAN O O
  
1. O O
Labs O O
as O O
per O O
flowsheet O O
( O O
add O O
to O O
Dr O O
. O O
  
Name O O
labs O O
ordered O O
today O O
) O O
. O O
  
2. O O
Continue O O
nasal B-Route B-Route
calcitonin B-Drug B-Drug
daily O O
. O O
  
3. O O
Followup O O
six O O
months O O
. O O
  
4. O O
Consider O O
Forteo B-Drug B-Drug
or O O
bisphosphonate B-Drug B-Drug
at O O
that O O
time O O
. O O
  
5. O O
Call O O
/ O O
followup O O
sooner O O
if O O
any O O
further O O
problems O O
, O O
questions O O
, O O
issues O O
arise O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
1 O O
: O O
24PM O O
EST O O
Hospital O O
Patient O O
Discharge O O
Instructions O O
Medications O O
It O O
is O O
the O O
responsibility O O
of O O
the O O
patient O O
or O O
patient O O
representative O O
to O O
confirm O O
the O O
list O O
of O O
medications O O
with O O
either O O
the O O
patient's O O
personal O O
care O O
provider O O
or O O
the O O
patient's O O
follow O O
- O O
up O O
care O O
provider O O
to O O
ensure O O
the O O
patient O O
has O O
an O O
appropriate O O
list O O
of O O
medications O O
to O O
take O O
at O O
home O O
. O O
  
Discharge O O
medications O O
calcitonin B-Drug B-Drug
( I-Drug I-Drug
salmon I-Drug I-Drug
) I-Drug I-Drug
( I-Drug I-Drug
Fortical I-Drug I-Drug
) I-Drug I-Drug
200 B-Dose B-Dose
unit I-Dose I-Dose
/ I-Dose I-Dose
dose I-Dose I-Dose
Aerosol I-Dose I-Dose
, O O
Spray B-Route B-Route
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
spray I-Dose I-Dose
nasal B-Route B-Route
DAILY B-Frequency B-Frequency
citalopram B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
QHS B-Frequency B-Frequency
cyclophosphamide B-Drug B-Drug
100mg B-Dose B-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
Monday B-Frequency B-Frequency
, I-Frequency I-Frequency
Thursday I-Frequency I-Frequency
cyclophosphamide B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
Tuesday B-Frequency B-Frequency
, I-Frequency I-Frequency
Wednesday I-Frequency I-Frequency
, I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, I-Frequency I-Frequency
Saturday I-Frequency I-Frequency
, I-Frequency I-Frequency
Sunday I-Frequency I-Frequency
ergocalciferol B-Drug B-Drug
( I-Drug I-Drug
vitamin I-Drug I-Drug
D2 I-Drug I-Drug
) I-Drug I-Drug
( I-Drug I-Drug
Vitamin I-Drug I-Drug
D I-Drug I-Drug
) I-Drug I-Drug
50 B-Dose B-Dose
, I-Dose I-Dose
000 I-Dose I-Dose
unit I-Dose I-Dose
Capsule I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
capsule I-Dose I-Dose
oral B-Route B-Route
QMON B-Frequency B-Frequency
QMON O O
fentaNYL B-Drug B-Drug
25 B-Dose B-Dose
mcg I-Dose I-Dose
/ I-Dose I-Dose
hour I-Dose I-Dose
Patch I-Dose I-Dose
72 I-Dose I-Dose
hr I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
each I-Dose I-Dose
transdermal B-Route B-Route
Q72H B-Frequency B-Frequency
Q72HAdditional O O
Instructions O O
: O O
CHANGE O O
PATCH O O
Q O O
72 O O
H O O
foLIC B-Drug B-Drug
Acid I-Drug I-Drug
0.4 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
furosemide B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
  
HYDROCODONE B-Drug B-Drug
5 I-Drug I-Drug
MG I-Drug I-Drug
/ I-Drug I-Drug
APAP I-Drug I-Drug
325 I-Drug I-Drug
MG I-Drug I-Drug
( I-Drug I-Drug
VICODIN I-Drug I-Drug
5 B-Dose B-Dose
MG I-Dose I-Dose
/ I-Dose I-Dose
325 I-Dose I-Dose
MG I-Dose I-Dose
) I-Dose I-Dose
1 B-Dose B-Dose
- I-Dose I-Dose
2 I-Dose I-Dose
TABLET I-Dose I-Dose
ORAL B-Route B-Route
TABLET O O
Q6HPRN B-Frequency B-Frequency
PAIN B-Indication B-Indication
Directions O O
: O O
2 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
PAIN B-Indication B-Indication
potassium B-Drug B-Drug
chloride I-Drug I-Drug
( I-Drug I-Drug
Klor I-Drug I-Drug
- I-Drug I-Drug
Con I-Drug I-Drug
M20 I-Drug I-Drug
) I-Drug I-Drug
20 I-Drug I-Drug
mEq I-Drug I-Drug
Tablet I-Drug I-Drug
, I-Drug I-Drug
ER I-Drug I-Drug
Particles I-Drug I-Drug
/ I-Drug I-Drug
Crystals I-Drug I-Drug
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
lisinopril B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
Additional O O
Instructions O O
: O O
HOLD O O
IF O O
SBP O O
< O O
___ O O
polyethylene B-Drug B-Drug
glycol I-Drug I-Drug
3350 I-Drug I-Drug
( I-Drug I-Drug
Miralax I-Drug I-Drug
) I-Drug I-Drug
17 B-Dose B-Dose
gram I-Dose I-Dose
Powder I-Dose I-Dose
in O O
Packet O O
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
each I-Dose I-Dose
oral B-Route B-Route
QHS B-Frequency B-Frequency
predniSONE B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
sulfamethoxazole B-Drug B-Drug
- I-Drug I-Drug
trimethoprim I-Drug I-Drug
800 B-Dose B-Dose
mg I-Dose I-Dose
- I-Dose I-Dose
160 I-Dose I-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
QMONWEDFRI B-Frequency B-Frequency
QMONWEDFRI O O
metoprolol B-Drug B-Drug
succinate I-Drug I-Drug
25 I-Drug I-Drug
mg I-Drug I-Drug
Tablet I-Drug I-Drug
Extended I-Drug I-Drug
Release I-Drug I-Drug
24 I-Drug I-Drug
hr I-Drug I-Drug
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
  
LORazepam B-Drug B-Drug
( I-Drug I-Drug
Ativan I-Drug I-Drug
) I-Drug I-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
QHS B-Frequency B-Frequency
PRN I-Frequency I-Frequency
anxiety B-Indication B-Indication
warfarin B-Drug B-Drug
( I-Drug I-Drug
Coumadin I-Drug I-Drug
) O O
5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
dailyAdditional O O
Instructions O O
: O O
Monday B-Frequency B-Frequency
, I-Frequency I-Frequency
Tuesday I-Frequency I-Frequency
, I-Frequency I-Frequency
Thursday I-Frequency I-Frequency
, I-Frequency I-Frequency
Friday I-Frequency I-Frequency
, I-Frequency I-Frequency
Saturday I-Frequency I-Frequency
, I-Frequency I-Frequency
Sunday I-Frequency I-Frequency
. O O
  
HOLD O O
COUMADIN B-Drug B-Drug
ON O O
Date O O
. O O
  
Please O O
have O O
your O O
INR O O
checked O O
on O O
Date O O
and O O
dose O O
Coumadin B-Drug B-Drug
accordingly O O
, O O
goal O O
INR O O
2 O O
- O O
3 O O
. O O
  
warfarin B-Drug B-Drug
( I-Drug I-Drug
Coumadin I-Drug I-Drug
) I-Drug I-Drug
2.5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
Wednesday I-Frequency I-Frequency
ondansetron B-Drug B-Drug
HCl I-Drug I-Drug
( I-Drug I-Drug
Zofran I-Drug I-Drug
) I-Drug I-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
eight I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
nausea B-Indication B-Indication
or O O
vomiting B-Indication B-Indication
Stopped O O
medications O O
None O O
Detailed O O
Instructions O O
Discharge O O
Instructions O O
Discharge O O
Instructions O O
from O O
Date O O
3 O O
: O O
14 O O
PM O O
: O O
  
PRN O O
Statement O O
/ O O
Explanation O O
: O O
In O O
the O O
Medications O O
section O O
above O O
, O O
you O O
may O O
see O O
the O O
term O O
"PRN." O O
This O O
term O O
means O O
"as O O
needed." O O
You O O
do O O
not O O
need O O
to O O
take O O
these O O
medications O O
unless O O
you O O
are O O
having O O
that O O
specific O O
symptom O O
. O O
  
You O O
are O O
being O O
discharged O O
from O O
: O O
Hospital O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Diagnoses O O
/ O O
Problems O O
During O O
this O O
Admission O O
: O O
Chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
due O O
to O O
mechanical B-SSLIF B-SSLIF
fall I-SSLIF I-SSLIF
. O O
  
Why O O
You O O
Were O O
Admitted O O
: O O
You O O
were O O
admitted O O
to O O
Hospital O O
because O O
you O O
fell B-SSLIF B-SSLIF
and O O
had O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
from O O
injuring B-SSLIF B-SSLIF
yourself I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
your I-SSLIF I-SSLIF
walker I-SSLIF I-SSLIF
. O O
  
We O O
also O O
made O O
sure O O
this O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
was O O
not O O
due O O
to O O
problems O O
with O O
your O O
heart O O
or O O
lungs O O
, O O
and O O
we O O
also O O
made O O
sure O O
that O O
, O O
given O O
your O O
AIHA B-SSLIF B-SSLIF
and O O
history O O
of O O
pulmonary B-SSLIF B-SSLIF
embolism I-SSLIF I-SSLIF
, O O
your O O
blood O O
looked O O
appropriate O O
. O O
  
Procedures O O
Performed O O
During O O
This O O
Hospitilization O O
: O O
None O O
. O O
  
Attending O O
Physician O O
: O O
Name O O
Name O O
, O O
MD O O
Attending O O
MSI O O
Number O O
: O O
Electronic_Identifiers O O
Primary O O
Care O O
Provider O O
: O O
Name O O
Name O O
, O O
MD O O
Primary O O
Care O O
MSI O O
Number O O
: O O
Identifiers O O
Health O O
Care O O
Proxy O O
Name O O
: O O
Name O O
Name O O
Name O O
Sr. O O
/ O O
Husband O O
  
HCP O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Dr O O
. O O
  
Name O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
Date O O
at O O
3 O O
: O O
40pm O O
Follow O O
Up O O
Appointment O O
With O O
: O O
Dr O O
. O O
  
Name O O
Follow O O
Up O O
Appointment O O
Date O O
: O O
After O O
discharge O O
from O O
rehab O O
Follow O O
Up O O
Appointment O O
Comments O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Pending O O
Studies O O
at O O
the O O
Time O O
of O O
Discharge O O
/ O O
Who O O
Should O O
be O O
Contacted O O
: O O
None O O
. O O
  
Other O O
Discharge O O
Instructions O O
: O O
Please O O
hold O O
your O O
Coumadin B-Drug B-Drug
on O O
Date O O
because O O
your O O
INR O O
was O O
3.1 O O
. O O
  
Please O O
have O O
your O O
INR O O
checked O O
on O O
Date O O
and O O
dose O O
Coumadin B-Drug B-Drug
accordingly O O
, O O
goal O O
INR O O
between O O
2 O O
and O O
3 O O
. O O
  
Notify O O
MD O O
For O O
Any O O
of O O
the O O
Following O O
: O O
Increased O O
Trouble B-SSLIF B-SSLIF
Breathing I-SSLIF I-SSLIF
or O O
Chest B-SSLIF B-SSLIF
Pain I-SSLIF I-SSLIF
, O O
Fever B-SSLIF B-SSLIF
- O O
Temperature O O
Higher O O
Than O O
101 O O
Degrees O O
, O O
Pain B-SSLIF B-SSLIF
Not O O
Improved O O
by O O
Medication O O
, O O
Bleeding B-SSLIF B-SSLIF
That O O
Soaks O O
Through O O
the O O
Bandage O O
, O O
Any O O
Other O O
New O O
or O O
Concerning O O
Symptom O O
Discharge O O
Disposition O O
: O O
Skilled O O
Nursing O O
Facility O O
Discharge O O
Activity O O
: O O
As O O
Tolerated O O
Special O O
Diet O O
Instructions O O
: O O
Heart O O
Healthy O O
Acute O O
Rehabilitation O O
: O O
Company O O
Acute O O
Rehabilitation O O
Phone O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Discharge O O
Planning O O
Coordinator O O
: O O
Name O O
Name O O
, O O
RN O O
Planning O O
Coordinator O O
Contact O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Physical O O
Therapy O O
Evaluation O O
Date O O
: O O
Date O O
Physical O O
Therapy O O
Diagnosis O O
: O O
Impaired B-SSLIF B-SSLIF
mobility I-SSLIF I-SSLIF
secondary O O
to O O
weakness B-SSLIF B-SSLIF
. O O
  
Physical O O
Therapy O O
Rehabilitation O O
Precautions O O
: O O
No O O
Restrictions O O
Physical O O
Therapy O O
Weight O O
Bearing O O
Instructions O O
: O O
No O O
Restrictions O O
Physical O O
Therapy O O
Discharge O O
Status O O
: O O
Recommend O O
d O O
/ O O
c O O
home O O
with O O
PT O O
services O O
vs. O O
to O O
inpatient O O
facility O O
. O O
  
Physical O O
Therapy O O
Equipment O O
: O O
Rolling O O
Walker O O
Physical O O
Therapist O O
Name O O
and O O
Contact O O
: O O
Name O O
Name O O
, O O
DPT O O
Occupational O O
Therapy O O
Evaluation O O
Date O O
: O O
Date O O
Occupational O O
Therapy O O
Rehabilitation O O
Diagnosis O O
: O O
decreased O O
self O O
- O O
care O O
due O O
to O O
fall B-SSLIF B-SSLIF
Occupational O O
Therapy O O
Problem O O
List O O
: O O
Decreased O O
Balance O O
, O O
Decreased O O
Mobility O O
, O O
Decreased O O
Self O O
- O O
Care O O
/ O O
Daily O O
Activities O O
, O O
Decreased O O
Strength O O
Occupational O O
Therapy O O
Discharge O O
Status O O
: O O
inpatient O O
rehab O O
facility O O
to O O
increase O O
functional O O
independence O O
and O O
safety O O
Occupational O O
Therapy O O
Equipment O O
: O O
Commode O O
, O O
Rolling O O
Walker O O
, O O
Tub O O
Seat O O
  
OT O O
Therapist O O
Name O O
and O O
Contact O O
Number O O
: O O
Name O O
Name O O
OTR O O
/ O O
L O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Smoking O O
Statement O O
: O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death B-SSLIF B-SSLIF
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die O O
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses O O
through O O
exposure O O
to O O
second O O
hand O O
smoke O O
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Discharge O O
Medication O O
Reconciliation O O
Statement O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
Authorization O O
Statement O O
: O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plans O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
Translator O O
Signature O O
/ O O
Relationship O O
: O O
______________________________________________________________________ O O
  
RN O O
Signature O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
Patient O O
/ O O
Responsible O O
Party O O
Signature O O
, O O
Relationship O O
, O O
Date O O
/ O O
Time O O
: O O
______________________________________________________________________ O O
General O O
Instructions O O
Hospital O O
Patient O O
: O O
Name O O
, O O
Name O O
  
Acct.# O O
: O O
Medical_Record_Number O O
  
MR# O O
: O O
Medical_Record_Number O O
Date O O
of O O
Birth O O
: O O
Date O O
Admit O O
: O O
Date O O
Discharge O O
: O O
  
Loc O O
: O O
Location O O
  
Dict O O
By O O
: O O
Name O O
Name O O
Name O O
PA O O
  
Dict O O
Date O O
: O O
Date O O
  
Trans O O
: O O
Date O O
19 O O
: O O
19 O O
PM O O
  
ICU O O
Interim O O
Hospital O O
Summary O O
DATE O O
OF O O
ADMISSION O O
: O O
Date O O
DATE O O
OF O O
TRANSFER O O
: O O
Date O O
History O O
of O O
present O O
illness O O
and O O
physical O O
exam O O
on O O
admission O O
was O O
performed O O
by O O
Name O O
Name O O
, O O
PA O O
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
The O O
patient O O
is O O
a O O
77 O O
- O O
year O O
- O O
old O O
female O O
with O O
a O O
history O O
of O O
lymphoma B-SSLIF B-SSLIF
status O O
post O O
splenectomy O O
, O O
warm B-SSLIF B-SSLIF
IgG I-SSLIF I-SSLIF
autoantibodies I-SSLIF I-SSLIF
with O O
refractory B-SSLIF B-SSLIF
anemia I-SSLIF I-SSLIF
, O O
pulmonary B-Indication B-Indication
embolism I-Indication I-Indication
in O O
Date O O
, O O
on O O
Coumadin B-Drug B-Drug
; O O
multiple O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
. O O
  
She O O
was O O
admitted O O
via O O
the O O
ED O O
status O O
post O O
fall B-SSLIF B-SSLIF
at O O
home O O
in O O
her O O
bathroom O O
. O O
  
Ultimately O O
, O O
they O O
were O O
able O O
to O O
get O O
her O O
up O O
and O O
place O O
her O O
in O O
a O O
chair O O
. O O
  
The O O
patient O O
was O O
then O O
very B-Severity B-Severity
weak B-SSLIF B-SSLIF
and O O
unable O O
to O O
get O O
up O O
from O O
the O O
chair O O
. O O
  
Family O O
brought O O
the O O
patient O O
to O O
the O O
Emergency O O
Department O O
where O O
she O O
was O O
found O O
to O O
be O O
hypoxic B-SSLIF B-SSLIF
to O O
the O O
70s O O
with O O
a O O
low B-Indication B-Indication
systolic I-Indication I-Indication
blood I-Indication I-Indication
pressure I-Indication I-Indication
. O O
  
She O O
was O O
placed O O
on O O
nasal O O
cannula O O
and O O
given O O
250 B-Dose B-Dose
mL I-Dose I-Dose
of O O
IV B-Route B-Route
fluids B-Drug B-Drug
x1 B-Dose B-Dose
and O O
transferred O O
to O O
CCU O O
for O O
further O O
management O O
. O O
  
In O O
the O O
ED O O
, O O
labs O O
were O O
significant O O
for O O
sodium O O
of O O
135 O O
, O O
potassium O O
4.1 O O
, O O
BUN O O
/ O O
creatinine O O
of O O
23 O O
/ O O
0.73 O O
. O O
  
Troponin O O
0.03 O O
. O O
  
BNP O O
186 O O
, O O
INR O O
3.6 O O
. O O
  
WBC O O
6.9 O O
, O O
H O O
and O O
H O O
11 O O
/ O O
32.7 O O
, O O
platelets O O
134 O O
, O O
000 O O
. O O
  
ED O O
interventions O O
include O O
250 O O
mL O O
IV O O
x1 O O
, O O
6 O O
L O O
of O O
nasal O O
cannula O O
. O O
  
Imaging O O
included O O
a O O
head O O
CT O O
that O O
was O O
negative O O
for O O
acute O O
intracranial B-SSLIF B-SSLIF
abnormality I-SSLIF I-SSLIF
and O O
a O O
chest O O
CT O O
PE O O
protocol O O
that O O
showed O O
no O O
evidence O O
of O O
pulmonary B-SSLIF B-SSLIF
embolism I-SSLIF I-SSLIF
, O O
bibasilar B-SSLIF B-SSLIF
segmental I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
subsegmental I-SSLIF I-SSLIF
atelectasis I-SSLIF I-SSLIF
as O O
well O O
as O O
patient's O O
known O O
subacute O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
and O O
rib B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Include O O
latex O O
, O O
Norvasc B-Drug B-Drug
, O O
Fioricet B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
Motrin B-Drug B-Drug
, O O
naproxen B-Drug B-Drug
. O O
  
PREADMISSION O O
MEDICATIONS O O
: O O
Calcitonin B-Drug B-Drug
200 B-Dose B-Dose
units I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
citalopram B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
cyclophosphamide B-Drug B-Drug
100 B-Dose B-Dose
mg I-Dose I-Dose
, O O
vitamin B-Drug B-Drug
D2 I-Drug I-Drug
, O O
fentanyl B-Drug B-Drug
75 B-Dose B-Dose
mcg I-Dose I-Dose
transdermally B-Route B-Route
, O O
folic B-Drug B-Drug
acid I-Drug I-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
Lasix B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
alternating B-Frequency B-Frequency
with I-Frequency I-Frequency
40 I-Frequency I-Frequency
mg I-Frequency I-Frequency
daily I-Frequency I-Frequency
, O O
Vicodin B-Drug B-Drug
2 B-Dose B-Dose
tablets I-Dose I-Dose
p.r.n. B-Frequency B-Frequency
, O O
potassium B-Drug B-Drug
20 B-Dose B-Dose
mEq I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
lisinopril B-Drug B-Drug
10 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
MiraLax B-Drug B-Drug
17 B-Dose B-Dose
g I-Dose I-Dose
at B-Frequency B-Frequency
bedtime I-Frequency I-Frequency
, O O
prednisone B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
Bactrim B-Drug B-Drug
1 B-Dose B-Dose
tablet I-Dose I-Dose
three B-Frequency B-Frequency
times I-Frequency I-Frequency
per I-Frequency I-Frequency
week I-Frequency I-Frequency
, O O
Ativan B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
p.r.n. B-Frequency B-Frequency
, O O
Coumadin B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
Zofran B-Drug B-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
p.r.n. B-Frequency B-Frequency
, O O
metoprolol B-Drug B-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
b.i.d. B-Frequency B-Frequency
  
PAST O O
MEDICAL O O
HISTORY O O
: O O
Hypertension B-SSLIF B-SSLIF
, O O
pulmonary B-SSLIF B-SSLIF
embolism I-SSLIF I-SSLIF
, O O
moderate B-Severity B-Severity
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
, O O
hemolytic B-SSLIF B-SSLIF
anemia I-SSLIF I-SSLIF
. O O
  
She O O
has O O
an O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
due O O
to O O
warm B-SSLIF B-SSLIF
IgE I-SSLIF I-SSLIF
antibodies I-SSLIF I-SSLIF
, O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
, O O
diagnosed O O
in O O
Date O O
, O O
status O O
post O O
splenectomy O O
, O O
severe B-Severity B-Severity
kyphosis B-SSLIF B-SSLIF
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
denies O O
dizziness B-SSLIF B-SSLIF
. O O
  
Denies O O
loss B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
consciousness I-SSLIF I-SSLIF
. O O
  
She O O
is O O
status O O
post O O
fall B-SSLIF B-SSLIF
. O O
  
Denies O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
denies O O
palpitations B-SSLIF B-SSLIF
. O O
  
Admits O O
to O O
leg B-SSLIF B-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
Admits O O
to O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
Denies O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
. O O
  
Denies O O
asthma B-SSLIF B-SSLIF
/ O O
wheezing B-SSLIF B-SSLIF
. O O
  
Denies O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
Denies O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
Admits O O
to O O
joint B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
with O O
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
hip I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
elbow I-SSLIF I-SSLIF
. O O
  
SOCIAL O O
HISTORY O O
: O O
The O O
patient O O
was O O
formerly O O
a O O
secretary O O
. O O
  
She O O
is O O
married O O
. O O
  
She O O
denies O O
smoking O O
, O O
denies O O
alcohol O O
use O O
. O O
  
FAMILY O O
HISTORY O O
: O O
Mother O O
died B-SSLIF B-SSLIF
due O O
to O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
Father O O
died B-SSLIF B-SSLIF
at O O
age O O
80 O O
from O O
COPD B-SSLIF B-SSLIF
. O O
  
Brother O O
died B-SSLIF B-SSLIF
at O O
age O O
42 O O
from O O
laryngeal B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
PHYSICAL O O
EXAMINATION O O
ON O O
ADMISSION O O
: O O
  
GENERAL O O
: O O
The O O
patient O O
is O O
ill B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
appearing I-SSLIF I-SSLIF
, O O
obese B-SSLIF B-SSLIF
, O O
not O O
in O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
She O O
has O O
normal O O
level O O
of O O
consciousness O O
, O O
calm O O
and O O
appropriate O O
, O O
oriented O O
x3 O O
, O O
GCS O O
15 O O
. O O
  
Cranial O O
nerves O O
normal O O
. O O
  
Motor O O
normal O O
. O O
  
CN O O
grossly O O
intact O O
. O O
  
HEAD O O
AND O O
NECK O O
: O O
Pupils O O
equal O O
, O O
reactive O O
to O O
light O O
. O O
  
Neck O O
with O O
normal O O
mobility O O
. O O
  
Ears O O
normal O O
external O O
exam O O
. O O
  
Nose O O
: O O
Normal O O
external O O
exam O O
. O O
  
Mouth O O
/ O O
Pharynx O O
: O O
Normal O O
. O O
  
PULMONARY O O
: O O
The O O
patient O O
is O O
not O O
intubated O O
. O O
  
She O O
has O O
scattered B-SSLIF B-SSLIF
rhonchi I-SSLIF I-SSLIF
throughout O O
. O O
  
CARDIOVASCULAR O O
: O O
S1 O O
normal O O
, O O
S2 O O
normal O O
, O O
regular O O
rate O O
and O O
rhythm O O
, O O
systolic B-SSLIF B-SSLIF
murmur I-SSLIF I-SSLIF
grade I-SSLIF I-SSLIF
III I-SSLIF I-SSLIF
/ I-SSLIF I-SSLIF
VI I-SSLIF I-SSLIF
at I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
base I-SSLIF I-SSLIF
, O O
holosystolic O O
. O O
  
Pulses O O
normal O O
. O O
  
CHEST O O
AND O O
BACK O O
: O O
Kyphotic B-SSLIF B-SSLIF
. O O
  
GI O O
: O O
No O O
organomegaly B-SSLIF B-SSLIF
. O O
  
Abdomen B-SSLIF B-SSLIF
softly I-SSLIF I-SSLIF
distended I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
Pain B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
palpation I-SSLIF I-SSLIF
of I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
elbow I-SSLIF I-SSLIF
, O O
good O O
range O O
of O O
motion O O
. O O
  
Pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
hip I-SSLIF I-SSLIF
. O O
  
SKIN O O
: O O
No O O
lesions B-SSLIF B-SSLIF
noted O O
. O O
  
LABORATORY O O
DATA O O
ON O O
ADMISSION O O
: O O
Sodium O O
135 O O
, O O
potassium O O
4.1 O O
, O O
bicarbonate O O
33 O O
, O O
chloride O O
97 O O
, O O
BUN O O
23 O O
, O O
creatinine O O
0.73 O O
, O O
glucose O O
174 O O
, O O
calcium O O
9.8 O O
, O O
WBC O O
6.9 O O
, O O
hemoglobin O O
11 O O
, O O
hematocrit O O
32.7 O O
, O O
platelets O O
134 O O
, O O
000 O O
. O O
  
PT O O
32.2 O O
, O O
INR O O
3.1 O O
, O O
PTT O O
33.9 O O
, O O
troponin O O
0.03 O O
. O O
  
Significant O O
imaging O O
throughout O O
hospitalization O O
includes O O
a O O
head O O
CT O O
that O O
shows O O
no O O
acute O O
intracranial B-SSLIF B-SSLIF
abnormality I-SSLIF I-SSLIF
. O O
  
CT O O
PE O O
protocol O O
shows O O
no O O
evidence O O
of O O
PE B-SSLIF B-SSLIF
, O O
but O O
did O O
show O O
bibasilar B-SSLIF B-SSLIF
subsegmental I-SSLIF I-SSLIF
atelectasis I-SSLIF I-SSLIF
. O O
  
X O O
- O O
ray O O
of O O
elbow O O
did O O
show O O
a O O
nondisplaced O O
fracture B-SSLIF B-SSLIF
, O O
lucency B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
olecranon I-SSLIF I-SSLIF
and O O
an O O
x O O
- O O
ray O O
of O O
her O O
left O O
that O O
was O O
negative O O
for O O
acute O O
fracture B-SSLIF B-SSLIF
. O O
  
HOSPITAL O O
COURSE O O
BY O O
SYSTEM O O
: O O
  
1. O O
Pulmonary O O
: O O
The O O
patient O O
with O O
a O O
history O O
of O O
PE B-Indication B-Indication
in O O
Date O O
on O O
Coumadin B-Drug B-Drug
. O O
  
The O O
patient O O
with O O
progressive O O
dyspnea B-SSLIF B-SSLIF
at O O
home O O
with O O
a O O
known O O
history O O
of O O
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
with O O
last O O
pulmonary O O
artery O O
pressure O O
noted O O
to O O
be O O
50 O O
mmHg O O
per O O
last O O
echocardiogram O O
in O O
Date O O
. O O
  
She O O
is O O
noted O O
to O O
saturate O O
to O O
80s O O
with O O
walking O O
and O O
recent O O
cardiology O O
appointment O O
. O O
  
She O O
is O O
scheduled O O
to O O
see O O
Dr O O
. O O
  
Name O O
Name O O
on O O
Date O O
for O O
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
followup O O
. O O
  
She O O
was O O
found O O
to O O
be O O
hypoxic B-SSLIF B-SSLIF
with I-SSLIF I-SSLIF
O2 I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
70s I-SSLIF I-SSLIF
following O O
a O O
fall B-SSLIF B-SSLIF
at O O
home O O
. O O
  
A O O
CT O O
PE O O
protocol O O
was O O
negative O O
for O O
PE B-SSLIF B-SSLIF
and O O
did O O
show O O
bibasilar B-SSLIF B-SSLIF
atelectasis I-SSLIF I-SSLIF
, O O
but O O
no O O
consolidation B-SSLIF B-SSLIF
. O O
  
She O O
was O O
started O O
on O O
oxymizer O O
on O O
admission O O
to O O
ICU O O
, O O
initially O O
requiring O O
6 O O
L O O
and O O
subsequently O O
weaned O O
to O O
5 O O
liters O O
of O O
oxymizer O O
. O O
  
She O O
does O O
have O O
a O O
poor B-SSLIF B-SSLIF
inspiratory I-SSLIF I-SSLIF
effort I-SSLIF I-SSLIF
on O O
exam O O
. O O
  
It O O
is O O
felt O O
that O O
hypoxia B-SSLIF B-SSLIF
is O O
likely O O
not O O
multifactorial O O
and O O
related O O
to O O
her O O
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
as O O
well O O
as O O
her O O
atelectasis B-SSLIF B-SSLIF
. O O
  
Repeat O O
echocardiogram O O
on O O
Date O O
did O O
show O O
worsening O O
with O O
her O O
PA O O
systolic O O
pressure O O
up O O
to O O
70 O O
mmHg O O
. O O
  
At O O
this O O
time O O
, O O
plan O O
is O O
to O O
continue O O
her O O
oxymizer O O
to O O
maintain O O
her O O
oxygen O O
saturations O O
greater O O
than O O
90% O O
. O O
  
She O O
is O O
receiving O O
aggressive O O
pulmonary O O
toilet O O
including O O
out O O
of O O
bed O O
to O O
chair O O
as O O
well O O
as O O
incentive O O
spirometry O O
. O O
  
She O O
will O O
continue O O
on O O
_____ O O
respiratory O O
protocol O O
. O O
  
We O O
are O O
monitoring O O
respiratory O O
status O O
very O O
closely O O
and O O
following O O
discharge O O
, O O
she O O
will O O
need O O
to O O
follow O O
up O O
with O O
Name O O
Name O O
for O O
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
followup O O
. O O
  
2. O O
Neuro O O
: O O
The O O
patient O O
has O O
a O O
history O O
of O O
chronic O O
pain B-Indication B-Indication
, O O
on O O
Vicodin B-Drug B-Drug
and O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
at O O
baseline O O
. O O
  
She O O
has O O
a O O
history O O
of O O
osteoporosis B-SSLIF B-SSLIF
with O O
history O O
of O O
multiple O O
fractures B-SSLIF B-SSLIF
including I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
ribs I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
thoracic I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
. O O
  
She O O
has O O
been O O
seen O O
by O O
Dr O O
. O O
  
Name O O
in O O
the O O
past O O
for O O
chronic O O
pain B-SSLIF B-SSLIF
and O O
it O O
was O O
felt O O
that O O
pain B-SSLIF B-SSLIF
may O O
be O O
related O O
to O O
neuropathy B-Indication B-Indication
and O O
she O O
was O O
started O O
on O O
Lyrica B-Drug B-Drug
, O O
which O O
she O O
did B-ADE B-ADE
not I-ADE I-ADE
tolerate I-ADE I-ADE
. O O
  
She O O
now O O
has O O
left B-SSLIF B-SSLIF
elbow I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
hip I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
status O O
post O O
a O O
fall B-SSLIF B-SSLIF
at O O
home O O
and O O
she O O
was O O
found O O
to O O
have O O
a O O
left B-SSLIF B-SSLIF
elbow I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
. O O
  
Left B-SSLIF B-SSLIF
hip I-SSLIF I-SSLIF
films I-SSLIF I-SSLIF
were I-SSLIF I-SSLIF
negative I-SSLIF I-SSLIF
for I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
. O O
  
Head O O
CT O O
was O O
negative O O
for O O
acute O O
abnormality O O
. O O
  
She O O
was O O
continued O O
on O O
her O O
home O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
. O O
  
She O O
was O O
initially O O
on O O
IV B-Route B-Route
fentanyl B-Drug B-Drug
for O O
pain B-Indication B-Indication
control O O
as O O
well O O
; O O
however O O
, O O
was O O
noted O O
to O O
develop O O
some B-Severity B-Severity
delirium B-ADE B-ADE
associated O O
with O O
IV B-Route B-Route
fentanyl B-Drug B-Drug
administration O O
. O O
  
This O O
was O O
transitioned O O
back O O
to O O
her O O
home O O
Vicodin B-Drug B-Drug
and O O
in O O
addition O O
she O O
was O O
continued O O
on O O
her O O
home O O
Celexa B-Drug B-Drug
. O O
  
3. O O
Cardiovascular O O
: O O
The O O
patient O O
has O O
a O O
history O O
of O O
hypertension B-Indication B-Indication
and O O
pulmonary B-SSLIF B-SSLIF
artery I-SSLIF I-SSLIF
hypertension I-SSLIF I-SSLIF
, O O
on O O
Lopressor B-Drug B-Drug
, O O
lisinopril B-Drug B-Drug
and O O
Lasix B-Drug B-Drug
at O O
baseline O O
. O O
  
Of O O
note O O
, O O
her O O
Lasix B-Drug B-Drug
was O O
recently O O
increased O O
to O O
10 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
to O O
20 B-Dose B-Dose
mg I-Dose I-Dose
alternating B-Frequency B-Frequency
with I-Frequency I-Frequency
40 I-Frequency I-Frequency
mg I-Frequency I-Frequency
throughout I-Frequency I-Frequency
the I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
She O O
has O O
been O O
noted O O
to O O
have O O
hypertension B-Indication B-Indication
in O O
the O O
past O O
, O O
so O O
she O O
was O O
on O O
increased O O
Lasix B-Drug B-Drug
dose O O
. O O
  
Had O O
been O O
upon O O
admission O O
to O O
the O O
ED O O
with O O
systolic B-Indication B-Indication
blood I-Indication I-Indication
pressure I-Indication I-Indication
in I-Indication I-Indication
the I-Indication I-Indication
70s I-Indication I-Indication
, O O
which O O
did O O
improve O O
with O O
IV B-Route B-Route
fluid B-Drug B-Drug
boluses B-Dose B-Dose
. O O
  
They O O
did O O
question O O
if O O
hypertension B-SSLIF B-SSLIF
is O O
related O O
to O O
over B-SSLIF B-SSLIF
diuresis I-SSLIF I-SSLIF
given O O
her O O
recent O O
up O O
titration O O
of O O
Lasix B-Drug B-Drug
. O O
  
Her O O
Lasix B-Drug B-Drug
was O O
held O O
and O O
the O O
patient O O
was O O
started O O
on O O
IV B-Route B-Route
fluids B-Drug B-Drug
and O O
her O O
systolic O O
blood O O
pressure O O
did O O
improve O O
and O O
is O O
currently O O
running O O
110 O O
- O O
120 O O
status O O
post O O
IV B-Route B-Route
fluid B-Drug B-Drug
resuscitation O O
. O O
  
IV B-Route B-Route
fluids B-Drug B-Drug
have O O
since O O
been O O
hep O O
locked O O
. O O
  
Troponins O O
were O O
trended O O
and O O
negative O O
. O O
  
Echocardiogram O O
was O O
performed O O
on O O
Date O O
which O O
showed O O
an O O
EF O O
of O O
55% O O
- O O
60% O O
, O O
mild B-Severity B-Severity
aortic B-SSLIF B-SSLIF
regurg I-SSLIF I-SSLIF
and O O
aortic B-SSLIF B-SSLIF
stenosis I-SSLIF I-SSLIF
, O O
mild B-Severity B-Severity
mitral B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
, O O
severe B-Severity B-Severity
tricuspid B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
and O O
pulmonary O O
artery O O
systolic O O
pressure O O
of O O
70 O O
mmHg O O
. O O
  
Overall O O
, O O
echo O O
did O O
show O O
worsening O O
of O O
her O O
tricuspid B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
and O O
pulmonary O O
artery O O
systolic O O
pressure O O
. O O
  
At O O
this O O
time O O
, O O
we O O
do O O
continue O O
to O O
hold O O
home O O
Lopressor B-Drug B-Drug
, O O
lisinopril B-Drug B-Drug
and O O
Lasix B-Drug B-Drug
given O O
her O O
marginal B-SSLIF B-SSLIF
blood I-SSLIF I-SSLIF
pressure I-SSLIF I-SSLIF
. O O
  
4. O O
Hematology O O
: O O
The O O
patient O O
has O O
a O O
history O O
of O O
PE B-Indication B-Indication
in O O
Date O O
, O O
on O O
Coumadin B-Drug B-Drug
. O O
  
Her O O
INR O O
was O O
2.6 O O
on O O
admission O O
. O O
  
She O O
was O O
continued O O
on O O
her O O
Coumadin B-Drug B-Drug
with O O
INR O O
of O O
2.2 O O
on O O
Date O O
. O O
  
She O O
does O O
have O O
a O O
history O O
of O O
lymphoma B-SSLIF B-SSLIF
status O O
post O O
splenectomy O O
in O O
Date O O
and O O
have O O
refractory B-Indication B-Indication
autoimmune I-Indication I-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
from O O
IgG B-SSLIF B-SSLIF
antibody I-SSLIF I-SSLIF
. O O
  
She O O
completed O O
4 B-Duration B-Duration
weekly I-Duration I-Duration
doses I-Duration I-Duration
of O O
Rituxan B-Drug B-Drug
_____ O O
followed O O
by O O
Dr O O
. O O
  
Name O O
. O O
  
Her O O
H O O
and O O
H O O
is O O
stable O O
at O O
8.9 O O
and O O
26.1 O O
this O O
a.m. O O
  
She O O
was O O
continued O O
on O O
her O O
home O O
prednisone B-Drug B-Drug
and O O
Zyrtec B-Drug B-Drug
, O O
Cytoxan B-Drug B-Drug
while O O
inpatient O O
. O O
  
5. O O
GI O O
: O O
The O O
patient O O
has O O
been O O
tolerating O O
a O O
diet O O
. O O
  
6. O O
Endocrine O O
: O O
The O O
patient O O
was O O
maintained O O
on O O
ICU O O
glycemic O O
protocol O O
due O O
to O O
hyperglycemia B-SSLIF B-SSLIF
related O O
to O O
stress B-SSLIF B-SSLIF
. O O
  
7. O O
Oncology O O
: O O
The O O
patient O O
has O O
a O O
history O O
of O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
, O O
which O O
was O O
diagnosed O O
in O O
Date O O
. O O
  
The O O
patient O O
was O O
treated O O
with O O
splenectomy O O
only O O
with O O
improvement O O
. O O
  
8. O O
Trauma O O
: O O
The O O
patient O O
is O O
status O O
post O O
fall B-SSLIF B-SSLIF
at O O
home O O
on O O
day O O
of O O
admission O O
. O O
  
She O O
had O O
left B-SSLIF B-SSLIF
elbow I-SSLIF I-SSLIF
fractures I-SSLIF I-SSLIF
, O O
was O O
evaluated O O
by O O
Ortho O O
and O O
sugar O O
- O O
tong O O
splint O O
is O O
currently O O
in O O
place O O
. O O
  
Left O O
hip O O
films O O
were O O
negative O O
for O O
fractures B-SSLIF B-SSLIF
. O O
  
Her O O
left O O
arm O O
is O O
currently O O
nonweightbearing O O
per O O
recommendations O O
. O O
  
PT O O
consult O O
has O O
been O O
placed O O
. O O
  
9. O O
Global O O
issues O O
: O O
The O O
patient O O
is O O
her O O
own O O
medical O O
decision O O
maker O O
. O O
  
Her O O
next O O
of O O
kin O O
is O O
her O O
daughter O O
. O O
  
GI B-Indication B-Indication
prophylaxis I-Indication I-Indication
is O O
Pepcid B-Drug B-Drug
given O O
her O O
anticoagulation B-Drug B-Drug
. O O
  
DVT B-Indication B-Indication
prophylaxis I-Indication I-Indication
, O O
therapeutic O O
INR O O
on O O
Coumadin B-Drug B-Drug
. O O
  
IV O O
access O O
peripheral O O
IVs O O
. O O
  
Foley O O
is O O
currently O O
in O O
place O O
. O O
  
She O O
is O O
a O O
full O O
code O O
and O O
she O O
is O O
currently O O
stable O O
for O O
transfer O O
to O O
the O O
floor O O
. O O
  
Attending O O
: O O
Name O O
Name O O
, O O
MD O O
  
Medical_Record_Number O O
cc O O
: O O
PATIENT O O
DISCHARGE O O
: O O
  
Allergies B-ADE B-ADE
: O O
  
Latex O O
Contrast O O
  
Lyrica B-Drug B-Drug
: O O
Severe O O
amlodipine B-Drug B-Drug
Codeine B-Drug B-Drug
gabapentin B-Drug B-Drug
Iodine B-Drug B-Drug
  
Motrin B-Drug B-Drug
naproxen B-Drug B-Drug
  
NSAIDS B-Drug B-Drug
( I-Drug I-Drug
Non I-Drug I-Drug
- I-Drug I-Drug
Steroidal I-Drug I-Drug
Anti I-Drug I-Drug
- I-Drug I-Drug
Inflammatory I-Drug I-Drug
Drug I-Drug I-Drug
) O O
Shellfish O O
PROBLEMS O O
/ O O
REASON O O
FOR O O
ADMISSION O O
: O O
  
Diagnosis O O
/ O O
Problem O O
During O O
This O O
Admission O O
: O O
Fall B-SSLIF B-SSLIF
, O O
hypoxia B-SSLIF B-SSLIF
, O O
hypotension B-SSLIF B-SSLIF
Why O O
You O O
Were O O
Admitted O O
: O O
Please O O
see O O
dictation O O
summary O O
for O O
further O O
detail O O
Attending O O
Physician O O
: O O
Name O O
Name O O
, O O
MD O O
Primary O O
Care O O
Provider O O
: O O
Name O O
Name O O
, O O
MD O O
PCP O O
MSI O O
Number O O
: O O
Identifiers O O
Phone O O
Number O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Follow O O
Up O O
Appointments O O
: O O
  
With O O
: O O
PCP O O
When O O
: O O
1 O O
week O O
With O O
: O O
Dr O O
. O O
  
Name O O
( O O
ortho O O
) O O
When O O
: O O
1 O O
week O O
Comments O O
: O O
Phone O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
With O O
: O O
Please O O
refer O O
to O O
d O O
/ O O
c O O
summary O O
for O O
further O O
f O O
/ O O
u O O
recommendations O O
Pending O O
Studies O O
at O O
Time O O
of O O
Discharge O O
? O O
: O O
No O O
Other O O
Discharge O O
Instructions O O
: O O
f O O
/ O O
u O O
daily O O
urine O O
output O O
/ O O
weightO2 O O
- O O
keep O O
sats O O
>88%Continue O O
left O O
elbow O O
splintPT O O
/ O O
OTINR O O
goal O O
2 O O
- O O
3Repeat O O
CBC O O
, O O
Chem O O
10 O O
, O O
INR O O
Date O O
Restrictions O O
: O O
  
Activity O O
: O O
Out O O
of O O
Bed O O
with O O
Assist O O
Diet O O
: O O
  
Diet O O
: O O
Heart O O
Healthy O O
Completed O O
By O O
: O O
Name O O
Name O O
MD O O
Date O O
/ O O
Time O O
: O O
Date O O
14 O O
: O O
07 O O
: O O
00 O O
Vital O O
Signs O O
: O O
  
Last O O
Bowel O O
Movement O O
: O O
Date O O
IV O O
Access O O
Care O O
: O O
  
Discharge O O
Instructions O O
: O O
Reviewed O O
Discharge O O
Instructions O O
with O O
Patient O O
/ O O
Authorized O O
Representative O O
, O O
Patient O O
/ O O
Authorized O O
Representative O O
Verbalized O O
Understanding O O
of O O
Discharge O O
Instructions O O
, O O
Patient O O
/ O O
Authorized O O
Representative O O
Received O O
Written O O
Instructions O O
, O O
and O O
Prescription O O
( O O
s O O
) O O
Provided O O
to O O
Patient O O
/ O O
Authorized O O
Representative O O
. O O
  
Smoking O O
: O O
Cigarette O O
smoking O O
increases O O
your O O
risk O O
of O O
illness O O
, O O
disability O O
and O O
death O O
. O O
  
About O O
438 O O
, O O
000 O O
people O O
in O O
the O O
United O O
States O O
die O O
each O O
year O O
from O O
smoking O O
. O O
  
Smoking O O
can O O
also O O
make O O
the O O
people O O
around O O
you O O
sick O O
with O O
lung B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
, O O
heart B-SSLIF B-SSLIF
disease I-SSLIF I-SSLIF
, O O
respiratory B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
and O O
other O O
illnesses B-SSLIF B-SSLIF
through O O
exposure B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
second I-SSLIF I-SSLIF
hand I-SSLIF I-SSLIF
smoke I-SSLIF I-SSLIF
. O O
  
Quitting O O
the O O
use O O
of O O
all O O
tobacco O O
will O O
help O O
you O O
and O O
those O O
around O O
you O O
stay O O
healthy O O
. O O
  
If O O
you O O
need O O
help O O
to O O
quit O O
tobacco O O
use O O
, O O
or O O
know O O
someone O O
who O O
needs O O
help O O
, O O
call O O
the O O
number O O
below O O
or O O
talk O O
to O O
your O O
doctor O O
. O O
  
Company O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Spanish O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
( O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
) O O
Discharge O O
Medication O O
Reconciliation O O
Statement O O
: O O
The O O
home O O
medication O O
list O O
and O O
current O O
medication O O
administration O O
record O O
( O O
MAR O O
) O O
were O O
reviewed O O
prior O O
to O O
this O O
transfer O O
or O O
discharge O O
. O O
  
Please O O
refer O O
to O O
the O O
companion O O
Discharge O O
Medication O O
Instruction O O
document O O
. O O
  
Completed O O
By O O
: O O
Name O O
Name O O
Name O O
RN O O
Date O O
/ O O
Time O O
: O O
Date O O
16 O O
: O O
21 O O
: O O
00 O O
Community O O
Referrals O O
: O O
  
Acute O O
Rehabilitation O O
: O O
Name O O
Equipment O O
: O O
  
Additional O O
Case O O
Manager O O
/ O O
Social O O
Worker O O
Discharge O O
Note O O
: O O
Nursing O O
, O O
PT O O
, O O
OT O O
, O O
Pulmonary O O
Discharge O O
Planning O O
Coordinator O O
Name O O
: O O
Name O O
Planning O O
Coordinator O O
Contact O O
Phone O O
Number O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Completed O O
By O O
: O O
Name O O
Name O O
Name O O
RN O O
Date O O
/ O O
Time O O
: O O
Date O O
15 O O
: O O
44 O O
: O O
00 O O
Discharge O O
Disposition O O
: O O
Acute O O
Facility O O
Authorization O O
: O O
Authorization O O
is O O
granted O O
to O O
this O O
facility O O
to O O
release O O
any O O
/ O O
all O O
information O O
necessary O O
for O O
hospital O O
claims O O
, O O
utilization O O
review O O
and O O
continuity O O
of O O
patient O O
care O O
. O O
  
Patient O O
and O O
/ O O
or O O
caregiver O O
has O O
received O O
discharge O O
instructions O O
and O O
demonstrated O O
clear O O
understanding O O
of O O
care O O
plans O O
for O O
discharge O O
and O O
medication O O
instructions O O
. O O
  
DISCHARGE O O
MEDICATION O O
INSTRUCTIONS O O
Results O O
of O O
Medication O O
List O O
query O O
DISCHARGE O O
MEDICATION O O
INSTRUCTIONS O O
Collected O O
Date O O
/ O O
Time O O
: O O
Date O O
16 O O
: O O
15 O O
: O O
47 O O
Medication O O
Name O O
, O O
Dose O O
, O O
Route O O
, O O
Instructions O O
metoprolol B-Drug B-Drug
tartrate I-Drug I-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
polyethylene B-Drug B-Drug
glycol I-Drug I-Drug
3350 I-Drug I-Drug
17 B-Dose B-Dose
gram I-Dose I-Dose
  
1 B-Dose B-Dose
each I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
predniSONE B-Drug B-Drug
5 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
sulfamethoxazole B-Drug B-Drug
- I-Drug I-Drug
trimethoprim I-Drug I-Drug
800 B-Dose B-Dose
mg I-Dose I-Dose
- I-Dose I-Dose
160 I-Dose I-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
Monday I-Frequency I-Frequency
, I-Frequency I-Frequency
Wednesday I-Frequency I-Frequency
, I-Frequency I-Frequency
Friday I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
ondansetron B-Drug B-Drug
HCl I-Drug I-Drug
( I-Drug I-Drug
Zofran I-Drug I-Drug
) I-Drug I-Drug
4 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
eight I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
nausea B-Indication B-Indication
or O O
vomiting B-Indication B-Indication
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
warfarin B-Drug B-Drug
( I-Drug I-Drug
Coumadin I-Drug I-Drug
) O O
2.5 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Extended O O
Instructions O O
: O O
goal O O
INR B-Indication B-Indication
2 I-Indication I-Indication
- I-Indication I-Indication
3 I-Indication I-Indication
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
fexofenadine B-Drug B-Drug
( I-Drug I-Drug
Allegra I-Drug I-Drug
) I-Drug I-Drug
180 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
citalopram B-Drug B-Drug
( I-Drug I-Drug
CeleXA I-Drug I-Drug
) I-Drug I-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
cyclophosphamide B-Drug B-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
  
2 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Extended O O
Instructions O O
: O O
100mg B-Dose B-Dose
QThursday B-Frequency B-Frequency
, O O
50mg B-Dose B-Dose
All B-Frequency B-Frequency
other I-Frequency I-Frequency
days I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
ergocalciferol B-Drug B-Drug
( I-Drug I-Drug
vitamin I-Drug I-Drug
D2 I-Drug I-Drug
) I-Drug I-Drug
( I-Drug I-Drug
Vitamin I-Drug I-Drug
D I-Drug I-Drug
) I-Drug I-Drug
50 B-Dose B-Dose
, I-Dose I-Dose
000 I-Dose I-Dose
unit I-Dose I-Dose
  
1 B-Dose B-Dose
capsule I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
Monday I-Frequency I-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
fentaNYL B-Drug B-Drug
25 B-Dose B-Dose
mcg I-Dose I-Dose
/ I-Dose I-Dose
hour I-Dose I-Dose
  
1 B-Dose B-Dose
each I-Dose I-Dose
transdermal B-Route B-Route
every B-Frequency B-Frequency
seventy I-Frequency I-Frequency
two I-Frequency I-Frequency
hours I-Frequency I-Frequency
Extended O O
Instructions O O
: O O
CHANGE O O
PATCH O O
Q O O
72 O O
H O O
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
foLIC B-Drug B-Drug
Acid I-Drug I-Drug
0.4 B-Dose B-Dose
mg I-Dose I-Dose
  
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
daily B-Frequency B-Frequency
Continued O O
By O O
: O O
Name O O
Name O O
, O O
MD O O
calcitonin B-Drug B-Drug
( I-Drug I-Drug
salmon I-Drug I-Drug
) I-Drug I-Drug
200 B-Dose B-Dose
unit I-Dose I-Dose
/ I-Dose I-Dose
dose I-Dose I-Dose
  
1 B-Dose B-Dose
spray I-Dose I-Dose
topical B-Route B-Route
daily B-Frequency B-Frequency
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
Name O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Visit O O
: O O
Date O O
Location O O
: O O
Named_Sites O O
Dictated O O
: O O
Date O O
Transcribed O O
: O O
Date O O
10 O O
: O O
44 O O
A O O
  
10 O O
: O O
11 O O
A O O
CLINIC O O
NOTE O O
MEDICAL O O
DIAGNOSES O O
: O O
  
1. O O
Marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
. O O
  
She O O
is O O
status O O
post O O
splenectomy O O
in O O
Date O O
. O O
  
She O O
had O O
an O O
associated O O
IgM B-SSLIF B-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
History O O
of O O
thrombocytopenia B-SSLIF B-SSLIF
secondary O O
to O O
problem O O
#1 O O
, O O
now O O
resolved O O
. O O
  
3. O O
Status O O
post O O
splenectomy O O
in O O
Date O O
, O O
which O O
was O O
complicated O O
by O O
postoperative O O
hemorrhage B-SSLIF B-SSLIF
requiring O O
intubation O O
and O O
an O O
ICU O O
stay O O
as O O
well O O
as O O
reoperation O O
and O O
numerous O O
units O O
of O O
blood O O
. O O
  
4. O O
History O O
of O O
diverticulitis B-SSLIF B-SSLIF
requiring O O
hospitalization O O
in O O
Date O O
with O O
intermittent O O
recurrences O O
. O O
  
5. O O
History O O
of O O
acute O O
pancreatitis B-SSLIF B-SSLIF
, O O
now O O
resolved O O
. O O
  
6. O O
Cellulitis B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
thigh I-Indication I-Indication
in O O
Date O O
requiring O O
antibiotics B-Drug B-Drug
, O O
now O O
resolved O O
. O O
  
7. O O
Status O O
post O O
right O O
total O O
hip O O
replacement O O
in O O
Date O O
with O O
postoperative O O
bleeding B-SSLIF B-SSLIF
. O O
  
8. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
9. O O
Carpal O O
tunnel O O
surgery O O
bilaterally O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
. O O
  
10. O O
Hernia O O
repair O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems I-SSLIF I-SSLIF
. O O
  
CURRENT O O
THERAPY O O
: O O
The O O
patient O O
is O O
status O O
post O O
splenectomy O O
for O O
her O O
lymphoma B-Indication B-Indication
and O O
has O O
had O O
no O O
further O O
chemotherapy B-Drug B-Drug
. O O
  
ADDITIONAL O O
MEDICATIONS O O
: O O
Allegra B-Drug B-Drug
, O O
atenolol B-Drug B-Drug
, O O
folic B-Drug B-Drug
acid I-Drug I-Drug
, O O
lisinopril B-Drug B-Drug
and O O
intermittent O O
lorazepam B-Drug B-Drug
. O O
  
INTERIM O O
HISTORY O O
: O O
Name O O
Name O O
returns O O
for O O
followup O O
of O O
her O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
She O O
is O O
doing O O
well O O
, O O
but O O
is O O
complaining O O
of O O
some B-Severity B-Severity
fatigue B-SSLIF B-SSLIF
. O O
  
She O O
says O O
that O O
heat O O
is O O
bothersome O O
to O O
her O O
and O O
when O O
it O O
is O O
very O O
warm O O
, O O
she O O
does O O
not O O
go O O
out O O
very O O
much O O
. O O
  
She O O
denies O O
any O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
or O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
musculoskeletal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
continues O O
to O O
work O O
1 O O
day O O
a O O
week O O
. O O
  
As O O
noted O O
above O O
, O O
she O O
did O O
have O O
a O O
hernia O O
repair O O
by O O
Dr O O
. O O
  
Name O O
approximately O O
1 O O
month O O
ago O O
. O O
  
She O O
had O O
no O O
complications O O
from O O
the O O
surgery O O
. O O
  
REVIEW O O
OF O O
SYSTEMS O O
: O O
The O O
patient O O
has O O
fatigue B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
fevers B-SSLIF B-SSLIF
, O O
night B-SSLIF B-SSLIF
sweats I-SSLIF I-SSLIF
, O O
chills B-SSLIF B-SSLIF
, O O
headache B-SSLIF B-SSLIF
or O O
visual B-SSLIF B-SSLIF
blurring I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
problems B-SSLIF B-SSLIF
swallowing I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
cough B-SSLIF B-SSLIF
, O O
dyspnea B-SSLIF B-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
, O O
PND B-SSLIF B-SSLIF
, O O
orthopnea B-SSLIF B-SSLIF
or O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
nausea B-SSLIF B-SSLIF
or O O
vomiting B-SSLIF B-SSLIF
. O O
  
Her O O
appetite O O
is O O
good O O
. O O
  
She O O
denies O O
any O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
or O O
GI B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
dysuria B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
increased B-SSLIF B-SSLIF
bruising I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
heat B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
cold I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
known I-SSLIF I-SSLIF
glucose I-SSLIF I-SSLIF
intolerance I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
significant B-Severity B-Severity
musculoskeletal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
skin B-SSLIF B-SSLIF
rash I-SSLIF I-SSLIF
. O O
  
FAMILY O O
HISTORY O O
: O O
Negative O O
for O O
lymphoma B-SSLIF B-SSLIF
. O O
  
Her O O
father O O
died B-SSLIF B-SSLIF
at O O
age O O
80 O O
of O O
COPD B-SSLIF B-SSLIF
and O O
her O O
mother O O
died B-SSLIF B-SSLIF
at O O
age O O
84 O O
of O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
One O O
brother O O
died B-SSLIF B-SSLIF
at O O
age O O
42 O O
of O O
laryngeal B-SSLIF B-SSLIF
carcinoma I-SSLIF I-SSLIF
. O O
  
The O O
patient's O O
performance O O
status O O
is O O
ECOG O O
0 O O
. O O
  
She O O
continues O O
to O O
work O O
part O O
- O O
time O O
. O O
  
She O O
tries O O
to O O
remain O O
active O O
and O O
does O O
all O O
activities O O
of O O
daily O O
living O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
VITAL O O
SIGNS O O
: O O
The O O
patient O O
was O O
afebrile B-SSLIF B-SSLIF
, O O
blood O O
pressure O O
160 O O
/ O O
86 O O
, O O
which O O
is O O
running O O
a O O
bit O O
high O O
for O O
her O O
. O O
  
Pulse O O
73 O O
and O O
regular O O
and O O
weight O O
173 O O
pounds O O
, O O
which O O
is O O
stable O O
. O O
  
HEENT O O
: O O
No O O
scleral B-SSLIF B-SSLIF
icterus I-SSLIF I-SSLIF
. O O
  
Pharynx O O
is O O
benign O O
. O O
  
NECK O O
: O O
Supple O O
, O O
no O O
adenopathy B-SSLIF B-SSLIF
, O O
no O O
supraclavicular B-SSLIF B-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
CHEST O O
: O O
Clear O O
to O O
percussion O O
and O O
auscultation O O
. O O
  
CARDIOVASCULAR O O
: O O
Regular O O
rhythm O O
with O O
no O O
murmur B-SSLIF B-SSLIF
heard O O
. O O
  
ABDOMEN O O
: O O
Soft O O
, O O
no O O
hepatosplenomegaly B-SSLIF B-SSLIF
, O O
no O O
abdominal B-SSLIF B-SSLIF
masses I-SSLIF I-SSLIF
, O O
no O O
inguinal B-SSLIF B-SSLIF
adenopathy I-SSLIF I-SSLIF
. O O
  
EXTREMITIES O O
: O O
No O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
, O O
petechiae B-SSLIF B-SSLIF
or O O
ecchymoses B-SSLIF B-SSLIF
. O O
  
NEUROLOGICAL O O
: O O
The O O
patient O O
is O O
alert O O
and O O
oriented O O
. O O
  
Strength O O
intact O O
and O O
gait O O
normal O O
. O O
  
LABORATORY O O
DATA O O
: O O
CBC O O
: O O
White O O
blood O O
cell O O
count O O
is O O
4900 O O
with O O
54.3 O O
polys O O
, O O
27.2 O O
lymphs O O
, O O
14.1 O O
monos O O
, O O
3.8 O O
eos O O
and O O
0.6 O O
basophils O O
, O O
a O O
platelet O O
count O O
is O O
194 O O
, O O
000 O O
and O O
hemoglobin O O
is O O
13.1 O O
with O O
hematocrit O O
of O O
39.3 O O
, O O
which O O
is O O
stable O O
. O O
  
MCV O O
is O O
95 O O
. O O
  
BUN O O
is O O
18 O O
, O O
creatinine O O
is O O
0.9 O O
. O O
  
AST O O
is O O
31 O O
, O O
ALT O O
is O O
36 O O
. O O
  
An O O
LDH O O
is O O
normal O O
at O O
225 O O
. O O
  
A O O
total O O
protein O O
is O O
6.8 O O
with O O
an O O
albumin O O
of O O
4.6 O O
. O O
  
An O O
IgM B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
continues I-SSLIF I-SSLIF
to I-SSLIF I-SSLIF
be I-SSLIF I-SSLIF
very I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
at O O
18 O O
. O O
  
Free O O
kappa O O
light O O
chains O O
are O O
22.9 O O
. O O
  
Free O O
lambda O O
light O O
chains O O
our O O
14.7 O O
with O O
a O O
kappa O O
to O O
lambda O O
ratio O O
that O O
is O O
normal O O
at O O
1.55 O O
. O O
  
The O O
patient's O O
IgM O O
when O O
she O O
was O O
initially O O
diagnosed O O
was O O
801 O O
. O O
  
ASSESSMENT O O
: O O
Name O O
Name O O
is O O
a O O
74 O O
- O O
year O O
- O O
old O O
female O O
with O O
a O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
. O O
  
She O O
initially O O
had O O
thrombocytopenia B-SSLIF B-SSLIF
, O O
which O O
has O O
resolved O O
. O O
  
She O O
is O O
status O O
post O O
splenectomy O O
as O O
her O O
only O O
treatment O O
. O O
  
Her O O
IgM B-SSLIF B-SSLIF
level I-SSLIF I-SSLIF
has I-SSLIF I-SSLIF
actually I-SSLIF I-SSLIF
decreased I-SSLIF I-SSLIF
and O O
a O O
paraprotein B-SSLIF B-SSLIF
is O O
no O O
longer O O
present O O
. O O
  
She O O
herself O O
is O O
doing O O
well O O
except O O
for O O
some B-Severity B-Severity
fatigue B-SSLIF B-SSLIF
. O O
  
The O O
patient O O
does O O
have O O
hypertension B-SSLIF B-SSLIF
, O O
which O O
is O O
not O O
very O O
well O O
controlled O O
. O O
  
PLAN O O
: O O
At O O
this O O
time O O
, O O
the O O
patient O O
will O O
be O O
followed O O
by O O
observation O O
only O O
. O O
  
She O O
will O O
return O O
for O O
followup O O
in O O
4 O O
months O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Date O O
16 O O
: O O
12 O O
  
____________________________ O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
  
FI O O
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Name O O
Name O O
Name O O
, O O
MD O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Named_Sites O O
Visit O O
: O O
  
Dictated O O
Date O O
4 O O
: O O
50 O O
P O O
Transcribed O O
Date O O
6 O O
: O O
51 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
PROCEDURE O O
NOTE O O
: O O
Name O O
Name O O
comes O O
to O O
clinic O O
today O O
for O O
a O O
bone O O
marrow O O
aspirate O O
and O O
biopsy O O
to O O
complete O O
staging O O
for O O
her O O
marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
. O O
  
The O O
procedure O O
was O O
explained O O
to O O
Mrs O O
. O O
  
Name O O
. O O
  
It O O
was O O
explained O O
that O O
it O O
would O O
be O O
done O O
in O O
the O O
posterior O O
iliac O O
crest O O
and O O
that O O
there O O
would O O
be O O
some O O
pain B-ADE B-ADE
and O O
burning B-ADE B-ADE
on O O
administration O O
of O O
the O O
lidocaine B-Drug B-Drug
. O O
  
There O O
would O O
also O O
be O O
pain B-SSLIF B-SSLIF
on O O
aspiration O O
and O O
discomfort B-SSLIF B-SSLIF
with O O
the O O
biopsy O O
. O O
  
Additional O O
side O O
effects O O
of O O
bleeding B-SSLIF B-SSLIF
and O O
infection B-SSLIF B-SSLIF
were O O
also O O
explained O O
. O O
  
The O O
patient O O
understood O O
the O O
procedure O O
, O O
and O O
consent O O
was O O
signed O O
. O O
  
A O O
timeout O O
was O O
done O O
. O O
  
There O O
were O O
appropriate O O
supplies O O
and O O
the O O
site O O
was O O
rechecked O O
. O O
  
The O O
patient O O
was O O
placed O O
in O O
the O O
prone O O
position O O
, O O
and O O
the O O
area O O
of O O
the O O
left O O
posterior O O
iliac O O
crest O O
was O O
cleansed O O
with O O
Betadine B-Drug B-Drug
and O O
infiltrated O O
with O O
2% B-Dose B-Dose
lidocaine B-Drug B-Drug
. O O
  
An O O
aspirate O O
sample O O
was O O
obtained O O
without O O
difficulty O O
. O O
  
Three O O
biopsy O O
attempts O O
were O O
made O O
, O O
and O O
a O O
reasonable O O
specimen O O
was O O
obtained O O
. O O
  
A O O
total O O
of O O
approximately O O
15 B-Dose B-Dose
mL I-Dose I-Dose
of O O
lidocaine B-Drug B-Drug
was O O
eventually O O
used O O
. O O
  
The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
. O O
  
An O O
Elastoplast O O
bandage O O
was O O
applied O O
. O O
  
The O O
patient O O
was O O
placed O O
on O O
her O O
back O O
for O O
approximately O O
20 O O
minutes O O
and O O
told O O
not O O
to O O
do O O
any O O
heavy O O
activity O O
or O O
shower O O
for O O
24 O O
hours O O
. O O
  
INTERPRETATION O O
OF O O
THE O O
BONE O O
MARROW O O
ASPIRATE O O
SMEAR O O
: O O
The O O
bone O O
marrow O O
aspirate O O
was O O
hypercellular O O
with O O
megakaryocytes O O
present O O
. O O
  
The O O
myeloid B-SSLIF B-SSLIF
to I-SSLIF I-SSLIF
erythroid I-SSLIF I-SSLIF
ratio I-SSLIF I-SSLIF
was I-SSLIF I-SSLIF
increased I-SSLIF I-SSLIF
at O O
approximately O O
5 O O
: O O
1 O O
with O O
normal O O
being O O
3 O O
: O O
1 O O
. O O
  
There O O
was O O
normal O O
maturation O O
of O O
the O O
myeloid O O
series O O
. O O
  
The O O
erythropoietic B-SSLIF B-SSLIF
series I-SSLIF I-SSLIF
appeared I-SSLIF I-SSLIF
megaloblastic I-SSLIF I-SSLIF
. O O
  
There O O
were O O
perhaps O O
increased B-SSLIF B-SSLIF
lymphocytes I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
specimens I-SSLIF I-SSLIF
, O O
but O O
I O O
could O O
not O O
diagnose O O
infiltrative B-SSLIF B-SSLIF
lymphoma I-SSLIF I-SSLIF
on O O
the O O
specimens O O
. O O
  
ASSESSMENT O O
: O O
The O O
bone O O
marrow O O
aspirate O O
is O O
nondiagnostic O O
. O O
  
The O O
biopsy O O
and O O
flow O O
cytometry O O
will O O
be O O
ready O O
by O O
next O O
week O O
. O O
  
I O O
will O O
, O O
however O O
, O O
not O O
be O O
surprise O O
if O O
the O O
marrow B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
positive I-SSLIF I-SSLIF
, O O
as O O
most O O
of O O
these O O
cases O O
do O O
show O O
positivity O O
in O O
the O O
marrow O O
. O O
  
She O O
then O O
will O O
be O O
presented O O
to O O
lymphoma O O
conference O O
and O O
hopefully O O
a O O
plan O O
of O O
therapy O O
will O O
be O O
made O O
within O O
the O O
next O O
2 O O
- O O
3 O O
weeks O O
. O O
  
Splenectomy O O
is O O
probably O O
the O O
treatment O O
of O O
choice O O
. O O
  
The O O
patient O O
will O O
return O O
in O O
two O O
weeks O O
to O O
discuss O O
the O O
results O O
. O O
  
She O O
will O O
call O O
before O O
if O O
she O O
is O O
having O O
any O O
difficulty O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Date O O
14 O O
: O O
33 O O
  
____________________________ O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
  
FI O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
. O O
  
Name O O
, O O
MD O O
Date O O
Name O O
Name O O
Name O O
, O O
MD O O
  
Street_Address O O
City O O
, O O
State O O
/ O O
Zipcode O O
RE O O
: O O
Name O O
, O O
Name O O
Hospital O O
# O O
: O O
Medical_Record_Number O O
DATE O O
OF O O
SERVICE O O
: O O
Date O O
Dear O O
Dr O O
. O O
  
Name O O
: O O
  
I O O
had O O
the O O
pleasure O O
of O O
seeing O O
Name O O
Name O O
along O O
with O O
her O O
husband O O
and O O
daughter O O
for O O
followup O O
today O O
in O O
the O O
Cardiovascular O O
Clinic O O
. O O
  
As O O
you O O
know O O
, O O
she O O
is O O
a O O
very O O
lovely O O
76 O O
- O O
year O O
- O O
old O O
female O O
that O O
I O O
follow O O
with O O
Dr O O
. O O
  
Name O O
in O O
the O O
setting O O
of O O
her O O
periods O O
of O O
worsening O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
along O O
with O O
dyspnea B-SSLIF B-SSLIF
and O O
fatigue B-SSLIF B-SSLIF
. O O
  
Her O O
most O O
recent O O
echocardiograms O O
demonstrated O O
the O O
ejection O O
fraction O O
to O O
be O O
well O O
preserved O O
; O O
however O O
, O O
there O O
is O O
evidence O O
of O O
both O O
diastolic B-SSLIF B-SSLIF
dysfunction I-SSLIF I-SSLIF
and O O
pulmonary B-SSLIF B-SSLIF
hypertension I-SSLIF I-SSLIF
. O O
  
The O O
mitral B-SSLIF B-SSLIF
valve I-SSLIF I-SSLIF
demonstrates I-SSLIF I-SSLIF
mild I-SSLIF I-SSLIF
prolapse I-SSLIF I-SSLIF
involving O O
the O O
posterior O O
leaflet O O
with O O
evidence O O
of O O
moderate B-Severity B-Severity
mitral B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
and O O
tricuspid B-SSLIF B-SSLIF
regurgitation I-SSLIF I-SSLIF
. O O
  
The O O
aortic B-SSLIF B-SSLIF
valve I-SSLIF I-SSLIF
is I-SSLIF I-SSLIF
bicuspid I-SSLIF I-SSLIF
with O O
mild B-Severity B-Severity
stenosis B-SSLIF B-SSLIF
/ I-SSLIF I-SSLIF
regurgitation I-SSLIF I-SSLIF
. O O
  
We O O
have O O
been O O
making O O
adjustments O O
in O O
her O O
diuretics O O
with O O
improvement O O
in O O
her O O
symptoms O O
. O O
  
She O O
did O O
present O O
to O O
the O O
ER O O
in O O
Date O O
with O O
acute O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
and O O
was O O
noted O O
to O O
have O O
multiple O O
subsegmental O O
pulmonary B-Indication B-Indication
emboli I-Indication I-Indication
for O O
which O O
she O O
has O O
since O O
been O O
on O O
warfarin B-Drug B-Drug
. O O
  
She O O
is O O
also O O
followed O O
by O O
Dr O O
. O O
  
Name O O
for O O
management O O
of O O
her O O
lymphoma B-SSLIF B-SSLIF
and O O
autoimmune B-Indication B-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
, O O
which O O
has O O
required O O
intermittent O O
doses O O
of O O
prednisone B-Drug B-Drug
. O O
  
I O O
last O O
saw O O
Name O O
back O O
in O O
early O O
Date O O
of O O
this O O
year O O
. O O
  
At O O
this O O
point O O
, O O
she O O
was O O
feeling O O
well O O
with O O
no O O
complaints O O
of O O
worsening O O
dyspnea B-SSLIF B-SSLIF
and O O
did O O
have O O
resolution O O
of O O
her O O
lower B-SSLIF B-SSLIF
extremity I-SSLIF I-SSLIF
swelling I-SSLIF I-SSLIF
. O O
  
Her O O
in O O
office O O
clinic O O
weight O O
was O O
in O O
the O O
range O O
of O O
155 O O
pounds O O
with O O
a O O
reported O O
home O O
weight O O
in O O
the O O
range O O
of O O
149 O O
- O O
155 O O
pounds O O
. O O
  
Of O O
note O O
, O O
her O O
previous O O
weight O O
in O O
Date O O
had O O
been O O
upwards O O
of O O
171 O O
pounds O O
. O O
  
Given O O
the O O
decrease O O
in O O
her O O
blood O O
pressure O O
to O O
98 O O
/ O O
52 O O
, O O
I O O
did O O
recommend O O
that O O
we O O
decrease O O
her O O
furosemide B-Drug B-Drug
to O O
10 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
as O O
well O O
and O O
as O O
well O O
the O O
lisinopril B-Drug B-Drug
to O O
10 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
from O O
20 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
She O O
had O O
been O O
reporting O O
periods O O
of O O
lightheadedness B-SSLIF B-SSLIF
. O O
  
She O O
was O O
recently O O
in O O
for O O
followup O O
with O O
Dr O O
. O O
  
Name O O
on O O
Date O O
. O O
  
She O O
had O O
recently O O
been O O
hospitalized O O
secondary O O
to O O
a O O
fall B-SSLIF B-SSLIF
and O O
was O O
noted O O
to O O
have O O
multiple O O
compression B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
of O O
her O O
thoracic O O
spine O O
. O O
  
She O O
was O O
reporting O O
worsening O O
dyspnea B-SSLIF B-SSLIF
, O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
no O O
palpitations B-SSLIF B-SSLIF
, O O
dizziness B-SSLIF B-SSLIF
or O O
lightheadedness B-SSLIF B-SSLIF
. O O
  
She O O
had O O
also O O
noted O O
increased O O
peripheral B-SSLIF B-SSLIF
edema I-SSLIF I-SSLIF
and O O
had O O
reported O O
a O O
recent O O
adjustment O O
in O O
her O O
steroids B-Drug B-Drug
. O O
  
At O O
this O O
time O O
, O O
Dr O O
. O O
  
Name O O
did O O
feel O O
that O O
her O O
dyspnea B-ADE B-ADE
was O O
likely O O
the O O
combined O O
effects O O
of O O
restrictive B-SSLIF B-SSLIF
lung I-SSLIF I-SSLIF
disease I-SSLIF I-SSLIF
in O O
the O O
setting O O
of O O
her O O
known O O
kyphosis B-SSLIF B-SSLIF
, O O
scoliosis B-SSLIF B-SSLIF
along O O
with O O
her O O
steroid B-Drug B-Drug
regimen O O
that O O
may O O
have O O
increased B-Indication B-Indication
her I-Indication I-Indication
volume I-Indication I-Indication
status I-Indication I-Indication
and I-Indication I-Indication
blood I-Indication I-Indication
pressure I-Indication I-Indication
. O O
  
Therefore O O
, O O
he O O
did O O
recommend O O
advancing O O
her O O
furosemide B-Drug B-Drug
to O O
20 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
and O O
increase O O
the O O
lisinopril B-Drug B-Drug
to O O
20 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
and O O
recommended O O
a O O
clinical O O
followup O O
. O O
  
On O O
presentation O O
today O O
, O O
Mrs O O
. O O
  
Name O O
blood O O
pressure O O
was O O
noted O O
at O O
140 O O
/ O O
81 O O
. O O
  
Her O O
in O O
- O O
office O O
clinic O O
weight O O
was O O
140 O O
pounds O O
3.2 O O
ounces O O
, O O
clinic O O
weight O O
on O O
Date O O
was O O
in O O
the O O
range O O
of O O
152 O O
pounds O O
. O O
  
She O O
reports O O
a O O
home O O
weight O O
today O O
of O O
135 O O
pounds O O
. O O
  
She O O
feels O O
that O O
her O O
level O O
of O O
dyspnea B-SSLIF B-SSLIF
has O O
lessened O O
. O O
  
She O O
has O O
had O O
no O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
no O O
palpitations B-SSLIF B-SSLIF
, O O
no O O
further O O
dizziness B-SSLIF B-SSLIF
, O O
lightheaded B-SSLIF B-SSLIF
, O O
no O O
further O O
falls B-SSLIF B-SSLIF
. O O
  
She O O
does O O
spend O O
a O O
fair O O
amount O O
of O O
time O O
sitting O O
because O O
of O O
chronic O O
pain B-SSLIF B-SSLIF
that O O
related O O
to O O
her O O
thoracic B-SSLIF B-SSLIF
fractures I-SSLIF I-SSLIF
. O O
  
She O O
had O O
also O O
had O O
a O O
fall B-SSLIF B-SSLIF
and O O
hit B-SSLIF B-SSLIF
her I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
sternal I-SSLIF I-SSLIF
region I-SSLIF I-SSLIF
for O O
which O O
she O O
continues O O
to O O
have O O
periods O O
of O O
significant B-Severity B-Severity
discomfort B-SSLIF B-SSLIF
. O O
  
She O O
has O O
not O O
been O O
utilizing O O
her O O
hydrocodone B-Drug B-Drug
/ I-Drug I-Drug
acetaminophen I-Drug I-Drug
regimen O O
as O O
directed O O
. O O
  
She O O
is O O
eating O O
and O O
drinking O O
adequately O O
. O O
  
She O O
has O O
had O O
no O O
further O O
rectal B-SSLIF B-SSLIF
bleeding I-SSLIF I-SSLIF
and O O
has O O
been O O
on O O
her O O
warfarin B-Drug B-Drug
managed O O
by O O
the O O
Named_Sites O O
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
  
VITAL O O
SIGNS O O
: O O
Blood O O
pressure O O
140 O O
/ O O
81 O O
. O O
  
GENERAL O O
: O O
Appears O O
fatigued B-SSLIF B-SSLIF
, O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
NEUROLOGIC O O
: O O
Alert O O
and O O
oriented O O
. O O
  
Mood O O
is O O
pleasant O O
. O O
  
SKIN O O
: O O
Slight B-Severity B-Severity
pallor B-SSLIF B-SSLIF
. O O
  
NECK O O
: O O
No O O
JVD B-SSLIF B-SSLIF
. O O
  
No O O
carotid B-SSLIF B-SSLIF
bruits I-SSLIF I-SSLIF
appreciated O O
. O O
  
LUNGS O O
: O O
Respirations O O
24 O O
and O O
unlabored B-SSLIF B-SSLIF
. O O
  
Clear O O
. O O
  
No O O
rales B-SSLIF B-SSLIF
, O O
rhonchi B-SSLIF B-SSLIF
or O O
wheeze B-SSLIF B-SSLIF
. O O
  
CARDIAC O O
: O O
Regular O O
rate O O
and O O
rhythm O O
with O O
a O O
grade B-Severity B-Severity
II I-Severity I-Severity
/ I-Severity I-Severity
VI I-Severity I-Severity
systolic B-SSLIF B-SSLIF
murmur I-SSLIF I-SSLIF
appreciated O O
throughout O O
the O O
precordium O O
. O O
  
ABDOMEN O O
: O O
Soft O O
. O O
  
EXTREMITIES O O
: O O
Lower O O
extremities O O
with O O
no O O
edema B-SSLIF B-SSLIF
bilaterally O O
. O O
  
CURRENT O O
MEDICATIONS O O
: O O
Allegra B-Drug B-Drug
, O O
calcitonin B-Drug B-Drug
, O O
Celexa B-Drug B-Drug
, O O
cyclophosphamide B-Drug B-Drug
, O O
fentanyl B-Drug B-Drug
patch B-Route B-Route
, O O
furosemide B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
hydrocodone B-Drug B-Drug
/ I-Drug I-Drug
acetaminophen I-Drug I-Drug
, O O
Klor B-Drug B-Drug
- I-Drug I-Drug
Con I-Drug I-Drug
20 B-Dose B-Dose
mEq I-Dose I-Dose
daily B-Frequency B-Frequency
, O O
lisinopril B-Drug B-Drug
20 B-Dose B-Dose
daily B-Frequency B-Frequency
, O O
metoprolol B-Drug B-Drug
succinate I-Drug I-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
twice B-Frequency B-Frequency
daily I-Frequency I-Frequency
, O O
ondansetron B-Drug B-Drug
, O O
prednisone B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
, O O
Bactrim B-Drug B-Drug
, O O
and O O
warfarin B-Drug B-Drug
. O O
  
ALLERGIES B-ADE B-ADE
: O O
Codeine B-Drug B-Drug
, O O
amlodipine B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
ibuprofen B-Drug B-Drug
, O O
latex O O
, O O
naproxen B-Drug B-Drug
, O O
nonsteroidal B-Drug B-Drug
, O O
shellfish O O
, O O
Lyrica B-Drug B-Drug
. O O
  
LABORATORY O O
DATA O O
: O O
Most O O
recent O O
blood O O
work O O
, O O
BUN O O
22 O O
, O O
creatinine O O
0.71 O O
, O O
hemoglobin O O
11.3 O O
, O O
hematocrit O O
33.4 O O
, O O
platelets O O
185 O O
, O O
000 O O
. O O
  
IMPRESSION O O
AND O O
PLAN O O
: O O
At O O
this O O
time O O
, O O
I O O
did O O
recommend O O
to O O
Mrs O O
. O O
  
Name O O
that O O
she O O
continue O O
the O O
current O O
dose O O
of O O
lisinopril B-Drug B-Drug
and O O
furosemide B-Drug B-Drug
. O O
  
She O O
is O O
still O O
on O O
a O O
high O O
dose O O
of O O
prednisone B-Drug B-Drug
, O O
which O O
in O O
combination O O
with O O
the O O
Lyrica B-Drug B-Drug
did O O
prompt O O
fluid B-ADE B-ADE
retention I-ADE I-ADE
. O O
  
She O O
feels O O
that O O
her O O
breathing O O
is O O
back O O
to O O
be O O
baseline O O
. O O
  
I O O
did O O
, O O
however O O
, O O
recommend O O
that O O
her O O
daughter O O
who O O
is O O
a O O
nurse O O
, O O
monitor O O
her O O
blood O O
pressures O O
closely O O
. O O
  
In O O
the O O
past O O
once O O
her O O
prednisone B-Drug B-Drug
was O O
tapered O O
to O O
a O O
lower O O
dose O O
she O O
did O O
have O O
a O O
decline B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
her I-SSLIF I-SSLIF
blood I-SSLIF I-SSLIF
pressure I-SSLIF I-SSLIF
and O O
we O O
may O O
need O O
to O O
make O O
further O O
adjustments O O
in O O
the O O
furosemide B-Drug B-Drug
and O O
lisinopril B-Drug B-Drug
regimen O O
. O O
  
Her O O
daughter O O
was O O
quite O O
concerned O O
with O O
the O O
fact O O
that O O
her O O
mother O O
is O O
sedentary O O
and O O
has O O
not O O
been O O
taking O O
her O O
pain B-Drug B-Drug
medication I-Drug I-Drug
. O O
  
Mrs O O
. O O
  
Name O O
did O O
state O O
that O O
she O O
will O O
wait O O
to O O
the O O
point O O
where O O
the O O
discomfort B-SSLIF B-SSLIF
is O O
intolerable B-Severity B-Severity
and O O
then O O
take O O
the O O
pain B-Drug B-Drug
medication I-Drug I-Drug
. O O
  
I O O
did O O
explain O O
that O O
given O O
her O O
multiple O O
fractures B-SSLIF B-SSLIF
that O O
it O O
would O O
be O O
best O O
that O O
she O O
be O O
consistent O O
with O O
her O O
pain B-Drug B-Drug
medication I-Drug I-Drug
and O O
continue O O
a O O
good O O
bowel O O
regimen O O
. O O
  
This O O
would O O
allow O O
her O O
to O O
be O O
more O O
active O O
and O O
not O O
be O O
so O O
deconditioned O O
, O O
which O O
could O O
also O O
further O O
aggravate O O
her O O
overall O O
sense O O
of O O
well O O
being O O
. O O
  
I O O
did O O
recommend O O
that O O
I O O
see O O
her O O
back O O
in O O
6 O O
weeks O O
once O O
her O O
steroids B-Drug B-Drug
have O O
been O O
tapered O O
down O O
to O O
reassess O O
her O O
blood O O
pressure O O
and O O
fluid O O
status O O
, O O
she O O
was O O
in O O
agreement O O
with O O
that O O
. O O
  
She O O
will O O
continue O O
her O O
warfarin B-Drug B-Drug
. O O
  
We O O
will O O
continue O O
to O O
monitor O O
her O O
echocardiograms O O
over O O
time O O
. O O
  
As O O
always O O
, O O
it O O
is O O
a O O
pleasure O O
to O O
follow O O
this O O
nice O O
lady O O
with O O
you O O
. O O
  
Sincerely O O
, O O
Name O O
Name O O
, O O
NP O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
MD O O
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
N.P. O O
Date O O
4 O O
: O O
25PM O O
EST O O
CHIEF O O
COMPLAINT O O
: O O
Established O O
osteoporosis B-SSLIF B-SSLIF
, O O
vitamin B-SSLIF B-SSLIF
D I-SSLIF I-SSLIF
deficiency I-SSLIF I-SSLIF
. O O
  
HISTORY O O
OF O O
PRESENT O O
ILLNESS O O
: O O
75 O O
- O O
year O O
- O O
old O O
RN O O
who O O
comes O O
in O O
today O O
with O O
her O O
daughter O O
and O O
her O O
husband O O
to O O
go O O
over O O
the O O
results O O
of O O
her O O
labs O O
and O O
to O O
determine O O
further O O
course O O
of O O
action O O
. O O
  
She O O
has O O
now O O
been O O
on O O
the O O
ergocalciferol B-Drug B-Drug
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
since O O
I O O
last O O
saw O O
her O O
in O O
Date O O
. O O
  
They O O
picked O O
it O O
up O O
that O O
day O O
. O O
  
She O O
feels O O
no O O
different O O
on O O
the O O
ergocalciferol B-Drug B-Drug
. O O
  
Her O O
prednisone B-Drug B-Drug
dose O O
has O O
been O O
decreased O O
and O O
now O O
she O O
is O O
only O O
taking O O
15 B-Dose B-Dose
mg I-Dose I-Dose
a B-Frequency B-Frequency
day I-Frequency I-Frequency
. O O
  
She O O
is O O
using O O
a O O
Lidoderm B-Drug B-Drug
patch B-Route B-Route
in O O
addition O O
to O O
the O O
hydromorphone B-Drug B-Drug
and O O
is O O
still O O
having O O
some O O
pain B-Indication B-Indication
in I-Indication I-Indication
her I-Indication I-Indication
left I-Indication I-Indication
shin I-Indication I-Indication
. O O
  
This O O
does O O
not O O
seem O O
to O O
resolve O O
. O O
  
MEDICATIONS O O
( O O
Reviewed O O
and O O
updated O O
) O O
: O O
Hydromorphone B-Drug B-Drug
. O O
  
Lidoderm B-Drug B-Drug
patch B-Route B-Route
. O O
  
Bactrim B-Drug B-Drug
. O O
  
Lorazepam B-Drug B-Drug
. O O
  
Lisinopril B-Drug B-Drug
. O O
  
Metoprolol B-Drug B-Drug
. O O
  
Prednisone B-Drug B-Drug
. O O
  
Folate B-Drug B-Drug
. O O
  
Ergocalciferol B-Drug B-Drug
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
. O O
  
PHYSICAL O O
EXAMINATION O O
: O O
Blood O O
pressure O O
162 O O
/ O O
80 O O
, O O
pulse O O
88 O O
, O O
weight O O
158.0 O O
pounds O O
, O O
BMI O O
29.4 O O
. O O
  
General O O
: O O
Sitting O O
comfortably O O
in O O
the O O
chair O O
in O O
no O O
acute O O
distress B-SSLIF B-SSLIF
. O O
  
LABS O O
( O O
Date O O
) O O
: O O
ICA O O
5.7 O O
, O O
phos O O
3.6 O O
, O O
ATA O O
negative O O
, O O
25D O O
25 O O
, O O
1 O O
, O O
25D O O
55 O O
, O O
PTH O O
10 O O
, O O
BALK O O
32.3 O O
, O O
Celiac O O
+ O O
/ O O
- O O
. O O
  
NTX O O
30 O O
. O O
  
LABS O O
( O O
Date O O
) O O
: O O
ICA O O
5.6 O O
, O O
CA O O
10.6 O O
, O O
ALB O O
4.3 O O
, O O
25D O O
45 O O
, O O
PTH O O
15 O O
, O O
BALK O O
34.5 O O
, O O
PTH O O
less O O
than O O
1.9 O O
, O O
ACE O O
10 O O
. O O
  
IMPRESSION O O
  
1. O O
Established O O
steroid B-Drug B-Drug
osteoporosis B-ADE B-ADE
. O O
  
With O O
fractures B-SSLIF B-SSLIF
that O O
occurred O O
prior O O
to O O
starting O O
the O O
prednisone B-Drug B-Drug
. O O
  
Does O O
have O O
some O O
issue O O
with O O
bone O O
quality O O
. O O
  
I O O
suspect O O
based O O
on O O
an O O
elevated B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
alkaline I-SSLIF I-SSLIF
phosphatase I-SSLIF I-SSLIF
on O O
two O O
occasions O O
even O O
with O O
an O O
improved O O
vitamin O O
D O O
. O O
  
NTX O O
is O O
not O O
markedly O O
elevated O O
. O O
  
Need O O
to O O
consider O O
whether O O
starting O O
antiresorptive B-Drug B-Drug
therapy I-Drug I-Drug
will O O
affect O O
bone O O
formation O O
and O O
not O O
just O O
bone O O
reabsorption O O
. O O
  
NTX O O
is O O
not O O
elevated O O
. O O
  
PTH B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
low I-SSLIF I-SSLIF
and O O
on O O
repeat O O
continues O O
to O O
be O O
low O O
. O O
  
Will O O
aggressively O O
treat O O
vitamin B-SSLIF B-SSLIF
D I-SSLIF I-SSLIF
deficiency I-SSLIF I-SSLIF
and O O
reassess O O
. O O
  
Will O O
check O O
osteocalcin O O
with O O
next O O
set O O
of O O
laboratories O O
. O O
  
2. O O
Hypercalcemia B-SSLIF B-SSLIF
. O O
  
Mildly B-Severity B-Severity
elevated B-SSLIF B-SSLIF
ionized I-SSLIF I-SSLIF
calcium I-SSLIF I-SSLIF
level I-SSLIF I-SSLIF
now O O
on O O
two O O
occasions O O
with O O
calcium O O
levels O O
in O O
the O O
normal O O
range O O
and O O
a O O
low B-SSLIF B-SSLIF
PTH I-SSLIF I-SSLIF
level I-SSLIF I-SSLIF
. O O
  
Most O O
likely O O
normal O O
variant O O
and O O
will O O
just O O
continue O O
to O O
follow O O
at O O
this O O
time O O
. O O
  
However O O
, O O
I O O
am O O
hesitant O O
about O O
using O O
Forteo B-Drug B-Drug
at O O
this O O
time O O
until O O
we O O
confirm O O
that O O
that O O
is O O
not O O
an O O
issue O O
or O O
progressing O O
. O O
  
The O O
Forteo B-Drug B-Drug
can O O
aggravate O O
hypercalcemia B-ADE B-ADE
. O O
  
3. O O
Elevated B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
alkaline I-SSLIF I-SSLIF
phosphatase I-SSLIF I-SSLIF
. O O
  
Mildly B-Severity B-Severity
elevated B-SSLIF B-SSLIF
bone I-SSLIF I-SSLIF
alkaline I-SSLIF I-SSLIF
phosphatase I-SSLIF I-SSLIF
. O O
  
Will O O
reassess O O
prior O O
to O O
next O O
visit O O
and O O
consider O O
bone O O
scan O O
once O O
vitamin O O
D O O
levels O O
are O O
in O O
goal O O
range O O
regularly O O
chronically O O
. O O
  
4. O O
Vitamin B-Indication B-Indication
D I-Indication I-Indication
deficiency I-Indication I-Indication
. O O
  
Responded O O
very O O
well O O
to O O
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
week I-Frequency I-Frequency
vitamin B-Drug B-Drug
D I-Drug I-Drug
without O O
any O O
changing O O
calcium O O
level O O
, O O
but O O
has O O
not O O
helped O O
with O O
shin B-SSLIF B-SSLIF
splints I-SSLIF I-SSLIF
. O O
  
Will O O
decrease O O
the O O
ergocalciferol B-Drug B-Drug
weekly O O
. O O
  
PLAN O O
  
1. O O
Decrease O O
ergocalciferol B-Drug B-Drug
weekly O O
. O O
  
2. O O
Followup O O
two O O
months O O
. O O
  
3. O O
Laboratories O O
prior O O
to O O
next O O
visit O O
. O O
  
4. O O
Consider O O
a O O
bone O O
scan O O
. O O
  
5. O O
ACE O O
level O O
pending O O
. O O
  
6. O O
Call O O
/ O O
followup O O
sooner O O
if O O
any O O
further O O
problems O O
, O O
questions O O
, O O
issues O O
arise O O
. O O
  
COUNSELING O O
: O O
The O O
full O O
15 O O
- O O
minute O O
visit O O
with O O
patient O O
and O O
her O O
husband O O
and O O
daughter O O
reviewing O O
the O O
above O O
issues O O
. O O
  
Electronically O O
signed O O
by O O
: O O
Name O O
Name O O
M.D. O O
Date O O
6 O O
: O O
25AM O O
EST O O
HOSPITAL O O
: O O
Hospital O O
HOSPITAL O O
MEDICINE O O
DISCHARGE O O
SUMMARY O O
Hospital O O
Day O O
# O O
: O O
5 O O
Patient O O
Name O O
: O O
Name O O
, O O
Name O O
Name O O
  
DOB O O
: O O
Date O O
Age O O
: O O
76 O O
Sex O O
: O O
F O O
Account O O
# O O
: O O
Medical_Record_Number O O
Medical O O
Record O O
# O O
: O O
Medical_Record_Number O O
Admission O O
Date O O
: O O
Date O O
; O O
Date O O
Discharge O O
Date O O
: O O
Date O O
; O O
Date O O
Location O O
: O O
Location O O
Attending O O
MD O O
Name O O
: O O
Name O O
, O O
Name O O
Resident O O
Name O O
: O O
Name O O
- O O
Name O O
, O O
Name O O
Pager O O
# O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Chief O O
Complaint O O
: O O
Shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
History O O
of O O
Present O O
Illness O O
: O O
76 O O
year O O
old O O
female O O
with O O
autoimmune B-SSLIF B-SSLIF
hemolytic I-SSLIF I-SSLIF
anemia I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
lymphoma B-SSLIF B-SSLIF
and O O
other O O
PMH O O
as O O
below O O
presented O O
to O O
hospital O O
ED O O
for O O
worsening O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
for O O
the O O
past O O
1 O O
week O O
. O O
  
Daughters O O
think O O
she O O
is O O
most O O
likely O O
short B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
for O O
more O O
than O O
a O O
month O O
. O O
  
She O O
has O O
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
on I-SSLIF I-SSLIF
exertion I-SSLIF I-SSLIF
and O O
on O O
Date O O
was O O
not O O
able O O
to O O
take O O
even O O
few O O
steps O O
and O O
was O O
in O O
resp B-SSLIF B-SSLIF
distress I-SSLIF I-SSLIF
after O O
that O O
. O O
  
She O O
was O O
also O O
feeling O O
air B-Indication B-Indication
hunger I-Indication I-Indication
and O O
feels O O
comfortable O O
on O O
oxygen B-Drug B-Drug
in O O
the O O
hospital O O
. O O
  
She O O
denies O O
any O O
fever B-SSLIF B-SSLIF
and O O
chills B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
cough B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
She O O
was O O
seen O O
by O O
cardiology O O
Dr O O
Name O O
for O O
possible O O
CHF B-SSLIF B-SSLIF
as O O
cause O O
of O O
SOB B-SSLIF B-SSLIF
and O O
was O O
started O O
on O O
PO B-Route B-Route
lasix B-Drug B-Drug
as O O
she O O
had O O
some O O
leg B-Indication B-Indication
swelling I-Indication I-Indication
as O O
well O O
. O O
  
Lasix B-Drug B-Drug
dose O O
was O O
recently O O
increased O O
from O O
20 B-Dose B-Dose
to O O
40 B-Dose B-Dose
as O O
she O O
had O O
worsening O O
SOB B-Indication B-Indication
. O O
  
She O O
continues O O
to O O
be O O
on O O
PO B-Route B-Route
prednsione B-Drug B-Drug
for O O
hemolytic B-Indication B-Indication
anemia I-Indication I-Indication
. O O
  
She O O
is O O
always O O
a O O
difficult O O
candidate O O
for O O
transfusion O O
due O O
to O O
antibodies B-SSLIF B-SSLIF
. O O
  
She O O
is O O
also O O
difficult O O
intubation O O
and O O
requires O O
flex O O
scope O O
She O O
complains O O
of O O
lower B-SSLIF B-SSLIF
back I-SSLIF I-SSLIF
pain I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
middle I-SSLIF I-SSLIF
. O O
  
She O O
denies O O
any O O
urinary B-SSLIF B-SSLIF
complaints I-SSLIF I-SSLIF
. O O
  
She O O
has O O
pain B-SSLIF B-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
leg I-SSLIF I-SSLIF
and O O
had O O
leg O O
duplex O O
a O O
few O O
months O O
ago O O
which O O
were O O
negative O O
for O O
DVT B-SSLIF B-SSLIF
. O O
  
She O O
denies O O
any O O
abdominal B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
, O O
diarrhea B-SSLIF B-SSLIF
, O O
constipation B-SSLIF B-SSLIF
. O O
  
Drug B-ADE B-ADE
Allergies I-ADE I-ADE
/ O O
ADR O O
from O O
Pharmacy O O
: O O
Contrast O O
, O O
Latex O O
, O O
amlodipine B-Drug B-Drug
, O O
Codeine B-Drug B-Drug
, O O
gabapentin B-Drug B-Drug
, O O
Iodine B-Drug B-Drug
, O O
Motrin B-Drug B-Drug
, O O
naproxen B-Drug B-Drug
, O O
NSAIDS B-Drug B-Drug
( O O
Non B-Drug B-Drug
- I-Drug I-Drug
Steroidal I-Drug I-Drug
Anti I-Drug I-Drug
- I-Drug I-Drug
Inflammatory I-Drug I-Drug
Drug I-Drug I-Drug
) O O
, O O
Shellfish O O
, O O
Shellfish O O
Past O O
Medical O O
/ O O
Surgical O O
History O O
: O O
1 O O
. O O
  
Marginal B-SSLIF B-SSLIF
zone I-SSLIF I-SSLIF
lymphoma I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
spleen I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
bone I-SSLIF I-SSLIF
marrow I-SSLIF I-SSLIF
diagnosed O O
in O O
Date O O
. O O
  
She O O
is O O
status O O
post O O
splenectomy O O
in O O
Date O O
. O O
  
She O O
had O O
an O O
associated O O
IgM B-SSLIF B-SSLIF
paraprotein I-SSLIF I-SSLIF
. O O
  
2. O O
Autoimmune B-Indication B-Indication
hemolytic I-Indication I-Indication
anemia I-Indication I-Indication
, O O
on O O
prednisone B-Drug B-Drug
since O O
Date O O
  
3. O O
History O O
of O O
thrombocytopenia B-SSLIF B-SSLIF
secondary O O
to O O
problem O O
#1 O O
, O O
now O O
resolved O O
. O O
  
4. O O
Status O O
post O O
splenectomy O O
in O O
Date O O
, O O
which O O
was O O
complicated O O
by O O
postoperative O O
hemorrhage B-SSLIF B-SSLIF
requiring O O
intubation O O
, O O
and O O
an O O
ICU O O
stay O O
as O O
well O O
as O O
reoperation O O
and O O
numerous O O
units O O
of O O
blood O O
. O O
  
5. O O
History O O
of O O
diverticulitis B-SSLIF B-SSLIF
requiring O O
hospitalization O O
in O O
Date O O
with O O
intermittent O O
recurrences O O
. O O
  
6. O O
History O O
of O O
acute O O
pancreatitis B-SSLIF B-SSLIF
, O O
now O O
resolved O O
Date O O
  
7. O O
Cellulitis B-Indication B-Indication
of I-Indication I-Indication
the I-Indication I-Indication
right I-Indication I-Indication
thigh I-Indication I-Indication
in O O
Date O O
requiring O O
antibiotics B-Drug B-Drug
, O O
now O O
resolved O O
. O O
  
8. O O
Status O O
post O O
right O O
total O O
hip O O
replacement O O
in O O
Date O O
with O O
postoperative O O
bleeding B-SSLIF B-SSLIF
. O O
  
9. O O
Hypertension B-SSLIF B-SSLIF
. O O
  
10. O O
Carpal O O
tunnel O O
surgery O O
bilaterally O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems O O
. O O
  
11. O O
Hernia O O
repair O O
in O O
Date O O
with O O
no O O
bleeding B-SSLIF B-SSLIF
problems O O
. O O
  
12. O O
L3 B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
4 I-SSLIF I-SSLIF
spinal I-SSLIF I-SSLIF
fractures I-SSLIF I-SSLIF
about O O
1 O O
- O O
2 O O
months O O
ago O O
. O O
  
13. O O
Lower B-SSLIF B-SSLIF
GI I-SSLIF I-SSLIF
bleed I-SSLIF I-SSLIF
secondary O O
to O O
ischemic B-SSLIF B-SSLIF
colitis I-SSLIF I-SSLIF
in O O
Date O O
FAMILY O O
HISTORY O O
/ O O
SOCIAL O O
HISTORY O O
Family O O
History O O
: O O
Negative O O
for O O
lymphoma B-SSLIF B-SSLIF
. O O
  
Her O O
father O O
died B-SSLIF B-SSLIF
at O O
age O O
80 O O
of O O
COPD B-SSLIF B-SSLIF
and O O
her O O
mother O O
died B-SSLIF B-SSLIF
at O O
age O O
84 O O
of O O
bladder B-SSLIF B-SSLIF
cancer I-SSLIF I-SSLIF
. O O
  
One O O
brother O O
died B-SSLIF B-SSLIF
at O O
age O O
42 O O
of O O
laryngeal B-SSLIF B-SSLIF
carcinoma I-SSLIF I-SSLIF
. O O
  
Home O O
Environment O O
/ O O
Family O O
/ O O
Significant O O
Background O O
/ O O
Values O O
: O O
lives O O
at O O
home O O
in O O
City O O
with O O
husband O O
. O O
  
Occupation O O
: O O
Patient O O
works O O
as O O
a O O
secretary O O
and O O
gardens O O
. O O
  
Smoking O O
History O O
: O O
Never O O
smoked O O
Alcohol O O
History O O
: O O
none O O
  
Illicits O O
History O O
: O O
denies O O
PROBLEM O O
LIST O O
/ O O
DISCHARGE O O
DIAGNOSES O O
Problem O O
List O O
: O O
1 O O
; O O
SOB B-SSLIF B-SSLIF
/ O O
DOE B-SSLIF B-SSLIF
2 O O
/ O O
2 O O
to O O
PE B-SSLIF B-SSLIF
Patient O O
was O O
oxygenating O O
well O O
on O O
4L O O
, O O
and O O
thus O O
the O O
O2 B-Drug B-Drug
was O O
titrated O O
down O O
to O O
2L B-Dose B-Dose
, O O
maintaining O O
an O O
O2 O O
saturation O O
of O O
>92% O O
. O O
  
She O O
continued O O
to O O
oxygenate O O
well O O
on O O
1L O O
, O O
but O O
trending O O
ambulatory O O
pulse O O
oximetry O O
on O O
1L O O
led O O
to O O
an O O
O2 O O
of O O
92% O O
and O O
some B-Severity B-Severity
shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
breath I-SSLIF I-SSLIF
. O O
  
She O O
was O O
started O O
on O O
coumadin B-Drug B-Drug
, O O
with O O
a O O
IV B-Route B-Route
heparin B-Drug B-Drug
bridge O O
, O O
for O O
a O O
goal O O
of O O
an O O
INR O O
between O O
2 O O
and O O
3 O O
. O O
  
In O O
order O O
to O O
facilitate O O
the O O
patient O O
going O O
home O O
, O O
the O O
IV B-Route B-Route
heparin B-Drug B-Drug
was O O
switched O O
lovenox B-Drug B-Drug
. O O
  
The O O
patient O O
will O O
go O O
home O O
on O O
lovenox B-Drug B-Drug
  
70mL B-Dose B-Dose
BID B-Frequency B-Frequency
until O O
she O O
has O O
a O O
therapeutic O O
INR O O
, O O
and O O
she O O
will O O
go O O
home O O
on O O
2L B-Dose B-Dose
of O O
oxygen B-Drug B-Drug
. O O
  
She O O
was O O
given O O
a O O
prescription O O
for O O
those O O
, O O
as O O
well O O
as O O
for O O
coumadin B-Drug B-Drug
. O O
  
ATTENDING O O
COMMENTS O O
: O O
Pt O O
had O O
complains O O
of O O
DOE B-SSLIF B-SSLIF
and O O
was O O
found O O
to O O
have O O
bilateral B-Indication B-Indication
subsegmental I-Indication I-Indication
PE I-Indication I-Indication
on O O
CT O O
chest O O
done O O
on O O
admission O O
. O O
  
She O O
was O O
initailly O O
started O O
on O O
heparin B-Drug B-Drug
drip B-Route B-Route
which O O
can O O
be O O
easily O O
titrated O O
given O O
her O O
co O O
- O O
morbidities O O
of O O
AIHA B-SSLIF B-SSLIF
and O O
recent O O
GIB B-SSLIF B-SSLIF
last O O
month O O
. O O
  
Her O O
H O O
/ O O
H O O
was O O
closely O O
monitored O O
and O O
remained O O
stable O O
. O O
  
Hematology O O
was O O
consulted O O
and O O
they O O
agreed O O
with O O
initial O O
anticoagulation O O
plans O O
with O O
heprain B-Drug B-Drug
drip B-Route B-Route
. O O
  
Since O O
her O O
condition O O
remained O O
stable O O
, O O
she O O
was O O
safely O O
transitioned O O
to O O
lovenox B-Drug B-Drug
for O O
bridging O O
and O O
coumadin B-Drug B-Drug
was O O
initiated O O
. O O
  
All O O
arrangements O O
made O O
for O O
her O O
to O O
continue O O
anticoag O O
under O O
close O O
monitoring O O
of O O
anticoag O O
clinic O O
. O O
  
She O O
was O O
also O O
provided O O
with O O
home O O
oxygen B-Drug B-Drug
as O O
ambulatory O O
pulseox B-Indication B-Indication
was I-Indication I-Indication
low I-Indication I-Indication
. O O
  
Her O O
goal O O
INR O O
is O O
2 O O
- O O
3 O O
. O O
  
She O O
also O O
gets O O
CBC O O
done O O
weekly O O
which O O
will O O
be O O
continued O O
. O O
  
Daughters O O
will O O
be O O
administering O O
the O O
loevnox B-Drug B-Drug
. O O
  
Explained O O
to O O
pt O O
that O O
lovenox B-Drug B-Drug
will O O
be O O
stopped O O
once O O
INR O O
is O O
therapeutic O O
. O O
  
INR O O
1.3 O O
on O O
discharge O O
  
2 O O
; O O
Respiratory B-Indication B-Indication
failure I-Indication I-Indication
Patient O O
has O O
not O O
experienced O O
respiratory B-Indication B-Indication
distress I-Indication I-Indication
during O O
hospital O O
course O O
. O O
  
ATTENDING O O
COMMENTS O O
: O O
sec O O
to O O
PE. B-Indication B-Indication
supplemental O O
O2 B-Drug B-Drug
  
3 O O
; O O
CAD B-SSLIF B-SSLIF
We O O
continued O O
with O O
the O O
patient's O O
home O O
medications O O
, O O
and O O
she O O
did O O
not O O
have O O
any O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
during O O
this O O
hospitalization O O
. O O
  
ATTENDING O O
COMMENTS O O
: O O
initial O O
bump O O
in O O
trops O O
in O O
setting O O
of O O
PE B-SSLIF B-SSLIF
. O O
  
No O O
chest B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
. O O
  
home O O
meds O O
were O O
continued O O
  
4 O O
; O O
Hemolytic B-Indication B-Indication
anemia I-Indication I-Indication
We O O
monitored O O
the O O
patient's O O
hemoglobin O O
and O O
hematocrit O O
regularly O O
, O O
and O O
continued O O
her O O
on O O
PO B-Route B-Route
prednisone B-Drug B-Drug
. O O
  
Her O O
H+H O O
Date O O
are O O
11.2 O O
and O O
32.1 O O
. O O
  
ATTENDING O O
COMMENTS O O
: O O
H O O
/ O O
H O O
remained O O
stable O O
. O O
  
she O O
was O O
contineud O O
on O O
home O O
dose O O
of O O
30 B-Dose B-Dose
mg I-Dose I-Dose
prednisone B-Drug B-Drug
daily B-Frequency B-Frequency
  
5 O O
; O O
Depression B-Indication B-Indication
We O O
continued O O
the O O
patient O O
on O O
citalopram B-Drug B-Drug
, O O
and O O
she O O
did O O
not O O
have O O
mood B-SSLIF B-SSLIF
symptoms I-SSLIF I-SSLIF
while O O
in O O
the O O
hospital O O
. O O
  
ATTENDING O O
COMMENTS O O
: O O
continue O O
citalopram B-Drug B-Drug
  
6 O O
; O O
Backache B-SSLIF B-SSLIF
The O O
patient O O
did O O
not O O
complain O O
of O O
significant B-Severity B-Severity
back B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
during O O
her O O
hospitalization O O
. O O
  
We O O
continued O O
her O O
home O O
medications O O
. O O
  
7 O O
; O O
Leg B-SSLIF B-SSLIF
pain I-SSLIF I-SSLIF
ATTENDING O O
COMMENTS O O
: O O
Pt O O
did O O
complain O O
of O O
left B-Indication B-Indication
leg I-Indication I-Indication
pain I-Indication I-Indication
( O O
chronic O O
) O O
. O O
  
Lidoderm B-Drug B-Drug
patch B-Route B-Route
helped O O
during O O
hospitalization O O
PHYSICAL O O
EXAM O O
Temp O O
: O O
36.4 O O
Pulse O O
: O O
82 O O
  
Resp O O
: O O
18 O O
  
BP O O
: O O
127 O O
/ O O
72 O O
Pulse O O
Ox O O
: O O
97% O O
on O O
2L O O
Physical O O
Exam O O
Systems O O
: O O
GENERAL O O
: O O
No O O
apparent O O
distress B-SSLIF B-SSLIF
EYES O O
/ O O
ENT O O
: O O
Pupils O O
equal O O
, O O
round O O
, O O
and O O
react O O
to O O
light O O
; O O
Conjunctivae O O
non B-SSLIF B-SSLIF
- I-SSLIF I-SSLIF
ictereric I-SSLIF I-SSLIF
; O O
No O O
oral B-SSLIF B-SSLIF
thrush I-SSLIF I-SSLIF
; O O
Moist O O
oral O O
mucosa O O
, O O
no O O
lesions B-SSLIF B-SSLIF
RESPIRATORY O O
: O O
Clear O O
to O O
auscultation O O
, O O
no O O
wheezing B-SSLIF B-SSLIF
, O O
rales B-SSLIF B-SSLIF
or O O
rhonchi B-SSLIF B-SSLIF
CARDIOVASCULAR O O
: O O
Regular O O
rate O O
rhythm O O
; O O
No O O
JVD B-SSLIF B-SSLIF
ABDOMINAL O O
: O O
Normoactive O O
bowel O O
sounds O O
; O O
Non O O
- O O
tender B-SSLIF B-SSLIF
, O O
no O O
masses B-SSLIF B-SSLIF
, O O
not O O
distended B-SSLIF B-SSLIF
, O O
no O O
rebound B-SSLIF B-SSLIF
, O O
no O O
guarding B-SSLIF B-SSLIF
  
NEUROLOGIC O O
: O O
Alert O O
oriented O O
x O O
3 O O
; O O
No O O
gross B-SSLIF B-SSLIF
deficits I-SSLIF I-SSLIF
PSYCH O O
: O O
Normal O O
mood O O
and O O
affect O O
Attending O O
comments O O
( O O
physical O O
exam O O
) O O
: O O
agree O O
with O O
exam O O
LABORATORY O O
/ O O
STUDIES O O
  
CBC O O
/ O O
Diff O O
: O O
Date O O
Name O O
Units O O
Range O O
09 O O
: O O
30 O O
  
WBC O O
  
RBC O O
  
HGB O O
g O O
/ O O
dL O O
12.0 O O
- O O
16.0 O O
11.2* O O
  
HCT O O
% O O
37.0 O O
- O O
47.0 O O
32.1* O O
  
MCV O O
  
PLT O O
NE O O
  
LY O O
  
MO O O
  
EO O O
  
BA O O
  
Coag O O
: O O
Date O O
Name O O
Units O O
Range O O
05 O O
: O O
00 O O
  
PT O O
seconds O O
9.6 O O
- O O
12.4 O O
14.0* O O
  
INR O O
2.0 O O
- O O
3.5 O O
1.3* O O
  
PTT O O
Radiology O O
: O O
Date O O
2 O O
: O O
37 O O
: O O
00 O O
AM O O
  
CT O O
: O O
Chest O O
- O O
PE B-SSLIF B-SSLIF
  
MR# O O
: O O
Medical_Record_Number O O
ACCT# O O
: O O
Medical_Record_Number O O
Patient O O
: O O
Name O O
, O O
Name O O
Name O O
  
DOB O O
: O O
Date O O
SEX O O
: O O
F O O
Requested O O
by O O
: O O
Name O O
, O O
Name O O
Reason O O
for O O
Study O O
: O O
Shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
Breath I-SSLIF I-SSLIF
- O O
- O O
pe O O
protocol O O
Exam O O
Date O O
/ O O
Time O O
: O O
Date O O
02 O O
: O O
37 O O
Exam O O
Type O O
: O O
CT O O
: O O
Chest O O
- O O
PE B-SSLIF B-SSLIF
Pregnancy O O
: O O
N O O
  
CT O O
scan O O
of O O
the O O
chest O O
with O O
intravenous O O
contrast O O
, O O
using O O
standard O O
protocol O O
. O O
  
INDICATION O O
: O O
Congestive B-SSLIF B-SSLIF
heart I-SSLIF I-SSLIF
failure I-SSLIF I-SSLIF
, O O
hypoxia B-SSLIF B-SSLIF
  
CRET O O
0.93 O O
Date O O
12 O O
: O O
10 O O
: O O
00AM O O
GFR O O
59 O O
Date O O
12 O O
: O O
10 O O
: O O
00AM O O
BUN O O
28 O O
Date O O
12 O O
: O O
10 O O
: O O
00AM O O
Shortness B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
Breath I-SSLIF I-SSLIF
- O O
- O O
pe O O
protocol O O
COMPARISON O O
: O O
Date O O
FINDINGS O O
: O O
  
Lines O O
/ O O
tubes O O
: O O
None O O
. O O
  
Lungs O O
and O O
Airways O O
there O O
is O O
segmental O O
and O O
subsegmental B-SSLIF B-SSLIF
pulmonary I-SSLIF I-SSLIF
embolism I-SSLIF I-SSLIF
identified I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
upper I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
middle I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
. O O
  
Subsegmental B-SSLIF B-SSLIF
pulmonary I-SSLIF I-SSLIF
embolism I-SSLIF I-SSLIF
also I-SSLIF I-SSLIF
seen I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
lingula I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
well I-SSLIF I-SSLIF
as I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
lower I-SSLIF I-SSLIF
lobe I-SSLIF I-SSLIF
. O O
  
Pulmonary O O
artery O O
is O O
prominent O O
in O O
caliber O O
, O O
measuring O O
3.6 O O
- O O
cm O O
in O O
diameter O O
Pleura O O
: O O
The O O
pleural O O
spaces O O
are O O
clear O O
. O O
  
Heart O O
and O O
mediastinum O O
: O O
There O O
is O O
a O O
1.9 B-Severity B-Severity
cm I-Severity I-Severity
dominant O O
right B-SSLIF B-SSLIF
thyroid I-SSLIF I-SSLIF
nodule I-SSLIF I-SSLIF
which O O
can O O
be O O
better O O
assessed O O
on O O
ultrasound O O
study O O
. O O
  
No O O
significant B-Severity B-Severity
mediastinal B-SSLIF B-SSLIF
, I-SSLIF I-SSLIF
hilar I-SSLIF I-SSLIF
or I-SSLIF I-SSLIF
axillary I-SSLIF I-SSLIF
lymphadenopathy I-SSLIF I-SSLIF
is O O
seen O O
. O O
  
The O O
heart B-SSLIF B-SSLIF
is I-SSLIF I-SSLIF
mildly I-SSLIF I-SSLIF
enlarged I-SSLIF I-SSLIF
in O O
size O O
. O O
  
Abdomen O O
: O O
There O O
is O O
small B-Severity B-Severity
hiatus B-SSLIF B-SSLIF
hernia I-SSLIF I-SSLIF
. O O
  
adrenal O O
glands O O
are O O
normal O O
. O O
  
Bones O O
: O O
The O O
bones O O
are O O
moderately B-Severity B-Severity
osteopenic B-SSLIF B-SSLIF
. O O
  
Old O O
healed O O
fracture B-SSLIF B-SSLIF
deformity I-SSLIF I-SSLIF
seen I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
right I-SSLIF I-SSLIF
10 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
9 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
8 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
7 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
6 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
fifth I-SSLIF I-SSLIF
ribs I-SSLIF I-SSLIF
. O O
  
Old O O
healed O O
fracture B-SSLIF B-SSLIF
deformity I-SSLIF I-SSLIF
also I-SSLIF I-SSLIF
seen I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
left I-SSLIF I-SSLIF
second I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
fourth I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
fifth I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
sixth I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
seventh I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
eighth I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
ninth I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
10th I-SSLIF I-SSLIF
ribs I-SSLIF I-SSLIF
. O O
  
Multilevel O O
compression B-SSLIF B-SSLIF
deformity I-SSLIF I-SSLIF
seen I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
thoracic I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
involving I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
T7 I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
T6 I-SSLIF I-SSLIF
vertebral I-SSLIF I-SSLIF
bodies I-SSLIF I-SSLIF
with O O
approximately O O
70% B-Severity B-Severity
loss B-SSLIF B-SSLIF
of I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
vertebral I-SSLIF I-SSLIF
body I-SSLIF I-SSLIF
heights I-SSLIF I-SSLIF
. O O
  
The O O
rib B-SSLIF B-SSLIF
and I-SSLIF I-SSLIF
thoracic I-SSLIF I-SSLIF
spine I-SSLIF I-SSLIF
fracture I-SSLIF I-SSLIF
deformities I-SSLIF I-SSLIF
are O O
new O O
since O O
prior O O
study O O
. O O
  
IMPRESSION O O
: O O
  
Subsegmental B-SSLIF B-SSLIF
pulmonary I-SSLIF I-SSLIF
embolism I-SSLIF I-SSLIF
bilateral B-SSLIF B-SSLIF
subsegmental I-SSLIF I-SSLIF
pulmonary I-SSLIF I-SSLIF
embolism I-SSLIF I-SSLIF
, O O
as O O
described O O
above O O
Prominent O O
pulmonary O O
entry O O
caliber O O
, O O
consistent O O
with O O
pulmonary B-SSLIF B-SSLIF
arterial I-SSLIF I-SSLIF
hypertension I-SSLIF I-SSLIF
Bilateral O O
multiple O O
old O O
healed O O
rib B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
deformities I-SSLIF I-SSLIF
. O O
  
Compression B-SSLIF B-SSLIF
fracture I-SSLIF I-SSLIF
deformity I-SSLIF I-SSLIF
in I-SSLIF I-SSLIF
the I-SSLIF I-SSLIF
T6 I-SSLIF I-SSLIF
, I-SSLIF I-SSLIF
T7 I-SSLIF I-SSLIF
and I-SSLIF I-SSLIF
T10 I-SSLIF I-SSLIF
vertebral I-SSLIF I-SSLIF
bodies I-SSLIF I-SSLIF
, O O
new O O
since O O
prior O O
study O O
from O O
Date O O
. O O
  
Communication O O
: O O
The O O
findings O O
were O O
comminuted O O
to O O
Dr O O
. O O
  
Name O O
, O O
Name O O
at O O
2 O O
: O O
40 O O
a.m. O O
on O O
Date O O
STAFF O O
: O O
Name O O
, O O
Name O O
Images O O
Personally O O
Reviewed O O
by O O
Attending O O
: O O
True O O
DISCHARGE O O
MEDICATIONS O O
/ O O
ALLERGIES O O
Finalized O O
Medications O O
at O O
Discharge O O
: O O
Date O O
1 O O
: O O
49 O O
: O O
40 O O
PM O O
citalopram B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
  
ENOXAPARIN B-Drug B-Drug
( I-Drug I-Drug
LOVENOX I-Drug I-Drug
) I-Drug I-Drug
70 B-Dose B-Dose
MG I-Dose I-Dose
= O O
0.7 B-Dose B-Dose
ML I-Dose I-Dose
Subcutaneous B-Route B-Route
SYRINGE O O
Q12H B-Frequency B-Frequency
for O O
30 B-Duration B-Duration
Days I-Duration I-Duration
Directions O O
: O O
0.7 O O
mL O O
subcutaneous O O
every O O
twelve O O
hours O O
ergocalciferol B-Drug B-Drug
( I-Drug I-Drug
vitamin I-Drug I-Drug
D2 I-Drug I-Drug
) I-Drug I-Drug
( I-Drug I-Drug
Vitamin I-Drug I-Drug
D I-Drug I-Drug
) I-Drug I-Drug
50 B-Dose B-Dose
, I-Dose I-Dose
000 I-Dose I-Dose
unit I-Dose I-Dose
Capsule I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
capsule I-Dose I-Dose
oral B-Route B-Route
QMON B-Frequency B-Frequency
QMON O O
foLIC B-Drug B-Drug
Acid I-Drug I-Drug
1 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
0.5 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
lidocaine B-Drug B-Drug
( I-Drug I-Drug
Lidoderm I-Drug I-Drug
) I-Drug I-Drug
5 B-Dose B-Dose
% I-Dose I-Dose
( I-Dose I-Dose
700 I-Dose I-Dose
mg I-Dose I-Dose
/ I-Dose I-Dose
patch I-Dose I-Dose
) I-Dose I-Dose
Adhesive O O
Patch O O
, O O
Medicated O O
, O O
Ordered O O
By O O
: O O
  
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
each I-Dose I-Dose
transdermal B-Route B-Route
DAILY B-Frequency B-Frequency
lisinopril B-Drug B-Drug
20 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
Additional O O
Instructions O O
: O O
HOLD O O
IF O O
SBP O O
< O O
___ O O
  
LORazepam B-Drug B-Drug
0.5 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Talya O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
three B-Frequency B-Frequency
times I-Frequency I-Frequency
a I-Frequency I-Frequency
day I-Frequency I-Frequency
PRN I-Frequency I-Frequency
ANXIETY B-Indication B-Indication
metoprolol B-Drug B-Drug
tartrate I-Drug I-Drug
25 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
twice B-Frequency B-Frequency
a I-Frequency I-Frequency
dayAdditional O O
Instructions O O
: O O
HOLD O O
IF O O
HR O O
< O O
___ O O
OR O O
SBP O O
< O O
___ O O
sulfamethoxazole B-Drug B-Drug
- I-Drug I-Drug
trimethoprim I-Drug I-Drug
800 B-Dose B-Dose
mg I-Dose I-Dose
- I-Dose I-Dose
160 I-Dose I-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
QMONWEDFRI B-Frequency B-Frequency
QMONWEDFRI O O
traMADol B-Drug B-Drug
50 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Route B-Route
every B-Frequency B-Frequency
six I-Frequency I-Frequency
hours I-Frequency I-Frequency
PRN I-Frequency I-Frequency
BACK B-Indication B-Indication
PAIN I-Indication I-Indication
polyethylene B-Drug B-Drug
glycol I-Drug I-Drug
3350 I-Drug I-Drug
( I-Drug I-Drug
Miralax I-Drug I-Drug
) I-Drug I-Drug
17 B-Dose B-Dose
gram I-Dose I-Dose
Powder I-Dose I-Dose
in O O
Packet O O
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
each I-Dose I-Dose
oral B-Route B-Route
DAILY B-Frequency B-Frequency
predniSONE B-Drug B-Drug
30 B-Dose B-Dose
mg I-Dose I-Dose
Tablet I-Dose I-Dose
, O O
Ordered O O
By O O
: O O
Name O O
Name O O
- O O
Name O O
Directions O O
: O O
1 B-Dose B-Dose
tablet I-Dose I-Dose
oral B-Frequency B-Frequency
daily I-Frequency I-Frequency
OTHER O O
INSTRUCTIONS O O
/ O O
FOLLOW O O
- O O
UP O O
Other O O
Instructions O O
: O O
Appointments O O
: O O
f O O
/ O O
u O O
with O O
Dr O O
. O O
  
Name O O
as O O
previously O O
scheduled O O
. O O
  
f O O
/ O O
u O O
with O O
PCP O O
in O O
1 O O
- O O
2 O O
weeks O O
Limitations O O
of O O
Treatment O O
: O O
Full O O
Code O O
Code O O
Status O O
Comments O O
: O O
confirmed O O
with O O
daughters O O
at O O
bedside O O
and O O
patient O O
Date O O
Contact O O
Info O O
for O O
Questions O O
About O O
Patient O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Disposition O O
: O O
home O O
with O O
services O O
Condition O O
of O O
Patient O O
on O O
Discharge O O
: O O
Good O O
COMMUNICATION O O
Referring O O
Physician O O
: O O
Name O O
, O O
Name O O
Primary O O
Care O O
MD O O
: O O
Name O O
, O O
Name O O
Forward O O
to O O
PCP O O
: O O
True O O
Other O O
MD O O
1 O O
: O O
Name O O
, O O
Name O O
Name O O
. O O
  
BILLING O O
DOCUMENTATION O O
Patient O O
Status O O
in O O
System O O
: O O
I O O
Billing O O
Documentation O O
: O O
Type O O
of O O
Service O O
Billed O O
: O O
Inpatient O O
Discharge O O
Services O O
Total O O
visit O O
time O O
( O O
including O O
unit O O
/ O O
floor O O
time O O
) O O
in O O
Mins O O
: O O
50 O O
Date O O
of O O
Service O O
: O O
Date O O
SIGNATURES O O
Resident O O
Signature O O
: O O
Electronically O O
signed O O
by O O
Name O O
Name O O
MD O O
at O O
17 O O
: O O
32 O O
Date O O
of O O
Resident O O
Signature O O
: O O
Date O O
Resident O O
Pager O O
: O O
Telephone O O
/ O O
Fax O O
/ O O
Pager O O
Attending O O
Attestation O O
: O O
I O O
saw O O
and O O
evaluated O O
the O O
patient O O
on O O
the O O
date O O
of O O
discharge O O
and O O
performed O O
discharge O O
day O O
services O O
( O O
examination O O
, O O
follow O O
up O O
planning O O
, O O
communication O O
, O O
and O O
education O O
) O O
, O O
as O O
needed O O
. O O
  
: O O
Name O O
Attending O O
Signature O O
: O O
Electronically O O
signed O O
by O O
Name O O
Name O O
, O O
MD O O
at O O
17 O O
: O O
42 O O
Date O O
of O O
Attending O O
Signature O O
: O O
Date O O
Patient O O
: O O
Name O O
, O O
Name O O
Acct.# O O
: O O
Medical_Record_Number O O
MR O O
# O O
: O O
Medical_Record_Number O O
  
D.O.B O O
: O O
Date O O
Date O O
of O O
Date O O
Location O O
: O O
Location O O
Visit O O
: O O
  
Dictated O O
Date O O
4 O O
: O O
43 O O
P O O
Transcribed O O
Date O O
7 O O
: O O
03 O O
  
: O O
: O O
P O O
CLINIC O O
NOTE O O
Name O O
is O O
here O O
for O O
MRI O O
followup O O
. O O
  
MRI O O
reveals O O
that O O
he O O
has O O
lateral B-SSLIF B-SSLIF
epicondylitis I-SSLIF I-SSLIF
with O O
no O O
evidence O O
of O O
a O O
fracture B-SSLIF B-SSLIF
or O O
a O O
mass B-SSLIF B-SSLIF
. O O
  
PLAN O O
: O O
The O O
patient O O
will O O
be O O
enrolled O O
in O O
a O O
course O O
of O O
physical O O
therapy O O
to O O
work O O
on O O
increasing O O
his O O
range O O
of O O
motion O O
and O O
optimizing O O
his O O
strength O O
, O O
as O O
well O O
as O O
pain O O
management O O
. O O
  
They O O
will O O
work O O
on O O
some O O
stretching O O
exercises O O
and O O
then O O
convert O O
him O O
to O O
a O O
home O O
program O O
. O O
  
He O O
will O O
follow O O
up O O
with O O
me O O
in O O
six O O
weeks O O
on O O
a O O
p.r.n. O O
basis O O
. O O
  
He O O
is O O
comfortable O O
with O O
the O O
plan O O
, O O
and O O
the O O
MRI O O
is O O
in O O
his O O
possession O O
in O O
case O O
he O O
needs O O
further O O
follow O O
up O O
. O O
  
E O O
- O O
Signed O O
By O O
Name O O
Name O O
Name O O
, O O
NP O O
Date O O
22 O O
: O O
11 O O
  
____________________________ O O
Name O O
Name O O
Name O O
, O O
NP O O
Patient O O
evaluated O O
by O O
and O O
note O O
dictated O O
by O O
: O O
Name O O
Name O O
Name O O
, O O
NP O O
  
FI O O
  
Medical_Record_Number O O
cc O O
: O O
Name O O
Name O O
Name O O
, O O
MD O O
